var images_info;if (!images_info) images_info =[]; images_info["75"]={"75000":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma CXR IV","title":"Cystic hygroma infiltrating lung in adult patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma infiltrating lung in adult patient</div><div class=\"cntnt\"><img style=\"width:359px; height:432px;\" src=\"images/PULM/75000_Cystic_hygroma_CXR_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows an anterior mediastinal mass with involvement of the adjacent left upper lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75000 Version 2.0</div></div></div>"},"75001":{"type":"graphic_diagnosticimage","displayName":"NSCLC hemidiaphragm para","title":"Peripheral nerve involvement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral nerve involvement</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/PULM/75001_NSCLC_hemidiaphragm_para.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left hemidiaphragm paralysis (confirmed by fluoroscopy) in a patient with extensive adenocarcinoma of the lung.</div><div id=\"graphicVersion\">Graphic 75001 Version 2.0</div></div></div>"},"75002":{"type":"graphic_table","displayName":"Work-up for apparently H pylori-negative NSAID-negative ulcers","title":"Work-up for apparently H. pylori-negative, NSAID-negative ulcers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Work-up for apparently H. pylori-negative, NSAID-negative ulcers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Etiologic factor</td> <td class=\"subtitle1\">Action</td> </tr> <tr> <td>Smoking</td> <td> <ul> <li>Careful history </li> </ul> </td> </tr> <tr> <td>Comorbid disease</td> <td> <ul> <li>Clinical evaluation </li> </ul> </td> </tr> <tr> <td><em>H. pylori</em> that has escaped detection</td> <td> <ul> <li>Perform at least two tests for <em>H. pylori </em></li> <li>Ensure testing is performed while the patient is off of PPIs, antibiotics, bismuth </li> <li>Consider four duodenal mucosal biopsies to detect isolated duodenal colonization </li> </ul> </td> </tr> <tr> <td>NSAIDs, aspirin, other potentially ulcerogenic drugs</td> <td> <ul> <li>Careful history </li> <li>Consider obtaining urine salicylate levels or platelet function tests to exclude surreptitious aspirin/NSAID use </li> </ul> </td> </tr> <tr> <td>Neoplasia, infection, infiltrative disease</td> <td> <ul> <li>Biopsy ulcers and surrounding mucosa, including in the duodenum </li> </ul> </td> </tr> <tr> <td>Acid hypersecretion</td> <td> <ul> <li>Measure fasting serum gastrin levels off of PPIs</li> <li>Measure basal acid output</li> <li>Consider measuring fasting serum gastrin following secretin stimulation in patients with normal fasting serum gastrin levels</li> </ul> </td> </tr> <tr> <td>Ischemic mechanisms</td> <td> <ul> <li>Exclude use of crack cocaine and methamphetamine </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><EM>H. pylori</EM>: <EM>Helicobacter pylori</EM>; NSAID: nonsteroidal anti-inflammatory drug; PPI: proton pump inhibitor.</div><div class=\"graphic_reference\">Adapted from: Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30:791.</div><div id=\"graphicVersion\">Graphic 75002 Version 6.0</div></div></div>"},"75003":{"type":"graphic_diagnosticimage","displayName":"Cushings disease MRI I","title":"Magnetic resonance imaging in Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging in Cushing's disease</div><div class=\"cntnt\"><img style=\"width:532px; height:271px;\" src=\"images/ENDO/75003_Cushings_disease_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thirty-seven-year-old woman with Cushing's disease caused by a 9 x 11 x 14 mm corticotroph macroadenoma. Left panel: Coronal section of unenhanced MR image of the sella turcica. The macroadenoma appears as an area of decreased signal intensity impinging upon the optic chasm above and the sphenoid sinus below (arrows). Right panel: Coronal gadolinium-enhanced MR image of the sella turcica. The microadenoma appears as an area of enhanced signal intensity with some areas of nonhomogeneity.</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div class=\"graphic_reference\">Reprinted with permission from Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia 1996.</div><div id=\"graphicVersion\">Graphic 75003 Version 5.0</div></div></div>"},"75004":{"type":"graphic_figure","displayName":"Course of acute B19 infection","title":"Course of parvovirus B19 infection","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Course of parvovirus B19 infection</div><div class=\"cntnt\"><img style=\"width:591px; height:314px;\" src=\"images/ID/75004_Course_of_acute_B19_infecti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the clinical course and laboratory abnormalities in normal hosts with parvovirus B19 infection. As expected for a virus that infects red cell precursors, a transient reticulocytopenia and slight drop in hemoglobin level develop during the viremic stage of infection; platelets and leukocytes (not shown) also fall during this period. Once the host mounts an immune response beginning 10 to 14 days after the infection, the viremia resolves and reticulocytes return. Note the biphasic timing of symptoms, during the peak viremia and again after the viremia has cleared. Rash, arthritis, and other symptoms typically associated with B19 occur during the second period.</div><div id=\"graphicVersion\">Graphic 75004 Version 2.0</div></div></div>"},"75006":{"type":"graphic_table","displayName":"Main bone morphogenic","title":"Main bone morphogenic proteins and noncollagenous bone matrix proteins and genes involved in vascular calcification in animals and humans","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Main bone morphogenic proteins and noncollagenous bone matrix proteins and genes involved in vascular calcification in animals and humans</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Function</td> <td class=\"subtitle1\">Vascular calcification</td> </tr> <tr> <td>Osteopontin</td> <td>Antiapoptotic signal for osteoclasts; chemotactic factor for MC and MP</td> <td>Recruitment of MP into area of vessel injury; osteopontin knockout mice develop stronger skeleton; osteopontin restrains mineralization</td> </tr> <tr> <td>Osteoprotegerin/RANKL</td> <td>Inhibitor of osteoclastogenesis; member of tumor necrosis factor-alpha receptor superfamily</td> <td>OPG inhibited by cyclosporine A; OPG inhibited by osteopontin; restrains mineralization</td> </tr> <tr> <td>Matrix GLA protein</td> <td>Expressed in chondrocytes and vascular smooth muscle cells and increased expression in lipid-rich plaque</td> <td>Knockout mice get dramatic early vascular calcification; warfarin effect on gamma-carboxylation (as osteocalcin); potent inhibitor of mineralization; inhibits bone morphogenic protein-2</td> </tr> <tr> <td>PTH recombinant protein</td> <td>Paracrine factor with potential humoral activity in hypercalcemia of malignancy; shares PTH1 receptor with PTH; involved with normal bone physiology</td> <td>Upregulated expression by vessel injury and angiotensin II; antagonizes procalcifying effect of vitamin D3; downregulates bone morphogenic protein-2</td> </tr> <tr> <td>Bone morphogenic protein-2</td> <td>Osteoblastic and mesenchymal differentiation</td> <td>Promotes ossification</td> </tr> <tr> <td>Bone morphogenic protein-7</td> <td>Differentiation factor; normal tubular epithelial differentiation; osteoblastic differentiation</td> <td>Null mouse has renal failure and agenesis; reverses heterotopic calcification in animal models</td> </tr> <tr> <td>Vitamin D</td> <td>Diverse functions through vitamin D receptor-dependent and independent pathways</td> <td>Medial calcification; vascular smooth muscle cells have vitamin D receptors; raised calcium-phosphate product</td> </tr> <tr> <td>Fetuin</td> <td>Synthesized in liver; soluble transforming growth factor-beta antagonist; negative acute phase reactant</td> <td>Knockout mice get ubiquitous soft tissue and vascular calcification; potent inhibitor of mineralization</td> </tr> <tr> <td>Pyrophosphate</td> <td>Naturally occurring inhibitor of calcification</td> <td>Loss-of-function mutations that result in decreased pyrophosphate cause idiopathic infantile arterial calcification</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MC: monocyte; MP: macrophage; OPG: osteoprotegerin; PTH: parathyroid hormone; RANKL: receptor activator of NF-kappaB ligand.</div><div class=\"graphic_reference\">Reproduced with permission from: Goldsmith D, Ritz E, Cvic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 2004; 66:1315. Copyright Â© 2004 Blackwell Publishing.</div><div id=\"graphicVersion\">Graphic 75006 Version 3.0</div></div></div>"},"75007":{"type":"graphic_diagnosticimage","displayName":"MRI hepatocellular carcinoma","title":"MRI of hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">MRI of hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:516px; height:207px;\" src=\"images/RADIOL/75007_MRIhepatocelCAdiagedt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatocellular carcinoma.&nbsp;MRI of the liver without and with contrast&nbsp;in a 73-year-old man with hepatitis C virus and cirrhosis. Axial fast spin echo T2-weighted image with fat saturation (A) shows a hyperintense&nbsp;mass&nbsp;with a thin low signal intensity capsule (arrow).&nbsp;Axial T1-weighted fat-saturated image in the delayed phase of contrast administration (B) shows washout in the tumor relative to adjacent liver while the capsule&nbsp;remains enhancing (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. Am J Roentgenol 2003; 180:441. Reprinted with permission from the American Journal of Roentgenology. Copyright Â© 2003 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 75007 Version 16.0</div></div></div>"},"75009":{"type":"graphic_picture","displayName":"Flag sign in malnutrition","title":"Flag sign in the hair of a child recovering from malnutrition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flag sign in the hair of a child recovering from malnutrition</div><div class=\"cntnt\"><img style=\"width:430px; height:312px;\" src=\"images/PEDS/75009_Flag_sign_malnutrition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The flag sign in the hair of a child recovering from Kwashiorkor. The picture was made at INCAP in Guatemala and used as a clinical standard for examiners in international nutrition surveys.</div><div class=\"graphic_reference\">Reproduced from: Interdepartmental Committee on Nutrition for National Defense (1963). Manual for Nutrition Surveys 2nd ed. Department of Health, Education and Welfare, Public Health Service, NIH, US Government Printing Office, Washington DC 1963.</div><div id=\"graphicVersion\">Graphic 75009 Version 3.0</div></div></div>"},"75010":{"type":"graphic_figure","displayName":"Ear anatomy","title":"Anatomy of the middle ear","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Anatomy of the middle ear</div><div class=\"cntnt\"><img style=\"width:533px; height:701px;\" src=\"images/EM/75010_Ear_anatomy_edit2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75010 Version 3.0</div></div></div>"},"75011":{"type":"graphic_table","displayName":"ACC AHA exercise arrhythmia","title":"ACC/AHA guideline summary: Exercise testing for arrhythmia evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Exercise testing for arrhythmia evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement that exercise testing for arrhythmia evaluation should be performed for the following indications:</td>\n\n</tr>\n<tr>\n<td>&#8226;&nbsp; To identify the appropriate settings in patients with rate adaptive pacemakers.</td>\n\n</tr>\n<tr>\n<td>&#8226;&nbsp; To evaluate patients with congenital complete heart block patients prior to initiation of increased physical activity or participation in competitive sports.</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Class IIa - The weight of evidence or opinion is in favor of benefit from exercise testing for arrhythmia evaluation for the following indications:</td>\n</tr>\n<tr>\n<td>&#8226;&nbsp; To evaluate suspected exercise-induced arrhythmias.</td>\n\n</tr>\n<tr>\n<td>&#8226;&nbsp; As part of the evaluation for medical, surgical, or ablative therapy in patients with known exercise-induced arrhythmias, including atrial fibrillation.</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Class IIb - The evidence or opinion is less well established that exercise testing for arrhythmia evaluation is beneficial for the following indications:</td>\n\n</tr>\n<tr>\n<td>&#8226;&nbsp; To evaluate ventricular premature beats in middle-aged patients without evidence of coronary artery disease.</td>\n\n</tr>\n<tr>\n<td>&#8226;&nbsp; To evaluate young patients with first-degree atrioventricular block, type I (Wenckebach) second degree atrioventricular block, left bundle branch block, right bundle branch block, or isolated ectopic beats prior to participation in competitive sports.</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Class III - There is evidence that exercise testing for arrhythmia evaluation is not useful and may be harmful in the following setting:</td>\n\n</tr>\n<tr>\n<td>&#8226;&nbsp; As part of the routine evaluation of isolated ectopic beats in young patients.</td>\n\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=1900&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ACC_AHA_exercise_arrhythmia.htm</title></head></div><div class=\"graphic_reference\">Data from Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.</div><div id=\"graphicVersion\">Graphic 75011 Version 2.0</div></div></div>"},"75013":{"type":"graphic_figure","displayName":"FV curves after treatment","title":"Flow-volume loops following acute bronchodilator treatment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow-volume loops following acute bronchodilator treatment</div><div class=\"cntnt\"><img style=\"width:344px; height:337px;\" src=\"images/PULM/75013_FV_curves_after_treatment.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dashed flow volume curve in each panel is the predicted relationship. A: The TLC is unchanged after bronchodilator therapy, but there is a fall in residual volume (RV) and an increase in total flow but not in peak expiratory flow (PEF). B: The bronchodilator causes an increase in flow rates without a shift in lung volume. In these first two examples, the measurement of lung volume is essentially noncontributory, as the FEV1 alone would be sensitive to the changes. C: The pre-bronchodilator flow-volume curve is shifted right and down, indicating hyperinflation and airflow limitation. The post-bronchodilator loop is markedly improved, although airflow is not totally normal. D: The change caused by bronchodilation is solely a fall in lung volumes, but flow at any given absolute volume (eg, dashed vertical line indicates an isovolume point for comparison) is significantly improved. The FEV1 may not change in this situation which is an example of an &quot;isovolume shift.&quot;</div><div id=\"graphicVersion\">Graphic 75013 Version 1.0</div></div></div>"},"75016":{"type":"graphic_picture","displayName":"Physical examination maneuver for osteitis pubis","title":"Physical examination maneuver for osteitis pubis","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Physical examination maneuver for osteitis pubis</div><div class=\"cntnt\"><img style=\"width:531px; height:451px;\" src=\"images/PC/75016_Phys_exam_man_ost_pubis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To assess the adductor and lower abdominal muscles, the patient should be placed supine on the examining table with hips and knees flexed 90 degrees. The athlete then performs an isometric adductor muscle contraction against the examiner's fist. A painful isometric muscle contraction is considered a positive test</div><div id=\"graphicVersion\">Graphic 75016 Version 2.0</div></div></div>"},"75017":{"type":"graphic_figure","displayName":"Pandemic influenza mortality 1918","title":"Combined influenza and pneumonia mortality, United States, 1911-1918","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Combined influenza and pneumonia mortality, United States, 1911-1918</div><div class=\"cntnt\"><img style=\"width:572px; height:413px;\" src=\"images/ID/75017_Pandemic_flu_1918_edit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">&quot;U-&quot; and &quot;W-&quot; shaped combined influenza and pneumonia mortality, by age at death, per 100,000 persons in each age group, United States, 1911-1918. Influenza- and pneumonia-specific death rates are plotted for the interpandemic years 1911-1917 (orange line) and for the pandemic year 1918 (green line).</div><div class=\"graphic_reference\">Reproduced from: Taubenberger JK, Morens DM. 1918 influenza: The mother of all pandemics. Emerg Infect Dis 2006; 12:15.</div><div id=\"graphicVersion\">Graphic 75017 Version 3.0</div></div></div>"},"75018":{"type":"graphic_waveform","displayName":"Sinus pause tutorial","title":"Sinus pause","html":"<div class=\"graphic normal\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Sinus pause</div><div class=\"cntnt\"><img style=\"width:455px; height:121px;\" src=\"images/CARD/75018_Sinus_pause_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus pause is the result of intermittent failure of sinus node impulse generation. This is manifest as a long RR cycle length (in this tracing P to P interval) which is longer than the RR interval of the underlying sinus rhythm. There is no relationship between the cycle length of the pause and that of the intrinsic sinus rhythm. The P-P interval for the beats before and after the pause are less than two times the underlying sinus P-P interval.</div><div id=\"graphicVersion\">Graphic 75018 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"75020":{"type":"graphic_table","displayName":"Empiric oral antibiotics animal bites","title":"Empiric oral antibiotic therapy for animal bites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric oral antibiotic therapy for animal bites</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic agents</td> <td class=\"subtitle1\">Adults</td> <td class=\"subtitle1\">Children</td> </tr> <tr> <td colspan=\"3\"><strong>Agent of choice</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Amoxicillin-clavulanate</td> <td>875/125 mg twice daily</td> <td>22.5 mg/kg per dose (amoxicillin component) two times daily (maximum 875 mg amoxicillin and 125 mg clavulanate per dose)</td> </tr> <tr> <td colspan=\"3\"><strong>Alternate empiric regimens include:</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>One of the following agents with activity against <em>P. multocida*</em>:</strong></td> </tr> <tr> <td class=\"indent2\">Doxycycline<sup>&#182;</sup></td> <td>100 mg twice daily</td> <td> <p>&#60;8 years old: Not recommended due to low risk of dental staining</p> <p>&#8805;8 years old: 2 mg/kg per dose twice daily (maximum 100 mg per dose)</p> </td> </tr> <tr> <td class=\"indent2\">TMP-SMX<sup>&#182;</sup></td> <td>1 double-strength tablet twice daily</td> <td>4 to&nbsp;6 mg/kg (trimethoprim component) per dose twice daily (maximum 160 mg trimethoprim per dose)</td> </tr> <tr> <td class=\"indent2\">Penicillin VK</td> <td>500 mg four times daily</td> <td>12.5 mg/kg per dose four times daily (maximum 500 mg per dose)</td> </tr> <tr> <td class=\"indent2\">Cefuroxime</td> <td>500 mg twice daily</td> <td>10 mg/kg per dose twice daily (maximum 500 mg per dose)</td> </tr> <tr> <td class=\"indent2\">Ciprofloxacin</td> <td>500 to 750 mg twice daily</td> <td> <p>Use with caution in children &#60;18 years of age; if unable to tolerate other choices:</p> 15 to 20&nbsp;mg/kg per dose twice daily (maximum 750 mg per dose)</td> </tr> <tr> <td class=\"indent2\">Levofloxacin&nbsp;</td> <td>750 mg once daily</td> <td>Use with caution in children &#60;18 years of age; if unable to tolerate other choices:<br /> &#60;5 years old: 10 mg/kg per dose twice daily (maximum 750 mg daily)<br /> &#8805;5 years old: 10 mg/kg per dose once daily (maximum 750 mg daily)</td> </tr> <tr> <td class=\"indent2\">Moxifloxacin</td> <td>400 mg once daily</td> <td>Not recommended; insufficient experience</td> </tr> <tr> <td class=\"indent3\" colspan=\"3\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>One of the following agents with anaerobic activity:</strong></td> </tr> <tr> <td class=\"indent2\">Metronidazole</td> <td>500 mg three times daily</td> <td>10 mg/kg per dose three times daily (maximum 500 mg per dose)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Clindamycin<sup>&#182;</sup></td> <td>450 mg three times daily</td> <td>10 mg/kg per dose three times daily (maximum 450 mg per dose)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.</div><div class=\"graphic_footnotes\">TMP-SMX: trimethoprim-sulfamethoxazole.<br />* The following agents have poor activity against <EM>P. multocida </EM>and should be avoided: cephalexin, dicloxacillin, and erythromycin.<br />Â¶&nbsp;May also be active against methicillin-resistant <EM>Staphylococcus aureus</EM> (check susceptibility testing).</div><div class=\"graphic_reference\">References:<br /><br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics (AAP). Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed., Kimberlin DW, Brady MT, Jackson MA, Long SA&nbsp;(Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015.</LI>&#xD;&#xA;<LI>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147.</LI></OL></div><div id=\"graphicVersion\">Graphic 75020 Version 10.0</div></div></div>"},"75021":{"type":"graphic_movie","displayName":"Dilated cardiomyopathy long axis echocardiogram","title":"Dilated cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilated cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/75021_laxdilcmconv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:267px; height:412px;\" src=\"images/CARD/75021_laxdilcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis view from a 2-D echocardiogram shows a markedly dilated and hypokinetic left ventricle. The left atrium is also enlarged and there is reduced excursion of the mitral and aortic valves suggesting a reduced stroke volume.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 75021 Version 2.0</div></div></div>"},"75023":{"type":"graphic_table","displayName":"Vestibular migraine criteria","title":"Criteria for vestibular migraine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for vestibular migraine</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>A. At least five episodes fulfilling criteria C and D</td> </tr> <tr> <td>B. A current or past history of migraine without aura or migraine with aura</td> </tr> <tr> <td>C. Vestibular symptoms of moderate or severe intensity, lasting between 5 minutes and 72 hours</td> </tr> <tr> <td>D. At least 50 percent of episodes are associated with at least one of the following three migrainous features:</td> </tr> <tr> <td class=\"indent1\">1. Headache with at least two of the following four characteristics:</td> </tr> <tr> <td class=\"indent2\">a) Unilateral location</td> </tr> <tr> <td class=\"indent2\">b) Pulsating quality</td> </tr> <tr> <td class=\"indent2\">c) Moderate or severe intensity</td> </tr> <tr> <td class=\"indent2\">d) Aggravation by routine physical activity</td> </tr> <tr> <td class=\"indent1\">2. Photophobia and phonophobia</td> </tr> <tr> <td class=\"indent1\">3. Visual aura</td> </tr> <tr> <td>E. Not better accounted for by another ICHD-3 diagnosis or by another vestibular disorder</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICHD-3: the International Classification of Headache Disorders, 3rd edition.</div><div class=\"graphic_reference\">Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 75023 Version 4.0</div></div></div>"},"75024":{"type":"graphic_picture","displayName":"Labial eruption","title":"Labial eruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Labial eruption</div><div class=\"cntnt\"><img style=\"width:504px; height:157px;\" src=\"images/PEDS/75024_Labial_eruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A reduction in the width of keratinized gingiva resulting from labial eruption of the left central incisor. <br />(B) After orthodontic alignment of the labially positioned left incisor, a gingival defect was observed. Localized recession occurred as the result of plaque accumulation in an area that was difficult to clean and had inadequate attached gingiva.</div><div class=\"graphic_reference\">Reproduced with permission from: Griffen AL. Periodontal problems in children and adolescents. In: Pediatric Dentistry, Infancy Through Adolescence, 3<SUP>rd</SUP> ed, Pinkham, Casamassimo, Fields, McTigue, Nowak (Eds), W.B. Saunders, 1999. p.376. Copyright Â© 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 75024 Version 3.0</div></div></div>"},"75026":{"type":"graphic_figure","displayName":"Abciximab and tirofiban produce similar outcomes at six months ","title":"Abciximab and tirofiban produce similar outcomes six months after PCI","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Abciximab and tirofiban produce similar outcomes six months after PCI</div><div class=\"cntnt\"><img style=\"width:468px; height:295px;\" src=\"images/CARD/75026_Abciximab_v_tirofiban_6_mon.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the TARGET trial of 4809 patients undergoing stenting, the primary end point (composite of death, nonfatal myocardial infarction, or urgent target vessel revascularization) was significantly lower with abciximab compared to tirofiban at 30 days, but no difference was apparent at six months.</div><div class=\"graphic_reference\">Data from Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Lancet 2002; 360:355.</div><div id=\"graphicVersion\">Graphic 75026 Version 3.0</div></div></div>"},"75027":{"type":"graphic_picture","displayName":"Vulvar papillomatosis papules","title":"Vulvar papillomatosis papules","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Vulvar papillomatosis papules</div><div class=\"cntnt\"><img style=\"width:498px; height:202px;\" src=\"images/OBGYN/75027_Vulvar_papillomatosis_papul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) On the inner edge of the labia minora are variably sized yellow papules. These are normal sebaceous glands-sebaceous hyperplasia.<br />(B) Vulvar papillomatosis. On either side of the hymenal ring are obvious filiform papules filling the whole area.</div><div class=\"graphic_reference\">Reproduced with permission from: Fisher BK, Margesson LJ. Genital Skin Disorders: Diagnosis and Treatment. Mosby, St. Louis, Missouri 1998. p.104. Copyright &copy; 1998 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 75027 Version 3.0</div></div></div>"},"75029":{"type":"graphic_picture","displayName":"Gray patch tinea kerion","title":"Kerion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kerion</div><div class=\"cntnt\"><img style=\"width:253px; height:327px;\" src=\"images/DERM/75029_Gray_patch_tinea_kerion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo shows kerion - a boggy, indurated erythematous plaque with pustules and exudate. Kerion is a form of immune response to the fungus that causes gray patch tinea capitis, Microsporum canis.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 75029 Version 2.0</div></div></div>"},"75030":{"type":"graphic_diagnosticimage","displayName":"Calcified granuloma CT","title":"Calcified pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcified pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:361px; height:255px;\" src=\"images/PULM/75030_Calcified_granuloma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Benign pattern of calcification in a solitary pulmonary nodule. There is diffuse calcification in this subpleural nodular granuloma.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75030 Version 2.0</div></div></div>"},"75032":{"type":"graphic_table","displayName":"Rapid overview: Management of acute coronary syndrome (ACS)","title":"Rapid overview: Management of acute coronary syndrome (ACS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Management of acute coronary syndrome (ACS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial assessment:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Consider the diagnosis in patients with chest discomfort, shortness of breath, or other suggestive symptoms. Women, older adults, and patients with diabetes may have \"atypical\" presentations. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obtain 12 lead ECG within 10 minutes of arrival; repeat every 10 to 15 minutes if initial ECG is nondiagnostic but clinical suspicion remains high (initial ECG often <strong>NOT</strong> diagnostic). </li> </ul> </td> </tr> <tr> <td class=\"indent3\">1. STEMI: ST segment elevations &#8805;1 mm (0.1 mV) in two anatomically contiguous leads or &#8805;2 mm (0.2 mV) in leads V2 and V3 <strong>OR</strong> new left bundle branch block and presentation consistent with ACS. If ECG suspicious but not diagnostic, consult cardiologist early.</td> </tr> <tr> <td class=\"indent3\">2. Non-STEMI or unstable angina: ST segment depressions or deep T wave inversions without Q waves or possibly no ECG changes.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obtain emergent cardiology consultation for ACS patients with cardiogenic shock, left heart failure, or sustained ventricular tachyarrhythmia. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Initial interventions:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Assess and stabilize airway, breathing, and circulation. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Attach cardiac and oxygen saturation monitors; provide supplemental oxygen as needed to maintain O<sub>2</sub> saturation &#62;90%. Establish IV access. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treat sustained ventricular arrhythmia rapidly according to ACLS protocols. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Give aspirin 325 mg (nonenteric coated) to be chewed and swallowed (unless aortic dissection is being considered). If oral administration is not feasible, give as rectal suppository. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Perform focused history and examination: Look for signs of hemodynamic compromise and left heart failure; determine baseline neurologic function, particularly if fibrinolytic therapy is to be given. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obtain blood for cardiac biomarkers (troponin preferred), electrolytes, hematocrit/hemoglobin. Perform coagulation studies for patients taking anticoagulants or as otherwise indicated (eg, known coagulopathy). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Give three sublingual nitroglycerin tablets (0.4 mg) one at a time, spaced five minutes apart, or one aerosol spray under tongue every five minutes for three doses <strong>IF</strong> patient has persistent chest discomfort, hypertension, or signs of heart failure <strong>AND</strong> there is no sign of hemodynamic compromise (eg, right ventricular infarction) and no use of phosphodiesterase inhibitors (eg, for erectile dysfunction); add IV nitroglycerin for persistent symptoms. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treat left heart failure if present: Give afterload-reducing agent (eg, nitroglycerin sublingual tablet and/or IV drip at 40 mcg/minute provided no hypotension and no phosphodiesterase inhibitors [eg, for erectile dysfunction]; titrate drip up quickly based on response); give loop diuretic (eg, intravenous furosemide); administer noninvasive positive pressure ventilation (eg, BLPAP) to appropriate patients. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Give beta blocker (eg, metoprolol tartrate 25 mg orally) <strong>IF</strong> no signs of heart failure and not at high risk for heart failure and no signs of hemodynamic compromise, bradycardia, or severe reactive airway disease. If hypertensive, may initiate beta blocker IV instead (eg, metoprolol tartrate 5 mg intravenous every five minutes for three doses as tolerated). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Give morphine sulfate (2 to 4 mg slow IV push every 5 to 15 minutes) for unacceptable, persistent discomfort or anxiety related to myocardial ischemia. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Start 80 mg of atorvastatin as early as possible and preferably before PCI in patients not on statin. If patient is taking a low to moderate intensity statin, switch to atorvastatin 80 mg. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Acute management STEMI:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Select reperfusion strategy: Primary PCI strongly preferred, especially for patients with cardiogenic shock, heart failure, late presentation, or contraindications to fibrinolysis. Activate cardiac catheterization team as indicated. For patients with symptoms of &#62;12 hours, fibrinolytic therapy is not indicated, but emergent PCI may be considered, particularly for patients with evidence of ongoing ischemia or those at high risk of death. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treat with fibrinolysis if PCI unavailable within <strong>120 minutes of first medical contact,</strong> symptoms &#60;12 hours, and no contraindications.* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>Give oral antiplatelet therapy (in addition to aspirin) to all patients:</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent3\">1. <strong>Patients treated with fibrinolytic therapy:</strong> Give clopidogrel loading dose 300 mg if age 75 years or less; if age over 75 years, give loading dose of 75 mg.</td> </tr> <tr> <td class=\"indent3\">2. <strong>Patients treated with no reperfusion therapy:</strong> Give ticagrelor loading dose 180 mg.</td> </tr> <tr> <td class=\"indent3\">3. <strong>Patients treated with primary PCI:</strong> Give ticagrelor loading dose of 180 mg or prasugrel loading dose of 60 mg (if no contraindications: prior stroke or TIA, or relative contraindications for prasugrel such as those age 75 years or older, weight less than 60 kg). For patients at high risk of bleeding or those for whom prasugrel or ticagrelor cannot be used, we give clopidogrel 600 mg.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>Give anticoagulant therapy to all patients:</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent3\">1. <strong>For patients treated with primary PCI,</strong> we prefer UFH to bivalirudin. This recommendation assumes that patients will receive a potent oral antiplatelet agent (ticagrelor or prasugrel), which we prefer to clopidogrel. For those patients who receive clopidogrel, we prefer bivalirudin.</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><strong>Dosing of UFH:</strong> An initial IV bolus of 50 to 70 units/kg up to a maximum of 5000 units. Additional heparin may be given in the catheterization laboratory based on the results of ACT monitoring. </li> <li><strong>Dosing of bivalirudin:</strong> Initial bolus of 0.75 mg/kg IV followed by IV infusion of 1.75 mg/kg per hour; can be discontinued after PCI. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">2. <strong>For patients treated with fibrinolysis,</strong> we prefer enoxaparin for patients not at high bleeding risk or fondaparinux for those at high bleeding risk. For those patients in whom PCI is possible or likely after fibrinolytic therapy, UFH is reasonable.</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><strong>Dosing of enoxaparin</strong> <ul> <li>Patients &#60;75 years: Loading dose of 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours; maximum of 100 mg for the first two subcutaneous doses. The first subcutaneous dose should be administered with the IV bolus. <ul> <li>Dose adjustment for renal impairment (CrCl &#60;30 mL/minute)*: Loading dose of 30 mg IV followed by 1 mg/kg subcutaneously every 24 hours. The first subcutaneous dose should be administered with the IV bolus. </li> </ul> </li> </ul> <ul> <li>Patients &#8805;75 years: No IV loading dose. Administer 0.75 mg/kg subcutaneously every 12 hours; maximum of 75 mg for the first two doses. <ul> <li>Dose adjustment for renal impairment (CrCl &#60;30 mL/minute)*: No IV loading dose. Administer 1 mg/kg subcutaneously every 24 hours. </li> </ul> </li> <li>Supplemental IV bolus&nbsp;dose for patients who will receive PCI&nbsp;after&nbsp;&#62;1 dose of therapeutic enoxaparin: 0.3 mg/kg if last enoxaparin dose was given 8 to 12 hours earlier; no supplemental IV dose if last enoxaparin dose was within 8 hours; use UFH if last enoxaparin dose was more than 12 hours ago. </li> </ul> </li> <li><strong>Dosing of UFH:</strong> IV bolus of 60 to 100 units/kg to a maximum of 4000 units, followed by an IV infusion of 12 units/kg per hour (maximum 1000 units per hour) adjusted to achieve a goal aPTT of approximately 50 to 70 seconds (1.5 to 2 times control). </li> <li><strong>Dosing of fondaparinux:</strong> 2.5 mg intravenously, followed by 2.5 mg subcutaneously every 24 hours. This drug should be avoided in&nbsp;CrCl &#60;30 mL/minute. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">3. <strong>For patients not receiving reperfusion therapy,</strong> we use enoxaparin or UFH.</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><strong>Dosing of enoxaparin: </strong>Dose same as for patients treated with fibrinolysis (refer to section 2 above). </li> <li><strong></strong><strong>Dosing of UFH:</strong> IV bolus of 50 to 70 units/kg to a maximum of 5000 units, followed by an IV infusion of 12 units/kg per hour adjusted to achieve a goal aPTT of approximately 50 to 70 seconds (1.5 to 2 times control). </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Acute management of unstable angina or non-STEMI:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>Give antiplatelet therapy (in addition to aspirin) to all patients:</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent3\">1. <strong>Patients not treated with an invasive approach:</strong> Give ticagrelor loading dose 180 mg. For these patients who are at very high risk (eg, recurrent ischemic discomfort, dynamic ECG changes, or hemodynamic instability), consider adding a GP IIb/IIIa inhibitor (either eptifibatide or tirofiban).</td> </tr> <tr> <td class=\"indent3\">2. <strong>For patients managed with an invasive approach:</strong> Give ticagrelor loading dose of 180 mg at presentation. Prasugrel loading dose of 60 mg may be used as an alternative if given after diagnostic coronary angiography.</td> </tr> <tr> <td class=\"indent4\">For patients age 75 years or older, who weigh less than 60 kg, or with past stroke or transient ischemic attack, ticagrelor or clopidogrel are preferred to prasugrel. Clopidogrel may be given in a dose of 300 to 600 mg, but we prefer 600 mg. For patients otherwise at high risk for bleeding due to prior hemorrhagic stroke, ongoing bleeding, bleeding diathesis, or clinically relevant anemia or thrombocytopenia, clopidogrel 300 to 600 mg is an option.</td> </tr> <tr> <td class=\"indent4\">For patients treated with an invasive approach and who receive bivalirudin, we do not recommend routinely giving a GP IIb/IIIa inhibitor; for those patients treated with heparin and who are troponin-positive, we suggest adding a GP IIb/IIIa inhibitor (either abciximab or eptifibatide) given after diagnostic angiography. For those undergoing an invasive approach who are at very high risk (eg, recurrent ischemic discomfort, dynamic ECG changes, or hemodynamic instability), we consider adding a GP IIb/IIIa inhibitor prior to diagnostic angiography (either eptifibatide or tirofiban) or after diagnostic angiography (abciximab or eptifibatide).&nbsp;Refer to&nbsp;text for dosing.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>Give anticoagulant therapy in all patients:</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent3\">1. <strong>For patients undergoing urgent catheterization (within four hours) or those managed with an early invasive strategy (angiography within 4 to 48 hours),</strong> we use either heparin or bivalirudin. We prefer initiation of heparin in the emergency department and a switch to bivalirudin in the catheterization laboratory.</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><strong>Dosing of UFH:</strong> IV bolus of 60 to 70 units/kg to a maximum of 5000 units, followed by an IV infusion of 12 units/kg per hour adjusted to achieve a goal aPTT of approximately 50 to 70 seconds (1.5 to 2 times control). </li> <li><strong>Dose of bivalirudin:</strong> If bivalirudin is given in the emergency department, IV bolus of 0.1 mg/kg and an infusion of 0.25 mg/kg per hour before angiography. If PCI is performed, an additional 0.5 mg/kg bolus is given and the infusion rate is increased to 1.75 mg/kg per hour. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">2. <strong>For patients receiving a noninvasive approach,</strong> we recommend either fondaparinux or enoxaparin.</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><strong>Enoxaparin</strong> is an alternative to UFH for patients not undergoing an early invasive approach. No loading dose is necessary. Dosing is 1 mg/kg subcutaneously every 12 hours. Dose adjustment for renal impairment (CrCl &#60;30 mL/minute)*: 1 mg/kg subcutaneously every 24 hours. </li> <li><strong>Fondaparinux:</strong> 2.5 mg subcutaneously every 24 hours. This drug should be avoided in patients with a&nbsp;CrCl &#60;30 mL/minute. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Other important considerations:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cocaine-related ACS: Give benzodiazepines (eg, lorazepam 2 to 4 mg IV every 15 minutes or so) as needed to alleviate symptoms; do <strong>NOT</strong> give beta blockers. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Stop NSAID therapy if possible. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Correct any electrolyte abnormalities, especially hypokalemia and hypomagnesemia, which often occur together. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>ECG: electrocardiogram; STEMI: ST-elevation myocardial infarction; ST: ST-segment; IV: intravenous; ACLS: advanced cardiac life support; BLPAP: bilevel positive airway pressure; PCI: percutaneous intervention; TIA: transient ischemic attack; UFH: unfractionated heparin; ACT: activated clotting time; CrCl: creatinine clearance estimated using Cockcroft-Gault equation (a calculator is available in UpToDate); aPTT: activated partial thromboplastin time; GP: glycoprotein; NSAID: nonsteroidal antiinflammatory drug.</FONT><br />* Repeated doses of low molecular weight heparin to patients with renal insufficiency may lead to accumulation and increased risk of bleeding to varying degrees.&nbsp;By contrast, UFH is not dependent primarily upon renal function for clearance and may be a preferred option for patients with CrCl &lt;20 mL/minute, kidney failure, or receiving dialysis.</div><div id=\"graphicVersion\">Graphic 75032 Version 30.0</div></div></div>"},"75033":{"type":"graphic_picture","displayName":"Wrist flexion examination","title":"Examination of wrist flexion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examination of wrist flexion</div><div class=\"cntnt\"><img style=\"width:432px; height:338px;\" src=\"images/EM/75033_Wrist_flexion_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pain with resisted wrist flexion with the elbow in full extension is characteristic of medial epicondylitis.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD.</div><div id=\"graphicVersion\">Graphic 75033 Version 2.0</div></div></div>"},"75034":{"type":"graphic_diagnosticimage","displayName":"2D TTE apical 4 chamber view","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical four-chamber position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical four-chamber position</div><div class=\"cntnt\"><img style=\"width:352px; height:311px;\" src=\"images/CARD/75034_Apical_4_chamber_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four-chamber view from a&nbsp;two-dimensional&nbsp;echocardiogram. The display shows the apex at the top of the screen with the left ventricle (LV) to the viewer's right.</div><div class=\"graphic_footnotes\">aML: anterior mitral leaflet; LA: left atrium; pML: posterior mitral valve leaflet; RA: right atrium; RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 75034 Version 6.0</div></div></div>"},"75036":{"type":"graphic_movie","displayName":"TEE LAA","title":"Left atrial appendage","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial appendage</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/75036_teeltaapconv.mp4\" style=\"width:324px;height:236px\"></div><img style=\"width:231px; height:208px;\" src=\"images/CARD/75036_teeltaap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows the left atrium (LA) and left atrial appendage (LAA).</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 75036 Version 3.0</div></div></div>"},"75038":{"type":"graphic_waveform","displayName":"F waves","title":"F waves","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">F waves</div><div class=\"cntnt\"><img style=\"width:522px; height:542px;\" src=\"images/NEURO/75038_F_waves.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The F wave is visible as a low amplitude late potential following the M response. External stimulation depolarizes peripheral nerves, triggering electrical potentials that propagate both proximally and distally. With motor nerves, electrical activity moving distally results in a direct motor response, the compound muscle action potential, also known as the CMAP or the M response. Electrical activity propagating proximally activates a small percentage of motor neurons (they \"backfire\"), which then generate the F wave. The F wave latency varies depending upon the conductivity of the <SPAN style=\"LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt\">subpopulation </SPAN>of motor neurons activated.</div><div id=\"graphicVersion\">Graphic 75038 Version 3.0</div></div></div>"},"75039":{"type":"graphic_table","displayName":"Nutrition needs preterm inf","title":"Comparison of parenteral and enteral fluid, energy, and nutrient intakes for stable, growing premature infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of parenteral and enteral fluid, energy, and nutrient intakes for stable, growing premature infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Component, units</td> <td class=\"subtitle1\" colspan=\"2\">Unit/kg/day (except as noted)</td> </tr> <tr> <td class=\"subtitle2\">Parenteral</td> <td class=\"subtitle2\">Enteral</td> </tr> <tr> <td>Water, mL</td> <td>120 to 160</td> <td>135 to 190</td> </tr> <tr> <td>Energy, kcal</td> <td>90 to 100</td> <td>110 to 130</td> </tr> <tr> <td>Protein, g</td> <td>3.2 to 3.8</td> <td>3.4 to 4.2</td> </tr> <tr> <td>Fat, g</td> <td>3 to 4</td> <td>5.3 to 7.2</td> </tr> <tr> <td>Carbohydrate, g</td> <td>9.7 to 15</td> <td>7 to 17</td> </tr> <tr> <td>Linoleic acid, mg</td> <td>340 to 800</td> <td>600 to 1440</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Vitamins</td> </tr> <tr> <td class=\"sublist1\">Vitamin A, int. unit</td> <td class=\"sublist_other\">700 to 1500</td> <td class=\"sublist_other\">700 to 1500</td> </tr> <tr> <td class=\"sublist1\">Vitamin D, int. unit</td> <td class=\"sublist_other\">40 to 160</td> <td class=\"sublist_other\">150 to 400</td> </tr> <tr> <td class=\"sublist1\">Vitamin E, int. unit</td> <td class=\"sublist_other\">2.8 to 3.5</td> <td class=\"sublist_other\">6 to 12</td> </tr> <tr> <td class=\"sublist1\">Vitamin K*, mcg</td> <td class=\"sublist_other\">10</td> <td class=\"sublist_other\">8 to 10</td> </tr> <tr> <td class=\"sublist1\">Thiamin (vitamin B1), mcg</td> <td class=\"sublist_other\">200 to 350</td> <td class=\"sublist_other\">180 to 240</td> </tr> <tr> <td class=\"sublist1\">Riboflavin (vitamin B2), mcg</td> <td class=\"sublist_other\">150 to 200</td> <td class=\"sublist_other\">250 to 360</td> </tr> <tr> <td class=\"sublist1\">Pyridoxine (vitamin B6), mcg</td> <td class=\"sublist_other\">150 to 200</td> <td class=\"sublist_other\">150 to 210</td> </tr> <tr> <td class=\"sublist1\">Vitamin B12, mcg</td> <td class=\"sublist_other\">0.3</td> <td class=\"sublist_other\">0.3</td> </tr> <tr> <td class=\"sublist1\">Niacin, mg</td> <td class=\"sublist_other\">4 to 6.8</td> <td class=\"sublist_other\">3.6 to 4.8</td> </tr> <tr> <td class=\"sublist1\">Folic Acid, mcg</td> <td class=\"sublist_other\">56</td> <td class=\"sublist_other\">25 to 50</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Electrolytes</td> </tr> <tr> <td class=\"sublist1\">Sodium, mg</td> <td class=\"sublist_other\">69 to 115</td> <td class=\"sublist_other\">69 to 115</td> </tr> <tr> <td class=\"sublist1\">Potassium, mg</td> <td class=\"sublist_other\">78 to 117</td> <td class=\"sublist_other\">78 to 117</td> </tr> <tr> <td class=\"sublist1\">Chloride, mg</td> <td class=\"sublist_other\">107 to 249</td> <td class=\"sublist_other\">107 to 249</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Minerals</td> </tr> <tr> <td class=\"sublist1\">Calcium, mg</td> <td class=\"sublist_other\">60 to 80</td> <td class=\"sublist_other\">100 to 220</td> </tr> <tr> <td class=\"sublist1\">Phosphorus, mg</td> <td class=\"sublist_other\">45 to 60</td> <td class=\"sublist_other\">60 to 140</td> </tr> <tr> <td class=\"sublist1\">Magnesium, mg</td> <td class=\"sublist_other\">4.3 to 7.2</td> <td class=\"sublist_other\">7.9 to 15</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Trace elements</td> </tr> <tr> <td class=\"sublist1\">Iron, mg</td> <td class=\"sublist_other\">100 to 200</td> <td class=\"sublist_other\">2000 to 4000</td> </tr> <tr> <td class=\"sublist1\">Zinc, mcg</td> <td class=\"sublist_other\">400</td> <td class=\"sublist_other\">1000 to 3000</td> </tr> <tr> <td class=\"sublist1\">Copper, mcg</td> <td class=\"sublist_other\">20</td> <td class=\"sublist_other\">120 to 150</td> </tr> <tr> <td class=\"sublist1\">Chromium, mcg</td> <td class=\"sublist_other\">0.05 to 0.3</td> <td class=\"sublist_other\">0.1 to 2.25</td> </tr> <tr> <td class=\"sublist1\">Manganese, mcg</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">0.7 to 7.5</td> </tr> <tr> <td class=\"sublist1\">Selenium, mcg</td> <td class=\"sublist_other\">1.5 to 4.5</td> <td class=\"sublist_other\">1.3 to 4.5</td> </tr> <tr> <td>Carnitine, mg</td> <td>~3</td> <td>~3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>The following conversion factors are used:</strong><br />Calcium: 40 mg = 1 mmoL = 2 mEq.<br />Phosphorus: 31 mg = 1 mmoL.<br />Magnesium: 24 mg = 1 mmoL = 2 mEq.<br />Sodium: 23 mg = 1 mmoL = 1 mEq.<br />Potassium: 39 mg = 1 mmoL = 1 mEq.<br />Chloride: 35 mg = 1 mmoL = 1 mEq.<br />Vitamin A: 1 mcg retinol = 3.33 int. unit vitamin A = 6 mcg beta-carotene = 1.83 mcg retinyl palmitate = 1 retinol equivalent (RE).<br />Vitamin E: 1 mg alpha-tocopherol = 1 int. unit vitamin E.<br />Vitamin D: 1 mcg vitamin D (cholecalciferol) = 40 int. unit vitamin D (cholecalciferol).<br />Niacin: 1 mg niacin = 1 niacin equivalent (NE) = 60 mg tryptophan.</div><div class=\"graphic_footnotes\">* Vitamin K, 0.5 to 1 mg given at birth.</div><div class=\"graphic_reference\">Reproduced with permission from: Schanler RJ, Anderson D. The Low Birth-Weight Infant: Inpatient Care. In: Nutrition in Pediatrics, 4th ed, Duggan C, Watkins JB, Walker WA (Eds), BC Decker Inc, Hamilton, Ontario, Canada 2008 Copyright &copy; 2008 PMPH-USA, Ltd.</div><div id=\"graphicVersion\">Graphic 75039 Version 6.0</div></div></div>"},"75040":{"type":"graphic_figure","displayName":"Pleural pressure volume curves","title":"Pleural pressure volume curves","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Pleural pressure volume curves</div><div class=\"cntnt\"><img style=\"width:562px; height:416px;\" src=\"images/PULM/75040_Pleu_press_curve_trap_lung.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The solid circles represent a normal pressure/volume (P/V) curve of a patient with a hepatic hydrothorax, and a calculated Pel of 3 cm H<sub>2</sub>O/L. The open circles represent the P/V curve of an entrapped lung associated with malignancy. The elastance during the first 1250 mL is normal. After 1250 mL fluid is removed, the slope of the curve becomes very steep and has a calculated elastance of 22 cm H<sub>2</sub>O/L. The pressure/volume curve depicted by the solid triangles is from a patient with a trapped lung. The initial mean pleural liquid pressure is negative, and there is a steep slope throughout the entire thoracentesis. The calculated elastance is 216 cm H<sub>2</sub>O/L.</div><div class=\"graphic_reference\">From: Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764. Copyright Â© 2004. Reproduced with permission from the American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 75040 Version 7.0</div></div></div>"},"75041":{"type":"graphic_table","displayName":"Rapid overview acute decompensated heart failure","title":"Rapid overview: Acute decompensated heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Acute decompensated heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Differential diagnosis: Pulmonary embolism, acute asthma, pneumonia, noncardiogenic pulmonary edema (eg, adult respiratory distress syndrome), pericardial tamponade or constriction</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms and signs</td> </tr> <tr> <td>Acute dyspnea, orthopnea, tachypnea, tachycardia, and hypertension are common</td> </tr> <tr> <td>Hypotension reflects severe disease and arrest may be imminent; assess for inadequate peripheral or end-organ perfusion</td> </tr> <tr> <td>Accessory muscles are often used to breathe</td> </tr> <tr> <td>Diffuse pulmonary crackles are common; wheezing (cardiac asthma) may be present</td> </tr> <tr> <td>S3 is a specific sign but may not be audible; elevated jugular venous pressure and/or peripheral edema may be present</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic studies</td> </tr> <tr> <td>Obtain ECG: Look for evidence of ischemia, infarction, arrhythmia (eg, AF), and left ventricular hypertrophy</td> </tr> <tr> <td>Obtain portable chest radiograph: Look for signs of pulmonary edema, cardiomegaly, alternative diagnoses (eg, pneumonia); normal radiograph does not rule out ADHF</td> </tr> <tr> <td>Obtain: Complete blood count; cardiac troponin; electrolytes (Na<sup>+</sup>, K<sup>+</sup>, Cl-, HCO<sub>3</sub><sup>-</sup>); BUN and creatinine; arterial blood gas (if severe respiratory distress); liver function tests;&nbsp;BNP or NT-proBNP if diagnosis is uncertain</td> </tr> <tr> <td>Perform bedside echocardiography if the cardiac or valvular function is not known</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Monitor oxygen saturation, vital signs, and cardiac rhythm</td> </tr> <tr> <td>Provide supplemental oxygen if hypoxic <span style=\"font-size: 10px; font-family: AdvOTb7819099;\">(SpO<sub>2</sub>&#60;</span><span style=\"font-size: 10px; font-family: AdvOTb7819099;\">90%)âââââââââââââââââââââââââ</span><span style=\"font-size: 10px; font-family: AdvOTb7819099;\"></span>, place two IV catheters, and position patient upright</td> </tr> <tr> <td>Provide NIV as needed, unless immediate intubation is required or NIV is otherwise contraindicated; have airway management equipment readily available; etomidate is a good induction agent for rapid sequence intubation in ADHF</td> </tr> <tr> <td class=\"sublist1_start\"> <p>Initiate diuretic therapy without delay to relieve congestion/fluid overload:</p> <ul> <li>Give IV loop diuretic furosemide 40 mg IV or torsemide 20 mg IV; or bumetanide 1 mg IV </li> <li>Higher doses are needed for patients taking diuretics chronically (eg, twice home dose)&nbsp;and in patients with renal dysfunction </li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\">Search for cause of ADHF (including: acute coronary syndrome, hypertension, arrhythmia, acute aortic or mitral regurgitation, aortic dissection, sepsis, renal failure, anemia, or drugs) and treat appropriately.</td> </tr> <tr> <td class=\"sublist1\">Patients with ADHF and AF with rapid ventricular rate often require medication (eg, digoxin) to slow their heart rate</td> </tr> <tr> <td class=\"sublist1\"><span class=\"sublist1\">Direct</span> current cardioversion is indicated for patients with new onset AF and hemodynamic instability or refractory symptoms despite rate control.</td> </tr> <tr> <td class=\"sublist1\"><span class=\"sublist1_start\">Obtain<span class=\"sublist1\">â</span><span class=\"sublist1_start\">ââââ</span></span><span class=\"sublist1_start\"> immediate cardiac surgery <span class=\"sublist1\">consultation</span> for acute aortic or mitral regurgitation or ascending aortic dissection</span></td> </tr> <tr> <td class=\"sublist1_start\">For patients with adequate end-organ perfusion (eg, normal or elevated blood pressure) and signs of ADHF with fluid overload:</td> </tr> <tr> <td class=\"sublist1\">If urgent afterload reduction is required, consider early&nbsp;vasodilator therapy: Give nitroprusside*&nbsp;for severe hypertension, or if&nbsp;acute aortic regurgitation or acute mitral regurgitation is present; titrate rapidly to effect (eg, start nitroprusside at 5 to 10 mcg/min and titrate up every five minutes as tolerated to a dose range of 5 to 400 mcg/min). </td> </tr> <tr> <td class=\"sublist1\"> <p>If response to diuretics to treat congestion/fluid overload is inadequate, give vasodilator to reduce preload: Give IV nitroglycerin in addition to diuretic therapy if persistent dyspnea or as a component of therapy in refractory HF and low cardiac output.<sup>&#182;</sup></p> <p>Start nitroglycerin* infusion at 5 to 10 mcg/min and titrate every three to five minutes as needed and tolerated based upon&nbsp;mean arterial blood pressure&nbsp;or SBP to a dose range of 10 to 200 mcg/min.</p> </td> </tr> <tr> <td class=\"sublist1_start\">For patients with known systolic HF (eg, documented low ejection fraction) presenting with signs of severe ADHF and cardiogenic shock, discontinue chronic beta bocker therapy and: </td> </tr> <tr> <td class=\"sublist1\">Give an IV inotrope* (eg, dobutamine or milrinone) and/or mechanical support (eg, intraaortic balloon counter pulsation)</td> </tr> <tr> <td class=\"sublist1_start\">For patients with known diastolic HF (ie, preserved systolic function) presenting with signs of severe ADHF and cardiogenic shock:</td> </tr> <tr> <td class=\"sublist1\">Treat for possible left ventricular outflow obstruction with a beta blocker, IV fluid (unless pulmonary edema is present), and give an IV vasopressor* (eg, phenylephrine or norepinephrine); do not give an inotrope or vasodilator. Obtain immediate echocardiogram as needed.</td> </tr> <tr> <td class=\"sublist1\">Consider possibility of acute mitral or aortic regurgitation, or aortic dissection, and need for emergent surgical intervention. Obtain immediate echocardiogram as needed.</td> </tr> <tr> <td class=\"sublist1_start\">For patients whose cardiac status is unknown but present with signs of severe ADHF (ie, pulmonary edema) and hypotension or signs of shock:</td> </tr> <tr> <td class=\"sublist1\">Give an IV inotrope* (eg, dobutamine or milrinone), with or without an IV vasopressor (eg, norepinephrine) and assess need for&nbsp;mechanical support (eg, intraaortic balloon counter pulsation); obtain immediate echocardiogram as needed.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; AF: atrial fibrillation; ADHF: acute decompensated heart failure; BUN: blood urea nitrogen; BNP: brain natriuretic peptide; IV: intravenous; NIV: noninvasive ventilation.<br />* Patients receiving vasodilator, vasopressor, or inotrope infusions require continuous noninvasive monitoring of blood pressure, heart rate and function, and oxygen saturation. <br />Â¶ Treatment of patients with heart failure&nbsp;with reduced ejection fraction with volume overload unresponsive to diuretics is guided by hemodynamics, which&nbsp;are most commonly imputed from the physical examination with right heart catheterization performed when required for selected cases; refer to accompanying text and separate topic review of management of refractory heart failure.</div><div id=\"graphicVersion\">Graphic 75041 Version 6.0</div></div></div>"},"75042":{"type":"graphic_figure","displayName":"Technique for deep suture","title":"Technique for placing a dermal suture","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Technique for placing a dermal suture</div><div class=\"cntnt\"><img style=\"width:542px; height:308px;\" src=\"images/EM/75042_Technique_for_deep_suture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Absorbable suture material should be used for dermal sutures. The knot is buried by placing the suture using an inverted technique in which the suture loop begins in the dermis. The needle is directed toward the skin surface, exiting near the dermal-epidermal junction. It is then inserted into the opposite side of the wound directly across from the point of exit. The loop is completed in the dermis at the level where the needle was initially placed.</div><div id=\"graphicVersion\">Graphic 75042 Version 3.0</div></div></div>"},"75043":{"type":"graphic_table","displayName":"Syndromic immunodeficiency","title":"Syndromic immunodeficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Syndromic immunodeficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"17%\"></colgroup><colgroup width=\"32%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name of syndrome</td> <td class=\"subtitle1\">Primary defect</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Immune defect</td> <td class=\"subtitle1\">Associated features</td> </tr> <tr class=\"divider_bottom\"> <td>Acrodermatitis enteropathica</td> <td>Specific organ dysfunction</td> <td><em>SLC39A4</em></td> <td>T, B, Ph</td> <td>Vesiculobullous dermatitis, alopecia, diarrhea; caused by zinc deficiency, may be associated with opportunistic infections</td> </tr> <tr class=\"divider_bottom\"> <td>ARPC1B deficiency</td> <td>Specific organ dysfunction</td> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; line-height: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"><em>ARPC1B</em></span></td> <td>B, Ph</td> <td>Thrombocytopenia, vasculitis</td> </tr> <tr class=\"divider_bottom\"> <td>Ataxia-telangiectasia</td> <td>Chromosomal instability and/or defective DNA repair</td> <td><em>ATM</em></td> <td>T, B</td> <td>Progressive cerebellar ataxia, telangiectasias (conjunctival), choreoathetosis</td> </tr> <tr class=\"divider_bottom\"> <td>Ataxia-telangiectasia-like disorder</td> <td>Chromosomal instability and/or defective DNA repair</td> <td><em>MRE11A</em></td> <td>T, B</td> <td>Progressive cerebellar ataxia, choreoathetosis</td> </tr> <tr class=\"divider_bottom\"> <td>B cell immunodeficiency, distal limb anomalies, and urogenital malformations (BILU) syndrome (Hoffman syndrome)</td> <td>Specific organ dysfunction</td> <td>?</td> <td>B</td> <td>Limb defects, urogenital malformations</td> </tr> <tr class=\"divider_bottom\"> <td>Bloom syndrome</td> <td>Chromosomal instability and/or defective DNA repair</td> <td><em>BLM</em></td> <td>T, B, NK</td> <td>Short stature, telangiectatic erythema of face, sensitivity to sunlight, pneumonia, otitis media, risk for leukemia/lymphoma</td> </tr> <tr class=\"divider_bottom\"> <td>Branched chain amino acidemias</td> <td>Inborn errors of metabolism</td> <td><em>MUT, IVD, PCCA/PCCB</em></td> <td>T, B, Ph</td> <td>Methylmalonic propionic and isovaleric acidemias, acidosis, vomiting, ketosis</td> </tr> <tr class=\"divider_bottom\"> <td>Cartilage-hair hypoplasia</td> <td>Specific organ dysfunction</td> <td><em>RMRP</em></td> <td>T, B, Ph</td> <td>Metaphyseal dysplasia, fine/sparse hair</td> </tr> <tr class=\"divider_bottom\"> <td>CD4 lymphocytopenia</td> <td>Immune dysregulation</td> <td>?</td> <td>T (+/&ndash; B, NK)</td> <td>Malignancy (particularly lymphomas), autoimmune disorders</td> </tr> <tr class=\"divider_bottom\"> <td>CHARGE association</td> <td>Growth deficiency</td> <td><em>CHD7, SEMA3E</em></td> <td>T, B</td> <td>Coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness</td> </tr> <tr class=\"divider_bottom\"> <td>Congenital disorders of glycosylation, Types Ia, Ig, Ik</td> <td>Inborn errors of metabolism</td> <td><em>PMM2, ALG12, ALG1</em></td> <td>B, Ph</td> <td>Decreased glycosylation hypotonia, poor growth, other organ systems may be involved depending on the type</td> </tr> <tr class=\"divider_bottom\"> <td>Deletion of short arm of chromosome 4 (4p16) (Wolf-Hirschhorn syndrome)</td> <td>Chromosomal abnormalities of number or structure</td> <td>Chromosome 4p16 deletion</td> <td>B</td> <td>Growth and developmental deficiency, \"Greek helmet\"-like facies, microcephaly, coloboma, respiratory infections</td> </tr> <tr class=\"divider_bottom\"> <td>DiGeorge syndrome</td> <td>Chromosomal abnormalities of number or structure</td> <td><em>Del22q11, del10p13, TBX1</em></td> <td>T</td> <td>Aortic arch anomalies, hypocalcemia, thymic hypoplasia, cleft palate, facial dysmorphism</td> </tr> <tr class=\"divider_bottom\"> <td>Dyskeratosis congenita (DKC) - Autosomal dominant</td> <td>Specific organ dysfunction</td> <td><em>TERC, TERT, TINF2</em></td> <td>T, B, Ph</td> <td>Atrophy and pigmentation of skin, nail dystrophy, leukoplakia of oral mucosa</td> </tr> <tr class=\"divider_bottom\"> <td>Dyskeratosis congenita (DKC) - Autosomal recessive</td> <td>Specific organ dysfunction</td> <td><em>NHP2, NOP10, RTEL1</em></td> <td>T, B, Ph</td> <td>Atrophy and pigmentation of skin, nail dystrophy, leukoplakia of oral mucosa</td> </tr> <tr class=\"divider_bottom\"> <td>Facial dysmorphism, immunodeficiency, livedo, and short stature (FILS) syndrome</td> <td>Specific organ dysfunction</td> <td><em>POLE1</em></td> <td>T, B</td> <td>Facial dysmorphism, livedo, short stature</td> </tr> <tr class=\"divider_bottom\"> <td>Familial intestinal polyatresia</td> <td>Specific organ dysfunction</td> <td><em>TTC7A</em></td> <td>T, B</td> <td>Multiple atresias from pylorus to rectum</td> </tr> <tr class=\"divider_bottom\"> <td>Griscelli syndrome, type 2</td> <td>Specific organ dysfunction</td> <td><em>RAB27A</em></td> <td>T, B, NK, Ph</td> <td>Partial albinism, frequent pyogenic infections, lymphohistiocytosis, episodic thrombocytopenia</td> </tr> <tr class=\"divider_bottom\"> <td>Growth hormone pathway defects</td> <td>Growth deficiency</td> <td><em>BTK, STAT5B</em></td> <td>T, B, NK</td> <td>Defects in growth hormone synthesis or sensitivity deficiency, sinopulmonary infections</td> </tr> <tr class=\"divider_bottom\"> <td>Hepatic veno-occlusive disease with immunodeficiency (VODI)</td> <td>Specific organ dysfunction</td> <td><em>SP110</em></td> <td>T, B</td> <td>Hepatic veno-occlusive disease</td> </tr> <tr class=\"divider_bottom\"> <td>Hereditary folate malabsorption</td> <td>Specific organ dysfunction</td> <td><em>SLC46A1</em></td> <td>T, B</td> <td>Megaloblastic anemia, convulsions, movement disorder</td> </tr> <tr class=\"divider_bottom\"> <td>Hoyeraal-Hreidarsson syndrome</td> <td>Specific organ dysfunction</td> <td><em>DKC1</em></td> <td>T, B, Ph</td> <td>Cerebellar hypoplasia, absent corpus callosum, microcephaly, growth failure, pancytopenia, fungal sepsis</td> </tr> <tr class=\"divider_bottom\"> <td>Hyper-IgE syndrome - Autosomal dominant (Type 1, Job syndrome)</td> <td>Specific organ dysfunction</td> <td><em>STAT3</em></td> <td>T, B</td> <td>Eczema, scoliosis, bone fractures, joint hyperextensibility, coarse facies</td> </tr> <tr class=\"divider_bottom\"> <td>Hyper-IgE syndrome - Autosomal recessive (Type 2)</td> <td>Specific organ dysfunction</td> <td><em>DOCK8</em></td> <td>T, B</td> <td>Eczema, malignancy, CNS vasculitis/stroke</td> </tr> <tr class=\"divider_bottom\"> <td>Hyper-IgE syndrome variant</td> <td>Specific organ dysfunction</td> <td><em>TYK2</em></td> <td>T, B</td> <td>Eczema, mycobacterial infection</td> </tr> <tr class=\"divider_bottom\"> <td>Hyper-IgE syndrome variant</td> <td>Specific organ dysfunction</td> <td><em>PGM3</em></td> <td>T, B, Ph</td> <td>Eczema, developmental delay, myoclonus</td> </tr> <tr class=\"divider_bottom\"> <td>Hypohidrotic/anhidrotic ectodermal dysplasia with immunodeficiency</td> <td>Specific organ dysfunction</td> <td><em>NEMO/NFKBIA</em></td> <td>T, B</td> <td>Alopecia, hypohidrosis/anhydrosis, tooth anomalies, hypogammaglobulinemia</td> </tr> <tr class=\"divider_bottom\"> <td>ICF syndrome</td> <td>Chromosomal instability and/or defective DNA repair</td> <td><em>DNMT3B</em></td> <td>T, B</td> <td>Mental retardation, chromosomal instability, facial dysmorphism; sinopulmonary, gastrointestinal, cutaneous infections</td> </tr> <tr class=\"divider_bottom\"> <td>Ikaros deficiency</td> <td>Specific organ dysfunction</td> <td><em>IKZF1</em></td> <td>B, Ph, NK</td> <td>Pancytopenia</td> </tr> <tr class=\"divider_bottom\"> <td>Immunodeficiency with multiple intestinal atresia</td> <td>Specific organ dysfunction</td> <td><em>TTC7A</em></td> <td>T, B</td> <td>Multiple atresias from pylorus to rectum</td> </tr> <tr class=\"divider_bottom\"> <td>Incontinentia pigmenti</td> <td>Specific organ dysfunction</td> <td><em>NEMO</em></td> <td>T, B, Ph</td> <td>Erythematous vesiculobullous eruptions, CNS involvement, swirling of macules or hyperpigmentation</td> </tr> <tr class=\"divider_bottom\"> <td>Kabuki syndrome</td> <td>Growth deficiency</td> <td><em>KMT2D, KDM6A</em></td> <td>B</td> <td>Long palpebral fissures, prominent eyelashes, skeletal anomalies, congenital heart disease, increased risk of autoimmune diseases</td> </tr> <tr class=\"divider_bottom\"> <td>Loeys-Dietz syndrome</td> <td>Specific organ dysfunction</td> <td><em>TGFBR1</em></td> <td>B</td> <td>Aortic aneurysm, cleft palate, hypertelorism, eczema</td> </tr> <tr class=\"divider_bottom\"> <td>Lysinuric protein intolerance</td> <td>Inborn errors of metabolism</td> <td><em>SLC7A7</em></td> <td>T, B, NK, Ph</td> <td>Dibasic aminoaciduria, hepatomegaly, failure to thrive, severe varicella infection</td> </tr> <tr class=\"divider_bottom\"> <td>Minichromosome maintenance complex component 4 (MCM4) deficiency</td> <td>Specific organ dysfunction</td> <td><em>MCM4</em></td> <td>NK</td> <td>Growth failure, microcephaly, glucocorticoid deficiency</td> </tr> <tr class=\"divider_bottom\"> <td>Missing or abnormal X chromosome (Turner syndrome; XO, isoX, ring X)</td> <td>Chromosomal abnormalities of number or structure</td> <td>X chromosome abnormality</td> <td>T, B</td> <td>Short stature, webbed neck, broad chest, ovarian dysgenesis, congenital lymphedema, pulmonary/ear infections, autoimmune disease (eg, thyroid disease, celiac disease, arthritis), gonadoblastoma (if Y chromosome material present)</td> </tr> <tr class=\"divider_bottom\"> <td>MTHFD1 deficiency</td> <td>Specific organ dysfunction</td> <td><em>MTHFD1</em></td> <td>T, B</td> <td>Megaloblastic anemia, neurologic abnormalities, hemolytic uremic syndrome</td> </tr> <tr class=\"divider_bottom\"> <td>Myotonic dystrophy</td> <td>Specific organ dysfunction</td> <td><em>DMPK, ZNF9</em></td> <td>B</td> <td>Myotonia, muscle wasting, cataract, hypogonadism, cardiac arrhythmia; caused by triplet repeat expansion</td> </tr> <tr class=\"divider_bottom\"> <td>Netherton syndrome</td> <td>Specific organ dysfunction</td> <td><em>SPINK5</em></td> <td>T, B, Ph</td> <td>Trichorrhexis invaginata (bamboo hair), ichthyosiform dermatitis, atopic diathesis, skin infections</td> </tr> <tr class=\"divider_bottom\"> <td>Nijmegen breakage syndrome</td> <td>Chromosomal instability and/or defective DNA repair</td> <td><em>NBS1</em></td> <td>T, B</td> <td>Microcephaly, mental retardation, prenatal-onset short stature, bird-like facies, malignancy (lymphoma), sinopulmonary and urinary tract infections</td> </tr> <tr class=\"divider_bottom\"> <td>OLEDAID syndrome</td> <td>Specific organ dysfunction</td> <td><em>NEMO</em></td> <td>B</td> <td>Anhidrotic ectodermal dysplasia, osteopetrosis, lymphedema</td> </tr> <tr class=\"divider_bottom\"> <td>Omenn syndrome</td> <td>Specific organ dysfunction</td> <td><em>RAG1/RAG2/ARTEMIS</em></td> <td>T, B</td> <td>Erythematous dermatitis, eosinophilia, lymphadenopathy, hemophagocytosis, severe combined immunodeficiency</td> </tr> <tr class=\"divider_bottom\"> <td>Postmeiotic segregation increased 2 deficiency</td> <td>Specific organ dysfunction</td> <td><em>PMS2</em></td> <td>B</td> <td>Cancer, brain anomalies, caf&#233; au lait macules</td> </tr> <tr class=\"divider_bottom\"> <td>Radiosensitivity, immunodeficiency, dysmorphic features and learning difficulties (RIDDLE) syndrome</td> <td>Chromosomal instability and/or defective DNA repair</td> <td><em>RNF168</em></td> <td>B</td> <td>Characteristic facies, learning difficulties, radiosensitivity</td> </tr> <tr class=\"divider_bottom\"> <td>Roifman syndrome</td> <td>Growth deficiency</td> <td><em>RNU4ATAC</em></td> <td>B</td> <td>Short stature, spondyloepiphyseal dysplasia, developmental delay</td> </tr> <tr class=\"divider_bottom\"> <td>Rubinstein-Taybi syndrome</td> <td>Growth deficiency</td> <td><em>EP300</em></td> <td>T, B</td> <td>Broad thumbs and halluces, prominent nasal septum below ala nasi, cryptorchidism, mental retardation</td> </tr> <tr class=\"divider_bottom\"> <td>Schimke immunoosseous dysplasia</td> <td>Growth deficiency</td> <td><em>SMARCAL1</em></td> <td>T, B</td> <td>Spondyloepiphyseal dysplasia, progressive neuropathy, episodic lymphopenia, pigmentary skin changes</td> </tr> <tr class=\"divider_bottom\"> <td>Severe dermatitis, allergy, metabolic wasting (SAM) syndrome</td> <td>Specific organ dysfunction</td> <td><em>DSG1</em></td> <td>B</td> <td>Eczema, palmoplantar keratoderma, hypotrichosis</td> </tr> <tr class=\"divider_bottom\"> <td>Short-limb skeletal dysplasia with immunodeficiency</td> <td>Growth deficiency</td> <td><em>ADA</em>, others</td> <td>T, B</td> <td>Short-limb skeletal dysplasia, metaphyseal dysplasia; may be associated with adenosine deaminase deficiency or Omenn syndrome; heterogeneous</td> </tr> <tr class=\"divider_bottom\"> <td>Sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD)</td> <td>Specific organ dysfunction</td> <td><em>TRNT1</em></td> <td>B</td> <td>Sideroblastic microcytic anemia, periodic fever, developmental delay</td> </tr> <tr class=\"divider_bottom\"> <td>SPENCD1 syndrome</td> <td>Growth deficiency</td> <td><em>SPENCD1</em></td> <td>T, B</td> <td>Spondyloenchodrodysplasia, autoimmune conditions</td> </tr> <tr class=\"divider_bottom\"> <td>Transcobalamin II deficiency</td> <td>Specific organ dysfunction</td> <td><em>TCN2</em></td> <td>B</td> <td>Transport protein for B12; severe megaloblastic anemia, leukopenia, thrombocytopenia</td> </tr> <tr class=\"divider_bottom\"> <td>Trichohepatoenteric syndrome</td> <td>Specific organ dysfunction</td> <td><em>TTC37</em></td> <td>B, Ph</td> <td>Severe infantile diarrhea, hepatic cirrhosis, Trichorrhexis nodosa, characteristic facies</td> </tr> <tr class=\"divider_bottom\"> <td>Trisomy 21 (Down syndrome)</td> <td>Chromosomal abnormalities of number or structure</td> <td>Chromosome 21</td> <td>T, B, Ph, NK</td> <td>Hypotonia, flat facies, upslanting palpebral fissures, mental retardation, sinopulmonary infections, risk of leukemia, autoimmune thyroiditis</td> </tr> <tr class=\"divider_bottom\"> <td>WHIM syndrome</td> <td>Specific organ dysfunction</td> <td><em>CXCR4</em></td> <td>T, B, Ph</td> <td>Warts, hypogammaglobulinemia, infection, myelokathexis</td> </tr> <tr class=\"divider_bottom\"> <td>Wiskott-Aldrich syndrome</td> <td>Specific organ dysfunction</td> <td><em>WAS</em></td> <td>T, B</td> <td>Severe eczema, thrombocytopenia, bloody diarrhea, recurrent infection</td> </tr> <tr> <td>Wiskott-Aldrich syndrome protein-interacting protein (WIP) deficiency</td> <td>Specific organ dysfunction</td> <td><em>WIPF1</em></td> <td>T, B</td> <td>Severe eczema, thrombocytopenia, recurrent infection</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T: T cell defect; B: B cell defect; NK: natural killer cell defect; Ph: phagocyte defect; IgE: immunoglobulin E; CNS: central nervous system; CHARGE: coloboma, heart defect, atresia choanae, retarded growth and development, genital abnormality, and ear abnormality; ICF: immunodeficiency, centromeric instability, and facial anomalies; OLEDAID: osteopetrosis, lymphedema, ectodermal dysplasia, anhidrotic type, and immune deficiency; WHIM: warts, hypogammaglobulinemia, infection, and myelokathexis.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ming JE, Stiehm ER. Genetic syndromic immunodeficiencies with antibody defects. Immunol Allergy Clin North Am 2008; 28:715.</li>&#xD;&#xA;    <li>Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75043 Version 5.0</div></div></div>"},"75044":{"type":"graphic_figure","displayName":"Bence Jones protein immunofix","title":"Urinary monoclonal protein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urinary monoclonal protein</div><div class=\"cntnt\"><img style=\"width:341px; height:166px;\" src=\"images/HEME/75044_Bence_Jones_protein_immunof.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofixation of a concentrated urine specimen from the previous patient with antisera to kappa and lambda light chains shows a discrete lambda band, indicating a monoclonal lambda light chain (ie, Bence Jones protein of lambda specificity).</div><div id=\"graphicVersion\">Graphic 75044 Version 1.0</div></div></div>"},"75045":{"type":"graphic_figure","displayName":"Facial sinus PI","title":"Sinuses of the face","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Sinuses of the face</div><div class=\"cntnt\"><img style=\"width:524px; height:514px;\" src=\"images/PI/75045_Facial_sinus_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;drawing shows the sinuses of the face.</div><div id=\"graphicVersion\">Graphic 75045 Version 7.0</div></div></div>"},"75046":{"type":"graphic_table","displayName":"NURSE acronym","title":"NURSE acronym for dealing with strong emotions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NURSE acronym for dealing with strong emotions</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Acronym</td>\r\n                    <td class=\"subtitle1\">Request</td>\r\n                    <td class=\"subtitle1\">Example</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>N</td>\r\n                    <td>Name</td>\r\n                    <td>It sounds like you are frustrated</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>U</td>\r\n                    <td>Understanding</td>\r\n                    <td>I cannot imagine what it would be like to be in this situation</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>R</td>\r\n                    <td>Respect</td>\r\n                    <td>You are asking all the right questions and doing an amazing job of being an advocate for your husband</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>S</td>\r\n                    <td>Support</td>\r\n                    <td>I will be around to answer any of your questions</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>E</td>\r\n                    <td>Explore</td>\r\n                    <td>Tell me more about what you are thinking</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 75046 Version 2.0</div></div></div>"},"75048":{"type":"graphic_table","displayName":"Adult Stills laboratory tests","title":"Laboratory tests in adult Still's disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory tests in adult Still's disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Elevated ESR</td> <td>99 percent</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">WBC </td> </tr> <tr> <td class=\"sublist1\">&#8805; 10,000/mm<sup>3</sup></td> <td class=\"sublist_other\">92 percent </td> </tr> <tr> <td class=\"sublist1\">&#8805; 15,000/mm<sup>3</sup></td> <td class=\"sublist_other\">81 percent </td> </tr> <tr> <td>Neutrophils &#8805; 80 percent</td> <td>88 percent</td> </tr> <tr> <td>Serum Albumin &#8804;3.5 g/dL</td> <td>81 percent</td> </tr> <tr> <td>Elevated liver enzymes (any)</td> <td>73 percent</td> </tr> <tr> <td>Anemia (Hgb &#8804;10 g/dL)</td> <td>68 percent</td> </tr> <tr> <td>Platelets &#8805;400,000/mm<sup>3</sup></td> <td>62 percent</td> </tr> <tr> <td>Negative ANA</td> <td>92 percent</td> </tr> <tr> <td>Negative RF</td> <td>93 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Pouchot et al and Ohta et al.</div><div id=\"graphicVersion\">Graphic 75048 Version 2.0</div></div></div>"},"75049":{"type":"graphic_table","displayName":"Predictors of survival HF","title":"Adverse predictors of survival in patients with heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adverse predictors of survival in patients with heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n      <td>High New York Heart Association (NYHA) functional class</td>\n    </tr>\n\n    <tr>\n      <td>Reduced left ventricular ejection fraction</td>\n    </tr>\n\n    <tr>\n      <td>Diastolic dysfunction</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1_start\">Right ventricular dysfunction</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Reduced right ventricular ejection fraction</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Right ventricular enlargement</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Tricuspid regurgitation</td>\n    </tr>\n\n    <tr>\n      <td>Low peak VO2 with maximal exercise</td>\n    </tr>\n\n    <tr>\n      <td>Exercise hemodynamics</td>\n    </tr>\n\n    <tr>\n      <td>Resting sinus tachycardia</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1_start\">Signs of reduced tissue perfusion</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Low mean arterial pressure</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Renal insufficiency</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Neurohumoral activation</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Hyponatremia due to increased antidiuretic hormone secretion</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Increases in plasma renin, norepinephrine, brain natriuretic peptide, and big endothelin-1</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1_start\">Comorbid factors</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Diabetes mellitus</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Ischemic heart disease, including extent of coronary artery disease</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1_start\">Additional predictors</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Echocardiographic findings</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Hemodynamic parameters</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Increase in pulse pressure</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Low heart rate response to exercise</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Reduced heart rate variability</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Hematologic abnormalities</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Low lymphocyte percentage</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">White blood cell count above 7000/&#181;L in ischemic cardiomyopathy</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Erythrocyte sedimentation rate above 15 mm/h</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Other</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Left bundle branch block</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Depression</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Mutant allele of the adenosine monophosphate deaminase 1 gene</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Nocturnal Cheyne-Stokes respiration</td>\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">More than 30 apneic or hypopneic episodes per hour</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75049 Version 1.0</div></div></div>"},"75050":{"type":"graphic_diagnosticimage","displayName":"Retrograde urethrogram with moderate stricture","title":"Retrograde urethrogram with moderate stricture","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Retrograde urethrogram with moderate stricture</div><div class=\"cntnt\"><img style=\"width:468px; height:376px;\" src=\"images/SURG/75050_Retro_urethro_mod_strict.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75050 Version 2.0</div></div></div>"},"75053":{"type":"graphic_figure","displayName":"Ixodes nymph populations in US","title":"Nymphal Ixodes scapularis populations in the United States","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Nymphal Ixodes scapularis populations in the United States</div><div class=\"cntnt\"><img style=\"width:602px; height:535px;\" src=\"images/ID/75053_Tick_spp_population_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Predicted and observed density of infected host-seeking <em>Ixodes scapularis</em> nymphs (DIN)/1000 m<sup>2</sup>.</div><div class=\"graphic_reference\">Reproduced with permission from: Diuk-Wasser MA, Gatewood Hoen A, Cislo P, et al. Human Risk of Infection with Borrelia burgdorferi, the Lyme Disease Agent, in Eastern United States. Am J Trop Med Hyg 2012; 86:320. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 75053 Version 9.0</div></div></div>"},"75055":{"type":"graphic_picture","displayName":"Skin biopsy NSF Light II","title":"High power light micrograph of a skin biopsy from a patient with nephrogenic systemic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High power light micrograph of a skin biopsy from a patient with nephrogenic systemic fibrosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/NEPH/75055_Skin_biopsy_NSF_Light_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A high magnification image of the same skin biopsy shows collagen bundles (pink and red) and numerous elongated cells (blue nuclei).</div><div class=\"graphic_reference\">With permission from: Shawn E Cowper, MD.</div><div id=\"graphicVersion\">Graphic 75055 Version 3.0</div></div></div>"},"75057":{"type":"graphic_picture","displayName":"Erythroid hyperplasia","title":"Erythroid hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythroid hyperplasia</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/HEME/75057_Erythroid_hyperplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with chronic hemolytic anemia showing markedly increased numbers of red cell precursors (erythroid hyperplasia). The majority of the cells in this field are basophilic or polychromatophilic normoblasts, with varying degrees of darkly staining nuclear chromatin. (Wright-Giemsa stain).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 75057 Version 1.0</div></div></div>"},"75059":{"type":"graphic_picture","displayName":"Neonatal herpes simplex virus neck vesicles","title":"Neck vesicles in neonate with herpes simplex virus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neck vesicles in neonate with herpes simplex virus infection</div><div class=\"cntnt\"><img style=\"width:250px; height:239px;\" src=\"images/PEDS/75059_Neonatal_HSV_neck_vesicles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The early, untreated skin lesions associated with neonatal herpes simplex virus (HSV) infection are characteristically clear vesicles on an erythematous base, often touching or \"kissing,\" or coalesced in groups of vesicles. Culture of the clear fluid aspirated or swabbed from the vesicles will readily grow HSV in 24 to 48 hours, and slides made from cells scraped from the base of the lesion will show HSV viral antigens by direct immunofluorescence assay (DFA).</div><div class=\"graphic_reference\">Courtesy of Gail J Demmler-Harrison, MD, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 75059 Version 3.0</div></div></div>"},"75060":{"type":"graphic_table","displayName":"10th percentile by gestational age and sex","title":"Tenth percentile of birth weight (g) for gestational age by gender: United States, 1991, single live births to resident mothers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tenth percentile of birth weight (g) for gestational age by gender: United States, 1991, single live births to resident mothers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gestational age, weeks</td> <td class=\"subtitle1\">Male</td> <td class=\"subtitle1\">Female</td> </tr> <tr> <td>20</td> <td class=\"centered\">270</td> <td class=\"centered\">256</td> </tr> <tr> <td>21</td> <td class=\"centered\">328</td> <td class=\"centered\">310</td> </tr> <tr> <td>22</td> <td class=\"centered\">388</td> <td class=\"centered\">368</td> </tr> <tr> <td>23</td> <td class=\"centered\">446</td> <td class=\"centered\">426</td> </tr> <tr> <td>24</td> <td class=\"centered\">504</td> <td class=\"centered\">480</td> </tr> <tr> <td>25</td> <td class=\"centered\">570</td> <td class=\"centered\">535</td> </tr> <tr> <td>26</td> <td class=\"centered\">644</td> <td class=\"centered\">592</td> </tr> <tr> <td>27</td> <td class=\"centered\">728</td> <td class=\"centered\">662</td> </tr> <tr> <td>28</td> <td class=\"centered\">828</td> <td class=\"centered\">760</td> </tr> <tr> <td>29</td> <td class=\"centered\">956</td> <td class=\"centered\">889</td> </tr> <tr> <td>30</td> <td class=\"centered\">1117</td> <td class=\"centered\">1047</td> </tr> <tr> <td>31</td> <td class=\"centered\">1308</td> <td class=\"centered\">1234</td> </tr> <tr> <td>32</td> <td class=\"centered\">1521</td> <td class=\"centered\">1447</td> </tr> <tr> <td>33</td> <td class=\"centered\">1751</td> <td class=\"centered\">1675</td> </tr> <tr> <td>34</td> <td class=\"centered\">1985</td> <td class=\"centered\">1901</td> </tr> <tr> <td>35</td> <td class=\"centered\">2205</td> <td class=\"centered\">2109</td> </tr> <tr> <td>36</td> <td class=\"centered\">2407</td> <td class=\"centered\">2300</td> </tr> <tr> <td>37</td> <td class=\"centered\">2596</td> <td class=\"centered\">2484</td> </tr> <tr> <td>38</td> <td class=\"centered\">2769</td> <td class=\"centered\">2657</td> </tr> <tr> <td>39</td> <td class=\"centered\">2908</td> <td class=\"centered\">2796</td> </tr> <tr> <td>40</td> <td class=\"centered\">2986</td> <td class=\"centered\">2872</td> </tr> <tr> <td>41</td> <td class=\"centered\">3007</td> <td class=\"centered\">2891</td> </tr> <tr> <td>42</td> <td class=\"centered\">2998</td> <td class=\"centered\">2884</td> </tr> <tr> <td>43</td> <td class=\"centered\">2977</td> <td class=\"centered\">2868</td> </tr> <tr> <td>44</td> <td class=\"centered\">2963</td> <td class=\"centered\">2853</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the American College of Obstetricians and Gynecologists (Obstetrics and Gynecology, 1996; 87:163).</div><div id=\"graphicVersion\">Graphic 75060 Version 4.0</div></div></div>"},"75061":{"type":"graphic_algorithm","displayName":"Management algorithm for priapism","title":"Management algorithm for priapism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management algorithm for priapism</div><div class=\"cntnt\"><img style=\"width:265px; height:495px;\" src=\"images/PC/75061_Mgmtalgorithmpriapism.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced from: Montague, DK, Jarow, J, Broderick, GA, et al. American Urological Association Guideline on the Management of Priapism. J Urol 2003; 170:1318. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 75061 Version 3.0</div></div></div>"},"75064":{"type":"graphic_figure","displayName":"Leukotriene modifiers","title":"Leukotriene modifiers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukotriene modifiers</div><div class=\"cntnt\"><img style=\"width:434px; height:398px;\" src=\"images/ALLRG/75064_Leukotriene_modifiers.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Source cells include mast cells, eosinophils, basophils, and macrophages. Zileuton inhibits 5-lipoxygenase (5-LO), while montelukast, zafirlukast, and pranlukast are antagonists of the CysLT1 receptor.</div><div class=\"graphic_footnotes\">PLA<SUB>2</SUB>: phospholipase A<SUB>2</SUB>; AA: arachidonic acid; 5-LO: 5-lipoxygenase; FLAP: 5-LO activating protein; LTA<SUB>4</SUB>: leukotriene A<SUB>4</SUB>; LTA<SUB>4</SUB>H: LTA<SUB>4</SUB> hydrolase; LTC<SUB>4</SUB>S: LTC<SUB>4</SUB> synthetase; LTB<SUB>4</SUB>: leukotriene B<SUB>4</SUB> arises from the hydrolysis of LTA<SUB>4</SUB> by LTA<SUB>4</SUB> hydrolase; LTC<SUB>4</SUB>: leukotriene C<SUB>4</SUB> arises from the conjugation of LTA<SUB>4</SUB> with reduced glutathione by LTC<SUB>4</SUB> synthetase; LTD<SUB>4</SUB>: leukotriene D<SUB>4</SUB> arises from LTC<SUB>4</SUB> by the rapid removal of glutamic acid in the extracellular microenvironment; LTE<SUB>4</SUB>: leukotriene E<SUB>4</SUB> arises from LTD<SUB>4</SUB> by the further removal of glycine in the extracellular microenvironment; BLT1: receptor for LTB<SUB>4</SUB>, no commercially available inhibitors; BLT2: receptor for LTB<SUB>4</SUB>, no commercially available inhibitors; CysLTS: cys-leukotrienes, LTC<SUB>4</SUB>, LTD<SUB>4</SUB>, LTE<SUB>4</SUB>; CysLT1: receptor for LTC<SUB>4</SUB>, LTD<SUB>4</SUB>, LTE<SUB>4</SUB>, inhibited by montelukast, pranlukast, and zafirlukast; CysLT2: receptor for LTC<SUB>4</SUB>, LTD<SUB>4</SUB>, LTE<SUB>4</SUB>, but not inhibited by montelukast, pranlukast, or zafirlukast.</div><div id=\"graphicVersion\">Graphic 75064 Version 5.0</div></div></div>"},"75066":{"type":"graphic_picture","displayName":"Impetigo vesiculopustules","title":"Impetigo vesiculopustules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Impetigo vesiculopustules</div><div class=\"cntnt\"><img style=\"width:322px; height:213px;\" src=\"images/ID/75066_Impetigo_vesiculopustules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impetigo vesiculopustules with crusting.</div><div class=\"graphic_reference\">Courtesy of Larry M Baddour, MD.</div><div id=\"graphicVersion\">Graphic 75066 Version 1.0</div></div></div>"},"75067":{"type":"graphic_table","displayName":"Vaccine true contraindications","title":"True contraindications to vaccine administration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">True contraindications to vaccine administration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Safety concern</td> <td class=\"subtitle1\">Reason for contraindication and recommended action</td> </tr> <tr> <td>Previous anaphylactic reaction to a specific vaccine </td> <td>Avoid revaccination with the specific vaccine because of risk of recurrence.</td> </tr> <tr> <td>History of anaphylaxis to eggs or egg-protein</td> <td>Avoid measles, mumps, influenza and yellow-fever vaccine because these vaccines are prepared in embryonated chicken eggs or cultures and vaccines may contain residual egg protein.</td> </tr> <tr> <td>Previous anaphylactic reaction to neomycin or streptomycin</td> <td>Avoid measles, mumps, rubella (MMR) vaccine because the MMR vaccine contains trace amounts of neomycin.</td> </tr> <tr> <td>History of severe systemic reactions to the cholera, typhoid or plague vaccine</td> <td>Avoid revaccination with the specific vaccine because of risk of recurrence.</td> </tr> <tr> <td>Adults who are immunocompromised as a result of disease or its treatment</td> <td>Avoid live virus vaccines because there is an increased risk of viral replication in immunocompromised individual. (Refer to UpToDate topics on immunizations in patients with cancer and transplant recipients.)</td> </tr> <tr> <td>Household members of immunocompromised patients</td> <td>Avoid oral polio because vaccine induced disease (if it occurs) could be transmitted to the immunocompromised individual. This concern does not apply to the MMR vaccine because infection with vaccine strain measles, mumps or rubella is not transmitted to others. (Refer to UpToDate topic on polio vaccination.)</td> </tr> <tr> <td>Pregnant women</td> <td>Avoid all live virus vaccines because of the potential risk to the fetus. (Refer to UpToDate topic on immunizations during pregnancy.)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: American College Physicians Task Force on Adult Immunization and Infectious Diseases Society of America. Guide for adult immunization. Philadelphia. American College of Physicians, 1994; Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1994; 43:1; and Gershon, AA, Gardner, P, Peter, G, et al. Clin Infect Dis 1997; 25:782.</div><div id=\"graphicVersion\">Graphic 75067 Version 2.0</div></div></div>"},"75068":{"type":"graphic_figure","displayName":"Chronic versus acute tamponade","title":"Pericardial pressure in acute and chronic tamponade","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Pericardial pressure in acute and chronic tamponade</div><div class=\"cntnt\"><img style=\"width:483px; height:344px;\" src=\"images/CARD/75068_Chronic_vs_acute_tamponade.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Volume curves recorded from data acquired during pericardiocentesis. Curve A (in red) plots data from a patient with hyperacute tamponade that followed laceration of a coronary artery during an angioplasty-stenting procedure. Note the extreme elevation of pericardial pressure and that withdrawal of only 100 mL, half the volume we could aspirate, lowered the pressure to 10 mmHg. Curve B (in blue) plots data from a patient who had a history of prior pericarditis, assumed to be of viral etiology. Subsequently he developed a chronic pericardial effusion that reached at least 1500 mL in volume. At the time of presentation to our service, the jugular venous pressure was 22 mmHg. Aspiration of 300 mL of pericardial fluid reduced the pericardial pressure to 10 mmHg, and removing another 600 mL achieved a nearly normal pericardial pressure. Aspiration of the remaining large effusion did not affect pericardial pressure. The curves of cases of intermediate acuity or chronicity would fall between these two extremes.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 75068 Version 2.0</div></div></div>"},"75070":{"type":"graphic_figure","displayName":"Urine osmolality vs gravity","title":"Urine osmolality versus specific gravity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine osmolality versus specific gravity</div><div class=\"cntnt\"><img style=\"width:369px; height:230px;\" src=\"images/NEPH/75070_Urine_osmolality_vs_gravity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between the specific gravity and osmolality of the urine from normal subjects who have neither glucose nor protein in the urine. For comparison, the relationship between the specific gravity and osmolality for glucose solutions is included. Glucose is larger than the main solutes in normal urine such as sodium, potassium, ammonium, and urea; as a result, a glucose solution has a higher specific gravity at a given osmolality than normal urine.</div><div class=\"graphic_reference\">Data from Miles B, Paton A, deWardener H, Br Med J 1954; 2:904.</div><div id=\"graphicVersion\">Graphic 75070 Version 1.0</div></div></div>"},"75072":{"type":"graphic_figure","displayName":"Dientamoeba fragilis life cycle","title":"<em>Dientamoeba fragilis</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\"><em>Dientamoeba fragilis</em> life cycle</div><div class=\"cntnt\"><img style=\"width:538px; height:416px;\" src=\"images/ID/75072_D_fragilis_lifecycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The complete life cycle of this parasite has not yet been determined, but assumptions were made based on clinical data. To date, the cyst stage has not been identified in <em>D. fragilis</em> life cycle, and the trophozoite is the only stage found in stools of infected individuals <strong>(1)</strong>. <em>D. fragilis</em> is probably transmitted by fecal-oral route <strong>(2)</strong> and transmission via helminth eggs (eg, <em>Ascaris</em>, <em>Enterobius</em> spp) has been postulated <strong>(3)</strong>. Trophozoites of <em>D. fragilis</em> have characteristically one or two nuclei <strong>(1,4)</strong>, and it is found in children complaining of intestinal (eg, intermittent diarrhea, abdominal pain) and other symptoms (eg, nausea, anorexia, fatigue, malaise, poor weight gain).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Dientamoeba fragilis infection. Available at: <a href=\"http://www.cdc.gov/dpdx/dientamoeba/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/dientamoeba/index.html</a>.</div><div id=\"graphicVersion\">Graphic 75072 Version 8.0</div></div></div>"},"75073":{"type":"graphic_picture","displayName":"Examples of well-differentiated NETs of the digestive organs","title":"Examples of well-differentiated neuroendocrine tumors (NETs)Â of the digestive organs","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Examples of well-differentiated neuroendocrine tumors (NETs)&nbsp;of the digestive organs</div><div class=\"cntnt\"><img style=\"width:579px; height:435px;\" src=\"images/ONC/75073_WelldiffNETsdigestive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) EC (enterochromaffin) cell NET (carcinoid) of the terminal ileum shows solid tumor nest with peritumoral fibrosis.<br />(B) Pancreatic NET with ribbon-like pattern and wide tumor-free spaces in between.<br />(C) Pancreatic insulinoma shows abundant amyloid deposition.<br />(D) Periampullary somatostatinoma shows tubuloglandular pattern with numerous psamomma bodies. (H&amp;E, 400x original magnification.)</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin stained.</div><div id=\"graphicVersion\">Graphic 75073 Version 3.0</div></div></div>"},"75074":{"type":"graphic_picture","displayName":"Congenital histiocytosis","title":"Congenital self-healing reticulohistiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital self-healing reticulohistiocytosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75074_Congenital_histiocytosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red-brown papules are present on the trunk of this infant with congenital self-healing reticulohistiocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75074 Version 4.0</div></div></div>"},"75078":{"type":"graphic_diagnosticimage","displayName":"M mode aorta hypertrophic CM","title":"M-mode echocardiogram in hypertrophic cardiomyopathy with dynamic obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram in hypertrophic cardiomyopathy with dynamic obstruction</div><div class=\"cntnt\"><img style=\"width:386px; height:252px;\" src=\"images/CARD/75078_M_mode_aorta_hypertrophic_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In hypertrophic cardiomyopathy there is altered diastolic function, with slow left ventricle relaxation and left atrial (LA) emptying; the aortic (Ao) root diastolic motion is altered so that early rapid posterior motion is not seen until atrial contraction. This pattern is the counterpart of the a-wave dominant diastolic pattern seen by Doppler. The net forward motion of the Ao is adequate, but the timing and distribution have changed. The initial opening of the aortic valve (AV) is normal but shows a prominent midsystolic closure or notch, which coincides with the onset of subaortic obstruction induced by the systolic contact of the mitral valve with the septum; the AV often reopens for the second half of systole.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 75078 Version 3.0</div></div></div>"},"75079":{"type":"graphic_diagnosticimage","displayName":"Mediastinal goiter MRI II","title":"Mediastinal goiter on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal goiter on MRI</div><div class=\"cntnt\"><img style=\"width:242px; height:288px;\" src=\"images/PULM/75079_Mediastinal_goiter_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal T1-weighted section through a mediastinal goiter (long arrow) shows it to be contiguous with the left lobe of the thyroid (short arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75079 Version 2.0</div></div></div>"},"75082":{"type":"graphic_picture","displayName":"CyA induced arteriolar injury","title":"Light micrograph showing cyclosporine-induced arteriolopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing cyclosporine-induced arteriolopathy</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/75082_CyA_induced_arteriolar_inju.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of cyclosporine-induced renal arteriolopathy. There is replacement of smooth muscle cells in the media by proteinaceous material (arrowheads), eventually leading to virtual obliteration of the vascular lumen (arrow).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75082 Version 3.0</div></div></div>"},"75083":{"type":"graphic_diagnosticimage","displayName":"Extrarenal pelvis","title":"Extrarenal pelvis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extrarenal pelvis</div><div class=\"cntnt\"><img style=\"width:288px; height:258px;\" src=\"images/NEPH/75083_Extrarenal_pelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal sonogram of the right kidney. The extrarenal pelvis (arrow) appears as a dilated proximal ureter. The absence of calyceal dilatation and the fact that the remainder of the ureter is not dilated distinguish this as an extrarenal pelvis.</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 75083 Version 2.0</div></div></div>"},"75084":{"type":"graphic_figure","displayName":"Layers of amnion chorion","title":"LayersÂ within theÂ amnion and the chorion","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Layers&nbsp;within the&nbsp;amnion and the chorion</div><div class=\"cntnt\"><img style=\"width:545px; height:439px;\" src=\"images/OBGYN/75084_Layersofamnionchorion.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75084 Version 4.0</div></div></div>"},"75087":{"type":"graphic_picture","displayName":"Myelinated nerve fibers","title":"Peripapillary myelinated nerve fibers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripapillary myelinated nerve fibers</div><div class=\"cntnt\"><img style=\"width:282px; height:361px;\" src=\"images/PEDS/75087_Myelinated_nerve_fibers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The white color and feathery borders are characteristic findings.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 75087 Version 1.0</div></div></div>"},"75088":{"type":"graphic_diagnosticimage","displayName":"Benign patterns calcifica","title":"Benign patterns of calcifications","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benign patterns of calcifications</div><div class=\"cntnt\"><img style=\"width:294px; height:603px;\" src=\"images/PC/75088_Benign_calcifications.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular calcifications are seen in the lateral aspect of the breast on a CC mammogram (Panel A). Multiple coarse &quot;popcorn&quot; calcifications are characteristic features of calcifying fibroadenomas (Panel B). Bilateral benign secretory calcifications are seen in CC views of both breasts (Panels C and D). The cigar or rod shape is better seen on the magnification view (Panel E).</div><div class=\"graphic_footnotes\">CC: craniocaudal.</div><div id=\"graphicVersion\">Graphic 75088 Version 2.0</div></div></div>"},"75089":{"type":"graphic_waveform","displayName":"Flow waveforms mechanical vent","title":"Ventilator flow and pressure waveforms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventilator flow and pressure waveforms</div><div class=\"cntnt\"><img style=\"width:330px; height:145px;\" src=\"images/PULM/75089_Flow_waveforms_mechanical_v.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Airway pressure (Paw) and flow rate shown for constant, decelerating, and sinusoidal inspiratory flow waveforms. Inspiratory time and tidal volume were held constant. Peak inspiratory airway pressures are similar with all waveforms, but mean airway pressure is highest with the decelerating inspiratory flow wave.</div><div class=\"graphic_reference\">Redrawn from Banner, MJ, Lanpontang, S, In: Current Respiratory Care, Kacmarek, RM, Stoller, JK (Eds), BC Decker, Philadelphia, 1988.</div><div id=\"graphicVersion\">Graphic 75089 Version 2.0</div></div></div>"},"75092":{"type":"graphic_table","displayName":"Diagnostic criteria VWD","title":"Diagnostic test levels for von Willebrand disease (VWD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic test levels for von Willebrand disease (VWD)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Assay\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   VWD\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   \"Low\" VWD\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>von Willebrand factor: Ristocetin cofactor activity (VWF:RCo)</td>\r\n  \r\n   <td>&#60;30 IU/dL*</td>\r\n  \r\n   <td>30-50 IU/dL</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>von Willebrand factor Antigen (VWF:Ag)</td>\r\n  \r\n   <td>&#60;30 IU/dL*</td>\r\n  \r\n   <td>30-50 IU/dL</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Factor VIII</td>\r\n  \r\n   <td>Decreased or normal*</td>\r\n  \r\n   <td>Decreased or normal</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">VWD: von Willebrand disease; IU: International units<br> * In type 2N VWD, VWF:RCo and VWF:Ag levels are usually 30-200 IU/dL and factor VIII levels are &lt;10-15 IU/dL.</div><div class=\"graphic_reference\">Adapted from: The National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of Von Willebrand Disease. Bethesda, MD: National Institutes of Health Publication 08-5832, December 2007.</div><div id=\"graphicVersion\">Graphic 75092 Version 1.0</div></div></div>"},"75096":{"type":"graphic_table","displayName":"Issues urin div selection","title":"Issues affecting urinary diversion selection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Issues affecting urinary diversion selection</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Cancer control</td>\n\t    <td class=\"subtitle1\">General health</td>\n\t    <td class=\"subtitle1\">Technical</td>\n\t    <td class=\"subtitle1\">Quality of life</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Risk of local recurrence</td>\n\t    <td>Age</td>\n\t    <td>Functioning urethra</td>\n\t    <td>Compliance</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Previous pelvic radiation</td>\n\t    <td>Previous surgeries</td>\n\t    <td>Tumor location</td>\n\t    <td>Sexual function</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Need for adjuvant therapy</td>\n\t    <td>Renal/hepatic function</td>\n\t    <td>Ability to catheterize</td>\n\t    <td>Body image</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Secondary malignancies</td>\n\t    <td>Medical comorbidities</td>\n\t    <td>Mesentery length</td>\n\t    <td>Urinary function</td>\n\t  </tr>\n\t  <tr>\n\t    <td rowspan=\"2\">Urethral or bladder neck involvement</td>\n\t    <td>Status of gastrointestinal tract</td>\n\t    <td>Bowel condition</td>\n\t    <td>Family support</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Body habitus</td>\n\t    <td>Operative time</td>\n\t    <td>Daily maintenance</td>\n\t  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75096 Version 1.0</div></div></div>"},"75098":{"type":"graphic_diagnosticimage","displayName":"Fibrous pleural tumor I PA","title":"Fibrous tumor of the pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrous tumor of the pleura</div><div class=\"cntnt\"><img style=\"width:315px; height:324px;\" src=\"images/PULM/75098_FibrouspleuraltumorIPA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph shows a mass at the left base replacing the left lateral costophrenic sulcus.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75098 Version 3.0</div></div></div>"},"75100":{"type":"graphic_table","displayName":"Hormonal birth control PI","title":"Hormonal birth control","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hormonal birth control</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Using the method</td> <td class=\"subtitle1\">Some side effects and risks</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Implantable rod</strong></p> <p>Hormones it contains: Progestin</p> Expected pregnancies per 100 women in first year of use: Less than 1</td> <td> <p>Must be inserted by a doctor.</p> <p>Nothing to do or remember.</p> Lasts up to 3 years.</td> <td>Most common side effects: <ul> <li>Bleeding between periods </li> <li>Changes in periods </li> </ul> <br /> Other possible side effects: <ul> <li>Headache </li> <li>Acne </li> <li>Sore breasts </li> <li>Weight gain </li> <li>Mood changes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>IUD with progestin</strong></p> <p>Hormones it contains: Progestin</p> Expected pregnancies per 100 women in first year of use: Less than 1</td> <td> <p>Must be inserted by a doctor.</p> <p>Nothing to do or remember.</p> Lasts 3 to 5 years depending on type.</td> <td>Most common side effects: <ul> <li>Bleeding between periods </li> <li>Regular periods may stop </li> </ul> <br /> Other possible side effects: <ul> <li>Cramps </li> </ul> <br /> Potential but uncommon risks: <ul> <li>IUD can slip out </li> <li>IUD can damage the uterus </li> <li>Insertion of IUD can lead to a type of infection that can make it hard for a woman to get pregnant after the IUD is removed </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Shot/injection</strong></p> <p>Hormones it contains: Progestin</p> Expected pregnancies per 100 women in first year of use: 6</td> <td>Doctor or nurse must give you a shot every 3 months.</td> <td>Most common side effects: <ul> <li>Bleeding between periods </li> <li>Regular periods may stop </li> </ul> <br /> Other possible side effects: <ul> <li>Temporary bone thinning </li> <li>Weight gain </li> <li>Mood changes </li> <li>Hair loss or increased hair on face or body </li> <li>Sore breasts </li> <li>Headache </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Progestin-only pill</strong></p> <p>Hormones it contains: Progestin</p> Expected pregnancies per 100 women in first year of use: 9</td> <td>You must swallow a pill at the same time every day.</td> <td>Most common side effects: <ul> <li>Bleeding between periods (this is more common with progestin-only pills than with combined estrogen-progestin pills) </li> </ul> <br /> Other possible side effects: <ul> <li>Sore breasts </li> <li>Acne </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Combination estrogen-progestin pill</strong></p> <p>Hormones it contains: Progestin and estrogen</p> Expected pregnancies per 100 women in first year of use: 9</td> <td>You must swallow a pill every day.</td> <td>Most common side effects: <ul> <li>Bleeding between periods </li> <li>Decreased bleeding during period </li> </ul> <br /> Other possible side effects: <ul> <li>Nausea </li> <li>Changes in mood </li> </ul> <br /> Rare but serious risks include: <ul> <li>Heart attack </li> <li>Stroke </li> <li>Blood clots </li> <li>High blood pressure </li> <li>Liver tumors </li> <li>Gallstones </li> <li>Yellowing of the skin or eyes (jaundice) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Patch</strong></p> <p>Hormones it contains: Progestin and estrogen</p> Expected pregnancies per 100 women in first year of use: 9</td> <td>You must wear a patch on your skin all the time for 3 weeks. Every week, you change the patch. During the 4th week, you go without a patch.</td> <td>Side effects and risks similar to those of combined estrogen-progestin pills, but the patch causes higher average levels of estrogen than most pills. This may increase the risk of blood clots.<br /> <br /> Other possible side effects: <ul> <li>Skin irritation where patch is applied </li> </ul> </td> </tr> <tr> <td> <p><strong>Vaginal ring</strong></p> <p>Hormones it contains: Progestin and estrogen</p> Expected pregnancies per 100 women in first year of use: 9</td> <td>You must put the ring into your vagina and leave it in for 3 weeks. During the 4th week, you go without a ring.</td> <td>Side effects and risks similar to those of combined estrogen-progestin pill. (Breast soreness and nausea may be less than with the pill.)<br /> <br /> Other possible side effects: <ul> <li>Vaginal discharge or irritation </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The methods listed here all require a prescription. This table applies to women without medical problems, such as a history of cancer, blood clots, or liver disease. If you have any medical problems, ask your doctor or nurse whether you should avoid any type of hormonal birth control. If you are breastfeeding, mention that to your doctor or nurse when you choose birth control.</div><div class=\"graphic_footnotes\">IUD: intrauterine device.</div><div id=\"graphicVersion\">Graphic 75100 Version 5.0</div></div></div>"},"75101":{"type":"graphic_table","displayName":"Masculinizing effects in female-to-male transgender persons","title":"Masculinizing effects in female-to-male transgender persons","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Masculinizing effects in female-to-male transgender persons</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Effect</td> <td class=\"subtitle1\">Onset (months)*</td> <td class=\"subtitle1\">Maximum (years)*</td> </tr> <tr> <td>Skin oiliness/acne</td> <td>1 to 6</td> <td>1 to 2</td> </tr> <tr> <td>Facial/body hair growth</td> <td>6 to 12</td> <td>4 to 5</td> </tr> <tr> <td>Scalp hair loss</td> <td>6 to 12</td> <td>&#182;</td> </tr> <tr> <td>Increased muscle mass/strength</td> <td>6 to 12</td> <td>2 to 5</td> </tr> <tr> <td>Fat redistribution</td> <td>1 to 6</td> <td>2 to 5</td> </tr> <tr> <td>Cessation of menses</td> <td>2 to 6</td> <td>&#916;</td> </tr> <tr> <td>Clitoral enlargement</td> <td>3 to 6</td> <td>1 to 2</td> </tr> <tr> <td>Vaginal atrophy</td> <td>3 to 6</td> <td>1 to 2</td> </tr> <tr> <td>Deepening of voice</td> <td>6 to 12</td> <td>1 to 2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Estimates represent clinical observations.<br />Â¶ Prevention and treatment as recommended for biological men.<br />Î Menorrhagia requires diagnosis and treatment by a gynecologist.</div><div class=\"graphic_reference\">Reproduced with permission from: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132. Copyright &copy; 2009 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 75101 Version 8.0</div></div></div>"},"75104":{"type":"graphic_picture","displayName":"Abscess fistulas and skin tags","title":"Anal fistulas and abscess in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anal fistulas and abscess in Crohn disease</div><div class=\"cntnt\"><img style=\"width:386px; height:252px;\" src=\"images/GAST/75104_Abscess_fistulas_and_skin_t.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows anterior perianal fistulas involving the vulva and anterior perineum (arrows) in a woman with Crohn disease being prepared for surgery. The surrounding skin is erythematous and indurated. An abscess (arrowhead) appears as a localized swelling. Hypertrophic skin tags (dashed arrows) in the anal canal are commonly observed in perianal Crohn disease and may be confused with external hemorrhoids.</div><div class=\"graphic_reference\">Courtesy of Alain Bitton, MD, FRCPC.</div><div id=\"graphicVersion\">Graphic 75104 Version 4.0</div></div></div>"},"75105":{"type":"graphic_table","displayName":"Chronic pancreatitis terms","title":"Endosonographic criteria and definitions of chronic pancreatitis (CP) and presumed histologic correlates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endosonographic criteria and definitions of chronic pancreatitis (CP) and presumed histologic correlates</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">EUS criteria for CP</td>\n<td class=\"subtitle1\">MST definition*</td>\n<td class=\"subtitle1\">Histological correlate</td>\n</tr>\n<tr>\n<td>Hyperechoic foci</td>\n<td>Small distinct reflectors</td>\n<td>Focal fibrosis</td>\n</tr>\n<tr>\n<td>Hyperechoic strand</td>\n<td>Small string-like hyperechoic structures</td>\n<td>Bridging fibrosis</td>\n</tr>\n<tr>\n<td>Lobular out gland margin</td>\n<td>No MST definition</td>\n<td>Fibrosis, glandular atrophy</td>\n</tr>\n<tr>\n<td>Lobularity</td>\n<td>Containing lobules-rounded homogeneous areas separated by strands of another echogenicity</td>\n<td>Interlobular fibrosis</td>\n</tr>\n<tr>\n<td>Cyst</td>\n<td>Abnormal anechoic round or oval structure</td>\n<td>Cysts/pseudocysts</td>\n</tr>\n<tr>\n<td>Stone</td>\n<td>Hyperechoic lesion with acoustic shadowing within a duct or gallbladder</td>\n<td>Calcified stones</td>\n</tr>\n<tr>\n<td>Calcification</td>\n<td>Hyperechoic lesion with acoustic shadow within a parenchymal organ or a mass</td>\n<td>Parenchymal calcification</td>\n</tr>\n<tr>\n<td>Ductal dilation</td>\n<td>No MST definition</td>\n<td>&#62;3 mm in head, &#62;2 mm in body, &#62;1 mm in tail</td>\n</tr>\n<tr>\n<td>Side branch dilation</td>\n<td>No MST definition</td>\n<td>Side branch dilation</td>\n</tr>\n<tr>\n<td>Duct irregularity</td>\n<td>Coarse, uneven outline of the duct</td>\n<td>Focal dilation/narrowing</td>\n</tr>\n<tr>\n<td>Hyperechoic duct margins</td>\n<td>No MST definition</td>\n<td>Periductal fibrosis</td>\n</tr>\n<tr>\n<td>Atrophy</td>\n<td>No MST definition</td>\n<td>Atrophy</td>\n</tr>\n<tr>\n<td>Inhomogeneous echo pattern</td>\n<td>No MST definition</td>\n<td>Edema</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Minimum Standard Terminology version 1.0. </div><div class=\"graphic_reference\">Dig Endosc 1998;10:158-184.</div><div id=\"graphicVersion\">Graphic 75105 Version 1.0</div></div></div>"},"75106":{"type":"graphic_figure","displayName":"Coronary heart disease mortality related to BP and age","title":"Coronary heart disease mortality related to blood pressure and age","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Coronary heart disease mortality related to blood pressure and age</div><div class=\"cntnt\"><img style=\"width:574px; height:415px;\" src=\"images/NEPH/75106_CHD_mortality_v_BP_and_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronary heart disease (CHD) mortality rate, pictured on a log scale with 95% confidence intervals (CI), in each decade of age in relation to the estimated usual systolic and diastolic blood pressure at the start of that decade. CHD mortality increases with both higher pressures and older ages. For diastolic pressure, each age-specific regression line ignores the left-hand point (ie, at slightly less than 75 mmHg) for which the risk lies significantly above the fitted regression line (as indicated by the broken line below 75 mmHg).</div><div class=\"graphic_footnotes\">IHD: ischemic heart disease.</div><div class=\"graphic_reference\">Reproduced from: Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903. Illustration used with the permission of Elsevier. All rights reserved.</div><div id=\"graphicVersion\">Graphic 75106 Version 9.0</div></div></div>"},"75107":{"type":"graphic_table","displayName":"Exercise prescription","title":"Exercise prescription for endurance and resistance training for cardiovascular fitness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Exercise prescription for endurance and resistance training for cardiovascular fitness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Endurance training</td> </tr> <tr> <td>Frequency</td> <td>Three to five days per week</td> </tr> <tr> <td>Intensity</td> <td>55 to 90% maximum HR or 40 to 85% maximum VO2&nbsp;or HRR</td> </tr> <tr> <td>Duration</td> <td>20 to 60 minutes</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Modality</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"3\">Lower extremity</td> <td class=\"sublist_other\">Walking</td> </tr> <tr> <td class=\"sublist_other\">Jogging/running</td> </tr> <tr> <td class=\"sublist_other\">Stairclimber</td> </tr> <tr> <td class=\"sublist1\">Upper extremity</td> <td class=\"sublist_other\">Arm ergometry</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"5\">Combined</td> <td class=\"sublist_other\">Rowing</td> </tr> <tr> <td class=\"sublist_other\">Cross-country ski machine</td> </tr> <tr> <td class=\"sublist_other\">Combined arm/leg cycle</td> </tr> <tr> <td class=\"sublist_other\">Swimming</td> </tr> <tr> <td class=\"sublist_other\">Aerobics</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Resistance training</td> </tr> <tr> <td>Frequency</td> <td>Two to three days per week</td> </tr> <tr> <td>Intensity</td> <td>One to three&nbsp;sets of 8 to 15 RM for each muscle group</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Modality</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"2\">Lower extremity</td> <td class=\"sublist_other\">Leg extensions, curls, presses</td> </tr> <tr> <td class=\"sublist_other\">Adductors/abductors</td> </tr> <tr> <td class=\"sublist1\" rowspan=\"5\">Upper extremity</td> <td class=\"sublist_other\">Biceps curls</td> </tr> <tr> <td class=\"sublist_other\">Triceps extensions</td> </tr> <tr> <td class=\"sublist_other\">Bench/overhead presses</td> </tr> <tr> <td class=\"sublist_other\">Lateral pulldowns/raises</td> </tr> <tr> <td class=\"sublist_other\">Benchovers/seated rowing</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Modalities listed here are not all-inclusive.<br />HR indicates 220 minus age or peak HR on exercise test.<br />HRR = peak HR&nbsp;minus resting HR; goal intensity is 40 to 85% of the HRR added to the resting HR.</div><div class=\"graphic_footnotes\">HR: heart rate; VO2: measured oxygen intake; HRR: heart rate reserve;&nbsp;RM: maximum number of times a load can be lifted before fatigue.</div><div class=\"graphic_reference\">Data from: Shephard RJ, Balady GJ. Circulation 1999; 99:963.</div><div id=\"graphicVersion\">Graphic 75107 Version 9.0</div></div></div>"},"75108":{"type":"graphic_picture","displayName":"Cochlear histology","title":"Cochlear embryology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cochlear embryology</div><div class=\"cntnt\"><img style=\"width:326px; height:279px;\" src=\"images/PEDS/75108_Cochlear_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This axial histologic section of the temporal bone at&nbsp;nine weeks' gestation demonstrates the rudimentary vestiblule (v) and cochlea (c), with only one turn.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 75108 Version 2.0</div></div></div>"},"75109":{"type":"graphic_figure","displayName":"Lesion complexity in UA","title":"Determinants of coronary lesion complexity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Determinants of coronary lesion complexity</div><div class=\"cntnt\"><img style=\"width:370px; height:210px;\" src=\"images/CARD/75109_Lesion_complexity_in_UA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lesion complexity (0 = no obstruction; 1 = simple stenosis; 2 = complex stenosis; 3 = thrombus; 4 = total occlusion) is related in an additive fashion to the clinical setting (worst in post-myocardial infarction) and to the severity and timing of the last anginal episode in patients wit unstable angina (UA).</div><div class=\"graphic_footnotes\">Severe class I: unstable angina without pain at rest; class II: pain at rest more than 48 hours before angiography; class III: pain at rest less than 48 hours before angiography.</div><div class=\"graphic_reference\">Data from Ahmed WH, Bittl JA, Braunwald E. Am J Cardiol 1993; 72:544.</div><div id=\"graphicVersion\">Graphic 75109 Version 2.0</div></div></div>"},"75110":{"type":"graphic_table","displayName":"DSM-IV-TR diagnostic criteria for anorexia nervosa","title":"DSM-IV-TR diagnostic criteria for anorexia nervosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV-TR diagnostic criteria for anorexia nervosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Refusal to maintain body weight at or above a minimally normal weight for age and height (eg, weight loss or failure to gain weight that leads to a body weight less than 85 percent of that expected for age and height).</td> </tr> <tr> <td>Intense fear of gaining weight or becoming fat, even though underweight.</td> </tr> <tr> <td>Disturbed perception of one's body weight or shape, undue influence of weight or shape on self-evaluation, or denial of the seriousness of the current low body weight.</td> </tr> <tr> <td>In postmenarcheal females, amenorrhea, ie, absence of at least three consecutive menstrual cycles. Menstruation that occurs only after hormonal treatment, eg, estrogen, is considered amenorrhea.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58518&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Adapted from: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Text Revision, Washington, DC 2000.</div><div id=\"graphicVersion\">Graphic 75110 Version 7.0</div></div></div>"},"75111":{"type":"graphic_figure","displayName":"Waldeyer's ring","title":"Waldeyer's ring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Waldeyer's ring</div><div class=\"cntnt\"><img style=\"width:390px; height:347px;\" src=\"images/PC/75111_Waldeyers_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Waldeyer's ring is the ring of lymphoid tissue in the pharynx formed by the palatine tonsils, pharyngeal tonsils, tubal tonsils, and lingual tonsils.</div><div id=\"graphicVersion\">Graphic 75111 Version 2.0</div></div></div>"},"75112":{"type":"graphic_table","displayName":"Classification of acute extremity ischemia","title":"Classification of acute extremity ischemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of acute extremity ischemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Viable</td>\n\n      <td class=\"subtitle1\">Threatened</td>\n\n      <td class=\"subtitle1\">Nonviable</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left_single\">Pain</td>\n\n      <td>Mild</td>\n\n      <td>Severe</td>\n\n      <td>Variable</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left_single\">Capillary\nrefill</td>\n\n      <td>Intact</td>\n\n      <td>Delayed</td>\n\n      <td>Absent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left_single\">Motor\ndeficit</td>\n\n      <td>None</td>\n\n      <td>Partial</td>\n\n      <td>Complete</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left_single\">Sensory\ndeficit</td>\n\n      <td>None</td>\n\n      <td>Partial</td>\n\n      <td>Complete</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left_single\">Arterial\nDoppler</td>\n\n      <td>Audible</td>\n\n      <td>Inaudible</td>\n\n      <td>Inaudible</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left_single\">Venous\nDoppler</td>\n\n      <td>Audible</td>\n\n      <td>Audible</td>\n\n      <td>Inaudible</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left_single\">Treatment</td>\n\n      <td>Urgent work-up</td>\n\n      <td>Emergency surgery</td>\n\n      <td>Amputation</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">From Rutherford RB, Semin Vasc Surg 1992; 5:4.</div><div id=\"graphicVersion\">Graphic 75112 Version 3.0</div></div></div>"},"75115":{"type":"graphic_diagnosticimage","displayName":"Achalasia PA Lat","title":"Achalasia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Achalasia</div><div class=\"cntnt\"><img style=\"width:432px; height:246px;\" src=\"images/GAST/75115_Achalasia_PA_Lat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PA and lateral chest x-rays from a patient with achalasia. The major findings are a widened mediastinum caused by the dilated esophagus, an air-fluid level in the upper chest due to retained fluid in the dilated esophagus (arrows), and absence of the gastric air bubble.</div><div class=\"graphic_reference\">Reproduced, courtesy of the Clinical Teaching Project of the American Gastroenterological AssociationÂ©. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 75115 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"75116":{"type":"graphic_table","displayName":"Biliary complic post LT","title":"Biliary complications after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biliary complications after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Bile leaks and biloma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Strictures</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Anastomotic</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Nonanastomotic</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Diffuse intrahepatic</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Common bile duct filling defects</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Stones</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Sludge</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Casts</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Sphincter of Oddi dysfunction</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Other complications</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Hemobilia </td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Mucocele</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Bactobilia</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Andres C&#225;rdenas, MD, MMSc.</div><div id=\"graphicVersion\">Graphic 75116 Version 1.0</div></div></div>"},"75119":{"type":"graphic_table","displayName":"Airway stent complications","title":"Airway stent-related complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Airway stent-related complications</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Complications</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Displacement</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mucus impaction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Granuloma formation at stent ends</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Obstruction from tumor or granuloma (uncovered stents)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Halitosis and chronic infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Perforation of airway wall</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemoptysis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pain</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cough</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Airway fire during laser resection</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Bolliger, CT, Mathur, PN, Beamis, JF, et al. Eur Respir J 2002; 19:365. Copyright &#169; 2002 European Respiratory Society Journals Ltd.</div><div id=\"graphicVersion\">Graphic 75119 Version 1.0</div></div></div>"},"75120":{"type":"graphic_figure","displayName":"Femoral artery anatomy","title":"Femoral artery anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Femoral artery anatomy</div><div class=\"cntnt\"><img style=\"width:284px; height:426px;\" src=\"images/PULM/75120_Femoral_artery_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the relationship of the common femoral artery to the femoral vein and femoral nerve.</div><div id=\"graphicVersion\">Graphic 75120 Version 1.0</div></div></div>"},"75123":{"type":"graphic_picture","displayName":"Multiple bedbug bites","title":"Bedbug bites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bedbug bites</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75123_Multiple_bedbug_bites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules on the trunk of a patient with bedbug bites.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" style=\"font-style: italic;\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75123 Version 7.0</div></div></div>"},"75124":{"type":"graphic_figure","displayName":"Ulnar nerve distribution","title":"Ulnar nerve distribution","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Ulnar nerve distribution</div><div class=\"cntnt\"><img style=\"width:458px; height:608px;\" src=\"images/NEURO/75124_Ulnar_nerve_distribution.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of the ulnar nerve and the muscles which it supplies.</div><div class=\"graphic_reference\">Reproduced from: Aids to the examination of the peripheral nervous system. The Guarantors of Brain. London: Bailliere Tindall, 1986. Illustration used with the permission of Elseiver Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 75124 Version 1.0</div></div></div>"},"75125":{"type":"graphic_picture","displayName":"Rash in erythema infectiosum","title":"Erythema infectiosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema infectiosum</div><div class=\"cntnt\"><img style=\"width:383px; height:252px;\" src=\"images/ID/75125_Rash_in_erythema_infectiosu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticulated blanching erythema on the extremities due to parvovirus B19. Rash is more common in children. The presence of intense erythema (a slapped cheek appearance) on the face is highly characteristic.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 75125 Version 7.0</div></div></div>"},"75126":{"type":"graphic_figure","displayName":"Repair median episiotomy","title":"Repair of a median episiotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a median episiotomy</div><div class=\"cntnt\"><img style=\"width:399px; height:589px;\" src=\"images/OBGYN/75126_Repair_median_episiotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. 2nd degree median episiotomy B. The vaginal epithelium to just outside the hymenal ring is reapproximated first. C. The perineal body and bulbocavernosus muscle are then reapproximated with intermittent or continuous sutures. The perineal skin can be reapproximated with a continuous running subcuticular suture D. Completed repair.</div><div id=\"graphicVersion\">Graphic 75126 Version 1.0</div></div></div>"},"75128":{"type":"graphic_figure","displayName":"Apical 4 chamber LA volume by planimetry","title":"Planimetry of the left atrium for volume calculation from the apical 4 chamber view","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Planimetry of the left atrium for volume calculation from the apical 4 chamber view</div><div class=\"cntnt\"><img style=\"width:479px; height:216px;\" src=\"images/CARD/75128_LA_volume_4_chamber_planime.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An end-systolic freeze-frame image from the four chamber view is used to obtain maximum left atrial (LA) volume; panel A is a schematic of the structures imaged and panel B is the actual echocardiogram. The lines shown within the LA in panel C were generated by a light pen digitizing system that allows calculation of a single plane (area-length) volume from the outline shown or the combination of this area-length outline to calculate atrial volume by a modified Simpson's rule or method of discs.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle; RA: right atrium; tv: tricuspid valve; pv: pulmonic valve; R: right; L: left; A: apex; B: base.</div><div id=\"graphicVersion\">Graphic 75128 Version 3.0</div></div></div>"},"75129":{"type":"graphic_algorithm","displayName":"Congenic breeding scheme","title":"Recombinant congenic breeding scheme","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Recombinant congenic breeding scheme</div><div class=\"cntnt\"><img style=\"width:488px; height:515px;\" src=\"images/PC/75129_Congenic_breeding_scheme.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">RC breeding scheme. Donor strain genetic material is shown in white and recipient genetic material is shown in black. There are 2 stages in the RC breeding program. The behavior of a schematic autosome pair is depicted during each of these stages. Stage 1 consists of repeated backcrosses to the recipient strain, so as to reduce the donor contribution to the genotype. There is no selection for donor alleles. Stage 2 occurs as independent sib-pairs from the second backcross generation are used to establish new inbred strains, with full-sib matings at each gneration. Inbreeding fixes the genotype of the strain, with most loci becoming homozygous by the 12th generation. The resulting array of genotypes is shown schematically at the bottom of the figure. Only 1 copy of the schematic autosome from each strain in the set is shown. The donor contributions in each strain in the set are map loci contributing to continuously varying traits and eliminates the need for genotyping to achieve the resolution achieved by QTL quantitatively similar, but the specific chromosome regions of donor genotype will differ from one strain to another.</div><div class=\"graphic_reference\">Adapted from: Demant P, Hart AA. Immunogenetics 1986; 24:416.</div><div id=\"graphicVersion\">Graphic 75129 Version 3.0</div></div></div>"},"75131":{"type":"graphic_figure","displayName":"Course of thyroiditis","title":"Characteristic course of thyroiditis (painless, postpartum, or subacute)","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Characteristic course of thyroiditis (painless, postpartum, or subacute)</div><div class=\"cntnt\"><img style=\"width:511px; height:324px;\" src=\"images/ENDO/75131_Course_of_thyroiditis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial thyroid inflammation damages thyroid follicles and activates proteolysis of the thyroglobulin stored within the follicles. The result is <STRONG>unregulated</STRONG> release of large amounts of T4 and T3 into the circulation and, therefore, hyperthyroidism. This state lasts only until the stores of thyroglobulin are exhausted because new hormone synthesis ceases. As the inflammation subsides, the thyroid follicles regenerate and thyroid hormone synthesis and secretion resume. There may be a transient period of hypothyroidism and increased TSH secretion before thyroid secretion becomes normal again. However, some patients have only a hyperthyroid or hypothyroid phase.</div><div class=\"graphic_footnotes\">T4: thyroxine; T3: triiodothyronine; RAI: radioiodine;&nbsp;TSH: thyroid-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 75131 Version 4.0</div></div></div>"},"75133":{"type":"graphic_picture","displayName":"Barretts esophagectomy Gross","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:231px; height:432px;\" src=\"images/GAST/75133_Barretts_esophagectomy_Gros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Esophagectomy specimen in a patient found to have high-grade dysplasia during endoscopic surveillance. Salmon-colored Barrett's mucosa has replaced the squamous mucosa circumferentially. Scattered erosions are visible (arrows).</div><div class=\"graphic_reference\">From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 75133 Version 3.0</div></div></div>"},"75134":{"type":"graphic_diagnosticimage","displayName":"Diverticular abscess CT","title":"Diverticular abscess of the sigmoid colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diverticular abscess of the sigmoid colon</div><div class=\"cntnt\"><img style=\"width:362px; height:288px;\" src=\"images/GAST/75134_Diverticular_abscess_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single axial CT scan of the pelvis demonstrates an abscess surrounding and compressing the sigmoid colon (arrow) which is markedly narrowed. There is a small amount of gas within the abscess (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 75134 Version 3.0</div></div></div>"},"75135":{"type":"graphic_table","displayName":"PP family receptor subtypes","title":"Pancreatic polypeptide family receptor subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pancreatic polypeptide family receptor subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Receptor</td> <td class=\"subtitle1\">Size</td> <td class=\"subtitle1\">Location</td> </tr> <tr> <td>Y1</td> <td>384 aa</td> <td>Hypothalamus</td> </tr> <tr> <td>Y2</td> <td>381 aa</td> <td>Brain, hippocampus</td> </tr> <tr> <td>Y3</td> <td>NA</td> <td>Brainstem</td> </tr> <tr> <td>Y4</td> <td>375 aa</td> <td>Colon, intestine</td> </tr> <tr> <td>Y5</td> <td>455 aa</td> <td>Hypothalamus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">aa: number of amino acids; NA: not available.</div><div id=\"graphicVersion\">Graphic 75135 Version 3.0</div></div></div>"},"75136":{"type":"graphic_figure","displayName":"ACE inhibitor in LV dysfunction","title":"Enalapril improves outcome in asymptomatic LV dysfunction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enalapril improves outcome in asymptomatic LV dysfunction</div><div class=\"cntnt\"><img style=\"width:397px; height:233px;\" src=\"images/CARD/75136_ACE_inhibitor_in_LV_dysfunc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the SOLVD prevention trial of 4228 patients (83 percent post-MI) with asymptomatic left ventricular dysfunction, prophylactic administration of enalapril reduced the probability of death or heart failure (p&lt;0.001).</div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; LV: left ventricular; MI: myocardial infarction.</div><div class=\"graphic_reference\">Data from: The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685.</div><div id=\"graphicVersion\">Graphic 75136 Version 5.0</div></div></div>"},"75137":{"type":"graphic_figure","displayName":"X-linked dominant pedigree","title":"Example of a pedigree showing X-linked dominant inheritance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of a pedigree showing X-linked dominant inheritance</div><div class=\"cntnt\"><img style=\"width:444px; height:240px;\" src=\"images/PC/75137_X-linked_dominant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">X-linked dominant. Features of X-linked dominant inheritance seen here include: lack of father-son transmission; 50% affected status rate among siblings of affected subjects. Mothers can transmit the disorder to sons and&nbsp;daughters, but fathers can only transmit the disorder to daughters, so there are often more affected females than males in a pedigree.&nbsp;Not depicted is the tendency for more severe disease among males.</div><div id=\"graphicVersion\">Graphic 75137 Version 6.0</div></div></div>"},"75141":{"type":"graphic_figure","displayName":"Coronal views of pharyngeal arch transformations","title":"Coronal views of pharyngeal arch transformations","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Coronal views of pharyngeal arch transformations</div><div class=\"cntnt\"><img style=\"width:614px; height:654px;\" src=\"images/SURG/75141_Coronal_view_pharyn_arch_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first pouch hardly changes (A). It remains as a thin barrier between outside and inside - the tympanic membrane of the ear. On the inner side is the auditory tube, which is open to the throat, and on the outer side is the ear canal. The remaining clefts smooth over as a result of expansion and descent of the second arch, leaving the possibility of a trapped cyst or fistula in the connective tissue of the neck (B). The second pouch harbors a condensation of lymphatic tissue - the future tonsil (C). Parathyroid glands and critical immunologic tissue (the thymus gland) develop from involutions of the third and fourth pouches. From the midline of the ventral pharynx, the thyroid gland originates from the lining of the foramen cecum and descends external to the gut tube (C).</div><div class=\"graphic_reference\">Adapted with permission from: Sadler TW. Langman's Medical Embryology, 10th Edition. Baltimore: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75141 Version 5.0</div></div></div>"},"75142":{"type":"graphic_diagnosticimage","displayName":"C5 compression fracture","title":"C5 compression fracture lateral view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">C5 compression fracture lateral view</div><div class=\"cntnt\"><img style=\"width:410px; height:404px;\" src=\"images/EM/75142_C5_compression_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 14-year-old male sustained a comminuted C5 compression fracture with 25 percent loss of anterior vertebral body height relative to the posterior portion (arrow) after a head on collision with hyperflexion while playing football.</div><div class=\"graphic_reference\">Courtesy of Alison Chantal Caviness, MD.</div><div id=\"graphicVersion\">Graphic 75142 Version 3.0</div></div></div>"},"75143":{"type":"graphic_picture","displayName":"Tuberous xanthomas in PBC","title":"Tuberous xanthomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberous xanthomas</div><div class=\"cntnt\"><img style=\"width:289px; height:318px;\" src=\"images/GAST/75143_Tuberous_xanthomas_in_PBC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tuberous xanthomas on the elbow of a woman with primary biliary cholangitis and a marked elevation in the serum cholesterol concentration (1400 mg/dL [36.4 mmol/L]).</div><div class=\"graphic_reference\">Courtesy of Marshall M Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 75143 Version 2.0</div></div></div>"},"75144":{"type":"graphic_diagnosticimage","displayName":"Adrenal hyperplasia MRI","title":"Bilateral adrenal hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral adrenal hyperplasia</div><div class=\"cntnt\"><img style=\"width:393px; height:288px;\" src=\"images/ENDO/75144_Adrenal_hyperplasia_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1-weighted MRI through the upper abdomen demonstrates enlargement of both adrenal glands (arrows). This finding could be caused by ACTH-dependent Cushing's syndrome or primary hyperaldosteronism due to adrenal hyperplasia.</div><div class=\"graphic_footnotes\">ACTH: corticotropin; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 75144 Version 4.0</div></div></div>"},"75146":{"type":"graphic_table","displayName":"Bulbar signs symptoms ALS","title":"Bulbar signs and symptoms associated with amyotrophic lateral sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bulbar signs and symptoms associated with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n\t<tbody>\r\n\t\t<tr>\r\n\t\t\t<td class=\"container\">\r\n\t\t\t\t<table cellspacing=\"0\">\r\n\t\t\t\t\t<tbody>\r\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Upper motor neuron signs</td></tr>\r\n\t\t\t\t\t\t<tr><td>Increased jaw reflex</td></tr>\r\n\t\t\t\t\t\t<tr><td>Jaw spasticity</td></tr>\r\n\t\t\t\t\t\t<tr><td>Facial diparesis (may be asymmetric)</td></tr>\r\n\t\t\t\t\t\t<tr><td>Increased facial reflexes</td></tr>\r\n\t\t\t\t\t\t<tr><td>Palmomental sign</td></tr>\r\n\t\t\t\t\t\t<tr><td>Poor palatal elevation</td></tr>\r\n\t\t\t\t\t\t<tr><td>Slow tongue movement</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Lower motor neuron signs</td></tr>\r\n\t\t\t\t\t\t<tr><td>Weak masseter and or pterygoids</td></tr>\r\n\t\t\t\t\t\t<tr><td>Difficulty maintaining jaw closure</td></tr>\r\n\t\t\t\t\t\t<tr><td>Facial diparesis (may be asymmetric)</td></tr>\r\n\t\t\t\t\t\t<tr><td>Poor palatal elevation</td></tr>\r\n\t\t\t\t\t\t<tr><td>Tongue weakness</td></tr>\r\n\t\t\t\t\t\t<tr><td>Muscle atrophy and fasciculations</td></tr>\r\n\t\t\t\t\t</tbody>\r\n\t\t\t\t</table>\r\n\t\t\t</td>\r\n\t\t\t<td class=\"container\">\r\n\t\t\t\t<table cellspacing=\"0\">\r\n\t\t\t\t\t<tbody>\r\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Upper motor neuron symptoms</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Jaw stiffness with difficulty opening the mouth</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Spontaneous clenching or biting</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Trismus</td></tr>\r\n\t\t\t\t\t\t<tr><td>Spontaneous jaw clonus</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Dysphagia</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Tongue incoordination disrupts the oral phase</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Pharyngeal muscle incoordination disrupts the pharyngeal phase</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Dysarthria</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Labial, lingual and/or pharyngeal components</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Spastic with slow, strained speech</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Laryngospasm</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Often triggered by secretions (eg, saliva) or food particles</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Rapid onset</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">\"Squeezing\" feeling, inability to speak, strained speech</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Short-lived, less than 30 seconds</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Pseudobulbar affect</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Inappropriate laughing, crying, and/or yawning</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Affective response &#62;&#62; emotional trigger</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Mood incongruent</td></tr>\r\n\t\t\t\t\t\t<tr><td>Sialorrhea (drooling)</td></tr>\r\n\t\t\t\t\t\t<tr><td>Difficulty managing pharyngeal secretions</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Lower motor neuron symptoms</td></tr>\r\n\t\t\t\t\t\t<tr><td>Incomplete eye closure</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Difficulty opening and/or closing the jaw</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Difficulty chewing</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Disarticulation of the temporomandibular joint when severe</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Poor lip closure and seal</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">May contribute to sialorrhea when severe</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Dysphagia</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Tongue weakness disrupts the oral phase</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Pharyngeal muscle weakness disrupts the pharyngeal phase</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Coughing and choking induced by drinking, eating or saliva secretion</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Often thin liquids followed by solids and thick liquids</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Dysarthria</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Labial, lingual and/or pharyngeal components</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Slurred, nasal and/or hoarse speech</td></tr>\r\n\t\t\t\t\t\t<tr><td>Hoarseness</td></tr>\r\n\t\t\t\t\t</tbody>\r\n\t\t\t\t</table>\r\n\t\t\t</td>\r\n\t\t</tr>\r\n\t</tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 75146 Version 1.0</div></div></div>"},"75147":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound normal renal Doppler","title":"Prenatal ultrasound normal renal Doppler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound normal renal Doppler</div><div class=\"cntnt\"><img style=\"width:320px; height:240px;\" src=\"images/OBGYN/75147_Normal_renal_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 75147 Version 2.0</div></div></div>"},"75148":{"type":"graphic_figure","displayName":"Nasal bone and cartilage","title":"Relationship of the bones and cartilages of the nose","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Relationship of the bones and cartilages of the nose</div><div class=\"cntnt\"><img style=\"width:569px; height:500px;\" src=\"images/ONC/75148_Nasalboneandcartilage.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lee N, Riaz N, Chen AM. General Principles and Management. In: Harrison LB, Kies M, Sessions RB (Eds). Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: Lippincott Williams &amp; Wilkins, 2013. Copyright Â© 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 75148 Version 11.0</div></div></div>"},"75150":{"type":"graphic_diagnosticimage","displayName":"Ruptured ovarian cyst","title":"Ruptured ovarian cyst","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Ruptured ovarian cyst</div><div class=\"cntnt\"><img style=\"width:468px; height:329px;\" src=\"images/OBGYN/75150_Ruptured_ovarian_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography. Arrows indicate free blood within peritoneal cavity surrounding liver and spleen.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 75150 Version 2.0</div></div></div>"},"75152":{"type":"graphic_table","displayName":"Causes brain death","title":"Common causes of neurologic death in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of neurologic death in children</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Traumatic brain injury</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intracranial hemorrhage</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ischemic/hypoxic insult</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Metabolic encephalopathy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Primary brain stem infarct</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Primary low grade CNS tumors</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Treated sepsis/meningitis</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Vyas, H, Evans, J. Management of a potential organ donor. In: Recent Advances in Pediatrics. David, TJ (Ed), Royal Society of Medicine Press Ltd 2002.</div><div id=\"graphicVersion\">Graphic 75152 Version 1.0</div></div></div>"},"75153":{"type":"graphic_figure","displayName":"Location scalp veins","title":"Location of scalp veins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Location of scalp veins</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/PEDS/75153_Location_scalp_veins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rubber band used for tourniquet.</div><div class=\"graphic_reference\">Reproduced with permission from Barkin, RM (Ed). Pediatric emergency medicine: Concepts and clinical practice, 2nd ed, Mosby, St. Louis 1997. p.147. Copyright 1997 W.B. Saunders Company.</div><div id=\"graphicVersion\">Graphic 75153 Version 1.0</div></div></div>"},"75155":{"type":"graphic_table","displayName":"Maneuvers mitral valve prolapse","title":"Alterations in S1-click interval and the character of the late systolic murmur during physiologic and pharmacologic maneuvers in mitral valve prolapse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alterations in S1-click interval and the character of the late systolic murmur during physiologic and pharmacologic maneuvers in mitral valve prolapse</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Maneuvers</td>\n\n      <td class=\"subtitle1\">S1-click interval</td>\n\n      <td class=\"subtitle1\">Onset of late systolic murmur in relation to S1</td>\n\n      <td class=\"subtitle1\">Duration of late systolic murmur in relation to total duration of systole</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Supine position</td>\n\n      <td>Increased</td>\n\n      <td>Late</td>\n\n      <td>Shorter</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Standing position</td>\n\n      <td>Decreased</td>\n\n      <td>Early</td>\n\n      <td>Longer</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Squatting*</td>\n\n      <td>Increased</td>\n\n      <td>Late</td>\n\n      <td>Shorter</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Valsalva (phase 2)</td>\n\n      <td>Decreased</td>\n\n      <td>Early</td>\n\n      <td>Longer</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hand grip</td>\n\n      <td>Increased</td>\n\n      <td>Late</td>\n\n      <td>Shorter</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Postectopic beat</td>\n\n      <td>Usually decreased</td>\n\n      <td>Usually late</td>\n\n      <td>Usually longer</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Amyl nitrite</td>\n\n      <td>Decreased</td>\n\n      <td>Early</td>\n\n      <td>Longer</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Phenylephrine</td>\n\n      <td>Increased</td>\n\n      <td>Late</td>\n\n      <td>Shorter</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* The delay in the onset of the click and a shortening of the late systolic murmur with squatting reflects a delay in prolapse induced by the increase in preload; the reverse changes occur with standing. However, as mitral regurgitation becomes more severe, the murmur may increase in intensity with squatting because of the increase in afterload.</div><div id=\"graphicVersion\">Graphic 75155 Version 1.0</div></div></div>"},"75156":{"type":"graphic_diagnosticimage","displayName":"Complete simple metacarpophalangeal thumb dislocation in a child","title":"Complete simple metacarpophalangeal thumb dislocation in a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete simple metacarpophalangeal thumb dislocation in a child</div><div class=\"cntnt\"><img style=\"width:360px; height:287px;\" src=\"images/EM/75156_Thumbdislocationxray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 9-year-old boy with a complete simple dorsal dislocation of the thumb MCP joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Lightdale-Miric N, Kozin SH. Fractures and Dislocations of the Hand and Carpal Bones in Children. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright Â© 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 75156 Version 12.0</div></div></div>"},"75157":{"type":"graphic_picture","displayName":"Xanthelasma in PBC","title":"Xanthelasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xanthelasma</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/GAST/75157_Xanthelasma_in_PBC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral xanthelasmata (due to cholesterol deposits in the periorbital skin folds) in a patient with marked hypercholesterolemia resulting from primary biliary cholangitis.</div><div class=\"graphic_reference\">Courtesy of Sanjiv Chopra, MD.</div><div id=\"graphicVersion\">Graphic 75157 Version 2.0</div></div></div>"},"75160":{"type":"graphic_table","displayName":"New single agts chemo","title":"Studies evaluating newer single agents chemotherapy in locally advanced and metastatic esophageal and gastric cancers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies evaluating newer single agents chemotherapy in locally advanced and metastatic esophageal and gastric cancers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug </td> <td class=\"subtitle1\">Cancer type </td> <td class=\"subtitle1\">Author </td> <td class=\"subtitle1\">N </td> <td class=\"subtitle1\">RR (percent) </td> </tr> <tr> <td rowspan=\"2\">Paclitaxel 24 hour infusion </td> <td>Esophageal</td> <td>Ajani J; 1994</td> <td>50</td> <td>32</td> </tr> <tr> <td>Gastric</td> <td>Ajani J; 1998</td> <td>18</td> <td>23</td> </tr> <tr> <td rowspan=\"2\">Paclitaxel weekly short infusion </td> <td>Esophageal</td> <td>Ilson D; 2007</td> <td>102</td> <td>15</td> </tr> <tr> <td>Gastric</td> <td>Kii T; 2006</td> <td>26</td> <td>14</td> </tr> <tr> <td rowspan=\"2\">Docetaxel </td> <td>Esophageal (first- and second-line)</td> <td>Muro K; 2004</td> <td>50</td> <td>20</td> </tr> <tr> <td>Gastric</td> <td>Mavroudis D; 2000</td> <td>30</td> <td>20</td> </tr> <tr> <td rowspan=\"2\">Irinotecan </td> <td>Esophagogastric</td> <td>Enzinger P; 2005</td> <td>43</td> <td>14</td> </tr> <tr> <td>Gastric</td> <td>Kohne C; 2003</td> <td>40</td> <td>20</td> </tr> <tr> <td rowspan=\"2\">Vinorelbine </td> <td>Esophageal SCC (first- and second-line)</td> <td>Conroy T; 1996</td> <td>46</td> <td>15</td> </tr> <tr> <td>Esophagogastric adenocarcinoma (first- and&nbsp;second-line)</td> <td>Kulke M; 2006</td> <td>29</td> <td>7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N: number of patients; RR: objective response rate; SCC: squamous cell carcinoma.</div><div class=\"graphic_reference\">Courtesy of Fidias P, El-Karak FR.</div><div id=\"graphicVersion\">Graphic 75160 Version 2.0</div></div></div>"},"75162":{"type":"graphic_table","displayName":"Classification prostatitis","title":"Classification of prostatitis with prostatic localization studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of prostatitis with prostatic localization studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"4\" width=\"12%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Category</td> <td class=\"subtitle1\" colspan=\"2\">Mid-stream urine<br /> (VB2)</td> <td class=\"subtitle1\" colspan=\"2\">Expressed prostatic secretion</td> <td class=\"subtitle1\" rowspan=\"2\">Organism</td> </tr> <tr> <td class=\"subtitle2\">White cells</td> <td class=\"subtitle2\">Culture</td> <td class=\"subtitle2\">White cells</td> <td class=\"subtitle2\">Culture</td> </tr> <tr> <td>ABP</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td>Enterobacteriaciae</td> </tr> <tr> <td>CBP</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td>Enterobacteriaciae</td> </tr> <tr> <td>CP/CPPS, inflammatory</td> <td class=\"centered\">&minus;</td> <td class=\"centered\">&minus;</td> <td class=\"centered\">+</td> <td class=\"centered\">&minus;</td> <td>None</td> </tr> <tr> <td>CP/CPPS, noninflammatory</td> <td class=\"centered\">&minus;</td> <td class=\"centered\">&minus;</td> <td class=\"centered\">&minus;</td> <td class=\"centered\">&minus;</td> <td>None</td> </tr> <tr> <td>Asymptomatic inflammatory prostatitis*</td> <td class=\"centered\">&minus;</td> <td class=\"centered\">&minus;</td> <td class=\"centered\">+</td> <td class=\"centered\">&minus;</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABP: acute bacterial prostatitis; CBP: chronic bacterial prostatitis; CP/CPPS: chronic prostatitis/chronic pelvic pain syndrome; VB2: clean-catch mid-stream urine specimen.<br />* Asymptomatic inflammatory prostatitis is generally detected incidentally, for example, on a biopsy performed for a different purpose.</div><div class=\"graphic_reference\">Adapted from: Doble A. Br J Urol 1994; 74:537 and Krieger JN, et al. JAMA 1999; 282:236.</div><div id=\"graphicVersion\">Graphic 75162 Version 3.0</div></div></div>"},"75163":{"type":"graphic_figure","displayName":"Septate uterus and vag septum","title":"Septate uterus: complete with associated vaginal septum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Septate uterus: complete with associated vaginal septum</div><div class=\"cntnt\"><img style=\"width:354px; height:291px;\" src=\"images/OBGYN/75163_Septateuterusandvagsept.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 75163 Version 15.0</div></div></div>"},"75164":{"type":"graphic_figure","displayName":"Mechanism of bundle branch reentrant ventricular tachycardia","title":"Mechanism of bundle branch reentrant ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanism of bundle branch reentrant ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:397px; height:256px;\" src=\"images/CARD/75164_Mechanism_of_BBRVT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the reentrant circuit in bundle branch reentrant venticular tachycardia (BBRVT) showing a ventricular premature beat that blocks in the right bundle branch (RBB), conducts slowly up the left bundle branch (LBB), activates the bundle of His, and returns antegradely down the RBB. If the RBB has recovered its excitability from the preceding beat, the circuit is completed and the reentrant circuit may become repetitive.</div><div id=\"graphicVersion\">Graphic 75164 Version 4.0</div></div></div>"},"75166":{"type":"graphic_diagnosticimage","displayName":"Tuberculous pleurisy I PA","title":"Pleural thickening due to tuberculous pleurisy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural thickening due to tuberculous pleurisy</div><div class=\"cntnt\"><img style=\"width:324px; height:316px;\" src=\"images/PULM/75166_TuberculouspleurisyIPA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tuberculous pleurisy with subacute diffuse pleural thickening. Frontal chest radiograph shows encasement of the right lung, which is poorly expanded. The right lateral costophrenic sulcus is blunted. The cardiomediastinal silhouette is shifted to the right.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75166 Version 4.0</div></div></div>"},"75169":{"type":"graphic_picture","displayName":"Scabies buttocks","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:400px; height:305px;\" src=\"images/DERM/75169_Scabies_buttocks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and nodules on the buttocks.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75169 Version 8.0</div></div></div>"},"75170":{"type":"graphic_picture","displayName":"Normal liver bx with Rx PBC","title":"Normalization of liver biopsy after methotrexate for primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normalization of liver biopsy after methotrexate for primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:291px; height:472px;\" src=\"images/GAST/75170_Normal_liver_bx_with_Rx_PBC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential liver biopsies in patient with primary biliary cholangitis (PBC). Top panel: Liver biopsy performed five years after the diagnosis of PBC and one year after treatment with colchicine (0.6 mg BID). The portal triads are greatly enlarged, somewhat edematous and infiltrated with mononuclear inflammatory cells. There is bridging of adjacent triads, and early nodule formation is evident. The biopsy is that of stage III to IV PBC. Bottom panel: Repeat liver biopsy after six years on methotrexate. The biopsy is normal except for a few portal triads that are minimally enlarged and infiltrated with mononuclear cells. There are no longer any features of PBC. The patient is asymptomatic and liver enzymes are normal. Masson trichrome, x 94.</div><div class=\"graphic_reference\">Reprinted by permission from: Kaplan M, DeLellis R, Wolfe H. Ann Intern Med 1997; 126:682.</div><div id=\"graphicVersion\">Graphic 75170 Version 4.0</div></div></div>"},"75171":{"type":"graphic_picture","displayName":"Plasma cell vulvitis1","title":"Plasma cell vulvitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma cell vulvitis</div><div class=\"cntnt\"><img style=\"width:345px; height:429px;\" src=\"images/OBGYN/75171_Plasma_cell_vulvitis1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 75171 Version 2.0</div></div></div>"},"75173":{"type":"graphic_table","displayName":"Male dyspareunia classification","title":"Male dyspareunia classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Male dyspareunia classification</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">I. Isolated ejaculatory pain (pain during or after ejaculation)</td> </tr> <tr> <td class=\"indent1\">a. Identifiable cause</td> </tr> <tr> <td class=\"indent1\">b. Idiopathic</td> </tr> <tr> <td class=\"subtitle2_left\">II. Chronic prostatitis/chronic pelvic pain syndrome</td> </tr> <tr> <td class=\"subtitle2_left\">III. Medical causes</td> </tr> <tr> <td class=\"indent1\">a. Peyronie's disease</td> </tr> <tr> <td class=\"indent1\">b. Phimosis </td> </tr> <tr> <td class=\"indent1\">c. Frenulum breve</td> </tr> <tr> <td class=\"indent1\">d. Ejaculatory duct obstruction/cyst/calculus</td> </tr> <tr> <td class=\"indent1\">e. Herniorrhaphy sequelae</td> </tr> <tr> <td class=\"indent1\">f. Pudendal nerve entrapment</td> </tr> <tr> <td class=\"indent1\">g. Genitourinary infections</td> </tr> <tr> <td class=\"indent1\">h. Interstitial cystitis</td> </tr> <tr> <td class=\"indent1\">i.&nbsp;Dermatologic conditions&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">IV. Other causes of sexual pain</td> </tr> <tr> <td class=\"indent1\">a. Psychologic</td> </tr> <tr> <td class=\"indent1\">b. Medications</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Luizzi, GI, Law, A. A guide to sexual pain in men. Practitioner 2005; 249:73.</div><div id=\"graphicVersion\">Graphic 75173 Version 3.0</div></div></div>"},"75174":{"type":"graphic_diagnosticimage","displayName":"CXR chronic MR","title":"Chest radiograph of patient with chronic mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of patient with chronic mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:333px; height:306px;\" src=\"images/CARD/75174_Mitral_regurgitation_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain chest radiograph from a female with known mitral regurgitation demonstrates cardiomegaly with left atrial (arrow) and left ventricular enlargement (arrowhead), as well as mild pulmonary venous redistribution, all features characteristic of mitral regurgitation.</div><div class=\"graphic_reference\">Photo courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 75174 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"75177":{"type":"graphic_figure","displayName":"Trichuriasis life cycle","title":"Trichuriasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Trichuriasis life cycle</div><div class=\"cntnt\"><img style=\"width:494px; height:494px;\" src=\"images/ID/75177_Trichuriasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The unembryonated eggs are passed with the stool <strong>(1)</strong>. In the soil, the eggs develop into a two-cell stage <strong>(2)</strong>, an advanced cleavage stage <strong>(3)</strong>, and then they embryonate <strong>(4)</strong>; eggs become infective in 15 to 30 days. After ingestion (soil-contaminated hands or food), the eggs hatch in the small intestine, and release larvae <strong>(5)</strong> that mature and establish themselves as adults in the colon <strong>(6)</strong>. The adult worms (approximately 4 cm in length) live in the cecum and ascending colon. The adult worms are fixed in that location, with the anterior portions threaded into the mucosa. The females begin to oviposit 60 to 70 days after infection. Female worms in the cecum shed between 3000 and 20,000 eggs per day. The life span of the adults is about one year.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Trichuriasis. Available at: <A href=\"http://www.cdc.gov/dpdx/trichuriasis/index.html\">http://www.cdc.gov/dpdx/trichuriasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 75177 Version 3.0</div></div></div>"},"75178":{"type":"graphic_figure","displayName":"BP norm birth to 1yr girls","title":"Age-specific percentiles of BP measurements in girls - birth to 12 months of age; Korotkoff phase IV (K4) used for diastolic BP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age-specific percentiles of BP measurements in girls - birth to 12 months of age; Korotkoff phase IV (K4) used for diastolic BP</div><div class=\"cntnt\"><img style=\"width:450px; height:606px;\" src=\"images/EM/75178_BPnormbirthto1yrgirls.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 79, Pages 1-25, Copyright Â© 1987 by the AAP.</div><div id=\"graphicVersion\">Graphic 75178 Version 13.0</div></div></div>"},"75179":{"type":"graphic_figure","displayName":"Ulnar nerve test","title":"Ulnar nerve test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulnar nerve test</div><div class=\"cntnt\"><img style=\"width:390px; height:414px;\" src=\"images/EM/75179_Ulnar_nerve_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The examiner attempts to remove a piece of paper being held between the patient's fingers. This method tests the motor function of the lumbrical muscles that are innervated by the ulnar nerve.</div><div id=\"graphicVersion\">Graphic 75179 Version 1.0</div></div></div>"},"75180":{"type":"graphic_figure","displayName":"Sigmoid loops examples","title":"Magnetic 3-D imaging colonoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic 3-D imaging colonoscopy</div><div class=\"cntnt\"><img style=\"width:432px; height:345px;\" src=\"images/GAST/75180_Sigmoid_loops_examples.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of common and uncommon sigmoid loops seen during colonoscopy (AP views). (A) Intubation to the mid-descending colon with a sigmoid 'N' spiral loop. (B) Sigmoid alpha loop with endoscope inserted to splenic flexure. (C) (Atypical) Reverse alpha loop with endoscope tip in descending colon. (D) Atypical counter-clockwise (reverse sigmoid) spiral loop with the endoscope tip in the proximal sigmoid colon. (E) Complex sigmoid spiral loop with endoscope inserted to the proximal sigmoid colon.</div><div class=\"graphic_reference\">Courtesy of Christopher B Williams BM, FRCP, FRCS.</div><div id=\"graphicVersion\">Graphic 75180 Version 1.0</div></div></div>"},"75181":{"type":"graphic_diagnosticimage","displayName":"Sonogram abn ut bleeding3","title":"Transvaginal pelvic sonogram of a patient with abnormal uterine bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transvaginal pelvic sonogram of a patient with abnormal uterine bleeding</div><div class=\"cntnt\"><img style=\"width:377px; height:272px;\" src=\"images/OBGYN/75181_Sonogram_abn_ut_bleeding3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The central uterine echo measures 9 mm and appears relatively homogeneous.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 75181 Version 2.0</div></div></div>"},"75183":{"type":"graphic_diagnosticimage","displayName":"Malignant perivascular nodules","title":"Perivascular nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perivascular nodules</div><div class=\"cntnt\"><img style=\"width:379px; height:241px;\" src=\"images/PULM/75183_Malignant_perivascular_nodu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small perivascular nodules, due to metastatic small cell carcinoma, are scattered diffusely throughout all compartments of the lung.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75183 Version 2.0</div></div></div>"},"75184":{"type":"graphic_diagnosticimage","displayName":"Subpulmonic effusion II PA","title":"Subpulmonic pleural effusion","html":"<div class=\"graphic normal\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Subpulmonic pleural effusion</div><div class=\"cntnt\"><img style=\"width:525px; height:277px;\" src=\"images/PULM/75184_Subpulmonic_effusion_II_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Right subpulmonic pleural effusion in patient after mediastinal irradiation. The right lung base is elevated as well as the right hilum. Right panel: After thoracentesis, a residual hydropneumothorax with a large right sided gas-liquid level ensues, thus proving that the elevation of the right lung base was not due to an elevated right hemidiaphragm but to a subpulmonic pleural effusion.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75184 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"75185":{"type":"graphic_table","displayName":"Treatment of BP fistula","title":"Experimental therapies that have been tried in ventilated patients with bronchopleural fistula","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Experimental therapies that have been tried in ventilated patients with bronchopleural fistula</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Technique</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Independent lung ventilation</td> <td>Requires double-lumen tube, more difficult to manage in ICU than in <strong>OR</strong>; can be done with one or two ventilators, with or without synchronization; literature consists of anecdotal cases</td> </tr> <tr> <td>High-frequency jet ventilation</td> <td>Uncontrolled clinical series from three groups, plus numerous case reports; most (not all) report decreased leak volume, but maintaining oxygenation is a problem in patients with ARDS; none of the devices used in reported literature are currently FDA-approved for use on adult patients</td> </tr> <tr> <td>Chest tube occlusion during inspiration</td> <td>Two case reports, three patients total; leaks decreased; this technique becomes impractical as number of chest tubes increases</td> </tr> <tr> <td>Application of PEEP to chest tube</td> <td>Four reports, six patients; leak decreased in five; lung could not be kept inflated in two patients; leaks tended to decrease; this technique is also impractical with increasing numbers of chest tubes</td> </tr> <tr> <td class=\"sublist1_start\">Bronchoscopic identification of affected bronchus, with leak occlusion by:</td> <td rowspan=\"12\">All individual case reports or two to five patient case series except for one series of 24 post-surgical patients treated with multiple silver nitrate applications; all reports are favorable, showing either decrease or cessation of leak</td> </tr> <tr> <td class=\"sublist1\">Balloon</td> </tr> <tr> <td class=\"sublist1\">Bronchial plug</td> </tr> <tr> <td class=\"sublist1\">Endobronchial valve</td> </tr> <tr> <td class=\"sublist1\">Lead fishing weight </td> </tr> <tr> <td class=\"sublist1\">Gelfoam</td> </tr> <tr> <td class=\"sublist1\">Oxidized regenerated cellulose</td> </tr> <tr> <td class=\"sublist1\">Tetracycline</td> </tr> <tr> <td class=\"sublist1\">Silver nitrate </td> </tr> <tr> <td class=\"sublist1\">Fibrin, autologous or commercial </td> </tr> <tr> <td class=\"sublist1\">Cyanoacrylate-based tissue glue</td> </tr> <tr> <td class=\"sublist1\">Nd-YAG laser</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75185 Version 2.0</div></div></div>"},"75187":{"type":"graphic_picture","displayName":"Forehead rhytides botulinum toxin injection sites","title":"Botulinum toxin injection sites for horizontal forehead rhytides","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin injection sites for horizontal forehead rhytides</div><div class=\"cntnt\"><img style=\"width:502px; height:417px;\" src=\"images/DERM/75187_Fore_rhyt_injec_sites_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The five injection sites in the mid-forehead (red) represent the sites for the injection of botulinum toxin into the frontalis muscle for horizonal forehead rhytides. Treatment of the brow depressors is also required, and is represented by the injection sites in the procerus and lateral obicularis oculi muscles (white).</div><div id=\"graphicVersion\">Graphic 75187 Version 3.0</div></div></div>"},"75188":{"type":"graphic_picture","displayName":"Mallory body alcohol hepatitis","title":"Mallory-Denk bodies in alcoholic hepatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mallory-Denk bodies in alcoholic hepatitis</div><div class=\"cntnt\"><img style=\"width:442px; height:288px;\" src=\"images/GAST/75188_Mallory_body_alcohol_hepati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a liver biopsy in alcoholic hepatitis shows macrovesicular fat and Mallory-Denk bodies (arrows), which are eosinophilic accumulations of intracellular material. Similar changes can occur in nonalcoholic steatohepatitis.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 75188 Version 3.0</div></div></div>"},"75190":{"type":"graphic_picture","displayName":"AVM pretreatment angiography","title":"Arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:339px; height:329px;\" src=\"images/NEURO/75190_AVM_pretreatment_angiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic angiographic appearance of an arteriovenous malformation before therapy.</div><div class=\"graphic_reference\">Courtesy of Guy Rordorf, MD.</div><div id=\"graphicVersion\">Graphic 75190 Version 1.0</div></div></div>"},"75191":{"type":"graphic_table","displayName":"Fetal neutrophil count by GA","title":"Fetal neutrophil count, 10<sup>9</sup>/L","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fetal neutrophil count, 10<sup>9</sup>/L</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">GA (weeks)</td> <td class=\"subtitle1\">5th percentile</td> <td class=\"subtitle1\">Mean</td> <td class=\"subtitle1\">95th percentile</td> </tr> <tr class=\"centered\"> <td>20</td> <td>0.03</td> <td>0.16</td> <td>0.42</td> </tr> <tr class=\"centered\"> <td>22</td> <td>0.04</td> <td>0.19</td> <td>0.47</td> </tr> <tr class=\"centered\"> <td>24</td> <td>0.07</td> <td>0.23</td> <td>0.55</td> </tr> <tr class=\"centered\"> <td>26</td> <td>0.10</td> <td>0.31</td> <td>0.70</td> </tr> <tr class=\"centered\"> <td>28</td> <td>0.17</td> <td>0.43</td> <td>0.94</td> </tr> <tr class=\"centered\"> <td>30</td> <td>0.27</td> <td>0.63</td> <td>1.33</td> </tr> <tr class=\"centered\"> <td>32</td> <td>0.44</td> <td>0.96</td> <td>1.98</td> </tr> <tr class=\"centered\"> <td>34</td> <td>0.74</td> <td>1.55</td> <td>3.12</td> </tr> <tr class=\"centered\"> <td>36</td> <td>1.28</td> <td>2.60</td> <td>5.19</td> </tr> <tr class=\"centered\"> <td>38</td> <td>2.28</td> <td>4.59</td> <td>9.14</td> </tr> <tr class=\"centered\"> <td>40</td> <td>4.23</td> <td>8.53</td> <td>17.09</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GA: gestational age.</div><div id=\"graphicVersion\">Graphic 75191 Version 4.0</div></div></div>"},"75192":{"type":"graphic_table","displayName":"Clues to the etiology of septic arthritis in children","title":"Clinical features associated with bacterial pathogens that cause arthritis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features associated with bacterial pathogens that cause arthritis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gram-positive bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> <td>All ages; may cause polyarticular infection; possible associated skin or soft tissue infection; MRSA may be associated with venous thromboembolism and pulmonary disease</td> </tr> <tr> <td class=\"indent1\">Coagulase-negative staphylococci</td> <td>Most common cause of bacterial arthritis associated with prosthetic joints</td> </tr> <tr> <td class=\"indent1\">Group A <em>Streptococcus</em> (<em>Streptococcus pyogenes</em>)</td> <td>May occur as a complication of concurrent varicella-zoster virus infection</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pneumoniae</em> (pneumococcus)</td> <td>Children younger than two years of age, typically without risk factors for invasive pneumococcal disease and without extra-articular manifestations of pneumococcal disease</td> </tr> <tr> <td class=\"indent1\">Group B <em>Streptococcus</em> (<em>Streptococcus agalactiae</em>)</td> <td>Infants younger than three months of age (usually two to four weeks)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Nocardia asteroides</em></td> <td>Chronic monoarticular arthritis with a granulomatous reaction</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gram-negative bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Kingella kingae</em></td> <td>Children 6 to 36 months; indolent onset; oral ulcers preceding musculoskeletal findings</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus influenzae</em> type b (Hib)</td> <td>Incompletely immunized children in areas with low Hib immunization rates</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><em>Neisseria gonorrhoeae</em></td> <td>Newborns; usually affects joints below the hip; may cause polyarticular infection</td> </tr> <tr> <td>Sexually active adolescents; usually occurs as part of disseminated infection with fever and rash; in girls, may precede onset of menses</td> </tr> <tr> <td class=\"indent1\"><em>Neisseria meningitidis</em></td> <td>May cause polyarticular infection; associated rash; postinfectious immune complex-mediated arthritis may occur two to three weeks after initiation of treatment of <em>N. meningitis</em> infections</td> </tr> <tr> <td class=\"indent1\"><em>Salmonella</em> species</td> <td>Children with sickle cell disease or related hemoglobinopathies; children in developing countries</td> </tr> <tr> <td class=\"indent1\">Non-<em>Salmonella</em> gram-negative bacilli</td> <td>Newborns; instrumentation of the gastrointestinal or urinary tract; immunocompromised host</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> <td>Puncture wounds; injectable drug use</td> </tr> <tr> <td class=\"indent1\"><em>Streptobacillus moniliformis</em> (rat bite fever)</td> <td>Rat bite; macular rash at time of presentation</td> </tr> <tr> <td class=\"indent1\"><em>Borrelia burgdorferi</em> (Lyme disease)</td> <td>Tick bite; history of erythema migrans rash; travel to or living in an endemic area; intermittent inflammatory arthritis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Brucella</em></td> <td>Travel to or living in an endemic area; ingestion of unpasteurized dairy products; chronic monoarticular arthritis with a granulomatous reaction</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Granulomatous arthritis</td> </tr> <tr> <td class=\"indent1\">Mycobacteria (tuberculosis and atypical species)</td> <td>Chronic monoarticular arthritis with a granulomatous reaction</td> </tr> <tr> <td class=\"indent1\"><em>Coccidioides </em>infection</td> <td>Coccidioidomycosis may produce an indolent arthritis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <em>S. aureus</em>.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Krogstad P. Septic arthritis. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7<SUP>th</SUP> ed, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.727.</LI>&#xD;&#xA;<LI>âOlarte L, Romero JR, Barson WJ, et al. Pneumococcal osteoarticular infections in children in the pneumococcal conjugate vaccine era. Abstract and poster presentation, 10<SUP>th</SUP> International Symposium on Pneumococci &amp; Pneumococcal Diseases, Glasgow, Scotland, June 2016.</LI></OL></div><div id=\"graphicVersion\">Graphic 75192 Version 16.0</div></div></div>"},"75193":{"type":"graphic_table","displayName":"Macrocephaly syndromes","title":"Clinical features of selected syndromes associated with macrocephaly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of selected syndromes associated with macrocephaly</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Clinical features (in addition to macrocephaly)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Predominantly cutaneous syndromes</td> </tr> <tr> <td class=\"indent1\"> <p>Tuberous sclerosis 1*</p> <a href=\"http://omim.org/entry/191100\" spellcheck=\"true\" target=\"_blank\">MIM #191100</a></td> <td>Facial angiofibromas, shagreen patch, hypopigmented macules, periungual fibromas, gingival fibromas</td> </tr> <tr> <td class=\"indent1\"> <p>Neurofibromatosis type 1*</p> <a href=\"http://omim.org/entry/162200\" spellcheck=\"true\" target=\"_blank\">MIM #162200</a></td> <td>Caf&#233;-au-lait spots, axillary freckling, dermal neurofibroma, short stature, Lisch nodules</td> </tr> <tr> <td class=\"indent1\"> <p>Linear epidermal nevus syndrome</p> <a href=\"http://omim.org/entry/163200\" spellcheck=\"true\" target=\"_blank\">MIM #163200</a></td> <td>Asymmetric overgrowth, coloboma (eyelids, iris, choroid), linear nevus sebaceous; associated with basal cell carcinoma</td> </tr> <tr> <td class=\"indent1\"> <p>Klippel-Trenaunay-Weber</p> <a href=\"http://omim.org/entry/149000\" spellcheck=\"true\" target=\"_blank\">MIM %149000</a></td> <td>Large cutaneous hemangioma with hypertrophy of related bones and soft tissues; syndactyly; polydactyly</td> </tr> <tr> <td class=\"indent1\"> <p>Proteus</p> <a href=\"http://omim.org/entry/176920\" spellcheck=\"true\" target=\"_blank\">MIM #176920</a></td> <td>Asymmetric, disproportionate overgrowth of body parts, epidermal nevi, hypertrophy of skin of soles, hemangioma (thorax, upper abdomen)</td> </tr> <tr> <td class=\"indent1\"> <p>Macrocephaly cutis marmorata telangiectatica congenita</p> <a href=\"http://omim.org/entry/602501\" spellcheck=\"true\" target=\"_blank\">MIM #602501</a></td> <td>Vascular mottling of the skin; congenital telangiectasias, syndactyly of second and third toes; polydactyly; asymmetry of the head, face, or body; nevus flammeus of the lip and/or philtrum; overgrowth with prenatal onset</td> </tr> <tr> <td class=\"indent1\"> <p>Nevoid basal cell carcinoma syndrome* (Gorlin syndrome)</p> <a href=\"http://omim.org/entry/109400\" spellcheck=\"true\" target=\"_blank\">MIM #109400</a></td> <td>Frontoparietal bossing, broad nasal bridge, coarse facial features, highly arched eyebrows, pouting lower lip; odontogenic keratocysts of the mandible and maxilla; increased risk of basal cell carcinoma</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\"><em>PTEN</em> hamartoma tumor syndromes</td> </tr> <tr> <td class=\"sublist2\"> <p>Bannayan-Riley-Ruvalcaba*</p> <a href=\"http://omim.org/entry/153480\" spellcheck=\"true\" target=\"_blank\">MIM #153480</a></td> <td class=\"sublist_other\">Lipomas, hemangiomas, pigmented macules; congenital macrosomia (birth weight usually &#62;4 kg) followed by postnatal growth deceleration and normal adult height; down-slanting palpebral fissures; increased risk of certain malignancies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\"> <p>Cowden* and Lhermitte-Duclos*</p> <a href=\"http://omim.org/entry/158350\" spellcheck=\"true\" target=\"_blank\">MIM #158350</a></td> <td class=\"sublist_other\">Birdlike facies; hypoplastic mandible and maxilla; cataract; microstomia; high-arched palate; pectus excavatum; genitourinary anomalies; skin tags; lipomas</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Predominantly overgrowth syndromes</td> </tr> <tr> <td class=\"indent1\"> <p>Sotos</p> <a href=\"http://omim.org/entry/117550\" spellcheck=\"true\" target=\"_blank\">MIM #117550</a></td> <td>High prominent forehead, down-slanting palpebral fissures, long pointed chin, high-arched palate; tall stature and advanced bone age; normal adult height</td> </tr> <tr> <td class=\"indent1\"> <p>Weaver*</p> <a href=\"http://omim.org/entry/277590\" spellcheck=\"true\" target=\"_blank\">MIM #277590</a></td> <td>Accelerated growth with prenatal onset, advanced bone age, broad forehead, flat occiput, long philtrum, camptodactyly, broad thumbs, loose skin, deep-set nails; deep palmar and plantar creases</td> </tr> <tr> <td class=\"indent1\"> <p>Simpson-Golabi-Behmel</p> <a href=\"http://omim.org/entry/312870\" spellcheck=\"true\" target=\"_blank\">MIM #312870</a></td> <td>Accelerated growth with prenatal onset (weight more affected than height), coarse facial features, down-slanting palpebral fissures, thickened lips, wide mouth, large tongue, high-arched palate, prominent jaw, short neck, supernumerary nipples, hepatomegaly</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Beckwith-Wiedemann*</p> <a href=\"http://omim.org/entry/130650\" spellcheck=\"true\" target=\"_blank\">MIM #130650</a></td> <td>Omphalocele (or other umbilical abnormalities), hemihypertrophy, coarse facial features, macroglossia, neonatal macrosomia, neonatal hypoglycemia, increased risk of certain tumors (eg, Wilms tumor, hepatoblastoma)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neuro-cardiofaciocutaneous syndromes<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"> <p>Noonan*</p> <a href=\"http://omim.org/entry/163950\" spellcheck=\"true\" target=\"_blank\">MIM #163950</a></td> <td>Short stature (postnatal onset), congenital heart defects (atrial septal defect, ventricular septal defect, pulmonic stenosis), webbed neck, abnormal chest, hypertelorism, down-slanting palpebral fissures, epicanthal folds, deafness (sensorineural); deeply grooved philtrum</td> </tr> <tr> <td class=\"indent1\"> <p>LEOPARD*</p> <a href=\"http://omim.org/entry/151100\" spellcheck=\"true\" target=\"_blank\">MIM #151100</a></td> <td>Lentigines, ECG conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, deafness (sensorineural)</td> </tr> <tr> <td class=\"indent1\"> <p>Costello*</p> <a href=\"http://omim.org/entry/218040\" spellcheck=\"true\" target=\"_blank\">MIM #218040</a></td> <td>Failure to thrive, short stature, developmental delay, coarse facial features, deep palmar and plantar creases, papillomata, cardiac abnormalities, risk for tumors</td> </tr> <tr> <td class=\"indent1\"> <p>Cardiofaciocutaneous</p> <a href=\"http://omim.org/entry/115150\" spellcheck=\"true\" target=\"_blank\">MIM #115150</a></td> <td>Cardiac abnormalities (atrial septal defect, pulmonic stenosis, hypertrophic cardiomyopathy), cutaneous abnormalities (ichthyosis, hyperkeratosis, hemangioma), postnatal short stature, prominent forehead, bitemporal narrowing, coarse facial features, prominent philtrum, down-slanting palpebral fissures, short upturned nose</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><EM>PTEN</EM>: phosphate and tensin homolog deleted on chromosome gene; ECG: electrocardiogram.<br />* Autosomal dominant inheritance.<br />Â¶ Associated with mutations in the Ras/mitogen-activated protein (MAP) kinase signaling pathway genes.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Williams CA, Dagli A, Battaglia A. Genetic disorders associated with macrocephaly. Am J Med Genet A 2008; 146A:2023.</LI>&#xD;&#xA;<LI>Olney AH. Macrocephaly syndromes. Semin Pediatr Neurol 2007; 14:128.</LI>&#xD;&#xA;<LI>Firth HV, Hurst JA, Hall JG. Macrocephaly. In: Oxford Desk Reference: Clinical Genetics, 1<SUP>st</SUP> ed. Oxford University Press, Oxford 2005. p.162.</LI></OL></div><div id=\"graphicVersion\">Graphic 75193 Version 11.0</div></div></div>"},"75194":{"type":"graphic_table","displayName":"Steps in staging ovarian cancer","title":"Steps in staging ovarian cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Steps in staging ovarian cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Obtain any free fluid for cytologic evaluation</td> </tr> <tr> <td>2. If no free fluid is present, obtain washings by instilling saline&nbsp;and recovering the fluid. The fluid should irrigate the cul de sac, paracolic gutters, and area beneath each diaphragm.</td> </tr> <tr> <td>3. Systematically explore all intraabdominal organs and surfaces: bowel, liver, gallbladder, diaphragms, mesentery, omentum, and the entire peritoneum should be visualized and palpated, as indicated</td> </tr> <tr> <td>4. Suspicious areas or adhesions should be biopsied. If there are no suspicious areas, multiple biopsies should be obtained from the peritoneum of the cul-de-sac, paracolic gutters, bladder, and intestinal mesentery when the disease appears confined to the ovary. These biopsies are not needed if the patient has advanced disease.</td> </tr> <tr> <td>5. The diaphragm should be biopsied or scraped for cytology. A laparoscope and biopsy instrument may be used.</td> </tr> <tr> <td>6. The omentum should be resected from the transverse colon.</td> </tr> <tr> <td>7. The retroperitoneum should be explored to evaluate pelvic nodes. Suspicious nodes should be removed and sent for frozen section examination. </td> </tr> <tr> <td>8. The paraaortic nodes should be exposed and enlarged nodes removed. Nodes superior to the inferior mesenteric artery should also be resected. </td> </tr> <tr> <td>9. In the absence of suspicious nodes, pelvic and paraaortic nodes should still be sampled to exclude the possibility of microscopic stage III disease. </td> </tr> <tr> <td>10. A total abdominal hysterectomy and bilateral salpingo-ophorectomy is performed. (Fertility-conserving surgery may be an option for some women).</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75194 Version 2.0</div></div></div>"},"75195":{"type":"graphic_table","displayName":"Urodynamic testing","title":"Types of urodynamic studies and measurements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of urodynamic studies and measurements</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Documentation of objective evidence of incontinence upon provocation</td>\n</tr>\n<tr>\n<td>Volume at first desire to void</td>\n</tr>\n<tr>\n<td>Intravesical, urethral, abdominal pressures during bladder filling and voiding</td>\n</tr>\n<tr>\n<td>Calculation of detrusor pressure</td>\n</tr>\n<tr>\n<td>Urine flow rate</td>\n</tr>\n<tr>\n<td>Residual bladder volume</td>\n</tr>\n<tr>\n<td>Leak point pressure</td>\n</tr>\n<tr>\n<td>Pressure flow studies relating flow rates to changes in pressure during bladder emptying</td>\n</tr>\n<tr>\n<td>Surface electromyography to indirectly measure pelvic floor and sphincter muscle contractility</td>\n</tr>\n<tr>\n<td>Videourodynamics to combine routine urodynamic studies with X-ray or ultrasound imaging</td>\n</tr>\n<tr>\n<td>Ambulatory urodynamics to evaluate patients while they perform their usual activities</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75195 Version 1.0</div></div></div>"},"75196":{"type":"graphic_picture","displayName":"HSV-2 lesion mimicking condyloma accuminata in HIV patient","title":"HSV-2 lesion mimicking condyloma accuminata in HIV-infected patient","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">HSV-2 lesion mimicking condyloma accuminata in HIV-infected patient</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/75196_HSV2_lesion_mimicking_condy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cory K, Valin N, Gozlan J, et al. Bipolar Hypertrophic Herpes: An Unusual Presentation of Acyclovir-Resistant Herpes Simplex Type 2 in a HIV-Infected Patient. Sex Transm Dis 2010; 37:126. Copyright Â© 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75196 Version 5.0</div></div></div>"},"75197":{"type":"graphic_figure","displayName":"Heterophyiasis life cycle","title":"Heterophyiasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 661px\" class=\"figure\"><div class=\"ttl\">Heterophyiasis life cycle</div><div class=\"cntnt\"><img style=\"width:641px; height:472px;\" src=\"images/ID/75197_Heterophyiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adults release embryonated eggs, each with a fully developed miracidium, and eggs are passed in the host's feces <STRONG>(1)</STRONG>. After ingestion by a suitable snail (first intermediate host), the eggs hatch and release miracidia, which penetrate the snail's intestine <STRONG>(2)</STRONG>. Genera <EM>Cerithidia</EM> and <EM>Pironella</EM> are important snail hosts in Asia and the Middle East, respectively. The miracidia undergo several developmental stages in the snail [ie, sporocysts <STRONG>(2a)</STRONG>, rediae <STRONG>(2b)</STRONG>, and cercariae <STRONG innerHtml>(2c)</STRONG>]. Many cercariae are produced from each rediae. The cercariae are released from the snail <STRONG>(3)</STRONG> and encyst as metacercariae in the tissues of a suitable fresh- or brackish-water fish (second intermediate host) <STRONG>(4)</STRONG>. The definitive host becomes infected by ingesting undercooked or salted fish containing metacercariae <STRONG>(5)</STRONG>. After ingestion, the metacercariae excyst, attach to the mucosa of the small intestine <STRONG innerHtml>(6)</STRONG>, and mature into adults (measuring 1.0 to 1.7 mm by 0.3 to 0.4 mm) <STRONG>(7)</STRONG>. In addition to humans, various fish-eating mammals (eg, cats and dogs) and birds can be infected by <EM>Heterophyes heterophyes</EM> <STRONG>(8)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Heterophyiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/heterophyiasis/index.html\">http://www.cdc.gov/dpdx/heterophyiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 75197 Version 6.0</div></div></div>"},"75198":{"type":"graphic_picture","displayName":"Molluscum eyelid","title":"Molluscum contagiosum on the eyelid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum on the eyelid</div><div class=\"cntnt\"><img style=\"width:400px; height:267px;\" src=\"images/DERM/75198_Molluscum_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solitary nodule of molluscum contagiosum in the middle of the left lower lid. There are no signs of secondary conjunctivitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease, Lippincott Williams &amp; Wilkins, Baltimore 2001. Copyright Â© 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75198 Version 2.0</div></div></div>"},"75199":{"type":"graphic_picture","displayName":"Bizzari-Giuffrida laryngoscope blade","title":"Bizzari-Giuffrida laryngoscope blade","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bizzari-Giuffrida laryngoscope blade</div><div class=\"cntnt\"><img style=\"width:396px; height:282px;\" src=\"images/EM/75199_BizzariGiuffridablade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bizzari-Giuffrida laryngoscope blade: no vertical flange is present, to allow insertion into small oral cavity or those patients who cannot open the mouth well.</div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 75199 Version 11.0</div></div></div>"},"75200":{"type":"graphic_algorithm","displayName":"Traumatized airway management algorithm","title":"Algorithm for acute management of traumatized airway","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Algorithm for acute management of traumatized airway</div><div class=\"cntnt\"><img style=\"width:588px; height:802px;\" src=\"images/EM/75200_Trauma_airway_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double set-up refers to simultaneous preparation for both direct oral intubation and emergency cricothyrotomy.</div><div class=\"graphic_footnotes\">IV: intravenous catheter; RSI: rapid sequence intubation; SaO<sub>2</sub>: arterial oxygen saturation; Sns: clinical signs; TTJV: transtracheal jet ventilation.</div><div id=\"graphicVersion\">Graphic 75200 Version 6.0</div></div></div>"},"75201":{"type":"graphic_table","displayName":"Distribution of somatostatin receptor subtypes","title":"Distribution of somatostatin receptor subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of somatostatin receptor subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Subtype 1</td>\n<td>Brain, pancreas, liver, GI tract, lung</td>\n</tr>\n<tr>\n<td>Subtype 2</td>\n<td>Brain, kidney</td>\n</tr>\n<tr>\n<td>Subtype 3</td>\n<td>Brain, pancreas</td>\n</tr>\n<tr>\n<td>Subtype 4</td>\n<td>Brain, lung</td>\n</tr>\n<tr>\n<td>Subtype 5</td>\n<td>Brain, heart, adrenal, pituitary, GI tract, skeletal muscle</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. N Engl J Med 1996; 334:246.</div><div id=\"graphicVersion\">Graphic 75201 Version 2.0</div></div></div>"},"75202":{"type":"graphic_diagnosticimage","displayName":"MRI pontine glioma","title":"Characteristic imaging findings of a diffuse infiltrating pontine glioma","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Characteristic imaging findings of a diffuse infiltrating pontine glioma</div><div class=\"cntnt\"><img style=\"width:496px; height:328px;\" src=\"images/PEDS/75202_MRI_pontine_glioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) There is diffuse expansion of the pons with mass effect and displacement of the fourth ventricle on this sagittal T1-weighted image. <br />(B) Similar findings are noted on this axial flair image of the same lesion.</div><div id=\"graphicVersion\">Graphic 75202 Version 3.0</div></div></div>"},"75204":{"type":"graphic_diagnosticimage","displayName":"Marked honeycombing in IPF CT","title":"Marked honeycombing in IPF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Marked honeycombing in IPF</div><div class=\"cntnt\"><img style=\"width:376px; height:280px;\" src=\"images/PULM/75204_Marked_honeycombing_in_IPF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Usual interstitial pneumonia pattern with marked honeycombing and traction bronchiectasis in both lower lobes along with an absence of ground glass changes. The peripheral regions of the lower lobes and middle lobe are typically involved, sparing the central parts of the lower lobes.</div><div class=\"graphic_footnotes\">IPF: idiopathic pulmonary fibrosis.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75204 Version 5.0</div></div></div>"},"75205":{"type":"graphic_figure","displayName":"Normal LV hemodynamics","title":"Normal left ventricular hemodynamics","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal left ventricular hemodynamics</div><div class=\"cntnt\"><img style=\"width:412px; height:350px;\" src=\"images/CARD/75205_Normal_LV_hemodynamics.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panel shows left ventricular (LV) volume versus time while the bottom panel shows the rate of change of LV volume (dV/dt). The cardiac cycle begins at end diastole (*). With the onset of systole, the LV volume decreases and reaches its minimum at end systole. Diastole, which begins at this point, has three distinct phases: rapid filling phase (RFP) during which the LV fills rapidly, dV/dt reaches its maximum, and the peak filling rate occurs; diastasis (D) during which there is little change in LV volume; and atrial systole (AS) in which active atrial contraction fills the LV which attains its end diastolic volume. Important diastolic parameters include the peak filling rate, the time to peak filling rate (TPFR), the percent contribution of atrial systole, and the first third filling fraction.</div><div id=\"graphicVersion\">Graphic 75205 Version 1.0</div></div></div>"},"75206":{"type":"graphic_figure","displayName":"Survival after transplant PAH","title":"Survival after lung transplantation for recipients with pulmonary arterialÂ hypertension (PAH): comparing single and bilateral lung transplant procedures","html":"<div class=\"graphic\"><div style=\"width: 699px\" class=\"figure\"><div class=\"ttl\">Survival after lung transplantation for recipients with pulmonary arterial&nbsp;hypertension (PAH): comparing single and bilateral lung transplant procedures</div><div class=\"cntnt\"><img style=\"width:679px; height:377px;\" src=\"images/PULM/75206_Survival_after_trnsplnt_PAH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival after single or bilateral lung transplantation for pulmonary arterial hypertension was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients.<br />Survival rates were compared using the log-rank test statistic.</div><div class=\"graphic_reference\">Reproduced from: Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Adult Lung and Heart-Lung Transplant Report-2014; Focus Theme: Retransplantation. J Heart Lung Transplant 2014; 33:1009. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 75206 Version 3.0</div></div></div>"},"75208":{"type":"graphic_figure","displayName":"Nitroprusside in RA stenosis","title":"Nitroprusside can lower GFR in bilateral renal artery stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nitroprusside can lower GFR in bilateral renal artery stenosis</div><div class=\"cntnt\"><img style=\"width:357px; height:214px;\" src=\"images/NEPH/75208_Nitroprusside_in_RA_stenosi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect on the glomerular filtration rate (GFR) of lowering the systemic blood pressure with increasing doses of nitroprusside in patients with unilateral (squares) and severe bilateral (circles) renal artery stenosis. The GFR remained relatively stable with unilateral disease but fell substantially with bilateral involvement. In the latter setting, renal perfusion pressure distal to the stenotic lesions presumably fell below the autoregulatory range despite the lack of interference with angiotensin II.</div><div class=\"graphic_reference\">Redrawn from: Textor SC, Novick AC, Tarazi RC, et al. Ann Intern Med 1985; 102:308.</div><div id=\"graphicVersion\">Graphic 75208 Version 3.0</div></div></div>"},"75209":{"type":"graphic_picture","displayName":"Histoplasmosis spleen","title":"Histoplasmosis in the spleen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histoplasmosis in the spleen</div><div class=\"cntnt\"><img style=\"width:375px; height:245px;\" src=\"images/ID/75209_Histoplasmosisspleen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin-stained section of splenic tissue (x1000) obtained from a patient with overwhelming histoplasmosis who presented with pneumonia. A macrophage in the center of the slide contains many yeast forms of <EM>Histoplasma capsulatum</EM>.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 75209 Version 2.0</div></div></div>"},"75210":{"type":"graphic_picture","displayName":"MTB in sputum","title":"<EM>Mycobacterium tuberculosis</EM> in sputum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Mycobacterium tuberculosis</EM> in sputum</div><div class=\"cntnt\"><img style=\"width:356px; height:240px;\" src=\"images/ID/75210_MTBinsputum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acid-fast stain of the same sputum (x1000). With this stain, the inflammatory cells appear blue and mycobacteria are red, thin, beaded rods.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 75210 Version 3.0</div></div></div>"},"75211":{"type":"graphic_picture","displayName":"Photomicrograph of urine sediment with white blood cells","title":"Photomicrograph of urine sediment with white blood cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photomicrograph of urine sediment with white blood cells</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/NEPH/75211_White_blood_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White blood cells in the urine sediment with nuclei and granular cytoplasm.</div><div class=\"graphic_reference\">Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.</div><div id=\"graphicVersion\">Graphic 75211 Version 2.0</div></div></div>"},"75214":{"type":"graphic_diagnosticimage","displayName":"Post-fracture pediatric hip avascular necrosis","title":"AVN of the hip after hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AVN of the hip after hip fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:318px;\" src=\"images/EM/75214_AVN_hip_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 10-year-old girl with Delbet type III fracture, who required open reduction and screw fixation, developed signs of AVN nine months after injury.</div><div class=\"graphic_footnotes\">AVN: avascular necrosis.</div><div class=\"graphic_reference\">Courtesy of Klane White, MD.</div><div id=\"graphicVersion\">Graphic 75214 Version 4.0</div></div></div>"},"75216":{"type":"graphic_picture","displayName":"Brown macular high-grade squamous intraepithelial vulvar lesion ","title":"Brown macular high-grade squamous intraepithelial lesion (HSIL) of vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brown macular high-grade squamous intraepithelial lesion (HSIL) of vulva</div><div class=\"cntnt\"><img style=\"width:292px; height:349px;\" src=\"images/OBGYN/75216_Brown_macular_lesion_of_VIN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High grade squamous intraepithelial lesion (HSIL) manifesting as a brown macular lesion of the vulva.</div><div class=\"graphic_reference\">Courtesy of Christine Holschneider, MD.</div><div id=\"graphicVersion\">Graphic 75216 Version 2.0</div></div></div>"},"75217":{"type":"graphic_table","displayName":"Androgen range child","title":"Typical ranges expected for serum androgens and steroid precursors in normal females and premature adrenarche*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical ranges expected for serum androgens and steroid precursors in normal females and premature adrenarche*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">17PREG (ng/dL)</td> <td class=\"subtitle1\">17PROG (ng/dL)</td> <td class=\"subtitle1\">11-Deoxy-Cortisol (ng/dL)</td> <td class=\"subtitle1\">Cortisol (microgram/dL)</td> <td class=\"subtitle1\">DHEAS (microgram/dL)</td> <td class=\"subtitle1\">DHEA (ng/dL)</td> <td class=\"subtitle1\">Androstenedione (ng/dL)</td> <td class=\"subtitle1\">Testosterone (ng/dL)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Baseline (8:00 AM)</td> </tr> <tr> <td class=\"indent1\">Children, 1-5 yr old</td> <td>10-105</td> <td>5-115</td> <td>20-160</td> <td>3-20</td> <td>5-35</td> <td>20-130</td> <td>10-50</td> <td>&#60;20</td> </tr> <tr> <td class=\"indent1\">Children, 6-10 yr old</td> <td>10-200</td> <td>5-115</td> <td>20-160</td> <td>3-20</td> <td>10-115</td> <td>20-345</td> <td>10-75</td> <td>&#60;20</td> </tr> <tr> <td class=\"indent1\"><em>Premature adrenarche</em></td> <td><em>20-350</em></td> <td><em>5-115</em></td> <td><em>20-160</em></td> <td><em>3-20</em></td> <td><em>40-130</em></td> <td><em>50-600</em></td> <td><em>20-75</em></td> <td><em>10-35</em></td> </tr> <tr> <td class=\"indent1\">Early pubertal girls</td> <td>35-350</td> <td>15-220</td> <td>20-160</td> <td>3-20</td> <td>35-130</td> <td>40-600</td> <td>40-175</td> <td>10-35</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Adult females, follicular phase<sup>&#182;</sup></td> <td>55-360</td> <td>15-150<sup>&#916;</sup></td> <td>20-160</td> <td>3-20</td> <td>75-255</td> <td>100-850</td> <td>60-200</td> <td>20-60</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">After ACTH<sub>1-24</sub> (Cosyntropin). Values are measured 30-60 minutes after &#8805;10 microgram/m<sup>2</sup> IV</td> </tr> <tr> <td class=\"indent1\">Children, 1-5 yr old</td> <td>45-350</td> <td>50-270</td> <td>95-300</td> <td>17-45</td> <td>5-35</td> <td>25-100</td> <td>15-70</td> <td>&#60;20</td> </tr> <tr> <td class=\"indent1\">Children, 6-10 yr old</td> <td>60-650</td> <td>85-300</td> <td>95-300</td> <td>17-45</td> <td>10-115</td> <td>70-320</td> <td>25-100</td> <td>&#60;20</td> </tr> <tr> <td class=\"indent1\"><em>Premature adrenarche</em></td> <td><em>80-750</em></td> <td><em>85-400</em></td> <td><em>95-300</em></td> <td><em>17-45</em></td> <td><em>40-130</em></td> <td><em>80-725</em></td> <td><em>25-230</em></td> <td><em>10-35</em></td> </tr> <tr> <td class=\"indent1\">Early pubertal girls</td> <td>150-750</td> <td>90-400</td> <td>95-300</td> <td>17-45</td> <td>35-130</td> <td>70-725</td> <td>55-230</td> <td>10-35</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Adult females, follicular phase</td> <td>150-1070</td> <td>35-160<sup>&#916;</sup></td> <td>95-300</td> <td>17-45</td> <td>75-255</td> <td>250-1470</td> <td>60-250</td> <td>20-60</td> </tr> <tr> <td><strong>Conversion multipliers to SI units</strong></td> <td><strong>0.0316 (nmol/L)</strong></td> <td><strong>0.0303 (nmol/L)</strong></td> <td><strong>0.0289 (nmol/L)</strong></td> <td><strong>0.0276 (micromol/L)</strong></td> <td><strong>0.0271 (micromol/L)</strong></td> <td><strong>0.0347 (nmol/L)</strong></td> <td><strong>0.0349 (nmol/L)</strong></td> <td><strong>0.0347 (nmol/L)</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DHEA: dehydroepiandrosterone; DHEAS: dehydroepiandrosterone sulfate; 17PREG: 17-hydroxypregnenolone; 17PROG: 17-hydroxyprogesterone.<br />* Ranges for radioimmunoassay after preparatory chromatography, except for cortisol and DHEAS. Values differ slightly among laboratories. <br />Â¶ 17PROG begins rising in the preovulatory phase and peaks as high as 400 ng/dL in the luteal phase of the cycle.<br />Î Normal women who are heterozygous for 21-hydroxylase deficiency usually have 17PROG levels &gt;140 ng/dl at baseline, and these women often have responses to ACTH greater than those shown.</div><div class=\"graphic_reference\">Modified with permission from: Rosenfield R. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Endocrinol Metab 2007; 92:787. http://jcem.endojournals.org/. Copyright &copy; 2007 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 75217 Version 8.0</div></div></div>"},"75218":{"type":"graphic_figure","displayName":"Infant upper GI anatomy PI","title":"Upper digestive system in a baby","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper digestive system in a baby</div><div class=\"cntnt\"><img style=\"width:435px; height:424px;\" src=\"images/PI/75218_Infant_upper_GI_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows where the esophagus and stomach are located in a baby. The lower esophageal sphincter is a muscle that normally keeps stomach juices from backing up into the esophagus.</div><div id=\"graphicVersion\">Graphic 75218 Version 4.0</div></div></div>"},"75219":{"type":"graphic_figure","displayName":"Deep veins of the lower extremity","title":"Deep veins of the lower extremity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep veins of the lower extremity</div><div class=\"cntnt\"><img style=\"width:429px; height:661px;\" src=\"images/PC/75219_Deep_veins_of_the_leg_2_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep veins of the right lower extremity. The paired tibial veins (anterior tibial, peroneal, and posterior tibial) are shown with their adjacent arteries. The bridging veins between the paired veins are also demonstrated. The popliteal and femoral veins are also sometimes duplicated (omitted from the diagram) with one of the duplicated segments frequently larger in caliber than the other.</div><div id=\"graphicVersion\">Graphic 75219 Version 6.0</div></div></div>"},"75220":{"type":"graphic_table","displayName":"Recommended screening for adults over 65 years","title":"Summary of screening, prevention, and counseling recommendations for adults age â¥65 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of screening, prevention, and counseling recommendations for adults age â¥65 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Priority problem</td> <td class=\"subtitle1\">Brief recommendation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Historical information and counseling</td> </tr> <tr> <td class=\"indent1\">Exercise</td> <td> <p>Moderate-to-vigorous aerobic activity&nbsp;three to&nbsp;five times per week</p> <p>Weight training or resistance exercises to maintain strength</p> <p>Flexibility activities to maintain range of motion</p> <p>Balance training to improve stability and prevent falls</p> </td> </tr> <tr> <td class=\"indent1\">Alcohol use</td> <td> <p>CAGE questionnaire</p> <p>Counseling to stop drinking</p> </td> </tr> <tr> <td class=\"indent1\">Tobacco use</td> <td> <p>Ongoing regular counseling to stop smoking</p> <p>Consideration of pharmacotherapy</p> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Medication use</td> <td class=\"sublist1_start\">Regular review of medication list for:</td> </tr> <tr> <td class=\"sublist1\">Completeness, accuracy, adherence, and affordability</td> </tr> <tr> <td class=\"sublist1\">Drug-drug, drug-disease interactions</td> </tr> <tr> <td class=\"sublist1\">Careful attention to use of specific drug types/classes including warfarin, digoxin, antidiabetic, analgesic, antihypertensive, psychotropic, and anticholinergic drugs</td> </tr> <tr> <td class=\"indent1\">Urinary incontinence (UI)</td> <td> <p>Inquire about presence and severity biannually</p> <p>Presence of UI should trigger medication review, GU exam, appropriate blood and urine tests</p> </td> </tr> <tr> <td class=\"indent1\">Driving</td> <td> <p>Consideration of driving problems in those with problems with vision, mobility, or cognition</p> <p>For demented patients, recommend stop driving or refer for detailed driving assessment</p> </td> </tr> <tr> <td class=\"indent1\">Social support</td> <td>Regular screening for financial and social support</td> </tr> <tr> <td class=\"indent1\">Elder mistreatment</td> <td>Routine direct questioning about problems with abuse or neglect</td> </tr> <tr> <td class=\"indent1\">Advance directives</td> <td>Discussion and documentation of preferences with living will and designation of healthcare power-of-attorney</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Physical examination and testing</td> </tr> <tr> <td class=\"indent1\">Blood pressure</td> <td> <p>Measure annually</p> <p>If treatment initiated, monitor orthostatic blood pressure, renal function, and electrolytes</p> </td> </tr> <tr> <td class=\"indent1\">Weight</td> <td>Weight loss of 10% or more per year triggers assessment of undernutrition, possible medical or medication-related causes, dental status, food security, food-related functional status, appetite and intake, swallow ability, and previous dietary restrictions</td> </tr> <tr> <td class=\"indent1\">Hearing and vision</td> <td> <p>Annual screening for hearing loss with patient inquiry and exam (Whisper test or handheld audiometry)</p> <p>Vision assessment as part of the routine workup for older adults with cognitive decline, functional impairment, or falls</p> </td> </tr> <tr> <td class=\"indent1\">Cognition</td> <td>Targeted screening in patients with memory complaints or new functional impairment with MMSE, Mini-Cog, Clock Drawing Test, Memory Impairment Screen, SLUMS, or MoCA</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Mood</td> <td class=\"sublist1_start\"> <p>Screen all older adults for depression with two questions:</p> <p>During the last month:</p> </td> </tr> <tr> <td class=\"sublist1\">1) Have you been bothered by feeling down, depressed, or hopeless?</td> </tr> <tr> <td class=\"sublist1\">2) Have you often been bothered by having little interest or pleasure in doing things?</td> </tr> <tr> <td class=\"indent1\">Gait and balance</td> <td>Get Up and Go Test</td> </tr> <tr> <td class=\"indent1\">Lipids</td> <td>Screen and treat older adults with CAD risk exceeding 10% over 10 years</td> </tr> <tr> <td class=\"indent1\">Bone density</td> <td>Screening densitometry for osteoporosis for women at age 65</td> </tr> <tr> <td class=\"indent1\">Abdominal aortic aneurysm (AAA)</td> <td>One-time screening ultrasound in men aged 65 to 75 with any history of smoking or family history of AAA requiring repair</td> </tr> <tr> <td class=\"indent1\">Diabetes</td> <td>Screen adults (to age 70) with BMI &#8805;25 kg/m<sup>2</sup>, hypertension or hyperlipidemia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cancer screening</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Cancer screening</td> <td class=\"sublist1_start\">Key considerations in older adults:</td> </tr> <tr> <td class=\"sublist1\">Life expectancy: Will this patient live long enough to benefit?</td> </tr> <tr> <td class=\"sublist1\">Potential harms: Procedural complications, anxiety, cost, and overdiagnosis</td> </tr> <tr> <td class=\"sublist1\">Individual patient preference</td> </tr> <tr> <td class=\"indent1\">Breast cancer</td> <td>Shared decision-making; if woman opts to be screened, biennial mammography if life expectancy is at least 10 years</td> </tr> <tr> <td class=\"indent1\">Colorectal cancer</td> <td> <p>Annual FOBT versus</p> <p>Screening colonoscopy every 10 years versus</p> <p>Flexible sigmoidoscopy every&nbsp;five years as long as life expectancy is at least&nbsp;five years</p> </td> </tr> <tr> <td class=\"indent1\">Cervical cancer</td> <td> <p>May safely discontinue Pap smears at or after age 65 after&nbsp;three consecutive normals within a 10-year period</p> <p>May discontinue after hysterectomy for benign indication</p> </td> </tr> <tr> <td class=\"indent1\">&nbsp;Lung cancer</td> <td>Annual low-dose chest CT scan for high-risk individuals to age 80 years; discontinue if person has not smoked for 15 years or if life expectancy is limited</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Immunization</td> </tr> <tr> <td class=\"indent1\">Tetanus-diptheria vaccine</td> <td>Booster every 10 years in patients who have received primary series (alternative: booster once after age 50); Tdap once</td> </tr> <tr> <td class=\"indent1\">Influenza vaccine</td> <td>Annual vaccination </td> </tr> <tr> <td class=\"indent1\"> <p>Pneumococcal vaccine (PCV13</p> <p>and PPSV23&nbsp;)</p> </td> <td> <p>Give PCV13 followed by PPSV23 6 to 12 months later, once after age 65</p> <p>Revaccinate PPSV23 once after age 65 if an initial vaccination was given before age 65 and&nbsp;five years have elapsed since the first dose</p> </td> </tr> <tr> <td class=\"indent1\">Herpes zoster vaccine</td> <td>One-time vaccination after age 50</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Aspirin</td> <td> <p>Consider daily aspirin in patients with five-year CAD risk of 3% or greater</p> <p>Weigh risks of gastrointestinal bleeding</p> </td> </tr> <tr> <td class=\"indent1\">Calcium and Vitamin D</td> <td>1200 mg of elemental calcium (diet and/or supplement) and at least 800&nbsp;international units&nbsp;of Vitamin D</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAGE: Cut down, Annoyed, Guilty, Eye-opener; GU: genitourinary; MMSE: Mini Mental State Examination; SLUMS: St. Louis University Mental Status Test; MoCA: Montreal Cognitive Assessment; BMI: body mass index; FOBT: fecal occult blood test; CT: computed tomography; CAD: coronary artery disease.</div><div id=\"graphicVersion\">Graphic 75220 Version 9.0</div></div></div>"},"75221":{"type":"graphic_diagnosticimage","displayName":"Tracheal diverticulum","title":"Tracheal diverticulum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal diverticulum</div><div class=\"cntnt\"><img style=\"width:360px; height:219px;\" src=\"images/PULM/75221_Tracheal_diverticulum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows a small gas-filled outpouching that originates from the right posterolateral aspect of the membranous tracheal wall.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75221 Version 2.0</div></div></div>"},"75222":{"type":"graphic_picture","displayName":"Incorrect lifting knees straight","title":"INCORRECT lifting mechanics: Knees straight/bending at the waist","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">INCORRECT lifting mechanics: Knees straight/bending at the waist</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/RHEUM/75222_Incorrect_lift_knees_stra.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sharon Alzner, MPT.</div><div id=\"graphicVersion\">Graphic 75222 Version 1.0</div></div></div>"},"75224":{"type":"graphic_figure","displayName":"Solute removal in PD","title":"Rates of solute diffusion in peritoneal dialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rates of solute diffusion in peritoneal dialysis</div><div class=\"cntnt\"><img style=\"width:405px; height:267px;\" src=\"images/NEPH/75224_Solute_removal_in_PD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dialysate-to-plasma concentration ratios (with 1.0 reflecting complete equilibration) for urea, creatinine, inulin, and protein during an eight-hour period in which dialysate is allowed to dwell in the peritoneum. Urea equilibration is so rapid that diffusion begins to level off at 90 to 120 minutes, and is essentially complete at 240 minutes. Thus, short dwell times will maximize the rate of urea removal. In comparison, larger molecules show a progressive decline in the rate of diffusion. Inulin diffusion, for example, increases linearly with time since a limiting concentration gradient is not approached. As a result, increasing the total time of dialysis enhances the rate of clearance of these larger molecules.</div><div class=\"graphic_reference\">Data from Popovich RP, Moncrief JW, Nolph KD, et al. Continuous ambulatory peritoneal dialysis. Ann Intern Med 1978; 88:449.</div><div id=\"graphicVersion\">Graphic 75224 Version 2.0</div></div></div>"},"75225":{"type":"graphic_picture","displayName":"Cicatrix concealed penis","title":"Cicatrix concealed penis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cicatrix concealed penis</div><div class=\"cntnt\"><img style=\"width:427px; height:154px;\" src=\"images/PEDS/75225_Cicatrix_concealed_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Concealed penis after circumcision due to cicatrix formation. <BR>(A) The cicatricial scar (distal arrows) traps and hides the penis. There is no exposed shaft skin. Note penile position (black arrow).<BR>(B) The tight circumferential scar (arrows) is incised and the penis is exposed. Almost all shaft skin was previously removed. <BR>(C) Surgical correction used skin multiple Z-plasties (arrows) for scrotal skin flaps to compensate for the lack of penile skin.</div><div class=\"graphic_reference\">Reproduced from: Casale A, Beck S, Cain M, et al. Concealed penis in childhood: A spectrum of etiology and treatment. J Urol 1999; 162:1165. Copyright Â© 1999. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 75225 Version 3.0</div></div></div>"},"75227":{"type":"graphic_figure","displayName":"Neurologic effects of organophosphate and carbamate agents","title":"Neurologic effects of organophosphate and carbamate agents","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Neurologic effects of organophosphate and carbamate agents</div><div class=\"cntnt\"><img style=\"width:530px; height:341px;\" src=\"images/PULM/75227_Neurotransmission_organopho.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACH: acetylcholine; Epi: epinephrine; NE: norepinephrine; NMJ: neuromuscular junction.</div><div id=\"graphicVersion\">Graphic 75227 Version 3.0</div></div></div>"},"75229":{"type":"graphic_figure","displayName":"Modified Mallampati airway classification","title":"The modified Mallampati classification for difficult laryngoscopy and intubation","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">The modified Mallampati classification for difficult laryngoscopy and intubation</div><div class=\"cntnt\"><img style=\"width:566px; height:292px;\" src=\"images/EM/75229_Mallampati_classification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The modified Mallampati classification<SUP>[1]</SUP> is a simple scoring system that relates the amount of mouth opening to the size of the tongue, and provides an estimate of space available for oral intubation by direct laryngoscopy. According to the Mallampati scale, class I is present when the soft palate, uvula, and pillars are visible; class II when the soft palate and base of the uvula are visible; class III when only the soft palate is visible; and class IV when only the hard palate is visible.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Samsoon GL, Young JR. Difficult tracheal intubation: a retrospective study. Anaesthesia 1987; 42:487.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75229 Version 8.0</div></div></div>"},"75230":{"type":"graphic_picture","displayName":"Urticarial drug eruption","title":"Urticarial drug eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticarial drug eruption</div><div class=\"cntnt\"><img style=\"width:324px; height:315px;\" src=\"images/ALLRG/75230_Urticarial_drug_eruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75230 Version 3.0</div></div></div>"},"75231":{"type":"graphic_table","displayName":"Selecting infant formulas","title":"Formula selection for infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Formula selection for infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Formula category and description</td> <td class=\"subtitle1\">Examples</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Prematurity</p> (For infants &#60;34 weeks gestational age and/or weight &#60;2 kg)</td> <td> <p><strong>Premature formula:</strong></p> <p>High in protein, calcium and phosphorus</p> <p>Includes medium-chain triglycerides (MCT), long chain fat, glucose polymers, and lactose</p> <p>Supplemented with additional calcium, phosphorus, Vit A, Vit D, folate, zinc, and iron</p> <p>Calcium: Phosphorus ratio of 2:1</p> <p>Available in concentrations: 20 kcal/oz, 24 kcal/oz, 30 kcal/oz</p> Low-iron formulations are available, but are not generally recommended</td> <td> <p>Enfamil Premature Lipil (20, 24, or 30 kcal/oz)</p> <p>Similac Special Care Advance (20, 24, or 30 kcal/oz)</p> <p>Breastmilk + Enfamil Human Milk Fortifier</p> <p>Breastmilk + Similac Human Milk Fortifier</p> <p>Gerber Good Start Premature (20, 24, or 30 kcal/oz)</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Former premature infants, post hospital discharge*</p> (For former premies, who are now &#62;2 kg or &#62;40 weeks corrected age. Use until 9 to 12 months corrected age.)</td> <td> <p><strong>Post-discharge formula:</strong></p> <p>Composition similar to above</p> Standard concentration is 22 kcal/oz</td> <td> <p>Similac Neosure</p> Enfacare Lipil</td> </tr> <tr class=\"divider_bottom\"> <td>Normal GI tract</td> <td> <p><strong>Standard infant formula:</strong></p> <p>Cow's milk protein</p> <p>Lactose</p> Long chain fat (vegetable oil blend); no MCT</td> <td> <p>Breastmilk</p> <p>Enfamil Premium</p> <p>Similac Advance</p> Gerber Good Start Gentle</td> </tr> <tr class=\"divider_bottom\"> <td>Primary or secondary lactose intolerance</td> <td> <p><strong>Lactose-free formula:</strong></p> <p>Milk protein isolate OR soy protein isolate</p> <p>Long chain fat</p> Lactose free</td> <td> <p>Similac Sensitive</p> <p>Prosobee</p> <p>Similac Isomil Advance</p> Gerber Good Start Soy</td> </tr> <tr class=\"divider_bottom\"> <td>Food protein intolerance (eg, cow's milk protein intolerance)</td> <td> <p><strong>Hydrolysate formula:</strong></p> <p>Cow's milk protein hydrolysate</p> <p>Long chain fat; variable MCT (0 to 55 percent of fat)</p> Lactose free</td> <td> <p>Enfamil Nutramigen</p> <p>Pregestimil</p> Similac Alimentum</td> </tr> <tr class=\"divider_bottom\"> <td>Severe protein allergy</td> <td> <p><strong>Elemental formula:</strong></p> <p>Free amino acids</p> <p>Moderate MCT (about 30 percent of fat); remainder long chain fat</p> Lactose free</td> <td> <p>Neocate Infant DHA &#38; ARA</p> <p>Elecare infant</p> <p>Puramino (previously known as Nutramigen AA)</p> <p>Alfamino Infant</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Malabsorption</p> <p>Intractable diarrhea</p> Steatorrhea</td> <td> <p><strong>Hydrolysate formula with MCT:</strong></p> <p>Cow's milk protein hydrolysate</p> <p>Long chain fats; moderate to high MCT (30 to 55 percent of fat)</p> Lactose free</td> <td> <p>Pregestimil</p> <p>Similac Alimentum Advance</p> <p>Gerber Extensive HA</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Impaired fat absorption</p> <p>Chylous effusion</p> <p>Lymphatic disorder</p> <p>Metabolic disorders</p> </td> <td> <p><strong>High MCT formula:</strong></p> <p>Intact protein</p> Very high MCT (84 to 90 percent of fat)</td> <td> <p>Portagen</p> <p>Monogen</p> <p>Enfaport</p> Lipistart</td> </tr> <tr class=\"divider_bottom\"> <td>Decreased renal function</td> <td> <p><strong>Renal formula for infants:</strong></p> <p>Cow's milk protein (60 percent whey/40 percent casein)</p> <p>Long chain fat</p> <p>Low iron</p> <p>Lower in potassium</p> Lower in Ca, Phos (maintaining 2:1 ratio)</td> <td>Similac PM 60/40</td> </tr> <tr> <td>Galactosemia</td> <td> <p><strong>Soy-based formula:</strong></p> <p>Soy-based protein</p> <p>Long chain fat</p> Lactose free (carbohydrate supplied by glucose polymers)</td> <td> <p>Enfamil ProSobee</p> <p>Similac Isomil</p> Gerber Good Start Soy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Use of these nutritionally enriched formulas for preterm infants after discharge is controversial, because a benefit has not been established. For more detail, refer to the topic review discussing the growth management of preterm infants.</div><div id=\"graphicVersion\">Graphic 75231 Version 11.0</div></div></div>"},"75232":{"type":"graphic_waveform","displayName":"Atrial tachycardia tutorial","title":"Atrial tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial tachycardia</div><div class=\"cntnt\"><img style=\"width:231px; height:96px;\" src=\"images/CARD/75232_Atrial_tachycardia_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial tachycardia is a supraventricular tachyarrhythmia that has a rate of 140 to 220 beats per minute. The QRS complexes occur at regular intervals (ie, there is constant RR cycle length), the P waves have a uniform morphology, and the PR interval is constant.</div><div id=\"graphicVersion\">Graphic 75232 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"75235":{"type":"graphic_table","displayName":"Interventions intracell calcium","title":"Interventions that theoretically alter diastolic cytosolic calcium levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interventions that theoretically alter diastolic cytosolic calcium levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Theoretical effect on diastolic Ca(i)2+</td> <td class=\"subtitle1\">Mechanisms/comments</td> </tr> <tr> <td>Ischemia or hypoxia</td> <td>Increase</td> <td>Decreased SR uptake and SL extrusion</td> </tr> <tr> <td>Digitalis</td> <td>Increase</td> <td>Increases NA(i)+ by Na+/K+ pump inhibition; Ca(i)2+ increased secondary to increased Na+ -Ca2+ exchange. Combination of ischemia or hypoxia + digitalis cause exaggerated diastolic dysfunction</td> </tr> <tr> <td>Ca2+ channel blocker</td> <td>Decrease</td> <td>Decreased Ca2+ entry by way of sarcolemma. Associated bradycardia prolongs diastole, allowing for greater calcium removal via SR and SL</td> </tr> <tr> <td>&#946;-adrenergic blocker</td> <td>&#177;</td> <td>Decreased c-AMP levels decrease Ca2+ entry via Ca2+-channel, but also decrease Ca2+ reuptake by SR. Associated bradycardia prolongs diastole as with Ca2+ channel blocker</td> </tr> <tr> <td>&#946;-adrenergic agonist</td> <td>&#177;</td> <td>Increased c-AMP levels increase Ca2+ entry, but also increase SR calcium reuptake by phospholamban regulation</td> </tr> <tr> <td>Phosphodiesterase inhibitors</td> <td>&#177;</td> <td>Same mechanisms as &#946;-adrenergic agonist</td> </tr> <tr> <td>Ca2+ agonist (BAYK8644)</td> <td>Increase</td> <td>Increased Ca2+ influx via L-type channels can produce Ca2+ overload</td> </tr> <tr> <td>Ca2+ ionophore (A23187)</td> <td>Increase</td> <td>Increased transsarcolemmal Ca2+ influx</td> </tr> <tr> <td>Na+ agonist (vertridine)</td> <td>Increase</td> <td>[Ca2+]i loading by Na+/Ca2+ exchange</td> </tr> <tr> <td>Na+ ionophore (monensin)</td> <td>Increase</td> <td>[Ca2+]i loading by Na+/Ca2+ exchange</td> </tr> <tr> <td>Antagonist of Na+/Ca2+ exchanger (dichlorobenzamil)</td> <td>&#177;</td> <td>Potential to affect [Na+]i</td> </tr> <tr> <td>&nbsp;Antagonist of Na+/H+ exchanger (amiloride)</td> <td>&#177;</td> <td>Potential to affect [Na+]i</td> </tr> <tr> <td>Inhibitor of SERCA2(caffeine)</td> <td>&#177;</td> <td>Multiple effects but blocks Ca2+ uptake after inducing&nbsp;Ca2+ release</td> </tr> <tr> <td>SR Ca2+ ATPase inhibitor (thapsigarin)</td> <td>&#177;</td> <td>Blocks Ca2+ uptake by inhibiting pump</td> </tr> <tr> <td>Inhibitor of RYR2 (ryanodine)</td> <td>&#177;</td> <td>Blocks Ca2+ release channel of SR leading to Ca2+ overload of vesicles and decreased uptake</td> </tr> <tr> <td>Phospholamban antibodies</td> <td>&#177;</td> <td>May enhance SR Ca2+ uptake by modifying function of phospholamban</td> </tr> <tr> <td>Mitochondrial inhibitors (FCCP)</td> <td>&#177;</td> <td>Decreased Ca2+ storage capacity of mitochondria in overload state</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">SERCA2: sarco(endo)plasmic reticulum Ca2+ ATPase pump; RYR2: ryanodine receptor 2.</div><div id=\"graphicVersion\">Graphic 75235 Version 2.0</div></div></div>"},"75238":{"type":"graphic_picture","displayName":"Lentigo maligna cheek 2","title":"Lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna</div><div class=\"cntnt\"><img style=\"width:389px; height:427px;\" src=\"images/DERM/75238_Lentigo_MalignaCrop_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lentigo maligna on the check of a 70-year-old woman.</div><div id=\"graphicVersion\">Graphic 75238 Version 1.0</div></div></div>"},"75239":{"type":"graphic_picture","displayName":"Centruroides exilicauda 1","title":"Centruroides exilicauda (sculpturatus) or bark scorpion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Centruroides exilicauda (sculpturatus) or bark scorpion</div><div class=\"cntnt\"><img style=\"width:396px; height:296px;\" src=\"images/EM/75239_C_exilicauda_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Banner Good Samaritan Medical Center, Department of Medical Toxicology.</div><div id=\"graphicVersion\">Graphic 75239 Version 2.0</div></div></div>"},"75242":{"type":"graphic_figure","displayName":"Female pelvic lymphadenectomy","title":"Female pelvic lymphadenectomy","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Female pelvic lymphadenectomy</div><div class=\"cntnt\"><img style=\"width:474px; height:357px;\" src=\"images/OBGYN/75242_Pelvic_lymphadenectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node dissection is begun by sharply and bluntly mobilizing the tissue lateral to the external iliac artery and vein, and moving this tissue until the external iliac artery can be identified. The dissection should be kept close to the artery to facilitate the resection. Using Metzenbaum scissors and forceps, the lymphatic tissue is then sharply dissected off the surface of the external and common iliac arteries, and reflected medially. With lateral traction at this time, the external iliac vein and obturator fossa can be identified.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 75242 Version 3.0</div></div></div>"},"75243":{"type":"graphic_diagnosticimage","displayName":"SCLC pos PET","title":"CT negative PET positive Paraneoplastic disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT negative PET positive Paraneoplastic disease</div><div class=\"cntnt\"><img style=\"width:432px; height:276px;\" src=\"images/PULM/75243_SCLC_pos_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 71-year-old man presented with a polyneuropathy thought secondary to a paraneoplastic syndrome as he had a high P/Q type calcium channel antibody present in serum. PET-CT showing intense metabolic activity in a normal sized left hilar node after CT was negative. Ultrasound guided bronchoscopy sampling revealed small cell lung cancer in this hilar node.</div><div class=\"graphic_footnotes\">PET: positron emission tomography; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 75243 Version 3.0</div></div></div>"},"75244":{"type":"graphic_figure","displayName":"Femoral nerve block","title":"Femoral nerve block","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Femoral nerve block</div><div class=\"cntnt\"><img style=\"width:496px; height:541px;\" src=\"images/SURG/75244_Femoral_nerve_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is placed in a supine position. The common femoral artery is palpated. The needle is inserted just below the inguinal ligament and 1.5 cm lateral to the artery. When stimulation of the femoral nerve produces twitches of the quadriceps muscle (ie, the \"patellar snap\"), the local anesthetic is injected.</div><div class=\"graphic_footnotes\">n.: nerve; a.: artery; v.: vein.</div><div id=\"graphicVersion\">Graphic 75244 Version 2.0</div></div></div>"},"75247":{"type":"graphic_table","displayName":"Catheters used for venous and arterial access","title":"Catheters used for venous and arterial access","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Catheters used for venous and arterial access</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Catheter type</td> <td class=\"subtitle1\">Entry site</td> <td class=\"subtitle1\">Length</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Peripheral venous catheters</td> <td>Usually inserted in veins of forearm or hand</td> <td>&#60;3 inches</td> <td>Phlebitis with prolonged use; rarely associated with bloodstream infection</td> </tr> <tr> <td>Peripheral arterial catheters</td> <td>Usually inserted in radial artery; can be placed in femoral, axillary, brachial, posterior tibial arteries</td> <td>&#60;3 inches</td> <td>Low infection risk; rarely associated with bloodstream infection</td> </tr> <tr> <td>Midline catheters</td> <td>Inserted via the antecubital fossa into the proximal basilic or cephalic veins; does not enter central veins, peripheral catheters</td> <td>3 to 8 inches</td> <td>Anaphylactoid reactions have been reported with catheters made of elastomeric hydrogel; lower rates of phlebitis than short peripheral catheters</td> </tr> <tr> <td>Non-tunneled central venous catheters</td> <td>Percutaneously inserted into central veins (subclavian, internal jugular, or femoral)</td> <td>&#8805;8 cm depending on patient size</td> <td>Account for majority of CRBSI</td> </tr> <tr> <td>Pulmonary artery catheters</td> <td>Inserted through a Teflon introducer in a central vein (subclavian, internal jugular, or femoral)</td> <td>&#8805;30 cm depending on patient size</td> <td>Usually heparin bonded; similar rates of bloodstream infection as CVCs; subclavian site preferred to reduce infection risk</td> </tr> <tr> <td>Peripherally inserted central venous catheters</td> <td>Inserted into basilic, cephalic, or brachial veins and enter the superior vena cava</td> <td>&#8805;20 cm depending on patient size</td> <td>Lower rate of infection than nontunneled CVCs</td> </tr> <tr> <td>Tunneled central venous catheters</td> <td>Implanted into subclavian, internal jugular, or femoral veins</td> <td>&#8805;8 cm depending on patient size</td> <td>Cuff inhibits migration of organisms into catheter tract; lower rate of infection than nontunneled CVC</td> </tr> <tr> <td>Totally implantable</td> <td>Tunneled beneath skin and have subcutaneous port accessed with a needle; implanted in subclavian or internal jugular vein</td> <td>&#8805;8 cm depending on patient size</td> <td>Lowest risk for CRBSI; improved patient self-image; no need for local catheter-site care; surgery required for catheter removal</td> </tr> <tr> <td>Umbilical catheters</td> <td>Inserted into either umbilical vein or umbilical artery</td> <td>&#8804;6 cm depending on patient size</td> <td>Risk for CRBSI similar with catheters placed in umbilical vein versus artery</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CRBSI: catheter-related bloodstream infection; CVC: central venous catheter.</div><div class=\"graphic_reference\">Reproduced from: O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52:e162, by permission of Oxford University Press. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 75247 Version 4.0</div></div></div>"},"75248":{"type":"graphic_diagnosticimage","displayName":"Pancreatoscope on fluoroscopy","title":"Introduction of a cholangiopancreatoscope into the pancreatic duct","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Introduction of a cholangiopancreatoscope into the pancreatic duct</div><div class=\"cntnt\"><img style=\"width:504px; height:502px;\" src=\"images/GAST/75248_Pancreatoscope_fluorosc_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image showing a cholangiopancreatoscope being passed through a therapeutic duodenoscope and into the pancreatic duct.</div><div id=\"graphicVersion\">Graphic 75248 Version 2.0</div></div></div>"},"75249":{"type":"graphic_figure","displayName":"Anatomic location of sinuses","title":"Anatomy of the sinuses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the sinuses</div><div class=\"cntnt\"><img style=\"width:400px; height:361px;\" src=\"images/ID/75249_Anatomic_location_of_sinuse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing showing location of the frontal, ethmoid, and maxillary sinuses.</div><div id=\"graphicVersion\">Graphic 75249 Version 2.0</div></div></div>"},"75250":{"type":"graphic_picture","displayName":"Cocci lung stain A","title":"<EM>Coccidioides</EM> spp in lung tissue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Coccidioides</EM> spp in lung tissue</div><div class=\"cntnt\"><img style=\"width:396px; height:310px;\" src=\"images/ID/75250_Cocci_lung_stain_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spherules of <EM>Coccidioides</EM> spp in a transbronchial biopsy specimen stained with hematoxylin and eosin.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Houck, MD.</div><div id=\"graphicVersion\">Graphic 75250 Version 3.0</div></div></div>"},"75251":{"type":"graphic_table","displayName":"Line infection prevention","title":"General recommendations for prevention of infections associated with any intravascular catheter in adult and pediatric patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General recommendations for prevention of infections associated with any intravascular catheter in adult and pediatric patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Health care worker education and training</td> </tr> <tr> <td>Educate health care workers regarding indication for intravascular catheter use, proper procedures for the insertion and maintenance, and infection control measures to prevent intravascular catheter-associated infections.</td> </tr> <tr> <td class=\"subtitle1_single\">Hand hygiene</td> </tr> <tr> <td>Observe proper hand hygiene either by washing hands with conventional antiseptic-containing soap and water or with waterless alcohol-based gels or foams. Use of gloves does not obviate the need for hand hygiene.</td> </tr> <tr> <td class=\"subtitle1_single\">Aseptic technique during catheter insertion and care</td> </tr> <tr> <td>Maintain aseptic technique for the insertion and care of intravascular catheters. Use maximal barrier precautions when inserting arterial or central venous catheters.</td> </tr> <tr> <td class=\"subtitle1_single\">Catheter site care</td> </tr> <tr> <td>Disinfect clean skin with an appropriate antiseptic before catheter insertion and at the time of dressing changes. A 2% chlorhexidine-based preparation is preferred, but there is no recommendation for its use in infants less than two months of age.</td> </tr> <tr> <td>Use sterile gauze or sterile transparent semipermeable dressing to cover the catheter site.</td> </tr> <tr> <td>Do not use topical antibiotic ointment or creams on insertion sites (except for dialysis catheters).</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of intravascular catheters</td> </tr> <tr> <td>Remove any intravascular catheter that is no longer essential.</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of administration sets</td> </tr> <tr> <td>Replace administration sets, including secondary sets and add-on devices, no more frequently than at 72-hour intervals, unless clinically indicated. Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion. Replace tubing used to administer propofol infusions every 6 to 12 hours, depending on its use, per the manufacturer's recommendation.</td> </tr> <tr> <td class=\"subtitle1_single\">Parenteral fluids</td> </tr> <tr> <td>Complete the infusion of lipid containing solutions within 24 hours of hanging the solution.</td> </tr> <tr> <td>Complete the infusion of lipid emulsions alone within 12 hours of hanging the solution.</td> </tr> <tr> <td>Complete infusions of blood or other blood products within four hours of hanging the blood.</td> </tr> <tr> <td class=\"subtitle1_single\">Intravenous injection ports</td> </tr> <tr> <td>Clean injection ports with 70% alcohol or an iodophor before accessing the system.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75251 Version 3.0</div></div></div>"},"75252":{"type":"graphic_picture","displayName":"Papular PKDL","title":"Patient with papular post-kala-azar dermal leishmaniasis (PKDL) ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with papular post-kala-azar dermal leishmaniasis (PKDL) </div><div class=\"cntnt\"><img style=\"width:320px; height:269px;\" src=\"images/ID/75252_Papular_PKDL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papular PKDL in a 14-year-old boy in Bihar, India. He had already been treated with more than 60 injections of sodium stibogluconate with only partial resolution of his rash.</div><div class=\"graphic_reference\">Reproduced with permission from: Caryn Bern, MD.</div><div id=\"graphicVersion\">Graphic 75252 Version 3.0</div></div></div>"},"75254":{"type":"graphic_picture","displayName":"Amyloid AA IF","title":"Immunofluorescence microscopy revealing secondary amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence microscopy revealing secondary amyloidosis</div><div class=\"cntnt\"><img style=\"width:378px; height:258px;\" src=\"images/NEPH/75254_Amyloid_AA_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in secondary amyloidosis using an anti-AA antiserum. Markedly positive staining is present in the glomeruli. Although not shown, there is also substantial amyloid deposition in the tubules.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75254 Version 2.0</div></div></div>"},"75256":{"type":"graphic_table","displayName":"ACC AHA diagnosis evaluation AR","title":"ACC/AHA guideline summary: Diagnosis and initial evaluation of aortic regurgitation (AR)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Diagnosis and initial evaluation of aortic regurgitation (AR)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Class I - There is evidence and/or general\nagreement that the following tests are indicated for the diagnosis and\ninitial evaluation in patients with AR</td>\n\n</tr>\n<tr>\n<td class=\"sublist1_start\">&#8226;&nbsp; Echocardiography</td>\n\n</tr>\n<tr>\n<td class=\"sublist1\">1. To confirm the diagnosis and to estimate the severity of acute or chronic AR.</td>\n\n</tr>\n<tr>\n<td class=\"sublist1\">2. To determine the cause of chronic AR, including\nassessment of valve morphology and the size and morphology of the\naortic root.</td>\n\n</tr>\n\n<tr>\n<td class=\"sublist1\">3. To determine left ventricular function and\ndetect left ventricular hypertrophy and left ventricular dimensions or\nvolumes in chronic AR.</td>\n\n</tr>\n\n<tr>\n<td class=\"sublist1\">4. Among patients with an enlarged aortic root, to assess both AR and the severity of aortic dilatation.</td>\n\n</tr>\n\n<tr>\n<td class=\"sublist1\">5. Among asymptomatic patients with chronic AR, to periodically reevaluate left ventricular size and function. </td>\n\n</tr>\n\n<tr>\n<td class=\"sublist1\">6. To reassess mild, moderate, or severe AR in patients who have new or changing symptoms.</td>\n\n</tr>\n\n<tr>\n<td class=\"sublist1_start\">&#8226;&nbsp; Radionuclide angiography or magnetic resonance imaging</td>\n\n</tr>\n<tr>\n<td class=\"sublist1\">1. For the initial and follow-up assessment of left ventricular volume and function at rest when echocardiography is suboptimal.</td>\n\n</tr>\n\n<tr>\n<td class=\"sublist1_start\">&#8226;&nbsp; Cardiac catheterization</td>\n\n</tr>\n<tr>\n<td class=\"sublist1\">1. With aortic root angiography and measurement of\nleft ventricular pressure to assess the severity of AR, left\nventricular function, and aortic root size when noninvasive tests are\ninconclusive or provide discrepant results from clinical findings.</td>\n\n</tr>\n\n\n\n<tr>\n<td class=\"subtitle1_single\">Class IIa -  The weight of evidence or\nopinion is in favor of efficacy of the following tests in patients with\nAR in the following settings</td>\n\n</tr>\n<tr>\n<td class=\"sublist1_start\">&#8226;&nbsp; Exercise stress testing in chronic AR</td>\n\n</tr>\n<tr>\n<td class=\"sublist1\">1. To assess functional capacity and symptom response in patients with a history of equivocal symptoms.</td>\n\n</tr>\n\n<tr>\n<td class=\"sublist1\">2. To assess symptoms and functional capacity prior to participation in athletic activity.</td>\n\n</tr>\n\n<tr>\n<td class=\"sublist1_start\">&#8226;&nbsp; Magnetic resonance imaging</td>\n\n</tr>\n<tr>\n<td class=\"sublist1\">1. To assess the severity of AR when echocardiography is not satisfactory.</td>\n\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Class IIb - The weight of evidence or\nopinion is less well established for the following test in patients\nwith AR in the following setting</td>\n\n</tr>\n<tr>\n<td class=\"sublist1_start\">&#8226;&nbsp; Exercise stress testing with radionuclide angiography</td>\n\n</tr>\n<tr>\n<td class=\"sublist1\">1. To assess left ventricular function in asymptomatic or symptomatic patients with chronic AR.</td>\n\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Class III - There is evidence and/or\ngeneral agreement that the following test is not useful in patients\nwith AR in the following settings</td>\n\n</tr>\n<tr>\n<td class=\"sublist1_start\">&#8226;&nbsp; Cardiac catheterization</td>\n\n</tr>\n<tr>\n<td class=\"sublist1\">1. When noninvasive tests are adequate and consistent with clinical findings and coronary angiography is not required.</td>\n\n</tr>\n\n<tr>\n<td class=\"sublist1\">2. In asymptomatic patients in whom noninvasive tests are adequate.</td>\n\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.</div><div id=\"graphicVersion\">Graphic 75256 Version 2.0</div></div></div>"},"75257":{"type":"graphic_picture","displayName":"Residual Barretts Lugol","title":"Chromoendoscopy showing residual Barrett's esophagus after photodynamic therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chromoendoscopy showing residual Barrett's esophagus after photodynamic therapy</div><div class=\"cntnt\"><img style=\"width:330px; height:311px;\" src=\"images/GAST/75257_Residual_Barretts_Lugol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic image after Lugol's chromoendoscopy, which shows an unstained small area of residual Barrett's esophagus following photodynamic therapy (green arrow). Note the adjacent normal black colored squamous mucosa, squamocolumnar junction, and unstained normal gastric cardiac mucosa (yellow arrow).</div><div class=\"graphic_reference\">Courtesy of Marcia I Canto, MD, MHS.</div><div id=\"graphicVersion\">Graphic 75257 Version 2.0</div></div></div>"},"75258":{"type":"graphic_picture","displayName":"En coup de sabre - central forehead","title":"En coup de sabre on the central forehead","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">En coup de sabre on the central forehead</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75258_En_coup_de_sabre_cent_fore.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A shiny, depressed, linear plaque is present on the central forehead.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75258 Version 4.0</div></div></div>"},"75259":{"type":"graphic_table","displayName":"HAS-BLED bleeding risk score","title":"Clinical characteristics comprising the HAS-BLED bleeding risk score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical characteristics comprising the HAS-BLED bleeding risk score</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Letter</td> <td class=\"subtitle1\">Clinical characteristic*</td> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\">HAS-BLED score<br /> (total points)</td> <td class=\"subtitle1\">Bleeds per 100 patient-years<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">H</td> <td>Hypertension (ie, uncontrolled blood pressure)</td> <td>1</td> <td>0</td> <td>1.13</td> </tr> <tr> <td class=\"indent1\">A</td> <td>Abnormal renal and liver function (1 point each)</td> <td>1 or 2</td> <td>1</td> <td>1.02</td> </tr> <tr> <td class=\"indent1\">S</td> <td>Stroke</td> <td>1</td> <td>2</td> <td>1.88</td> </tr> <tr> <td class=\"indent1\">B</td> <td>Bleeding tendency or predisposition</td> <td>1</td> <td>3</td> <td>3.74</td> </tr> <tr> <td class=\"indent1\">L</td> <td>Labile INRs (for patients taking warfarin)</td> <td>1</td> <td>4</td> <td>8.70</td> </tr> <tr> <td class=\"indent1\">E</td> <td>Elderly (age greater than 65 years)</td> <td>1</td> <td>5 to 9</td> <td>Insufficient data</td> </tr> <tr> <td class=\"indent1\">D</td> <td>Drugs (concomittant aspirin or NSAIDs) or excess alcohol&nbsp;use&nbsp;(1 point each)</td> <td>1 or 2</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">&nbsp;</td> <td>Maximum 9 points</td> <td colspan=\"2\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The HAS-BLED bleeding risk score has only been validated in patients with atrial fibrillation receiving warfarin. Refer to UpToDate topics on anticoagulation in patients with atrial fibrillation and on specific anticoagulants for further information and other bleeding risk scores and their performance relative to clinical judgement. </div><div class=\"graphic_footnotes\">INR: international normalized ratio; NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* Hypertension is defined as systolic blood pressure &gt;160 mmHg. Abnormal&nbsp;renal function is defined as the presence of chronic dialysis, renal transplantation, or serum creatinine â¥200 micromol/L. Abnormal liver function is defined as chronic hepatic disease (eg, cirrhosis) or biochemical evidence of significant hepatic derangement (eg, bilirubin more than two times the&nbsp;upper limit of normal, plus one or more of aspartate transaminase, alanine transaminase, and/or alkaline phosphatase more than three times the upper limit normal). Bleeding predisposition includes chronic bleeding disorder or&nbsp;previous bleeding requiring hospitalization or transfusion. Labile INRs for a patient on warfarin&nbsp;includes unstable INRs, excessively high&nbsp;INRs, or&nbsp;&lt;60 percent&nbsp;time in therapeutic range. <br />Â¶&nbsp;Based on initial validation cohort from Pisters R. A novel-user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093. Actual rates of&nbsp;bleeding in contemporary cohorts may vary from these estimates.</div><div class=\"graphic_reference\">Original figure modified for this publication. Lip GY. Implications of the CHA2DS2-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011; 124:111. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 75259 Version 11.0</div></div></div>"},"75260":{"type":"graphic_table","displayName":"Survival rates for extremely preterm infants","title":"Selected studies reporting survival for infants 22 to 25 weeks gestation during the initial NICU admission","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected studies reporting survival for infants 22 to 25 weeks gestation during the initial NICU admission</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup span=\"5\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\"><sup></sup>Study</td> <td class=\"subtitle1\" rowspan=\"2\">Region/country</td> <td class=\"subtitle1\" rowspan=\"2\">Study years</td> <td class=\"subtitle1\" colspan=\"5\">Survival [n/N (percent)] by gestational age (week)</td> </tr> <tr> <td class=\"subtitle2\">22</td> <td class=\"subtitle2\">23</td> <td class=\"subtitle2\">24</td> <td class=\"subtitle2\">25</td> <td class=\"subtitle2\">Total</td> </tr> <tr> <td>EPICure*<sup>[1]</sup></td> <td>UK; Ireland</td> <td>1995</td> <td>2/22 (9)</td> <td>26/131 (20)</td> <td>100/298 (34)</td> <td>186/357 (52)</td> <td>314/811 (39)</td> </tr> <tr> <td>Epipage<sup>&#182;[2]</sup></td> <td>9 regions in France</td> <td>1997</td> <td>0/16 (0)</td> <td>0/30 (0)</td> <td>13/42 (31)</td> <td>59/119 (50)</td> <td>72/207 (35)</td> </tr> <tr> <td>Epipage<sup>&#182;[3]</sup></td> <td>26 regions in France</td> <td>2011</td> <td>0/58 (0)</td> <td>1/89&nbsp;(1)</td> <td>58/186 (31)</td> <td>182/308 (59)</td> <td>241/641 (38)</td> </tr> <tr> <td>Epibel*<sup>[4]</sup></td> <td>19 perinatal centers in Belgium</td> <td>1999 to 2000</td> <td>0/2 (0)</td> <td>1/18 (6)</td> <td>19/65 (29)</td> <td>50/90 (56)</td> <td>175/322 (54)</td> </tr> <tr> <td rowspan=\"3\">Field*<sup>[5,6]</sup></td> <td rowspan=\"3\">Trent, UK</td> <td>1994 to 1999</td> <td>0/15 (0)</td> <td>15/81 (19)</td> <td>40/165 (24)</td> <td>119/229 (52)</td> <td>174/490 (36)</td> </tr> <tr> <td>2000 to 2005</td> <td>0/9 (0)</td> <td>12/65 (18)</td> <td>82/198 (41)</td> <td>142/229 (63)</td> <td>236/497 (47)</td> </tr> <tr> <td>2006 to 2010</td> <td>0/1 (0)</td> <td>16/80 (20)</td> <td>66/151 (44)</td> <td>137/204 (67)</td> <td>219/436 (50)</td> </tr> <tr> <td rowspan=\"3\">Carlo<sup>[7]</sup></td> <td rowspan=\"3\">23 NRN sites, USA</td> <td class=\"sublist1_start\" colspan=\"6\">1993 to 2009</td> </tr> <tr> <td class=\"indent1\">ANS</td> <td>32/118 (27)</td> <td>480/1147 (42)</td> <td>1799/2976 (60)</td> <td>2721/3555 (77)</td> <td>5032/7796 (64)</td> </tr> <tr> <td class=\"indent1\">No ANS</td> <td>50/283 (18)</td> <td>225/831 (27)</td> <td>399/814 (49)</td> <td>528/804 (66)</td> <td>1202/2732 (44)</td> </tr> <tr> <td><span lang=\"JA\" style=\"font-size: 13px; font-family: Cambria;\"></span> <p>NEPS1*<sup>[8]</sup></p> </td> <td>Norway</td> <td>1999 to 2000</td> <td>0/2 (0)</td> <td>9/23 (39)</td> <td>35/68 (60)</td> <td>55/69 (80)</td> <td>99/152 (65)</td> </tr> <tr> <td>NEPS2<sup>&#916;[9] </sup> <p><span style=\"color: #ff0000;\"></span></p> </td> <td><span style=\"color: black;\">Norway&nbsp;</span></td> <td><span style=\"color: black;\">2013 to 2014</span></td> <td><span style=\"color: black;\">3/17 (18)</span></td> <td><span style=\"color: black;\">12/42 (29)</span></td> <td><span style=\"color: black;\">35/62 (56)</span></td> <td><span style=\"color: black;\">59/70 (84)</span></td> <td><span style=\"color: black;\">109/191 (57)</span></td> </tr> <tr> <td><span style=\"color: black;\">Tyson<sup>&#9674;</sup></span><sup>[10]</sup></td> <td>19 NRN sites, USA</td> <td>1998 to 2003</td> <td>(5)</td> <td>(26)</td> <td>(56)</td> <td>(75)</td> <td>2267/4446 (51)</td> </tr> <tr> <td>Ishii*<sup>[11]</sup></td> <td>20 NRN sites, Japan</td> <td>2003 to 2005</td> <td>28/75 (37)</td> <td>158/245 (64)</td> <td>258/332 (78)</td> <td>347/405 (86)</td> <td>791/1057 (75)</td> </tr> <tr> <td>Itabashi*<sup>[12]</sup></td> <td>Japan</td> <td>2005</td> <td>33/97 (34)</td> <td>153/282 (54)</td> <td>324/423 (77)</td> <td>428/501 (85)</td> <td>938/1303 (72)</td> </tr> <tr> <td>EXPRESS<span style=\"color: black;\"><sup>&#167;</sup></span><sup>[13]</sup></td> <td>Sweden</td> <td>2004 to 2007</td> <td>5/51 (10)</td> <td>53/101 (53)</td> <td>96/144 (67)</td> <td>167/205 (81)</td> <td>321/501 (64)</td> </tr> <tr> <td>Stoll*<sup>[14]</sup></td> <td>20 NRN sites, USA</td> <td>2003 to 2007</td> <td>25/421 (6)</td> <td>226/871 (26)</td> <td>754/1370 (55)</td> <td>1079/1498 (72)</td> <td>2084/4160 (50)</td> </tr> <tr> <td>Stoll<sup>*[15]</sup></td> <td>26 NRN sites, USA</td> <td>2012</td> <td>7/75 (9)</td> <td>50/150 (33)</td> <td>174/269 (65)</td> <td>249/308 (81)</td> <td>480/802 (60)</td> </tr> <tr> <td>Anderson<span style=\"color: black;\"><sup>&#916;</sup></span><sup>[16]</sup></td> <td>State of California</td> <td>2007 to 2011</td> <td>29/450 (6)</td> <td>162/602 (27)</td> <td>458/766 (60)</td> <td>621/796 (78)</td> <td>1270/2614 (49)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NICU: neonatal intensive care unit; UK: United Kingdom; NRN: Neonatal Research Network; ANS: antenatal steroid therapy.<br />* Survival of NICU admissions to discharge.<br />Â¶ Survival of live births including infants who died in the delivery room and were not admitted to the NICU.&nbsp;<br />Î Survival of live births to one year.<br />â<FONT color=black>&nbsp;Survival of NICU admissions until 18 to 22 months corrected age.<br />âÂ§&nbsp;Survival of NICU admissions to one year.</FONT></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Costeloe K, Hennessy E, Gibson AT, et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000; 106:659.</LI>&#xD;&#xA;<LI>Larroque B, BrÃ©art G, Kaminski M, et al. Survival of very preterm infants: Epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed 2004; 89:F139.</LI>&#xD;&#xA;<LI>Ancel PY, Goffinet F, et al. Survival and morbidity of preterm children born at 22 through 34 weeksâ gestation in France in 2011: Results of the EPIPAGE-2 Cohort Study. JAMA Pediatrics 2015; 169:230. </LI>&#xD;&#xA;<LI>Vanhaesebrouck P, Allegaert K, Bottu J, et al. The EPIBEL Study: Outcomes to discharge from hospital fpr extremely preterm infants in Belgium. Pediatrics 2004; 114:663.</LI>&#xD;&#xA;<LI>Field DJ, Dorling JS, Manktelow BN, Draper ES. Survival of extremely premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. BMJ 2008; 336:1221.</LI>&#xD;&#xA;<LI>Seaton SE, King S, Manktelow BN, et al. Arch Dis Child Fetal Neontal Ed 2013; 98:F15.</LI>&#xD;&#xA;<LI>Carlo WA, McDonald SA, Fanaroff AA, et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA 2011; 306:2348.</LI>&#xD;&#xA;<LI>Markestad T, Kaaresen PI, RÃ¸nnestad A, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics 2005; 115:1289.</LI>&#xD;&#xA;<LI>Stensvold HJ, Klingenberg C, Stoen R, et al. Neonatal morbidity and 1-year survival of extremely preterm infants. Pediatrics 2017.</LI>&#xD;&#xA;<LI>Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity--moving beyond gestational age. N Engl J Med 2008; 358:1672.</LI>&#xD;&#xA;<LI>Ishii N, Kono Y, Yonemoto N, et al. Outcomes of infants born at 22 and 23 weeks' gestation. Pediatrics 2013; 132:62.</LI>&#xD;&#xA;<LI>Itabashi K, Horiuchi T, Kusuda S, et al. Mortality rates for extremely low birth weight infants born in Japan in 2005. Pediatrics 2009; 123:445.</LI>&#xD;&#xA;<LI>EXPRESS Group, Fellman V, HellstrÃ¶m-Westas L, et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009; 301:2225.</LI>&#xD;&#xA;<LI>Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.</LI>&#xD;&#xA;<LI>Stoll BJ, Hansen NI, Bell EF, et al. Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA 2015; 314:1039.</LI>&#xD;&#xA;<LI>Anderson JG, Baer RJ, Partridge JC, et al. Survival and Major Morbidity of Extremely Preterm Infants: A Population-Based Study. Pediatrics 2016;138:320154434.</LI></OL></div><div id=\"graphicVersion\">Graphic 75260 Version 10.0</div></div></div>"},"75261":{"type":"graphic_diagnosticimage","displayName":"Intracranial translucency","title":"Intracranial translucency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracranial translucency</div><div class=\"cntnt\"><img style=\"width:338px; height:582px;\" src=\"images/OBGYN/75261_Intracranial_translucency.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal view of a normal fetal head and posterior fossa at 12<SUP>4/7</SUP> weeks of gestation. In the normal fetus, the intracranial translucency (IT) is a fluid-filled area (the fourth ventricle) in the normal posterior brain in the mid-sagittal plane at the time of the nuchal translucency study at 11 to 13 weeks of gestation.<BR>(B) Sagittal view of&nbsp;a fetal head at 12<SUP>6/7</SUP> weeks of gestation with lack of visualization intracranial translucency (IT).&nbsp;This has been described as an early marker for open spina bifida.</div><div class=\"graphic_footnotes\">TH: thalamus; BS: brain stem; IT: intracranial translucency; CP: choroid plexus; FCM: future cistern magna; OB: occipital bone.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 75261 Version 2.0</div></div></div>"},"75263":{"type":"graphic_picture","displayName":"Cap polyposis Endosc III","title":"Cap polyposis","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Cap polyposis</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/GAST/75263_Cap_polyposis_Endosc_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 75263 Version 1.0</div></div></div>"},"75264":{"type":"graphic_figure","displayName":"Disability letter","title":"Sample clinician letter","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Sample clinician letter</div><div class=\"cntnt\"><img style=\"width:598px; height:776px;\" src=\"images/PC/75264_Disability_letter.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: O'Connell, JJ, Zevin, BD, Quick, PD, et al. Documenting Disability: Simple Strategies for Medical Providers. The National Health Care for the Homeless Council's website, 2007. Available at: http://www.nhchc.org/DocumentingDisability.pdf. Copyright &#169; 2007 National Health Care for the Homeless Council.</div><div id=\"graphicVersion\">Graphic 75264 Version 1.0</div></div></div>"},"75265":{"type":"graphic_figure","displayName":"Hyperopia flat cornea","title":"Hyperopia with flat cornea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperopia with flat cornea</div><div class=\"cntnt\"><img style=\"width:396px; height:360px;\" src=\"images/PC/75265_Hyperopia_flat_cornea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A flat cornea focuses light behind the retina resulting in hyperopia.</div><div id=\"graphicVersion\">Graphic 75265 Version 3.0</div></div></div>"},"75267":{"type":"graphic_picture","displayName":"Intrauterine pressure catheter","title":"Intrauterine pressure catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intrauterine pressure catheter</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/75267_Intrauterine_press_cath.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Copyright &#169; Clinical Innovations, LLC. Koala&#174; Intrauterine Pressure Catheter IPC-5000.</div><div id=\"graphicVersion\">Graphic 75267 Version 1.0</div></div></div>"},"75270":{"type":"graphic_picture","displayName":"Photo birth 6","title":"Delivery sequence from crowning through birth of the newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delivery sequence from crowning through birth of the newborn</div><div class=\"cntnt\"><img style=\"width:432px; height:290px;\" src=\"images/OBGYN/75270_Photo_birth_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The body easily follows the shoulders.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169;2009.</div><div id=\"graphicVersion\">Graphic 75270 Version 1.0</div></div></div>"},"75272":{"type":"graphic_figure","displayName":"Endarterectomy severe stenosis","title":"Carotid endarterectomy prevents stroke in symptomatic patients with a severe stenosis","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Carotid endarterectomy prevents stroke in symptomatic patients with a severe stenosis</div><div class=\"cntnt\"><img style=\"width:486px; height:224px;\" src=\"images/CARD/75272_Endarterectomy_severe_steno.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The European Carotid Surgery Trial included 778 patients with a history of a stroke, TIA, or retinal infarct who had a severe carotid stenosis (70 to 99 percent). Left panel: The percent of patients free of disabling or fatal stroke was higher with carotid endarterectomy than medical therapy, even when considering surgical death (94 versus 89 percent, p</div><div class=\"graphic_reference\">Data from European Carotid Surgery Trialist Collaborative Group. Lancet 1991; 337:1235.</div><div id=\"graphicVersion\">Graphic 75272 Version 1.0</div></div></div>"},"75273":{"type":"graphic_table","displayName":"Opts poor resp opioid","title":"Options when a patient is poorly responsive to an opioid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Options when a patient is poorly responsive to an opioid</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Approach</td> <td class=\"subtitle1\">Options</td> </tr> <tr> <td>Try to find a more effective opioid</td> <td>Opioid rotation</td> </tr> <tr> <td>Try to open the \"therapeutic window\"</td> <td>More aggressive side effect management</td> </tr> <tr> <td>Try adding a systemic or spinal co-analgesic to reduce the opioid requirement</td> <td>Add a systemic NSAID or an adjuvant analgesic, or trial of neuraxial (intrathecal, intraspinal) analgesia</td> </tr> <tr> <td>Try adding a nonpharmacologic approach to reduce the opioid requirement</td> <td>Consider neural blockade, a neurostimulatory approach, or a psychological or rehabilitative therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug.</div><div id=\"graphicVersion\">Graphic 75273 Version 4.0</div></div></div>"},"75275":{"type":"graphic_diagnosticimage","displayName":"CPAM newborn CT scan","title":"Computed tomography of the chest in a newborn with congenital pulmonary airway malformation (CPAM)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of the chest in a newborn with congenital pulmonary airway malformation (CPAM)*</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/PEDS/75275_CCAM_newborn_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography of the chest in a newborn with type 2 congenital pulmonary airway malformation (CPAM). Multiple small cysts are demonstrated in the apex of the right upper lobe.</div><div class=\"graphic_footnotes\">* CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD.</div><div id=\"graphicVersion\">Graphic 75275 Version 4.0</div></div></div>"},"75277":{"type":"graphic_table","displayName":"Prev PA cath infection","title":"Prevention of infection with central (pulmonary) arterial catheters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of infection with central (pulmonary) arterial catheters</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Replacement and relocation of catheter</td> </tr> <tr> <td>Do not routinely replace pulmonary artery catheters.</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of catheter-site dressing</td> </tr> <tr> <td>Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled. Replace dressings more frequently in diaphoretic patients.</td> </tr> <tr> <td>There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of administration sets</td> </tr> <tr> <td>Replace administration sets, including secondary sets and add-on devices, no more frequently than at 72-hour intervals, unless clinically indicated.</td> </tr> <tr> <td>Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion. <strong>No recommendation*</strong> for replacement of tubing used for intermittent infusions.</td> </tr> <tr> <td>Replace tubing used to administer propofol infusions every 6 or 12 hours, depending on its use.</td> </tr> <tr> <td class=\"subtitle1_single\">Hang time for parenteral fluids</td> </tr> <tr> <td>Complete infusion of lipids or lipid-containing parenteral nutrition fluids (eg, 3-in-1 solutions) given alone, complete the infusion within 12 hours of hanging the emulsion.</td> </tr> <tr> <td>Complete infusion of blood or blood products within four hours of hanging the blood.</td> </tr> <tr> <td><strong>No recommendation*</strong> for nonlipid-containing parenteral nutrition fluids.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* No recommendation is made when there is insufficient data in the literature.</div><div id=\"graphicVersion\">Graphic 75277 Version 2.0</div></div></div>"},"75279":{"type":"graphic_table","displayName":"Fetal platelet count by GA","title":"Platelet count, 10<sup>9</sup>/L","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Platelet count, 10<sup>9</sup>/L</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">GA</td>\n<td class=\"subtitle1\">5th percentile</td>\n<td class=\"subtitle1\">Mean</td>\n<td class=\"subtitle1\">95th percentile</td>\n</tr>\n<tr>\n<td>20</td>\n<td>145</td>\n<td>219</td>\n<td>293</td>\n</tr>\n<tr>\n<td>22</td>\n<td>148</td>\n<td>222</td>\n<td>297</td>\n</tr>\n<tr>\n<td>24</td>\n<td>151</td>\n<td>225</td>\n<td>300</td>\n</tr>\n<tr>\n<td>26</td>\n<td>154</td>\n<td>229</td>\n<td>303</td>\n</tr>\n<tr>\n<td>28</td>\n<td>157</td>\n<td>232</td>\n<td>306</td>\n</tr>\n<tr>\n<td>30</td>\n<td>160</td>\n<td>235</td>\n<td>310</td>\n</tr>\n<tr>\n<td>32</td>\n<td>163</td>\n<td>238</td>\n<td>313</td>\n</tr>\n<tr>\n<td>34</td>\n<td>166</td>\n<td>241</td>\n<td>316</td>\n</tr>\n<tr>\n<td>36</td>\n<td>169</td>\n<td>244</td>\n<td>319</td>\n</tr>\n<tr>\n<td>38</td>\n<td>172</td>\n<td>247</td>\n<td>323</td>\n</tr>\n<tr>\n<td>40</td>\n<td>175</td>\n<td>250</td>\n<td>326</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75279 Version 1.0</div></div></div>"},"75281":{"type":"graphic_table","displayName":"Congenital anomaly patterns","title":"Recognizable patterns of multiple congenital anomalies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recognizable patterns of multiple congenital anomalies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Pattern </td> <td class=\"subtitle1\">Definition </td> </tr> <tr> <td>Syndrome</td> <td>Pattern of anomalies that occur together and are associated with a set number of signs and symptoms</td> </tr> <tr> <td>Sequence</td> <td>Pattern of anomalies in which a single known defect in development causes a cascade of subsequent abnormalities</td> </tr> <tr> <td>Field defect</td> <td>Pattern of anomalies caused by disturbance of a developmental field (a region of the embryo that develops in a contiguous physical space)</td> </tr> <tr> <td>Association</td> <td>Two or more anomalies that are not pathogenetically related and occur together more frequently than expected by chance</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75281 Version 3.0</div></div></div>"},"75282":{"type":"graphic_picture","displayName":"Stool on virtual colonoscopy","title":"Stool on virtual colonoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stool on virtual colonoscopy</div><div class=\"cntnt\"><img style=\"width:252px; height:244px;\" src=\"images/GAST/75282_Stool_on_virtual_colonoscop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Virtual colonoscopy of the ascending colon shows stool adherent to the wall.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75282 Version 1.0</div></div></div>"},"75283":{"type":"graphic_figure","displayName":"Improved BMT outcomes in AA","title":"Improved outcomes with bone marrow transplantation in aplastic anemia when using antithymocyte globulin in the conditioning regimen","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Improved outcomes with bone marrow transplantation in aplastic anemia when using antithymocyte globulin in the conditioning regimen</div><div class=\"cntnt\"><img style=\"width:549px; height:221px;\" src=\"images/HEME/75283_Improved_BMT_outcomes_in_AA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of chronic graft-versus-host disease (left) and Kaplan-Meier estimates of survival (right) in 78 patients with aplastic anemia receiving HLA-identical bone marrow transplants and GVHD prophylaxis with methotrexate and cyclosporine; 39 of the patients were conditioned with cyclophosphamide and ATG (current patients) and 39 were conditioned with cyclophosphamide alone (historical patients). The newer regimen was associated with a significant reduction in chronic GVHD and a significant improvement in eight-year survival (92 versus 72 percent).</div><div class=\"graphic_reference\">Data from Storb R, Leisenring W, Anasett, C, et al. Blood 1997; 89:3890.</div><div id=\"graphicVersion\">Graphic 75283 Version 4.0</div></div></div>"},"75284":{"type":"graphic_diagnosticimage","displayName":"Regional odontodysplagia","title":"Panoramic radiograph: Regional odontodysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Panoramic radiograph: Regional odontodysplasia</div><div class=\"cntnt\"><img style=\"width:413px; height:248px;\" src=\"images/PEDS/75284_Regional_odontodysplagia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This panoramic radiograph shows regional odontodysplasia that resulted in failure of normal tooth development and eruption in the posterior maxillary arch (see arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Copyright Â© 2000 WB Saunders.</div><div id=\"graphicVersion\">Graphic 75284 Version 4.0</div></div></div>"},"75287":{"type":"graphic_figure","displayName":"Structure T cell receptor","title":"The structure of the T cell receptor (TCR)/CD3 complex","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">The structure of the T cell receptor (TCR)/CD3 complex</div><div class=\"cntnt\"><img style=\"width:549px; height:233px;\" src=\"images/RHEUM/75287_Structure_T_cell_receptor.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The TCR is made up of two disulfide-linked chains, alpha and beta, (or gamma and delta); the CD3 complex consists of five polypeptides, one each of gamma and delta, two of epsilon, and a disulfide-linked homodimer of two zeta chains [zeta]<SUB>2</SUB>, or a heterodimer of zeta and eta (shown here). The carboxyl termini of these proteins are intracytoplasmic. ZAP-70 and fyn are tyrosine kinases important in T cell activation.</div><div class=\"graphic_footnotes\">ZAP-70: zeta chain-associated protein kinase of 70 kiloDaltons.</div><div id=\"graphicVersion\">Graphic 75287 Version 3.0</div></div></div>"},"75288":{"type":"graphic_table","displayName":"EOX for advanced esophagogastric cancer","title":"Epirubicin, oxaliplatin, and capecitabine (EOX) for advanced esophagogastric cancer<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epirubicin, oxaliplatin, and capecitabine (EOX) for advanced esophagogastric cancer<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 21 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Epirubicin</strong></td> <td>50 mg/m<sup>2</sup> IV</td> <td>Administer into a free flowing IV solution with normal saline*, generally over 3 to 20 minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Oxaliplatin</strong></td> <td>130 mg/m<sup>2</sup> IV<sup>&#916;</sup></td> <td>Dilute with 500 mL 5 percent dextrose in water (D5W) and administer over two hours*.</td> <td>Day 1</td> </tr> <tr> <td><strong>Capecitabine</strong><sup>&#9674;</sup></td> <td>625 mg/m<sup>2</sup> per dose by mouth</td> <td>Twice daily; take with water within 30 minutes after a meal.</td> <td>Days 1 through 21</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> Epirubicin plus oxaliplatin: MODERATE; oral capecitabine alone: LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> There is no standard premedication regimen for prophylaxis of infusion reactions with this regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Epirubicin is a vesicant; oxaliplatin is an irritant but can cause significant tissue damage. Avoid extravasation of either agent. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not warranted (incidence of febrile neutropenia with the EOX regimen was 10 percent in two trials<sup>[1,2]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Lower starting doses of capecitabine and oxaliplatin may be needed in patients with renal impairment<sup>[3,4]</sup>. Lower starting doses of epirubicin may be needed in patients with preexisting renal or hepatic impairment<sup>[5]</sup>. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Maneuvers to prevent neurotoxicity:</strong> Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Cardiac issues:</strong> Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline LVEF prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. In the original EOX protocol, patients were excluded from receiving epirubicin if their LVEF was below the normal range<sup>[2]</sup>.</p> QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Swallowing status:</strong> Capecitabine tablets should be swallowed whole. Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count on day 1 prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes (especially magnesium and phosphate) and liver and renal function once per cycle on day 1.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for stomatitis, diarrhea, and palmar-plantar erythrodysesthesias during therapy.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for neurotoxicity prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor cumulative epirubicin dose. Reassess LVEF periodically during EOX therapy as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Hold epirubicin until the platelets are &#8805;100,000/microL and the absolute neutrophil count is &#8805;1500/microL. In the original EOX protocol, day 1 epirubicin doses were delayed until the platelet count was &#8805;100,000/microL and the total white blood cell count was &#8805;2000/microL<sup>[2]</sup>. The dose of epirubicin was reduced by 25 percent for a second episode of treatment delay due to myelosuppression or for febrile neutropenia. Oxaliplatin was delayed by one week if the neutrophil count was &#60;1000/microL or the platelet count was &#60;75,000/microL. After recovery from grade 2 to 4 thrombocytopenia or grade 3 or 4 neutropenia, the dose of oxaliplatin was reduced to 100 mg/m<sup>2</sup>. There were no dose reductions for capecitabine based on blood counts.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Mucositis, diarrhea, nausea and vomiting:</strong> In the original protocol, capecitabine was stopped if patents developed grade 2&nbsp;or 3stomatitis, diarrhea, or nausea and vomiting<sup>[2]</sup>. If grade 3 toxicity was controlled adequately within two days, capecitabine was resumed at full dose after resolution&nbsp;to &#8804;grade 1&nbsp;toxicity. If grade 2 toxicity recurred, the dose was reduced by 25 percent; a third time, by 50 percent, and after the fourth episode, treatment was discontinued. If grade 3 toxicity took longer than two days to resolve, the capecitabine dose for the next cycle was reduced by 25 percent; if grade 3 toxicity recurred, the dose was reduced by 50 percent, and if it recurred again, the drug was discontinued. For grade 4 mucositis, diarrhea, or nausea or vomiting, the drug was either discontinued or the dose reduced by 50 percent. For persistent grade 3 to 4 diarrhea or stomatitis after appropriate capecitabine reduction, the dose of oxaliplatin was reduced to 100 mg/m<sup>2</sup>. Doses of capecitabine that are omitted for toxicity are not replaced or restored. Instead, the patient should resume the planned treatment cycles at the modified dose<sup>[3]</sup>.<span style=\"color: #ff0000;\"> </span><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neurotoxicity:</strong> In the original protocol, oxaliplatin was delayed for one week for persistent grade 1 or worse neuropathy<sup>[2]</sup>. After recovery of persisting grade 1 to 2 neuropathy between cycles, or for any grade 3 to 4 neuropathy lasting for 7 to 14 days, the dose of oxaliplatin was reduced to 100 mg/m<sup>2</sup>. Omit oxaliplatin for persistent grade 3 to 4 neuropathy lasting longer than 14 days.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Palmar-plantar erythrodysesthesias:</strong> In the original trial, capecitabine was withheld for grade 2 or higher palmar-plantar erythrodysesthesias until resolution and the subsequent doses reduced by 15 percent for grade 2, 30 percent for grade 3, and 50 percent for grade 4 toxicity<sup>[2]</sup>. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226;<strong>Other toxicity (including&nbsp; hepatotoxicity):</strong> Hold epirubicin until all non-hematologic toxicity resolves to &#8804;grade 1<sup>[5]</sup>. Reduce epirubicin dose by 25 percent for any grade 3/4 non-hematologic toxicity in previous cycles.</p> <p><span style=\"color: black;\">For capecitabine: For the first, second, and third occurrence of grade 2 toxicity, hold capecitabine<sup>[3]</sup>. After resolution to grade 1 or less, resume treatment (first occurrence, no dosage adjustment; second occurrence, 75 percent of the starting dose; third occurrence, 50 percent of the starting dose)</span><span style=\"color: black;\">. For the fourth occurrence of a grade 2 toxicity, discontinue capecitabine therapy. Grade 3: For the first and second occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment at a reduced dose (first occurrence, 75 percent of the starting dose; second occurrence, 50 percent of the starting dose). For the third occurrence of a grade 3 toxicity, discontinue capecitabine therapy. Grade 4: Discontinue capecitabine therapy. Alternatively, hold capecitabine therapy, and begin next treatment at 50 percent of the starting dose when toxicity resolves to grade 1 or less; discontinue treatment for fist recurrence of grade 4 toxicity.</span></p> </td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, dose should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; ECG: electrocardiogram; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Oxaliplatin is incompatible with normal saline, and a D5W flush is recommended prior to starting the drug infusion.<br />&Delta; Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.<br /><span class=\"lozenge\">&loz;</span> âNo capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cunningham D, et al. N Engl J Med 2008; 358:36.</li>&#xD;&#xA;    <li>Sumpter K, et al. Br J Cancer 2005; 92:1976.</li>&#xD;&#xA;    <li>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).</li>&#xD;&#xA;    <li>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).</li>&#xD;&#xA;    <li>Epirubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75288 Version 25.0</div></div></div>"},"75291":{"type":"graphic_picture","displayName":"Penile chancre in syphilis","title":"Primary syphilis: Penile chancre","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary syphilis: Penile chancre</div><div class=\"cntnt\"><img style=\"width:203px; height:306px;\" src=\"images/ID/75291_Penile_chancre_in_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chancre due to syphilis is an ulcerative lesion that is often painless and has an indurated character. Chancres arise at the site of initial inoculation of the organism.</div><div class=\"graphic_reference\">Courtesy of Charles B Hicks, MD.</div><div id=\"graphicVersion\">Graphic 75291 Version 3.0</div></div></div>"},"75293":{"type":"graphic_figure","displayName":"Peak pollen periods in the United States PI","title":"Peak pollen periods in the United States","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Peak pollen periods in the United States</div><div class=\"cntnt\"><img style=\"width:551px; height:508px;\" src=\"images/PI/75293_Peak_pollen_periods_US_PI.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75293 Version 2.0</div></div></div>"},"75294":{"type":"graphic_figure","displayName":"Voltage mass relation amyloid","title":"Low voltage-mass relationship in amyoid cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Low voltage-mass relationship in amyoid cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:485px; height:333px;\" src=\"images/CARD/75294_Voltage_mass_relation_amylo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The voltage-mass relationship in patients with amyloidosis, with or without cardiac symptoms, aortic valve disease, and pericardial disease. The square represents the normal range. Patients with symptomatic cardiac amyloid (green circles and black circle) had low voltage and high mass. In comparison, pericardial disease (blue squares) was associated with low voltage and low mass, and aortic valve disease (asterisks) was associated with high voltage and high mass.</div><div class=\"graphic_reference\">Data from Carroll JD, Gaasch WH, McAdam KPWJ. Am J Cardiol 1982; 49:9.</div><div id=\"graphicVersion\">Graphic 75294 Version 2.0</div></div></div>"},"75295":{"type":"graphic_figure","displayName":"Acquired lipodystrophy","title":"Patients with acquired lipodystrophies","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Patients with acquired lipodystrophies</div><div class=\"cntnt\"><img style=\"width:521px; height:586px;\" src=\"images/ENDO/75295_Acquiredlipodystrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lipodystrophy in a man with&nbsp;HIV who received antiretroviral therapy containing a protease inhibitor for six years. Note the loss of fat from the face, arms, and legs; increased abdominal fat; and buffalo hump.<br />(B) Acquired partial lipodystrophy in a woman with Barraquer-Simons' syndrome. The loss of subcutaneous fat from the face, neck, arms, thorax, and upper abdomen began in adolescence. Note the excess subcutaneous fat in the legs.<br />(C) Acquired generalized lipodystrophy. The generalized loss of subcutaneous adipose tissue began in adolescence. Complications include severe insulin resistance, hyperinsulinemia, hypertriglyceridemia, and low serum high-density lipoprotein cholesterol concentrations.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 75295 Version 5.0</div></div></div>"},"75296":{"type":"graphic_figure","displayName":"Antegrade AV conduction through an accessory pathway","title":"Antegrade atrioventricular conduction through an accessory pathway","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Antegrade atrioventricular conduction through an accessory pathway</div><div class=\"cntnt\"><img style=\"width:454px; height:300px;\" src=\"images/CARD/75296_AccessoryAVpathwayspedsI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of atrioventricular conduction in the presence of an accessory pathway with antegrade conduction. The normal pacemaker is in the sinoatrial (SA) node at the junction of the superior vena cava and the right atrium (shown in green). The SA node activates the right and left atria. Ventricular activation results from the impulse traversing the atrioventricular&nbsp;(AV) node, the specialized infranodal conducting system (His bundle and bundle and fascicular branches, shown in red), thereby activating the ventricular myocardium (shown in yellow). In addition, however, the presence of an accessory pathway (AP) which conducts in the antegrade direction causes early activation (preexcitation) of a portion of the left ventricle (shown in blue). The degree of preexcitation depends upon the time required to conduct through the right and left atria, the AP, and the ventricular myocardium as compared to conduction through the normal pathways. The inset on the right shows the electrocardiogram (ECG) timing of these events. The net effect is a QRS complex that is a fusion of ventricular preexcitation (blue) and normal excitation (yellow). The combination of preexcitation and normal excitation leads to a short PR interval, a delta wave, and prolongation of the QRS duration. This ECG pattern is referred to as the Wolff-Parkinson-White pattern.</div><div id=\"graphicVersion\">Graphic 75296 Version 4.0</div></div></div>"},"75297":{"type":"graphic_diagnosticimage","displayName":"Intussusception Air contrast III","title":"Intussusception","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intussusception</div><div class=\"cntnt\"><img style=\"width:332px; height:432px;\" src=\"images/GAST/75297_Intussusception_Air_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Air contrast enema after successful reduction of the intussusception: post-evaluation film.</div><div class=\"graphic_reference\">Courtesy of Nancy Fitzgerald, MD and Taylor Chung, MD.</div><div id=\"graphicVersion\">Graphic 75297 Version 4.0</div></div></div>"},"75301":{"type":"graphic_figure","displayName":"Loop of Henle transport","title":"Ion transport in loop of Henle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ion transport in loop of Henle</div><div class=\"cntnt\"><img style=\"width:440px; height:221px;\" src=\"images/NEPH/75301_LoopofHenletransport.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the transport mechanisms in the thick ascending limb of the loop of Henle. The Na-K-ATPase pump in the basolateral (peritubular) membrane pumps sodium (Na) out of, and potassium (K) into, the cell. This creates a low intracellular Na concentration, which drives many of the cell's reabsorptive processes. The entry of filtered sodium chloride (NaCl) into the cells is mediated by an electroneutral Na-K-2Cl (NKCC2) cotransporter in the apical (luminal) membrane. This is also called the furosemide-sensitive cotransporter. The energy for this process is provided by the favorable inward electrochemical gradient for Na (the intracellular Na concentration is very low, and the cell interior is electronegative). The inward movement of K and Cl occurs against their electrochemical gradients and is powered by the inward movement of Na into the cell. The reabsorbed Na (which has entered the cell) is pumped out by the Na-K-ATPase pump. The concentration of K in the filtrate and tubular fluid is much lower than that of Na and Cl, and much of the reabsorbed K recycles back into the lumen through K channels (ROMK) in the apical membrane to allow continued NaCl reabsorption. This movement of cationic K into the lumen plus the flux of reabsorbed Cl out of the cell and&nbsp;into the peritubular capillary (via Cl channels) causes the lumen to become more positively <FONT color=black>charged compared</FONT> with the cell and peritubular space. This lumen electropositivity creates an electrical gradient that promotes the passive reabsorption of cationsâNa, calcium (Ca), and magnesium (Mg)âvia the paracellular pathway between the cells. The most important Cl channels in these cells are ClC-Kb. Also present but not as critical are the ClC-Ka channels. Each of these Cl channels requires interaction with a small protein called barttin to function normally. The single Cl channel shown in the figure represents both intact ClC-Ka and ClC-Kb channels.</div><div id=\"graphicVersion\">Graphic 75301 Version 11.0</div></div></div>"},"75302":{"type":"graphic_diagnosticimage","displayName":"PUV VUR urine extravasation","title":"Urine extraction observed in a voiding cystourethrogram in a patient with posterior urethal valves","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine extraction observed in a voiding cystourethrogram in a patient with posterior urethal valves</div><div class=\"cntnt\"><img style=\"width:327px; height:385px;\" src=\"images/PEDS/75302_PUV_VUR_urine_extravasation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Voiding cystourethrogram of a&nbsp;patient with severe urethral obstruction secondary to posterior urethral valves with&nbsp;high grade vesicoureteral&nbsp;reflux&nbsp;and urinary extravasation from kidney (white arrows).</div><div class=\"graphic_reference\">Courtesy of Nicholas Holmes, MD.</div><div id=\"graphicVersion\">Graphic 75302 Version 3.0</div></div></div>"},"75303":{"type":"graphic_picture","displayName":"Corneal ulcers","title":"Corneal infiltrates or ulcers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal infiltrates or ulcers</div><div class=\"cntnt\"><img style=\"width:393px; height:258px;\" src=\"images/PC/75303_Corneal_ulcers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two small corneal white spots that are either infiltrates or ulcers (indicated by the arrows) are shown with normal light illumination.</div><div class=\"graphic_reference\">Courtesy of Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 75303 Version 1.0</div></div></div>"},"75304":{"type":"graphic_table","displayName":"Therapeutic roles for hyperbaric oxygen","title":"Therapeutic roles for hyperbaric oxygen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic roles for hyperbaric oxygen</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Air or gas embolism</td>\n</tr>\n<tr>\n<td>Carbon monoxide poisoning</td>\n</tr>\n<tr>\n<td>Decompression sickness</td>\n</tr>\n<tr>\n<td>Clostridial myonecrosis</td>\n</tr>\n<tr>\n<td>Crush injury and other forms of traumatic ischemia</td>\n</tr>\n<tr>\n<td>Enhanced healing of problematic wounds, including diabetic wounds</td>\n</tr>\n<tr>\n<td>Severe anemia</td>\n</tr>\n<tr>\n<td>Actinomycotic brain abscess</td>\n</tr>\n<tr>\n<td>Necrotizing soft tissue infections</td>\n</tr>\n<tr>\n<td>Refractory osteomyelitis</td>\n</tr>\n<tr>\n<td>Radiation necrosis of soft tissue and bone</td>\n</tr>\n<tr>\n<td>Compromised skin grafts and flaps</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75304 Version 2.0</div></div></div>"},"75305":{"type":"graphic_diagnosticimage","displayName":"Pelvic lateral compression fracture type I","title":"Pelvic lateral compression fracture: Type I","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Pelvic lateral compression fracture: Type I</div><div class=\"cntnt\"><img style=\"width:569px; height:526px;\" src=\"images/EM/75305_Pelvic_lat_comp_fx1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Type I lateral compression fracture with bilateral superior and inferior rami fractures and left sacral fracture. B) Inlet view showing greater detail of the pelvic ring disruption. C) Outlet view illustrating greater detail of the sacral fracture in addition to the bilateral rami fractures.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 75305 Version 3.0</div></div></div>"},"75306":{"type":"graphic_diagnosticimage","displayName":"Sunrise view of the patella","title":"Sunrise view of the patella","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sunrise view of the patella</div><div class=\"cntnt\"><img style=\"width:432px; height:320px;\" src=\"images/EM/75306_Sunrise_patella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sunrise view of the patella provides a clear view of the patellofemoral joint. It will often reveal fractures not seen on the anterior posterior or lateral views.</div><div class=\"graphic_reference\">Courtesy of Patrice Eiff, MD.</div><div id=\"graphicVersion\">Graphic 75306 Version 3.0</div></div></div>"},"75307":{"type":"graphic_picture","displayName":"Staphylococcal abscess","title":"Staphylococcal abscess on the neck of a patient with hyperimmunoglobulin E syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Staphylococcal abscess on the neck of a patient with hyperimmunoglobulin E syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:279px;\" src=\"images/ALLRG/75307_Staphylococcal_abscess.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75307 Version 2.0</div></div></div>"},"75308":{"type":"graphic_figure","displayName":"T4 RIA with anti T4 antibodies","title":"Radioimmunoassay curve for T4 with anti-T4 antibodies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radioimmunoassay curve for T4 with anti-T4 antibodies</div><div class=\"cntnt\"><img style=\"width:340px; height:257px;\" src=\"images/ENDO/75308_T4_RIA_with_anti_T4_antibod.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If endogenous human anti-T4 antibodies are present and bind radiolabeled T4 (*T4) then the amount of *T4 that binds to rabbit anti-T4 antibody and then is precipitated by goat anti-rabbit gamma globulin is reduced. Low percent *T4 binding correlates with high serum concentrations of T4, giving a spuriously high result.</div><div class=\"graphic_footnotes\">T4: thyroxine.</div><div id=\"graphicVersion\">Graphic 75308 Version 3.0</div></div></div>"},"75309":{"type":"graphic_picture","displayName":"Shoulder ROM with cane PI","title":"Shoulder ROM with cane","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Shoulder ROM with cane</div><div class=\"cntnt\"><img style=\"width:477px; height:591px;\" src=\"images/PI/75309_Shoulder_ROM_with_cane_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hold a cane (or dowel) with two hands. The arms should be held down with the elbows against the body and the thumbs on the front of the cane (away from the body).<br />(B-C) Lift cane with both hands above head, keeping arms and back straight. Reach back until you feel a stretch in the shoulders (this should not hurt). Hold for 5 seconds. Lower the arms and rest. Repeat 10 times.</div><div id=\"graphicVersion\">Graphic 75309 Version 5.0</div></div></div>"},"75310":{"type":"graphic_table","displayName":"Gynecologic causes of acute pelvic pain","title":"Gynecologic causes of acute pelvic pain in the adolescent female*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gynecologic causes of acute pelvic pain in the adolescent female*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Life- or organ-threatening</td> </tr> <tr> <td>Ectopic pregnancy</td> </tr> <tr> <td>Acute abruption</td> </tr> <tr> <td>Uterine rupture</td> </tr> <tr> <td>Ovarian torsion&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td>Dysmenorrhea</td> </tr> <tr> <td>Mittelschmerz</td> </tr> <tr> <td>Pelvic inflammatory disease</td> </tr> <tr> <td>Ruptured ovarian cyst</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td>Spontaneous abortion</td> </tr> <tr> <td>Developmental anomalies of the m&#252;llerian duct</td> </tr> <tr> <td>Endometriosis</td> </tr> <tr> <td>Ovarian tumor</td> </tr> <tr> <td>Vaginal foreign body</td> </tr> <tr> <td>Chemical irritant</td> </tr> <tr> <td>Sexual assault (sexual abuse)</td> </tr> <tr> <td>Somaticization</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on causes of abdominal pain in children for a discussion of gastrointestinal and urologic causes of pelvic pain in the adolescent female.</div><div id=\"graphicVersion\">Graphic 75310 Version 4.0</div></div></div>"},"75311":{"type":"graphic_picture","displayName":"Peripheral IV placement 3","title":"Peripheral IV placement: Local anaesthetic","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral IV placement: Local anaesthetic</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/EM/75311_Peripheral_IV_placement_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A subcutaneous wheal of local anesthetic (eg, 1 percent lidocaine) may be placed over the venipuncture site to reduce pain.</div><div class=\"graphic_reference\">Courtesy of Robert Frank, MD.</div><div id=\"graphicVersion\">Graphic 75311 Version 2.0</div></div></div>"},"75312":{"type":"graphic_figure","displayName":"OUCHER pain scale","title":"OUCHER pain scale","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">OUCHER pain scale</div><div class=\"cntnt\"><img style=\"width:197px; height:600px;\" src=\"images/SURG/75312_OUCHER.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The OUCHER pain scale uses both pictures and numbers. The pictures can be used for preschool children, while older children can also use the numerical scale. The scales include pictures of Caucasian, African-American, Hispanic, Asian, and First Nation children. The example here depicts a Caucasian child.</div><div class=\"graphic_reference\">The Caucasian version of the Oucher was developed and copyrighted in 1983 by Judith E Beyer, Ph.D., RN, (University of Missouri-Kansas City School of Nursing, Retired), USA. For more information, please visit <a href=\"http://www.oucher.org/\" target=\"_blank\">http://www.oucher.org</a>. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 75312 Version 3.0</div></div></div>"},"75313":{"type":"graphic_movie","displayName":"FAST subxiphoid tamponade","title":"FAST: Subxiphoid view of cardiac tamponade","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">FAST: Subxiphoid view of cardiac tamponade</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/75313_FASTsubxiphoidtampmovie.mp4\" style=\"width:480px;height:320px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/75313_FASTsubxiphoidtampimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This subxiphoid view of the heart shows a large pericardial effusion causing tamponade.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 75313 Version 1.0</div></div></div>"},"75314":{"type":"graphic_picture","displayName":"Erythema multiforme genital","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75314_Erythema_multiforme_genital.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions are present on the penis of this patient with erythema multiforme. A target-like lesion is present on the distal glans.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75314 Version 4.0</div></div></div>"},"75317":{"type":"graphic_picture","displayName":"HUS IF IV","title":"Immunofluorescence microscopy showing fibrin deposition in thrombotic microangiopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence microscopy showing fibrin deposition in thrombotic microangiopathy</div><div class=\"cntnt\"><img style=\"width:378px; height:261px;\" src=\"images/NEPH/75317_HUS_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in the hemolytic uremic syndrome shows fibrin deposition (bright yellow areas) in branches of a muscular renal artery.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75317 Version 5.0</div></div></div>"},"75319":{"type":"graphic_diagnosticimage","displayName":"Scintigraphy hydrothorax","title":"Abdominal and thoracic scintigraphy demonstrating hydrothorax in a peritoneal dialysis patient","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Abdominal and thoracic scintigraphy demonstrating hydrothorax in a peritoneal dialysis patient</div><div class=\"cntnt\"><img style=\"width:452px; height:235px;\" src=\"images/NEPH/75319_Scintigraphy_Hydrothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) At 30 minutes, no thoracic activity is noted. At&nbsp;four hours (B), there is focal accumulation of activity at the level of dome of right diaphragm as well as less intense focus just above the level of the right diaphragm medially (arrows). Imaging at 20 hours (C) post-dialysate exchange reveals further accumulation of activity medially just above the right diaphragm, as well as a slight degree of diffuse activity on the right hemithorax (arrows), d (diaphragm).</div><div class=\"graphic_reference\">Reproduced with permission from: Walker JV, Fish MB. Scintigraphic detection of abdominal wall and diaphragmatic peritoneal leaks in patients on continuous ambulatory peritoneal dialysis. J Nucl Med 1988; 29:1596. Copyright &copy; 1988 Society of Nuclear Medicine.</div><div id=\"graphicVersion\">Graphic 75319 Version 4.0</div></div></div>"},"75320":{"type":"graphic_table","displayName":"Mortality per 1000 live births by plurality","title":"Infant, neonatal, postnatal mortality per 1000 live births by plurality","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infant, neonatal, postnatal mortality per 1000 live births by plurality</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Infant deaths<br /> (birth to 1 year)</td> <td class=\"subtitle1\">Neonatal deaths<br /> (birth to day 28)</td> <td class=\"subtitle1\">Postneonatal<br /> (day 29 to 1 year)</td> </tr> <tr> <td><strong>Singletons</strong></td> <td class=\"centered\">11.2</td> <td class=\"centered\">7.8</td> <td class=\"centered\">3.4</td> </tr> <tr> <td><strong>Twins</strong></td> <td class=\"centered\">66.4</td> <td class=\"centered\">55.9</td> <td class=\"centered\">10.5</td> </tr> <tr> <td><strong>Triplets</strong>*</td> <td class=\"centered\">190.4</td> <td class=\"centered\">168.8</td> <td class=\"centered\">21.6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Triplets and higher order multiple gestations.<br />Calculated from US Vital Statistics, 1998 and from US Public Health Service. Healthy People 2000: National Health Promotion and Disease Prevention Objectives, DHHS Pub. No. (PHS)90-50212. Washington, DC: US Department of Health and Human Services, Public Health Service; 1990.</div><div class=\"graphic_reference\">Reproduced with permission from: Oleszczuk JJ, Oleszczuk AK, Keith LG. Twin and triplet birth: facts, figures, and costs. Female patient 2003; 28:11. Copyright Â© 2003 Jaroslaw J Oleszczuk, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75320 Version 3.0</div></div></div>"},"75322":{"type":"graphic_table","displayName":"Drugs immune hemolytic anemia","title":"Drugs associated with immune hemolytic anemia and/or a positive DAT (Coombs test)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs associated with immune hemolytic anemia and/or a positive DAT (Coombs test)*</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Aceclofenac</td> </tr> <tr> <td>Acetaminophen</td> </tr> <tr> <td>Aminopyrine/pyramidon</td> </tr> <tr> <td>Amoxicillin</td> </tr> <tr> <td>Amphotericin B</td> </tr> <tr> <td>Ampicillin</td> </tr> <tr> <td>Antazoline</td> </tr> <tr> <td>Butizide</td> </tr> <tr> <td>Carbenicillin</td> </tr> <tr> <td>Carbimazole</td> </tr> <tr> <td>Carboplatin</td> </tr> <tr> <td>Carbromal</td> </tr> <tr> <td>Catergen/cyanidanol</td> </tr> <tr> <td>Cefamandole</td> </tr> <tr> <td>Cefazolin</td> </tr> <tr> <td>Cefixime</td> </tr> <tr> <td>Cefotaxime</td> </tr> <tr> <td>Cefotetan</td> </tr> <tr> <td>Cefoxitin</td> </tr> <tr> <td>Ceftazidime</td> </tr> <tr> <td>Ceftizoxime</td> </tr> <tr> <td>Ceftriaxone</td> </tr> <tr> <td>Cephalexin</td> </tr> <tr> <td>Cephaloridine</td> </tr> <tr> <td>Cephalothin</td> </tr> <tr> <td>Chlordiazepoxide</td> </tr> <tr> <td>Chlorinated hydrocarbons</td> </tr> <tr> <td>Chlorpromazine</td> </tr> <tr> <td>Chlorpropamide</td> </tr> <tr> <td>Cianidanol</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Cladribine</td> </tr> <tr> <td>Clavulanate potassium</td> </tr> <tr> <td>Diclofenac</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>Diethylstilbestrol</td> </tr> <tr> <td>Diphenylhydantoin</td> </tr> <tr> <td>Dipyrone</td> </tr> <tr> <td>Erythromycin</td> </tr> <tr> <td>Etodolac</td> </tr> <tr> <td>Fenoprofen</td> </tr> <tr> <td>Fludarabine</td> </tr> <tr> <td>Fluorescein</td> </tr> <tr> <td>Fluoroquinolones (eg, temafloxacin)</td> </tr> <tr> <td>Fluorouracil</td> </tr> <tr> <td>Glafenine</td> </tr> <tr> <td>Hydralazine</td> </tr> <tr> <td>Hydrochlorothiazide</td> </tr> <tr> <td>9-hydroxy-methyl- ellipticinium</td> </tr> <tr> <td>Ibuprofen</td> </tr> <tr> <td>Indene derivatives (eg, sulindac)</td> </tr> <tr> <td>Insulin</td> </tr> <tr> <td>Interferon</td> </tr> <tr> <td>Interleukin-2</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>Latamoxef</td> </tr> <tr> <td>Levodopa</td> </tr> <tr> <td>Mefenamic acid</td> </tr> <tr> <td>Mefloquine</td> </tr> <tr> <td>Melphalan</td> </tr> <tr> <td>6-mercaptopurine</td> </tr> <tr> <td>Methicillin</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Methyldopa</td> </tr> <tr> <td>Metrizoate-based radiographic contrast media</td> </tr> <tr> <td>Nafcillin</td> </tr> <tr> <td>Nomifensine</td> </tr> <tr> <td>Norfloxacin</td> </tr> <tr> <td>Oxaliplatin</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td>p-aminosalicylic acid</td> </tr> <tr> <td>Penicillin G</td> </tr> <tr> <td>Phenacetin</td> </tr> <tr> <td>Piperacillin</td> </tr> <tr> <td>Probenecid</td> </tr> <tr> <td>Procainamide</td> </tr> <tr> <td>Propyphenazone</td> </tr> <tr> <td>Quinidine</td> </tr> <tr> <td>Quinine</td> </tr> <tr> <td>Ranitidine</td> </tr> <tr> <td>Rifampicin</td> </tr> <tr> <td>Sodium pentothal/thiopental</td> </tr> <tr> <td>Stibophen</td> </tr> <tr> <td>Streptokinase</td> </tr> <tr> <td>Streptomycin</td> </tr> <tr> <td>Sulbactam sodium</td> </tr> <tr> <td>Sulindac</td> </tr> <tr> <td>Sulfonamides</td> </tr> <tr> <td>Sulfasalazine</td> </tr> <tr> <td>Sulfonylurea derivatives</td> </tr> <tr> <td>(eg, chlorpropamide and tolbutamide)</td> </tr> <tr> <td>Suprofen</td> </tr> <tr> <td>Tazobactam sodium</td> </tr> <tr> <td>Teicoplanin</td> </tr> <tr> <td>Temafloxacin</td> </tr> <tr> <td>Teniposide</td> </tr> <tr> <td>Tetracycline</td> </tr> <tr> <td>Ticarcillin</td> </tr> <tr> <td>Tolbutamide</td> </tr> <tr> <td>Tolmetin</td> </tr> <tr> <td>Triamterene</td> </tr> <tr> <td>Trimetallic anhydride</td> </tr> <tr> <td>Zomepirac</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DAT: direct antiglobulin test.<br />* Only drugs with serologic evidence for the presence of antibodies (indirect and/or direct) have been included in this table.</div><div class=\"graphic_reference\">Reproduced with permission from: Arndt P, Garraty G. The changing spectrum of drug-induced immune hemolytic anemia. Seminars in Hematology 2005; 42:138. Copyright Â© 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 75322 Version 7.0</div></div></div>"},"75323":{"type":"graphic_diagnosticimage","displayName":"SARS CT","title":"Severe acute respiratory syndrome (SARS) coronavirus pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe acute respiratory syndrome (SARS) coronavirus pneumonia</div><div class=\"cntnt\"><img style=\"width:449px; height:315px;\" src=\"images/ID/75323_SARSCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution computed tomography (CT) scan shows extensive bilateral ground-glass opacities. The patient was a 48-year-old man with SARS coronavirus pneumonia.</div><div class=\"graphic_reference\">Reproduced with permission from: Viruses, Mycoplasma, and Chlamydia. In: Imaging of pulmonary infections. MÃ¼ller NL, Franquet T, Kyung SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 75323 Version 8.0</div></div></div>"},"75325":{"type":"graphic_diagnosticimage","displayName":"Roux limb inversion","title":"Roux limb inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Roux limb inversion</div><div class=\"cntnt\"><img style=\"width:398px; height:655px;\" src=\"images/SURG/75325_Roux_limb_inversion_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">48-year-old woman with Roux limb inversion.<br> (A) Patient was given medium-density barium in patient-controlled boluses. Spot image from initial fluoroscopic examination shows alimentary limb is dilated (arrowheads) but more distal small bowel is of normal caliber (arrow). Fluoroscopic assessment shows no definable cause at transition point.<br> (B) Radiograph 2 weeks after A shows persistence of contrast material in alimentary limb.<br> (C) Follow-up fluoroscopic examination was performed after bowel preparation to clear contrast material from alimentary limb. Image obtained after administration of medium-density barium through jejunal tube shows biliary limb of normal caliber. Peristalsis is antegrade within biliary limb. At distal anastomosis, divergent flow of contrast material is evident antegrade into common limb (white asterisk) and retrograde into alimentary limb (black asterisk). Thin arrows indicate direction of peristalsis.<br> (D) Spot image obtained minutes after C shows continued abnormal retrograde peristalsis (arrow) diverting contrast material farther up alimentary limb.<br> (E) After acquisition of D, patient was given water-soluble contrast material orally in patient-controlled boluses. Spot image shows dilated gastric pouch (thick arrow) and flaccid and featureless proximal alimentary limb (arrowheads). Peristalsis was initially antegrade (thin arrows).<br> (F) Fluoroscopic image shows that with full distention of alimentary limb by contrast material, abrupt reversal of peristalsis (arrow) is evident with return of contrast material to gastric pouch and subsequent marked patient emesis, essentially reproducing symptoms of food intolerance.</div><div class=\"graphic_reference\">Reprinted with the permission of the American Journal of Roentgenology. Mitchell MT, Gasparaitis AE, Alverdy JC. Imaging findings in roux-en-o and other misconstructions: Rare but serious complications of roux-en-y gastric bypass surgery. AJR Am J Roentgenol 2008; 190:367. Copyright Â© 2008 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 75325 Version 7.0</div></div></div>"},"75326":{"type":"graphic_diagnosticimage","displayName":"Pagetic tibia","title":"Pagetic tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pagetic tibia</div><div class=\"cntnt\"><img style=\"width:255px; height:576px;\" src=\"images/RHEUM/75326_Pagetic_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a pagetic tibia. Note the thickened cortex, with cortical tunneling by pagetic osteoclasts. Lytic lesions (osteoclast resorption) coupled with blastic lesions (osteoblast bone formation) are causing this abnormal bone remodeling, resulting in deformity and structural impairment of bone. Note sparing of the fibula.</div><div class=\"graphic_reference\">Courtesy of Margaret Seton, MD.</div><div id=\"graphicVersion\">Graphic 75326 Version 1.0</div></div></div>"},"75327":{"type":"graphic_figure","displayName":"Chronic respiratory alkalosis","title":"Compensatory response to chronic respiratory alkalosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Compensatory response to chronic respiratory alkalosis</div><div class=\"cntnt\"><img style=\"width:228px; height:244px;\" src=\"images/NEPH/75327_Chronic_respiratory_alkalos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Combined significance bands for plasma pH and concentrations of H+ and HCO3- in chronic respiratory alkalosis in humans. In uncomplicated chronic respiratory alkalosis, values for the H+ and HCO3- concentrations will, with an estimated 95 percent probability, fall within the band. Values lying outside the band indicate the presence of a complicating metabolic acid-base disturbance. Note that the compensatory reduction in the plasma HCO3- concentration is so effective that there is little fall in pH.</div><div class=\"graphic_reference\">Gennari JF, Goldstein MB, Schwartz WB. J Clin Invest 1972; 51:1722. By copyright permission of the American Society for Clinical Investigation.</div><div id=\"graphicVersion\">Graphic 75327 Version 2.0</div></div></div>"},"75328":{"type":"graphic_diagnosticimage","displayName":"Oblique fracture of the middle phalanx - AP view","title":"Oblique fracture of the middle phalanx: AP view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique fracture of the middle phalanx: AP view</div><div class=\"cntnt\"><img style=\"width:156px; height:432px;\" src=\"images/EM/75328_Mid_phalanx_oblique_fx1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph shows an oblique fracture of the middle phalanx. Note the slight displacement at the distal end of the fracture.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 75328 Version 5.0</div></div></div>"},"75330":{"type":"graphic_figure","displayName":"Hypocretins in narcolepsy","title":"Possible roles of orexins (hypocretins) in the pathology of narcolepsy","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Possible roles of orexins (hypocretins) in the pathology of narcolepsy</div><div class=\"cntnt\"><img style=\"width:564px; height:197px;\" src=\"images/PULM/75330_Hypocretins_in_narcolepsy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of orexin signaling could cause cataplexy by reducing activity in the brainstem's motor excitatory systems or by providing less suppression of the motor inhibitory systems. Loss of orexin could cause sleepiness by reducing activity in the cholinergic and monoaminergic arousal systems or by reducing inhibition of sleep-promoting neurons in the rostral hypothalamus (preoptic area).</div><div class=\"graphic_reference\">Adapted from Siegel, JM. Cell 1999; 98:409.</div><div id=\"graphicVersion\">Graphic 75330 Version 1.0</div></div></div>"},"75335":{"type":"graphic_table","displayName":"Abdominal pain history PI","title":"Abdominal pain history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abdominal pain history</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pain</td> </tr> <tr> <td>When did it start? Is it better, worse, or about the same?</td> </tr> <tr> <td>When does it occur? Is it sharp, dull, crampy?</td> </tr> <tr> <td>Is it constant, or does it come and go?</td> </tr> <tr> <td>Where does it hurt? Does it move to other areas?</td> </tr> <tr> <td>How severe is the pain?</td> </tr> <tr> <td>Does the pain wake the child from sleep?</td> </tr> <tr> <td>How do you know the child is in pain?</td> </tr> <tr> <td>How does the family respond to the child's pain?</td> </tr> <tr> <td>Have any tests been done by other health care providers? If so, bring records.</td> </tr> <tr> <td>Does anything make the pain worse or better? (eg, bowel movement, walking, resting, medications)</td> </tr> <tr> <td class=\"subtitle1_single\">Other symptoms</td> </tr> <tr> <td>Has the child lost weight? Was it intentional or unintentional?</td> </tr> <tr> <td>Are there other symptoms? (eg, nausea, vomiting, gas, diarrhea)</td> </tr> <tr> <td>Do meals or specific foods cause pain?</td> </tr> <tr> <td>Are there respiratory symptoms? (eg, coughing, wheezing, hoarse voice)</td> </tr> <tr> <td class=\"subtitle1_single\">Habits</td> </tr> <tr> <td>Have the child's eating habits changed? (eg, restricting foods, binge eating)</td> </tr> <tr> <td>How frequently does the child move his/her bowels? Is he/she ever \"too busy\" to finish a bowel movement?</td> </tr> <tr> <td>Have there been episodes of unintentional fecal loss (soiling) recently?</td> </tr> <tr> <td class=\"subtitle1_single\">Social history</td> </tr> <tr> <td>Has the child's attendance at school or social activities been affected by his/her pain?</td> </tr> <tr> <td>Are there any known stressors for the child or adolescent? (eg, divorce, move, death, school performance)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75335 Version 3.0</div></div></div>"},"75336":{"type":"graphic_table","displayName":"Developmental milestones 12 through 24 months","title":"Developmental milestones: 12 through 24 months","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Developmental milestones: 12 through 24 months</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"9\">Approximate chronologic age</td> </tr> <tr> <td class=\"subtitle2\">12 months</td> <td class=\"subtitle2\">13 months</td> <td class=\"subtitle2\">14 months</td> <td class=\"subtitle2\">15 months</td> <td class=\"subtitle2\">16 months</td> <td class=\"subtitle2\">18 months</td> <td class=\"subtitle2\">20 months</td> <td class=\"subtitle2\">22 months</td> <td class=\"subtitle2\">24 months</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gross motor</strong></td> <td> <ul> <li>Stands well with arms high and legs splayed (posterior protection) </li> <li>Independent steps </li> </ul> </td> <td> <ul> <li>Walks with arms high and out (high guard) </li> </ul> </td> <td> <ul> <li>Stands without pulling up </li> <li>Falls by collapse </li> <li>Walks well </li> </ul> </td> <td> <ul> <li>Stoops to pick up toy </li> <li>Creeps up stairs </li> <li>Runs stiff-legged </li> <li>Walks carrying toy </li> <li>Climbs on furniture </li> </ul> </td> <td> <ul> <li>Stands on one foot with slight support </li> <li>Walks backwards </li> <li>Walks up stairs, one hand held </li> </ul> </td> <td> <ul> <li>Creeps down stairs </li> <li>Runs well </li> <li>Seats self in small chair </li> <li>Throws ball (standing) </li> </ul> </td> <td> <ul> <li>Squats in play </li> <li>Carries large object </li> <li>Goes up stairs, one hand held </li> </ul> </td> <td> <ul> <li>Goes up stairs, holding rail, both feet on each step </li> <li>Kicks ball with demo </li> <li>Walks with one foot on walking board </li> </ul> </td> <td> <ul> <li>Walks down stairs, holding rail, both feet on each step </li> <li>Kicks ball without demo </li> <li>Throws overhand </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fine motor/writing</strong></td> <td> <ul> <li>Scribbles after demo </li> <li>Fine pincer grasp of pellet </li> <li>Holds crayon </li> <li>Attempts tower of two cubes </li> </ul> </td> <td> <ul> <li>Attempts to release pellet in bottle </li> </ul> </td> <td> <ul> <li>Attempts to release pellet in bottle </li> <li>Imitates back-forth scribble </li> <li>Adds third cube to a two-cube tower </li> <li>Puts round peg in and out of hole </li> </ul> </td> <td> <ul> <li>Builds three- to four-cube tower </li> <li>Places 10 cubes in cup </li> <li>Releases pellet into bottle </li> </ul> </td> <td> <ul> <li>Puts several round pegs in board with urging </li> <li>Scribbles spontaneously </li> </ul> </td> <td> <ul> <li>Makes four-cube tower </li> <li>Crudely imitates vertical stroke </li> </ul> </td> <td> <ul> <li>Completes round peg board without urging </li> <li>Makes five- to six-cube tower </li> <li>Completes square peg board </li> </ul> </td> <td> <ul> <li>Closes box with lid </li> <li>Imitates vertical stroke </li> <li>Imitates circular scribble </li> </ul> </td> <td> <ul> <li>Makes a single-line \"train\" of cubes </li> <li>Imitates circle </li> <li>Imitates horizontal line </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Self-help</strong></td> <td> <ul> <li>Cooperates in dressing </li> <li>Finger feeds part of meal </li> <li>Takes hat off </li> </ul> </td> <td> <ul> <li>Drinks from cup with some spilling </li> </ul> </td> <td> <ul> <li>Removes socks/shoes </li> <li>Chews well </li> <li>Puts spoon in mouth, typically turning it over </li> </ul> </td> <td> <ul> <li>Uses spoon with some spilling </li> <li>Attempts to brush own hair </li> <li>Fusses to be changed </li> </ul> </td> <td> <ul> <li>Picks up and drinks from cup </li> <li>Fetches and carries objects (same room) </li> </ul> </td> <td> <ul> <li>Removes garment </li> <li>Gets onto adult chair unaided </li> <li>Moves about house without adult </li> </ul> </td> <td> <ul> <li>Places only edibles in mouth </li> <li>Feeds self with spoon (entire meal) </li> </ul> </td> <td> <ul> <li>Uses spoon well </li> <li>Drinks from cup well </li> <li>Unzips zippers </li> <li>Puts shoes on partway </li> </ul> </td> <td> <ul> <li>Opens door using knob </li> <li>Sucks through straw </li> <li>Takes off clothes without buttons </li> <li>Pulls off pants </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cognitive/academic</strong></td> <td> <ul> <li>Rattles spoon in cup </li> <li>Lifts box lid to find toy </li> </ul> </td> <td> <ul> <li>Dangles ring by string </li> <li>Reaches around clear barrier to obtain object </li> <li>Unwraps toy in cloth </li> </ul> </td> <td> <ul> <li>Dumps pellet out of bottle after demo </li> </ul> </td> <td> <ul> <li>Turns pages in book </li> <li>Places circle in single shape puzzle <p><span style=\"font-size: 1.8em; color: #ff0000; padding-right: 5px;\"><strong></strong></span></p> </li> </ul> </td> <td> <ul> <li>Dumps pellet out without demo </li> <li>Finds toy observed to be hidden under layers of covers </li> <li>Places circle in form board <p><span style=\"font-size: 1.8em; color: #ff0000; padding-right: 5px;\"><strong>â¯</strong></span><span style=\"font-size: 2em;\"><strong>â³</strong></span><span style=\"font-size: 2.5em; padding-left: 3px;\">â»</span></p> </li> </ul> </td> <td> <ul> <li>Matches pairs of objects </li> <li>Re-places circle in form board after it has been turned around (usually with trial and error) <p><span style=\"font-size: 2.5em; padding-right: 3px;\">â»</span><span style=\"font-size: 2em;\"><strong>â½</strong></span><span style=\"font-size: 1.8em; color: #ff0000; padding-left: 5px;\"><strong>â¯</strong></span></p> </li> </ul> </td> <td> <ul> <li>Returns to search for object hidden under cloth after not finding it in an adult's closed fists </li> <li>Places circle and square in form board <p><span style=\"font-size: 1.8em; color: #ff0000; padding-right: 5px;\"><strong>â¯</strong></span><span style=\"font-size: 2em;\"><strong>â³</strong></span><span style=\"font-size: 2.5em; color: #ff0000; padding-left: 3px;\">â»</span></p> </li> </ul> </td> <td> <ul> <li>Completes form board with three shapes <p><span style=\"font-size: 1.8em; color: #ff0000; padding-right: 5px;\"><strong>â¯</strong></span><span style=\"font-size: 2em; color: #ff0000;\"><strong>â³</strong></span><span style=\"font-size: 2.5em; color: #ff0000; padding-left: 3px;\">â»</span></p> </li> </ul> </td> <td> <ul> <li>Sorts objects </li> <li>Matches objects to pictures </li> <li>Shows use of familiar objects </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Social/emotional</strong></td> <td> <ul> <li>Shows objects to parents to share interest </li> <li>Points in order to get desired object (proto-imperative pointing) </li> </ul> </td> <td> <ul> <li>Shows desire to please caregiver </li> <li>Solitary play </li> <li>Functional play </li> </ul> </td> <td> <ul> <li>Points at object to express interest (eg, to get parent to name it [proto-declarative pointing]) </li> <li>Purposeful exploration of toys through trial and error </li> </ul> </td> <td> <ul> <li>Shows empathy (eg, someone else cries, child looks sad) </li> <li>Hugs adult in reciprocation </li> <li>Recognizes without a demo that a toy requires activation and hands it to an adult if can't operate </li> </ul> </td> <td> <ul> <li>Kisses by touching lips to skin </li> <li>Periodically visually relocates caregiver </li> <li>Self-conscious: Embarrassed when aware of people observing </li> </ul> </td> <td> <ul> <li>Passes M-CHAT </li> <li>Engages in pretend play with other people (eg, tea party, birthday party) </li> <li>Begins to show shame (when done wrong) and possessiveness </li> </ul> </td> <td> <ul> <li>Begins to have thoughts about feelings </li> <li>Engages in tea party with stuffed animals </li> <li>Kisses with pucker </li> </ul> </td> <td> <ul> <li>Watches other children intensely </li> <li>Begins to show defiant behavior </li> </ul> </td> <td> <ul> <li>Parallel play </li> <li>Begins to mask emotions for social etiquette </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Receptive language</strong></td> <td> <ul> <li>Follows one-step command with gesture </li> <li>Recognizes names of two objects, looks when named </li> </ul> </td> <td> <ul> <li>Looks appropriately when asked \"Where's the ball?,\" etc </li> </ul> </td> <td> <ul> <li>Follows one-step command without gesture (eg, \"give it\") </li> </ul> </td> <td> <ul> <li>Points to one body part </li> <li>Points to one object of three </li> <li>Gets object from another room upon demand </li> </ul> </td> <td> <ul> <li>Understands simple commands (eg, \"Bring to mommy\") </li> <li>Points to one picture when named </li> </ul> </td> <td> <ul> <li>Points to two of three objects when named </li> <li>Points to three objects </li> <li>Points to self </li> <li>Understands \"mine\" </li> <li>Points to familiar people when named </li> </ul> </td> <td> <ul> <li>Points to three pictures </li> <li>Begins to understand her/him/me </li> </ul> </td> <td> <ul> <li>Points to four to five pictures when named </li> <li>Points to five to six body parts </li> <li>Points to four pieces of clothing when named </li> </ul> </td> <td> <ul> <li>Follows two-step command </li> <li>Understands \"me\"/\"you\" </li> <li>Points to 5 to 10 pictures </li> </ul> </td> </tr> <tr> <td><strong>Expressive language</strong></td> <td> <ul> <li>Points in order to get desired object (proto-imperative pointing) </li> <li>Uses several gestures with vocalizing (eg, waving, reaching, etc) </li> </ul> </td> <td> <ul> <li>Uses three words </li> <li>Immature jargoning (inflections without real words) </li> </ul> </td> <td> <ul> <li>Names one object </li> <li>Points at object to express interest (eg, to get parent to name it [proto-declarative pointing]) </li> </ul> </td> <td> <ul> <li>Uses three to five words </li> <li>Mature jargoning (with real words) </li> </ul> </td> <td> <ul> <li>Uses 5 to 10 words </li> </ul> </td> <td> <ul> <li>Uses 10 to 25 words </li> <li>Uses giant words (eg, \"all gone,\" \"stop that\") </li> <li>Imitates environmental sounds (eg, animals) </li> <li>Names one picture on demand </li> </ul> </td> <td> <ul> <li>Holophrases (\"Mommy?\" and points at keys, meaning \"These are mommy's keys\") </li> <li>Two-word combinations </li> <li>Answers requests with \"no\" </li> </ul> </td> <td> <ul> <li>Uses 25 to 50 words </li> <li>Asks for more </li> <li>Adds one to two words per week </li> </ul> </td> <td> <ul> <li>Uses two-word sentences (noun + verb) </li> <li>Telegraphic speech </li> <li>50+ words in vocabulary </li> <li>50% intelligibility </li> <li>Refers to self by name </li> <li>Names three pictures </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">M-CHAT: Modified Checklist for Autism in Toddlers. </div><div class=\"graphic_reference\">Â© 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS: Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.</div><div id=\"graphicVersion\">Graphic 75336 Version 11.0</div></div></div>"},"75337":{"type":"graphic_picture","displayName":"Erythema migrans multiple","title":"Multiple erythema migrans lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple erythema migrans lesions</div><div class=\"cntnt\"><img style=\"width:260px; height:509px;\" src=\"images/PEDS/75337_Erthm_mgrn_mltpl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythema migrans lesions of early disseminated Lyme disease. In Panel A, the more typical primary lesion is on the abdomen, with a smaller secondary lesion on the upper thigh.</div><div class=\"graphic_reference\">Courtesy of Eugene D Shapiro, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 75337 Version 2.0</div></div></div>"},"75338":{"type":"graphic_table","displayName":"Newborn procedure analgesia","title":"Analgesia for specific neonatal procedures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Analgesia for specific neonatal procedures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Stepwise interventions with increasing analgesia as the degree of anticipated procedural pain increases*</strong> <ul class=\"decimal_heading\"> <li><strong>Step 1:</strong> Nonpharmacologic measures: pacifier, oral sucrose, swaddling, kangaroo care (skin-to-skin contact with the mother), sensorial saturation </li> <li><strong>Step 2:</strong> Topical anesthetics (topical lidocaine, lidocaine-prilocaine cream, tetracaine gel) </li> <li><strong>Step 3:</strong> Acetaminophen: orally (10 to 15 mg/kg once), or rectally (15 to 25 mg/kg once), or intravenously (10 to 20 mg/kg once); maintenance doses may be repeated&nbsp;as needed&nbsp;for post-procedural analgesia (see UpToDate topics on prevention and treatment of neonatal pain for dosing) </li> <li><strong>Step 4:</strong> Opioids: slow intravenous infusion of fentanyl (0.5 to 2 mcg/kg) or morphine (10 to 30 mcg/kg) as single dose only for pain control </li> <li><strong>Step 5:</strong> Lidocaine: subcutaneous infiltration 0.5 mL/kg of 1%&nbsp;(10 mg/mL) lidocaine solution<strong>&nbsp;or</strong> 0.25 mL/kg of 2% (20 mg/mL)&nbsp;lidocaine solution up to a maximum dose of 3 to 5 mg/kg or as nerve block </li> <li><strong>Step 6:</strong> Deep sedation/analgesia using fentanyl (2 to 4 mcg/kg once) or morphine (50 to 100 mcg/kg once), combined&nbsp;with propofol (1 to 2 mg/kg once, use with caution if hypotensive), or&nbsp;ketamine (1 to 2 mg/kg once); for brief procedures, use remifentanil as preferred opioid (1 to 3 mcg/kg once, infuse slowly to avoid chest wall rigidity),&nbsp;or ketamine (1 to 2 mg/kg once) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\">Procedures</td> <td class=\"subtitle1\">Stepwise interventions</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Tracheal aspiration<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup>&#182;</sup></span></td> <td>Step 1; consider pharmacologic therapy using lidocaine 1% (0.3 mL/kg once)&nbsp;via endotracheal tube or low-dose IV fentanyl (0.3 mcg/kg)</td> <td>Perform rapidly, limit catheter insertion to the tip of the&nbsp;endotracheal tube only</td> </tr> <tr> <td>Heelstick<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup>&#182;</sup></span></td> <td>Step 1 &#38; use mechanical lance</td> <td>Venipuncture is more efficient, less painful; Steps 2, 3, &#38; heel warming are ineffective</td> </tr> <tr> <td>Adhesive removal</td> <td>Use solvent swab or aquaphor ointment; consider Step 1</td> <td>&nbsp;</td> </tr> <tr> <td>Gastric tube insertion<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup>&#182;</sup></span></td> <td>Step 1; consider Step 2</td> <td>Perform rapidly, use lubricant, avoid injury</td> </tr> <tr> <td>Venipuncture<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup>&#182;</sup></span></td> <td>Steps 1 &#38; 2</td> <td>Requires less time &#38; less resampling than heelstick</td> </tr> <tr> <td>Arterial puncture<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup><span style=\"font-size: 13px;\">&#182;</span></sup></span></td> <td>Steps 1 &#38; 2; consider Step 5</td> <td>More painful than venipuncture</td> </tr> <tr> <td>Intravenous cannulation<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup><span style=\"font-size: 13px;\">&#182;</span></sup></span></td> <td>Steps 1 &#38; 2</td> <td>&nbsp;</td> </tr> <tr> <td>Chest physiotherapy</td> <td>Gentle positioning; consider Step 4 if a chest tube is present</td> <td>Avoid areas of injured or inflamed skin, drains, or catheters</td> </tr> <tr> <td>Removal of intravenous catheter</td> <td>Use solvent swab; consider Step 1</td> <td>&nbsp;</td> </tr> <tr> <td>Wound treatment<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup><span style=\"font-size: 13px;\">&#182;</span></sup></span></td> <td>Step 1; consider Steps 2, 4, 5, or 6 depending upon the extent of the wound</td> <td>See also \"dressing change\"</td> </tr> <tr> <td>Brief tracheal intubation (eg, for surfactant administration)</td> <td>Step&nbsp;4, in some cases, consider a small dose of IV ketamine (0.5 mg/<span style=\"color: #ff0000;\"></span>kg once), or IV dexmedetomidine (0.2 mcg/kg once), or IV remifentanil (2 mcg/kg once). Atropine (0.02 mg/kg IV) may be given before&nbsp;intubation to avoid reflex bradycardia due to vagal stimulation. Short-acting muscle relaxant may be considered if an experienced clinician is present.</td> <td>Superiority of a specific drug regimen over the others has not been investigated</td> </tr> <tr> <td>Prolonged tracheal intubation (for mechanical ventilation)</td> <td>Step 6,&nbsp;if&nbsp;an experienced clinician is present,&nbsp;muscle relaxant is strongly advised to avoid traumatic intubation; may give atropine (0.02 mg/kg IV)</td> <td>Superiority of a specific drug regimen over the others has not been investigated</td> </tr> <tr> <td>Central line placement</td> <td>Steps 1, 2, 5; consider Step 6</td> <td>Some centers prefer using general anesthesia</td> </tr> <tr> <td>Finger stick<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup><span style=\"font-size: 13px;\">&#182;</span></sup></span></td> <td>Step 1 &#38; use mechanical lance</td> <td>Venipuncture is more efficient, less painful; Steps 2 &#38; 3 are ineffective</td> </tr> <tr> <td>Umbilical catheterization</td> <td>Steps 1, 2,&nbsp;3, or 5,&nbsp;avoid sutures on skin</td> <td>Cord tissue is not innervated, avoid injury to skin</td> </tr> <tr> <td>Bladder compression<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup><span style=\"font-size: 13px;\">&#182;</span></sup></span></td> <td>Consider Steps 1, 3, or 4</td> <td>&nbsp;</td> </tr> <tr> <td>Tracheal extubation</td> <td>Use solvent swab or aquaphor ointment, consider Steps 1, 3</td> <td>Step 1 may be used after the procedure</td> </tr> <tr> <td>Subcutaneous injection<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup><span style=\"font-size: 13px;\">&#182;</span></sup></span></td> <td>Avoid if possible, use Steps 1 &#38; 2 if cannot avoid procedure</td> <td>&nbsp;</td> </tr> <tr> <td>Intramuscular injection<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup><span style=\"font-size: 13px;\">&#182;</span></sup></span></td> <td>Avoid if possible, use Steps 1 &#38; 2 if cannot avoid procedure</td> <td>&nbsp;</td> </tr> <tr> <td>Dressing change</td> <td>Step 1; consider Step 3, 4, or 6 (if extensive)</td> <td>&nbsp;</td> </tr> <tr> <td>Lumbar puncture</td> <td>Steps 1, 2, 3,&nbsp;5, with careful positioning</td> <td>Consider Step 4 if patient is intubated/ventilated</td> </tr> <tr> <td>Peripheral arterial line<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup><span style=\"font-size: 13px;\">&#182;</span></sup></span></td> <td>Steps 1 &#38; 2; consider Steps 4, 5</td> <td>&nbsp;</td> </tr> <tr> <td>Circumcision</td> <td>Steps 1, 2, 5; consider Step 4 pre-procedure and Step 3 pre-&nbsp;and/or post-procedure</td> <td>Step 5: Distal, ring, or dorsal penile nerve blocks (DPNB); liposomal lidocaine is more effective than DPNB</td> </tr> <tr> <td>Suprapubic bladder aspiration</td> <td>Steps 1 &#38; 2; consider Steps 3,&nbsp;4, or 5</td> <td>&nbsp;</td> </tr> <tr> <td>Arterial or venous cutdown</td> <td>Steps 1, 2, 3,&nbsp;4, 5; consider Step 6</td> <td>Avoid if possible</td> </tr> <tr> <td>Peripheral insertion of central catheter (PICC line placement)</td> <td>Steps 1 &#38; 2; consider Steps 3, 4, &#38; 5</td> <td>Some centers prefer using general anesthesia</td> </tr> <tr> <td>Eye examination for retinopathy of prematurity</td> <td>Step 4, 5,&nbsp;6; if step 6 is used,&nbsp;combination therapy with propofol and ketamine may be considered</td> <td>D<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">eep sedation with short-acting drugs like propofol and remifentanil </span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The medication doses listed in this table are for term neonates; preterm and low birth weight neonates may require adjustment of dose and/or interval. Some agents listed in this table are not recommended in preterm neonates (eg, midazolam). Refer to accompanying text and Lexicomp pediatric drug monographs for additional recommendations.<br />Â¶&nbsp;The frequency of these procedures can be reduced without sacrificing the quality of neonatal care.</div><div class=\"graphic_reference\">Reproduced with permission from: KJS Anand, MD.</div><div id=\"graphicVersion\">Graphic 75338 Version 7.0</div></div></div>"},"75339":{"type":"graphic_table","displayName":"Pertussis Rx and prophylaxis","title":"Recommended oral antimicrobial treatment and postexposure prophylaxis for pertussis, by age group","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended oral antimicrobial treatment and postexposure prophylaxis for pertussis, by age group</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age group</td> <td class=\"subtitle1\" colspan=\"3\">Primary agents</td> <td class=\"subtitle1\">Alternate agent*</td> </tr> <tr> <td class=\"subtitle2\">Azithromycin</td> <td class=\"subtitle2\">Erythromycin</td> <td class=\"subtitle2\">Clarithromycin</td> <td class=\"subtitle2\">TMP-SMX</td> </tr> <tr> <td>&#60;1 month</td> <td>Recommended agent; 10 mg/kg per day in a single dose for 5 days (only limited safety data available)</td> <td>Not preferred; erythromycin is associated with infantile hypertrophic pyloric stenosis; use if azithromycin is unavailable; 40 mg/kg per day in&nbsp;four divided doses for 14 days</td> <td>Not recommended (safety data unavailable)</td> <td>Contraindicated for infants aged &#60;2 months (risk for kernicterus)</td> </tr> <tr> <td>1 to 5 months</td> <td>10 mg/kg per day in a single dose for 5 days</td> <td>40 mg/kg per day in&nbsp;four divided doses for&nbsp;14 days </td> <td>15 mg/kg per day in&nbsp;two divided doses for 7 days</td> <td>Contraindicated at age &#60;2 months; for infants aged &#8805;2 months, TMP 8 mg/kg per day, SMX 40 mg/kg per day in&nbsp;two divided doses for 14 days</td> </tr> <tr> <td>Infants (aged &#8805;6 months) and children</td> <td>10 mg/kg in a single dose on day 1 (maximum: 500 mg); then 5 mg/kg per day (maximum:&nbsp;250 mg) on days 2 through 5<sup>&#182;</sup></td> <td>40 mg/kg per day in&nbsp;four divided doses for 7 to 14 days (maximum: 2 g per day)</td> <td>15 mg/kg per day in&nbsp;two divided doses for 7 days (maximum: 1 g per day)</td> <td>TMP 8 mg/kg per day, SMX 40 mg/kg per day in&nbsp;two divided doses for 14 days (maximum TMP 320 mg, SMX 1600 mg per day)</td> </tr> <tr> <td>Adults</td> <td>500 mg in a single dose on day 1 then 250 mg per day on days 2 through 5<sup>&#182;</sup></td> <td>2 g (base) per day in&nbsp;four divided doses for 7 to 14 days</td> <td>1 g per day in&nbsp;two divided doses for 7 days</td> <td>TMP 320 mg per day, SMX 1600 mg per day in 2 divided doses for 14 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TMP-SMX: trimethoprim-sulfamethoxazole&nbsp;(cotrimoxazole). <br />* TMP-SMX can be used as an alternative agent to macrolides in patients aged â¥2 months who are allergic to macrolides, who cannot tolerate macrolides, or who are infected with a rare macrolide-resistant strain of <EM>Bordetella pertussis</EM>. One&nbsp;double strength (DS) tablet contains trimethoprim&nbsp;160 mg with sulfamethoxazole 800 mg. <br />Â¶ A shorter course (ie, three days) of azithromycin for treatment or postexposure prophylaxis of <EM>B. pertussis</EM> has not been validated and is not recommended.</div><div class=\"graphic_reference\">Data from: <br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.611.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis. 2005 CDC guidelines. MMWR 2005; 54:10.</LI></OL></div><div id=\"graphicVersion\">Graphic 75339 Version 7.0</div></div></div>"},"75341":{"type":"graphic_picture","displayName":"Trichinella larvae in muscle","title":"<EM>Trichinella</EM> larvae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Trichinella</EM> larvae</div><div class=\"cntnt\"><img style=\"width:445px; height:288px;\" src=\"images/ID/75341_Trichinella_larvae_in_muscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Trichinella</EM> larvae are seen in an undigested muscle biopsy specimen compressed between microscope slides.</div><div class=\"graphic_reference\">Courtesy of Peter F Weller, MD.</div><div id=\"graphicVersion\">Graphic 75341 Version 2.0</div></div></div>"},"75345":{"type":"graphic_table","displayName":"WHO MEC for women with HIV AIDS","title":"World Health Organization medical eligibility for contraceptive use: HIV/AIDS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization medical eligibility for contraceptive use: HIV/AIDS</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">COC</td> <td class=\"subtitle1\">CIC</td> <td class=\"subtitle1\">P/R</td> <td class=\"subtitle1\">POP</td> <td class=\"subtitle1\"> <p>DMPA</p> NET-EN</td> <td class=\"subtitle1\"> <p>LNG/ETG</p> Implants</td> <td class=\"subtitle1\">Cu-IUD</td> <td class=\"subtitle1\">LNG-IUD</td> </tr> <tr> <td rowspan=\"2\"><strong>High risk of HIV</strong></td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td>Initiation: 2</td> <td>Initiation: 2</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td rowspan=\"2\"><strong>HIV-infected</strong></td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td>Initiation: 2</td> <td>Initiation: 2</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td rowspan=\"2\"><strong>AIDS</strong></td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td>Initiation: 3</td> <td>Initiation: 3</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Clinically well on ARV therapy</td> <td class=\"divider_bottom\" rowspan=\"2\" colspan=\"6\">See antiretroviral therapy (ARV)</td> <td>Initiation: 2/3</td> <td>Initiation: 2/3</td> </tr> <tr class=\"divider_bottom\"> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"9\">Other infections</td> </tr> <tr> <td class=\"indent1\" colspan=\"9\"><strong>Schistosomiasis</strong></td> </tr> <tr> <td class=\"indent2\">Uncomplicated</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent2\">Fibrosis of the liver</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\" colspan=\"9\"><strong>Tuberculosis</strong></td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Non-pelvic</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td>Initiation: 1</td> <td>Initiation: 1</td> </tr> <tr> <td>Continuation: 1</td> <td>Continuation: 1</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Known pelvic</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td class=\"centered\" rowspan=\"2\">1</td> <td>Initiation: 4</td> <td>Initiation: 4</td> </tr> <tr> <td>Continuation: 3</td> <td>Continuation: 3</td> </tr> <tr> <td class=\"indent1\"><strong>Malaria</strong></td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">1: A condition for which there is no restriction for the use of the contraceptive method.<br />2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.<br />3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.<br />4: A condition which represents an unacceptable health risk if the contraceptive method is used.</div><div class=\"graphic_footnotes\">COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.</div><div class=\"graphic_reference\">Reproduced with permission from: http://www.who.int/reproductive-health/publications/mec/summary.html. Copyright &copy; 2006 World Health Organization.<br />Reaffirmed February 16, 2012.</div><div id=\"graphicVersion\">Graphic 75345 Version 5.0</div></div></div>"},"75346":{"type":"graphic_table","displayName":"Screening for fetal anomalies","title":"Ultrasound screening for fetal anomalies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ultrasound screening for fetal anomalies</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Reference</td>\n<td class=\"subtitle1\">Fetuses, n</td>\n<td class=\"subtitle1\">Prevalence, percent</td>\n<td class=\"subtitle1\">Malformed fetuses, n</td>\n<td class=\"subtitle1\">Malformed fetuses detected by ultrasound, n</td>\n<td class=\"subtitle1\">Sensitivity, percent</td>\n</tr>\n<tr>\n<td>Campbell (1983b)</td>\n<td>9526</td>\n<td>0.3</td>\n<td>33</td>\n<td>27</td>\n<td>82</td>\n</tr>\n<tr>\n<td>Stoll (1992)</td>\n<td>133,350</td>\n<td>1.9</td>\n<td>2481</td>\n<td>663</td>\n<td>27</td>\n</tr>\n<tr>\n<td>Li (1988)</td>\n<td>678</td>\n<td>2.4</td>\n<td>16</td>\n<td>3</td>\n<td>19</td>\n</tr>\n<tr>\n<td>Kullendorff (1984)</td>\n<td>6020</td>\n<td>2.0</td>\n<td>120</td>\n<td>23</td>\n<td>19</td>\n</tr>\n<tr>\n<td>Rosendahl (1989)</td>\n<td>9012</td>\n<td>1.0</td>\n<td>93</td>\n<td>54</td>\n<td>58</td>\n</tr>\n<tr>\n<td>Hegge (1988)</td>\n<td>4781</td>\n<td>0.5</td>\n<td>25</td>\n<td>16</td>\n<td>64</td>\n</tr>\n<tr>\n<td>Brocks (1991)</td>\n<td>14,297</td>\n<td>0.5</td>\n<td>74</td>\n<td>59</td>\n<td>80</td>\n</tr>\n<tr>\n<td>Levi (1991)</td>\n<td>15,868</td>\n<td>2.4</td>\n<td>381</td>\n<td>154</td>\n<td>40</td>\n</tr>\n<tr>\n<td>Lys (1989)</td>\n<td>8316</td>\n<td>2.3</td>\n<td>190</td>\n<td>27</td>\n<td>14</td>\n</tr>\n<tr>\n<td>Macquart-Moulin (1989)</td>\n<td>21,061</td>\n<td>0.9</td>\n<td>196</td>\n<td>147</td>\n<td>75</td>\n</tr>\n<tr>\n<td>Ashe (1996)</td>\n<td>6869</td>\n<td>1.2</td>\n<td>83</td>\n<td>11</td>\n<td>13</td>\n</tr>\n<tr>\n<td>Ashe (1996)</td>\n<td>6969</td>\n<td>1.0</td>\n<td>72</td>\n<td>27</td>\n<td>38</td>\n</tr>\n<tr>\n<td>Baronciani (1995)</td>\n<td>169,157</td>\n<td>2.0</td>\n<td>3448</td>\n<td>984</td>\n<td>29</td>\n</tr>\n<tr>\n<td>Bertrand (1985)</td>\n<td>43,364</td>\n<td>2.7</td>\n<td>1180</td>\n<td>242</td>\n<td>21</td>\n</tr>\n<tr>\n<td>Eik-Nes (1992)</td>\n<td>10,317</td>\n<td>2.5</td>\n<td>258</td>\n<td>113</td>\n<td>44</td>\n</tr>\n<tr>\n<td>Constantine (1991)</td>\n<td>8549</td>\n<td>1.7</td>\n<td>143</td>\n<td>91</td>\n<td>64</td>\n</tr>\n<tr>\n<td>Crane (1994)</td>\n<td>7575</td>\n<td>2.4</td>\n<td>182</td>\n<td>65</td>\n<td>36</td>\n</tr>\n<tr>\n<td>Achiron (1991)</td>\n<td>800</td>\n<td>1.8</td>\n<td>14</td>\n<td>8</td>\n<td>57</td>\n</tr>\n<tr>\n<td>Papp (1995)</td>\n<td>51,675</td>\n<td>1.5</td>\n<td>786</td>\n<td>286</td>\n<td>36</td>\n</tr>\n<tr>\n<td>Luck (1992)</td>\n<td>8523</td>\n<td>0.9</td>\n<td>75</td>\n<td>49</td>\n<td>65</td>\n</tr>\n<tr>\n<td>Chambers (1995)</td>\n<td>19,497</td>\n<td>1.2</td>\n<td>235</td>\n<td>121</td>\n<td>52</td>\n</tr>\n<tr>\n<td>Shirley (1992)</td>\n<td>6183</td>\n<td>1.4</td>\n<td>87</td>\n<td>54</td>\n<td>62</td>\n</tr>\n<tr>\n<td>Chitty (1991)</td>\n<td>8342</td>\n<td>1.5</td>\n<td>125</td>\n<td>93</td>\n<td>74</td>\n</tr>\n<tr>\n<td>Stoll (1995)</td>\n<td>56,453</td>\n<td>2.4</td>\n<td>1375</td>\n<td>520</td>\n<td>38</td>\n</tr>\n<tr>\n<td>Levi (1995)</td>\n<td>9601</td>\n<td>2.4</td>\n<td>235</td>\n<td>120</td>\n<td>51</td>\n</tr>\n<tr>\n<td>Grandjean (1999)</td>\n<td>170,800</td>\n<td>2.2</td>\n<td>3685</td>\n<td>2363</td>\n<td>64</td>\n</tr>\n<tr>\n<td>Lee (1998)</td>\n<td>3004</td>\n<td>0.8</td>\n<td>23</td>\n<td>8</td>\n<td>35</td>\n</tr>\n<tr>\n<td>Skupsi (1996)</td>\n<td>860</td>\n<td>1.6</td>\n<td>14</td>\n<td>3</td>\n<td>21</td>\n</tr>\n<tr>\n<td>Gillerot (1995)</td>\n<td>41,074</td>\n<td>3.2</td>\n<td>1294</td>\n<td>305</td>\n<td>24</td>\n</tr>\n<tr>\n<td>Anderson (1995)</td>\n<td>7880</td>\n<td>1.8</td>\n<td>144</td>\n<td>84</td>\n<td>58</td>\n</tr>\n<tr>\n<td>D'Ottavio (1997)</td>\n<td>3514</td>\n<td>1.5</td>\n<td>52</td>\n<td>42</td>\n<td>81</td>\n</tr>\n<tr>\n<td>Boyd (1998)</td>\n<td>33,375</td>\n<td>2.2</td>\n<td>725</td>\n<td>396</td>\n<td>55</td>\n</tr>\n<tr>\n<td>Economides (1998)</td>\n<td>1632</td>\n<td>1.0</td>\n<td>17</td>\n<td>14</td>\n<td>82</td>\n</tr>\n<tr>\n<td>Behrens (1999)</td>\n<td>11,172</td>\n<td>2.5</td>\n<td>275</td>\n<td>125</td>\n<td>46</td>\n</tr>\n<tr>\n<td>Eurenius (1999)</td>\n<td>8345</td>\n<td>1.7</td>\n<td>145</td>\n<td>32</td>\n<td>22</td>\n</tr>\n<tr>\n<td>Stefos (1999)</td>\n<td>7236</td>\n<td>2.2</td>\n<td>162</td>\n<td>130</td>\n<td>80</td>\n</tr>\n<tr>\n<td><strong>Totals</strong></td>\n<td><strong>925,675</strong></td>\n<td><strong>2.0</strong></td>\n<td><strong>18,443</strong></td>\n<td><strong>7460</strong></td>\n<td><strong>40</strong></td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Levi, S. Ultrasound in prenatal diagnosis: polemics around routine ultrasound screening for second trimester fetal malformations. Prenat Diagn 2002; 22:285.</div><div id=\"graphicVersion\">Graphic 75346 Version 1.0</div></div></div>"},"75347":{"type":"graphic_figure","displayName":"Thyroid hormone action part B","title":"Mediation of thyroid hormone action","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Mediation of thyroid hormone action</div><div class=\"cntnt\"><img style=\"width:483px; height:200px;\" src=\"images/ENDO/75347_Thyr_horm_act_part_B.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Binding of T3 disrupts binding of CoR to the TR-RXR heterodimer, promotes binding of CoA, and increases mRNA expression.</div><div class=\"graphic_footnotes\">CoA: co-activator; CoR: co-repressor; RXR: retinoid X receptor; T3: triiodothyronine; TR: thyroid hormone receptor; TRE: thyroid hormone response element.</div><div class=\"graphic_reference\">Modified from: Refetoff S, Weiss RE. Resistance to thyroid hormone. In: Molecular Genetics of Endocrine Disorders, Thakker TV (Ed), Chapman &amp; Hill, London, 1997, p.89.</div><div id=\"graphicVersion\">Graphic 75347 Version 3.0</div></div></div>"},"75349":{"type":"graphic_figure","displayName":"CNS tumor incidence rates","title":"Malignant CNS tumor age-specific incidence rates by anatomic site and age all races, both sexes, SEER, 1975-95","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Malignant CNS tumor age-specific incidence rates by anatomic site and age all races, both sexes, SEER, 1975-95</div><div class=\"cntnt\"><img style=\"width:504px; height:531px;\" src=\"images/ONC/75349_CNS_tumor_incidence_rates.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Ries, LAG, Smith, MA, Gurney, JG (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999.</div><div id=\"graphicVersion\">Graphic 75349 Version 1.0</div></div></div>"},"75350":{"type":"graphic_figure","displayName":"Mesh support pectus","title":"Mesh support of pectus excavatum","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Mesh support of pectus excavatum</div><div class=\"cntnt\"><img style=\"width:472px; height:683px;\" src=\"images/PEDS/75350_Mesh_support_pectus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75350 Version 1.0</div></div></div>"},"75351":{"type":"graphic_table","displayName":"Prevalence renal anomalies","title":"Prevalence of renal anomalies detected by ultrasonography in 709,030 births*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of renal anomalies detected by ultrasonography in 709,030 births*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of renal malformation</td> <td class=\"subtitle1\">Number of cases detected antenatally<sup>&#182;</sup><br /> (percent of antenatal diagnoses)</td> <td class=\"subtitle1\">Total number of cases, detected antenatally and postnatally<br /> (percent of total cases)</td> <td class=\"subtitle1\">Percent of total cases detected antenatally</td> </tr> <tr> <td>Dilatation of upper tract</td> <td class=\"centered\">259 (28)</td> <td class=\"centered\">309 (27)</td> <td class=\"centered\">84</td> </tr> <tr> <td>Unilateral multicystic dysplastic kidney</td> <td class=\"centered\">102 (11)</td> <td class=\"centered\">105 (9)</td> <td class=\"centered\">97</td> </tr> <tr> <td>Unilateral renal agenesis</td> <td class=\"centered\">36 (4)</td> <td class=\"centered\">58 (5)</td> <td class=\"centered\">62</td> </tr> <tr> <td>Bilateral renal agenesis/dysgenesis</td> <td class=\"centered\">86 (9)</td> <td class=\"centered\">95 (8)</td> <td class=\"centered\">91</td> </tr> <tr> <td>Polycystic kidney disease</td> <td class=\"centered\">27 (3)</td> <td class=\"centered\">31 (3)</td> <td class=\"centered\">87</td> </tr> <tr> <td>Supernumerary kidney</td> <td class=\"centered\">37 (4)</td> <td class=\"centered\">39 (3)</td> <td class=\"centered\">95</td> </tr> <tr> <td>Ectopic kidney</td> <td class=\"centered\">15 (2)</td> <td class=\"centered\">27 (2.5)</td> <td class=\"centered\">56</td> </tr> <tr> <td>Posterior urethral valves</td> <td class=\"centered\">19 (2)</td> <td class=\"centered\">27 (2.5)</td> <td class=\"centered\">70</td> </tr> <tr> <td>Solitary cyst</td> <td class=\"centered\">19 (2)</td> <td class=\"centered\">25 (2)</td> <td class=\"centered\">76</td> </tr> <tr> <td>Bladder exstrophy</td> <td class=\"centered\">10 (1)</td> <td class=\"centered\">19 (2)</td> <td class=\"centered\">53</td> </tr> <tr> <td>Syndrome with chromosomal defect</td> <td class=\"centered\">107 (12)</td> <td class=\"centered\">128 (11)</td> <td class=\"centered\">84</td> </tr> <tr> <td>Syndrome without identified chromosomal defect</td> <td class=\"centered\">54 (6)</td> <td class=\"centered\">64 (6)</td> <td class=\"centered\">54</td> </tr> <tr> <td>Multiple malformations<sup>&#916;</sup></td> <td class=\"centered\">130 (14)</td> <td class=\"centered\">176 (16)</td> <td class=\"centered\">74</td> </tr> <tr> <td>Total</td> <td class=\"centered\">924 (100)</td> <td class=\"centered\">1130 (100)</td> <td class=\"centered\">82</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Total number of births included live births, stillbirths, and abortions.<br />Â¶ Mean gestatational age of antenatal detection 24.3 weeks (range 18.5 to 28.3).<br />Î Multiple malformations defined as at least one renal malformation and one or more major malformation of another system.</div><div class=\"graphic_reference\">Data from: Wiesel A, Queisser-Luft A, Clementi M, et al. Prenatal detection of congenital renal malformations by fetal ultrasonographic examination: an analysis of 709,030 births in 12 European countries. Eur J Med Genet 2005; 48:131.</div><div id=\"graphicVersion\">Graphic 75351 Version 6.0</div></div></div>"},"75352":{"type":"graphic_figure","displayName":"Timeline course HUS in children","title":"Progression of E coli O157:H7 infections in children","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Progression of E coli O157:H7 infections in children</div><div class=\"cntnt\"><img style=\"width:499px; height:309px;\" src=\"images/PEDS/75352_Timeline_course_HUS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">About&nbsp;three days after ingestion of the organism, the patient develops diarrhea, abdominal pain, fever, and vomiting. The diarrhea becomes bloody&nbsp;one to&nbsp;three days later, rarely on the first day. In 80 to 90 percent of infected children with positive cultures, visible blood is present in the stools. When bloody diarrhea first develops, the patient has a normal platelet count, creatinine concentration, and packed-cell volume, with no red-cell fragmentation. However, if studies of the coagulation and fibrinolytic systems are done early in the illness, there is evidence that thrombin generation is increased, fibrin deposition is occurring, and plasminogen activation is suppressed.</div><div class=\"graphic_footnotes\">HUS: hemolytic uremic syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coliand haemolytic uraemic syndrome. Lancet 2005; 365:1073. Copyright Â©2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 75352 Version 3.0</div></div></div>"},"75354":{"type":"graphic_figure","displayName":"HRT and colorectal CA WHI","title":"Hormone replacement therapy reduces rates of invasive colorectal cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hormone replacement therapy reduces rates of invasive colorectal cancer</div><div class=\"cntnt\"><img style=\"width:383px; height:221px;\" src=\"images/ENDO/75354_HRT_and_colorectal_CA_WHI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Women's Health Initiative, combined estrogen-progestin replacement therapy was associated with a significant reduction in the cumulative hazard of invasive colorectal cancer (hazard ratio 0.56, unadjusted 95 percent CI 0.38 to 0.81).</div><div class=\"graphic_reference\">Data from: Estrogen and progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350:991.</div><div id=\"graphicVersion\">Graphic 75354 Version 2.0</div></div></div>"},"75355":{"type":"graphic_table","displayName":"Travelers diarrhea rx","title":"Oral agents for self-treatment of travelers' diarrhea in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral agents for self-treatment of travelers' diarrhea in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Duration&nbsp;</td> <td class=\"subtitle1\">Comment&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Azithromycin&nbsp;</td> <td>1000 mg once</td> <td>&nbsp;Single dose</td> <td rowspan=\"2\"> <ul> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Preferred for travelers from Southeast Asia and&nbsp;pregnant women</span> </li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">The 1000 mg dose may be associated with nausea</span> </li> </ul> <p>&nbsp;</p> </td> </tr> <tr> <td>500 mg once daily&nbsp;</td> <td>Three-day course</td> </tr> <tr> <td>Levofloxacin</td> <td>500 mg once daily </td> <td>Single dose or three-day course</td> <td rowspan=\"4\"> <ul> <li>Fluoroquinolones are associated with multiple adverse events </li> </ul> </td> </tr> <tr> <td rowspan=\"2\">Ciprofloxacin</td> <td>750 mg&nbsp;once</td> <td>Single dose</td> </tr> <tr> <td>500 mg&nbsp;twice daily</td> <td>Three-day course&nbsp;</td> </tr> <tr> <td>Ofloxacin</td> <td>400 mg&nbsp;once daily</td> <td>Single dose or three-day course</td> </tr> <tr> <td>Rifaximin</td> <td>200 mg three times daily</td> <td>Three-day course&nbsp;</td> <td> <ul> <li>Not for use with invasive diarrhea </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report. J Travel Med 2017; 24:S57.</div><div id=\"graphicVersion\">Graphic 75355 Version 6.0</div></div></div>"},"75356":{"type":"graphic_figure","displayName":"Carvedilol in HF II","title":"Overall benefit of carvedilol in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Overall benefit of carvedilol in heart failure</div><div class=\"cntnt\"><img style=\"width:422px; height:283px;\" src=\"images/CARD/75356_Carvedilol_in_HF_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis of event-free survival (survival without hospitalization) in patients with chronic heart failure who were maintained on digoxin, diuretics, and an angiotensin-converting enzyme inhibitor and then treated with carvedilol or placebo. Therapy with carvedilol was associated with a 38 percent increase in event-free survival.</div><div class=\"graphic_footnotes\">HF: heart failure.</div><div class=\"graphic_reference\">Data from: Packer M, Bristow MR, Cohn JN, et al for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.&nbsp;N Engl J Med 1996; 334:1349.</div><div id=\"graphicVersion\">Graphic 75356 Version 3.0</div></div></div>"},"75361":{"type":"graphic_figure","displayName":"Glutathione synthesis pathway","title":"Biosynthesis of glutathione","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biosynthesis of glutathione</div><div class=\"cntnt\"><img style=\"width:397px; height:347px;\" src=\"images/HEME/75361_Glutathione_synthesis_pathw.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the pathway for biosynthesis of glutathione from cysteine, glutamic acid, ATP, and glycine. The end product of these reactions, glutathione, serves as a feedback inhibitor of the first enzyme in the pathway, gamma-glutamyl cysteine synthetase. In the absence of glutathione synthetase, this inhibition cannot take place, and increased amounts of the intermediate, gamma-glutamyl cysteine are formed. This is converted to the intermediate 5' oxyproline (5' oxoproline, pyroglutamic acid), which is present in increased amounts in glutathione synthetase deficiency.</div><div id=\"graphicVersion\">Graphic 75361 Version 2.0</div></div></div>"},"75362":{"type":"graphic_figure","displayName":"Survival in beta thalassemia major","title":"Survival beyond 12 years of age in beta thalassemia major","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival beyond 12 years of age in beta thalassemia major</div><div class=\"cntnt\"><img style=\"width:446px; height:350px;\" src=\"images/HEME/75362_Survival_in_beta_thal_major.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph shows the survival beyond age 12 of four consecutive 10-year cohorts of children surviving to age 12 with beta thalassemia major. Cohorts are dated from time of birth.</div><div class=\"graphic_reference\">Data reproduced with permission from:&nbsp;Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.&nbsp;Lancet 2000; 355:2051.</div><div id=\"graphicVersion\">Graphic 75362 Version 2.0</div></div></div>"},"75364":{"type":"graphic_table","displayName":"Indications for speech and language evaluation","title":"Indications for speech and language evaluation in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for speech and language evaluation in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Concern by the parent, teacher, professional, or other caregiver about the child's speech or language</td> </tr> <tr> <td>Slowed or stagnant speech and language development</td> </tr> <tr> <td>Excessive drooling</td> </tr> <tr> <td>Difficulty sucking, chewing, or swallowing</td> </tr> <tr> <td>Difficulty coordinating movements of lips, tongue, and jaw</td> </tr> <tr> <td>No babbling by 9 months</td> </tr> <tr> <td>No first words by 15 months</td> </tr> <tr> <td>No consistent words by 18 months</td> </tr> <tr> <td>No word combinations by 24 months</td> </tr> <tr> <td>Speech is difficult for parents to understand at 24 months</td> </tr> <tr> <td>Speech is difficult for strangers to understand at 36 months</td> </tr> <tr> <td>Dysfluencies (stutters) consist of more than tension-free whole-word repetitions</td> </tr> <tr> <td>Child is frustrated by communication difficulty</td> </tr> <tr> <td>Child is teased by peers for \"talking funny\"</td> </tr> <tr> <td>Child avoids talking situations</td> </tr> <tr> <td>Child acquires vocabulary and sentence structure but does not use language appropriately for communicative purposes</td> </tr> <tr> <td>Language is unusual or confused, or ideas are not expressed clearly</td> </tr> <tr> <td>Child cannot follow instructions without supplemental visual cues</td> </tr> <tr> <td>Loss of milestones</td> </tr> <tr> <td>Poor memory skills at 5 to 6 years</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=78447&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">References: <br /><OL>&#xD;&#xA;<LI>Flax JF, Rapin I. Evaluating children with delayed speech and language. Contemp Pediatr 1998; 15:164.</LI>&#xD;&#xA;<LI>Sturner RA, Howard BJ. Preschool development. 1: Communicative and motor aspects. Pediatr Rev 1997; 18:291.</LI>&#xD;&#xA;<LI>Johnson CP, Blasco PA. Infant growth and development. Pediatr Rev 1997; 18:224.</LI></OL></div><div id=\"graphicVersion\">Graphic 75364 Version 5.0</div></div></div>"},"75365":{"type":"graphic_picture","displayName":"Patch granuloma annulare","title":"Patch granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patch granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75365_Patch_granuloma_annulare.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, nonscaly patch is present on the leg of this patient with patch-type granuloma annulare.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75365 Version 3.0</div></div></div>"},"75366":{"type":"graphic_diagnosticimage","displayName":"Parasternal short axis color Doppler","title":"Parasternal short axis view through the base of the heart with color flow Doppler imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal short axis view through the base of the heart with color flow Doppler imaging</div><div class=\"cntnt\"><img style=\"width:277px; height:524px;\" src=\"images/CARD/75366_Short_axis_color_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal short axis view is recorded from the base of the heart. Color flow Doppler imaging during systole (panel A) demonstrates normal systolic flow from the right ventricular outflow tract (RVOT) to the main pulmonary artery (MPA). The flow signal is red in the proximal RVOT as it travels towards the transducer. As it moves at right angles to the interrogating beam, the signal briefly disappears. When the flow turns away from the transducer and exits into the MPA, it is coded blue. Imaging from short axis view through the base of the heart during diastole (panel B) shows diastolic flow signal (red) from pulmonic valve (PV) denoting trivial pulmonic regurgitation (PR) which is found in 90 percent of normals.</div><div class=\"graphic_footnotes\">Ao: aorta; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 75366 Version 6.0</div></div></div>"},"75367":{"type":"graphic_figure","displayName":"Incisions radical vulvectomy","title":"Examples of incisions used for radical vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examples of incisions used for radical vulvectomy</div><div class=\"cntnt\"><img style=\"width:289px; height:613px;\" src=\"images/OBGYN/75367_Incisions_radical_vulvectom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Radical vulvectomy&nbsp;via butterfly incision. (B) Modified radical vulvectomy: triple incision technique, a skin bridge is left between the radical vulvectomy and the groin incisions. (C) Modified radical vulvectomy: anterior horseshoe incision.</div><div id=\"graphicVersion\">Graphic 75367 Version 2.0</div></div></div>"},"75368":{"type":"graphic_figure","displayName":"Hot liquid balloon ablation 2","title":"Hot liquid balloon endometrial ablation ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hot liquid balloon endometrial ablation </div><div class=\"cntnt\"><img style=\"width:434px; height:354px;\" src=\"images/OBGYN/75368_Thermachoice_ablation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Uterine coverage with Thermachoice uterine balloon endometrial ablation system.</div><div class=\"graphic_reference\">Reproduced with permission from: Loffer, FD. Gynecare ThermaChoice Uterine Balloon Therapy System: First on the market, long-term results. OBG Management 2005. Copyright &#169; 2005 Dowden Health Media.</div><div id=\"graphicVersion\">Graphic 75368 Version 2.0</div></div></div>"},"75369":{"type":"graphic_diagnosticimage","displayName":"MRA of cerebral AVM","title":"Magnetic resonance angiogram of a frontotemporal arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance angiogram of a frontotemporal arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:281px; height:364px;\" src=\"images/PEDS/75369_Frontotemporal_AVM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance angiogram in a thirteen-year-old girl with hemiparesis showing a large right frontotemporal arteriovenous malformation with arterial feeders and nidus (arrows) and the large venous drainer (arrowheads).</div><div id=\"graphicVersion\">Graphic 75369 Version 5.0</div></div></div>"},"75371":{"type":"graphic_picture","displayName":"Preauricular pit","title":"Preauricular pit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Preauricular pit</div><div class=\"cntnt\"><img style=\"width:261px; height:343px;\" src=\"images/PEDS/75371_Preauricular_pit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the small punctum in the preauricular area. This preauricular pit is draining squamous material.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 75371 Version 1.0</div></div></div>"},"75372":{"type":"graphic_diagnosticimage","displayName":"Tethered cord syndrome","title":"Tethered cord syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tethered cord syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:507px;\" src=\"images/PEDS/75372_Tethered_cord_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2 sagittal magnetic resonance imaging (MRI) study&nbsp;of a patient with tethered cord syndrome (TCS). One can see the thickened filum (arrow) and the low-lying conus (asterisk) that are often seen, yet are not necessary, for this diagnosis.</div><div class=\"graphic_reference\">Courtesy of Chaouki El-Khoury, BS, MD.</div><div id=\"graphicVersion\">Graphic 75372 Version 3.0</div></div></div>"},"75373":{"type":"graphic_picture","displayName":"Devitalization in KCS","title":"Severe dry eye","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe dry eye</div><div class=\"cntnt\"><img style=\"width:397px; height:273px;\" src=\"images/RHEUM/75373_Devitalization_in_KCS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorescein dye shows devitalized surface epithelial cells because of severe dryness.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 75373 Version 2.0</div></div></div>"},"75374":{"type":"graphic_figure","displayName":"Progression vasc neuropathy","title":"Progression of vasculitic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Progression of vasculitic neuropathy</div><div class=\"cntnt\"><img style=\"width:402px; height:300px;\" src=\"images/RHEUM/75374_Progression_vasc_neuropathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vasculitic neuropathy begins by involvement of both sensory (hashed areas) and motor nerve (black areas) distribution. As the process progresses (moving left to right on the figure), it becomes more confluent and symmetrical.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 75374 Version 2.0</div></div></div>"},"75375":{"type":"graphic_picture","displayName":"AIDS related KS skin","title":"Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:418px; height:238px;\" src=\"images/ONC/75375_AIDS_related_KS_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin lesions in a patient with AIDS-related Kaposi's sarcoma who presented with simultaneous cutaneous and gastrointestinal disease.</div><div class=\"graphic_reference\">By permission from van den Brink, MR, Dezube, BJ, J Clin Oncol 1997; 15:1283.</div><div id=\"graphicVersion\">Graphic 75375 Version 1.0</div></div></div>"},"75378":{"type":"graphic_figure","displayName":"Linkage one pedigree","title":"Linkage in one pedigree","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linkage in one pedigree</div><div class=\"cntnt\"><img style=\"width:317px; height:275px;\" src=\"images/PC/75378_Linkage_one_pedigree.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">All affected subjects (denoted as shaded) have a presumed disease genotype of Dd (ie, assumption of an autosomal dominant trait). The genotyped marker (with alleles 1, 2, or 3) appears to be linked in this pedigree with the disease locus, as all affected subjects harbor the 1 allele - this marker tracks with disease status.</div><div id=\"graphicVersion\">Graphic 75378 Version 2.0</div></div></div>"},"75379":{"type":"graphic_table","displayName":"Risk factors for SIDS","title":"Epidemiologic risk factors for SIDS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epidemiologic risk factors for SIDS</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">General factors</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Low birth weight</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Racial/ethnic differences (increased risk in nonwhite races)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Gender - male greater than female</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Climate - twofold increased risk in cold versus warm months</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Maternal and antenatal factors</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Smoking, illicit drugs&nbsp;</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Young, unmarried, no high school degree&nbsp;</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Late or no prenatal care&nbsp;</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Poor gestational weight gain&nbsp;</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pregnancy complications (placenta previa, abruption, premature rupture of membranes)&nbsp;</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Anemia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Urinary tract infection, sexually transmitted disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Short interpregnancy interval</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Neonatal factors</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Prematurity</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Small for gestational age</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Vital signs - <strong>not</strong> a risk</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Apnea of prematurity - <strong>not</strong> a risk</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Post neonatal factors</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Prone sleep position - 1.3-fold increased risk</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sleep environment - soft sleep surfaces, loose bedding accessories, bed-sharing</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Recent gastrointestinal illness</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Listlessness</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Breast feeding -&nbsp;<strong>reduces</strong> risk</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Recent upper respiratory infection - <strong>not</strong> a risk</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Immunizations - <strong>not</strong> a risk</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">SIDS: sudden infant death syndrome.</div><div class=\"graphic_reference\">Data from: Hoffman HJ, Damus K, Hillman L, Krongrad E. Risk factors for SIDS. Results of the National Institute of Child Health and Human Development SIDS Cooperative Epidemiological Study. Ann N Y Acad Sci 1988; 533:13.</div><div id=\"graphicVersion\">Graphic 75379 Version 4.0</div></div></div>"},"75380":{"type":"graphic_figure","displayName":"Differentiation of helper T cells","title":"Differentiation of helper T cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Differentiation of helper T cells</div><div class=\"cntnt\"><img style=\"width:334px; height:422px;\" src=\"images/RHEUM/75380_Differentiation_of_ThO_cell.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When antigen is presented by APCs to Th0 lymphocytes, Th0 cells may differentiate into either Th1 or Th2 subtypes. In humans, Th1 cells express IFN-gamma and TGF-beta, whereas Th2 cells express IL-4, IL-5, and IL-9. Both sets of human lymphocytes express IL-2, IL-3, IL-10, IL-13, and GM-CSF. Th1 cells induce macrophage activation and granuloma formation. Th2 cells induce atopy and promote IgE, mast cell, and eosinophil production. This fundamental division in T cells appears to correlate with the phenotypic expression of various human diseases.</div><div class=\"graphic_footnotes\">APC: antigen-presenting cell; Th0: undifferentiated T helper cell; Th1: T helper type 1 cell; Th2: T helper type 2 cell; IFN-gamma: interferon-gamma; TGF-beta: tumor growth factor-beta; NO: nitric oxide; IL: interleukin; GM-CSF: granulocyte macrophage colony-stimulating factor; DTH: delayed-type hypersensitivity.</div><div class=\"graphic_reference\">Reproduced with permission from: Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997; 99:S764. Copyright &copy; 1997 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 75380 Version 4.0</div></div></div>"},"75381":{"type":"graphic_figure","displayName":"Left colon resection for a splenic flexure lesion","title":"Left colon resection for a splenic flexure lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left colon resection for a splenic flexure lesion</div><div class=\"cntnt\"><img style=\"width:434px; height:544px;\" src=\"images/SURG/75381_Splenic-flexure-lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a left colectomy for a malignant lesion located at the splenic flexure.</div><div id=\"graphicVersion\">Graphic 75381 Version 1.0</div></div></div>"},"75382":{"type":"graphic_picture","displayName":"Hemotympanum","title":"Hemotympanum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemotympanum</div><div class=\"cntnt\"><img style=\"width:324px; height:291px;\" src=\"images/EM/75382_Hemotympanum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The older, dark-brown, bloody fluid in this right middle ear has colored the tympanic membrane black.</div><div class=\"graphic_reference\">Reproduced with permission from: Garcia M. Basilar Skull Fracture. In: Greenberg's Text-Atlas of Emergency Medicine, Greenberg MI, Hendrickson RG, Silverberg M, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright Â© 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 75382 Version 11.0</div></div></div>"},"75383":{"type":"graphic_table","displayName":"Causes of insulin resistance","title":"Major causes of insulin resistance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of insulin resistance</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inherited states of target cell resistance</td> </tr> <tr> <td>Leprechaunism (insulin-receptor mutations)</td> </tr> <tr> <td>Rabson-Mendenhall syndrome (insulin-receptor mutations)</td> </tr> <tr> <td>Type A syndrome of insulin resistance (insulin-receptor mutations in some, unknown signalling defect in most)</td> </tr> <tr> <td>Some lipodystrophies</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary insulin resistance</td> </tr> <tr> <td>Obesity (free fatty acids and adipocytokines may contribute)</td> </tr> <tr> <td>Excess counterregulatory hormones (glucocorticoids, catecholamines, growth hormone, placental lactogen)</td> </tr> <tr> <td>Type 2 diabetes mellitus (secondary to obesity and other factors)</td> </tr> <tr> <td>Inactivity</td> </tr> <tr> <td>Stress, infection (counterregulatory hormones)</td> </tr> <tr> <td>Pregnancy (placental lactogen)</td> </tr> <tr> <td>Immune mediated (anti-insulin antibodies, anti-insulin receptor antibodies in type B syndrome)</td> </tr> <tr> <td>Miscellaneous (starvation, uremia, cirrhosis, ketoacidosis)</td> </tr> <tr> <td class=\"subtitle1_single\">Multifactorial etiology of insulin resistance</td> </tr> <tr> <td>Hypertension</td> </tr> <tr> <td>Polycystic ovary syndrome</td> </tr> <tr> <td>Metabolic syndrome</td> </tr> <tr> <td>Most cases of type 2 diabetes mellitus</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75383 Version 3.0</div></div></div>"},"75384":{"type":"graphic_picture","displayName":"Anterior uveitis in a patient with IBD","title":"Anterior uveitis in a patient with inflammatory bowel disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior uveitis in a patient with inflammatory bowel disease</div><div class=\"cntnt\"><img style=\"width:233px; height:177px;\" src=\"images/GAST/75384_Anterior_uveitis_IBD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior uveitis in a patient with inflammatory bowel disease is characterized by injection of the conjunctiva and opacity in the anterior chamber.</div><div class=\"graphic_reference\">Courtesy of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 75384 Version 4.0</div></div></div>"},"75385":{"type":"graphic_algorithm","displayName":"Testing algorithm for Lynch syndrome","title":"Testing algorithm for Lynch syndrome","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Testing algorithm for Lynch syndrome</div><div class=\"cntnt\"><img style=\"width:624px; height:608px;\" src=\"images/GAST/75385_Test_algorithm_Lynch.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MSI: microsatellite instability; IHC: immunohistochemistry; MSI-L: low MSI; MSS: microsatellite stable; MSI-H: high MSI; MMR: mismatch repair.<br />* Proceeding with <EM>MLH1 </EM>methylation studies and <EM>BRAF</EM> v600E mutation analysis on tumor before germline genetic testing can be considered, particularly if the individual does not meet revised Bethesda guidelines.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodenberger M, Lindor NM. Lynch syndrome and MYH-associated polyposis: review and testing strategy. J Clin Gastroenterol 2011; 45:488. Copyright Â© 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75385 Version 12.0</div></div></div>"},"75386":{"type":"graphic_table","displayName":"Heme intermediates","title":"Intermediates of the heme biosynthetic pathway, chemical alterations that occur when they accumulate, routes of excretion, and samples collected for their measurement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intermediates of the heme biosynthetic pathway, chemical alterations that occur when they accumulate, routes of excretion, and samples collected for their measurement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Pathway intermediate*</td> <td class=\"subtitle1\">Chemically altered forms<sup>&#182;</sup></td> <td class=\"subtitle1\">Primary routes of excretion</td> <td class=\"subtitle1\">Samples for measurement<sup>&#916;</sup></td> </tr> <tr> <td>&#948;-Aminolevulinic acid</td> <td>None</td> <td>Kidney</td> <td>Urine, plasma</td> </tr> <tr> <td>Porphobilinogen</td> <td>Porphobilin; uroporphyrin</td> <td>Kidney</td> <td>Urine, plasma</td> </tr> <tr> <td>Uroporphyrinogen (octacarboxyl porphyrin) I &#38; III</td> <td>Uroporphyrin I &#38; III</td> <td>Kidney</td> <td>Urine, plasma</td> </tr> <tr> <td>Heptacarboxyl porphyrinogen I &#38; III</td> <td>Heptacarboxyl porphyrin I &#38; III</td> <td>Kidney</td> <td>Urine, plasma</td> </tr> <tr> <td>Hexacarboxyl porphyrinogen I &#38; III</td> <td>Heptacarboxyl porphyrin I &#38; III</td> <td>Kidney</td> <td>Urine, plasma</td> </tr> <tr> <td>Pentacarboxyl porphyrinogen I &#38; III</td> <td>Pentacarboxyl porphyrin I &#38; III</td> <td>Kidney</td> <td>Urine, plasma</td> </tr> <tr> <td>Coproporphyrinogen (tetracarboxyl porphyrinogen) I &#38; III</td> <td>Coproporphyrin I &#38; III</td> <td>Kidney and liver</td> <td>Urine, feces, plasma</td> </tr> <tr> <td>Protoporphyrinogen IX</td> <td>Protoporphyrin IX</td> <td>Liver</td> <td>Feces, plasma</td> </tr> <tr> <td>Protoporphyrin IX</td> <td>None</td> <td>Liver</td> <td>Feces, erythrocytes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All intermediates are colorless and nonfluorescent, with the exception of protoporphyrin, which is reddish and fluorescent.<br />Â¶&nbsp;The autooxidized porphyrins are reddish and fluorescent; porphobilin is brownish.<br />Î Urine and fecal porphyrins are fractionated if the total is increased; plasma porphyrins may be fractionated, but for differential diagnosis it is preferred to determine the fluorescence peak at neutral pH.</div><div class=\"graphic_reference\">Provided by Karl Anderson, MD, FACP.</div><div id=\"graphicVersion\">Graphic 75386 Version 4.0</div></div></div>"},"75387":{"type":"graphic_diagnosticimage","displayName":"3D reconstruction CT hamate fracture","title":"3D reconstruction CT hamate fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">3D reconstruction CT hamate fracture</div><div class=\"cntnt\"><img style=\"width:324px; height:343px;\" src=\"images/EM/75387_Hamate_fracture_CT_reconstr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This three-dimensional reconstruction was created from multiple CT sections. The overlapping fragments resulting from a comminuted fracture of the hamate are shown (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 75387 Version 7.0</div></div></div>"},"75388":{"type":"graphic_figure","displayName":"Cutaneous innervation of the arm","title":"Cutaneous innervation of the arm","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Cutaneous innervation of the arm</div><div class=\"cntnt\"><img style=\"width:524px; height:580px;\" src=\"images/SURG/75388_Upper_ext_cutaneous_innerv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">n.: nerve.</div><div id=\"graphicVersion\">Graphic 75388 Version 3.0</div></div></div>"},"75390":{"type":"graphic_table","displayName":"Etiology of lower extremity ischemia","title":"Etiology of lower extremity ischemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of lower extremity ischemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major causes</td> </tr> <tr> <td>Atherosclerosis</td> </tr> <tr> <td>Thombosed aneurysm</td> </tr> <tr> <td>Arterial injury</td> </tr> <tr> <td>Arterial dissection</td> </tr> <tr> <td>Atheroembolism</td> </tr> <tr> <td>Thromboembolism</td> </tr> <tr> <td>Thromboangiitis obliterans (Buerger's disease)</td> </tr> <tr> <td class=\"subtitle1_single\">Other causes</td> </tr> <tr> <td class=\"sublist1_start\">Aorto-iliac</td> </tr> <tr> <td class=\"sublist1\">Retroperitoneal fibrosis</td> </tr> <tr> <td class=\"sublist1\">Radiation fibrosis</td> </tr> <tr> <td class=\"sublist1\">Tumor</td> </tr> <tr> <td class=\"sublist1_start\">Iliac</td> </tr> <tr> <td class=\"sublist1\">Fibromuscular dysplasia</td> </tr> <tr> <td class=\"sublist1\">Iliac endofibrosis (athletic injury)</td> </tr> <tr> <td class=\"sublist1_start\">Iliofemoral</td> </tr> <tr> <td class=\"sublist1\">Pseudoxanthoma elasticum</td> </tr> <tr> <td class=\"sublist1_start\">Popliteal</td> </tr> <tr> <td class=\"sublist1\">Popliteal entrapment</td> </tr> <tr> <td class=\"sublist1\">Adventitial cystic disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75390 Version 1.0</div></div></div>"},"75391":{"type":"graphic_picture","displayName":"Cutaneous polyarteritis nodosa","title":"Cutaneous polyarteritis nodosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous polyarteritis nodosa</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75391_Cutan_polyarteritis_nodosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerated, erythematous nodules in polyarteritis nodosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75391 Version 3.0</div></div></div>"},"75392":{"type":"graphic_figure","displayName":"Upper endoscopy PI","title":"Upper endoscopy","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Upper endoscopy</div><div class=\"cntnt\"><img style=\"width:520px; height:673px;\" src=\"images/PI/75392_Upper-endoscopy-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During an upper endoscopy, you lie down and the doctor puts a thin tube with a camera and light on the end (called an endoscope) into your mouth and down into your esophagus, stomach, and duodenum (the first part of your small intestine). The camera sends pictures from inside your body to a television screen. That way, your doctor can see the inside of your esophagus, stomach, and duodenum.</div><div id=\"graphicVersion\">Graphic 75392 Version 4.0</div></div></div>"},"75393":{"type":"graphic_diagnosticimage","displayName":"Cavitary TB","title":"Cavitary tuberculosis in an adolescent male","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavitary tuberculosis in an adolescent male</div><div class=\"cntnt\"><img style=\"width:316px; height:432px;\" src=\"images/ID/75393_Cavitary_TB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cavitary tuberculosis in an adolescent male. There is infiltrate and a cavity along the horizontal fissure on the right. Note the absence of hilar adenopathy, which is typical of so-called reactivation or adult-type tuberculosis in adolescents.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 75393 Version 2.0</div></div></div>"},"75394":{"type":"graphic_table","displayName":"Somatropic axis HIV","title":"Alterations in the somatotropic axis in HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alterations in the somatotropic axis in HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">&nbsp;</td>\r\n                    <td class=\"subtitle1\">HIV-infected, no wasting or lipodystrophy</td>\r\n                    <td class=\"subtitle1\">HIV-infected, lipodystrophy</td>\r\n                    <td class=\"subtitle1\">AIDS wasting</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>GH</td>\r\n                    <td>Normal</td>\r\n                    <td>&#8595;</td>\r\n                    <td>&#8593;</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>IGF-1</td>\r\n                    <td>Normal</td>\r\n                    <td>Normal</td>\r\n                    <td>&#8595;</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>IGF-BP-3</td>\r\n                    <td>Normal</td>\r\n                    <td>Normal</td>\r\n                    <td>Normal or &#8595;</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">GH: growth hormone; IGF-1: insulin-like growth factor-1; IGF-BP-3: insulin-like growth factor-binding protein-3.</div><div id=\"graphicVersion\">Graphic 75394 Version 2.0</div></div></div>"},"75397":{"type":"graphic_figure","displayName":"Jet nebulizer","title":"Jet nebulizer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jet nebulizer</div><div class=\"cntnt\"><img style=\"width:370px; height:372px;\" src=\"images/PEDS/75397_Jet_nebulizer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A jet flow of driving gas creates an area of low pressure above the medication reservoir, generating an aerosol. The baffle helps ensure the formation of respirable particles and prevents inhalation of oversized droplets of medication. Most nebulizers require a flow rate of 8 liters per minute for optimum performance.</div><div id=\"graphicVersion\">Graphic 75397 Version 2.0</div></div></div>"},"75398":{"type":"graphic_picture","displayName":"Superficial partial-thickness burn","title":"Superficial partial-thickness burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial partial-thickness burn</div><div class=\"cntnt\"><img style=\"width:367px; height:283px;\" src=\"images/EM/75398_Superficialpartialthickb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blistering burns that blanch with pressure characterize superficial partial-thickness burns. They are also typically moist and weep.</div><div class=\"graphic_reference\">Courtesy of Eric D Morgan, MD,&nbsp;and William F Miser, MD.</div><div id=\"graphicVersion\">Graphic 75398 Version 4.0</div></div></div>"},"75399":{"type":"graphic_figure","displayName":"Regulation thyroid hormone production","title":"Regulation of thyroid hormone production","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Regulation of thyroid hormone production</div><div class=\"cntnt\"><img style=\"width:540px; height:565px;\" src=\"images/ENDO/75399_hypothal_pituitary_thyroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TRH increases the secretion of TSH, which stimulates the synthesis and secretion of T3 and T4 by the thyroid gland. T3 and T4 inhibit the secretion of TSH, both directly and indirectly by suppressing the release of TRH. T4 is converted to T3 in the liver and many other tissues by the action of T4 monodeiodinases. Some T4 and T3 is conjugated with glucuronide and sulfate in the liver, excreted in the bile, and partially hydrolyzed in the intestine. Some T4 and T3 formed in the intestine may be reabsorbed. Drug interactions may occur at any of these sites.</div><div class=\"graphic_footnotes\">TRH: thyrotropin-releasing hormone; TSH: thyroid-stimulating hormone; T4: thyroxine; T3: triiodothyronine.</div><div id=\"graphicVersion\">Graphic 75399 Version 8.0</div></div></div>"},"75400":{"type":"graphic_diagnosticimage","displayName":"Crohn colitis sacculation BE","title":"Chronic Crohn colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic Crohn colitis</div><div class=\"cntnt\"><img style=\"width:259px; height:288px;\" src=\"images/GAST/75400_Crohns_colitis_saccula_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium enema demonstrates sacculations along the medial border of the ascending colon (arrows) produced by scarring and fibrosis in a patient with Crohn disease.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75400 Version 4.0</div></div></div>"},"75402":{"type":"graphic_table","displayName":"Virus induced airway obstruction","title":"Potential mechanisms of virus-induced airway obstruction and asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential mechanisms of virus-induced airway obstruction and asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Increased airway responsiveness</td> </tr> <tr> <td class=\"indent1\">Increased sensitivity</td> </tr> <tr> <td class=\"indent1\">Increased maximal response</td> </tr> <tr> <td class=\"subtitle1_single\">Altered neural control mechanisms</td> </tr> <tr> <td class=\"sublist2_start\">Enhanced parasympathetic efferent signal</td> </tr> <tr> <td class=\"sublist2\">Decreased M2 receptor function</td> </tr> <tr> <td class=\"sublist2\">M2-independent factors</td> </tr> <tr> <td class=\"sublist2_start\">Sensory C fibers</td> </tr> <tr> <td class=\"sublist2\">Increased neuropeptide release</td> </tr> <tr> <td class=\"sublist2\">Loss of neutral endopeptidase</td> </tr> <tr> <td class=\"sublist2_start\">Defective nonadrenergic, noncholinergic responses</td> </tr> <tr> <td class=\"sublist2\">Decreased nitric oxide production</td> </tr> <tr> <td class=\"subtitle1_single\">Altered small airway geometry</td> </tr> <tr> <td class=\"indent1\">Airway wall thickening</td> </tr> <tr> <td class=\"sublist2_start\">Plugging of the lumen</td> </tr> <tr> <td class=\"sublist2\">Mucus secretion</td> </tr> <tr> <td class=\"sublist2\">Cellular debris</td> </tr> <tr> <td class=\"subtitle1_single\">Increased airway inflammation</td> </tr> <tr> <td class=\"sublist2_start\">Nonspecific immune responses</td> </tr> <tr> <td class=\"sublist2\">Epithelial cells</td> </tr> <tr> <td class=\"sublist2\">Endothelial cells</td> </tr> <tr> <td class=\"sublist2\">Macrophages and monocytes</td> </tr> <tr> <td class=\"sublist2\">Granulocytes</td> </tr> <tr> <td class=\"sublist2_start\">T cell responses to viral infection</td> </tr> <tr> <td class=\"sublist2\">Antigen independent</td> </tr> <tr> <td class=\"sublist2\">Antigen specific</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Redrawn from: Folkerts G, Busse WW, Nijkamp FP, et al. Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med 1998; 157:1708.</div><div id=\"graphicVersion\">Graphic 75402 Version 5.0</div></div></div>"},"75403":{"type":"graphic_figure","displayName":"QRS alignment methods","title":"QRS alignment methods","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">QRS alignment methods</div><div class=\"cntnt\"><img style=\"width:360px; height:430px;\" src=\"images/CARD/75403_QRS_alignment_methods.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Optimal beat alignment permits the averaging of signals at physiologically corresponding timepoints. Sliding template alignment provides the greatest precision and may be computed by maximizing the dot-product between candidate beats and a template. QRS peak and upstroke fiducial methods are less precise but still used. The P-wave triggered signal averaged ECG requires P-wave alignment, typically with a sliding template approach.</div><div id=\"graphicVersion\">Graphic 75403 Version 1.0</div></div></div>"},"75404":{"type":"graphic_picture","displayName":"Palmoplantar pustulosis - plantar","title":"Palmoplantar pustulosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palmoplantar pustulosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75404_Palm_pustulosis_plantar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple brown macules and pustules are present in an erythematous, hyperkeratotic plaque on the plantar foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75404 Version 3.0</div></div></div>"},"75405":{"type":"graphic_diagnosticimage","displayName":"Muscular VSD multiple color still frame","title":"Muscular VSD multiple color still frame","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Muscular VSD multiple color still frame</div><div class=\"cntnt\"><img style=\"width:548px; height:377px;\" src=\"images/CARD/75405_Muscular_VSD_multiple_color.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paired apical images with and without color flow mapping show a large posterior muscular VSD and two smaller apical muscular VSDs (arrows). Though the larger posterior defect near the crux is easily seen without color flow mapping, the apical defects are more easily missed without color flow Doppler interrogation of the septum.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium; LV: left ventricle; RV: right ventricle; VSD: ventricular septal defect; arrows: multiple muscular VSDs.</div><div id=\"graphicVersion\">Graphic 75405 Version 4.0</div></div></div>"},"75407":{"type":"graphic_figure","displayName":"Capillary leak in dengue","title":"Capillary leak in dengue virus infection","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Capillary leak in dengue virus infection</div><div class=\"cntnt\"><img style=\"width:540px; height:428px;\" src=\"images/ID/75407_Capillary_leak_in_dengue.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proposed model by which dengue virus (DV) produces a capillary leak syndrome. Monocytes (Mo) are thought to be the primary cellular target for DV. Serotype crossreactive antibodies (Ab), present at the time of second DV infection, bind to virions without neutralization and then enhance the entry of virus into monocytic cells expressing immunoglobulin receptors (FcÎ³R), as show in the left side of the picture. Serotype crossreactive memory T cells, also present at the time of secondary DV infection, recognize viral antigens in the context of class I and II major histocompatibility complex (MHC) molecules. These T cells produce cytokines, such as interferon-gamma (IFNÎ³) and tumor necrosis factors (TNF) alpha and beta, and lyse DV-infected monocytes. TNF-alpha is also produced in monocytes in response to DV infection and/or interactions with T cells. These cytokines have direct effects on endothelial cells (EC) to induce plasma leakage. Interferon-gamma activates monocytes to increase the expression of MHC molecules and immunoglobulin receptors and the production of TNF-alpha. The complement cascade, activated by virus-antibody complexes and by several cytokines, releases the complement anaphylatoxins C3a and C5a which further increase capillary permeability. Interleukin-2 may contribute by facilitating T cell proliferation.</div><div id=\"graphicVersion\">Graphic 75407 Version 2.0</div></div></div>"},"75408":{"type":"graphic_diagnosticimage","displayName":"Disseminated coccidioidomycosis","title":"MRI of patient with disseminated coccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of patient with disseminated coccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:294px; height:592px;\" src=\"images/ID/75408_Disseminated_cocci_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">42-year-old woman with paranoid schizophrenia who presented with weight loss, fever, and malaise. Patient had previously been evaluated at another hospital for multiple vertebral lesions and right breast mass that was eroding through right anterior chest wall.<br />(A) Sagittal T2-weighted magnetic resonance&nbsp;image (MRI) of cervical spine shows large paraspinal fluid collection (arrowheads) with contiguous vertebral body involvement from C5 to T3 with relative sparing of intervertebral disks.<br />(B) Sagittal T2-weighted MRI of thoracic spine shows T7 to T8 discitis and osteomyelitis with anterior epidural extension (arrow) and resultant spinal cord compression and edema (arrowhead).</div><div class=\"graphic_reference\">From: Wilde GE, Emery C, Lally JF. Radiological reasoning: Miliary disease, vertebral osteomyelitis, and soft-tissue abscess. AJR Am J Roentgenol 2008; 190:S11-7. Reprinted with permission from the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 75408 Version 15.0</div></div></div>"},"75409":{"type":"graphic_movie","displayName":"Prosthetic mitral valve four chamber echocardiogram","title":"Prosthetic mitral valve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prosthetic mitral valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/75409_4chpromvconv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:234px; height:372px;\" src=\"images/CARD/75409_4chpromv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view of 2-D echocardiogram shows a normally functioning ball-cage prosthetic mitral valve.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 75409 Version 2.0</div></div></div>"},"75411":{"type":"graphic_table","displayName":"Modified Rankin scale","title":"Modified Rankin scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Rankin scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Score</td> <td class=\"subtitle1_single\">Description</td> </tr> <tr> <td class=\"indent1\">0</td> <td>No symptoms at all</td> </tr> <tr> <td class=\"indent1\">1</td> <td>No significant disability despite symptoms; able to carry out all usual duties and activities</td> </tr> <tr> <td class=\"indent1\">2</td> <td>Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance</td> </tr> <tr> <td class=\"indent1\">3</td> <td>Moderate disability; requiring some help, but able to walk without assistance</td> </tr> <tr> <td class=\"indent1\">4</td> <td>Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance</td> </tr> <tr> <td class=\"indent1\">5</td> <td>Severe disability; bedridden, incontinent, and requiring constant nursing care and attention</td> </tr> <tr> <td class=\"indent1\">6</td> <td>Dead</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Van Swieten JC, Koudstaa PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19:604. Copyright Â© 1988 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75411 Version 12.0</div></div></div>"},"75412":{"type":"graphic_diagnosticimage","displayName":"Echo assessment rt ventricle1","title":"Echocardiographic assessment of right ventricle in an infant with congenital diaphragmatic hernia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Echocardiographic assessment of right ventricle in an infant with congenital diaphragmatic hernia</div><div class=\"cntnt\"><img style=\"width:540px; height:182px;\" src=\"images/OBGYN/75412_Echo_assessment_rt_ventricl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prolonged elevated pulmonary vascular resistance leads to a dilated, non-compliant right ventricle.</div><div class=\"graphic_reference\">Courtesy of Holly L Hedrick, MD.</div><div id=\"graphicVersion\">Graphic 75412 Version 3.0</div></div></div>"},"75414":{"type":"graphic_figure","displayName":"Pomeroy tubal ligation A","title":"Pomeroy tubal ligation A","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pomeroy tubal ligation A</div><div class=\"cntnt\"><img style=\"width:316px; height:450px;\" src=\"images/OBGYN/75414_Pomeroy_tubal_ligation_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 75414 Version 1.0</div></div></div>"},"75416":{"type":"graphic_picture","displayName":"Surgical excision of paget disease of the nipple","title":"Surgical excision of paget disease of the nipple","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Surgical excision of paget disease of the nipple</div><div class=\"cntnt\"><img style=\"width:514px; height:599px;\" src=\"images/ONC/75416_Surgical_excis_Paget_br_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photographs of gross appearance of a wide excision specimen containing Paget disease of the breast involving the nipple. Bottom panel demonstrates higher magnification view.</div><div class=\"graphic_reference\">Courtesy of Donald L Weaver, MD.</div><div id=\"graphicVersion\">Graphic 75416 Version 5.0</div></div></div>"},"75417":{"type":"graphic_table","displayName":"Differential diagnosis blister pustule infant","title":"Vesiculopustular lesions in neonates and infants that require treatment and/or monitoring","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vesiculopustular lesions in neonates and infants that require treatment and/or monitoring</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"42%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Infectious conditions</td> </tr> <tr> <td class=\"indent1\">Congenital herpes simplex virus (HSV)</td> <td>Grouped or single vesicles on erythematous base in crops on skin and mucous membranes; lesions usually appear between one and two weeks of age; may be associated with nonspecific signs of serious illness: temperature instability, respiratory distress, poor feeding, lethargy</td> <td>Requires antiviral therapy; significant morbidity and mortality if untreated</td> </tr> <tr> <td class=\"indent1\">Neonatal varicella zoster virus</td> <td>Grouped or single vesicles on erythematous base in crops on skin and mucous membranes</td> <td>Requires antiviral therapy; associated with significant morbidity and mortality</td> </tr> <tr> <td class=\"indent1\">Congenital syphilis</td> <td>Blisters, erosions that frequently involve the palms and soles; other manifestations include rhinitis, anemia, jaundice, hepatomegaly</td> <td>Requires antibiotic therapy; late manifestations in untreated infants may include central nervous system, skeletal, and dental abnormalities; hearing loss; and interstitial keratitis</td> </tr> <tr> <td class=\"indent1\">Staphylococcal pustulosis</td> <td>Erythematous papules, pustules, honey-colored crusts often in areas of trauma</td> <td>Requires antibiotic therapy; Gram stain and culture of lesions should be obtained; may be associated with systemic/invasive infection</td> </tr> <tr> <td class=\"indent1\">Staphylococcal scalded skin syndrome (SSSS)</td> <td>Fever, irritability, diffuse blanching erythema, flaccid blisters; positive Nikolsky sign*</td> <td>Requires antibiotic therapy; cultures should be obtained from any suspected focus of infection (eg, blood, urine, nasopharynx, umbilicus)</td> </tr> <tr> <td class=\"indent1\">Streptococcal infections</td> <td>May mimic staphylococcal infections</td> <td>Same as for staphylococcal pustulosis and SSSS</td> </tr> <tr> <td class=\"indent1\">Listeria</td> <td>Pustules of the skin and mucus membranes may be present in early onset disease (&#60;7 days of age)</td> <td>Requires antibiotic therapy; may be associated with septicemia and/or meningitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Candidiasis</td> <td>Erythematous macules and papules evolving to pustules and vesicles</td> <td>Requires antifungal therapy; has the potential to disseminate via the bloodstream in susceptible hosts</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Congenital disorders</td> </tr> <tr> <td class=\"indent1\">Epidermolysis bullosa</td> <td>Blister development with little or no trauma</td> <td>Management involves prevention of trauma, careful wound care, and treatment of infection</td> </tr> <tr> <td class=\"indent1\">Epidermolytic hyperkeratosis</td> <td>Widespread blistering and erythema and or hyperkeratosis; denuded areas of skin</td> <td>Increased susceptibility to cutaneous infection</td> </tr> <tr> <td class=\"indent1\">Aplasia cutis congenita</td> <td>Erosions present at birth that&nbsp;re-epithelialize to form hypertrophic or atrophic scar; involves the epidermis and dermis</td> <td>May be associated with other disorders (eg, trisomy 13, 4p-)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Incontinentia pigmenti</td> <td>Four stages that may occur simultaneously: linear streaks of erythematous papules and vesicles; warty papules or plaques in linear or swirling patterns; swirled; hypopigmented patches or streaks</td> <td>Majority of cases associated with neurologic, ocular, dental, and structural abnormalities</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Scabies</td> <td>May be seen in infants as young as three to four weeks of age but never present at birth; vesicles, pustules, and papules; rare burrows on hands, feet, trunk, genitalia</td> <td>Requires treatment with scabicide and measures to prevent spread</td> </tr> <tr> <td class=\"indent1\">Cutaneous mastocytosis</td> <td>Bullous eruptions with hemorrhage; positive Darier sign<sup>&#182;</sup></td> <td>Requires symptomatic therapy and avoidance of triggers</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Nikolsky sign: Separation of the upper dermis and wrinkling of the skin with application of gentle pressure.<br />Â¶ Darier sign: Urticaria and erythema with rubbing, scratching, or stroking.</div><div id=\"graphicVersion\">Graphic 75417 Version 6.0</div></div></div>"},"75418":{"type":"graphic_table","displayName":"Gaucher treatment goals","title":"Therapeutic goals in the treatment of Gaucher disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic goals in the treatment of Gaucher disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Manifestation</td> <td class=\"subtitle1\">Goals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Anemia</td> </tr> <tr> <td class=\"indent1\"> <p>Hgb &#60;12 g/dL in males &#62;12 years</p> <p>Hgb &#60;11 g/dL in females &#62;12 years</p> <p>Hgb &#60;10.5 g/dL in children 2 to 12 years</p> <p>Hgb &#60;9.5 g/dL in children 6 months to 2 years</p> Hgb &#60;10.1 g/dL in children &#60;6 months</td> <td>Increase Hgb within 12 to 24 months: <ul class=\"decimal_heading\"> <li>To &#8805;11 g/dL for children and females &#62;12 years </li> <li>To &#8805;12 g/dL for males &#62;12 years </li> <li>Eliminate dependency on blood transfusions </li> <li>Reduce fatigue, dyspnea, angina </li> <li>Maintain improved Hgb values achieved after the first 12 to 24 months of therapy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Moderate: <ul class=\"decimal_heading\"> <li>Platelet count between 60,000 and 120,000/microL </li> </ul> Severe: <ul class=\"decimal_heading\"> <li>Platelet count &#60;60,000 </li> </ul> Risk for surgical or obstetrical bleeding: <ul class=\"decimal_heading\"> <li>Platelet count &#60;30,000/microL </li> </ul> </td> <td>All patients: <ul class=\"decimal_heading\"> <li>Increase platelet count in the first 12 months of treatment to prevent surgical, obstetrical, and spontaneous bleeding </li> </ul> Patients with splenectomy: <ul class=\"decimal_heading\"> <li>Normalization of platelet count by one year of treatment </li> </ul> Patients with intact spleen: <ul class=\"decimal_heading\"> <li>Moderate thrombocytopenia: <ul> <li>Increase the platelet count by 1.5- to 2-fold in first year; approach low normal level by second year </li> </ul> </li> <li>Severe thrombocytopenia: <ul> <li>Increase the platelet count by 1.5-fold during the first year and continue to increase slightly during the second through fifth years; double platelet count by second year; complete normalization is not expected </li> <li>Avoid splenectomy </li> <li>Maintain stable platelet counts to eliminate risks of bleeding after a maximal response has been achieved </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hepatomegaly</td> </tr> <tr> <td class=\"indent1\">Moderate: <ul class=\"decimal_heading\"> <li>Liver mass &#62;1.25 times the normal 2.5% of total body weight in kg (assessed by quantitative imaging, preferably MRI) </li> </ul> Severe: <ul class=\"decimal_heading\"> <li>Liver mass &#62;2.5 times normal volume </li> </ul> </td> <td> <p>Reduce and maintain the liver volume to 1 to 1.5 times normal volume</p> Reduce liver volume by 20 to 30% within the first two years of treatment and by 30 to 40% by the third to fifth year</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Splenomegaly</td> </tr> <tr> <td class=\"indent1\"> <p>Splenic mass &#62;the normal 0.2% of total body weight in kg</p> Moderate: <ul class=\"decimal_heading\"> <li>&#62;5 and &#8804;15 times normal volume </li> </ul> Severe: <ul class=\"decimal_heading\"> <li>&#62;15 times normal volume (assessed by quantitative imaging, preferably MRI) </li> </ul> </td> <td> <p>Reduce and maintain spleen volume to &#8804;2 to times normal</p> <p>Reduce the spleen volume by 30 to 50% within the first year and to 50 to 60% by the second to fifth years</p> Alleviate symptoms due to splenomegaly (abdominal distension, early satiety, new splenic infarction)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skeletal pathology</td> </tr> <tr> <td class=\"indent1\">Focal disease: <ul class=\"decimal_heading\"> <li>Lytic and sclerotic lesions associated with infarction, thrombosis, and inflammatory processes that can progress to osteonecrosis </li> </ul> Local disease: <ul class=\"decimal_heading\"> <li>Remodeling defects of the long bones and long bone deformities </li> </ul> Generalized osteopenia and osteoporosis</td> <td>All patients: <ul class=\"decimal_heading\"> <li>Retain skeletal function by preventing the onset of new skeletal complications </li> <li>Lessen or eliminate bone pain within first or second year </li> <li>Prevent bone crises or decrease frequency </li> <li>Prevent osteonecrosis and subchondral joint collapse </li> <li>Improve bone mineral density </li> </ul> In children: <ul class=\"decimal_heading\"> <li>Attain normal or ideal peak skeletal mass </li> <li>Increase cortical and trabecular BMD by second year </li> </ul> In adults: <ul class=\"decimal_heading\"> <li>Increase trabecular BMD by three to five years </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Growth</td> </tr> <tr> <td>&nbsp;</td> <td> <p>Normalize growth such that child achieves a normal height according to population and family history by the third year of treatment</p> Achieve normal onset of puberty</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pulmonary involvement</td> </tr> <tr> <td>&nbsp;</td> <td> <p>Reverse hepatopulmonary syndrome and dependency on oxygen</p> <p>Ameliorate pulmonary hypertension (ERT plus other therapies)</p> Improve functional status and quality of life</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Functional health and well being</td> </tr> <tr> <td>&nbsp;</td> <td> <p>Improve or restore physical function for carrying out normal daily activities and fulfilling functional roles</p> Improve scores from baseline of validated quality-of-life instruments within the second or third year, depending upon disease burden</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Hgb: hemoglobin; MRI: magnetic resonance imaging; BMD: bone mineral density; ERT: enzyme-replacement therapy.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4.</li>&#xD;&#xA;    <li>Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75418 Version 5.0</div></div></div>"},"75419":{"type":"graphic_diagnosticimage","displayName":"Volvulus corkscrew","title":"Volvulus corkscrew","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Volvulus corkscrew</div><div class=\"cntnt\"><img style=\"width:461px; height:499px;\" src=\"images/PEDS/75419_Volvulus_corkscrew.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This upper gastrointestinal contrast study demonstrates the corkscrew appearance of the twisted small bowel in volvulus.</div><div class=\"graphic_reference\">Reproduced with permission from Carlo Buonomo, MD, Children's Hospital-Boston. Copyright Â© Carlo Buonomo, MD.</div><div id=\"graphicVersion\">Graphic 75419 Version 2.0</div></div></div>"},"75422":{"type":"graphic_table","displayName":"Oral medications for dystonia","title":"Oral medications for the treatment of dystonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral medications for the treatment of dystonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pharmacologic agent</td> <td class=\"subtitle1\">Efficacy and comment</td> <td class=\"subtitle1\">Side effects</td> </tr> <tr> <td class=\"sublist1_start\">Dopamine agonists</td> <td rowspan=\"2\">Dramatic response in the dopa responsive form of dystonia; effective in 10 to 15 percent of patients with other types of dystonia; more rapid upward titration possible</td> <td rowspan=\"2\">Nausea (especially at initiation of therapy); may worsen dystonia; rapid discontinuation possible</td> </tr> <tr> <td class=\"sublist1\">Carbidopa/Levodopa</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Anticholinergic/antihistaminic</td> <td rowspan=\"6\">Effective in approximately 40 percent of patients, mainly children; benefit limited by side effects; requires slow upward titration</td> <td rowspan=\"6\">Dry mouth (may lead to dental caries); blurred vision; exacerbation of acute-angle glaucoma; urinary retention; memory problems; sedation; confusion; hallucinations; heat intolerance</td> </tr> <tr> <td class=\"sublist1\">Trihexyphenidyl</td> </tr> <tr> <td class=\"sublist1\">Benztropine</td> </tr> <tr> <td class=\"sublist1\">Procyclidine</td> </tr> <tr> <td class=\"sublist1\">Diphenhydramine</td> </tr> <tr> <td class=\"sublist1\">Ethopropazine</td> </tr> <tr class=\"divider_top\"> <td>Baclofen</td> <td>Effective in approximately 20 percent of patients; high doses tolerated in children; benefits limited by side effects; intrathecal baclofen minimally successful; withdrawal effects on sudden discontinuation</td> <td>Nausea; sedation; dysphoria; muscle weakness (in those with spasticity associated)</td> </tr> <tr class=\"divider_top\"> <td>Clonazepam</td> <td>Effective in approximately 15 percent of patients; possibility for addiction; withdrawal effects on sudden discontinuation</td> <td>Sedation; depression; confusion; dependence</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Muscle relaxants</td> <td rowspan=\"3\">Limited benefit in some patients; side effects frequent</td> <td rowspan=\"3\">Sedation; dysphoria</td> </tr> <tr> <td class=\"sublist1\">Tizanidine</td> </tr> <tr> <td class=\"sublist1\">Cyclobenzaprine</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Anticonvulsant medications</td> <td rowspan=\"3\">Benefit in less than 10 percent of patients</td> <td rowspan=\"3\">Ataxia; sedation</td> </tr> <tr> <td class=\"sublist1\">Carbamazepine</td> </tr> <tr> <td class=\"sublist1\">Gabapentin</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Dopamine-depleting agents</td> <td rowspan=\"2\">Requires a very slow upward titration (4 weeks between dose increases)</td> <td rowspan=\"2\">Depression; dysphoria; parkinsonism</td> </tr> <tr> <td class=\"sublist1\">Tetrabenazine</td> </tr> <tr class=\"divider_top\"> <td>Dopamine receptor blocking agents</td> <td>Effective in up to 25 percent of patients; clozapine requires weekly blood counts and may cause life threatening agranulocytosis</td> <td>The possibility of tardive dyskinesia and the other adverse effects from this class of medications severely limits usefulness; not recommended for dystonia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75422 Version 4.0</div></div></div>"},"75423":{"type":"graphic_table","displayName":"Maternal age-related risk common fetal trisomy across pregnancy","title":"Maternal age-related risk for common fetal trisomies across pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maternal age-related risk for common fetal trisomies across pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"12%\"></colgroup><colgroup width=\"1%\"></colgroup><colgroup span=\"3\" width=\"7%\"></colgroup><colgroup width=\"1%\"></colgroup><colgroup span=\"3\" width=\"7%\"></colgroup><colgroup width=\"1%\"></colgroup><colgroup span=\"3\" width=\"7%\"></colgroup><colgroup width=\"1%\"></colgroup><colgroup span=\"3\" width=\"7%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Maternal age<br /> (years)</td> <td rowspan=\"34\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Down syndrome/trisomy 21 risk (1:n)</td> <td rowspan=\"34\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Edwards syndrome/trisomy 18 risk (1:n)</td> <td rowspan=\"34\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Patau syndrome/trisomy 13 risk (1:n)</td> <td rowspan=\"34\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Combined trisomy 21/18/13 risk (1:n)</td> </tr> <tr> <td class=\"subtitle2\">CVS</td> <td class=\"subtitle2\">Amnio</td> <td class=\"subtitle2\">Term</td> <td class=\"subtitle2\">CVS</td> <td class=\"subtitle2\">Amnio</td> <td class=\"subtitle2\">Term</td> <td class=\"subtitle2\">CVS</td> <td class=\"subtitle2\">Amnio</td> <td class=\"subtitle2\">Term</td> <td class=\"subtitle2\">CVS</td> <td class=\"subtitle2\">Amnio</td> <td class=\"subtitle2\">Term</td> </tr> <tr> <td class=\"centered\">18</td> <td class=\"centered\">1150</td> <td class=\"centered\">1210</td> <td class=\"centered\">1495</td> <td class=\"centered\">2520</td> <td class=\"centered\">3150</td> <td class=\"centered\">9010</td> <td class=\"centered\">6985</td> <td class=\"centered\">7945</td> <td class=\"centered\">13,700</td> <td class=\"centered\">710</td> <td class=\"centered\">790</td> <td class=\"centered\">1175</td> </tr> <tr> <td class=\"centered\">19</td> <td class=\"centered\">1145</td> <td class=\"centered\">1205</td> <td class=\"centered\">1490</td> <td class=\"centered\">2515</td> <td class=\"centered\">3145</td> <td class=\"centered\">8985</td> <td class=\"centered\">6970</td> <td class=\"centered\">7930</td> <td class=\"centered\">13,670</td> <td class=\"centered\">705</td> <td class=\"centered\">785</td> <td class=\"centered\">1165</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">20</td> <td class=\"centered\">1135</td> <td class=\"centered\">1200</td> <td class=\"centered\">1475</td> <td class=\"centered\">2510</td> <td class=\"centered\">3135</td> <td class=\"centered\">8960</td> <td class=\"centered\">6955</td> <td class=\"centered\">7905</td> <td class=\"centered\">13,635</td> <td class=\"centered\">705</td> <td class=\"centered\">780</td> <td class=\"centered\">1160</td> </tr> <tr> <td class=\"centered\">21</td> <td class=\"centered\">1125</td> <td class=\"centered\">1185</td> <td class=\"centered\">1460</td> <td class=\"centered\">2500</td> <td class=\"centered\">3125</td> <td class=\"centered\">8930</td> <td class=\"centered\">6925</td> <td class=\"centered\">7875</td> <td class=\"centered\">13,580</td> <td class=\"centered\">695</td> <td class=\"centered\">775</td> <td class=\"centered\">1150</td> </tr> <tr> <td class=\"centered\">22</td> <td class=\"centered\">1110</td> <td class=\"centered\">1165</td> <td class=\"centered\">1440</td> <td class=\"centered\">2490</td> <td class=\"centered\">3110</td> <td class=\"centered\">8885</td> <td class=\"centered\">6890</td> <td class=\"centered\">7835</td> <td class=\"centered\">13,510</td> <td class=\"centered\">690</td> <td class=\"centered\">765</td> <td class=\"centered\">1135</td> </tr> <tr> <td class=\"centered\">23</td> <td class=\"centered\">1090</td> <td class=\"centered\">1150</td> <td class=\"centered\">1415</td> <td class=\"centered\">2470</td> <td class=\"centered\">3090</td> <td class=\"centered\">8825</td> <td class=\"centered\">6840</td> <td class=\"centered\">7780</td> <td class=\"centered\">13,410</td> <td class=\"centered\">680</td> <td class=\"centered\">755</td> <td class=\"centered\">1115</td> </tr> <tr> <td class=\"centered\">24</td> <td class=\"centered\">1065</td> <td class=\"centered\">1120</td> <td class=\"centered\">1380</td> <td class=\"centered\">2450</td> <td class=\"centered\">3060</td> <td class=\"centered\">8745</td> <td class=\"centered\">6770</td> <td class=\"centered\">7700</td> <td class=\"centered\">13,275</td> <td class=\"centered\">670</td> <td class=\"centered\">740</td> <td class=\"centered\">1095</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">25</td> <td class=\"centered\">1030</td> <td class=\"centered\">1085</td> <td class=\"centered\">1340</td> <td class=\"centered\">2415</td> <td class=\"centered\">3020</td> <td class=\"centered\">8630</td> <td class=\"centered\">6675</td> <td class=\"centered\">7590</td> <td class=\"centered\">13,090</td> <td class=\"centered\">650</td> <td class=\"centered\">720</td> <td class=\"centered\">1065</td> </tr> <tr> <td class=\"centered\">26</td> <td class=\"centered\">975</td> <td class=\"centered\">1030</td> <td class=\"centered\">1285</td> <td class=\"centered\">2375</td> <td class=\"centered\">2970</td> <td class=\"centered\">8480</td> <td class=\"centered\">6545</td> <td class=\"centered\">7445</td> <td class=\"centered\">12,840</td> <td class=\"centered\">625</td> <td class=\"centered\">690</td> <td class=\"centered\">1025</td> </tr> <tr> <td class=\"centered\">27</td> <td class=\"centered\">925</td> <td class=\"centered\">975</td> <td class=\"centered\">1220</td> <td class=\"centered\">2320</td> <td class=\"centered\">2900</td> <td class=\"centered\">8280</td> <td class=\"centered\">6375</td> <td class=\"centered\">7250</td> <td class=\"centered\">12,500</td> <td class=\"centered\">600</td> <td class=\"centered\">660</td> <td class=\"centered\">980</td> </tr> <tr> <td class=\"centered\">28</td> <td class=\"centered\">855</td> <td class=\"centered\">900</td> <td class=\"centered\">1140</td> <td class=\"centered\">2245</td> <td class=\"centered\">2805</td> <td class=\"centered\">8010</td> <td class=\"centered\">6145</td> <td class=\"centered\">6990</td> <td class=\"centered\">12,050</td> <td class=\"centered\">560</td> <td class=\"centered\">620</td> <td class=\"centered\">920</td> </tr> <tr> <td class=\"centered\">29</td> <td class=\"centered\">770</td> <td class=\"centered\">825</td> <td class=\"centered\">1045</td> <td class=\"centered\">2145</td> <td class=\"centered\">2680</td> <td class=\"centered\">7660</td> <td class=\"centered\">5850</td> <td class=\"centered\">6655</td> <td class=\"centered\">11,470</td> <td class=\"centered\">515</td> <td class=\"centered\">575</td> <td class=\"centered\">850</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">30</td> <td class=\"centered\">685</td> <td class=\"centered\">730</td> <td class=\"centered\">935</td> <td class=\"centered\">2020</td> <td class=\"centered\">2525</td> <td class=\"centered\">7215</td> <td class=\"centered\">5475</td> <td class=\"centered\">6225</td> <td class=\"centered\">10,735</td> <td class=\"centered\">465</td> <td class=\"centered\">520</td> <td class=\"centered\">770</td> </tr> <tr> <td class=\"centered\">31</td> <td class=\"centered\">590</td> <td class=\"centered\">630</td> <td class=\"centered\">815</td> <td class=\"centered\">1865</td> <td class=\"centered\">2330</td> <td class=\"centered\">6655</td> <td class=\"centered\">5015</td> <td class=\"centered\">5700</td> <td class=\"centered\">9830</td> <td class=\"centered\">410</td> <td class=\"centered\">455</td> <td class=\"centered\">675</td> </tr> <tr> <td class=\"centered\">32</td> <td class=\"centered\">490</td> <td class=\"centered\">535</td> <td class=\"centered\">695</td> <td class=\"centered\">1675</td> <td class=\"centered\">2095</td> <td class=\"centered\">5990</td> <td class=\"centered\">4475</td> <td class=\"centered\">5085</td> <td class=\"centered\">8770</td> <td class=\"centered\">350</td> <td class=\"centered\">390</td> <td class=\"centered\">580</td> </tr> <tr> <td class=\"centered\">33</td> <td class=\"centered\">400</td> <td class=\"centered\">430</td> <td class=\"centered\">570</td> <td class=\"centered\">1460</td> <td class=\"centered\">1825</td> <td class=\"centered\">5220</td> <td class=\"centered\">3870</td> <td class=\"centered\">4400</td> <td class=\"centered\">7585</td> <td class=\"centered\">290</td> <td class=\"centered\">325</td> <td class=\"centered\">480</td> </tr> <tr> <td class=\"centered\">34</td> <td class=\"centered\">310</td> <td class=\"centered\">345</td> <td class=\"centered\">455</td> <td class=\"centered\">1225</td> <td class=\"centered\">1535</td> <td class=\"centered\">4380</td> <td class=\"centered\">3235</td> <td class=\"centered\">3680</td> <td class=\"centered\">6345</td> <td class=\"centered\">230</td> <td class=\"centered\">260</td> <td class=\"centered\">385</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">35</td> <td class=\"centered\">240</td> <td class=\"centered\">260</td> <td class=\"centered\">350</td> <td class=\"centered\">990</td> <td class=\"centered\">1235</td> <td class=\"centered\">3530</td> <td class=\"centered\">2615</td> <td class=\"centered\">2975</td> <td class=\"centered\">5130</td> <td class=\"centered\">180</td> <td class=\"centered\">200</td> <td class=\"centered\">300</td> </tr> <tr> <td class=\"centered\">36</td> <td class=\"centered\">180</td> <td class=\"centered\">195</td> <td class=\"centered\">265</td> <td class=\"centered\">765</td> <td class=\"centered\">955</td> <td class=\"centered\">2725</td> <td class=\"centered\">2055</td> <td class=\"centered\">2335</td> <td class=\"centered\">4030</td> <td class=\"centered\">135</td> <td class=\"centered\">150</td> <td class=\"centered\">225</td> </tr> <tr> <td class=\"centered\">37</td> <td class=\"centered\">130</td> <td class=\"centered\">145</td> <td class=\"centered\">195</td> <td class=\"centered\">565</td> <td class=\"centered\">710</td> <td class=\"centered\">2025</td> <td class=\"centered\">1580</td> <td class=\"centered\">1800</td> <td class=\"centered\">3100</td> <td class=\"centered\">99</td> <td class=\"centered\">115</td> <td class=\"centered\">170</td> </tr> <tr> <td class=\"centered\">38</td> <td class=\"centered\">95</td> <td class=\"centered\">105</td> <td class=\"centered\">145</td> <td class=\"centered\">410</td> <td class=\"centered\">510</td> <td class=\"centered\">1455</td> <td class=\"centered\">1210</td> <td class=\"centered\">1375</td> <td class=\"centered\">2370</td> <td class=\"centered\">72</td> <td class=\"centered\">83</td> <td class=\"centered\">125</td> </tr> <tr> <td class=\"centered\">39</td> <td class=\"centered\">71</td> <td class=\"centered\">79</td> <td class=\"centered\">110</td> <td class=\"centered\">290</td> <td class=\"centered\">360</td> <td class=\"centered\">1035</td> <td class=\"centered\">930</td> <td class=\"centered\">1060</td> <td class=\"centered\">1825</td> <td class=\"centered\">53</td> <td class=\"centered\">61</td> <td class=\"centered\">94</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">40</td> <td class=\"centered\">52</td> <td class=\"centered\">60</td> <td class=\"centered\">85</td> <td class=\"centered\">205</td> <td class=\"centered\">255</td> <td class=\"centered\">735</td> <td class=\"centered\">730</td> <td class=\"centered\">830</td> <td class=\"centered\">1430</td> <td class=\"centered\">39</td> <td class=\"centered\">45</td> <td class=\"centered\">72</td> </tr> <tr> <td class=\"centered\">41</td> <td class=\"centered\">40</td> <td class=\"centered\">46</td> <td class=\"centered\">66</td> <td class=\"centered\">150</td> <td class=\"centered\">185</td> <td class=\"centered\">530</td> <td class=\"centered\">590</td> <td class=\"centered\">670</td> <td class=\"centered\">1160</td> <td class=\"centered\">30</td> <td class=\"centered\">35</td> <td class=\"centered\">56</td> </tr> <tr> <td class=\"centered\">42</td> <td class=\"centered\">32</td> <td class=\"centered\">38</td> <td class=\"centered\">54</td> <td class=\"centered\">110</td> <td class=\"centered\">140</td> <td class=\"centered\">395</td> <td class=\"centered\">495</td> <td class=\"centered\">560</td> <td class=\"centered\">970</td> <td class=\"centered\">23</td> <td class=\"centered\">28</td> <td class=\"centered\">45</td> </tr> <tr> <td class=\"centered\">43</td> <td class=\"centered\">27</td> <td class=\"centered\">31</td> <td class=\"centered\">45</td> <td class=\"centered\">87</td> <td class=\"centered\">110</td> <td class=\"centered\">310</td> <td class=\"centered\">425</td> <td class=\"centered\">485</td> <td class=\"centered\">840</td> <td class=\"centered\">19</td> <td class=\"centered\">23</td> <td class=\"centered\">37</td> </tr> <tr> <td class=\"centered\">44</td> <td class=\"centered\">22</td> <td class=\"centered\">26</td> <td class=\"centered\">39</td> <td class=\"centered\">70</td> <td class=\"centered\">88</td> <td class=\"centered\">250</td> <td class=\"centered\">380</td> <td class=\"centered\">435</td> <td class=\"centered\">745</td> <td class=\"centered\">16</td> <td class=\"centered\">19</td> <td class=\"centered\">32</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"centered\">45</td> <td class=\"centered\">19</td> <td class=\"centered\">23</td> <td class=\"centered\">34</td> <td class=\"centered\">60</td> <td class=\"centered\">74</td> <td class=\"centered\">215</td> <td class=\"centered\">350</td> <td class=\"centered\">395</td> <td class=\"centered\">685</td> <td class=\"centered\">14</td> <td class=\"centered\">16</td> <td class=\"centered\">28</td> </tr> <tr> <td class=\"centered\">46</td> <td class=\"centered\">18</td> <td class=\"centered\">21</td> <td class=\"centered\">31</td> <td class=\"centered\">52</td> <td class=\"centered\">65</td> <td class=\"centered\">185</td> <td class=\"centered\">325</td> <td class=\"centered\">370</td> <td class=\"centered\">640</td> <td class=\"centered\">12</td> <td class=\"centered\">15</td> <td class=\"centered\">25</td> </tr> <tr> <td class=\"centered\">47</td> <td class=\"centered\">16</td> <td class=\"centered\">19</td> <td class=\"centered\">29</td> <td class=\"centered\">47</td> <td class=\"centered\">59</td> <td class=\"centered\">170</td> <td class=\"centered\">310</td> <td class=\"centered\">355</td> <td class=\"centered\">610</td> <td class=\"centered\">11</td> <td class=\"centered\">14</td> <td class=\"centered\">24</td> </tr> <tr> <td class=\"centered\">48</td> <td class=\"centered\">15</td> <td class=\"centered\">18</td> <td class=\"centered\">27</td> <td class=\"centered\">44</td> <td class=\"centered\">55</td> <td class=\"centered\">155</td> <td class=\"centered\">300</td> <td class=\"centered\">340</td> <td class=\"centered\">590</td> <td class=\"centered\">11</td> <td class=\"centered\">13</td> <td class=\"centered\">22</td> </tr> <tr> <td class=\"centered\">49</td> <td class=\"centered\">15</td> <td class=\"centered\">18</td> <td class=\"centered\">26</td> <td class=\"centered\">41</td> <td class=\"centered\">52</td> <td class=\"centered\">150</td> <td class=\"centered\">290</td> <td class=\"centered\">330</td> <td class=\"centered\">570</td> <td class=\"centered\">10</td> <td class=\"centered\">12</td> <td class=\"centered\">21</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table shows the expected prevalence of three common autosomal trisomies (21, 18, and 13) individually (first three boxed columns) and together (last boxed column). Within each of these groups, the prevalence is shown at three different times in gestation. These include at the time of chorionic villus sampling at about 11 to 13 weeks of gestation, amniocentesis at about 15 to 18 weeks of gestation, and at term. Each row of the table shows these results for a given maternal age (eg, the row \"35 years\" includes women age 35.0 through 35.9, average 35.5 years) at the expected date of delivery. For example, consider a 32.4-year-old woman being counseled prior to a CVS procedure who has no specific indications of an abnormality other than age (eg, no abnormal ultrasound findings or pregnancy history of aneuploidy). The chance that the CVS will identify a fetus with Down syndrome is 1:490, with trisomy 18 is 1:1675, and with trisomy 13 is 1:4475. Together, these pose a current combined risk of 1:350. However, her chance of having a term birth with Down syndrome (1:696), trisomy 18 (1:5990), or trisomy 13 (1:8770) is lower. Together, these pose a term risk of 1:580.</div><div class=\"graphic_footnotes\">CVS: chorionic villus sampling; amnio: amniocentesis.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Morris JK, Savva GM. The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet 2008; 146A:827.</li>&#xD;&#xA;    <li>Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002; 9:2.</li>&#xD;&#xA;    <li>Savva GM, Morris JK, Mutton DE, Alberman E. Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat Diagn 2006; 26:499.</li>&#xD;&#xA;    <li>Savva GM, Walker K, Morris JK. The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome). Prenat Diagn 2010; 30:57.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75423 Version 10.0</div></div></div>"},"75424":{"type":"graphic_diagnosticimage","displayName":"Mass and comedo","title":"Mammogram grouped calcifications A","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mammogram grouped calcifications A</div><div class=\"cntnt\"><img style=\"width:432px; height:332px;\" src=\"images/ONC/75424_Mass_and_comedo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spot compression view of a mammogram showing a high-density spiculated mass (arrow) with heterogeneous linear clacifications in a ductal distribution (arrowheads). These \"casting\" calcifications are characteristic of high-grade ductal carcinoma in situ [DCIS]. Pathology revealed infiltrating duct cell carcinoma with DCIS, comedo type.</div><div class=\"graphic_reference\">Courtesy of Lisa E Esserman, MD.</div><div id=\"graphicVersion\">Graphic 75424 Version 4.0</div></div></div>"},"75426":{"type":"graphic_picture","displayName":"Gibbus deformity","title":"Gibbus deformity of the spine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gibbus deformity of the spine</div><div class=\"cntnt\"><img style=\"width:252px; height:378px;\" src=\"images/PEDS/75426_Gibbus_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: McKusick VA. Heritable Disorders of Connective Tissue, 4th ed, Mosby, St. Louis 1972. Copyright Â© 1972 Elsevier.</div><div id=\"graphicVersion\">Graphic 75426 Version 2.0</div></div></div>"},"75429":{"type":"graphic_table","displayName":"Foodborne illnesses in the United States","title":"Estimates of domestically acquired foodborne illnesses in the United States*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimates of domestically acquired foodborne illnesses in the United States*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pathogen</td> <td class=\"subtitle1\">Estimated number of cases per year (mean)</td> <td class=\"subtitle1\">Foodborne (percent)<sup>&#182;</sup></td> <td class=\"subtitle1\">Travel related (percent)</td> <td class=\"subtitle1\">Hospitalization rate (percent)<sup>&#916;</sup></td> <td class=\"subtitle1\">Death rate (percent)<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Bacillus cereus</em>, foodborne</td> <td>63,400</td> <td>100</td> <td>&#60;1</td> <td>0.4</td> <td>0</td> </tr> <tr> <td class=\"indent1\"><em>Brucella</em> spp</td> <td>839</td> <td>50</td> <td>16</td> <td>55</td> <td>0.9</td> </tr> <tr> <td class=\"indent1\"><em>Campylobacter</em> spp</td> <td>845,024</td> <td>80</td> <td>20</td> <td>17.1</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\"><em>Clostridium botulinum</em>, foodborne</td> <td>55</td> <td>100</td> <td>&#60;1</td> <td>82.6</td> <td>17.3</td> </tr> <tr> <td class=\"indent1\"><em>Clostridium perfringens</em>, foodborne</td> <td>965,958</td> <td>100</td> <td>&#60;1</td> <td>0.6</td> <td>&#60;0.1</td> </tr> <tr> <td class=\"indent1\">STEC O157</td> <td>63,153</td> <td>68</td> <td>4</td> <td>46.2</td> <td>0.5</td> </tr> <tr> <td class=\"indent1\">STEC non-O157</td> <td>112,752</td> <td>82</td> <td>18</td> <td>12.8</td> <td>0.3</td> </tr> <tr> <td class=\"indent1\">ETEC, foodborne</td> <td>17,894</td> <td>100</td> <td>55</td> <td>0.8</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Diarrheagenic <em>Escherichia coli </em>other than STEC and ETEC</td> <td>11,982</td> <td>30</td> <td>&#60;1</td> <td>0.8</td> <td>0</td> </tr> <tr> <td class=\"indent1\"><em>Listeria monocytogenes</em></td> <td>1591</td> <td>99</td> <td>3</td> <td>94</td> <td>15.9</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium bovis</em></td> <td>60</td> <td>95</td> <td>70</td> <td>55</td> <td>4.7</td> </tr> <tr> <td class=\"indent1\"><em>Salmonella </em>spp, nontyphoidal</td> <td>1,027,561</td> <td>94</td> <td>11</td> <td>27.2</td> <td>0.5</td> </tr> <tr> <td class=\"indent1\"><em>Salmonella enterica </em>serotype typhi</td> <td>1821</td> <td>96</td> <td>67</td> <td>75.7</td> <td>0</td> </tr> <tr> <td class=\"indent1\"><em>Shigella</em> spp</td> <td>131,254</td> <td>31</td> <td>15</td> <td>20.2</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em>, foodborne</td> <td>241,148</td> <td>100</td> <td>&#60;1</td> <td>6.4</td> <td>&#60;0.1</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus</em> spp group A, foodborne</td> <td>11,217</td> <td>100</td> <td>&#60;1</td> <td>0.2</td> <td>0</td> </tr> <tr> <td class=\"indent1\"><em>Vibrio cholerae</em>, toxigenic</td> <td>84</td> <td>100</td> <td>70</td> <td>43.1</td> <td>0</td> </tr> <tr> <td class=\"indent1\"><em>Vibrio vulnificus</em></td> <td>96</td> <td>47</td> <td>2</td> <td>91.3</td> <td>34.8</td> </tr> <tr> <td class=\"indent1\"><em>Vibrio parahaemolyticus</em></td> <td>34,664</td> <td>86</td> <td>10</td> <td>22.5</td> <td>0.9</td> </tr> <tr> <td class=\"indent1\"><em>Vibrio</em> spp, other</td> <td>17,564</td> <td>57</td> <td>11</td> <td>37.1</td> <td>3.7</td> </tr> <tr> <td class=\"indent1\"><em>Yersinia enterocolitica</em></td> <td>97,656</td> <td>90</td> <td>7</td> <td>34.4</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><em>Subtotal</em></td> <td>3,645,773</td> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Parasites</td> </tr> <tr> <td class=\"indent1\"><em>Cryptosporidium </em>spp</td> <td>57,616</td> <td>8</td> <td>9</td> <td>25</td> <td>0.3</td> </tr> <tr> <td class=\"indent1\"><em>Cyclospora cayetanensis</em></td> <td>11,407</td> <td>99</td> <td>42</td> <td>6.5</td> <td>0</td> </tr> <tr> <td class=\"indent1\"><em>Giardia intestinalis</em></td> <td>76,840</td> <td>7</td> <td>8</td> <td>8.8</td> <td>0.1</td> </tr> <tr> <td class=\"indent1\"><em>Toxoplasma gondii</em></td> <td>86,686</td> <td>50</td> <td>&#60;1</td> <td>2.6</td> <td>0.2</td> </tr> <tr> <td class=\"indent1\"><em>Trichinella</em> spp</td> <td>156</td> <td>100</td> <td>4</td> <td>24.3</td> <td>0.2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><em>Subtotal</em></td> <td>232,705</td> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Viruses</td> </tr> <tr> <td class=\"indent1\">Astrovirus</td> <td>15,433</td> <td>&#60;1</td> <td>0</td> <td>0.4</td> <td>&#60;0.1</td> </tr> <tr> <td class=\"indent1\">Hepatitis A virus</td> <td>1566</td> <td>7</td> <td>41</td> <td>31.5</td> <td>2.4</td> </tr> <tr> <td class=\"indent1\">Norovirus</td> <td>5,461,731</td> <td>26</td> <td>&#60;1</td> <td>0.03</td> <td>&#60;0.1</td> </tr> <tr> <td class=\"indent1\">Rotavirus</td> <td>15,433</td> <td>&#60;1</td> <td>0</td> <td>1.7</td> <td>&#60;0.1</td> </tr> <tr> <td class=\"indent1\">Sapovirus</td> <td>15,433</td> <td>&#60;1</td> <td>0</td> <td>0.4</td> <td>&#60;0.1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><em>Subtotal</em></td> <td>5,509,597</td> <td colspan=\"4\">&nbsp;</td> </tr> <tr> <td><strong>Total</strong></td> <td><strong>9,388,075</strong></td> <td colspan=\"4\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ETEC: enterotoxigenic <EM>Escherichia coli</EM>; STEC: Shiga toxin-producing <EM>Escherichia coli</EM>.<br />* All estimates based on United States population in 2006.<br />Â¶ Percentage foodborne among domestically acquired illness.<br />Î For laboratory-confirmed illnesses. Unadjusted hospitalization and death rates are presented here. These rates were doubled to adjust for underdiagnosis before being applied to the number of laboratory-confirmed cases to estimate the total number of hospitalizations and deaths. The hospitalization and death rates for atrovirus, norovirus, rotavirus, and sapovirus presented here are the percentage of total estimated illness and were not subject to further adjustment.</div><div class=\"graphic_reference\">Adapted from: Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States&mdash;major pathogens. Emerg Infect Dis 2011; 17:7.</div><div id=\"graphicVersion\">Graphic 75429 Version 7.0</div></div></div>"},"75430":{"type":"graphic_diagnosticimage","displayName":"CT scan of Petersens hernia after gastric bypass","title":"Computed tomography (CT) scan of Petersen's hernia after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Computed tomography (CT) scan of Petersen's hernia after gastric bypass</div><div class=\"cntnt\"><img style=\"width:546px; height:316px;\" src=\"images/SURG/75430_CT_scan_Petersens_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan read as normal in a gastric bypass patient. Note the non-contrast filled loops of bowel on the right side of the abdomen, which is herniated bowel through Petersen's defect and confirmed intra-operatively.</div><div id=\"graphicVersion\">Graphic 75430 Version 5.0</div></div></div>"},"75431":{"type":"graphic_picture","displayName":"Dermoscopy of scabies","title":"Scabies mite appearance on dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scabies mite appearance on dermoscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/75431_Dermoscopy_scabies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dark triangular shape in this image represents the head of the scabies mite.</div><div class=\"graphic_reference\">Reproduced with permission from: DermNet NZ. For more information, visit <A spellcheck=true href=\"http://dermnetnz.org/\" target=_blank>http://dermnetnz.org/</A>. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 75431 Version 3.0</div></div></div>"},"75432":{"type":"graphic_picture","displayName":"Standing thigh stretch","title":"Flexibility exercise: Thigh (standing)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexibility exercise: Thigh (standing)</div><div class=\"cntnt\"><img style=\"width:369px; height:297px;\" src=\"images/PC/75432_Standing_thigh_stretch_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Here's an exercise that stretches your thigh muscles. If you've had hip or back surgery, talk with your doctor before trying this stretch. <ol> <li>Stand behind a sturdy chair with your feet shoulder-width apart and your knees straight, but not locked. </li> <li>Hold on to the chair for balance with your right hand. </li> <li>Bend your left leg back and grab your foot in your left hand. Keep your knee pointed to the floor. If you can't grab your ankle, loop a resistance band, belt, or towel around your foot and hold both ends. </li> <li>Gently pull your leg until you feel a stretch in your thigh. </li> <li>Hold position for 10 to 30 seconds. </li> <li>Repeat at least three to five times. </li> <li>Repeat at least three to five times with your right leg. </li> </ol></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 75432 Version 2.0</div></div></div>"},"75433":{"type":"graphic_figure","displayName":"Seldinger cricothyrotomy step 2","title":"Seldinger cricothyrotomy technique: Step 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seldinger cricothyrotomy technique: Step 2</div><div class=\"cntnt\"><img style=\"width:428px; height:509px;\" src=\"images/EM/75433_Cric_Seldinger_step_two.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apply a small amount of negative pressure on the syringe and insert the needle carefully into the cricothyroid membrane at a 45 degree angle with the needle oriented caudad.</div><div id=\"graphicVersion\">Graphic 75433 Version 3.0</div></div></div>"},"75434":{"type":"graphic_table","displayName":"Comparison of findings in neuropathy, myopathy, and NMJ disorder","title":"Comparison of findings in neuropathy, myopathy, and NMJ disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of findings in neuropathy, myopathy, and NMJ disorders</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1\">&nbsp;</td>\n    <td class=\"subtitle1\">Neuropathy</td>\n    <td class=\"subtitle1\">Myopathy</td>\n    <td class=\"subtitle1\">Neuromuscular junction</td>\n  </tr>\n  <tr>\n    <td>Typical distribution</td>\n    <td>Distal &#62; proximal</td>\n    <td>Proximal &#62; distal</td>\n    <td>Diffuse (oculomotor and bulbar early)</td>\n  </tr>\n  <tr>\n    <td>Reflexes</td>\n    <td>Decreased</td>\n    <td>Normal to decreased</td>\n    <td>Normal</td>\n  </tr>\n  <tr>\n    <td>Sensory involvement</td>\n    <td>Present</td>\n    <td>Absent</td>\n    <td>Absent</td>\n  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">1/22/2010--Requested permission (JD).\r\n1/22/2010--Permission granted; figures back to Katy for any changes Jon might want to make (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=12331&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Neuro_vs_myopathy_vs_NMJ.htm</title></head></div><div class=\"graphic_reference\">Reprinted with permission from: Asimos, AW. Weakness: A Systematic Approach to Acute, Non-traumatic, Neurologic and Neuromuscular Causes. Emergency Medicine Practice 2002; 4:1. Copyright Â© 2002 EB Practice, LLC. All rights reserved. http://www.ebmedicine.net.</div><div id=\"graphicVersion\">Graphic 75434 Version 2.0</div></div></div>"},"75436":{"type":"graphic_picture","displayName":"Epinephrine auto-inject PI","title":"Using an epinephrine autoinjector","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Using an epinephrine autoinjector</div><div class=\"cntnt\"><img style=\"width:528px; height:405px;\" src=\"images/PI/75436_Epinephr_autoinject_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows how to use an epinephrine autoinjector. When using an autoinjector, hold it in your fist, with your fingers away from either end. Press it firmly into your outer thigh and hold it in place for at least a few seconds. (Check the directions that come with your autoinjector so you know how long to hold it.)<br /><br />It is best to sit down and if you feel dizzy, to lie down. If you pass out, another person should lower you to the ground and raise your legs up to help blood flow to your heart and brain.</div><div id=\"graphicVersion\">Graphic 75436 Version 9.0</div></div></div>"},"75438":{"type":"graphic_picture","displayName":"Cellular NSIP histology","title":"Nonspecific interstitial pneumonia, cellular pattern","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Nonspecific interstitial pneumonia, cellular pattern</div><div class=\"cntnt\"><img style=\"width:462px; height:323px;\" src=\"images/PULM/75438_Cellular_NSIP_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The interstitium is infiltrated by a moderate chronic inflammatory infiltrate; fibrosis is absent. The infiltrate consists of lymphocytes and plasma cells.</div><div id=\"graphicVersion\">Graphic 75438 Version 2.0</div></div></div>"},"75439":{"type":"graphic_figure","displayName":"GRE binding in asthma","title":"Glucocorticoid response element (GRE) binding in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glucocorticoid response element (GRE) binding in asthma</div><div class=\"cntnt\"><img style=\"width:429px; height:278px;\" src=\"images/PULM/75439_GRE_binding_in_asthma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of dexamethasone (1 &#181;M) on glucocorticoid receptor binding to specific consensus dsDNA binding sequences for GRE in nuclear extracts obtained from peripheral blood mononuclear cells from steroid-sensitive (SS, n=6) and steroid-resistant (SR, n=7) asthmatic patients and from normal subjects (Normal, n=3). Mean values are shown at different times after addition of dexamethasone to the cells.</div><div class=\"graphic_footnotes\">* p&lt;0.05.<br> &#8226; p&lt;0.005 (ANOVA).</div><div class=\"graphic_reference\">Redrawn from Adcock I, Lane S, Brown C, et al, J Immunol 1995;154(7):3503.</div><div id=\"graphicVersion\">Graphic 75439 Version 1.0</div></div></div>"},"75440":{"type":"graphic_picture","displayName":"Nipple retraction","title":"Nipple retraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nipple retraction</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/75440_Nipple_retraction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nipple retraction occurs when only a part of the nipple is drawn in because it is tethered by a single duct, resulting in a slit-like appearance.</div><div id=\"graphicVersion\">Graphic 75440 Version 1.0</div></div></div>"},"75441":{"type":"graphic_figure","displayName":"CLIP score Kaplan Meier","title":"Kaplan-Meier estimated survival curves based on the CLIP score (log rank test)","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Kaplan-Meier estimated survival curves based on the CLIP score (log rank test)</div><div class=\"cntnt\"><img style=\"width:456px; height:289px;\" src=\"images/GAST/75441_CLIP_score_Kaplan_Meier.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89:2266.</div><div id=\"graphicVersion\">Graphic 75441 Version 2.0</div></div></div>"},"75442":{"type":"graphic_table","displayName":"Causes of hypertriglyceridemia","title":"Primary disorders of triglyceride metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary disorders of triglyceride metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Disorder</td>\n\n      <td class=\"subtitle1\">Lipid levels</td>\n\n      <td class=\"subtitle1\">Confirmatory studies</td>\n\n      <td class=\"subtitle1\">Physical findings</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Type I hyperlipoproteinemia</td>\n\n      <td>TG &#62;99th percentile</td>\n\n      <td>Overnight refrigerated plasma sample with creamy\nsupernatant and clear infranatant; chylomicrons verified by\nultracentrifugation; LPL activity &#60;10 percent normal; apo C-II\ndeficiency; absence of secondary causes</td>\n\n      <td>Eruptive xanthomata (50 percent); hepatosplenomegaly;\nlipemia retinalis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mixed hypertriglyceridemia (type V)</td>\n\n      <td>TG &#62;99th percentile</td>\n\n      <td>Overnight refrigerated plasma sample with creamy\nsupernatant and cloudy infranatant; LPL activity reduced; apo C-II\ndeficiency; apo C-III inhibitor may be present infranatant;</td>\n\n      <td>Eruptive xanthomata</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Familial dysbetalipoproteinemia (type III)</td>\n\n      <td>TC &#62;90th percentile; TG &#62;90th percentile</td>\n\n      <td>VLDL-chol/total TG &#8805;0.3; Chylomicron and VLDL\nremnants; apo E2/2 phenotype; apo E variant isoform</td>\n\n      <td>Xanthomata palmare striatum; tuberoeruptive xanthomata\n(in patients without obstructive liver disease)</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=3319&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Causes_of_hypertriglyceride.htm</title></head></div><div class=\"graphic_lgnd\">Summary of diagnostic criteria for the different forms of hypertriglyceridemia.</div><div class=\"graphic_footnotes\">TC: total cholesterol; TG: total triglycerides; LPL: lipoprotein lipase. <br> Summary of diagnostic crieria for the different forms of hypertriglyceridema. </div><div class=\"graphic_reference\">Adapted from: Rosenson RS, Frauenheim WA, Tangney CC. Dyslipidemias and the secondary prevention of coronary heart disease. Dis Mon 1994; 40:369.</div><div id=\"graphicVersion\">Graphic 75442 Version 2.0</div></div></div>"},"75443":{"type":"graphic_table","displayName":"Causes of nonspecific pl effus","title":"Potential causes of nonspecific pleural effusions after cardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential causes of nonspecific pleural effusions after cardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Early nonspecific effusions (&#60;30 days in postoperative course)</td> </tr> <tr> <td class=\"indent1\">Topical cardiac cooling</td> </tr> <tr> <td class=\"indent1\">Surgical interruption of mediastinal lymphatic channels</td> </tr> <tr> <td class=\"indent1\">Pleurotomy</td> </tr> <tr> <td class=\"indent1\">Isolated pleural effusion due to postpericardiotomy syndrome before onset of other syndromic manifestations</td> </tr> <tr> <td class=\"subtitle1_single\">Late nonspecific effusions (&#62;30 days in postoperative course)</td> </tr> <tr> <td class=\"indent1\">Pericarditis</td> </tr> <tr> <td class=\"indent1\">Pleural inflammation</td> </tr> <tr> <td class=\"indent1\">Incomplete resolution of postpericardiotomy syndrome</td> </tr> <tr> <td class=\"indent1\">Constrictive pericarditis</td> </tr> <tr> <td class=\"indent1\">Trapped lung</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75443 Version 4.0</div></div></div>"},"75444":{"type":"graphic_picture","displayName":"Constrictive bronchiolitis Low","title":"Constrictive bronchiolitis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Constrictive bronchiolitis</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/PULM/75444_Constrictive_bronchioliti2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of constrictive bronchiolitis in a patient with long standing rheumatoid arthritis and progressive airflow obstruction. There is luminal narrowing caused by peribronchiolar scarring and luminal mucus. Hematoxylin and eosin stain.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 75444 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Section through a bronchiole</div><div class=\"cntnt\"><img style=\"width:220px; height:251px;\" src=\"images/PULM/74793_Normal_bronchiole.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchioles are distinguished from bronchi by a lack of glands and cartilage. Hematoxylin and eosin stain.</div><div class=\"graphic_reference\">From: Corrin, B. Development and structure of the normal lung. In: Clinical Atlas Respiratory Diseases, Turner-Warwick, M, Hodson, ME, Corrin, B, Kerr, IH (Eds), JB Lippincott, London, 1989.</div><div id=\"graphicVersion\">Graphic 74793 Version 1.0</div></div></div>"},"75445":{"type":"graphic_picture","displayName":"Nasal pillows","title":"Nasal pillows","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal pillows</div><div class=\"cntnt\"><img style=\"width:255px; height:500px;\" src=\"images/PULM/75445_Nasal_pillows.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Mirage Swift mask (ResMed, Inc) has nasal \"pillows\" that fit into nares. This mask design removes the sealing surface from the nose and mouth and minimizes hardware over the eyes.</div><div class=\"graphic_reference\">Copyright Â© ResMed 2010. Used with permission.</div><div id=\"graphicVersion\">Graphic 75445 Version 3.0</div></div></div>"},"75446":{"type":"graphic_table","displayName":"RA disease activity indices","title":"Rheumatoid arthritis disease activity indices: Calculation, cutpoints, and ranges of composite indices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rheumatoid arthritis disease activity indices: Calculation, cutpoints, and ranges of composite indices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">No of variables</td> <td class=\"subtitle1\">Acute phase reactant</td> <td class=\"subtitle1\">Formulae (CRP in mg/L for DAS and DAS28, and in mg/dL for SDAI; GH: VAS in mm; PGA and EGA: VAS in cm)</td> <td class=\"subtitle1\">Cutpoints</td> <td class=\"subtitle1\">Response criteria</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">DAS* </td> <td>4</td> <td>ESR</td> <td>= 0.54 x &#8730;(Ritchie) + 0.065 x SJC44 + 0.33 x log<sub>nat</sub>(ESR) + 0.0072 x GH</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>REM &#60;1.6</p> <p>LDA &#60;2.4</p> <p>MDA &#60;3.7</p> HDA &#8805;3.7</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>CRP</td> <td>= 0.54 x &#8730;(Ritchie) + 0.065 x SJC44 + 0.17 x log<sub>nat</sub>(CRP+1) + 0.0072 x GH + 0.45</td> <td>n.v.</td> </tr> <tr> <td>3</td> <td>ESR</td> <td>= 0.54 x &#8730;(Ritchie) + 0.065 x SJC44 + 0.33 x log<sub>nat</sub>(ESR) + 0.22</td> <td>n.v.</td> </tr> <tr class=\"divider_bottom\"> <td>3</td> <td>CRP</td> <td>= 0.54 x &#8730;(Ritchie) + 0.065 x SJC44 + 0.17 x log<sub>nat</sub>(CRP+1) + 0.65</td> <td>n.v.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">DAS28*</td> <td>4</td> <td>ESR</td> <td>= 0.56 x &#8730;(TJC28) + 0.28 x &#8730;(SJC28) + 0.70 x log<sub>nat</sub>(ESR) + 0.014 x GH</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>REM &#60;2.6</p> <p>LDA 2.6-3.2</p> <p>MDA &#62;3.2-5.1</p> HDA &#62;5.1</td> <td> <p>Moderate &#62;0.6</p> Major &#62;1.2<sup>&#182;</sup></td> </tr> <tr> <td>4</td> <td>CRP</td> <td>= 0.56 x &#8730;(TJC28) + 0.28 x &#8730;(SJC28) + 0.36 x log<sub>nat</sub>(CRP+1) + 0.014 x GH + 0.96</td> <td>n.v.</td> </tr> <tr> <td>3</td> <td>ESR</td> <td>= [0.56 x &#8730;(TJC28) + 0.28 x &#8730;(SJC28) + 0.70* x log<sub>nat</sub>(ESR)] x 1.08 + 0.16</td> <td>n.v.</td> </tr> <tr class=\"divider_bottom\"> <td>3</td> <td>CRP</td> <td>= [0.56 x &#8730;(TJC28) + 0.28*&#8730;(SJC28) + 0.36* log<sub>nat</sub>(CRP+1)] x 1.10 + 1.15</td> <td>n.v.</td> </tr> <tr class=\"divider_bottom\"> <td>SDAI</td> <td>5</td> <td>CRP</td> <td>SJC28 + TJC28 + PGA + EGA + CRP</td> <td>REM &#8804;3.3; LDA &#8804;11; MDA &#8804;26; HDA &#62;26</td> <td> <p>Minor &#8805;50 percent</p> <p>Moderate &#8805;70 percent</p> Major &#8805;85 percent</td> </tr> <tr> <td>CDAI</td> <td>4</td> <td>-</td> <td>SJC28 + TJC28 + PGA + EGA</td> <td>REM &#8804;2.8; LDA &#8804;10; MDA &#8804;22; HDA &#62;22</td> <td> <p>Minor &#8805;50 percent</p> <p>Moderate &#8805;70 percent</p> Major &#8805;85 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DAS: Disease Activity Score; DAS28: DAS based on 28 joint counts; Ritchie: Ritchie articular index; SJC28, SJC44: swollen joint counts based on the evaluation of 28 or 44 joints, respectively; TJC28: tender joint count based on 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; GH: global health; PGA, EGA: patient and evaluator global assessment of disease activity; REM: remission; LDA: low disease activity; MDA: moderate disease activity; HDA: high disease activity; n.v.: not validated.<br />* Formulae for the DAS and the DAS28 variations obtained from the Internet: www.das-score.nl/index.html (Accessed Sept 13, 2006).<br />Â¶ Plus change in category as detailed in the text.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Aletaha D, Ward MM, Machold KP, Nell VPK, et al. Remission and active Disease in Rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005; 52:2625.</li>&#xD;&#xA;    <li>Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23:S100.</li>&#xD;&#xA;    <li>Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 2012.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75446 Version 3.0</div></div></div>"},"75448":{"type":"graphic_diagnosticimage","displayName":"Occipital fracture","title":"Occipital fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Occipital fracture</div><div class=\"cntnt\"><img style=\"width:323px; height:355px;\" src=\"images/EM/75448_Occipital_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This computed tomography of the head identifies an occipital fracture (arrow) with an associated posterior epidural hematoma.</div><div id=\"graphicVersion\">Graphic 75448 Version 2.0</div></div></div>"},"75449":{"type":"graphic_picture","displayName":"Endoclip polypec ulcer endo","title":"Endoclip placement at gastric polypectomy site","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Endoclip placement at gastric polypectomy site</div><div class=\"cntnt\"><img style=\"width:522px; height:169px;\" src=\"images/GAST/75449_Endoclip_polypec_ulcer_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 52 year old male was referred for nausea and vomiting. After initial evaluation, an endoscopy was performed which revealed a 3cm long pedunculated gastric polyp. The polyp originated in the pre-pyloric region of the stomach and prolapsed through the pylorus into the duodenal bulb. The polyp was resected using a hot snare. After the resection, a large secondary ulcer exposing the submucosa remained. Though there was no active bleeding, two endoclips were placed to close the defect completely. The patient was placed on twice daily esomeprazole and was given instructions to avoid NSAIDS and aspirin. No bleeding or other complications were noted during follow up. The pathology showed that this was an inflammatory polyp with features of high grade dysplasia.</div><div class=\"graphic_reference\">Courtesy of Ilseung Cho, MD.</div><div id=\"graphicVersion\">Graphic 75449 Version 2.0</div></div></div>"},"75450":{"type":"graphic_figure","displayName":"Tissue factor and coagulation","title":"Coagulation cascade initiated by tissue factor release at the site of tissue injury","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Coagulation cascade initiated by tissue factor release at the site of tissue injury</div><div class=\"cntnt\"><img style=\"width:554px; height:588px;\" src=\"images/HEME/75450_Tissue_factor_and_coagulati.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Factors in squares are inactive forms, whereas factors in circles are active enzymes.</div><div class=\"graphic_footnotes\">PT: prothrombin; Th: thrombin.</div><div class=\"graphic_reference\">Adapted from: Ferguson JJ, et al. Eur Heart J 1998; 19(Suppl D):D6.</div><div id=\"graphicVersion\">Graphic 75450 Version 2.0</div></div></div>"},"75451":{"type":"graphic_figure","displayName":"Tennis elbow injection","title":"\"Tennis elbow\" injection","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">\"Tennis elbow\" injection</div><div class=\"cntnt\"><img style=\"width:468px; height:302px;\" src=\"images/RHEUM/75451_Tennis_elbow_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the elbow flexed and pronated, the needle is inserted at the most tender area on the anterolateral aspect of the external condyle of the humerus. A combination of glucocorticoid and local anesthetic is injected in several areas.</div><div class=\"graphic_reference\">Reproduced from Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.</div><div id=\"graphicVersion\">Graphic 75451 Version 4.0</div></div></div>"},"75453":{"type":"graphic_table","displayName":"Renal replacement comparison PI","title":"The benefits and downsides of kidney transplant, peritoneal dialysis, and hemodialysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The benefits and downsides of kidney transplant, peritoneal dialysis, and hemodialysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Benefits</td> <td class=\"subtitle1\">Downsides</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Kidney transplant</strong></td> <td> <ul> <li>People who get a kidney transplant usually live longer and have a better quality of life than people who are treated with dialysis </li> </ul> </td> <td> <ul> <li>A kidney transplant is major surgery </li> <li>It can be hard to find a donor kidney </li> <li>People with certain medical conditions can't have a kidney transplant </li> <li>After surgery, you need to take medicines every day for the rest of your life. These medicines could cause you to get severe infections or cancer. </li> <li>After surgery, your body might \"reject\" your new kidney </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Peritoneal dialysis</strong></td> <td> <ul> <li>You can do it at home, which gives you more freedom and control over your life </li> <li>It doesn't involve needles </li> <li>You can do it overnight while you sleep </li> <li>You don't need anyone to help you if you learn how to do it yourself </li> <li>You don't need to limit your diet as much as with hemodialysis </li> </ul> </td> <td> <ul> <li>It can be hard to learn how to do it </li> <li>It increases the chance that you will get an infection in your belly </li> </ul> </td> </tr> <tr> <td><strong>Hemodialysis</strong></td> <td> <ul> <li>You might have the option of doing it at home, which gives you more freedom and control over your life </li> <li>If you have it in a dialysis center, you don't have to learn to do it yourself, and doctors and nurses can watch you more closely </li> <li>You do it fewer days each week than peritoneal dialysis </li> </ul> </td> <td> <ul> <li>If you do it at home, you will need to get special training and equipment, and have someone to help you </li> <li>If you have it in a center, you will need to travel there and back at least 3 times a week </li> <li>You will have needles put in your arm each time </li> <li>Your access can get infected or stop working </li> <li>During dialysis, you might feel lightheaded or have trouble breathing </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75453 Version 3.0</div></div></div>"},"75454":{"type":"graphic_diagnosticimage","displayName":"Imaging of Mirizzi syndrome","title":"Mirizzi syndrome seen on magnetic resonance cholangiopancreatography (MRCP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mirizzi syndrome seen on magnetic resonance cholangiopancreatography (MRCP)</div><div class=\"cntnt\"><img style=\"width:432px; height:399px;\" src=\"images/GAST/75454_Imaging_Mirizzi_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mirizzi syndrome. Two calculi in the dilated cystic duct (arrowheads), which parallels the extrahepatic bile duct. The inferior calculus (arrow) eroded through the wall of the cystic duct into the extrahepatic bile duct, bridging the two structures and resulting in obstruction of the bile duct.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg RL. An atlas of differential diagnosis, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75454 Version 4.0</div></div></div>"},"75455":{"type":"graphic_figure","displayName":"Vesicoureteral reflux PI","title":"Urinary tract in children","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Urinary tract in children</div><div class=\"cntnt\"><img style=\"width:542px; height:419px;\" src=\"images/PI/75455_Vesicoureteral_reflux_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures show the organs of the urinary tract in a girl and a boy. Urine is made in the kidneys, and then flows down the ureters to the bladder. In a child with vesicoureteral reflux, some urine flows backwards from the bladder towards the kidneys through the ureter.</div><div id=\"graphicVersion\">Graphic 75455 Version 1.0</div></div></div>"},"75459":{"type":"graphic_diagnosticimage","displayName":"Interictal PET scan","title":"PET hypometabolism","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">PET hypometabolism</div><div class=\"cntnt\"><img style=\"width:515px; height:298px;\" src=\"images/NEURO/75459_Interictal_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An interictal PET scan after intravenous injection of Fluorine-18-fluoro-2-deoxy-D-glucose (FDG), showing left temporal hypometabolism, medial more than lateral (see boxed area), but extending to the insula and possibly to the parietal region.</div><div class=\"graphic_footnotes\">PET: positron emission tomography.</div><div class=\"graphic_reference\">Figure courtesy of Hiba Arif, MD and Lawrence J Hirsch, MD.</div><div id=\"graphicVersion\">Graphic 75459 Version 5.0</div></div></div>"},"75460":{"type":"graphic_picture","displayName":"Histol vertical growth melan 2","title":"Vertical growth phase melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vertical growth phase melanoma</div><div class=\"cntnt\"><img style=\"width:361px; height:292px;\" src=\"images/ONC/75460_Histol_vertical_growth_mela.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a light photomicrograph showing a vertical growth phase nodular melanoma in which the tumor cells extend deep into the dermis. The lesion is clearly invasive.</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 75460 Version 1.0</div></div></div>"},"75461":{"type":"graphic_table","displayName":"PaO2 in cyanotic heart disease","title":"Mean PaO<sub>2</sub> values in various types of cyanotic heart disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mean PaO<sub>2</sub> values in various types of cyanotic heart disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Conditions</td> <td class=\"subtitle1\" colspan=\"2\">Mean PaO<sub>2</sub> (mmHg)</td> </tr> <tr> <td class=\"subtitle2\"> <p>Room air</p> FiO<sub>2</sub> = 0.21</td> <td class=\"subtitle2\"> <p>100 percent oxygen</p> FiO<sub>2</sub> = 1</td> </tr> <tr> <td>Common mixing lesion*</td> <td class=\"centered\">42</td> <td class=\"centered\">64</td> </tr> <tr> <td>HLHS</td> <td class=\"centered\">47</td> <td class=\"centered\">79</td> </tr> <tr> <td>POTO<sup>&#182;</sup></td> <td class=\"centered\">39</td> <td class=\"centered\">45 </td> </tr> <tr> <td>TGA</td> <td class=\"centered\">30</td> <td class=\"centered\">39</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Mean arterial partial pressure of oxygen (PaO<sub>2</sub>) for specific cyanotic heart defects during hyperoxia test with administration of room air or 100 percent oxygen.</div><div class=\"graphic_footnotes\">FiO<SUB>2</SUB>: fractional inspired oxygen concentration; HLHS: hypoplastic left heart syndrome; POTO: pulmonary outflow tract obstruction; TGA: transposition of the great arteries.<br />* Lesions include total anomalous pulmonary venous connection, tricuspid atresia with large ventricular septal defect, truncus arteriosus, double outlet right ventricle, and single ventricle without pulmonary stenosis.<br />Â¶ Lesions include tetralogy of Fallot, tetralogy of Fallot associated with pulmonary atresia, tricuspid atresia associated with small ventricular septal defect, double outlet right ventricle associated with pulmonary stenosis, and single ventricle associated with pulmonary stenosis.</div><div class=\"graphic_reference\">Data from: Jones RW, Baumer JH, Joseph MC, Shinebourne EA. Arterial oxygen tension and response to oxygen breathing in differential diagnosis of congenital heart disease in infancy. Arch Dis Child 1976; 51:667.</div><div id=\"graphicVersion\">Graphic 75461 Version 10.0</div></div></div>"},"75462":{"type":"graphic_figure","displayName":"Prognosis of MI in relation to ST changes at 90 minutes","title":"Prognosis of myocardial infarction in relation to ST changes at 90 minutes","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Prognosis of myocardial infarction in relation to ST changes at 90 minutes</div><div class=\"cntnt\"><img style=\"width:496px; height:280px;\" src=\"images/CARD/75462_Prognosis_v_ST_persistence.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">All ST changes measured in lead with maximum change at baseline. Persistence of bundle-branch block is prognostic indication for worst outcome except when there is &lt;2 mm change at 90 minutes with an inferior infarction, when it indicates medium prognosis.</div><div class=\"graphic_footnotes\">* Baseline ST elevation &gt;4.5 mm.<br>â¢ Baseline ST elevation â¤4.5 mm.</div><div class=\"graphic_reference\">Reproduced with permission from Varma C, Brecker S. Lancet 2001; 358:1473, based on data from Schroder K, Wegscheider K, Zeymer U, et al. Lancet 2001; 358:1479. Copyright Â© 2001, The Lancet Ltd.</div><div id=\"graphicVersion\">Graphic 75462 Version 3.0</div></div></div>"},"75464":{"type":"graphic_figure","displayName":"Pituitary surgery PI","title":"Surgery to remove a pituitary tumor","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Surgery to remove a pituitary tumor</div><div class=\"cntnt\"><img style=\"width:500px; height:470px;\" src=\"images/PI/75464_Transsphenoidal_surg_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this kind of surgery (called &quot;transsphenoidal surgery&quot;), the surgeon makes a small cut deep inside the nose. Then the surgeon inserts special tools into the &quot;sphenoid sinus,&quot; the hollow space below the pituitary gland. That way the surgeon has access to the pituitary gland and can remove the tumor. In some cases, surgeons do the surgery using a special tool called an &quot;endoscope,&quot; which is a long tube with a tiny camera and a light on the end.</div><div id=\"graphicVersion\">Graphic 75464 Version 4.0</div></div></div>"},"75466":{"type":"graphic_picture","displayName":"CLL proliferation centers","title":"Chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic lymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:333px; height:287px;\" src=\"images/HEME/75466_CLL_proliferation_centers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node from a patient with CLL shows a diffuse infiltrative pattern. The best clues to the diagnosis are the pale-staining pseudofollicles (arrows).</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 75466 Version 1.0</div></div></div>"},"75467":{"type":"graphic_table","displayName":"Clinical syndromes by Vibrio species","title":"Vibriosis cases by species, selected patient demographic characteristics, and outcomes, United States, 2014","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vibriosis cases by species, selected patient demographic characteristics, and outcomes, United States, 2014</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"10\" width=\"8%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Genus and species of <em>Vibrionaceae</em></td> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Cases</td> <td class=\"subtitle1\" colspan=\"4\">Demographic characteristics</td> <td class=\"subtitle1\" colspan=\"4\">Outcomes</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Age (years)</td> <td class=\"subtitle2\" colspan=\"2\">Sex</td> <td class=\"subtitle2\" colspan=\"2\">Hospitalizations</td> <td class=\"subtitle2\" colspan=\"2\">Deaths</td> </tr> <tr> <td class=\"subtitle3\">N</td> <td class=\"subtitle3\">Percent</td> <td class=\"subtitle3\">Median</td> <td class=\"subtitle3\">Range</td> <td class=\"subtitle3\">Male (n/N)</td> <td class=\"subtitle3\">Percent</td> <td class=\"subtitle3\">n/N</td> <td class=\"subtitle3\">Percent</td> <td class=\"subtitle3\">n/N</td> <td class=\"subtitle3\">Percent</td> </tr> <tr> <td><em>V. parahaemolyticus</em></td> <td class=\"centered\">605</td> <td class=\"centered\">48</td> <td class=\"centered\">47</td> <td class=\"centered\">4-96</td> <td class=\"centered\">396/603</td> <td class=\"centered\">66</td> <td class=\"centered\">86/575</td> <td class=\"centered\">15</td> <td class=\"centered\">4/389</td> <td class=\"centered\">1</td> </tr> <tr> <td><em>V. alginolyticus</em></td> <td class=\"centered\">239</td> <td class=\"centered\">19</td> <td class=\"centered\">36.5</td> <td class=\"centered\">2-91</td> <td class=\"centered\">176/239</td> <td class=\"centered\">74</td> <td class=\"centered\">32/222</td> <td class=\"centered\">14</td> <td class=\"centered\">0/180</td> <td class=\"centered\">0</td> </tr> <tr> <td><em>V. vulnificus</em></td> <td class=\"centered\">124</td> <td class=\"centered\">10</td> <td class=\"centered\">59.5</td> <td class=\"centered\">10-93</td> <td class=\"centered\">101/124</td> <td class=\"centered\">81</td> <td class=\"centered\">97/123</td> <td class=\"centered\">79</td> <td class=\"centered\">21/117</td> <td class=\"centered\">18</td> </tr> <tr> <td><em>V. cholerae</em> (excluding toxigenic O1 and O139)*</td> <td class=\"centered\">80</td> <td class=\"centered\">6</td> <td class=\"centered\">50.5</td> <td class=\"centered\">3-90</td> <td class=\"centered\">54/80</td> <td class=\"centered\">68</td> <td class=\"centered\">36/79</td> <td class=\"centered\">46</td> <td class=\"centered\">3/65</td> <td class=\"centered\">5</td> </tr> <tr> <td><em>V. fluvialis</em></td> <td class=\"centered\">71</td> <td class=\"centered\">6</td> <td class=\"centered\">59.5</td> <td class=\"centered\">6-91</td> <td class=\"centered\">43/71</td> <td class=\"centered\">61</td> <td class=\"centered\">26/70</td> <td class=\"centered\">37</td> <td class=\"centered\">1/61</td> <td class=\"centered\">2</td> </tr> <tr> <td><em>V. mimicus</em></td> <td class=\"centered\">31</td> <td class=\"centered\">2</td> <td class=\"centered\">53</td> <td class=\"centered\">0-90</td> <td class=\"centered\">16/30</td> <td class=\"centered\">53</td> <td class=\"centered\">17/30</td> <td class=\"centered\">57</td> <td class=\"centered\">1/31</td> <td class=\"centered\">3</td> </tr> <tr> <td><em>Grimontia hollisae</em> (formerly <em>V. hollisae</em>)</td> <td class=\"centered\">10</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">47</td> <td class=\"centered\">24-71</td> <td class=\"centered\">9/10</td> <td class=\"centered\">90</td> <td class=\"centered\">4/10</td> <td class=\"centered\">40</td> <td class=\"centered\">0/9</td> <td class=\"centered\">0</td> </tr> <tr> <td><em>Photobacterium damselae</em> subsp. <em>damselae</em> (formerly <em>V. damsela</em>)</td> <td class=\"centered\">6</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">56.5</td> <td class=\"centered\">20-76</td> <td class=\"centered\">4/6</td> <td class=\"centered\">67</td> <td class=\"centered\">1/5</td> <td class=\"centered\">20</td> <td class=\"centered\">0/6</td> <td class=\"centered\">0</td> </tr> <tr> <td><em>V. harveyi</em></td> <td class=\"centered\">4</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">53.5</td> <td class=\"centered\">21-83</td> <td class=\"centered\">3/4</td> <td class=\"centered\">75</td> <td class=\"centered\">0/4</td> <td class=\"centered\">0</td> <td class=\"centered\">0/4</td> <td class=\"centered\">0</td> </tr> <tr> <td><em>V. metschnikovii</em></td> <td class=\"centered\">3</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">53</td> <td class=\"centered\">50-69</td> <td class=\"centered\">1/3</td> <td class=\"centered\">33</td> <td class=\"centered\">0/2</td> <td class=\"centered\">0</td> <td class=\"centered\">0/3</td> <td class=\"centered\">0</td> </tr> <tr> <td><em>V. furnissii</em></td> <td class=\"centered\">1</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">79</td> <td class=\"centered\">79-79</td> <td class=\"centered\">1/1</td> <td class=\"centered\">100</td> <td class=\"centered\">0/1</td> <td class=\"centered\">0</td> <td class=\"centered\">0/1</td> <td class=\"centered\">0</td> </tr> <tr> <td><em>V. metoecus</em></td> <td class=\"centered\">1</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">54</td> <td class=\"centered\">54-54</td> <td class=\"centered\">0/1</td> <td class=\"centered\">0</td> <td class=\"centered\">0/1</td> <td class=\"centered\">0</td> <td class=\"centered\">0/1</td> <td class=\"centered\">0</td> </tr> <tr> <td><em>V. navarrensis</em></td> <td class=\"centered\">1</td> <td class=\"centered\">&#60;1</td> <td class=\"centered\">7</td> <td class=\"centered\">7-7</td> <td class=\"centered\">0/1</td> <td class=\"centered\">0</td> <td class=\"centered\">0/1</td> <td class=\"centered\">0</td> <td class=\"centered\">0/1</td> <td class=\"centered\">0</td> </tr> <tr> <td>Species not identified</td> <td class=\"centered\">52</td> <td class=\"centered\">4</td> <td class=\"centered\">44</td> <td class=\"centered\">3-86</td> <td class=\"centered\">36/52</td> <td class=\"centered\">69</td> <td class=\"centered\">11/47</td> <td class=\"centered\">23</td> <td class=\"centered\">0/41</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td>Multiple species<sup>&#182;</sup></td> <td class=\"centered\">24</td> <td class=\"centered\">2</td> <td class=\"centered\">50</td> <td class=\"centered\">3-72</td> <td class=\"centered\">11/24</td> <td class=\"centered\">46</td> <td class=\"centered\">16/23</td> <td class=\"centered\">70</td> <td class=\"centered\">4/22</td> <td class=\"centered\">18</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>1252</strong></td> <td class=\"centered\"><strong>100</strong></td> <td class=\"centered\"><strong>48</strong></td> <td class=\"centered\"><strong>0-96</strong></td> <td class=\"centered\"><strong>851/1249</strong></td> <td class=\"centered\"><strong>68</strong></td> <td class=\"centered\"><strong>326/1193</strong></td> <td class=\"centered\"><strong>27</strong></td> <td class=\"centered\"><strong>34/931</strong></td> <td class=\"centered\"><strong>4</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes non-toxigenic <em>V. cholerae</em> (non-O1, non-O139 [78 cases], and O1 [2 cases]).<br />&para; The following combinations of <em>Vibrio</em> species were isolated from patients infected with multiple species: <em>V. alginolyticus</em>, <em>V. parahaemolyticus</em> (4 patients); <em>V. fluvialis</em>, <em>V. parahaemolyticus</em> (2 patients); <em>V. mimicus</em>, <em>V. fluvialis</em> (1 patient); <em>V. cholerae</em> non-O1, non-O139, <em>V. parahaemolyticus</em> (3 patients); <em>V. cholerae</em> non-O1, non-O139, <em>Vibrio</em> species not identified (2 patients); <em>V. fluvialis</em>, <em>V. vulnificus</em> (1 patient); <em>V. parahaemolyticus</em>, <em>V. vulnificus</em> (5 patients); <em>V. parahaemolyticus</em>, <em>Vibrio</em> species not identified (1 patient); <em>V. alginolyticus</em>, <em>Vibrio</em> species not identified (1 patient); <em>V. vulnificus</em>, <em>Vibrio</em> species not identified (1 patient); <em>V. alginolyticus</em>, <em>V. vulnificus</em> (2 patients); <em>V. mimicus</em>, <em>V. cholera</em> serogroup not specified (1 patient). None of these are included in the rows for individual species.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. COVIS Annual Summary, 2014. Atlanta: US Department of Health and Human Services, 2014. Available at: <a href=\"http://www.cdc.gov/nationalsurveillance/pdfs/covis-annual-summary-2014-508c.pdf\" target=\"_blank\">http://www.cdc.gov/nationalsurveillance/pdfs/covis-annual-summary-2014-508c.pdf</a> (Accessed on July 18, 2016).</div><div id=\"graphicVersion\">Graphic 75467 Version 7.0</div></div></div>"},"75469":{"type":"graphic_table","displayName":"Organisms soft tissue infection","title":"Organisms associated with soft tissue infection following water exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Organisms associated with soft tissue infection following water exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Exposure</td> <td class=\"subtitle1\">Clinical syndromes</td> </tr> <tr> <td><em>Aeromonas</em> spp*</td> <td>Fresh water</td> <td>Rapidly developing infection associated with fever; sepsis</td> </tr> <tr> <td><em>Edwardsiella tarda</em>*</td> <td>Fresh water</td> <td>Cellulitis, occasionally, fulminant infection with bacteremia</td> </tr> <tr> <td><em>Erysipelothrix rhusiopathiae</em></td> <td>Puncture wounds from shrimp, crabs, and fish</td> <td>Indolent localized cutaneous eruption; erysipeloid</td> </tr> <tr> <td><em>Vibrio vulnificus</em>*</td> <td>Salt or brackish water</td> <td>Rapidly progressive necrotizing infection; bullous cellulitis; sepsis</td> </tr> <tr> <td><em>Mycobacterium marinum</em></td> <td>Salt or fresh water including fish tanks</td> <td>Indolent infection; papules progressing to shallow ulcers; ascending lesions may resemble sporotrichosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Infection associated with patients with underlying liver disease, iron-overload syndromes, and cancer; infection in these high-risk groups particularly fulminant.</div><div id=\"graphicVersion\">Graphic 75469 Version 3.0</div></div></div>"},"75472":{"type":"graphic_table","displayName":"Muscle characteristics myotonic dystrophy I and II","title":"Muscle characteristics of myotonic dystrophy (DM), types I and II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscle characteristics of myotonic dystrophy (DM), types I and II</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of DM</td> <td class=\"subtitle1\">Muscle groups commonly affected</td> <td class=\"subtitle1\">Clinical myotonia (grip and percussion)*</td> <td class=\"subtitle1\">Muscle pain<sup>&#182;</sup></td> <td class=\"subtitle1\">Respiratory muscle involvement<sup>&#916;</sup></td> <td class=\"subtitle1\">Dysphagia and dysarthria<sup>&#916;</sup></td> </tr> <tr> <td>DM I (Steinert's disease)</td> <td>Facial, neck, forearm, hand intrinsic, foot dorsiflexor</td> <td>Common and often pronounced</td> <td>Yes (Rarely a presenting complaint)</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>DM II (Proximal myotonic myopathy)</td> <td>Neck flexor, elbow extensor, finger flexor, hip flexor</td> <td>Mild or inobvious</td> <td>Yes (Often a presenting complaint)</td> <td>Uncommon</td> <td>Uncommon</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Electrical myotonia is found in both disorders.<br />Â¶ Pain is generally not correlated with myotonia.<br />Î Important contributors to pneumonia and respiratory failure.</div><div id=\"graphicVersion\">Graphic 75472 Version 3.0</div></div></div>"},"75473":{"type":"graphic_table","displayName":"Clinical and lab features of primary myelofibrosis","title":"Clinical and laboratory features of 1000 consecutive patients with primary myelofibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and laboratory features of 1000 consecutive patients with primary myelofibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Result (percent)</td> </tr> <tr> <td>Median age, years (range)</td> <td>65 (14 to 92)</td> </tr> <tr> <td>Males</td> <td>62</td> </tr> <tr> <td>Constitutional symptoms</td> <td>34</td> </tr> <tr> <td>Spleen &#62;10 cm below left costal margin</td> <td>31</td> </tr> <tr> <td>Red cell transfusions required</td> <td>38</td> </tr> <tr> <td>Hemoglobin &#60;10 g/dL</td> <td>54</td> </tr> <tr> <td>White blood cell count &#62;25,000/microL</td> <td>16</td> </tr> <tr> <td>White blood cell count &#60;4000/microL</td> <td>16</td> </tr> <tr> <td>Platelet count &#60;100,000/microL</td> <td>26</td> </tr> <tr> <td>Circulating blasts &#8805;1 percent</td> <td>56</td> </tr> <tr> <td>JAK2 V617F mutation present</td> <td>61</td> </tr> <tr> <td>MPL mutation present</td> <td>8</td> </tr> <tr> <td>IDH mutation present</td> <td>4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 2012; 87:25.</div><div id=\"graphicVersion\">Graphic 75473 Version 1.0</div></div></div>"},"75475":{"type":"graphic_picture","displayName":"Radiation enteritis capsule","title":"Radiation enteritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiation enteritis</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/GAST/75475_Radiation_enteritis_capsule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abnormal jejunal villi and lacteals secondary to radiation enteritis as seen during capsule endoscopy.</div><div class=\"graphic_reference\">Courtesy of Ingram Roberts MD.</div><div id=\"graphicVersion\">Graphic 75475 Version 1.0</div></div></div>"},"75477":{"type":"graphic_picture","displayName":"Urothelial CIS E","title":"Urothelial carcinoma in situ (CIS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma in situ (CIS)</div><div class=\"cntnt\"><img style=\"width:432px; height:308px;\" src=\"images/ONC/75477_Urothelial_CIS_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75477 Version 1.0</div></div></div>"},"75479":{"type":"graphic_table","displayName":"Etiology of microcephaly","title":"Selected causes of microcephaly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected causes of microcephaly</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Isolated microcephaly (true microcephaly, microcephaly vera)</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive (eg, autosomal recessive primary microcephaly types 1 through 6, Amish lethal microcephaly)</td> </tr> <tr> <td class=\"indent1\">Autosomal dominant</td> </tr> <tr> <td class=\"indent1\">X-linked microcephaly</td> </tr> <tr> <td class=\"subtitle1_single\">Chromosomal abnormalities and syndromes</td> </tr> <tr> <td class=\"indent1\">Trisomies (eg, 21, 18, 13)</td> </tr> <tr> <td class=\"indent1\">Monosomy 1p36 deletion</td> </tr> <tr> <td class=\"indent1\">Seckel syndrome</td> </tr> <tr> <td class=\"indent1\">Smith-Lemli-Opitz syndrome</td> </tr> <tr> <td class=\"indent1\">Williams-Beuren syndrome (7q11.23 deletion)</td> </tr> <tr> <td class=\"indent1\">Cornelia de Lange syndrome</td> </tr> <tr> <td class=\"indent1\">Miller-Dieker lissencephaly syndrome (17p13.3 deletion)</td> </tr> <tr> <td class=\"indent1\">Wolf-Hirschhorn syndrome (4p deletion)</td> </tr> <tr> <td class=\"indent1\">Cri-du-chat syndrome (5p15.2 deletion)</td> </tr> <tr> <td class=\"indent1\">Mowat-Wilson syndrome</td> </tr> <tr> <td class=\"indent1\">Rubinstein-Taybi syndrome</td> </tr> <tr> <td class=\"indent1\">Aicardi-Gouti&#232;res syndrome</td> </tr> <tr> <td class=\"indent1\">Cockayne syndrome</td> </tr> <tr> <td class=\"indent1\">Bloom syndrome</td> </tr> <tr> <td class=\"indent1\">Angelman syndrome</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neuroanatomic abnormalities</td> </tr> <tr> <td class=\"indent1\">Neural tube defects (eg, anencephaly, hydranencephaly, encephalocele)</td> </tr> <tr> <td class=\"indent1\">Holoprosencephaly</td> </tr> <tr> <td class=\"indent1\">Atelencephaly (aprosencephaly)</td> </tr> <tr> <td class=\"indent1\">Lissencephaly</td> </tr> <tr> <td class=\"indent1\">Schizencephaly</td> </tr> <tr> <td class=\"indent1\">Polymicrogyria</td> </tr> <tr> <td class=\"indent1\">Pachygyria (macrogyria)</td> </tr> <tr> <td class=\"indent1\">Fetal brain disruption sequence</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic disorders</td> </tr> <tr> <td class=\"indent1\">Maternal diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Untreated maternal phenylketonuria</td> </tr> <tr> <td class=\"indent1\">Phenylketonuria</td> </tr> <tr> <td class=\"indent1\">Methylmalonic aciduria</td> </tr> <tr> <td class=\"indent1\">Citrullinemia</td> </tr> <tr> <td class=\"indent1\">Neuronal ceroid lipofuscinosis</td> </tr> <tr> <td class=\"subtitle1_single\">Environmental causes</td> </tr> <tr> <td class=\"indent1\">Congenital infection (eg, cytomegalovirus, herpes simplex virus, rubella, varicella, toxoplasmosis, human immunodeficiency virus, syphilis, enterovirus,&nbsp;Zika virus)</td> </tr> <tr> <td class=\"indent1\">Meningitis</td> </tr> <tr> <td class=\"indent1\">In utero drug or toxin exposure (eg, alcohol, tobacco, marijuana, cocaine, heroin, antineoplastic agents, antiepileptic agents, radiation, toluene)</td> </tr> <tr> <td class=\"indent1\">Perinatal insult (eg, hypoglycemia, hypothyroidism, hypopituitarism, hypoadrenalism)</td> </tr> <tr> <td class=\"indent1\">Anoxia/ischemia</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75479 Version 7.0</div></div></div>"},"75481":{"type":"graphic_picture","displayName":"Post-fistula excision with a circumareolar incision","title":"Post-fistula excision with a circumareolar incision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post-fistula excision with a circumareolar incision</div><div class=\"cntnt\"><img style=\"width:396px; height:320px;\" src=\"images/PC/75481_Mammary_duct_fistula_D.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fistulectomy through a circumareolar incision produces a satisfactory cosmetic outcome and is the preferred approach.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 75481 Version 5.0</div></div></div>"},"75483":{"type":"graphic_picture","displayName":"Cryptococcus neoformans Sabouraud agar","title":"<EM>Cryptococcus neoformans</EM> on Sabouraud agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Cryptococcus neoformans</EM> on Sabouraud agar</div><div class=\"cntnt\"><img style=\"width:378px; height:240px;\" src=\"images/ID/75483_CneoformansSabouraudsaga.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Culture of <EM>Cryptococcus neoformans </EM>on Sabouraud agar.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 75483 Version 3.0</div></div></div>"},"75487":{"type":"graphic_table","displayName":"Acute ischemic stroke syndromes","title":"Acute ischemic stroke syndromes according to vascular territory","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute ischemic stroke syndromes according to vascular territory</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Artery involved</td> <td class=\"subtitle1\">Syndrome</td> </tr> <tr class=\"divider_bottom\"> <td>Anterior cerebral artery</td> <td> <p>Motor and/or sensory deficit (leg &#62; face, arm)</p> <p>Grasp, sucking reflexes</p> Abulia, paratonic rigidity, gait apraxia</td> </tr> <tr class=\"divider_bottom\"> <td>Middle cerebral artery</td> <td> <p>Dominant hemisphere: aphasia, motor and sensory deficit (face, arm &#62; leg &#62; foot), may be complete hemiplegia if internal capsule involved, homonymous hemianopia</p> Non-dominant hemisphere: neglect, anosognosia, motor and sensory deficit (face, arm &#62; leg &#62; foot), homonymous hemianopia</td> </tr> <tr class=\"divider_bottom\"> <td>Posterior cerebral artery</td> <td>Homonymous hemianopia; alexia without agraphia (dominant hemisphere); visual hallucinations, visual perseverations (calcarine cortex); sensory loss, choreoathetosis, spontaneous pain (thalamus); III nerve palsy, paresis of vertical eye movement, motor deficit (cerebral peduncle, midbrain)</td> </tr> <tr class=\"divider_bottom\"> <td>Penetrating vessels</td> <td> <p>Pure motor hemiparesis (classic lacunar syndromes)</p> <p>Pure sensory deficit</p> <p>Pure sensory-motor deficit</p> <p>Hemiparesis, homolateral ataxia</p> Dysarthria/clumsy hand</td> </tr> <tr class=\"divider_bottom\"> <td>Vertebrobasilar</td> <td> <p>Cranial nerve palsies</p> <p>Crossed sensory deficits</p> <p>Diplopia, dizziness, nausea, vomiting, dysarthria, dysphagia, hiccup</p> <p>Limb and gait ataxia</p> <p>Motor deficit</p> <p>Coma</p> Bilateral signs suggest basilar artery disease</td> </tr> <tr> <td>Internal carotid artery</td> <td>Progressive or stuttering onset of MCA syndrome, occasionally ACA syndrome as well if insufficient collateral flow</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75487 Version 6.0</div></div></div>"},"75488":{"type":"graphic_figure","displayName":"Malignant polyp biopsy","title":"Malignant polyp","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Malignant polyp</div><div class=\"cntnt\"><img style=\"width:516px; height:403px;\" src=\"images/GAST/75488_Malignant_polyp_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration showing that biopsy of a polyp containing a malignant focus is inadequate for excluding malignancy.</div><div id=\"graphicVersion\">Graphic 75488 Version 2.0</div></div></div>"},"75490":{"type":"graphic_table","displayName":"Hidradenitis suppurativa - associated disorders","title":"Disorders associated with hidradenitis suppurativa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with hidradenitis suppurativa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Autoimmune/inflammatory disorders</td> </tr> <tr> <td>Metabolic syndrome</td> </tr> <tr> <td>Crohn disease</td> </tr> <tr> <td>Ulcerative colitis</td> </tr> <tr> <td>SAPHO syndrome*</td> </tr> <tr> <td>Pyoderma gangrenosum</td> </tr> <tr> <td>Beh&#231;et's disease</td> </tr> <tr> <td>Spondylarthropathy</td> </tr> <tr> <td>Acne conglobata alone or in the setting of the follicular occlusion triad<sup>&#182;</sup></td> </tr> <tr> <td>PAPASH syndrome<sup>&#916;</sup></td> </tr> <tr> <td>PASH&nbsp;syndrome<sup>â&#9674;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td>Squamous cell carcinoma</td> </tr> <tr> <td>Adenocarcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic disorders</td> </tr> <tr> <td>Pachyonychia congenita</td> </tr> <tr> <td>Dowling-Degos disease</td> </tr> <tr> <td>Keratitis-ichthyosis-deafness (KID) syndrome</td> </tr> <tr> <td>Down syndrome</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*&nbsp;SAPHO: Synovitis, acne, pustulosis, hyperostosis, osteitis<br />Â¶&nbsp;The follicular occlusion triad consists of hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp.<br />Î PAPASH: Pyogenic arthritis, pyoderma gangrenosum, acne, and suppurative hidradenitis<br />â PASH: Pyoderma gangrenosum, acne, and suppurative hidradenitis</div><div class=\"graphic_reference\">Data from: Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2:9.</div><div id=\"graphicVersion\">Graphic 75490 Version 4.0</div></div></div>"},"75491":{"type":"graphic_algorithm","displayName":"Rx chronic AF rate control","title":"Management algorithm of permanent atrial fibrillation - rate control","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Management algorithm of permanent atrial fibrillation - rate control</div><div class=\"cntnt\"><img style=\"width:510px; height:351px;\" src=\"images/CARD/75491_Rx_chronic_AF_rate_control.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75491 Version 1.0</div></div></div>"},"75493":{"type":"graphic_diagnosticimage","displayName":"Radiographic appearance of a thymic carcinoid on CT scan","title":"Radiographic appearance of a thymic carcinoid tumor on computed tomography (CT) scanning","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Radiographic appearance of a thymic carcinoid tumor on computed tomography (CT) scanning</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/75493_CT_thymic_carcinoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial contrast-enhanced CT image of the chest showing a homogeneously enhancing anterior mediastinal mass encasing the great vessels and extending to the anterior chest wall, consistent with a pathologically proven thymic carcinoid tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: Elsayes KM, Menias CO, Bowerson M, et al. Imaging of carcinoid tumors: Spectrum of findings with pathologic and clinical correlations. J Comput Assist Tomogr 2011; 35:72. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75493 Version 6.0</div></div></div>"},"75494":{"type":"graphic_table","displayName":"Lymphomatoid papulosis differential","title":"Differential diagnosis of lymphomatoid papulosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of lymphomatoid papulosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">LyP</td> <td class=\"subtitle1\">Systemic ALCL</td> <td class=\"subtitle1\">Mycosis fungoides</td> <td class=\"subtitle1\">Pityriasis lichenoides</td> <td class=\"subtitle1\">Arthropod bite</td> <td class=\"subtitle1\">Scabies</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Clinical</strong></td> <td>Self-healing papulonodular skin lesions</td> <td>Frequent secondary skin lesions, lymphadenopathy B symptoms</td> <td>Scaling erythematous patches, plaques, tumors, +/&ndash; lymphadenopathy</td> <td>Scaling erythematous hemorrhagic lesions</td> <td>Exposure</td> <td> <p>Itchy lesions</p> Responds well to scabies treatment</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Histopathology/ immunophenotype</strong></td> <td>Atypical CD30, CD4+ cells surrounded by inflammatory cells</td> <td> <p>Lack of epidermotropic cerebriform cells</p> ALK+, EMA+; ALK&ndash; in patients over 30</td> <td> <p>Epidermotropism of cerebriform cells</p> CD30+ with large cell transformation</td> <td> <p>Interface dermatitis, necrotic keratinocytes, extravasated erythrocytes</p> CD8&#62;CD4, few CD30+ cells</td> <td> <p>Punctum, insect parts</p> <p>Polymorphous</p> <p>Inflammation</p> CD30+ cells may be present</td> <td> <p>Presence of mite</p> CD30+ cells and B cells present</td> </tr> <tr> <td><strong>Genetics</strong></td> <td> <p>Clonal in 60%</p> <p>Aneuploidy of type A</p> <p>Lack of t(2;5)</p> <p>Recurrent&nbsp;rearrangement of 6p25.3&nbsp;</p> <p>&nbsp;</p> </td> <td> <p>t(2;5) often present</p> <p>No IRF4 translocation</p> Clonal <em>TCR</em> rearrangement</td> <td> <p>Lack of t(2;5)</p> Complex karyotype, clonal or oligoclonal <em>TCR</em> rearrangement</td> <td>Clonal <em>TCR</em> rearrangement in 50 percent</td> <td>No abnormalities</td> <td>No abnormalities</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALK: anaplastic lymphoma kinase; EMA: epithelial membrane antigen; TCR: T cell receptor.</div><div id=\"graphicVersion\">Graphic 75494 Version 6.0</div></div></div>"},"75497":{"type":"graphic_picture","displayName":"Punct epithelial erosions","title":"Dry eye disease with punctate epithelial erosions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dry eye disease with punctate epithelial erosions</div><div class=\"cntnt\"><img style=\"width:366px; height:494px;\" src=\"images/PC/75497_Punct_epithelial_erosions.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75497 Version 1.0</div></div></div>"},"75498":{"type":"graphic_diagnosticimage","displayName":"Pulmonary LAM PA","title":"Pulmonary lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:334px; height:362px;\" src=\"images/PULM/75498_Pulmonary_LAM_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior roentgenogram in a 37-year-old woman with pulmonary lymphangioleiomyomatosis shows normal lung volume and difficult to see cystic changes in all lung zones.</div><div class=\"graphic_reference\">Courtesy of Robert S Crausman, MD and Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 75498 Version 2.0</div></div></div>"},"75499":{"type":"graphic_table","displayName":"Timing of withdrawal","title":"Timing of alcohol withdrawal syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Timing of alcohol withdrawal syndromes</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Syndrome\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Clinical findings\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Onset after last drink\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Minor withdrawal</td>\r\n  \r\n   <td>Tremulousness, mild anxiety, headache, diaphoresis, palpitations, anorexia, GI upset; Normal mental status</td>\r\n  \r\n   <td>6 to 36 hours</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Seizures</td>\r\n  \r\n   <td>Single or brief flurry of generalized, tonic-clonic seizures, short post-ictal period; Status epilepticus rare</td>\r\n  \r\n   <td>6 to 48 hours</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Alcoholic hallucinosis</td>\r\n  \r\n   <td>Visual, auditory, and/or tactile hallucinations with intact orientation and normal vital signs</td>\r\n  \r\n   <td>12 to 48 hours</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Delirium tremens</td>\r\n  \r\n   <td>Delirium, agitation, tachycardia, hypertension, fever, diaphoresis</td>\r\n  \r\n   <td>48 to 96 hours</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 75499 Version 1.0</div></div></div>"},"75500":{"type":"graphic_diagnosticimage","displayName":"DISH radiographs cervical spine","title":"Cervical spine in diffuse idiopathic skeletal hyperostosis","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Cervical spine in diffuse idiopathic skeletal hyperostosis</div><div class=\"cntnt\"><img style=\"width:488px; height:260px;\" src=\"images/RHEUM/75500_DISHradiographscervicals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral views of the cervical spine in two individuals with DISH. The disc height is well preserved in both. The individual with more extensive involvement (right panel) complained of mild dysphagia.</div><div class=\"graphic_footnotes\">DISH: diffuse idiopathic skeletal hyperostosis.</div><div class=\"graphic_reference\">Courtesy of John Esdaile, MD.</div><div id=\"graphicVersion\">Graphic 75500 Version 3.0</div></div></div>"},"75501":{"type":"graphic_figure","displayName":"Heart failure action plan - page 2","title":"Heart failure action plan - page 2","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Heart failure action plan - page 2</div><div class=\"cntnt\"><img style=\"width:592px; height:792px;\" src=\"images/PI/75501_Heart_failure_chart_2_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Based on the Heart Failure Action Plan provided by Access III of the Lower Cape Fear, Inc.</div><div id=\"graphicVersion\">Graphic 75501 Version 4.0</div></div></div>"},"75502":{"type":"graphic_waveform","displayName":"RNS study MG","title":"Repetitive nerve stimulation (RNS) study in myasthenia gravis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repetitive nerve stimulation (RNS) study in myasthenia gravis</div><div class=\"cntnt\"><img style=\"width:432px; height:141px;\" src=\"images/NEURO/75502_RNS_study_MG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Successive compound motor action potentials (CMAPs) from the abductor pollicis brevis muscle are displayed after six stimuli at 3 Hertz. A decremental response (ie, a decline in the response amplitude) is seen. It is maximal at 38 percent by the fourth response in this example. Sensitivity: 5 mV/div; Sweep speed: 5 msec/div.</div><div id=\"graphicVersion\">Graphic 75502 Version 2.0</div></div></div>"},"75504":{"type":"graphic_picture","displayName":"Weighted pendulum PI","title":"Weighted pendulum stretch exercise","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Weighted pendulum stretch exercise</div><div class=\"cntnt\"><img style=\"width:523px; height:596px;\" src=\"images/PI/75504_Weighted_pendulum_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A weight of 5 to 10 pounds is held lightly in the hand (a filled gallon container weighs eight pounds). The muscles of the shoulder should be relaxed! The arm is kept vertical and close to the body (bending over too far may cause pinching of the rotator cuff tendons). The arm is allowed to swing back and forth or in a small circle (no greater than 12 inches [30 centimeters] in diameter). A properly performed stretching exercise may cause a deep achy pain, either in the armpit or down the inner aspect of the arm. This exercise can be performed just as effectively while sitting. The exercise should not be performed in people with acromioclavicular separation, glenohumeral dislocation, and hypermobility.</div><div id=\"graphicVersion\">Graphic 75504 Version 4.0</div></div></div>"},"75505":{"type":"graphic_table","displayName":"Antibody tests celiac","title":"Sensitivity and specificity of antibody tests for celiac disease in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity of antibody tests for celiac disease in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Sensitivity, (percent)</td> <td class=\"subtitle1\">Specificity, (percent)</td> </tr> <tr> <td>Tissue transglutaminase; tTG&nbsp;(IgA, human)<sup>[1-3]</sup></td> <td>90 to 100</td> <td>95 to 100</td> </tr> <tr> <td>Anti-endomysial antibody (IgA)<sup>[1]</sup></td> <td>93 to 100</td> <td>98 to 100</td> </tr> <tr> <td>Deamidated gliadin peptide; DGP (IgA)*<sup>[4]</sup></td> <td>80&nbsp;to 91</td> <td>91&nbsp;to 95</td> </tr> <tr> <td>Deamidated gliadin peptide; DGP (IgG)*<sup>[4]</sup></td> <td>88&nbsp;to 95</td> <td>86&nbsp;to 98</td> </tr> <tr> <td>Antigliadin antibody IgA<sup><span style=\"font-size: 13px;\">[1]</span></sup>&nbsp;</td> <td>52 to 100&nbsp;</td> <td>72 to 100&nbsp;</td> </tr> <tr> <td>Antigliadin antibody IgG<sup><span style=\"font-size: 13px;\">[1]</span></sup>&nbsp;</td> <td>83 to 100&nbsp;</td> <td>47 to 94&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Sensitivity and specificity&nbsp;of DGP may be better in children younger than two years of age as compared with tTG or anti-endomysial antibodies.<SUP>[5]</SUP></div><div class=\"graphic_reference\">References <ol> <li>Hill, ID. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? Gastroenterology 2005; 128 (4 Suppl 1):S25 </li> <li>Basso, D, Guariso, G, Fasolo, M, et al. A new indirect chemiluminescent immunoassay to measure anti-tissue transglutaminase antibodies. J Pediatr Gastroenterol Nutr 2006; 43:613. </li> <li>Lewis NR, Scott BB. Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther 2010; 31:73. </li> <li>Agardh D. Antibodies against synthetic deamidated gliadin peptides and tissue transglutaminase for the identification of childhood celiac disease. Clin Gastroenterol Hepatol 2007; 5:1276.</li> <li>Mubarak A, Gmelig-Meyling FHJ, Wolters VM et al. Immunoglobulin G antibodies against deamidated-gliadin-peptides outperform anti-endomysium and tissue transglutaminase antibodies in children &lt;2 years age. APMIS 2011; 119:894. </li> </ol></div><div id=\"graphicVersion\">Graphic 75505 Version 4.0</div></div></div>"},"75506":{"type":"graphic_picture","displayName":"Vincents curtsy","title":"Holding maneuvers in children with voiding dysfunction","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Holding maneuvers in children with voiding dysfunction</div><div class=\"cntnt\"><img style=\"width:524px; height:591px;\" src=\"images/PEDS/75506_Vincents_curtsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image courtesy of Dr. Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 75506 Version 2.0</div></div></div>"},"75509":{"type":"graphic_diagnosticimage","displayName":"MRI of temporal lobe glioma","title":"MRI of temporal lobe glioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of temporal lobe glioma</div><div class=\"cntnt\"><img style=\"width:285px; height:356px;\" src=\"images/PEDS/75509_Temporal_lobe_glioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2 MRI (axial view) of focal left temporal lobe hyperintensity (arrow) caused by a glioma in a nine-year-old girl with the new onset of partial complex seizures.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 75509 Version 4.0</div></div></div>"},"75510":{"type":"graphic_picture","displayName":"Herpetic whitlow","title":"Herpetic whitlow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpetic whitlow</div><div class=\"cntnt\"><img style=\"width:288px; height:358px;\" src=\"images/DERM/75510_Herpetic_whitlow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In addition to erythema, swelling, and pain, herpetic whitlow is characterized by the presence of vesicular or pustular lesions. Patients may also experience fever, lymphadenitis, and epitrochlear or axillary lymphadenopathy.</div><div class=\"graphic_reference\">Reproduced with permission from: Nikkels AF, Peirard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am J Clin Dermatol 2002; 3:479. Copyright &#169; 2002 Adis International.</div><div id=\"graphicVersion\">Graphic 75510 Version 5.0</div></div></div>"},"75511":{"type":"graphic_table","displayName":"Physiologic values in postop","title":"Expected hemodynamic variables in the immediate post-operative period","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected hemodynamic variables in the immediate post-operative period</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Parameter</td>\n\n      <td class=\"subtitle1\">Expected value</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mean arterial pressure (MAP)</td>\n\n      <td>60 - 90 mmHg</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Systolic blood pressure (SBP)</td>\n\n      <td>90 - 140 mmHg</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Right atrial pressure (RAP)</td>\n\n      <td>5 - 15 mmHg</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary artery wedge pressure (PAWP)</td>\n\n      <td>10 - 15 mmHg</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac index (CI)</td>\n\n      <td>2.2 - 4.4 L/min/M2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Systemic vascular resistance (SVR)</td>\n\n      <td>1400 - 2800 dyn-s-cm5</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75511 Version 1.0</div></div></div>"},"75513":{"type":"graphic_figure","displayName":"Port placement right colectomy","title":"Port placement right colectomy*","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Port placement right colectomy*</div><div class=\"cntnt\"><img style=\"width:457px; height:587px;\" src=\"images/SURG/75513_Ports_lap_right_colectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An open technique is used to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through this port. Two ports are placed in the lower abdomen and one or more 5 mm ports are placed in the upper midline. The surgeon and the assistant stand on the patient's left side.<br> Either the suprapubic port or the left lower quadrant port can be used to introduce the surgical stapler for transection of the colon. The upper midline port is useful for mobilizing the hepatic flexure. The resected colon can be removed through a mini-laparotomy at the umbilicus or through a small Pfannenstiel incision.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 75513 Version 4.0</div></div></div>"},"75514":{"type":"graphic_table","displayName":"X-linked agammaglobulinemia","title":"Diagnostic criteria for X-linked agammaglobulinemia (XLA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for X-linked agammaglobulinemia (XLA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitive diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male patient with less than 2% CD19+ B cells and at least one of the following:</td> </tr> <tr> <td class=\"sublist1\">1. Mutation in Btk.</td> </tr> <tr> <td class=\"sublist1\">2. Absent Btk mRNA on Northern blot analysis of neutrophils or monocytes.</td> </tr> <tr> <td class=\"sublist1\">3. Absent Btk protein in monocytes or platelets.</td> </tr> <tr> <td class=\"sublist1\">4. Maternal cousins, uncles, or nephews with less than 2% CD19+ B cells.</td> </tr> <tr> <td class=\"subtitle1_single\">Probable diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male patient with less than 2% CD19+ B cells in whom all of the following are positive:</td> </tr> <tr> <td class=\"sublist1\">1. Onset of recurrent bacterial infections in the first five years of life.</td> </tr> <tr> <td class=\"sublist1\">2. Serum IgG, IgM, and IgA more than 2 SD below normal for age.</td> </tr> <tr> <td class=\"sublist1\">3. Absent isohemagglutinins and/or poor response to vaccines.</td> </tr> <tr> <td class=\"sublist1\">4. Other causes of hypogammaglobulinemia have been excluded.</td> </tr> <tr> <td class=\"subtitle1_single\">Possible diagnosis*</td> </tr> <tr> <td class=\"sublist1_start\">Male patient with less than 2% CD19+ B cells in whom other causes of hypogammaglobulinemia have been excluded and at least one of the following is positive:</td> </tr> <tr> <td class=\"sublist1\">1. Onset of recurrent bacterial infections in the first five years of life.</td> </tr> <tr> <td class=\"sublist1\">2. Serum IgG, IgM, and IgA more than 2 SD below normal for age.</td> </tr> <tr> <td class=\"sublist1\">3. Absent isohemagglutinins.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CD: cluster of differentiation; BtK: Bruton tyrosine kinase; mRNA: messenger ribonucleic acid; IgG: immunoglobulin G; IgM: immunoglobulin M; IgA: immunoglobulin A; SD: standard deviation.<br />* Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85% probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some, but not all, of the characteristic clinical or laboratory findings of a particular disorder.</div><div class=\"graphic_reference\">From: Conley ME, Notarangelo LD, Etzioni A. Clin Immunol 1999; 93:190.</div><div id=\"graphicVersion\">Graphic 75514 Version 4.0</div></div></div>"},"75516":{"type":"graphic_table","displayName":"Endometriosis pain by stage","title":"Percentage of endometriosis patients with pain according to stage of disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentage of endometriosis patients with pain according to stage of disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Stage </td>\n\n      <td class=\"subtitle1\"> Occurrence of pain,&nbsp; percent</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td> I</td>\n\n      <td>40</td>\n\n    </tr>\n\n    <tr>\n\n      <td> II</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td> III</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td> IV </td>\n\n      <td>12</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Fedele, L, Parazzini, F, Bianchi, S, et al. Fertil Steril 1990; 53:155.</div><div id=\"graphicVersion\">Graphic 75516 Version 1.0</div></div></div>"},"75517":{"type":"graphic_figure","displayName":"Rectal ultrasound transducer with needle guide","title":"Rectal ultrasound transducer with needle guide","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Rectal ultrasound transducer with needle guide</div><div class=\"cntnt\"><img style=\"width:471px; height:618px;\" src=\"images/SURG/75517_Rectal-ultrasound-transducer-with-needle-guide.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The needle guide is attached directly to the transrectal ultrasound transducer.</div><div class=\"graphic_reference\">Courtesy of RN Alheid.</div><div id=\"graphicVersion\">Graphic 75517 Version 2.0</div></div></div>"},"75518":{"type":"graphic_picture","displayName":"Unstable comminuted distal phalanx shaft fracture","title":"Unstable comminuted distal phalanx shaft fracture with nail bed laceration","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Unstable comminuted distal phalanx shaft fracture with nail bed laceration</div><div class=\"cntnt\"><img style=\"width:514px; height:301px;\" src=\"images/SURG/75518_Unstab_comm_fing_shaft_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shaft fractures are usually stable and can be managed with a simple splint that immobilizes the distal interphalangeal joint (DIPJ) but leaves the proximal interphalangeal joint (PIPJ) free. However, comminution of the distal phalanx shaft can render the fracture unstable. In such cases, open reduction with internal fixation (ORIF) is needed. This figure shows a comminuted unstable distal phalanx fracture requiring ORIF.</div><div id=\"graphicVersion\">Graphic 75518 Version 6.0</div></div></div>"},"75520":{"type":"graphic_figure","displayName":"Egg donor synchronization schedule","title":"Synchronization schedule between an egg donor and female recipient","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Synchronization schedule between an egg donor and female recipient</div><div class=\"cntnt\"><img style=\"width:568px; height:440px;\" src=\"images/ENDO/75520_Egg_donor_synch_sched_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic figure demonstrating a typical synchronization schedule between an egg donor and the female recipient. Cleavage stage embryos are transferred on day 3 and blastocysts on day 5 post-fertilization.</div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; SC: subcutaneous; IM: intramuscular; hCG: human chorionic gonadotropin.</div><div id=\"graphicVersion\">Graphic 75520 Version 3.0</div></div></div>"},"75521":{"type":"graphic_diagnosticimage","displayName":"Clavicle fracture with callus","title":"Clavicle fracture with callus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Clavicle fracture with callus</div><div class=\"cntnt\"><img style=\"width:504px; height:254px;\" src=\"images/EM/75521_Clav_fx_callus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This close up view from a plain radiograph shows a completely displaced middle third fracture, two weeks after injury. In this young male, early callus is already present along the periosteum between the two fracture fragments (arrow). Because the injury was two weeks old and healing was well underway, conservative treatment was instituted.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 75521 Version 2.0</div></div></div>"},"75523":{"type":"graphic_waveform","displayName":"ECG with atrial fibrillation with preexcitation in WPW syndrome","title":"12-lead electrocardiogram showing atrial fibrillation with preexcitation in Wolff-Parkinson-White (WPW) syndrome","html":"<div class=\"graphic normal\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram showing atrial fibrillation with preexcitation in Wolff-Parkinson-White (WPW) syndrome</div><div class=\"cntnt\"><img style=\"width:550px; height:313px;\" src=\"images/CARD/75523_Atrial_fib_in_WPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG in this patient with Wolff-Parkinson-White syndrome shows atrial fibrillation with a rapid ventricular response of over 300 beats per minute and fully aberrant QRS complexes. This results from rapid atrioventricular transmission of impulses via a rapidly conducting accessory pathway.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 75523 Version 6.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"75525":{"type":"graphic_table","displayName":"INH reactions","title":"Adverse reactions to chronic INH","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adverse reactions to chronic INH</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Hepatotoxicity</td>\n</tr>\n\n<tr>\n<td>Peripheral neuropathy</td>\n</tr>\n\t\n<tr>\n<td>Lupus-like syndrome</td>\n</tr>\n\n<tr>\n<td>Flushing</td>\n</tr>\n\n<tr>\n<td>Hypersensitivity</td>\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75525 Version 1.0</div></div></div>"},"75526":{"type":"graphic_picture","displayName":"Follicular thyroid cancer","title":"Follicular thyroid cancer: Appearance on surgical histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Follicular thyroid cancer: Appearance on surgical histology</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/ENDO/75526_follicular_thyroid_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen demonstrating thyroid epithelium with follicular differentiation extending through the capsule of the tumor and invading a blood vessel.</div><div class=\"graphic_reference\">Courtesy of Stephanie L Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75526 Version 4.0</div></div></div>"},"75528":{"type":"graphic_table","displayName":"Pretreatment evaluation MF","title":"Recommended evaluation/initial staging of the patient with mycosis fungoides/SÃ©zary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended evaluation/initial staging of the patient with mycosis fungoides/SÃ©zary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Evaluation and staging </td> </tr> <tr> <td class=\"subtitle2_single\">Complete physical examination, including: </td> </tr> <tr> <td class=\"indent1\">Determination of type(s) of skin lesions </td> </tr> <tr> <td class=\"indent1\">Estimate percentage of BSA involved by patches, plaques, and tumor lesions and note any ulceration or folliculocentricity of lesions. The patient's palm (including all fingers) is approximately 1 percent of BSA.* </td> </tr> <tr> <td class=\"indent1\">Identification of any palpable lymph node, especially those &#8805;1.5 cm in largest diameter or firm, irregular, clustered, or fixed </td> </tr> <tr> <td class=\"indent1\">Identification of any organomegaly </td> </tr> <tr> <td class=\"subtitle2_single\">Skin biopsy </td> </tr> <tr> <td class=\"indent1\">Essential: At least two skin biopsies should be obtained of different anatomic areas and morphology for H&#38;E evaluation. If only one biopsy can be obtained, then the lesion that has the most scaling and induration should be chosen. </td> </tr> <tr> <td class=\"indent1\">If needed: Immunophenotyping to include at least the following markers: CD2, CD3, CD4, CD5, CD7, and CD8, beta-F1 (to confirm alpha-beta TCR), and a B cell marker, such as CD20; CD30 may also be indicated in cases where lymphomatoid papulosis, anaplastic lymphoma, or large-cell transformation is considered.</td> </tr> <tr> <td class=\"indent1\">If needed: Evaluation for clonality of TCR gene rearrangement.</td> </tr> <tr> <td class=\"subtitle2_single\">Blood tests </td> </tr> <tr> <td class=\"indent1\">CBC with manual differential (assess for S&#233;zary cells), comprehensive chemistries, LDH </td> </tr> <tr> <td class=\"indent1\">Analysis for abnormal lymphocytes by either S&#233;zary cell count with determination of the absolute number of S&#233;zary cells and/or flow cytometry (including CD4<sup>+ </sup>/ CD7<sup>-</sup> or CD4<sup>+ </sup>/ CD26<sup>-</sup>)</td> </tr> <tr> <td class=\"indent1\">If needed: TCR gene rearrangement and relatedness to any clone in skin </td> </tr> <tr> <td class=\"subtitle2_single\">Radiologic tests </td> </tr> <tr> <td class=\"indent1\">Radiologic tests are not necessary in patients with T<sub>1</sub>N<sub>0</sub>B<sub>0</sub> or T<sub>2a</sub>N<sub>0</sub>B<sub>0 </sub>stage disease who are otherwise healthy and without complaints directed to a specific organ system. </td> </tr> <tr> <td class=\"indent1\">In all other patients, contrast-enhanced CT scan of chest, abdomen, and pelvis (neck included if clinically indicated) or whole body integrated PET-CT is recommended to further evaluate any potential lymphadenopathy, visceral involvement, or abnormal laboratory tests; in patients unable to safely undergo CT scans, MRI may be substituted. </td> </tr> <tr> <td class=\"subtitle2_single\">Lymph node biopsy </td> </tr> <tr> <td class=\"indent1\">Excisional biopsy is indicated in those patients with a node that is at least 1.5 cm (confirmed by imaging) in diameter; and/or is firm, irregular, clustered, or fixed; and/or significantly PET avid. </td> </tr> <tr> <td class=\"indent1\">Site of biopsy: Preference is given to the largest lymph node draining an involved area of the skin or if FDG-PET scan data are available, the node with highest standardized uptake value. </td> </tr> <tr> <td class=\"indent1\">Analysis: Pathologic assessment by light microscopy, flow cytometry, and TCR gene rearrangement.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BSA: body surface area; TCR: T cell receptor; CBC: complete blood count; LDH: lactate dehydrogenase;&nbsp;CT: computed tomography; PET-CT: positron emission tomography/computed tomography; MRI: magnetic resonance imaging; FDG-PET: <SUP>18</SUP>F-fluoro-2-deoxyglucose positron emission tomography.<br />*A more specific BSA calculation can be calculated using the \"mSWAT\" system: mSWAT = (percent BSA of patches) (1) + (percent BSA of plaques) (2) + (percent BSA of tumor) (4).</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and SÃ©zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713.</LI></OL>This table was created using research originally published in Blood. Modified from: Prince HM, Whittaker S, Hoppe RT. How I treat my mycosis fungoides and SÃ©zary syndrome. Blood 2009; 114:4337. Copyright Â© 2009 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 75528 Version 5.0</div></div></div>"},"75529":{"type":"graphic_diagnosticimage","displayName":"Postop CBD stricture stented","title":"Cholecystectomy-related stricture treated by stent placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholecystectomy-related stricture treated by stent placement</div><div class=\"cntnt\"><img style=\"width:252px; height:373px;\" src=\"images/GAST/75529_Postop_CBD_stricture_stente.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two 10 French stents have been placed side by side. the patient will receive periodic three monthly stent changes for 12 months.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 75529 Version 4.0</div></div></div>"},"75530":{"type":"graphic_diagnosticimage","displayName":"Perinephric abscess CT","title":"Perinephric abscess on computed tomography scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perinephric abscess on computed tomography scan</div><div class=\"cntnt\"><img style=\"width:369px; height:277px;\" src=\"images/ID/75530_Perinephric_abscess_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan shows a large perinephric phlegmon with loculation adjacent to the right kidney.</div><div class=\"graphic_reference\">Courtesy of Olivier Helenon, MD, Hopital Necker, Paris.</div><div id=\"graphicVersion\">Graphic 75530 Version 3.0</div></div></div>"},"75531":{"type":"graphic_figure","displayName":"Taenia solium life cycle","title":"<EM>Taenia solium</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Taenia solium</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:504px; height:615px;\" src=\"images/ID/75531_Taenia_solium_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cysticercosis is an infection of both humans and pigs with the larval stages of the cestode <EM>Taenia solium</EM>. This infection is caused by ingestion of eggs shed in the feces of a human tapeworm carrier <STRONG>(1)</STRONG>. Pigs and humans become infected by ingesting eggs or gravid proglottids <STRONG>(2,7)</STRONG>. Humans are infected by ingestion of eggs spread directly from another tapeworm carrier, from the environment, or by autoinfection. In the latter case, humans infected with adult <EM>T. solium </EM>can ingest eggs produced by that tapeworm, most likely by adherence of eggs to the hands and subsequent spread from hand to mouth. Once eggs are ingested, oncospheres hatch in the intestine <STRONG innerHtml>(3,8)</STRONG>, invade the intestinal wall, and migrate to striated muscles as well as the brain and other tissues, where they develop into cysticerci <STRONG>(9)</STRONG>. In humans, cysts may cause serious sequellae if they localize in the brain, resulting in neurocysticercosis. The parasite life cycle is completed, resulting in human tapeworm infection, when humans ingest undercooked pork containing cysticerci <STRONG>(4)</STRONG>. Cysts evaginate and attach to the small intestine by their scolex <STRONG>(5)</STRONG>. Adult tapeworms develop, (up to 2 to 7 m in length and produce less than 1000 proglottids, each with approximately 50,000 eggs) and reside in the small intestine for years <STRONG>(6)</STRONG>.</div><div class=\"graphic_reference\">Cysticercosis. http://www.dpd.cdc.gov/ dpdx/HTML/Cysticercosis.htm.</div><div id=\"graphicVersion\">Graphic 75531 Version 2.0</div></div></div>"},"75535":{"type":"graphic_picture","displayName":"Stomatocytes","title":"Stomatocytosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stomatocytosis</div><div class=\"cntnt\"><img style=\"width:360px; height:244px;\" src=\"images/HEME/75535_Stomatocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear showing multiple stomatocytes characterized by a mouth-shaped area of central pallor.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 75535 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"75536":{"type":"graphic_table","displayName":"ASCO summary guideline recs","title":"Summary of the joint ASCO/CAP guideline recommendations for assessment of HER2 status","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of the joint ASCO/CAP guideline recommendations for assessment of HER2 status</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Optimal algorithm for HER2 testing</td> </tr> <tr> <td class=\"indent1\">Positive for HER2 is either IHC HER2 3+ (defined as uniform intense membrane staining of &#62;10 percent of invasive tumor cells) or FISH amplified (ratio of HER2 to CEP17 of &#62;2.0 or &#60;2.0 plus average HER2 gene copy number &#62;6 signals/cell)</td> </tr> <tr> <td class=\"indent1\">Equivocal for HER2 is defined as either IHC 2+ or FISH ratio of &#60;2.0 or average HER2 gene copy number four to six signals/cell</td> </tr> <tr> <td class=\"indent1\">Negative for HER2 is defined as either IHC 0-1+ or FISH ratio of &#60;2.0 or average HER2 gene copy number of &#60;4 signals/nucleus for test systems without an internal control probe</td> </tr> <tr> <td class=\"sublist2_start\">These definitions depend on laboratory documentation of the following:</td> </tr> <tr> <td class=\"sublist2\">1. Proof of initial testing validation</td> </tr> <tr> <td class=\"sublist2\">2. Ongoing internal QA procedures</td> </tr> <tr> <td class=\"sublist2\">3. External proficiency testing</td> </tr> <tr> <td class=\"sublist2\">Routine periodic performance monitoring</td> </tr> <tr> <td class=\"indent1\">If technical issues prevent one or both tests performed from being reported as positive, negative, or equivocal, the result should be reported as HER2 test result is indeterminate</td> </tr> <tr> <td class=\"subtitle1_single\">Optimal FISH testing requirements</td> </tr> <tr> <td class=\"sublist2_start\">Test is rejected and repeated if:</td> </tr> <tr> <td class=\"sublist2\">Controls are not as expected</td> </tr> <tr> <td class=\"sublist2\">Observer cannot find and count as least two areas of invasive tumor</td> </tr> <tr> <td class=\"sublist2\">&#62;25 percent of signals are unfavorable due to weak signals</td> </tr> <tr> <td class=\"sublist2\">&#62;10 percent of signals occur over cytoplasm</td> </tr> <tr> <td class=\"sublist2\">Nuclear resolution is poor</td> </tr> <tr> <td class=\"sublist2\">Autofluorescence is strong</td> </tr> <tr> <td class=\"indent1\">The entire ISH slide should be scanned prior to counting at least 20 cells or use IHC to define the areas of potential HER2 amplification</td> </tr> <tr> <td class=\"indent1\">If there is a second population of cells with increased HER2 signals/cell and consists of more than 10 percent of tumor cells on the slide, a separate counting of at least 20 non-overlapping cells must also be performed with this cell population and reported</td> </tr> <tr> <td class=\"indent1\">Counting should compare patterns in normal breast and tumor cells if bright-field ISH is used; if the tumor cell pattern is neither normal nor clearly amplified, expert opinion should be sought</td> </tr> <tr> <td class=\"subtitle1_single\">Optimal IHC testing requirements</td> </tr> <tr> <td class=\"sublist2_start\">Test is rejected and repeated or tested by FISH if:</td> </tr> <tr> <td class=\"sublist2\">Controls are not as expected</td> </tr> <tr> <td class=\"sublist2\">Artifacts involve most of sample</td> </tr> <tr> <td class=\"sublist2\">Sample has strong membrane staining of normal breast ducts (internal controls)</td> </tr> <tr> <td class=\"sublist2_start\">Interpretation follows guideline recommendation</td> </tr> <tr> <td class=\"sublist2\">Positive HER2 result requires homogeneous, dark circumferential (chicken wire) pattern in &#62;10 percent of invasive tumor</td> </tr> <tr> <td class=\"sublist2\">Interpreters have method to maintain consistency and competency</td> </tr> <tr> <td class=\"indent1\">Sample is subjected to confirmatory FISH testing if equivocal based on initial results</td> </tr> <tr> <td class=\"indent1\">Report must include guideline-detailed elements</td> </tr> <tr> <td class=\"subtitle1_single\">Optimal tissue handling requirements</td> </tr> <tr> <td class=\"indent1\">Time from tissue acquisition to fixation should be within one hour; samples from HER2 testing are fixed in 10 percent neutral buffered formalin for 6 to 72 hours; any exceptions to this process must be included in reporting</td> </tr> <tr> <td class=\"indent1\">Samples should be sliced at 5 to 10 mm intervals after appropriate gross inspection and margins designation and placed in sufficient volume of neutral buffered formalin</td> </tr> <tr> <td class=\"indent1\">Sections should ideally not be used for HER2 testing if cut &#62;6 weeks earlier; this may vary with primary fixation or storage conditions</td> </tr> <tr> <td class=\"indent1\">Time to fixation and duration of fixation if available should be recorded for each sample</td> </tr> <tr> <td class=\"subtitle1_single\">Optimal internal validation procedure</td> </tr> <tr> <td class=\"indent1\">Validation of test must be done before test is offered</td> </tr> <tr> <td class=\"indent1\">Laboratories performing these tests should be following all accreditation requirements</td> </tr> <tr> <td class=\"indent1\">Initial testing validation should conform to the published 2010 ASCO/CAP recommendations for IHC testing of ER and RT guidance validation requirements with 20 negative and 20 positive FDA-approved assays and 40 negative and 40 positive for laboratory-developed tests; laboratories are responsible for ensuring the reliability and accuracy of their testing results</td> </tr> <tr> <td class=\"subtitle1_single\">Optimal internal QA procedures</td> </tr> <tr> <td class=\"indent1\">Initial test validation</td> </tr> <tr> <td class=\"indent1\">Ongoing quality control and equipment maintenance</td> </tr> <tr> <td class=\"indent1\">Initial and ongoing laboratory personnel training and competency assessment</td> </tr> <tr> <td class=\"indent1\">Use of standard operating procedures including routine use of control materials</td> </tr> <tr> <td class=\"indent1\">Revalidation of procedure if changed</td> </tr> <tr> <td class=\"indent1\">Ongoing competency assessment and education of pathologists</td> </tr> <tr> <td class=\"subtitle1_single\">Optimal external proficiency assessment</td> </tr> <tr> <td class=\"indent1\">Participation in external proficiency testing program with at least two testing events (mailings)/year</td> </tr> <tr> <td class=\"sublist2_start\">Satisfactory performance requires at least 90 percent correct responses on graded challenges for either test</td> </tr> <tr> <td class=\"sublist2\">Unsatisfactory performance will require laboratory to respond according to accreditation agency program requirements</td> </tr> <tr> <td class=\"subtitle1_single\">Optimal laboratory accreditation</td> </tr> <tr> <td class=\"sublist2_start\">Onsite inspection every other year with annual requirement for self-inspection</td> </tr> <tr> <td class=\"sublist2\">Reviews laboratory validation, procedures, QA results and processes, results and reports</td> </tr> <tr> <td class=\"sublist2\">Unsatisfactory performance results in suspension of laboratory testing for HER2 for that method</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ASCO: American Society of Clinical Oncology; CAP: College of American Pathologists; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; FISH: fluorescent in situ hybridization; CEP17: chromosome 17 centromere; QA: quality assurance.</div><div class=\"graphic_reference\">Revised with information from:<br /><ol>&#xD;&#xA;    <li>Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013. DOI: JCO.2013.50.9984.</li>&#xD;&#xA;</ol>&#xD;&#xA;Modified from: Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Onc 2007; 25:118. Copyright &copy; 2007 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 75536 Version 6.0</div></div></div>"},"75538":{"type":"graphic_figure","displayName":"RTH hormonal response","title":"Pituitary and peripheral tissues responses to the administration of L-T3 in RTH","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Pituitary and peripheral tissues responses to the administration of L-T3 in RTH</div><div class=\"cntnt\"><img style=\"width:577px; height:700px;\" src=\"images/PEDS/75538_RTH_hormonal_response.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Responses to the administration of incremental doses of L-T3 in three representative subjects: with RTH due to TRÎ² gene mutation (left), RTH without a mutation in the TR genes (nonTR RTH, right), and a normal individual (center). The hormone was given in three incremental doses, each for three days.<br />(A) Thyrotroph responses to TSH-releasing hormone (TRH) stimulation. Compared with normal, TSH responses are less suppressible by L-T3.<br />(B) Peripheral tissues responses. Note the stimulation of ferritin and sex hormone binding globulin (SHBG) and the suppression of cholesterol and creatine kinase (CK) in the normal subject. Responses in affected subjects, with or without a TRÎ² gene mutation, were blunted or paradoxical.</div><div class=\"graphic_footnotes\">RTH: resistance to thyroid hormone; TR: thyroid hormone receptor; TR&beta;: thyroid hormone receptor beta gene; TR&alpha;: thyroid hormone receptor alpha gene; TSH: thyroid stimulating hormone; TRH: thyrotropin releasing hormone.</div><div class=\"graphic_reference\">Reproduced with permission from: WWW.THYROIDMANAGER.ORG, the comprehensive free on-line web text-book, Chapter 16d, by Samuel Refetoff, MD, version 7 June 2008.</div><div id=\"graphicVersion\">Graphic 75538 Version 12.0</div></div></div>"},"75539":{"type":"graphic_table","displayName":"Sources and effects of fat","title":"Sources and main effects of dietary fat","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sources and main effects of dietary fat</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of fat</td> <td class=\"subtitle1\">Chief food sources</td> <td class=\"subtitle1\">Leading food contributors in diets of adults in the United States*</td> <td class=\"subtitle1\">Effects on cholesterol</td> <td class=\"subtitle1\">Effects on coronary heart disease</td> </tr> <tr> <td>Trans fatty acids, from partially hydrogenated vegetable oils</td> <td>Stick and full-fat margarine; commercial baked goods; deep-fried foods</td> <td>Fast food; margarines; commercial baked goods (sweet rolls, cookies, donuts)</td> <td>Increases LDL cholesterol, lowers HDL cholesterol</td> <td>Increases risk of coronary heart disease</td> </tr> <tr> <td>Saturated fatty acids</td> <td>Dairy foods; red meat; some plant oils (coconut, palm)</td> <td>Dairy foods, especially cheese, milk, ice cream; red meat</td> <td>Increases total cholesterol</td> <td>May increase risk of coronary heart disease</td> </tr> <tr> <td>Monounsaturated fatty acids</td> <td>Vegetable sources (canola, olive oil); also from meat, dairy</td> <td>Beef; margarines; chicken; olive oil</td> <td>Lowers LDL cholesterol&nbsp;and triglycerides, maintains HDL cholesterol</td> <td>Probably has no association</td> </tr> <tr> <td>Polyunsaturated fatty acids; n-6</td> <td>Safflower, sunflower, and corn oils</td> <td>Mayonnaise; margarines; salad dressing; nuts; chicken; peanut butter</td> <td>Lowers LDL cholesterol, HDL cholesterol, and triglycerides</td> <td>Uncertain</td> </tr> <tr> <td>Polyunsaturated fatty acids; n-3</td> <td> <p>Canola, soybean, flaxseed, walnut oil, wheat germ, vegetables of cabbage family</p> For longer-chain n-3 fatty acids: seafood, especially fatty fish </td> <td>Alpha-linolenic acid (18:3): mayonnaise, salad dressing, margarines, beef; longer-chain n-3: tuna, other dark fish, shrimp</td> <td>Lowers LDL cholesterol&nbsp;and triglycerides, maintains HDL cholesterol</td> <td>May reduce risk of coronary heart disease</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Leading food contributors combines the fatty acid content of the food with the frequency with which individuals eat that food.</div><div class=\"graphic_footnotes\">LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol.<br />* Data from participants in the ongoing Nurses' Health Study (women) and Health Professionals' Follow-up Study (men).</div><div id=\"graphicVersion\">Graphic 75539 Version 8.0</div></div></div>"},"75540":{"type":"graphic_diagnosticimage","displayName":"Nodules in pneumoconiosis CT","title":"Coal worker's pneumoconiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coal worker's pneumoconiosis</div><div class=\"cntnt\"><img style=\"width:304px; height:276px;\" src=\"images/PULM/75540_Nodules_in_pneumoconiosis_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple centrilobular nodules are visible diffusely.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75540 Version 2.0</div></div></div>"},"75541":{"type":"graphic_figure","displayName":"Division of uterosacral ligms","title":"Opening the rectovaginal space during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Opening the rectovaginal space during hysterectomy</div><div class=\"cntnt\"><img style=\"width:509px; height:411px;\" src=\"images/OBGYN/75541_Division_of_uterosacral_lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Opening the rectovaginal space allows clamping and division of uterosacral ligaments.</div><div id=\"graphicVersion\">Graphic 75541 Version 2.0</div></div></div>"},"75542":{"type":"graphic_figure","displayName":"Xerocytosis flow cytometry","title":"Flow cytometry studies in Hereditary xerocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow cytometry studies in Hereditary xerocytosis</div><div class=\"cntnt\"><img style=\"width:321px; height:484px;\" src=\"images/HEME/75542_Xerocytosis_flow_cytometry.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution histograms for red blood cell volume (mean corpuscular volume) and mean cell hemoglobin concentration in a normal control (top) and a patient with hereditary xerocytosis (bottom). Hereditary xerocytosis is characterized by a shift of the mean corpuscular (red cell) volume to higher values, which is indicative of the presence of reticulocytes and younger cells, and of the mean cell hemoglobin concentration to higher values, which is indicative of the presence of hyperchromic cells.</div><div class=\"graphic_reference\">Courtesy of Carlo Brugnara, MD.</div><div id=\"graphicVersion\">Graphic 75542 Version 3.0</div></div></div>"},"75547":{"type":"graphic_figure","displayName":"Direction of flow of cerebrospinal fluid","title":"Direction of flow of cerebrospinal fluid","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Direction of flow of cerebrospinal fluid</div><div class=\"cntnt\"><img style=\"width:542px; height:536px;\" src=\"images/OBGYN/75547_Flow_of_cerebral_spinal_flu.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75547 Version 4.0</div></div></div>"},"75548":{"type":"graphic_picture","displayName":"Ovarian hyperthecosis light","title":"Ovarian hyperthecosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ovarian hyperthecosis</div><div class=\"cntnt\"><img style=\"width:320px; height:258px;\" src=\"images/ENDO/75548_Ovarian_hyperthecosis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph from a woman with ovarian hyperthecosis shows nests of steroidogenically active luteinized theca cells in the ovarian stroma. These cells, which are large and lighter looking (arrows), are derived from differentiation of the ovarian interstitial cells. Hematoxylin and eosin x 400.</div><div class=\"graphic_reference\">Courtesy of Manubai Nagamani, MD.</div><div id=\"graphicVersion\">Graphic 75548 Version 3.0</div></div></div>"},"75549":{"type":"graphic_picture","displayName":"Mucus barrier disruption","title":"Disruption of the mucus barrier","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disruption of the mucus barrier</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/GAST/75549_Mucus_barrier_disruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A prolific Serpulina biofilm adherent to the mucosa (green serpentine covering the mucosa), which creates access for other colonic bacteria (yellow for bacteroides and red fluorescence for Eubacterium rectale x400).</div><div class=\"graphic_reference\">Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.</div><div id=\"graphicVersion\">Graphic 75549 Version 2.0</div></div></div>"},"75552":{"type":"graphic_diagnosticimage","displayName":"Scapholunate advanced collapse","title":"Scapholunate advanced collapse wrist","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapholunate advanced collapse wrist</div><div class=\"cntnt\"><img style=\"width:327px; height:432px;\" src=\"images/EM/75552_Scphlnt_advnc_cllps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph above shows the wrist of a patient who presented in delayed fashion following an injury. This posterior anterior view taken with the patient's fist clenched, shows an abnormal widening at the scapholunate articulation (arrow), early proximal migration of the capitate (arrowhead), and radioscaphoid joint space narrowing (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Kenneth E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 75552 Version 3.0</div></div></div>"},"75553":{"type":"graphic_picture","displayName":"Resisted thumb abduction","title":"Resisted thumb abduction","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Resisted thumb abduction</div><div class=\"cntnt\"><img style=\"width:504px; height:201px;\" src=\"images/EM/75553_Resisted_thumb_abd_final.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75553 Version 1.0</div></div></div>"},"75554":{"type":"graphic_figure","displayName":"Purine interconversion and degradation","title":"Purine interconversion and degradation in humans","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Purine interconversion and degradation in humans</div><div class=\"cntnt\"><img style=\"width:661px; height:820px;\" src=\"images/RHEUM/75554_Purine_intercon_degrad_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using abbreviated structural diagrams this figure schematically shows the two purine nucleotides (adenosine monophosphate and guanosine monophosphate), nucleosides (adenosine and guanosine), and bases (adenine and guanine) as well as the corresponding intermediary molecules (inosine monophosphate, inosine, and hypoxanthine). All endogenously produced and dietary purines share the same final pathway of degradation: via inosine, hypoxanthine, xanthine, and urate/uric acid. The enzyme xanthine oxidase, which catalyzes two steps in this process, is inhibited by the drugs allopurinol and febuxostat. The enzymes hypoxanthine-guanine phosphoribosyltransferase (HPRT) and adenine phosphoribosyltransferase (APRT) catalyze salvage of purine bases by recycling them to ribonucleotides without increased net purine synthesis.</div><div class=\"graphic_footnotes\">5'-NT: 5-prime nucleotidase; ADA: adenosine deaminase; AK: adenosine kinase; AMPD: adenosine monophosphate deaminase; APRT: adenine phosphoribosyltransfersase; GDA: guanine deaminase (or guanase); HPRT: hypoxanthine-guanine phosphoribosyltransferase; PNP: purine nucleoside phosphorylase; XO: xanthine oxidase.</div><div class=\"graphic_reference\">Courtesy of Jerry Greene, MD.</div><div id=\"graphicVersion\">Graphic 75554 Version 2.0</div></div></div>"},"75555":{"type":"graphic_picture","displayName":"Haley-Haley histology","title":"Histopathologic findings in Hailey-Hailey disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathologic findings in Hailey-Hailey disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/75555_Haley_Haley_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy from the axilla of a 58-year-old woman who complained of a chronic, erosive, irritated, intertriginous eruption for years. The histologic examination reveals suprabasilar clefting of the epidermis; full thickness acantholysis with some dyskeratosis near the granular layer; and sparse, perivascular, lymphocytic infiltrate in the papillary dermis with scattered eosinophils. These findings are typical of Hailey-Hailey disease. Direct immunofluorescence was negative.</div><div class=\"graphic_reference\">Copyright Â© Nathan Jones, MSIV, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 75555 Version 5.0</div></div></div>"},"75556":{"type":"graphic_figure","displayName":"Direct compression bleeding","title":"Direct manual pressure to control bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Direct manual pressure to control bleeding</div><div class=\"cntnt\"><img style=\"width:352px; height:412px;\" src=\"images/EM/75556_Direct_compression_bleeding.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75556 Version 2.0</div></div></div>"},"75557":{"type":"graphic_figure","displayName":"Normal activation of RET","title":"RET receptor tyrosine kinase: Normal situation","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">RET receptor tyrosine kinase: Normal situation</div><div class=\"cntnt\"><img style=\"width:474px; height:318px;\" src=\"images/ENDO/75557_Normal_activation_of_RET.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GFRa: co-receptor glial cell line-derived neurotrophic factor-receptor family-a.</div><div id=\"graphicVersion\">Graphic 75557 Version 3.0</div></div></div>"},"75558":{"type":"graphic_figure","displayName":"Turner syndrome growth chart","title":"Growth chart for children with Turner syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Growth chart for children with Turner syndrome</div><div class=\"cntnt\"><img style=\"width:406px; height:500px;\" src=\"images/PEDS/75558_Turner_syndrome_growth_char.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Reiser, P, Davenport, M. Turner syndrome: A guide for families. Turner Syndrome Society of the United States, Houston, TX 2002. Copyright &#169; 2002 Turner Syndrome Society-US.</div><div id=\"graphicVersion\">Graphic 75558 Version 1.0</div></div></div>"},"75559":{"type":"graphic_table","displayName":"Sample exchange system menu","title":"Sample exchange system meal plan","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample exchange system meal plan</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Exchange pattern</td> <td class=\"subtitle1\">Sample menu</td> <td class=\"subtitle1\">Carbohydrate count (g)</td> </tr> <tr> <td rowspan=\"5\">8 AM</td> <td class=\"sublist1_start\" colspan=\"3\">3 carbohydrate group</td> </tr> <tr> <td class=\"sublist1\">2 starch</td> <td class=\"sublist_other\">1 English muffin</td> <td class=\"sublist_other\">30</td> </tr> <tr> <td class=\"sublist1\">1 fruit</td> <td class=\"sublist_other\">1 1/4 c strawberries</td> <td class=\"sublist_other\">15</td> </tr> <tr> <td>1 protein group</td> <td>1/4 c cottage cheese</td> <td>-</td> </tr> <tr> <td>1 fat group</td> <td>1 tsp margarine</td> <td>-</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> <td class=\"subtitle2_left\">Total: 45</td> </tr> <tr> <td rowspan=\"7\">12 PM</td> <td class=\"sublist1_start\" colspan=\"3\">4 carbohydrate group</td> </tr> <tr> <td class=\"sublist1\">2 starch</td> <td class=\"sublist_other\">2 slices of bread</td> <td class=\"sublist_other\">30</td> </tr> <tr> <td class=\"sublist1\">1 fruit</td> <td class=\"sublist_other\">1 orange</td> <td class=\"sublist_other\">15</td> </tr> <tr> <td class=\"sublist1\">1 vegetable</td> <td class=\"sublist_other\">1 c salad</td> <td class=\"sublist_other\">-</td> </tr> <tr> <td class=\"sublist1\">1 milk</td> <td class=\"sublist_other\">8 oz skim milk</td> <td class=\"sublist_other\">12</td> </tr> <tr> <td>3 protein group</td> <td>3 oz chicken</td> <td>-</td> </tr> <tr> <td>1 fat group</td> <td>1 tbsp low fat mayo</td> <td>-</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> <td class=\"subtitle2_left\">Total: 57</td> </tr> <tr> <td rowspan=\"2\">3 PM</td> <td class=\"sublist1_start\" colspan=\"3\">1 carbohydrate group</td> </tr> <tr> <td class=\"sublist1\">1 fruit or 1 starch</td> <td class=\"sublist_other\">1 apple or 6 crackers</td> <td class=\"sublist_other\">15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> <td class=\"subtitle2_left\">Total: 15</td> </tr> <tr> <td rowspan=\"7\">6 PM</td> <td class=\"sublist1_start\" colspan=\"3\">4 carbohydrate group</td> </tr> <tr> <td class=\"sublist1\">2 starch</td> <td class=\"sublist_other\">1 c potato</td> <td class=\"sublist_other\">30</td> </tr> <tr> <td class=\"sublist1\">1 fruit</td> <td class=\"sublist_other\">1/2 c fruit salad</td> <td class=\"sublist_other\">15</td> </tr> <tr> <td class=\"sublist1\">1 vegetable</td> <td class=\"sublist_other\">1 c salad</td> <td class=\"sublist_other\">-</td> </tr> <tr> <td class=\"sublist1\">1 milk</td> <td class=\"sublist_other\">8 oz skim milk</td> <td class=\"sublist_other\">12</td> </tr> <tr> <td>6 protein group</td> <td>6 oz fish</td> <td>-</td> </tr> <tr> <td>1 fat group</td> <td>2 tbsp low fat salad dressing</td> <td>-</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> <td class=\"subtitle2_left\"><strong>Total: 57</strong></td> </tr> <tr> <td rowspan=\"3\">9 PM</td> <td class=\"sublist1_start\" colspan=\"3\">1 carbohydrate group</td> </tr> <tr> <td class=\"sublist1\">1 starch</td> <td class=\"sublist_other\">6 crackers</td> <td class=\"sublist_other\">15</td> </tr> <tr> <td>1 protein</td> <td>2 tbsp peanut butter</td> <td>-</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> <td class=\"subtitle2_left\"><strong>Total: 15</strong></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75559 Version 3.0</div></div></div>"},"75560":{"type":"graphic_picture","displayName":"Acute rejection vascular II","title":"Vascular pattern of acute lung transplant rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vascular pattern of acute lung transplant rejection</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/PULM/75560_Acute_rejection_vascular_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of acute vascular rejection demonstrating a perivascular lymphocytic infiltrate.</div><div class=\"graphic_reference\">Courtesy of L Kobzik, MD.</div><div id=\"graphicVersion\">Graphic 75560 Version 1.0</div></div></div>"},"75561":{"type":"graphic_diagnosticimage","displayName":"Micronodules PA","title":"Micronodular pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micronodular pattern</div><div class=\"cntnt\"><img style=\"width:377px; height:350px;\" src=\"images/PULM/75561_Micronodules_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard International Labor Office film for small rounded opacities, less than 1.5 mm in diameter (micronodules).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75561 Version 4.0</div></div></div>"},"75565":{"type":"graphic_table","displayName":"TNM staging prostate CA","title":"Tumor node metastasis (TNM) stage definitions for prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tumor node metastasis (TNM) stage definitions for prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Primary tumor (T)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Clinical (cT)</td> </tr> <tr> <td class=\"indent1\">TX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td class=\"sublist2_start\">T1</td> <td class=\"sublist_other_start\">Clinically inapparent tumor neither palpable nor visible by imaging</td> </tr> <tr> <td class=\"sublist2\">T1a</td> <td class=\"sublist_other\">Tumor incidental histologic finding in 5% or less of tissue resected</td> </tr> <tr> <td class=\"sublist2\">T1b</td> <td class=\"sublist_other\">Tumor incidental histologic finding in more than 5% of tissue resected</td> </tr> <tr> <td class=\"sublist2\">T1c</td> <td class=\"sublist_other\">Tumor identified by needle biopsy (eg, because of elevated PSA)</td> </tr> <tr> <td class=\"sublist2_start\">T2</td> <td class=\"sublist_other_start\">Tumor confined within prostate*</td> </tr> <tr> <td class=\"sublist2\">T2a</td> <td class=\"sublist_other\">Tumor involves one-half of one lobe or less</td> </tr> <tr> <td class=\"sublist2\">T2b</td> <td class=\"sublist_other\">Tumor involves more than one-half of one lobe but not both lobes</td> </tr> <tr> <td class=\"sublist2\">T2c</td> <td class=\"sublist_other\">Tumor involves both lobes</td> </tr> <tr> <td class=\"sublist2_start\">T3</td> <td class=\"sublist_other_start\">Tumor extends through the prostate capsule<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">T3a</td> <td class=\"sublist_other\">Extracapsular extension (unilateral or bilateral)</td> </tr> <tr> <td class=\"sublist2\">T3b</td> <td class=\"sublist_other\">Tumor invades seminal vesicle(s)</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pathologic (pT)<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist2_start\">pT2</td> <td class=\"sublist_other_start\">Organ confined</td> </tr> <tr> <td class=\"sublist2\">pT2a</td> <td class=\"sublist_other\">Unilateral, one-half of one side or less</td> </tr> <tr> <td class=\"sublist2\">pT2b</td> <td class=\"sublist_other\">Unilateral, involving more than one-half of side but not both sides</td> </tr> <tr> <td class=\"sublist2\">pT2c</td> <td class=\"sublist_other\">Bilateral disease</td> </tr> <tr> <td class=\"sublist2_start\">pT3</td> <td class=\"sublist_other_start\">Extraprostatic extension</td> </tr> <tr> <td class=\"sublist2\">pT3a</td> <td class=\"sublist_other\">Extraprostatic extension or microscopic invasion of bladder neck<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist2\">pT3b</td> <td class=\"sublist_other\">Seminal vesicle invasion</td> </tr> <tr> <td class=\"indent1\">pT4</td> <td>Invasion of rectum, levator muscles, and/or pelvic wall</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Regional lymph nodes (N)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Clinical</td> </tr> <tr> <td class=\"indent1\">NX</td> <td>Regional lymph nodes were not assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td>Metastasis in regional lymph node(s)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pathologic</td> </tr> <tr> <td class=\"indent1\">pNX</td> <td>Regional nodes not sampled</td> </tr> <tr> <td class=\"indent1\">pN0</td> <td>No positive regional nodes</td> </tr> <tr> <td class=\"indent1\">pN1</td> <td>Metastases in regional node(s)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Distant metastasis (M)<sup>&#167;</sup></td> </tr> <tr> <td>M0</td> <td>No distant metastasis</td> </tr> <tr> <td class=\"sublist1_start\">M1</td> <td class=\"sublist_other_start\">Distant metastasis</td> </tr> <tr> <td class=\"sublist1\">M1a</td> <td class=\"sublist_other\">Nonregional lymph node(s)</td> </tr> <tr> <td class=\"sublist1\">M1b</td> <td class=\"sublist_other\">Bone(s)</td> </tr> <tr> <td class=\"sublist1\">M1c</td> <td class=\"sublist_other\">Other site(s) with or without bone disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Tumor found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c.<br />Â¶&nbsp;Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is classified not as T3 but as T2.<br />Î There is no pathologic T1 classification.<br /><FONT class=lozenge>â</FONT> Positive surgical margin should be indicated by an R1 descriptor (residual microscopic disease).<br />Â§ When more than one site of metastasis is present, the most advanced category is used. pM1c is most advanced.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 75565 Version 17.0</div></div></div>"},"75566":{"type":"graphic_algorithm","displayName":"Algorithm refractory Crohn","title":"Algorithm for management of refractory Crohn disease in children","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of refractory Crohn disease in children</div><div class=\"cntnt\"><img style=\"width:508px; height:906px;\" src=\"images/PEDS/75566_AlgorefractoryCrohn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm reflects the author's practice for most patients, but decisions may vary depending on patient characteristics and preferences and availability of drugs. Other approaches are reasonable and are used successfully by other experts. For example, some clinicians routinely proceed directly to an anti-TNF agent instead of using immunomodulator monotherapy, or choose biologic agents in a different order.</div><div class=\"graphic_footnotes\">&#xD;&#xA;&#x9;6-MP: mercaptopurine; AZA: azathioprine; MTX: methotrexate; TNF: tumor necrosis factor; PCDAI: pediatric ulcerative colitis activity index.<br />&#x9;&#xD;&#xA;&#x9;* Risk factors for complicated disease include severe perianal disease; steroid unresponsiveness; deep colonic fissuring; extensive disease involving the mid-small bowel; or severe growth failure in late puberty.<br />&#x9;&#xD;&#xA;&#x9;&para; Surgical resection also may be appropriate in some patients with growth failure and whose disease is limited to a discrete area of the intestine.<br />&#x9;&#xD;&#xA;&#x9;&Delta; The choice between infliximab and adalimumab typically depends on clinician and patient preferences, such as a preference for subcutaneous administration (adalimumab) versus infusions (infliximab).<br />&#x9;&#xD;&#xA;&#x9;<span class=\"lozenge\">&loz;</span> Expert opinion varies about how long to continue combination therapy after starting infliximab or adalimumab. Infliximab with low-dose MTX is increasingly used for combination therapy, primarily due to concerns about malignancy risk with 6MP/AZA. Some clinicians elect to use anti-TNF monotherapy with careful monitoring of therapeutic drug levels instead of combination treatment. For a discussion of the relative risks and benefits, refer to the text of the topic on management of Crohn disease in children and adolescents.<br />&#x9;&#xD;&#xA;&#x9;&sect; Severe adverse effects that warrant discontinuation of infliximab or adalimumab include a severe infusion reaction, refractory psoriasis, drug-induced lupus, or serum sickness. In case a drug is stopped because of an opportunistic infection, it is reasonable to consider resuming the original drug once the infection is cleared.<br />&#x9;&#xD;&#xA;&#x9;&yen; A good response is suggested by improvement in clinical symptoms within four to eight weeks, or a sustained decrease in PCDAI score by 12.5 or more points, ideally confirmed within three to six months by objective data (eg, improvements in erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], repeat imaging with magnetic resonance enterography [MRE], or colonoscopy).<br />&#x9;&#xD;&#xA;&#x9;&#8225; Infliximab dosing starts at 5 mg/kg per dose IV. If the response to standard dosing is incomplete, the treatment may be escalated by increasing the dose to 10 mg/kg and/or by increasing the frequency of infusions. Adalimumab treatment is typically escalated by increasing the frequency of administration from once every two weeks to once a week. Dose escalation is generally attempted before changing to a different drug, but therapeutic drug monitoring of levels and antibodies is suggested to help determine whether dose escalation or changing medications is warranted. For example, patients who have active disease, low levels of infliximab, and low or no levels of antibodies to infliximab may benefit from dose escalation. In contrast, patients with low infliximab concentrations and high titers of antibodies to infliximab will most likely need a different agent. Refer to UpToDate topic for further information about adjustment of the doses and dosing interval.</div><div id=\"graphicVersion\">Graphic 75566 Version 11.0</div></div></div>"},"75567":{"type":"graphic_waveform","displayName":"First degree AV block II","title":"First degree AV block II","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">First degree AV block II</div><div class=\"cntnt\"><img style=\"width:331px; height:123px;\" src=\"images/CARD/75567_First_degree_AV_block_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram of lead II showing normal sinus rhythm, first degree atrioventricular block with a markedly prolonged PR interval of approximately 0.40 sec, and a widened QRS complex (0.16 sec) due to concurrent left bundle branch block.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 75567 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"75568":{"type":"graphic_picture","displayName":"Complete rectal prolapse","title":"Complete rectal prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete rectal prolapse</div><div class=\"cntnt\"><img style=\"width:299px; height:269px;\" src=\"images/PEDS/75568_Complete_rectal_prolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The everted rectal wall appears as a tubular mass made up of several concentric mucosal folds.</div><div class=\"graphic_reference\">Reproduced with permission from Nelson, H, Dozois, R. Prolapse of the rectum. In: Sabiston Review of Surgery, 3rd ed, Townsend, CM, Sabiston, DC, WB Saunders, Philadelphia, 2001. p.978. Copyright Â© 2001 Mayo Foundation for Medical Education and Research</div><div id=\"graphicVersion\">Graphic 75568 Version 2.0</div></div></div>"},"75569":{"type":"graphic_figure","displayName":"Ravitch repair pectus","title":"Modified Ravitch repair for pectus excavatum or carinatum","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Modified Ravitch repair for pectus excavatum or carinatum</div><div class=\"cntnt\"><img style=\"width:461px; height:682px;\" src=\"images/PEDS/75569_Ravitch_repair_pectus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the modified Ravitch procedure, an&nbsp;Adkins strut is&nbsp;used to internally support and brace the pectus repair.&nbsp; It is placed across the lower anterior chest, posterior to the sternum and costal cartilages, with the tip emerging on each side through a small incision in the perichondrial sheath. The strut is attached to the anterior surface of the appropriate rib on each side with fine wire. The xiphoid and each of the deformed costal cartilages are reattached to the sternum with nonabsorbable sutures. The lateral ends of the costal cartilages are sutured back to the ribs. The periosteum is sutured over the wedge osteotomy. Finely minced segments of the cartilage chips are placed in all sites where the costal cartilage is reattached and around the sites where the strut emerges from the chest.</div><div id=\"graphicVersion\">Graphic 75569 Version 8.0</div></div></div>"},"75570":{"type":"graphic_waveform","displayName":"Biventricular enlarge tutorial","title":"Combined ventricular hypertrophy","html":"<div class=\"graphic normal\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Combined ventricular hypertrophy</div><div class=\"cntnt\"><img style=\"width:505px; height:236px;\" src=\"images/CARD/75570_Biventricular_enlarge_tutor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ECG satisfies voltage criteria for left ventricular hypertrophy (S in V2 + R in V5 &gt;35 mm), combined with a prominent R wave in V1 and right axis deviation (suggestive of right ventricular hypertrophy).</div><div id=\"graphicVersion\">Graphic 75570 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"75571":{"type":"graphic_picture","displayName":"Two-year-old female with Chediak-Higashi syndrome","title":"Two-year-old female with Chediak-Higashi syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-year-old female with Chediak-Higashi syndrome</div><div class=\"cntnt\"><img style=\"width:394px; height:286px;\" src=\"images/ALLRG/75571_CHSpatientphoto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note silver sheen to hair and mixed pigmentation on face.</div><div class=\"graphic_reference\">Courtesy of Robert Roberts, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75571 Version 6.0</div></div></div>"},"75573":{"type":"graphic_picture","displayName":"Epiblepharon with trichiasis","title":"Epiblepharon with trichiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epiblepharon with trichiasis</div><div class=\"cntnt\"><img style=\"width:360px; height:207px;\" src=\"images/PEDS/75573_Epiblepharon_with_trichiasi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epiblepharon is an extra fold of skin along the lower lid margin, just below the eyelashes, that extends over the medial canthal tendon. Epiblepharon may cause in-turning of the eyelashes (trichiasis).</div><div class=\"graphic_reference\">Adapted with permission from: Paysse EA, Coats DK, Cassidy M. Refinements Volume III/Number 2. San Francisco: American Academy of Opthalmology, 1999.</div><div id=\"graphicVersion\">Graphic 75573 Version 3.0</div></div></div>"},"75574":{"type":"graphic_figure","displayName":"Penile anatomy in exstrophy","title":"Penile anatomy in bladder exstrophy","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Penile anatomy in bladder exstrophy</div><div class=\"cntnt\"><img style=\"width:510px; height:235px;\" src=\"images/PEDS/75574_Penile_anatomy_in_exstrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Penile anatomy in boys born with bladder exstrophy. The penis is shorter than normal because of a short anterior corporal segment (ACL).</div><div class=\"graphic_footnotes\">ACL: anterior corporal length; PCL: posterior corporal length; TCL: total corporal length; ISD: intersymphyseal distance; aCC: corpora cavernosa subtended angle; Cdiam: corpus cavernosum diameter; ICD: intercorporal distance.</div><div class=\"graphic_reference\">Reproduced with permission from: Silver RI, Yang A, Ben-Chaim J, et al. Penile length in adulthood after exstrophy reconstruction. J Urol 1997; 157:999. Copyright Â© 1997 Elsevier.</div><div id=\"graphicVersion\">Graphic 75574 Version 3.0</div></div></div>"},"75576":{"type":"graphic_table","displayName":"Criteria for pulmonary metastatic disease in osteosarcoma","title":"Criteria for pulmonary metastatic disease as used in the EURAMOS I (AOST0331) osteosarcoma trial","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for pulmonary metastatic disease as used in the EURAMOS I (AOST0331) osteosarcoma trial</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">CT chest finding</td> <td class=\"subtitle1\">Interpretation</td> </tr> <tr> <td class=\"centered\"> <p>One or more pulmonary/pleural nodule(s) &#8805;1 cm</p> <p><strong>OR</strong></p> <p>Three or more nodules &#8805;0.5 cm maximum diameter</p> </td> <td class=\"centered\">\"Certain\" pulmonary metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"centered\">Fewer or smaller lesions</td> <td class=\"centered\">\"Possible\" metastatic disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75576 Version 2.0</div></div></div>"},"75577":{"type":"graphic_figure","displayName":"Spacer nebulizer PI","title":"Using a spacer or a nebulizer","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Using a spacer or a nebulizer</div><div class=\"cntnt\"><img style=\"width:515px; height:686px;\" src=\"images/PI/75577_SpacernebulizerPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This child is using a spacer with his inhaler. When she presses down on the canister, a puff of medicine is released into the spacer, and sits there until the child breathes it in.<br />(B) This child is using a nebulizer. This is a machine that turns the medicine into a fine mist. The child then breathes in the medicine through a mask.</div><div id=\"graphicVersion\">Graphic 75577 Version 6.0</div></div></div>"},"75578":{"type":"graphic_waveform","displayName":"ECG WPW tutorial","title":"12-lead electrocardiogram (ECG) showing the Wolff-Parkinson-White pattern","html":"<div class=\"graphic normal\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing the Wolff-Parkinson-White pattern</div><div class=\"cntnt\"><img style=\"width:536px; height:222px;\" src=\"images/CARD/75578_WPWsyndrometutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two main electrocardiographic features of Wolff-Parkinson-White (WPW) pattern include a short PR interval (&lt;0.12 seconds) and a delta wave (arrows). The QRS complex is wide (&gt;0.12 seconds) and represents a fusion beat; the initial portion (delta wave) results from rapid ventricular activation via the accessory pathway (preexcitation), while the termination of ventricular activation is via the normal conduction system, leading to a fairly normal terminal portion of the QRS.</div><div id=\"graphicVersion\">Graphic 75578 Version 7.0</div></div><div style=\"width: 466px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:466px; height:324px;\" src=\"images/CARD/58149_Sinusrhythm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal sinus rhythm at a rate of 71 beats/minute, a P wave axis of 45Â°, and a PR interval of 0.15 seconds.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 58149 Version 4.0</div></div></div>"},"75579":{"type":"graphic_picture","displayName":"Melker cricothyrotomy catheter","title":"Melker cricothyrotomy catheter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Melker cricothyrotomy catheter</div><div class=\"cntnt\"><img style=\"width:504px; height:242px;\" src=\"images/EM/75579_Melker_cric_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cricothyrotomy catheter is pictured above.</div><div class=\"graphic_reference\">Reproduced with permission from COOK Medical. Copyright Â© 2008.</div><div id=\"graphicVersion\">Graphic 75579 Version 3.0</div></div></div>"},"75580":{"type":"graphic_picture","displayName":"Pretibial myxedema I","title":"Pretibial myxedema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pretibial myxedema</div><div class=\"cntnt\"><img style=\"width:280px; height:416px;\" src=\"images/ENDO/75580_Infiltrative_dermopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pretibial myxedema&nbsp;in a patient with Graves' disease showing bilateral involvement with an orange-peel appearance.</div><div class=\"graphic_reference\">Courtesy of Terry F Davies, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 75580 Version 2.0</div></div></div>"},"75581":{"type":"graphic_table","displayName":"Phytophotodermatitis causes","title":"Some potential causes of phytophotodermatitis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some potential causes of phytophotodermatitis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Plant family</td> <td class=\"subtitle1\">Common name(s)</td> </tr> <tr> <td rowspan=\"9\">Apiaceae (Umbelliferae)</td> <td>Angelica</td> </tr> <tr> <td>Celery</td> </tr> <tr> <td>Cow parsley, wild chervil</td> </tr> <tr> <td>Cow parsnip, hogweed</td> </tr> <tr> <td>Dill</td> </tr> <tr> <td>Fennel</td> </tr> <tr> <td>Giant hogweed</td> </tr> <tr> <td>Parsley</td> </tr> <tr> <td>Parsnip</td> </tr> <tr> <td rowspan=\"7\">Rutaceae</td> <td>Bergamot orange</td> </tr> <tr> <td>Bitter orange</td> </tr> <tr> <td>Burning bush, gas plant</td> </tr> <tr> <td>Grapefruit</td> </tr> <tr> <td>Lemon</td> </tr> <tr> <td>Lime</td> </tr> <tr> <td>Rue</td> </tr> <tr> <td>Moraceae</td> <td>Fig</td> </tr> <tr> <td>Fabaceae (Leguminosae)</td> <td>Bavachee, scurf-pea (<em>Psoralea corylifolia</em>)</td> </tr> <tr> <td>Cruciferae</td> <td>Mustard</td> </tr> <tr> <td>Ranunculaceae</td> <td>Buttercup</td> </tr> <tr> <td>Hypericaceae</td> <td>St. John's wort (can cause systemic phytophotodermatitis)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Other plants have also been implicated.</div><div id=\"graphicVersion\">Graphic 75581 Version 2.0</div></div></div>"},"75582":{"type":"graphic_picture","displayName":"LV free wall rupture post MI","title":"Left ventricular free wall rupture after MI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular free wall rupture after MI</div><div class=\"cntnt\"><img style=\"width:360px; height:287px;\" src=\"images/CARD/75582_LV_free_wall_rupture_post_M.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathologic specimen showing free wall rupture (arrow) and hemopericardium after a myocardial infarction.</div><div class=\"graphic_reference\">From Edwards, WD, Applied anatomy of the heart. In: Cardiology: Fundamentals and Practice, Brandenburg, RO, Fuster, V, Guiliani, ER, McGoon, DC (Eds), Year Book, Chicago, 1987, pp. 47-109.</div><div id=\"graphicVersion\">Graphic 75582 Version 1.0</div></div></div>"},"75583":{"type":"graphic_diagnosticimage","displayName":"Bronchiectasis PA","title":"Bronchiectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiectasis</div><div class=\"cntnt\"><img style=\"width:432px; height:357px;\" src=\"images/PULM/75583_Bronchiectasis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A posterior-anterior chest radiograph with walls of airways dilated and thickened (arrow) in the right upper lobe as seen in allergic bronchopulmonary aspergillosis. In the left upper lobe are airways filled with mucus and cellular debris.</div><div id=\"graphicVersion\">Graphic 75583 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"75586":{"type":"graphic_table","displayName":"Carboplatin plus etoposide for small cell lung cancer","title":"Carboplatin plus etoposide for chemotherapy-naÃ¯ve extensive-stage small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carboplatin plus etoposide for chemotherapy-naÃ¯ve extensive-stage small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days, for a maximum of six cycles. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Carboplatin</td> <td>AUC* = 5 mg/mL &times; min IV</td> <td>Dilute in 250 mL normal saline (NS)<sup>&#182;</sup> and administer over 30 minutes.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Etoposide</td> <td>100 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL NS<sup>&#182;</sup> or 5% dextrose in water (D5W) to final concentration &#60;0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur.</td> <td>Days 1, 2, and 3</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE on day 1 and LOW on days 2 and 3. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Carboplatin and etoposide are irritants. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Routine primary prophylaxis with hematopoietic growth factors is not recommended (incidence of febrile neutropenia is about 5%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.* A lower starting dose of etoposide may be needed for patients with renal or liver impairment.<sup>[2]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Electrolytes and liver and renal function prior to each cycle of chemotherapy. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment based on myelotoxicity was not reported in the final publication. Per protocol, cycles were delayed for up to 42 days to allow neutrophils to return to &#8805;1500/microL and platelets to &#8805;100,000/microL.<sup>[1]</sup> However, the United States Prescribing Information recommends that the dose of carboplatin be reduced by 25% if platelets are &#60;50,000/microL and/or ANC is &#60;500/microL. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nonhematologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Chemotherapy should be held for grade 3 and 4 nonhematologic toxicities (except for neurotoxicity) and is only restarted after the toxicity has resolved to patient's baseline.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>No formal etoposide dosing recommendations were reported in this publication. However, accepted dose reductions per product information may be found in the literature. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Alterations in renal function during therapy may require a recalculation of the carboplatin dose. </li> <li>Refer to UpToDate topic on \"Dosing of anticancer agents in adults\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count.<br />&#x9;&#x9;&#x9;&#x9;&#x9;* AUC (area under the concentration &times; time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) &times; (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />&#x9;&#x9;&#x9;&#x9;&#x9;&para; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Socinski MA, et al. J Clin Oncol 2009; 27:4787.</LI>&#xD;&#xA;<LI>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 75586 Version 22.0</div></div></div>"},"75587":{"type":"graphic_figure","displayName":"Drug Rx in silent ischemia","title":"Efficacy of nifedipine and atenolol on silent ischemia","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Efficacy of nifedipine and atenolol on silent ischemia</div><div class=\"cntnt\"><img style=\"width:514px; height:243px;\" src=\"images/CARD/75587_Drug_Rx_in_silent_ischemia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crossover trial of the effect of therapy on 24 patients with silent ischemia. Compared with placebo, both atenolol and nifedipine significantly decreased the number (left) and duration (right) of silent ischemic events during the monitoring period. However, atenolol was significantly more effective than nifedipine.</div><div class=\"graphic_reference\">Data from: Deedwania PC, Carbajal EV, Nelson JR, et al. J Am Coll Cardiol 1991; 17:963.</div><div id=\"graphicVersion\">Graphic 75587 Version 2.0</div></div></div>"},"75588":{"type":"graphic_figure","displayName":"Placement of precordial leads","title":"Placement of precordial leads","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Placement of precordial leads</div><div class=\"cntnt\"><img style=\"width:302px; height:281px;\" src=\"images/CARD/75588_Placement_of_precordial_lea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The horizontal plane (chest or precordial) leads are placed with electrodes in the designated locations.</div><div id=\"graphicVersion\">Graphic 75588 Version 1.0</div></div></div>"},"75589":{"type":"graphic_table","displayName":"Cephalosporins and penicillins with identical side chains","title":"Cephalosporins and penicillins with identical side chains","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cephalosporins and penicillins with identical side chains</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Amoxicillin:<br /> Has side chains that are identical to:</td> </tr> <tr> <td>Cefadroxil</td> </tr> <tr> <td>Cefprozil</td> </tr> <tr> <td>Cefatrizine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Ampicillin:<br /> Has side chains that are identical to:</td> </tr> <tr> <td>Cefaclor</td> </tr> <tr> <td>Cephalexin</td> </tr> <tr> <td>Cephradine</td> </tr> <tr> <td>Cephaloglycin</td> </tr> <tr> <td>Loracarbef (a carbacephem)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">List of cephalosporins that share identical R1-group side chains with R-group side chain of amoxicillin and ampicillin. Note that clinical cross-reactivity has only been reported among beta-lactams with <strong>identical</strong> side chains and not among those with similar side chains.</div><div id=\"graphicVersion\">Graphic 75589 Version 5.0</div></div></div>"},"75590":{"type":"graphic_algorithm","displayName":"Diagnosis neutrocytic ascites","title":"Distinguishing spontaneous from secondary bacterial peritonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distinguishing spontaneous from secondary bacterial peritonitis</div><div class=\"cntnt\"><img style=\"width:398px; height:650px;\" src=\"images/GAST/75590_Diagnosis_neutrocytic_ascit.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Redrawn from: Akrivladis EA, Runyon BA. Gastroenterology 1990; 98:127.</div><div id=\"graphicVersion\">Graphic 75590 Version 3.0</div></div></div>"},"75592":{"type":"graphic_picture","displayName":"Adynamic bone disease","title":"Micrograph showing adynamic or aplastic bone disease in end-stage renal disease","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph showing adynamic or aplastic bone disease in end-stage renal disease</div><div class=\"cntnt\"><img style=\"width:378px; height:258px;\" src=\"images/NEPH/75592_Adynamic_bone_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone biopsy showing adynamic or aplastic bone disease in end-stage renal failure. This disorder is characterized by reductions in bone formation and bone resorption that are manifested histologically by thin osteoid seams (red lines at the bone surface; arrows) and little or no evidence of cellular activity.</div><div class=\"graphic_reference\">Courtesy of L Darryl Quarles, MD.</div><div id=\"graphicVersion\">Graphic 75592 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Micrograph showing normal bone histology</div><div class=\"cntnt\"><img style=\"width:382px; height:269px;\" src=\"images/NEPH/66330_Normalboneedit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic appearance of normal bone.<br />(Left panel) Goldner Masson trichrome stain shows mineralized lamellar bone in blue and adjacent nonmineralized osteoid in red-brown. Osteoid usually comprises less than 25% of bone surfaces. The cellular area between the osseous structures is the marrow space.<br />(Right panel) Villanueva-stained section viewed under polarized light following time-spaced tetracycline labeling. Osteoid appears orange, mineralized bone is green, and tetracycline markers appear as luminescent yellow-green bands within bone and beneath osteoid (arrow). The distinct dual bands represent active mineralized bone formation.</div><div class=\"graphic_reference\">Courtesy of L Darryl Quarles, MD.</div><div id=\"graphicVersion\">Graphic 66330 Version 6.0</div></div></div>"},"75594":{"type":"graphic_table","displayName":"Fetal radiation exposure","title":"Fetal radiation doses associated with common radiologic examinations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fetal radiation doses associated with common radiologic examinations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"75%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of examination</td> <td class=\"subtitle1\">Fetal dose* (mGy)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Very low-dose examinations (&#60;0.1 mGy)</td> </tr> <tr> <td class=\"indent1\">Cervical spine radiography (anteroposterior and lateral views)</td> <td>&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Radiography of any extremity</td> <td>&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Mammography (two views)</td> <td>0.001 to 0.01</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chest radiography (two views)</td> <td>0.0005 to 0.01</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Low- to moderate-dose examinations (0.1 to 10 mGy)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Radiography</td> </tr> <tr> <td class=\"indent2\">Abdominal radiography</td> <td>0.1 to 3.0</td> </tr> <tr> <td class=\"indent2\">Lumbar spine radiography</td> <td>1.0 to 10</td> </tr> <tr> <td class=\"indent2\">Intravenous pyelography</td> <td>5 to 10</td> </tr> <tr> <td class=\"indent2\">Double-contrast barium enema</td> <td>1.0 to 20</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">CT</td> </tr> <tr> <td class=\"indent2\">Head or neck CT</td> <td>1.0 to 10</td> </tr> <tr> <td class=\"indent2\">Chest CT or CT pulmonary angiography</td> <td>0.01 to 0.66</td> </tr> <tr> <td class=\"indent2\">Limited CT pelvimetry (single axial section through the femoral heads)</td> <td>&#60;1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Nuclear medicine</td> </tr> <tr> <td class=\"indent2\">Low-dose perfusion scintigraphy</td> <td>0.1 to 0.5</td> </tr> <tr> <td class=\"indent2\">Technetium-99m bone scintigraphy</td> <td>4 to 5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Pulmonary digital subtraction angiography</td> <td>0.5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Higher-dose examinations (10 to 50 mGy)</td> </tr> <tr> <td class=\"indent1\">Abdominal CT</td> <td>1.3 to 35</td> </tr> <tr> <td class=\"indent1\">Pelvic CT</td> <td>10 to 50</td> </tr> <tr> <td class=\"indent1\"><sup>18</sup>F PET/CT whole-body scintigraphy</td> <td>10 to 50</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Annual average background radiation = 1.1 to 2.5 mGy.</div><div class=\"graphic_footnotes\">CT: computed tomography; PET: positron emission tomography; <SUP>18</SUP>F: 2-[fluorine-18]fluoro-2-deoxy-D-glucose.<br />* Fetal exposure varies with gestational age, maternal body habitus, and exact parameters.<br /></div><div class=\"graphic_reference\">Reproduced with permission from: Tremblay E, ThÃ©rasse E, Thomassin-Naggara I, Trop I. Quality initiatives: guidelines for use of medical imaging during pregnancy and lactation. Radiographics 2012; 32:897. Copyright Â© 2012 RSNA.</div><div id=\"graphicVersion\">Graphic 75594 Version 7.0</div></div></div>"},"75595":{"type":"graphic_diagnosticimage","displayName":"Thick intertwin membrane","title":"Thick intertwin membrane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thick intertwin membrane</div><div class=\"cntnt\"><img style=\"width:421px; height:242px;\" src=\"images/OBGYN/75595_Thick_intertwin_membrane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow points to a thick intertwin membrane characteristic of a dichorionic twin pregnancy in the first trimester. A and B refer to the two twin sacs.</div><div id=\"graphicVersion\">Graphic 75595 Version 3.0</div></div></div>"},"75596":{"type":"graphic_figure","displayName":"Immunoglobulin genes","title":"Immunoglobulin genes","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Immunoglobulin genes</div><div class=\"cntnt\"><img style=\"width:482px; height:195px;\" src=\"images/ALLRG/75596_Immunoglobulin_genes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mu&nbsp;(Âµ) and delta (Î´) C genes are those nearest to the assembled VDJ sequence. Transcription of a complete immunoglobulin heavy chain gene starts at the V sequence and proceeds through the mu (Âµ) and delta (Î´) sequences before terminating. The mature B cell expresses both IgM and IgD, which are the only isotypes produced by B lymphocytes prior to contact with antigen.</div><div class=\"graphic_footnotes\">L: light chain gene; C: constant; V: variable sequence of heavy chain gene; D: diversity sequence; J: joining sequence of heavy chain gene; Âµ: mu; Î´: delta; Î³: gamma; Î±: alpha; Îµ: epsilon; IgM: immunoglobulin M; IgD: immunoglobulin D.</div><div id=\"graphicVersion\">Graphic 75596 Version 2.0</div></div></div>"},"75599":{"type":"graphic_picture","displayName":"Acne conglobata","title":"Acne conglobata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acne conglobata</div><div class=\"cntnt\"><img style=\"width:324px; height:360px;\" src=\"images/PC/75599_Acne_conglobata.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lippincott Williams &amp; Wilkins. Copyright &#169;2008.</div><div id=\"graphicVersion\">Graphic 75599 Version 1.0</div></div></div>"},"75601":{"type":"graphic_figure","displayName":"Waveforms Swan Ganz tip","title":"Waveforms by location of the pulmonary artery (PA) catheter tip","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Waveforms by location of the pulmonary artery (PA) catheter tip</div><div class=\"cntnt\"><img style=\"width:597px; height:337px;\" src=\"images/PULM/75601_Waveforms_Swan_Ganz_tip.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tracings obtained in the right atrium or pulmonary capillary wedge position share similar morphology. The transition from the right ventricle to the pulmonary artery tracing can be identified by the increase in diastolic pressure and the presence of a dicrotic notch. The diastolic \"step-up\" results from the transducer crossing the pulmonic valve; the dicrotic notch reflects closing of the pulmonic valve.</div><div class=\"graphic_reference\">Redrawn from Marino Pl. The ICU Book, Philadelphia, Lea and Feliger, 1991, p. 103.</div><div id=\"graphicVersion\">Graphic 75601 Version 3.0</div></div></div>"},"75602":{"type":"graphic_table","displayName":"Estimated TB incidence and prevalence by country","title":"Estimated epidemiological burden of tuberculosis cases, 2013","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated epidemiological burden of tuberculosis cases, 2013</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"23%\"></colgroup><colgroup span=\"11\" width=\"7%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Population<br /> (thousands)</td> <td class=\"subtitle1\" colspan=\"2\">Mortality*</td> <td class=\"subtitle1\" colspan=\"2\">HIV-positive TB mortality</td> <td class=\"subtitle1\" colspan=\"2\">Prevalence</td> <td class=\"subtitle1\" colspan=\"2\">Incidence</td> <td class=\"subtitle1\" colspan=\"2\">HIV prevalence in incident TB cases (%)</td> </tr> <tr> <td>Afghanistan</td> <td class=\"centered\">30,552</td> <td class=\"centered\">42</td> <td class=\"centered\">27-53</td> <td class=\"centered\">0.3</td> <td class=\"centered\">0.2-0.3</td> <td class=\"centered\">340</td> <td class=\"centered\">178-554</td> <td class=\"centered\">189</td> <td class=\"centered\">167-212</td> <td class=\"centered\">0.34</td> <td class=\"centered\">0.29-0.40</td> </tr> <tr> <td>Bangladesh<sup>&#182;</sup></td> <td class=\"centered\">156,595</td> <td class=\"centered\">51</td> <td class=\"centered\">33-69</td> <td class=\"centered\">0.1</td> <td class=\"centered\">&#60;0.1-0.2</td> <td class=\"centered\">402</td> <td class=\"centered\">210-656</td> <td class=\"centered\">224</td> <td class=\"centered\">199-253</td> <td class=\"centered\">0.12</td> <td class=\"centered\">&#60;0.1-0.16</td> </tr> <tr> <td>Brazil</td> <td class=\"centered\">200,362</td> <td class=\"centered\">2.2</td> <td class=\"centered\">1.3-3.4</td> <td class=\"centered\">1.0</td> <td class=\"centered\">0.8-1.4</td> <td class=\"centered\">57</td> <td class=\"centered\">27-99</td> <td class=\"centered\">46</td> <td class=\"centered\">41-52</td> <td class=\"centered\">14</td> <td class=\"centered\">13-16</td> </tr> <tr> <td>Cambodia</td> <td class=\"centered\">15,135</td> <td class=\"centered\">66</td> <td class=\"centered\">42-92</td> <td class=\"centered\">3.9</td> <td class=\"centered\">3.0-5.0</td> <td class=\"centered\">715</td> <td class=\"centered\">604-834</td> <td class=\"centered\">400</td> <td class=\"centered\">366-444</td> <td class=\"centered\">3.9</td> <td class=\"centered\">3.4-4.4</td> </tr> <tr> <td>China</td> <td class=\"centered\">1,385,567</td> <td class=\"centered\">3.0</td> <td class=\"centered\">2.9-3.1</td> <td class=\"centered\">&#60;0.1</td> <td class=\"centered\">&#60;0.1-0.1</td> <td class=\"centered\">94</td> <td class=\"centered\">82-107</td> <td class=\"centered\">70</td> <td class=\"centered\">66-77</td> <td class=\"centered\">0.46</td> <td class=\"centered\">0.22-0.79</td> </tr> <tr> <td>DR Congo</td> <td class=\"centered\">67,514</td> <td class=\"centered\">68</td> <td class=\"centered\">33-78</td> <td class=\"centered\">9.5</td> <td class=\"centered\">0.3-35</td> <td class=\"centered\">549</td> <td class=\"centered\">285-898</td> <td class=\"centered\">326</td> <td class=\"centered\">297-356</td> <td class=\"centered\">7.5</td> <td class=\"centered\">0.13-27</td> </tr> <tr> <td>Ethiopia</td> <td class=\"centered\">94,101</td> <td class=\"centered\">32</td> <td class=\"centered\">17-50</td> <td class=\"centered\">5.9</td> <td class=\"centered\">3.8-8.5</td> <td class=\"centered\">211</td> <td class=\"centered\">170-257</td> <td class=\"centered\">224</td> <td class=\"centered\">188-276</td> <td class=\"centered\">11</td> <td class=\"centered\">7.4-14</td> </tr> <tr> <td>India<sup>&#916;</sup></td> <td class=\"centered\">1,252,140</td> <td class=\"centered\">19</td> <td class=\"centered\">12-28</td> <td class=\"centered\">3.0</td> <td class=\"centered\">2.5-3.5</td> <td class=\"centered\">211</td> <td class=\"centered\">143-294</td> <td class=\"centered\">171</td> <td class=\"centered\">162-184</td> <td class=\"centered\">5.7</td> <td class=\"centered\">4.8-6.6</td> </tr> <tr> <td>Indonesia<sup>&#9674;</sup></td> <td class=\"centered\">249,866</td> <td class=\"centered\">25</td> <td class=\"centered\">14-37</td> <td class=\"centered\">1.6</td> <td class=\"centered\">0.9-2.5</td> <td class=\"centered\">272</td> <td class=\"centered\">138-450</td> <td class=\"centered\">183</td> <td class=\"centered\">164-207</td> <td class=\"centered\">3.2</td> <td class=\"centered\">2.1-4.5</td> </tr> <tr> <td>Kenya</td> <td class=\"centered\">44,354</td> <td class=\"centered\">20</td> <td class=\"centered\">12-27</td> <td class=\"centered\">21</td> <td class=\"centered\">17-27</td> <td class=\"centered\">283</td> <td class=\"centered\">156-447</td> <td class=\"centered\">268</td> <td class=\"centered\">261-275</td> <td class=\"centered\">41</td> <td class=\"centered\">39-42</td> </tr> <tr> <td>Mozambique</td> <td class=\"centered\">25,834</td> <td class=\"centered\">69</td> <td class=\"centered\">36-101</td> <td class=\"centered\">148</td> <td class=\"centered\">105-198</td> <td class=\"centered\">559</td> <td class=\"centered\">303-893</td> <td class=\"centered\">552</td> <td class=\"centered\">442-680</td> <td class=\"centered\">57</td> <td class=\"centered\">39-74</td> </tr> <tr> <td>Myanmar</td> <td class=\"centered\">53,259</td> <td class=\"centered\">49</td> <td class=\"centered\">29-71</td> <td class=\"centered\">8.0</td> <td class=\"centered\">6.3-9.9</td> <td class=\"centered\">473</td> <td class=\"centered\">364-595</td> <td class=\"centered\">373</td> <td class=\"centered\">340-413</td> <td class=\"centered\">8.8</td> <td class=\"centered\">7.8-9.8</td> </tr> <tr> <td>Nigeria</td> <td class=\"centered\">173,615</td> <td class=\"centered\">94</td> <td class=\"centered\">39-156</td> <td class=\"centered\">49</td> <td class=\"centered\">27-78</td> <td class=\"centered\">326</td> <td class=\"centered\">246-418</td> <td class=\"centered\">338</td> <td class=\"centered\">194-506</td> <td class=\"centered\">25</td> <td class=\"centered\">10-44</td> </tr> <tr> <td>Pakistan</td> <td class=\"centered\">182,143</td> <td class=\"centered\">56</td> <td class=\"centered\">25-92</td> <td class=\"centered\">0.5</td> <td class=\"centered\">0.3-0.9</td> <td class=\"centered\">342</td> <td class=\"centered\">284-406</td> <td class=\"centered\">275</td> <td class=\"centered\">205-357</td> <td class=\"centered\">0.53</td> <td class=\"centered\">0.3-0.83</td> </tr> <tr> <td>Philippines</td> <td class=\"centered\">98,394</td> <td class=\"centered\">27</td> <td class=\"centered\">25-29</td> <td class=\"centered\">&#60;0.1</td> <td class=\"centered\">&#60;0.1-&#60;0.1</td> <td class=\"centered\">438</td> <td class=\"centered\">385-495</td> <td class=\"centered\">292</td> <td class=\"centered\">261-331</td> <td class=\"centered\">0.11</td> <td class=\"centered\">&#60;0.1-0.14</td> </tr> <tr> <td>Russian Federation</td> <td class=\"centered\">142,834</td> <td class=\"centered\">12</td> <td class=\"centered\">12-13</td> <td class=\"centered\">1.0</td> <td class=\"centered\">0.7-1.3</td> <td class=\"centered\">114</td> <td class=\"centered\">51-201</td> <td class=\"centered\">89</td> <td class=\"centered\">82-100</td> <td class=\"centered\">6.2</td> <td class=\"centered\">5.2-7.3</td> </tr> <tr> <td>South Africa</td> <td class=\"centered\">52,776</td> <td class=\"centered\">48</td> <td class=\"centered\">28-73</td> <td class=\"centered\">121</td> <td class=\"centered\">90-158</td> <td class=\"centered\">715</td> <td class=\"centered\">396-1130</td> <td class=\"centered\">860</td> <td class=\"centered\">776-980</td> <td class=\"centered\">61</td> <td class=\"centered\">50-71</td> </tr> <tr> <td>Thailand</td> <td class=\"centered\">67,011</td> <td class=\"centered\">12</td> <td class=\"centered\">7.3-18</td> <td class=\"centered\">2.8</td> <td class=\"centered\">2.0-3.6</td> <td class=\"centered\">149</td> <td class=\"centered\">72-252</td> <td class=\"centered\">119</td> <td class=\"centered\">106-134</td> <td class=\"centered\">15</td> <td class=\"centered\">12-17</td> </tr> <tr> <td>Uganda</td> <td class=\"centered\">37,579</td> <td class=\"centered\">11</td> <td class=\"centered\">5.8-18</td> <td class=\"centered\">19</td> <td class=\"centered\">13-26</td> <td class=\"centered\">154</td> <td class=\"centered\">85-243</td> <td class=\"centered\">166</td> <td class=\"centered\">149-193</td> <td class=\"centered\">52</td> <td class=\"centered\">42-62</td> </tr> <tr> <td>UR Tanzania</td> <td class=\"centered\">49,253</td> <td class=\"centered\">12</td> <td class=\"centered\">7.0-17</td> <td class=\"centered\">12</td> <td class=\"centered\">9.8-15</td> <td class=\"centered\">172</td> <td class=\"centered\">92-277</td> <td class=\"centered\">164</td> <td class=\"centered\">157-170</td> <td class=\"centered\">37</td> <td class=\"centered\">35-39</td> </tr> <tr> <td>Viet Nam</td> <td class=\"centered\">91,680</td> <td class=\"centered\">19</td> <td class=\"centered\">13-26</td> <td class=\"centered\">2.1</td> <td class=\"centered\">1.3-3.2</td> <td class=\"centered\">209</td> <td class=\"centered\">86-384</td> <td class=\"centered\">144</td> <td class=\"centered\">121-174</td> <td class=\"centered\">7.2</td> <td class=\"centered\">5.4-9.1</td> </tr> <tr class=\"divider_bottom\"> <td>Zimbabwe</td> <td class=\"centered\">14,150</td> <td class=\"centered\">40</td> <td class=\"centered\">25-52</td> <td class=\"centered\">153</td> <td class=\"centered\">121-189</td> <td class=\"centered\">409</td> <td class=\"centered\">235-630</td> <td class=\"centered\">552</td> <td class=\"centered\">474-643</td> <td class=\"centered\">72</td> <td class=\"centered\">55-86</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td><strong>High-burden countries</strong></td> <td class=\"centered\"><strong>4,484,710</strong></td> <td class=\"centered\"><strong>21</strong></td> <td class=\"centered\"><strong>18-25</strong></td> <td class=\"centered\"><strong>6.7</strong></td> <td class=\"centered\"><strong>5.6-7.9</strong></td> <td class=\"centered\"><strong>208</strong></td> <td class=\"centered\"><strong>183-235</strong></td> <td class=\"centered\"><strong>165</strong></td> <td class=\"centered\"><strong>158-173</strong></td> <td class=\"centered\"><strong>12</strong></td> <td class=\"centered\"><strong>11-14</strong></td> </tr> <tr> <td class=\"indent1\">AFR</td> <td class=\"centered\">927,371</td> <td class=\"centered\">42</td> <td class=\"centered\">32-54</td> <td class=\"centered\">32</td> <td class=\"centered\">27-38</td> <td class=\"centered\">300</td> <td class=\"centered\">263-341</td> <td class=\"centered\">280</td> <td class=\"centered\">251-311</td> <td class=\"centered\">34</td> <td class=\"centered\">29-39</td> </tr> <tr> <td class=\"indent1\">AMR</td> <td class=\"centered\">970,821</td> <td class=\"centered\">1.5</td> <td class=\"centered\">1.2-1.7</td> <td class=\"centered\">0.6</td> <td class=\"centered\">0.6-0.7</td> <td class=\"centered\">38</td> <td class=\"centered\">30-48</td> <td class=\"centered\">29</td> <td class=\"centered\">28-31</td> <td class=\"centered\">11</td> <td class=\"centered\">11-12</td> </tr> <tr> <td class=\"indent1\">EMR</td> <td class=\"centered\">616,906</td> <td class=\"centered\">23</td> <td class=\"centered\">15-34</td> <td class=\"centered\">0.3</td> <td class=\"centered\">0.2-0.4</td> <td class=\"centered\">165</td> <td class=\"centered\">143-189</td> <td class=\"centered\">121</td> <td class=\"centered\">100-144</td> <td class=\"centered\">0.94</td> <td class=\"centered\">0.67-1.2</td> </tr> <tr> <td class=\"indent1\">EUR</td> <td class=\"centered\">907,053</td> <td class=\"centered\">4.1</td> <td class=\"centered\">4.0-4.2</td> <td class=\"centered\">0.4</td> <td class=\"centered\">0.4-0.5</td> <td class=\"centered\">51</td> <td class=\"centered\">39-65</td> <td class=\"centered\">39</td> <td class=\"centered\">38-41</td> <td class=\"centered\">6.0</td> <td class=\"centered\">5.6-6.4</td> </tr> <tr> <td class=\"indent1\">SEAR</td> <td class=\"centered\">1,855,068</td> <td class=\"centered\">23</td> <td class=\"centered\">18-30</td> <td class=\"centered\">2.6</td> <td class=\"centered\">2.2-3.0</td> <td class=\"centered\">244</td> <td class=\"centered\">188-307</td> <td class=\"centered\">183</td> <td class=\"centered\">175-192</td> <td class=\"centered\">4.9</td> <td class=\"centered\">4.4-5.5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">WPR</td> <td class=\"centered\">1,858,410</td> <td class=\"centered\">5.8</td> <td class=\"centered\">5.4-6.3</td> <td class=\"centered\">0.3</td> <td class=\"centered\">0.2-0.3</td> <td class=\"centered\">121</td> <td class=\"centered\">109-134</td> <td class=\"centered\">87</td> <td class=\"centered\">82-92</td> <td class=\"centered\">1.4</td> <td class=\"centered\">1.2-1.6</td> </tr> <tr class=\"highlight_gray_text\"> <td><strong>Global</strong></td> <td class=\"centered\"><strong>7,135,628</strong></td> <td class=\"centered\"><strong>16</strong></td> <td class=\"centered\"><strong>14-18</strong></td> <td class=\"centered\"><strong>5.0</strong></td> <td class=\"centered\"><strong>4.3-5.8</strong></td> <td class=\"centered\"><strong>159</strong></td> <td class=\"centered\"><strong>143-176</strong></td> <td class=\"centered\"><strong>126</strong></td> <td class=\"centered\"><strong>121-131</strong></td> <td class=\"centered\"><strong>13</strong></td> <td class=\"centered\"><strong>12-14</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Rates per 100,000 population except where indicated.<sup>&sect;</sup></div><div class=\"graphic_footnotes\">* Mortality excludes deaths among HIV-positive tuberculosis (TB) cases. Deaths among HIV-positive TB cases are classified as HIV deaths according to ICD-10 and are shown separately in this table.<br />&para; Estimates of TB disease burden have not been approved by the National Tuberculosis Program (NTP) in Bangladesh and a joint reassessment will be undertaken following completion of the prevalence survey planned for 2015.<br />&Delta; Estimates for India have not yet been officially approved by the Ministry of Health &amp; Family Welfare, Government of India, and should therefore be considered provisional.<br /><span class=\"lozenge\">&loz;</span> As this report went to press, estimates for Indonesia were being revised based on the results of the 2013 to 2014 national TB prevalence survey. Updated estimates will be published online.<br />&sect; Best estimates are followed by the lower and upper bounds of the 95 percent uncertainty interval.</div><div class=\"graphic_reference\">Reproduced with permission from: Global Tuberculosis Report 2014. Geneva, World Health Organization, 2014. Copyright &copy; 2014 World Health Organization. Available at: <a href=\"http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1\" target=\"_blank\">http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1</a>. (Accessed on January 15, 2015).</div><div id=\"graphicVersion\">Graphic 75602 Version 7.0</div></div></div>"},"75603":{"type":"graphic_picture","displayName":"Fusarium infection hard palate","title":"<EM>Fusarium </EM>infection hard palate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium </EM>infection hard palate</div><div class=\"cntnt\"><img style=\"width:396px; height:268px;\" src=\"images/ID/75603_Fusar_infect_hard_palate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Black necrotic hard palate caused by <EM>Fusarium</EM> species in a 29-year-old patient with leukemia and fusarial sinusitis and pneumonia. The infection later became disseminated and involved multiple organs, including the skin.</div><div class=\"graphic_reference\">Reproduced from: Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immuncompromised hosts: Implications for diagnosis and management. Clin Infect Dis 2002; 35:909 by permission of Oxford University Press. Copyright Â© 2002.</div><div id=\"graphicVersion\">Graphic 75603 Version 3.0</div></div></div>"},"75605":{"type":"graphic_table","displayName":"ANCA accuracy in GN in adults","title":"ANCA results for pauci-immune crescentic glomerulonephritis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ANCA results for pauci-immune crescentic glomerulonephritis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\">Clinical presentation</td>\n\n\t\t\t<td class=\"subtitle1\">Prevalence of PI-CGN</td>\n\n\t\t\t<td class=\"subtitle1\">PPV for PI-CGN</td>\n\n\t\t\t<td class=\"subtitle1\">NPV for PI-CGN</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Rapidly progressive glomerulonephritis*</td>\n\n\t\t\t<td>47 percent (106/224)</td>\n\n\t\t\t<td>98 percent</td>\n\n\t\t\t<td>80 percent</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Hematuria, proteinuria, and creatinine &#62;3 mg/dL</td>\n\n\t\t\t<td>21 percent (181/862)</td>\n\n\t\t\t<td>92 percent</td>\n\n\t\t\t<td>93 percent</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Hematuria, proteinuria, and creatinine 1.5-3 mg/dL</td>\n\n\t\t\t<td>7 percent (51/685)</td>\n\n\t\t\t<td>77 percent</td>\n\n\t\t\t<td>98 percent</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Hematuria, proteinuria, and creatinine &#60;1.5 mg/dL</td>\n\n\t\t\t<td>2 percent (13/768)</td>\n\n\t\t\t<td>47 percent</td>\n\n\t\t\t<td>99 percent</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n\t\t\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=35067&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ANCA_accuracy_in_GN_in_adul.htm</title></head></div><div class=\"graphic_lgnd\">Estimated positive predictive values (PPV) and negative predictive values (NPV) of ANCA results for pauci-immune crescentic glomerulonephritis (PI-CGN) in adults (&gt;18 years old) with different clinical presentations using an assay approach (that has a 72.5 percent sensitivity and a 98.4 percent specificity).</div><div class=\"graphic_footnotes\">* This clinical presentation presumed from renal biopsy showing &gt;50 percent of glomeruli with crescents.</div><div class=\"graphic_reference\">Adapted from: Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int 1998; 53:796.</div><div id=\"graphicVersion\">Graphic 75605 Version 2.0</div></div></div>"},"75607":{"type":"graphic_figure","displayName":"Stillbirth risk by GA","title":"Hazard (risk) of stillbirth for singleton births without congenital anomalies by maternal age and gestational age, 2001-2002","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Hazard (risk) of stillbirth for singleton births without congenital anomalies by maternal age and gestational age, 2001-2002</div><div class=\"cntnt\"><img style=\"width:523px; height:319px;\" src=\"images/OBGYN/75607_Stillbirth_risk_by_GA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hazard of stillbirth at each gestation week was estimated by the number of stillbirths occurring during that week divided by the number of ongoing pregnancies at the beginning of that week minus half of the live births in that week. <br /></div><div class=\"graphic_reference\">Reproduced with permission from: Reddy UM, Ko CW, Willinger M. Maternal age and the risk of stillbirth throughout pregnancy in the United States. Am J Obstet Gynecol 2006; 195:764. Copyright Â©2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 75607 Version 3.0</div></div></div>"},"75608":{"type":"graphic_picture","displayName":"Retained TT","title":"Retained tympanostomy tube with surrounding moist squamous debris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retained tympanostomy tube with surrounding moist squamous debris</div><div class=\"cntnt\"><img style=\"width:396px; height:355px;\" src=\"images/PEDS/75608_Retained_TT.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 75608 Version 1.0</div></div></div>"},"75609":{"type":"graphic_picture","displayName":"Acute tinea pedis KOH","title":"Acute tinea pedis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute tinea pedis</div><div class=\"cntnt\"><img style=\"width:392px; height:259px;\" src=\"images/PC/75609_Acute_tinea_pedis_KOH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmented, branched dermatophyte hyphae are visible on this potassium hydroxide (KOH) preparation from a patient with acute tinea pedis infection. KOH preparations of skin scrapings from all dermatophyte infections show similar hyphal structures.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 75609 Version 3.0</div></div></div>"},"75610":{"type":"graphic_table","displayName":"Effect of electrical current","title":"Pathophysiologic effects of different intensities of electrical current","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathophysiologic effects of different intensities of electrical current</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Current intensity</td>\n\n      <td class=\"subtitle1\">Effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1 mA</td>\n\n      <td>Tingling sensation; almost not perceptible</td>\n\n    </tr>\n\n    <tr>\n      <td>3-5 mA</td>\n      <td>\"Let-go\" current for an average child</td>\n    </tr>\n    <tr>\n      <td>6-9 mA</td>\n      <td>\"Let-go\" current for an average adult</td>\n    </tr>\n    <tr>\n      <td>16 mA</td>\n      <td>Maximum current a person can grasp and \"let go\"</td>\n    </tr>\n    <tr>\n      <td>16-20 mA</td>\n      <td>Tetany of skeletal muscles</td>\n    </tr>\n    <tr>\n      <td>20-50 mA</td>\n      <td>Paralysis of respiratory muscles; respiratory arrest</td>\n    </tr>\n    <tr>\n      <td>50-100 mA</td>\n      <td>Threshold for ventricular fibrillation</td>\n    </tr>\n    <tr>\n      <td>&#62;2 A</td>\n      <td>Asystole</td>\n    </tr>\n    <tr>\n\n      <td>15-30 A</td>\n\n      <td>Common household circuit breakers</td>\n\n    </tr>\n    <tr>\n      <td>240 A</td>\n      <td>Maximal intensity of household current (U.S.)</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Koumbourlis, AC. Electrical injuries. Crit Care Med 2002; 30:S425. Copyright &#169; 2002 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 75610 Version 1.0</div></div></div>"},"75611":{"type":"graphic_figure","displayName":"Closure rectovaginal fistula3","title":"Repair of a small rectovaginal fistula through a transvaginal approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a small rectovaginal fistula through a transvaginal approach</div><div class=\"cntnt\"><img style=\"width:342px; height:452px;\" src=\"images/OBGYN/75611_Closure_rectovaginal_fist2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The puborectalis fibers are reapproximated in the midline to give a third layer of closure.</div><div id=\"graphicVersion\">Graphic 75611 Version 1.0</div></div></div>"},"75612":{"type":"graphic_picture","displayName":"Resectoscope assembly 3","title":"Hysteroscopy: Resectoscope assembly 3","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopy: Resectoscope assembly 3</div><div class=\"cntnt\"><img style=\"width:432px; height:271px;\" src=\"images/OBGYN/75612_Resectoscope_assembly_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Linda D Bradley, MD.</div><div id=\"graphicVersion\">Graphic 75612 Version 2.0</div></div></div>"},"75613":{"type":"graphic_picture","displayName":"Two-piece mandibular advancement splint","title":"Mandibular advancement splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mandibular advancement splint</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/PULM/75613_Mandibular_advan_splint_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Another example of a two-piece device, with full occlusal coverage, and a titratable slot and flange coupling mechanism in the vicinity of the posterior teeth, permitting mouth opening and closing whilst in advancement (SomnoMed MAS, SomnoMed Ltd, Australia).</div><div class=\"graphic_reference\">Reproduced with permission from: SomnoMed, Inc. http://www.somnomed.com.au/index.php?id=281.</div><div id=\"graphicVersion\">Graphic 75613 Version 3.0</div></div></div>"},"75614":{"type":"graphic_figure","displayName":"GAP flap breast reconstruction","title":"GAP flap breast reconstruction","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">GAP flap breast reconstruction</div><div class=\"cntnt\"><img style=\"width:463px; height:538px;\" src=\"images/SURG/75614_GAP-flap-breast-reconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For patients who do not have sufficient lower abdominal fat for reconstructive flaps, but who prefer the use of autologous tissue, a more viable donor site may be the buttock area. For this free flap, perforating vessels from either the superior gluteal artery (SGAP flap) or the inferior gluteal artery (IGAP flap) can be used as the vascular supply for the transferred tissue. For the SGAP flap, upper buttock tissue is used, resulting in a donor site scar that is concealable under most swimwear. If an IGAP flap is performed, the donor site scar lies within the lower buttock crease.</div><div id=\"graphicVersion\">Graphic 75614 Version 1.0</div></div></div>"},"75615":{"type":"graphic_figure","displayName":"Organization of the human T cell receptor-alpha chain locus","title":"Organization of the human T cell receptor-alpha chain locus","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Organization of the human T cell receptor-alpha chain locus</div><div class=\"cntnt\"><img style=\"width:547px; height:96px;\" src=\"images/ALLRG/75615_Human_TCR_alpha_chain.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are 49 V alpha genes, of which&nbsp;7 are pseudogenes in some haplotypes. Five of these V alpha genes may also recombine with gene segments in the delta-chain&nbsp;locus. One V delta gene is also in the V alpha region. There are 61 J alpha gene segments, of which&nbsp;3 are pseudogenes, and&nbsp;8 are not utilized, although they contain open reading frames (ORFs). There is a single C alpha gene.</div><div class=\"graphic_reference\">Adapted from: Leiden JM. Transcriptional regulation of T cell receptor genes. Annu Rev Immunol 1993; 11:539.</div><div id=\"graphicVersion\">Graphic 75615 Version 5.0</div></div></div>"},"75616":{"type":"graphic_diagnosticimage","displayName":"Hepatic toxocariasis","title":"Hepatic toxocariasis","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Hepatic toxocariasis</div><div class=\"cntnt\"><img style=\"width:561px; height:469px;\" src=\"images/ID/75616_Hepatic_toxocariasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 43-year-old man with hepatic toxocariasis. Contrast-enhanced arterial (A), portal phases (B), and equilibrium phase (C). Computed tomography&nbsp;images display two small triangular and oval nodules in the periphery of the liver. The nodules are clearly seen on portal venous phase image but not clearly seen on arterial and equilibrium phase images.</div><div class=\"graphic_reference\">Reproduced from: Lim JH. Toxocariasis of the liver: visceral larva migrans. Abdom Imaging 2008; 33:151, with kind permission of Springer Science + Business Media B.V. Copyright Â© 2008.</div><div id=\"graphicVersion\">Graphic 75616 Version 7.0</div></div></div>"},"75617":{"type":"graphic_picture","displayName":"Photomicrograph of a BMU","title":"Photomicrograph of a basic multicellular unit","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Photomicrograph of a basic multicellular unit</div><div class=\"cntnt\"><img style=\"width:504px; height:400px;\" src=\"images/ENDO/75617_Photomicrograph_BMU.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A group of osteoclasts with tartrate-resistant acid phosphatase-positive red granules erodes through a trabecula in murine vertebral cancellous bone. Pale yellow erythrocytes are seen in the blood vessels that transported the osteoclast precursors to the erosion cavity. Trailing behind the osteoclasts, teams of teal-colored osteoblasts forming new bone are bringing up the rear. Teal-colored osteocytes buried individually in the mineralized matrix (beige) are seen above and below the BMU.</div><div class=\"graphic_footnotes\">BMU: basic multicellular unit.</div><div class=\"graphic_reference\">Reproduced with permission from: Weinstein RS, Jia D, Powers CC, et al. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 2004; 145:1980. Copyright Â© 2004 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 75617 Version 2.0</div></div></div>"},"75618":{"type":"graphic_table","displayName":"Counterregulatory response hypoglycemia","title":"Counterregulatory response to hypoglycemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Counterregulatory response to hypoglycemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Glucose</td> <td class=\"subtitle1\">Insulin</td> <td class=\"subtitle1\">Glucagon</td> <td class=\"subtitle1\">Epinephrine</td> </tr> <tr> <td>Nondiabetic</td> <td>&#8595;</td> <td>Decreases</td> <td>Increases</td> <td>Increases</td> </tr> <tr> <td>T1DM</td> <td>&#8595;</td> <td>No Decrease*</td> <td>No Increase*</td> <td>Attenuated Increase*<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">T2DM</td> </tr> <tr> <td class=\"sublist1\">Early</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">Decreases</td> <td class=\"sublist_other\">Increases</td> <td class=\"sublist_other\">Increases</td> </tr> <tr> <td class=\"sublist1\">Late (Absolute endogenous insulin deficient)</td> <td class=\"sublist_other\">&#8595;</td> <td class=\"sublist_other\">No Decrease*</td> <td class=\"sublist_other\">No Increase*</td> <td class=\"sublist_other\">Attenuated Increase*<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Iatrogenic hypoglycemia is the result of the interplay of absolute or relative therapeutic insulin excess and compromised physiological and behavioral defenses against falling plasma glucose concentrations in type 1 diabetes mellitus (T1DM) and advanced type 2 diabetes mellitus (T2DM).</div><div class=\"graphic_footnotes\">* Defective glucose counterregulation.<br />Â¶ Hypoglycemia unawareness.</div><div class=\"graphic_reference\">Courtesy of Dr. Philip Cryer.</div><div id=\"graphicVersion\">Graphic 75618 Version 3.0</div></div></div>"},"75619":{"type":"graphic_table","displayName":"Evaluation fever after OLT","title":"Evaluation of fever after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of fever after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial studies</td> </tr> <tr> <td class=\"subtitle2_single\">History and physical examination</td> </tr> <tr> <td class=\"subtitle2_single\">Laboratory testing</td> </tr> <tr> <td class=\"indent1\">Complete blood count, liver enzymes</td> </tr> <tr> <td class=\"indent1\">Urinalysis, urine culture</td> </tr> <tr> <td class=\"indent1\">Sputum Gram stain</td> </tr> <tr> <td class=\"indent1\">Blood cultures</td> </tr> <tr> <td class=\"subtitle2_single\">Radiologic testing</td> </tr> <tr> <td class=\"indent1\">Chest X-ray</td> </tr> <tr> <td class=\"subtitle1_single\">Additional studies based upon clinical setting</td> </tr> <tr> <td>CMV rapid antigen or CMV quantitative PCR testing</td> </tr> <tr> <td>Chest CT and/or bronchoscopy</td> </tr> <tr> <td>Ultrasound of liver +/- cholangiogram</td> </tr> <tr> <td>Head CT and lumbar puncture</td> </tr> <tr> <td>Abdominal imaging: CT with contrast, magnetic resonance imaging (MRCP)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; CMV: cytomegalovirus; MRCP: magnetic resonance cholangiopancreatography; PCR: polymerase chain reaction.</div><div id=\"graphicVersion\">Graphic 75619 Version 5.0</div></div></div>"},"75621":{"type":"graphic_table","displayName":"Drugs that can cause neuroleptic malignant syndrome","title":"Drugs that can cause neuroleptic malignant syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that can cause neuroleptic malignant syndrome</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neuroleptic agents</td> </tr> <tr> <td>Aripiprazole</td> </tr> <tr> <td>Chlorpromazine</td> </tr> <tr> <td>Clozapine</td> </tr> <tr> <td>Fluphenazine</td> </tr> <tr> <td>Haloperidol</td> </tr> <tr> <td>Olanzapine</td> </tr> <tr> <td>Paliperidone</td> </tr> <tr> <td>Perphenazine</td> </tr> <tr> <td>Quetiapine</td> </tr> <tr> <td>Risperidone</td> </tr> <tr> <td>Thioridazine</td> </tr> <tr> <td>Ziprasidone</td> </tr> <tr> <td>Amisulpride</td> </tr> <tr> <td>Zotepine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Antiemetic agents</td> </tr> <tr> <td>Domperidone</td> </tr> <tr> <td>Droperidol</td> </tr> <tr> <td>Metoclopramide</td> </tr> <tr> <td>Prochlorperazine</td> </tr> <tr> <td>Promethazine</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75621 Version 2.0</div></div></div>"},"75622":{"type":"graphic_table","displayName":"Common cold treatments in pregnancy 2","title":"Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Effect in randomly controlled trial<br /> (not pregnant)</td> <td class=\"subtitle1\">Pregnancy data</td> </tr> <tr> <td rowspan=\"5\">Zinc gluconate</td> <td rowspan=\"5\">The evidence of zinc efficacy for treating the common cold is inconclusive at best, and any beneficial effect is minor.</td> <td>The use of zinc for the treatment of the common cold is probably not justified in pregnancy. The noxious taste of zinc lozenges limit their usefulness particularly in pregnant patients.</td> </tr> <tr> <td>Animal experiments have produced variable but frequently concerning results regarding the safety of high dose zinc supplementation in pregnancy (including increased skeletal defects in mice, exencephaly in hamsters, and an increased incidence of congenital malformations in rats).</td> </tr> <tr> <td>Elevated zinc levels in the fetus have been associated with anencephaly and meningomyelocele in some studies but not in others. It is unclear whether this finding simply reflects physiologic abnormalities associated with these defects.</td> </tr> <tr> <td>One recent report found one infant with a heart defect and one with microcephaly among 26 infants born to 19 mothers treated with zinc for Wilson's disease. This population is too small to estimate whether zinc exposure played any role in the observed defects.</td> </tr> <tr> <td>Zinc deficiency is associated with impaired fertility and low birth weight but is rare in the western world.</td> </tr> <tr> <td>Vitamin C</td> <td>Current extensive literature does not appear to support the use of vitamin C therapy for the common cold.</td> <td>Little pregnancy data available however, there is concern that large doses of this vitamin may be harmful during pregnancy. Ascorbic acid appears in the fetus in concentrations higher than those in the mother and pregnant guinea pigs fed large doses of ascorbic acid gave birth to offspring with increased rates of ascorbic acid catabolism. A human parallel to this was seen in two reported cases of mothers who ingested daily high doses of vitamin C and after birth the infants developed scurvy due to an excessively rapid metabolism of vitamin C presumably induced in utero.</td> </tr> <tr> <td>Echinacea</td> <td>No evidence to support efficacy.</td> <td>Recent data reporting on 206 exposed pregnancies found no increased incidence of anomalies compared with controls.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75622 Version 4.0</div></div></div>"},"75623":{"type":"graphic_diagnosticimage","displayName":"Sonogram short umbilical cord","title":"Sonogram of short umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sonogram of short umbilical cord</div><div class=\"cntnt\"><img style=\"width:403px; height:253px;\" src=\"images/OBGYN/75623_Sonogram_short_umbilical_co.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75623 Version 2.0</div></div></div>"},"75624":{"type":"graphic_diagnosticimage","displayName":"Dysostosis skull radiograph","title":"Dysostosis skull radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dysostosis skull radiograph</div><div class=\"cntnt\"><img style=\"width:331px; height:310px;\" src=\"images/PEDS/75624_Dysostosis_skull_radiograph_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dysostosis multiplex seen on a lateral skull radiograph with expansion of sella turcica.</div><div class=\"graphic_reference\">Courtesy of Ed Wraith, MD.</div><div id=\"graphicVersion\">Graphic 75624 Version 3.0</div></div></div>"},"75625":{"type":"graphic_diagnosticimage","displayName":"Plain film radiography of the hip","title":"Plain film radiography of the hip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain film radiography of the hip</div><div class=\"cntnt\"><img style=\"width:396px; height:392px;\" src=\"images/RADIOL/75625_Acute_hip_trauma_plain_film.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left hip after trauma. Frontal radiograph of the left hip in a patient with left hip pain following recent fall shows no distinct fracture.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 75625 Version 3.0</div></div></div>"},"75626":{"type":"graphic_figure","displayName":"Gell Coombs IVa to IVd","title":"T cell-mediated hypersensitivity reactions (Gell and Coombs types IVa to IVd)","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">T cell-mediated hypersensitivity reactions (Gell and Coombs types IVa to IVd)</div><div class=\"cntnt\"><img style=\"width:613px; height:462px;\" src=\"images/ALLRG/75626_Gell_Coombs_IVa-d.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IFN-gamma: interferon-gamma; TNF-alpha: tumor necrosis factor-alpha; Th1: T helper type 1; IL: interleukin; Th2: T helper type 2; CTL: cytotoxic lymphocyte; GM-CSF: granulocyte monocyte colony-stimulating factor; PMN: polymorphonuclear cell; AGEP: acute-generalized exanthematous pustulosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Celik G, Pichler WJ, Adkinson NF Jr. Drug Allergy. In: Middleton's Allergy Principles &amp; Practice, 7th ed, Adkinson NF, et al (Ed), Mosby Elsevier, Philadelphia 2009. p.1205-1226. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 75626 Version 8.0</div></div></div>"},"75627":{"type":"graphic_table","displayName":"Cardiac injury scale","title":"Cardiac injury scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiac injury scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Injury description</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">I</td> <td>Blunt cardiac injury with minor ECG abnormality (nonspecific ST or T wave changes, premature atrial or ventricular contraction, or persistent sinus tachycardia)</td> </tr> <tr> <td>Blunt or penetrating pericardial wound without cardiac injury, cardiac tamponade, or cardiac herniation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">II</td> <td>Blunt cardiac injury with heart block or ischemic changes without cardiac failure</td> </tr> <tr> <td>Penetrating tangential cardiac wound up to but not extending through endocardium, without tamponade</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">III</td> <td>Blunt cardiac injury with sustained or multifocal ventricular contractions</td> </tr> <tr> <td>Blunt or penetrating cardiac injury with septal rupture, pulmonary or tricuspid incompetence, papillary muscle dysfunction, or distal coronary artery occlusion without cardiac failure</td> </tr> <tr> <td>Blunt pericardial laceration with cardiac herniation</td> </tr> <tr> <td>Blunt cardiac injury with cardiac failure</td> </tr> <tr> <td>Penetrating tangential myocardial wound up to but not through endocardium, with tamponade</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">IV</td> <td>Blunt or penetrating cardiac injury with septal rupture, pulmonary or tricuspid incompetence, papillary muscle dysfunction, or distal coronary artery occlusion producing cardiac failure</td> </tr> <tr> <td>Blunt or penetrating cardiac injury with aortic or mitral incompetence</td> </tr> <tr> <td>Blunt or penetrating cardiac injury of the right ventricle, right or left atrium</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">V</td> <td>Blunt or penetrating cardiac injury with proximal coronary artery occlusion</td> </tr> <tr> <td>Blunt or penetrating left ventricular perforation</td> </tr> <tr> <td>Stellate injuries &#60;50 percent tissue loss of the right ventricle, right or left atrium</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">VI</td> <td>Blunt avulsion of the heart</td> </tr> <tr> <td>Penetrating wound producing &#62;50 percent tissue loss of a chamber</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=92325&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Advance one grade for multiple penetrating wounds to a single chamber or multiple chamber involvement.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore EE, Malangoni MA, Cogbill TH, et al. Organ injury scaling. IV: Thoracic vascular, lung, and diaphragm. J Trauma 1994; 36:299. Copyright Â© 1994 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75627 Version 5.0</div></div></div>"},"75628":{"type":"graphic_table","displayName":"Risk factors for date rape","title":"Risk factors for date rape","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for date rape</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Age 16 to 24 years</td> </tr> <tr> <td>Previous history of physical or sexual victimization</td> </tr> <tr> <td>Greater number of dating or sexual partners</td> </tr> <tr> <td>Acceptance of rape myths*</td> </tr> <tr> <td>Strong belief in traditional gender roles</td> </tr> <tr> <td>Date-specific factors (eg, going somewhere to be alone, expenses paid by date)</td> </tr> <tr> <td>Alcohol or drug use (promotes misinterpretation of behaviors and impairs ability for self-defense)</td> </tr> <tr> <td>Pressure by date to use alcohol or drugs</td> </tr> <tr> <td>Beverages spiked with \"date rape\" drugs (eg, flunitrazepam [Rohypnol], 3,4-methylendioxymethamphetamine [MDMA or ecstasy], ketamine, gamma hydroxybutyrate [GHB])</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Rape myths are prejudiced, stereotyped, or false beliefs about rape, rape victims, and rapists (eg, \"Most rapists are strangers\"; \"Any healthy woman can resist a rapist if she really wants to\").</div><div id=\"graphicVersion\">Graphic 75628 Version 3.0</div></div></div>"},"75629":{"type":"graphic_figure","displayName":"Mortality after thrombolysis based on TIMI flow ","title":"TIMI grade 3 coronary flow is associated with improved survival after thrombolysis","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">TIMI grade 3 coronary flow is associated with improved survival after thrombolysis</div><div class=\"cntnt\"><img style=\"width:494px; height:248px;\" src=\"images/CARD/75629_Thrombolysis_and_TIMI_flow.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the GUSTO-I trial, the 30-day mortality rate after thrombolysis for acute ST elevation myocardial infarction varied with the degree of vessel patency achieved. The mortality was lowest (4.3 percent) in patients with TIMI grade 3 (normal) flow in the infarct-related artery at 90 minutes. Partial restoration of flow (TIMI grade 2) did not improve outcomes compared to no or or faint flow (TIMI grade 0 or 1).</div><div class=\"graphic_reference\">Data from The GUSTO Investigators. N Engl J Med 1993; 329:673.</div><div id=\"graphicVersion\">Graphic 75629 Version 5.0</div></div></div>"},"75630":{"type":"graphic_figure","displayName":"Bowing fracture reduction","title":"Bowing fracture reduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bowing fracture reduction</div><div class=\"cntnt\"><img style=\"width:418px; height:248px;\" src=\"images/EM/75630_Bowing_fx_reduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduction technique of bow fracture over fulcrum.</div><div class=\"graphic_reference\">Reproduced with permission from: Sanders WE, Heckman JD. Traumatic plastic deformation of the radius and ulna: a closed method of correction of deformity. Clin Orthop 1984; 188:58. Copyright &#169; 1984 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75630 Version 5.0</div></div></div>"},"75634":{"type":"graphic_waveform","displayName":"EEG Benign epilepsy with centrotemporal spikes BCECTS","title":"A 10-second EEG segment showing the typical sharp waves of BCECTS","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">A 10-second EEG segment showing the typical sharp waves of BCECTS</div><div class=\"cntnt\"><img style=\"width:505px; height:263px;\" src=\"images/PEDS/75634_EEG_BCECTS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 10-second segment shows the typical sharp waves of benign childhood epilepsy with centrotemporal spikes (BCECTS).&nbsp;They are markedly more frequent in sleep (stages I and II here) than in wakefulness. The morphology is typical with aduration of almost 200 ms and a high amplitude aftergoing slow wave (as high as the sharp wave). The distribution is centro-temporal, and as in this example they are often bilateral and independent. The dipole with frontal positivity is also typical and would be best shown on a referential montage.</div><div class=\"graphic_footnotes\">EEG: electroencephalography.</div><div class=\"graphic_reference\">Courtesy of Selim R Benbadis, MD.</div><div id=\"graphicVersion\">Graphic 75634 Version 4.0</div></div></div>"},"75636":{"type":"graphic_figure","displayName":"Withdraw theophylline in asthma","title":"The effect of abrupt withdrawal of theophylline in five children with glucocorticoid-dependent asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The effect of abrupt withdrawal of theophylline in five children with glucocorticoid-dependent asthma</div><div class=\"cntnt\"><img style=\"width:397px; height:231px;\" src=\"images/PULM/75636_Withdraw_theophylline_in_as.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel represents the average daily scores for symptoms of asthma and the number of extra respiratory treatments (RT) with bronchodilator. The right panel shows the average daily dose of prednisone required to treat the patient during theophylline (T) and placebo (P) treatment periods.</div><div class=\"graphic_reference\">Redrawn from Brenner, M, Berkowitz, R, Marshall, N, Strunk, RC, Clin Allergy 1988; 18:143.</div><div id=\"graphicVersion\">Graphic 75636 Version 1.0</div></div></div>"},"75637":{"type":"graphic_figure","displayName":"Dialysis patients who received ICD devices","title":"The number of dialysis patients who received ICD devices","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">The number of dialysis patients who received ICD devices</div><div class=\"cntnt\"><img style=\"width:524px; height:296px;\" src=\"images/NEPH/75637_Dialysis_pts_ICD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Number of patients receiving an implantable cardioverter-defibrillator (ICD) device by apparent secondary versus primary prevention. Annual counts of ICD implantations in US dialysis patients. Secondary prevention ascertained by the presence of at least one diagnosis for cardiac arrest or ventricular arrhythmia.</div><div class=\"graphic_reference\">Reproduced from: Charytan DM, Patrick AR, Liu J, et al. Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States. Am J Kidney Dis 2011; 58:409. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 75637 Version 4.0</div></div></div>"},"75638":{"type":"graphic_diagnosticimage","displayName":"Acetabular transverse and posterior wall fractures","title":"Acetabular transverse and posterior wall fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acetabular transverse and posterior wall fractures</div><div class=\"cntnt\"><img style=\"width:387px; height:407px;\" src=\"images/EM/75638_Acetab_fx_trns_pst_wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The appearance on the anteroposterior view is similar to that of a pure transverse fracture with disruption of five of the six radiograph landmarks; only the radiographic U (which maintains its normal relationship to the ilioischial line) remains intact. The posterior wall fragment is seen as an oblique cortical line overlying the intact roof (arrow).<br />(B) The obturator oblique shows the transverse fracture, the subluxation of the femoral head with the ischiopubic fragment, as well as the posterior wall fragment. It is easy to see on this view how the femoral head may abrade against the fracture edge while the hip is subluxated.<br />(C) The iliac oblique view highlights the fracture line exiting the greater sciatic notch as well as the posterior wall fragment superimposed on the roof of the acetabulum (arrowhead).<br />(D) This computed tomography section shows the posterior wall fracture (dashed arrow) with a column fracture line typical of a transverse fracture (double arrow).</div><div class=\"graphic_reference\">Originally published in: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Reproduced with permission. Copyright &copy; Berton R. Moed, MD.</div><div id=\"graphicVersion\">Graphic 75638 Version 3.0</div></div></div>"},"75639":{"type":"graphic_figure","displayName":"Tirofiban elevated troponin I","title":"Tirofiban improves outcome in patients with a non-ST elevation ACS and a positive serum tropinin I","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Tirofiban improves outcome in patients with a non-ST elevation ACS and a positive serum tropinin I</div><div class=\"cntnt\"><img style=\"width:495px; height:376px;\" src=\"images/CARD/75639_Tirofiban_elevated_troponin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the PRISM trial, tirofiban significantly reduced the 30-day event rate in 629 patients with a non-ST elevation acute coronary syndrome (ACS) who had evidence of myocardial necrosis based upon a positive serum troponin I level (&#8805;1 &#181;g/L) (4.9 versus 13 percent for heparin). The significant benefit of tirofiban was seen in patients managed medically (hazard ratio 0.30) and in those undergoing revascularization (hazard ratio 0.37).</div><div class=\"graphic_reference\">Data from Heeschen C, Hamm CW, Goldmann B, et al. Lancet 1999; 354:1757.</div><div id=\"graphicVersion\">Graphic 75639 Version 3.0</div></div></div>"},"75640":{"type":"graphic_figure","displayName":"Cell divisions spermatogenesis","title":"Cell divisions during spermatogenesis","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Cell divisions during spermatogenesis</div><div class=\"cntnt\"><img style=\"width:530px; height:342px;\" src=\"images/ENDO/75640_Cell_divisions_spermatogene.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each spermatogonium that undergoes differentiation after puberty gives rise to 16 primary spermatocytes, each of which then enters meiosis and gives rise to four spermatids and finally four spermatozoa. Thus, each of the&nbsp;three million spermatogonia that begin the process every day gives rise to 64 spermatozoa. Since about one-half of potential sperm are lost during this process, approximately 100 million sperm are produced each day.</div><div class=\"graphic_reference\">Reproduced with permission from: Griffin JE, Wilson JD, Disorders of the testes and male reproductive tract. In: Williams Textbook of Endocrinology, 7th ed, Wilson JD, Foster DW (Eds), Saunders, Philadelphia 1985, p.810.</div><div id=\"graphicVersion\">Graphic 75640 Version 3.0</div></div></div>"},"75641":{"type":"graphic_figure","displayName":"Histoplasma clinical syndromes","title":"Clinical course following exposure to Histoplasma capsulatum","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Clinical course following exposure to Histoplasma capsulatum</div><div class=\"cntnt\"><img style=\"width:530px; height:706px;\" src=\"images/ID/75641_Histoplasma_clinical_syndromes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histoplasmosis remains asymptomatic in most healthy individuals following low level exposure. Symptomatic infection usually&nbsp;causes self-limited pulmonary illnesses, rheumatologic manifestations, erythema nodosum, or pericarditis, but a heavy inoculum can cause diffuse pulmonary involvement. The variation in clinical course noted in the illustration above depends on the extent of exposure to the organism (ie, ~1 percent of individuals exposed to a low inoculum develop self-limited symptomatic infection compared with ~50 percent of individuals exposed to a high inoculum). Persons with emphysema may develop chronic pulmonary histoplasmosis with cavity formation, and individuals at the extremes of age or with underlying immunosuppressive conditions can develop progressive disseminated disease. Rarely, patients manifest chronic inflammatory conditions such as fibrosing mediastinitis or a sarcoidosis-like illness.</div><div class=\"graphic_reference\">Courtesy of Joseph Wheat, MD.</div><div id=\"graphicVersion\">Graphic 75641 Version 6.0</div></div></div>"},"75642":{"type":"graphic_waveform","displayName":"Basic case 2 with answer","title":"Complete RBBB","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Complete RBBB</div><div class=\"cntnt\"><img style=\"width:478px; height:293px;\" src=\"images/CARD/75642_Basic_case_2_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing characteristic changes in the precordial leads in complete RBBB. The asynchronous activation of the two ventricles increases the QRS duration (0.13 sec). The terminal forces are rightward and anterior due the delayed activation of the right ventricle, resulting in an rsR' pattern in the anterior-posterior lead V1 and a wide negative S wave in the left-right lead V6 (and, not shown, in lead I).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 75642 Version 2.0</div></div></div>"},"75645":{"type":"graphic_table","displayName":"Solitary nerve root lesions of the lumbosacral spine","title":"Solitary nerve root lesions of the lumbosacral spine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Solitary nerve root lesions of the lumbosacral spine</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Root</td> <td class=\"subtitle1\">Pain</td> <td class=\"subtitle1\">Sensory loss</td> <td class=\"subtitle1\">Weakness</td> <td class=\"subtitle1\">Stretch reflex loss</td> </tr> <tr> <td>L1</td> <td>Inguinal region</td> <td>Inguinal region</td> <td>Rarely hip flexion</td> <td>None</td> </tr> <tr> <td>L2-L3-L4</td> <td>Back, radiating into anterior thigh, and at times medial lower leg</td> <td>Anterior thigh, occasionally medial lower leg</td> <td>Hip flexion, hip adduction, knee extension</td> <td>Patellar tendon</td> </tr> <tr> <td>L5</td> <td>Back, radiating into buttock, lateral thigh, lateral calf and dorsum foot, great toe</td> <td>Lateral calf, dorsum foot, web space between first and second toe</td> <td>Hip abduction, knee flexion, foot dorsiflexion, toe extension and flexion, foot inversion and eversion</td> <td>Semitendinosus/semimembranosus (internal hamstrings) tendon</td> </tr> <tr> <td>S1</td> <td>Back, radiating into buttock, lateral or posterior thigh, posterior calf, lateral or plantar foot </td> <td>Posterior calf, lateral or plantar aspect of foot</td> <td>Hip extension, knee flexion, plantar flexion of the foot </td> <td>Achilles tendon</td> </tr> <tr> <td>S2-S3-S4</td> <td>Sacral or buttock pain radiating into the posterior aspect of the leg or the perineum</td> <td>Medial buttock, perineal, and perianal regions</td> <td>Weakness may be minimal, with urinary and fecal incontinence as well as sexual dysfunction</td> <td>Bulbocavernosus, anal wink</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75645 Version 4.0</div></div></div>"},"75646":{"type":"graphic_figure","displayName":"Etiology cardiomyopathy outcome","title":"Outcome with a cardiomyopathy is related to the etiology","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Outcome with a cardiomyopathy is related to the etiology</div><div class=\"cntnt\"><img style=\"width:513px; height:329px;\" src=\"images/CARD/75646_Etiologycardiomyopathyout.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 1230 patients with a cardiomyopathy of various etiologies, the adjusted Kaplan-Meier estimates of survival&nbsp;are related to the underlying cause of cardiomyopathy; only idiopathic cardiomyopathy and cardiomyopathy due to causes for which survival was significantly different from that in patients with idiopathic cardiomyopathy are shown. The best outcome is in those with a peripartum cardiomyopathy, and the worst outcome is in those with an infiltrative cardiomyopathy or that due to HIV infection.</div><div class=\"graphic_reference\">Data from Felker CM, Thompson RE, Hare JM, et al. N Engl J Med 2000; 342:1077.</div><div id=\"graphicVersion\">Graphic 75646 Version 2.0</div></div></div>"},"75647":{"type":"graphic_picture","displayName":"Trichiasis in ocular cicatricial pemphigoid","title":"Trichiasis in ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Trichiasis in ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:540px; height:358px;\" src=\"images/DERM/75647_Trichiasis_ocul_cicatricial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distortion of the adnexal relationships and trichiasis (eyelashes turning in to touch the cornea) are present.</div><div id=\"graphicVersion\">Graphic 75647 Version 1.0</div></div></div>"},"75648":{"type":"graphic_algorithm","displayName":"Acute dysphagia child fever","title":"Acute dysphagia in children with fever","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Acute dysphagia in children with fever</div><div class=\"cntnt\"><img style=\"width:610px; height:990px;\" src=\"images/EM/75648_Acute_dysphagia_child_fever.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system; TEN: toxic epidermal necrolysis.<br />* Presence of fever may be variable.</div><div id=\"graphicVersion\">Graphic 75648 Version 3.0</div></div></div>"},"75649":{"type":"graphic_diagnosticimage","displayName":"Lateral malleolus definition","title":"Lateral malleolus definition","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral malleolus definition</div><div class=\"cntnt\"><img style=\"width:298px; height:480px;\" src=\"images/EM/75649_Lat_malleolus_definition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is no single, widely accepted definition of the anatomic margins of the lateral malleolus. For the purpose of this review, the lateral malleolus refers to the distal part of the fibula that articulates with the talus and distal tibia. Lateral malleolar fractures lie between the distal tip of the fibula (inferior yellow line) and the most proximal portion of the fibula that lies directly adjacent to the tibia in the tibial groove (superior yellow line).</div><div class=\"graphic_reference\">Courtesy of Patrice Eiff, MD.</div><div id=\"graphicVersion\">Graphic 75649 Version 3.0</div></div></div>"},"75651":{"type":"graphic_picture","displayName":"Niemann Pick cells","title":"Niemann Pick Cells on bone marrow aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Niemann Pick Cells on bone marrow aspirate</div><div class=\"cntnt\"><img style=\"width:422px; height:288px;\" src=\"images/HEME/75651_Niemann_Pick_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with Niemann Pick disease, showing two large macrophages laden with sphingomyelin, giving the cytoplasm a &quot;foamy&quot; appearance (arrows).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD and William C Moloney, MD.</div><div id=\"graphicVersion\">Graphic 75651 Version 2.0</div></div></div>"},"75653":{"type":"graphic_diagnosticimage","displayName":"Importance correct position","title":"Importance of correct positioning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Importance of correct positioning</div><div class=\"cntnt\"><img style=\"width:404px; height:426px;\" src=\"images/PC/75653_Importance_correct_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both figures show the MLO view of the left breast. In Panel A, the posterior breast tissues are not included. The pectoralis muscle is barely visible. Upon better positioning of the same breast (Panel B), the large irregular mass becomes obvious.</div><div class=\"graphic_footnotes\">MLO: mediolateral oblique.</div><div id=\"graphicVersion\">Graphic 75653 Version 2.0</div></div></div>"},"75654":{"type":"graphic_table","displayName":"Red eyes that must be referred emergently or urgently","title":"Red eyes that must be referred emergently or urgently","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Red eyes that must be referred emergently or urgently</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Angle closure glaucoma</td> <td>Emergent</td> </tr> <tr> <td>Hyphema</td> <td>Emergent</td> </tr> <tr> <td>Hypopyon</td> <td>Emergent</td> </tr> <tr> <td>Iritis</td> <td>Urgent</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Infectious keratitis</td> </tr> <tr> <td class=\"sublist1\">Bacterial&nbsp;</td> <td class=\"sublist_other\">Emergent</td> </tr> <tr> <td class=\"sublist1\">Viral</td> <td class=\"sublist_other\">Urgent</td> </tr> <tr> <td>Scleritis</td> <td>Urgent </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75654 Version 2.0</div></div></div>"},"75655":{"type":"graphic_diagnosticimage","displayName":"Scaphoid fracture","title":"Scaphoid fracture","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scaphoid fracture</div><div class=\"cntnt\"><img style=\"width:313px; height:320px;\" src=\"images/PC/75655_Scaphoid_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 15-year-old suffered acute pain and swelling in the wrist after a fall on an outstretched arm. Initial x-rays were normal, but this film taken two weeks after the injury demonstrates a fracture line through the middle third of the scaphoid.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 75655 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal wrist radiograph</div><div class=\"cntnt\"><img style=\"width:342px; height:297px;\" src=\"images/PC/61652_Normal_wrist_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anterior-posterior view of the wrist is normal. The width of the articular cartilage is 2 mm and is identical to the width of the intercarpal joints.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61652 Version 3.0</div></div></div>"},"75657":{"type":"graphic_diagnosticimage","displayName":"Left lung atelectasis","title":"Complete atelectasis of the left lung","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete atelectasis of the left lung</div><div class=\"cntnt\"><img style=\"width:377px; height:289px;\" src=\"images/PULM/75657_Left_lung_atelectasis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bedside chest radiograph of a intubated patient with complete left lung atelectasis. The endotracheal tube was advanced too far into the airway, obstructing the left mainstem bronchus. The left hemithorax is completely opaque. The cardiac silhouette is totally obscured due to its deviation into the left hemithorax.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75657 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"75659":{"type":"graphic_picture","displayName":"Insertion site infection in HIV","title":"Insertion site infection due to staphylococcus aureus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insertion site infection due to staphylococcus aureus</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/ID/75659_Insertion_site_infection_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breakdown of the skin with pus at the insertion site of a one-month old central venous catheter in an HIV-infected patient.</div><div class=\"graphic_reference\">Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams &amp; Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 75659 Version 6.0</div></div></div>"},"75661":{"type":"graphic_figure","displayName":"Radioautography bands PCN pneumococci","title":"Radioautography enzyme bands for penicillin susceptibility among pneumococci","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radioautography enzyme bands for penicillin susceptibility among pneumococci</div><div class=\"cntnt\"><img style=\"width:198px; height:270px;\" src=\"images/ID/75661_Radioautography_bands_PCN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five distinct bands, each representing a different enzyme, are detected after incubation with penicillin-susceptible pneumococci. Reduced or absent labeling of one or more of the five bands results when strains have reduced susceptibility to penicillin. Labeling can generally be restored after incubation with higher penicillin concentrations.</div><div class=\"graphic_reference\">Reproduced with permission from: Markiewicz Z, Tomasz A. Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci. J Clin Microbiol 1989; 27:405. Copyright Â© 1989 American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 75661 Version 3.0</div></div></div>"},"75668":{"type":"graphic_picture","displayName":"Osteoblasts","title":"Osteoblasts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteoblasts</div><div class=\"cntnt\"><img style=\"width:433px; height:288px;\" src=\"images/HEME/75668_Osteoblasts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A clump of osteoblasts is seen in this bone marrow aspirate. The cells have a small, highly eccentric nucleus, and are similar in appearance to plasma cells. One distinguishing feature is the large Golgi zone separate from the nucleus (arrow).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD and William C Moloney, MD.</div><div id=\"graphicVersion\">Graphic 75668 Version 1.0</div></div></div>"},"75669":{"type":"graphic_figure","displayName":"NASCET endarterectomy stroke","title":"Benefit of carotid endarterectomy after recent ipsilateral nondisabling stroke or TIA in the NASCET trial","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benefit of carotid endarterectomy after recent ipsilateral nondisabling stroke or TIA in the NASCET trial</div><div class=\"cntnt\"><img style=\"width:392px; height:262px;\" src=\"images/NEURO/75669_Endarterec_stroke_NASCE_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The NASCET&nbsp;included 659 patients with a recent TIA or nondisabling stroke and a 70 to 99 percent carotid stenosis who were randomly assigned to carotid endarterectomy or medical therapy. After a two-year follow-up, the cumulative risk of any ipsilateral stroke was significantly lower in the endarterectomy group compared with the medical treatment group (9 versus 26 percent). The Kaplan-Meier survival curve shows the probability of event-free survival after randomization at six-month intervals.</div><div class=\"graphic_footnotes\">NASCET: North American Symptomatic Carotid Endarterectomy Trial; TIA: transient ischemic attack.</div><div class=\"graphic_reference\">Data from: North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325:445.</div><div id=\"graphicVersion\">Graphic 75669 Version 7.0</div></div></div>"},"75670":{"type":"graphic_figure","displayName":"Event recorder PI","title":"Cardiac event recorder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac event recorder</div><div class=\"cntnt\"><img style=\"width:306px; height:413px;\" src=\"images/PI/75670_Event_recorder_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An event recorder is a portable device patients can use to measure their heart rhythm for a short time. The patient must activate the recorder and hold it to the chest when they feel symptoms. It is useful for patients that have intermittent symptoms that may not be captured with other forms of testing.</div><div id=\"graphicVersion\">Graphic 75670 Version 4.0</div></div></div>"},"75671":{"type":"graphic_picture","displayName":"Mucoceles","title":"Mucoceles","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Mucoceles</div><div class=\"cntnt\"><img style=\"width:511px; height:362px;\" src=\"images/PEDS/75671_Mucocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucocele on the tongue of 7-year-old (A and B) and lower lip of 8.5-year-old (C and D).</div><div class=\"graphic_reference\">Courtesy of Martha Ann Keels, DDS, PhD.</div><div id=\"graphicVersion\">Graphic 75671 Version 7.0</div></div></div>"},"75672":{"type":"graphic_figure","displayName":"Scrotal anatomy","title":"Normal testicular anatomy","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Normal testicular anatomy</div><div class=\"cntnt\"><img style=\"width:476px; height:467px;\" src=\"images/PEDS/75672_Scrotal_anatomy_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The testicle is vertical and its anterior portion is surrounded by the tunica vaginalis.</div><div id=\"graphicVersion\">Graphic 75672 Version 3.0</div></div></div>"},"75673":{"type":"graphic_figure","displayName":"Morphologic types of ventricular free wall rupture","title":"Morphologic types of ventricular free wall rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morphologic types of ventricular free wall rupture</div><div class=\"cntnt\"><img style=\"width:445px; height:424px;\" src=\"images/CARD/75673_Morphology_ventricular_rupt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Six morphologic tyes of ventricular free wall rupture were identified at autopsy or surgery in 28 patients: 1: Through and through rupture of the infarcted area with normal wall thickness; 2: Expansion of soft necrotic zone with rupture of the wall; 3: Numerous small perforations within an area of myomalacia (multicanalicular rupture); 4: Rupture of the outer layers of the infarcted area in presence of normal wall thickness; 5: Large epicardial hematoma under pressure (covert rupture); 6: Hemorrhagic infarction with grossly intact but abraded and leaking epicardial surface (bleeding infarct).</div><div class=\"graphic_reference\">Reprinted from Purcaro, A, Costantini, C, Ciampani, N, et al. Diagnostic criteria and management of subacute ventricular free wall rupture complicating acute myocardial infarction. Am J Cardiol 1997; 80(4):397- 405. Copyright 1997, with permission from Excerpta Medica, Inc.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 75673 Version 2.0</div></div></div>"},"75674":{"type":"graphic_picture","displayName":"LIP with nodular inflammation","title":"Lymphocytic interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocytic interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:400px; height:361px;\" src=\"images/PULM/75674_LIP_with_nodular_inflammati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of&nbsp;lung biopsy showing lymphocytic interstitial pneumonia&nbsp;with diffuse nodular inflammation of the pulmonary interstitium.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 75674 Version 2.0</div></div></div>"},"75678":{"type":"graphic_picture","displayName":"Ross River virus rash","title":"Rash of Ross River virus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash of Ross River virus infection</div><div class=\"cntnt\"><img style=\"width:361px; height:236px;\" src=\"images/ID/75678_Ross_River_virus_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Approximately 50 percent of patients with Ross River virus infection present with a rash consisting of scattered, 1 to 5 mm, discrete maculopapular lesions on the limbs and trunk.</div><div class=\"graphic_reference\">Courtesy of Michael Richards, MB, BS, FRACP.</div><div id=\"graphicVersion\">Graphic 75678 Version 2.0</div></div></div>"},"75679":{"type":"graphic_figure","displayName":"Structure of the tooth","title":"Structure of the tooth","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of the tooth</div><div class=\"cntnt\"><img style=\"width:432px; height:411px;\" src=\"images/ID/75679_Structure_of_the_tooth.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Leeson CR, Leeson TS, Paparo AA. Textbook of Histology, 5th ed, WB Saunders, Philadelphia, 1985, p.318.</div><div id=\"graphicVersion\">Graphic 75679 Version 3.0</div></div></div>"},"75681":{"type":"graphic_picture","displayName":"Periocular atopic dermatitis","title":"Atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/75681_Periocular_atopic_derma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and scale on the periocular skin in atopic dermatitis. The pruritus associated with eyelid involvement can be severe.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75681 Version 4.0</div></div></div>"},"75682":{"type":"graphic_table","displayName":"Example of epinephrine infusion (4 micrograms/mL) - Adult","title":"Example of epinephrine infusion (4 micrograms/mL) - Adult","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of epinephrine infusion (4 micrograms/mL) - Adult</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Example of preparation of epinephrine infusion for refractory symptoms of anaphylaxis (adult patient) for emergency/critical care units</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"3\"> <p>Final concentration: Epinephrine 4 mcg/mL</p> Add 1 mg (1000 mcg) of epinephrine to 250 mL bag of 0.9% normal saline (NS) or 5% dextrose water (D5W)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Preparation</td> </tr> <tr> <td colspan=\"3\"> <ol> <li><strong>CHECK</strong> vial strength. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"> <ol start=\"2\"> <li>To prepare epinephrine infusion for a final concentration of 4 mcg/mL, dilute <strong>10 mL</strong> of <strong>0.1 mg/mL</strong> epinephrine (may also be&nbsp;labeled as&nbsp;1:10,000) <strong>OR</strong> <strong>1 mL</strong> of <strong>1 mg/mL</strong> epinephrine (may also be labeled as 1:1000) in <strong>250 mL</strong> bag of 0.9% NS or D5W.* </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Administration</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"> <ul> <li> <p>Start the epinephrine&nbsp;infusion&nbsp;at<strong>&nbsp;0.1 mcg/kg/minute</strong> using a programmable infusion pump while continuously monitoring the patient's cardiac rhythm and blood pressure (ie, approximately 6 to 10 mcg/minute in most adults). </p> </li> <li> <p>Using a body weight of 70 kg as an example, you can&nbsp;determine the infusion rate&nbsp;to deliver a dose of 0.1 mcg/kg/minute&nbsp;from&nbsp;a&nbsp;4 mcg/mL bag as follows:</p> </li> </ul> <ol> <li>Multiply 0.1 mcg/kg/minute dose by 70 kg body weight to determine dose in mcg/minute (= 7 mcg/minute) </li> <li>Use this table to convert&nbsp;7 mcg/minute to infusion rate&nbsp;of&nbsp;1.75&nbsp;mL/minute (= 105 mL/hour) </li> </ol> <ul> <li> <p>Every two to three minutes, increase the infusion rate by approximately one-half of the starting rate until the blood pressure and perfusion improve. For more detail, refer to the UpToDate topic on emergency treatment of anaphylaxis.&nbsp;</p> </li> <li> <p>In morbidly obese adults, we suggest initiating the infusion using a standard, ie, non-weight-based dose (eg, up to&nbsp;10 mcg/minute initially)&nbsp;and titrating to effect.</p> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2\">Adult infusion dose</td> <td class=\"subtitle2\" colspan=\"2\">Administration rate for infusion pump to deliver adult dose shown</td> </tr> <tr> <td class=\"subtitle3\">mcg per minute</td> <td class=\"subtitle3\">mL per minute</td> <td class=\"subtitle3\">mL per hour</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">0.25</td> <td class=\"centered\">15</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">2</td> <td class=\"centered\">0.5</td> <td class=\"centered\">30</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">0.75</td> <td class=\"centered\">45</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">4</td> <td class=\"centered\">1</td> <td class=\"centered\">60</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">1.25</td> <td class=\"centered\">75</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">6</td> <td class=\"centered\">1.5</td> <td class=\"centered\">90</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">1.75</td> <td class=\"centered\">105</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">8</td> <td class=\"centered\">2</td> <td class=\"centered\">120</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">2.25</td> <td class=\"centered\">135</td> </tr> <tr class=\"divider_bottom highlight_blue_text\"> <td class=\"centered\">10</td> <td class=\"centered\">2.5</td> <td class=\"centered\">150</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">2.75</td> <td class=\"centered\">165</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">12</td> <td class=\"centered\">3</td> <td class=\"centered\">180</td> </tr> <tr> <td class=\"centered\">13</td> <td class=\"centered\">3.25</td> <td class=\"centered\">195</td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"centered\">14</td> <td class=\"centered\">3.5</td> <td class=\"centered\">210</td> </tr> <tr> <td class=\"centered\">15</td> <td class=\"centered\">3.75</td> <td class=\"centered\">225</td> </tr> <tr class=\"divider_bottom highlight_blue_text\"> <td class=\"centered\">16</td> <td class=\"centered\">4</td> <td class=\"centered\">240</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The above table is provided as an example. There are other acceptable concentrations. </LI>&#xD;&#xA;<LI>Intravenous epinephrine, like all vasopressors, can cause life-threatening hypertension, cardiac ischemia, and ventricular arrhythmias. It should be administered ONLY by clinicians trained and experienced in dose titration of intravenous epinephrine using continuous noninvasive electronic monitoring of heart rate and blood pressure. </LI>&#xD;&#xA;<LI>Epinephrine is an ischemia-causing agent and vesicant. Monitor infusion site for extravasation. Central&nbsp;venous catheter&nbsp;administration is preferred when available. Refer to the&nbsp;Lexicomp drug reference for information on managing extravasation including infiltration of phentolamine.</LI>&#xD;&#xA;<LI>To reduce the risk of making a medication error, we suggest that centers have available an institutionally approved protocol for epinephrine infusion that includes steps on how to prepare and administer the infusion by programmable infusion pump and standard concentration(s).</LI></UL></div><div class=\"graphic_footnotes\">* Unused diluted solutions should be discarded within 24 hours or less of preparation, depending on local standards.<br /></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gahart BL, Nazareno AR, Ortega MQ. Gahart's 2016 Intravenous Medications: A Handbook for Nurses and Health Professionals, 32nd ed, Elsevier-Mosby, St. Louis, MO 2016.</LI>&#xD;&#xA;<LI>Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477.</LI></OL></div><div id=\"graphicVersion\">Graphic 75682 Version 9.0</div></div></div>"},"75683":{"type":"graphic_waveform","displayName":"Acute anteroseptal MI tutorial","title":"Acute anteroseptal myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Acute anteroseptal myocardial infarction</div><div class=\"cntnt\"><img style=\"width:521px; height:148px;\" src=\"images/CARD/75683_Acute_anteroseptal_MI_tutor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ST segment elevation in V1 and V2 is characteristic of an acute anteroseptal infarct. There is also reciprocal ST segment depression in V5 and V6.</div><div id=\"graphicVersion\">Graphic 75683 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"75684":{"type":"graphic_figure","displayName":"Prostate ca incidence over time","title":"Prostate cancer: Changes over time in average annual age-adjusted incidence and mortality rates in the United States, 1975 to 2014","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Prostate cancer: Changes over time in average annual age-adjusted incidence and mortality rates in the United States, 1975 to 2014</div><div class=\"cntnt\"><img style=\"width:754px; height:330px;\" src=\"images/PC/75684_Prostate_ca_incidence_edt4.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of prostate cancer in the United States during the widespread use of screening with prostate-specific antigen (PSA).</div><div class=\"graphic_reference\">Reproduced from: Cancer Stat Facts: Prostate Cancer. Surveillance Epidemiology and End Results (SEER) Program. National Cancer Institute. Available at: <A href=\"http://seer.cancer.gov/\" target=_blank>http://seer.cancer.gov/</A> (Accessed on May 9, 2017).</div><div id=\"graphicVersion\">Graphic 75684 Version 10.0</div></div></div>"},"75685":{"type":"graphic_picture","displayName":"Severe dry eye 2","title":"Dry eye disease with loss of luster of the conjunctival and corneal surface associated with breakdown of the normal ocular epithelial surfaces","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dry eye disease with loss of luster of the conjunctival and corneal surface associated with breakdown of the normal ocular epithelial surfaces</div><div class=\"cntnt\"><img style=\"width:432px; height:287px;\" src=\"images/PC/75685_Severe_dry_eye_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75685 Version 1.0</div></div></div>"},"75686":{"type":"graphic_waveform","displayName":"Airway pressure mechanical vent","title":"Airway pressures during various modes of ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airway pressures during various modes of ventilation</div><div class=\"cntnt\"><img style=\"width:310px; height:337px;\" src=\"images/PULM/75686_Airway_pressure_mechanical.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Airway pressures (Paw) during inspiration and expiration with controlled mechanical ventilation (CMV), assist-control (AC), intermittent mandatory ventilation delivered by a continuous flow circuit (IMV-CF), and synchronized intermittent mandatory ventilation delivered by demand valve circuit (SIMV-DV).</div><div class=\"graphic_reference\">Data from Tobin, MJ, Dantzker, DR, In: Cardiopulmonary Critical Care, Dantzker, DR (Ed), Grune and Stratton, Orlando, 1986.</div><div id=\"graphicVersion\">Graphic 75686 Version 2.0</div></div></div>"},"75687":{"type":"graphic_diagnosticimage","displayName":"Mitral flow velocities","title":"Mitral flow inflow velocities","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Mitral flow inflow velocities</div><div class=\"cntnt\"><img style=\"width:524px; height:302px;\" src=\"images/CARD/75687_Mitral_flow_vel.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Sherif F Nagueh.</div><div id=\"graphicVersion\">Graphic 75687 Version 3.0</div></div></div>"},"75688":{"type":"graphic_table","displayName":"Education at 2nd follow up","title":"Delivery of asthma education by clinicians during patient care visits: recommendations for second followup visit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Delivery of asthma education by clinicians during patient care visits: recommendations for second followup visit</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Assessment questions</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Focus on:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Expectations of visit</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Goals of treatment</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Medications</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Quality of life</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Ask relevant questions from previous visit and also ask:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"Have you noticed anything in your home, work, or school that makes your asthma worse?\"</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"Describe for me how you know when to call your doctor or go to the hospital for asthma care.\"</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"What questions do you have about the action plan?\" \"Can we make it easier?\"</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">\"Are your medications causing you any problems?\"</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\"> Information</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Teach or review in simple language:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">Relevant environmental control/avoidance strategies:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">How to identify home, work, or school exposures that can cause or worsen asthma</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">How to control house-dust mites, animal exposure if applicable</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">How to avoid cigarette smoke (active and passive)</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Review all medications.</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2_start\">Review and interpret from daily diary:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Peak flow measures</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist2\">Symptom scores</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\"> Skills</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle2_single\">Teach or review and demonstrate:</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Inhaler/spacer/holding chamber technique.</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Peak flow monitoring technique.</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\">Use of daily self-management plan. Review and adjust as needed.</td></tr>\n\t\t\t\t\t\t<tr><td class=\"indent1\" rowspan=\"5\">Review use of action plan. Confirm that patient knows what to do if asthma gets worse.</td></tr></tbody></table></td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75688 Version 1.0</div></div></div>"},"75689":{"type":"graphic_picture","displayName":"Malignant mesothelioma Light","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:360px; height:233px;\" src=\"images/PULM/75689_Malignant_mesothelioma_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of an epithelial malignant mesothelioma. The sheets of pleomorphic cells are epithelial in appearance, with eosinophilic cytoplasm and fairly well-defined cell borders. Cytoplasmic vacuoles (arrow) are present, which can lead to confusion with a signet ring type of adenocarcinoma. These vacuoles can be shown by electron microscopy to contain crystallized hyaluronic acid.</div><div class=\"graphic_reference\">Courtesy of Giuseppe G Pietra, MD.</div><div id=\"graphicVersion\">Graphic 75689 Version 1.0</div></div></div>"},"75690":{"type":"graphic_picture","displayName":"Glycolipid Glomerular podocytes","title":"Plastic embedded tissue showing in site deposition of glycolipid in glomerular podocytes (toluidine blue stain, original magnification X80)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plastic embedded tissue showing in site deposition of glycolipid in glomerular podocytes (toluidine blue stain, original magnification X80)</div><div class=\"cntnt\"><img style=\"width:432px; height:369px;\" src=\"images/NEPH/75690_GlycolipidGlomerularpodoc.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81:122. Copyright Â© 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75690 Version 8.0</div></div></div>"},"75693":{"type":"graphic_table","displayName":"Dining out allergy tips PI","title":"Avoiding food allergens when dining out","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Avoiding food allergens when dining out</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td    class=\"subtitle1_single\">\n   Tips:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   1. Consumers should clearly state that they have a food allergy (not just a distaste for the food) to the person who is directly responsible for preparing the meal (ie, the cook or manager, rather than the waitstaff).\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   2. Carry a supply of pre-printed cards with clear information about which foods cannot be eaten (see below). Remind the cook or manager that cooking containers and serving utensils cannot be contaminated with the allergenic food. As an example, it may be necessary to use a clean pan or glassware rather than a shared grill or blender.\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   3. Food that is fried in oil may be reused for frying allergenic foods and should be avoided. The oil becomes contaminated easily with protein from previously cooked foods.\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   4. Ingredient lists on menus should not be trusted at face value. If a food allergen is not listed, the person should verify that it is not used to prepare or garnish the dish. This also applies to \"secret\" ingredients. Avoid the food if the server/cook is not sure about the ingredients.\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   5. People with peanut or tree nut allergies should be especially careful of ice cream parlors, bakeries, and Asian restaurants. These types of restaurants frequently use peanut/tree nut ingredients and are prone to cross-contact.\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   6. Buffets and salad bars should probably be avoided because of the high risk of cross-contact.\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   7. Report allergic reactions to restaurant staff immediately. Do not wait to see if the reaction will get better on its own. Staff should call 911 immediately.\n   </td>\n   </tr>\n   <tr>\n   <td    class=\"subtitle1_single\">\n   Example of pre-printed food allergy card\n   </td>\n   </tr>\n   <tr>\n   <td>I am allergic to peanuts and tree nuts. This includes peanut butter, peanut oil, peanuts, walnuts, almonds, pine nuts, and cashews. If I eat even a tiny amount of one of these foods, I may have a sudden, severe allergic reaction, stop breathing, or even die. I cannot eat foods prepared in oil used to fry any of the foods listed above (even if it was days ago). If a dish contains nuts, it is not enough to pick out the nuts. The person preparing my food needs to wash their hands and put on clean gloves before preparing my food. The food prep surface needs to be cleaned with a cleaning solution to eliminate any peanut or tree nut residue.</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 75693 Version 3.0</div></div></div>"},"75695":{"type":"graphic_picture","displayName":"Intradermal cyst injection","title":"Intradermal injection of inflamed acne cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intradermal injection of inflamed acne cyst</div><div class=\"cntnt\"><img style=\"width:355px; height:281px;\" src=\"images/PC/75695_Intradermal_cyst_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 75695 Version 1.0</div></div></div>"},"75696":{"type":"graphic_picture","displayName":"Xanthrogranulomatous chol Light","title":"Xanthogranulomatous cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xanthogranulomatous cholecystitis</div><div class=\"cntnt\"><img style=\"width:417px; height:276px;\" src=\"images/GAST/75696_Xanthrogranulomatous_chol_L.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of a gallbladder with xanthogranulomatous cholecystitis showing the typical foamy macrophages (thin arrow), fibroblasts (double arrows), giant cells (thick arrow), and mononuclear cells.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 75696 Version 2.0</div></div></div>"},"75699":{"type":"graphic_figure","displayName":"AV nodal physiology","title":"Physiology of the AV node in AF","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Physiology of the AV node in AF</div><div class=\"cntnt\"><img style=\"width:461px; height:184px;\" src=\"images/CARD/75699_AV_nodal_physiology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The atrioventricular (AV) node modulates the response between the atrium and the ventricle. In atrial fibrillation, the atrial rate is up to 600 beats per minute while the ventricular rate in response is 90 to 170 beats per minute; this difference in the rate results from several properties of the AV node that impede impulse conduction. The AV node generates a slow action potential (AP) that is mediated by calcium (Ca++) ion currents; the node is therefore slow response tissue. Parasympathetic innervation via the vagus nerve also slows conduction, while activation of the sympathetic nervous system speeds conduction.</div><div id=\"graphicVersion\">Graphic 75699 Version 1.0</div></div></div>"},"75701":{"type":"graphic_table","displayName":"Concepts regarding evaluation of illness after travel","title":"Key concepts in the evaluation of illness associated with travel","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key concepts in the evaluation of illness associated with travel</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Diseases unrelated to travel can appear after exotic travel</td>\n</tr>\n<tr>\n<td>Infections can be acquired en route or on brief layovers</td>\n</tr>\n<tr>\n<td>Fever related to tropical exposures usually begins during travel or shortly after return, but can rarely be delayed for months or years</td>\n</tr>\n<tr>\n<td>Defining the range of relevant incubation periods can help limit the differential diagnosis</td>\n</tr>\n<tr>\n<td>Malaria is still possible even if an initial malaria smear is negative</td>\n</tr>\n<tr>\n<td>Patients with acute falciparum malaria may have a normal physical examination and no fever when first seen</td>\n</tr>\n<tr>\n<td>Early symptoms of self-limited infections and life-threatening infections may be indistinguishable</td>\n</tr>\n<tr>\n<td>Risks for infectious diseases and manifestations of infections in local residents and in visitors to a geographic region may differ widely</td>\n</tr>\n<tr>\n<td>Risks for infectious diseases vary from one tropical area to another and may vary depending upon the season and year</td>\n</tr>\n<tr>\n<td>Familiar infectious diseases acquired in a tropical, developing area may have an unusual resistance pattern or may be acquired during an unexpected time of year (eg, influenza in July)</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=31294&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Keys_to_fever_in_travelers.htm</title></head></div><div id=\"graphicVersion\">Graphic 75701 Version 3.0</div></div></div>"},"75703":{"type":"graphic_table","displayName":"SCIT practice parameter","title":"Summary statements from allergen immunotherapy practice parameters (3rd update) addressing prevention of severe systemic reactions to subcutaneous immunotherapy (SCIT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary statements from allergen immunotherapy practice parameters (3rd update) addressing prevention of severe systemic reactions to subcutaneous immunotherapy (SCIT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Uncontrolled asthma</td> </tr> <tr> <td class=\"indent1\">Risk factors for severe immunotherapy reactions include symptomatic asthma and injections administered during periods of symptom exacerbation. Before the administration of the allergy injection, the patient should be evaluated for the presence of asthma or allergy symptom exacerbation. One might also consider an objective measure of airway function (eg, peak flow) for the asthmatic patient before allergy injections.</td> </tr> <tr> <td class=\"indent1\">Medical conditions that reduce the patient's ability to survive the systemic allergic reaction or the resultant treatment are relative contraindications for allergen immunotherapy. Examples include severe asthma uncontrolled by pharmacotherapy and significant cardiovascular disease.</td> </tr> <tr> <td class=\"indent1\">Allergen immunotherapy in asthmatic patients should not be initiated unless the patient's asthma is stable with pharmacotherapy.</td> </tr> <tr> <td class=\"subtitle1_single\">Optimizing safety in the clinic setting</td> </tr> <tr> <td class=\"indent1\">Because most systemic reactions that result from allergen immunotherapy occur within 30 minutes after an injection, patients should remain in the clinician's office at least 30 minutes after an injection. Some patients may need to wait longer, such as patients with prior systemic reactions that occurred later than 30 minutes after an injection.</td> </tr> <tr> <td class=\"indent1\">Allergen immunotherapy should be administered in a setting where procedures that can reduce the risk of anaphylaxis are in place and where the prompt recognition and treatment of anaphylaxis is ensured.</td> </tr> <tr> <td class=\"subtitle1_single\">Concomitant administration of beta blockers and ACE inhibitors</td> </tr> <tr> <td class=\"indent1\">Beta-adrenergic blocking agents might make allergen immunotherapy-related systemic reactions more difficult to treat and delay the recovery. Therefore a cautious attitude should be adopted toward the concomitant use of beta-blocker agents and inhalant allergen immunotherapy. However, immunotherapy is indicated in patients with life-threatening stinging insect hypersensitivity who also require beta-blocker medications because the risk of the stinging insect hypersensitivity is greater than the risk of an immunotherapy-related systemic reaction.</td> </tr> <tr> <td class=\"indent1\">ACE inhibitors have been associated with a greater risk for more severe systemic reactions from venom immunotherapy, as well as from field stings. ACE inhibitor discontinuation should be considered for patients receiving venom immunotherapy.</td> </tr> <tr> <td class=\"subtitle1_single\">Local reactions</td> </tr> <tr> <td class=\"indent1\">Published studies indicate that individual local reactions do not appear to be predictive of subsequent systemic reactions. However, some patients with greater frequency of large local reactions might be at an increased risk for future systemic reactions.</td> </tr> <tr> <td class=\"subtitle1_single\">Dose adjustments and administration in patients with prior systemic reactions</td> </tr> <tr> <td class=\"indent1\">The dose of allergen immunotherapy extract should be appropriately reduced after a systemic reaction if immunotherapy is continued.</td> </tr> <tr> <td class=\"indent1\">Patients at high risk of systemic reactions, where possible, should receive immunotherapy in the office of the clinician who prepared the patient's allergen immunotherapy extract.</td> </tr> <tr> <td class=\"subtitle1_single\">Administration of SCIT during periods of high allergen exposure</td> </tr> <tr> <td class=\"indent1\">Immunotherapy given during periods when the patient is exposed to increased levels of allergen to which they are sensitive might be associated with an increased risk of a systemic reaction. Consider not increasing or even reducing the immunotherapy dose in highly sensitive patients during the time period when they are exposed to increased levels of allergen, especially if they are experiencing an exacerbation of their symptoms.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE inhibitors: angiotensin-converting enzyme inhibitors.</div><div class=\"graphic_reference\">Cox L, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Suppl):S1.</div><div id=\"graphicVersion\">Graphic 75703 Version 10.0</div></div></div>"},"75704":{"type":"graphic_waveform","displayName":"Advanced case 14 with answer","title":"Duchenne's muscular dystrophy","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Duchenne's muscular dystrophy</div><div class=\"cntnt\"><img style=\"width:463px; height:379px;\" src=\"images/CARD/75704_Advanced_case_14_with_answe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic findings in Duchenne's muscular dystrophy include resting sinus tachycardia, deep infero- lateral Q waves, and a tall R in lead V1 due to the underlying cardiomyopathy which is often associated with posterobasal fibrosis of the left ventricle. Left atrial enlargement, as indicated by the prominent negative P wave in lead V1, and marked right axis deviation are also present.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 75704 Version 3.0</div></div></div>"},"75705":{"type":"graphic_diagnosticimage","displayName":"Ascending aortic dissection on echocardiogram","title":"Ascending aortic dissection on echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ascending aortic dissection on echocardiogram</div><div class=\"cntnt\"><img style=\"width:290px; height:342px;\" src=\"images/CARD/75705_Long_axis_aortic_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Modified long axis view shows a proximal dissection of the aortic root (Ao), with a flap extending to the aortic valve (V). This aortic pathology is seen by imaging the ascending aorta one interspace above the usual long axis precordial window.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 75705 Version 3.0</div></div></div>"},"75709":{"type":"graphic_figure","displayName":"Mechanism antiplatelet agents","title":"Mechanism of action of antiplatelet agents","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Mechanism of action of antiplatelet agents</div><div class=\"cntnt\"><img style=\"width:531px; height:390px;\" src=\"images/CARD/75709_Mechanism_antiplatelet_agen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the mechanism of action of antiplatelet agents. When vascular cells are damaged, platelets bind to exposed collagen via glycoprotein (GP) Ib/IX receptors complexed to von Willebrand factor. These bound platelets undergo degranulation, releasing adenosine diphosphate (ADP) and numerous other substances, including thromboxane A2, serotonin, and epinephrine, that play a role in the recruitment and aggregation process. The released ADP binds to two types of receptors, a low-affinity type 2 purinergic receptor (P2Y12) and a high-affinity purinergic receptor (P2Y1). Ticlopidine and clopidogrel block the binding of ADP to the type 2 purinergic receptor and prevent activation of the GP IIb/IIIa receptor complex and the subsequent aggregation of platelets. The GP IIb/IIIa receptor antagonists prevent platelet aggregation by blocking the binding of the GP IIb/IIIa receptor to fibrinogen, thereby inhibiting fibrinogen-platelet bridging.</div><div class=\"graphic_reference\">Reprinted by permission from Sharis PJ, Cannon CP, Loscalzo J. Ann Intern Med 1998; 129:394.</div><div id=\"graphicVersion\">Graphic 75709 Version 4.0</div></div></div>"},"75710":{"type":"graphic_table","displayName":"Alkaline diuresis in poisons","title":"Agents for which alkaline diuresis may enhance elimination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents for which alkaline diuresis may enhance elimination</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>2,4-D chlorphenoxyacetic acid (herbicide)</td>\n</tr>\n<tr>\n<td>Chlorpropamide</td>\n</tr>\n<tr>\n<td>Salicylates</td>\n</tr>\n<tr>\n<td>Diflunisal</td>\n</tr>\n<tr>\n<td>Fluoride</td>\n</tr>\n<tr>\n<td>Methotrexate</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Barbiturates</td>\n</tr>\n<tr><td class=\"sublist1\">Phenobarbital</td></tr><tr><td class=\"sublist1\">Primidone</td></tr><tr><td class=\"sublist1\">Barbital</td></tr><tr>\n<td>Sulfonamides</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75710 Version 1.0</div></div></div>"},"75714":{"type":"graphic_figure","displayName":"First-dose diuretic response","title":"Peak diuresis after first dose of loop diuretic","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peak diuresis after first dose of loop diuretic</div><div class=\"cntnt\"><img style=\"width:367px; height:294px;\" src=\"images/NEPH/75714_Firstdosediureticrespons.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increase in urinary sodium excretion (UNa) after intravenous bumetanide, given as a continuous infusion (solid line) or as a bolus (dashed line), in patients with stable chronic kidney disease. The continuous infusion produced a 30% greater increase in UNa than bolus therapy due to a more favorable rate of diuretic excretion. In addition, the natriuretic response declined over time with both regimens. With the bolus, for example, the peak natriuretic response to the second dose was 25% less than that to the first.</div><div class=\"graphic_reference\">Data from Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115:360.</div><div id=\"graphicVersion\">Graphic 75714 Version 5.0</div></div></div>"},"75715":{"type":"graphic_table","displayName":"Effects of lipid lowering drugs on serum lipids","title":"Average effects of different classes of lipid lowering drugs on serum lipids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Average effects of different classes of lipid lowering drugs on serum lipids</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug class</td> <td class=\"subtitle1\">Serum LDL cholesterol<br /> (% change)</td> <td class=\"subtitle1\">Serum HDL cholesterol<br /> (% change)</td> <td class=\"subtitle1\">Serum triglycerides<br /> (% change)</td> </tr> <tr> <td>Bile acid sequestrants</td> <td>&#8595; 15 to 30</td> <td>0 to slight increase</td> <td>No change or increase</td> </tr> <tr> <td>Cholesterol absorption inhibitors</td> <td>&#8595; 17</td> <td>&#8593; 1</td> <td>&#8595; 7 to 8</td> </tr> <tr> <td>Fenofibrate (micronized form)</td> <td>&#8595; 6 to 20</td> <td>&#8593; 5 to 20<sup>&#182;</sup></td> <td>&#8595; 41 to 53</td> </tr> <tr> <td>Gemfibrozil&#9674;</td> <td>&#8595; 10 to 15</td> <td>&#8593; 5 to 20<sup>&#182;</sup></td> <td>&#8595; 35 to 50</td> </tr> <tr> <td>Neomycin</td> <td>&#8595; 20 to 25</td> <td>No change</td> <td>No change</td> </tr> <tr> <td>Nicotinic acid (niacin)</td> <td>&#8595; 10 to 25</td> <td>&#8593; 15 to 35</td> <td>&#8595; 25 to 30</td> </tr> <tr> <td>Omega 3 fatty acids<sup>&#916;</sup></td> <td>&#8593; 4 to 49</td> <td>&#8593; 5 to 9</td> <td>&#8595; 23 to 45</td> </tr> <tr> <td>PCSK9 inhibitors</td> <td>&#8595;&nbsp;38 to 72</td> <td>&#8593;&nbsp;4 to 9</td> <td>&#8595; 2 to 23</td> </tr> <tr> <td>Statins</td> <td>&#8595; 20 to 60</td> <td>&#8593; 5 to 10</td> <td>&#8595; 10 to 33</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein; HDL: high-density lipoprotein; â: increase; â: decrease; PCSK9 inhibitors: proprotein convertase subtilisin kexin type 9 inhibitors.<br />Â¶ Increases of 20% are seen in patients with very high triglycerides; increases of 5% are more typical with fibrate monotherapy in patients with lower triglycerides.<br />Î 4&nbsp;g daily or 12 to 15 g of less purified form of omega-3 fatty acids.<br />â When used for the treatment of hypertriglyceridemia, LDL cholesterol may increase.</div><div id=\"graphicVersion\">Graphic 75715 Version 12.0</div></div></div>"},"75717":{"type":"graphic_picture","displayName":"Disseminated candidiasis nodule","title":"Nodules in disseminated candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodules in disseminated candidiasis</div><div class=\"cntnt\"><img style=\"width:247px; height:360px;\" src=\"images/ID/75717_Disseminated_candidiasis_no.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large erythematous, nodular lesions with central necrosis in a patient with acute leukemia and disseminated candidiasis.</div><div class=\"graphic_reference\">Courtesy of Paula Jones, MD.</div><div id=\"graphicVersion\">Graphic 75717 Version 1.0</div></div></div>"},"75719":{"type":"graphic_table","displayName":"Relationship between birth weight and shoulder dystocia","title":"Incidence of shoulder dystocia by birth weight in pregnancies with and without maternal diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of shoulder dystocia by birth weight in pregnancies with and without maternal diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Birth weight<br /> (g)</td> <td class=\"subtitle1\">Shoulder dystocia in nondiabetic pregnancies <br /> (%)</td> <td class=\"subtitle1\">Shoulder dystocia in diabetic pregnancies<br /> (%)</td> </tr> <tr> <td>Less than 4000</td> <td>0.1 to 1.1</td> <td>0.6 to 3.7</td> </tr> <tr> <td>4000 to 4499</td> <td>1.1 to 10.0</td> <td>4.9 to 23.1</td> </tr> <tr> <td>4500 or more</td> <td>2.7 to 22.6</td> <td>20.0 to 50.0</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Acker DB, Sachs BP, Friedman EA. Risk factors for shoulder dystocia. Obstet Gynecol 1985; 66:762.</li>&#xD;&#xA;    <li>Nesbitt TS, Gilbert WM, Herrchen B. Shoulder dystocia and associated risk factors with macrosomic infants born in California. Am J Obstet Gynecol 1998; 179:476.</li>&#xD;&#xA;    <li>Sandmire HF, O'Halloin TJ. Shoulder dystocia: its incidence and associated risk factors. Int J Gynaecol Obstet 1988; 26:65.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75719 Version 7.0</div></div></div>"},"75721":{"type":"graphic_table","displayName":"Congenital rubella ssx","title":"Frequency and clinical course of selected clinical findings following intrauterine rubella infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency and clinical course of selected clinical findings following intrauterine rubella infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Manifestations in infancy</td> </tr> <tr> <td class=\"subtitle2\">Clinical manifestation</td> <td class=\"subtitle2\">Frequency</td> <td class=\"subtitle2\">Typical time of onset</td> <td class=\"subtitle2\">Course</td> </tr> <tr> <td>Hearing impairment</td> <td>60 percent</td> <td>Early infancy</td> <td>Permanent</td> </tr> <tr> <td class=\"sublist1_start\">Heart defect</td> <td>45 percent</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Patent ductus arteriosus</td> <td class=\"sublist_other\">20 percent</td> <td class=\"sublist_other\">Early infancy</td> <td class=\"sublist_other\">Permanent</td> </tr> <tr> <td class=\"sublist1\">Peripheral pulmonic stenosis*</td> <td class=\"sublist_other\">12 percent</td> <td class=\"sublist_other\">Early infancy</td> <td class=\"sublist_other\">Permanent</td> </tr> <tr> <td>Microcephaly</td> <td>27 percent</td> <td>Neonatal</td> <td>Permanent</td> </tr> <tr> <td>Cataracts</td> <td>25 percent</td> <td>Early infancy</td> <td>Permanent</td> </tr> <tr> <td>Low birth weight (&#60;2500 g)</td> <td>23 percent</td> <td>Neonatal</td> <td>Poor weight gain may persist</td> </tr> <tr> <td>Hepatosplenomegaly</td> <td>19 percent</td> <td>Neonatal</td> <td>Transient</td> </tr> <tr> <td>Purpura</td> <td>17 percent</td> <td>Neonatal</td> <td>Transient</td> </tr> <tr> <td>Intellectual disability (mental retardation)</td> <td>13 percent</td> <td>Variable</td> <td>Permanent</td> </tr> <tr> <td>Meningoencephalitis</td> <td>10 percent</td> <td>Neonatal</td> <td>Transient</td> </tr> <tr> <td>Radiolucent bone lesions</td> <td>7 percent</td> <td>Neonatal</td> <td>Transient</td> </tr> <tr> <td>Retinopathy</td> <td>5 percent</td> <td>Early infancy</td> <td>Permanent</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Late-onset manifestations<sup>&#182;</sup></td> </tr> <tr> <td colspan=\"3\">Hearing loss</td> <td>Permanent</td> </tr> <tr> <td colspan=\"3\">Intellectual disability</td> <td>Permanent</td> </tr> <tr> <td colspan=\"3\">Diabetes mellitus</td> <td>Permanent</td> </tr> <tr> <td colspan=\"3\">Thyroid dysfunction<sup>&#916;</sup></td> <td>Permanent</td> </tr> <tr> <td colspan=\"3\">Progressive panencephalitis</td> <td>Permanent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes pulmonary arterial hypoplasia, supravalvular stenosis, valvular stenosis, and peripheral branch stenosis.<br />Â¶ The frequency of these manifestations is not known, given the difficulty of establishing a diagnosis of congenital rubella infection in individuals older than one year of age.<br />Î Includes hyperthyroidism, hypothyroidism, and thyroiditis.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000; 31:85.</LI>&#xD;&#xA;<LI>Banatvala JE, Brown DW. Rubella. Lancet 2004; 363:1127.</LI></OL></div><div id=\"graphicVersion\">Graphic 75721 Version 3.0</div></div></div>"},"75722":{"type":"graphic_diagnosticimage","displayName":"Coal workers pneumoconiosis PA","title":"Coal worker's pneumoconiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coal worker's pneumoconiosis</div><div class=\"cntnt\"><img style=\"width:360px; height:358px;\" src=\"images/PULM/75722_Coal_workers_pneumoconiosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple noncalcified micronodules throughout both lungs.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75722 Version 3.0</div></div></div>"},"75723":{"type":"graphic_picture","displayName":"Mucous membrane pemphigoid vaginal","title":"Mucous membrane pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucous membrane pemphigoid</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/75723_Mucous_membrane_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions are present on the genital mucosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75723 Version 3.0</div></div></div>"},"75725":{"type":"graphic_picture","displayName":"Portal hypertensive gastropathy","title":"Portal hypertensive gastropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Portal hypertensive gastropathy</div><div class=\"cntnt\"><img style=\"width:285px; height:265px;\" src=\"images/GAST/75725_Portal_hypertensive_gastrop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy in portal hypertensive gastropathy reveals a characteristic fine white reticular pattern separating areas of pinkish mucosa, giving the gastric mucosa a &quot;snakeskin&quot; appearance.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.</div><div id=\"graphicVersion\">Graphic 75725 Version 1.0</div></div></div>"},"75726":{"type":"graphic_algorithm","displayName":"Steroid refractory UC","title":"Steroid-refractory ulcerative colitis","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Steroid-refractory ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:561px; height:577px;\" src=\"images/GAST/75726_Steroid_refractory_UC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">6-MP: 6-mercaptopurine; AZA: azathioprine; anti-TNF: anti-tumor necrosis factor agents.</div><div id=\"graphicVersion\">Graphic 75726 Version 3.0</div></div></div>"},"75730":{"type":"graphic_diagnosticimage","displayName":"Lupus sclerosis MRI","title":"Lupus sclerosis on magnetic resonance imaging of the brain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus sclerosis on magnetic resonance imaging of the brain</div><div class=\"cntnt\"><img style=\"width:258px; height:291px;\" src=\"images/RHEUM/75730_Lupus_sclerosis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging of the brain showing plaques that resemble the demyelinated lesions seen in patients with&nbsp; multiple sclerosis.</div><div class=\"graphic_reference\">Courtesy of Shahram Khoshbin, MD.</div><div id=\"graphicVersion\">Graphic 75730 Version 3.0</div></div></div>"},"75731":{"type":"graphic_figure","displayName":"Risk model SCD HCM","title":"Risk of sudden death in HCM","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Risk of sudden death in HCM</div><div class=\"cntnt\"><img style=\"width:423px; height:374px;\" src=\"images/CARD/75731_RiskmodelSCDHCM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A set of four predictors of sudden death were analyzed to develop a risk stratification algorithm in a study of 368 patients with HCM. The predictors included a history of syncope and/or a family history of sudden death, a left ventricular wall thickness â¥30 mm, nonsustained ventricular tachycardia on ambulatory monitoring, and an abnormal blood pressure response to exercise (refer to text). This bar graph shows the percentage of each risk factor group (zero, one, two, and three risk factors) in which patients died during follow-up (black bars = sudden death; hatched bars = congestive cardiac failure or transplant; white = all deaths). The majority of deaths were sudden, and the greatest proportion occurred in patients with multiple risk factors.</div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy.</div><div class=\"graphic_reference\">Data from Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36:2212.</div><div id=\"graphicVersion\">Graphic 75731 Version 3.0</div></div></div>"},"75732":{"type":"graphic_figure","displayName":"Perforation of the cervical esophagus","title":"Perforation of the cervical esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perforation of the cervical esophagus</div><div class=\"cntnt\"><img style=\"width:391px; height:572px;\" src=\"images/SURG/75732_Perf_cerv_eso-edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a flexible esophagoscope perforating Killian's triangle, which is the posterior space between the oblique inferior constrictor and the cricopharyngeus muscle.</div><div id=\"graphicVersion\">Graphic 75732 Version 4.0</div></div></div>"},"75734":{"type":"graphic_figure","displayName":"Schematic figure demonstrating hd access in series with circulat","title":"Schematic figure demonstrating hemodialysis access in series with circulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic figure demonstrating hemodialysis access in series with circulation</div><div class=\"cntnt\"><img style=\"width:322px; height:331px;\" src=\"images/NEPH/75734_Hemodialysis_in_series.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the performance of hemodialysis in which the access is in series with the systemic circulation. In this setting, all of the blood would go through the dialyzer and urea removal would be maximized.</div><div id=\"graphicVersion\">Graphic 75734 Version 4.0</div></div></div>"},"75737":{"type":"graphic_picture","displayName":"Erosion incus","title":"A retraction pocket cholesteatoma of the posterosuperior quadrant with erosion of the incus long process","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A retraction pocket cholesteatoma of the posterosuperior quadrant with erosion of the incus long process</div><div class=\"cntnt\"><img style=\"width:288px; height:298px;\" src=\"images/ALLRG/75737_Erosionincus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A retraction pocket cholesteatoma of the posterosuperior quadrant. The incus long process is eroded leaving the drum adherent to the stapes head (S). An effusion is present in the middle ear and squamous debris emanates from the attic (the pneumatized space just superior to the middle ear, also called the epitympanum).</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 120, Pages 603-8, Copyright Â© 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 75737 Version 13.0</div></div></div>"},"75738":{"type":"graphic_picture","displayName":"Dyshidrotic eczema foot","title":"Dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:430px; height:321px;\" src=\"images/PC/75738_Dyshidrotic_eczema_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dyshidrotic eczema can present with vesicles on feet and should be distinguished from acute tinea pedis.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75738 Version 3.0</div></div></div>"},"75740":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber LA myxoma","title":"Left atrial myxoma seen during echocardiography from the apical 4 chamber view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma seen during echocardiography from the apical 4 chamber view</div><div class=\"cntnt\"><img style=\"width:329px; height:270px;\" src=\"images/CARD/75740_4chamberleftatrialmyxom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large, partially calcified left atrial (LA) myxoma (T) was found incidentally during a chest pain work-up (left panel). The tumor shows very little motion during parts of the cardiac cycle. Although the tumor appears obstructive, a continuous wave Doppler (CWD) shows no mitral valve (MV) inflow tract obstruction (right panel).</div><div class=\"graphic_footnotes\">LV: left ventricle; RA: right atrium; RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 75740 Version 5.0</div></div></div>"},"75742":{"type":"graphic_figure","displayName":"AML OS by age","title":"Overall survival according to age irrespective of management (Panel A, n = 2767), and patients with de novo AML, fit for intensive treatment, and with WHO/ECOG performance status 0 to II (Panel B, n = 1229)","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Overall survival according to age irrespective of management (Panel A, n = 2767), and patients with de novo AML, fit for intensive treatment, and with WHO/ECOG performance status 0 to II (Panel B, n = 1229)</div><div class=\"cntnt\"><img style=\"width:469px; height:708px;\" src=\"images/HEME/75742_AML_OS_by_age.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">This research was originally published in Blood. Juliusson, G, Antunovic, P, Derolf, A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179. Copyright &#169; 2009 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 75742 Version 1.0</div></div></div>"},"75743":{"type":"graphic_figure","displayName":"LVEF predicts six-month mortality after STEMI","title":"LVEF predicts six-month mortality after STEMI","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">LVEF predicts six-month mortality after STEMI</div><div class=\"cntnt\"><img style=\"width:487px; height:310px;\" src=\"images/CARD/75743_LVEFsixmonthmortalityMI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 1194 patients with an acute ST segment elevation myocardial infarction (STEMI) treated with thrombolysis, the resting left ventricular ejection fraction (LVEF) measured by radionuclide angiography (RNA) was a powerful predictor of six-month mortality. The highest risk group was those with an LVEF &lt;30 percent.</div><div class=\"graphic_reference\">Data from Burns RJ, Gibbons RJ,&nbsp;Yi Q, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002; 39:30.</div><div id=\"graphicVersion\">Graphic 75743 Version 5.0</div></div></div>"},"75747":{"type":"graphic_figure","displayName":"Airway in a person with sleep apnea PI","title":"Airway in a person with sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Airway in a person with sleep apnea</div><div class=\"cntnt\"><img style=\"width:453px; height:624px;\" src=\"images/PI/75747_Apnea_vs_normal_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normally when a person sleeps, the airway remains open, and air can pass from the nose and mouth to the lungs. In a person with sleep apnea, parts of the throat and mouth drop into the airway and block off the flow of air. This can cause loud snoring and interrupt breathing for short periods.</div><div id=\"graphicVersion\">Graphic 75747 Version 5.0</div></div></div>"},"75748":{"type":"graphic_table","displayName":"Pediatric physical activity for CV health","title":"Activity recommendations for cardiovascular health from the Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Activity recommendations for cardiovascular health from the Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Activity recommendations</td> </tr> <tr> <td rowspan=\"2\">0 to 12 months</td> <td>Parents should create an environment promoting and modeling physical activity and limiting sedentary time</td> </tr> <tr> <td><em>Supportive actions:</em><br /> <ul> <li>Discourage TV viewing altogether </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">1 to 4 years</td> <td>Unlimited active playtime in safe, supportive environment</td> </tr> <tr> <td>Limit sedentary time, especially TV/video</td> </tr> <tr> <td><em>Supportive actions:</em> <ul> <li>For children &#60;2 years, discourage television viewing altogether </li> <li>Limit total media time to no more than 1 to 2 hours of quality programming per day </li> <li>No TV in child's bedroom </li> <li>Encourage family activity at least once per week </li> <li>Counsel routine activity for parents as role models for children </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">5 to 10 years</td> <td>Moderate to vigorous physical activity* every day</td> </tr> <tr> <td>Limit daily leisure screen time (TV/video/computer)</td> </tr> <tr> <td><em>Supportive actions:</em><br /> <ul> <li>Prescribe moderate to vigorous activity* 1 hour/day with vigorous intensity physical activity<sup>&#182;</sup> on 3 days/week </li> <li>Limit total media time to no more than 1 to 2 hours of quality programming per day </li> <li>No TV in child's bedroom </li> <li>Take activity and screen time history from child once a year </li> <li>Match physical activity recommendations with energy intake </li> <li>Recommend appropriate safety equipment relative to each sport </li> <li>Support recommendations for daily physical education in schools </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">11 to 17 years</td> <td>Moderate to vigorous physical activity* every day</td> </tr> <tr> <td>Limit leisure time TV/video/computer use</td> </tr> <tr> <td><em>Supportive actions:</em><br /> <ul> <li>Encourage adolescents to aim for 1 hour/day of moderate to vigorous daily activity*, with vigorous intense physical activity<sup>&#182;</sup> on 3 days/week </li> <li>Encourage no TV in bedroom </li> <li>Limit total media time to no more than 1 to 2 hours of quality programming per day </li> <li>Match activity recommendations with energy intake </li> <li>Take activity and screen time history from adolescent at health supervision visits </li> <li>Encourage involvement in year-round, physical activities </li> <li>Support continued family activity once a week and/or family support of adolescent's physical activity program </li> <li>Endorse appropriate safety equipment relative to each sport </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">18 to 21 years</td> <td>Moderate to vigorous physical activity* every day</td> </tr> <tr> <td>Limit leisure time TV/video/computer</td> </tr> <tr> <td><em>Supportive actions:</em><br /> <ul> <li>Support goal of 1 hour/day of moderate to vigorous daily activity with vigorous intense physical activity on 3 days/week </li> <li>Recommend that combined leisure screen time not exceed 2 hours/day </li> <li>Activity and screen time history at health supervision visits </li> <li>Encourage involvement in year-round, lifelong physical activities </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Examples of moderate to vigorous physical activities are jogging or playing baseball.<br /><SUP>Â¶</SUP>&nbsp;Examples of vigorous physical activities are running, playing singles tennis, or playing soccer.</div><div class=\"graphic_reference\">Modified from: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Available at:&nbsp;<A href=\"https://www.nhlbi.nih.gov/node/80139\">https://www.nhlbi.nih.gov/node/80139</A> (Accessed on January 3, 2012).</div><div id=\"graphicVersion\">Graphic 75748 Version 5.0</div></div></div>"},"75752":{"type":"graphic_table","displayName":"Uncommon causes of viral meningitis","title":"Viruses uncommonly associated with meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Viruses uncommonly associated with meningitis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1\">\n   Viruses\n   </td>\n   <td   class=\"subtitle1\">\n   Transmission\n   </td>\n   <td   class=\"subtitle1\">\n   Distribution\n   </td>\n   </tr>\n   <tr>\n   <td>Mumps</td>\n   <td>Human to human: airborne</td>\n   <td>Worldwide</td>\n   </tr>\n   <tr>\n   <td>Measles virus</td>\n   <td>Human to human: droplets</td>\n   <td>Worldwide</td>\n   </tr>\n   <tr>\n   <td>Lymphocytic choriomeningitis virus</td>\n   <td>Animal to human: aerosol or ingestion of contaminated food or dust from urine, feces, secretions of infected rodents</td>\n   <td>Worldwide</td>\n   </tr>\n   <tr>\n   <td>Human immunodeficiency virus</td>\n   <td>Human to human</td>\n   <td>Worldwide</td>\n   </tr>\n   <tr>\n   <td>Parainfluenza viruses</td>\n   <td>Human to human: airborne/droplets and fomites</td>\n   <td>Worldwide</td>\n   </tr>\n   <tr>\n   <td>Rotavirus</td>\n   <td>Human to human: oral-fecal</td>\n   <td>Worldwide</td>\n   </tr>\n   <tr>\n   <td>Parvovirus B19</td>\n   <td>Human to human: airborne, percutaneous, and vertical transmission</td>\n   <td>Worldwide</td>\n   </tr>\n   <tr>\n   <td>Coronavirus</td>\n   <td>Human to human: airborne (probable animal to human)</td>\n   <td>Worldwide</td>\n   </tr>\n   <tr>\n   <td>Smallpox</td>\n   <td>Human to human: droplets</td>\n   <td>Eradicated</td>\n   </tr>\n   <tr>\n   <td>Human metapneumovirus</td>\n   <td>Human to human: likely direct contact with contaminated secretions*</td>\n   <td>Worldwide</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">\n   Vaccine associated\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Vaccinia\n   </td>\n   <td>&nbsp;</td>\n   <td>Limited to vaccine use</td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Measles\n   </td>\n   <td>&nbsp;</td>\n   <td>Worldwide</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">* No formal studies have been performed.</div><div id=\"graphicVersion\">Graphic 75752 Version 2.0</div></div></div>"},"75753":{"type":"graphic_diagnosticimage","displayName":"Pancoast tumor MRI III","title":"Right apical Pancoast tumor on magnetic resonance imaging (MRI)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right apical Pancoast tumor on magnetic resonance imaging (MRI)</div><div class=\"cntnt\"><img style=\"width:316px; height:338px;\" src=\"images/PULM/75753_Pancoast_tumor_MRI_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal magnetic resonance image (MRI) of the upper chest in a patient with a right apical Pancoast tumor highlighted by T1-weighted imaging. Vertebral destruction by the tumor is also noted (arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75753 Version 4.0</div></div></div>"},"75756":{"type":"graphic_picture","displayName":"Botulinum toxin injection - chin","title":"Botulinum toxin injection in the chin","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin injection in the chin</div><div class=\"cntnt\"><img style=\"width:581px; height:121px;\" src=\"images/DERM/75756_Botul_toxin_inject_chin2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Improvement in peau d'orange chin (A) after injection with botulinum toxin (B).</div><div id=\"graphicVersion\">Graphic 75756 Version 1.0</div></div></div>"},"75757":{"type":"graphic_picture","displayName":"Lentigines before laser therapy","title":"Lentigines on the dorsal hands before laser treatment","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Lentigines on the dorsal hands before laser treatment</div><div class=\"cntnt\"><img style=\"width:576px; height:244px;\" src=\"images/DERM/75757_Lentigines_before_laser.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75757 Version 2.0</div></div></div>"},"75758":{"type":"graphic_table","displayName":"Diseases caused or exacerbated by high altitude","title":"Medical conditions caused or exacerbated by high altitude","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical conditions caused or exacerbated by high altitude</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High-altitude illness </td> </tr> <tr> <td>Acute mountain sickness/High-altitude cerebral edema&nbsp;(AMS/HACE)</td> </tr> <tr> <td>High-altitude pulmonary edema (HAPE)</td> </tr> <tr> <td class=\"subtitle1_single\">Altitude-related illness (partial list) </td> </tr> <tr> <td class=\"subtitle2_single\">Acute </td> </tr> <tr> <td class=\"indent1\">High-altitude headache </td> </tr> <tr> <td class=\"indent1\">High-altitude pharyngitis and bronchitis </td> </tr> <tr> <td class=\"indent1\">High-altitude syncope </td> </tr> <tr> <td class=\"indent1\">Acute hypoxia </td> </tr> <tr> <td class=\"indent1\">Organic brain syndrome </td> </tr> <tr> <td class=\"indent1\">Peripheral edema </td> </tr> <tr> <td class=\"indent1\">Sleep periodic breathing (central sleep apnea)</td> </tr> <tr> <td class=\"indent1\">Ultraviolet keratitis (snow blindness) </td> </tr> <tr> <td class=\"indent1\">High-altitude retinopathy </td> </tr> <tr> <td class=\"indent1\">Hypothermia and frostbite </td> </tr> <tr> <td class=\"indent1\">High-altitude deterioration </td> </tr> <tr> <td class=\"indent1\">Reentry pulmonary edema&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Chronic </td> </tr> <tr> <td class=\"indent1\">Chronic mountain sickness (Monge's disease, chronic mountain polycythemia) </td> </tr> <tr> <td class=\"indent1\">High-altitude pulmonary hypertension, with or without right heart failure </td> </tr> <tr> <td class=\"indent1\">Reentry pulmonary edema </td> </tr> <tr> <td class=\"indent1\">Problems of pregnancy: preeclampsia, hypertension, and low-birth-weight infants </td> </tr> <tr> <td class=\"subtitle1_single\">Problems potentially exacerbated by high altitude (partial list) </td> </tr> <tr> <td>Various congenital and valvular heart diseases</td> </tr> <tr> <td>Hypertension&nbsp;</td> </tr> <tr> <td>Primary and secondary pulmonary hypertension</td> </tr> <tr> <td>Symptomatic coronary artery disease</td> </tr> <tr> <td>Poorly compensated heart failure</td> </tr> <tr> <td>Chronic obstructive pulmonary disease&nbsp;</td> </tr> <tr> <td>Sickle cell disease and trait</td> </tr> <tr> <td>Sleep disordered breathing (including central sleep apnea)</td> </tr> <tr> <td>Urinary retention from BPH</td> </tr> <tr> <td>High-risk pregnancy</td> </tr> <tr> <td>Radial keratotomy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADHF: Acute decompensated heart failure; BPH: Benign prostatic hyperplasia; COPD: Chronic obstructive pulmonary disease</div><div id=\"graphicVersion\">Graphic 75758 Version 4.0</div></div></div>"},"75759":{"type":"graphic_picture","displayName":"Prolapsed internal hemorrhoids","title":"Prolapsed internal hemorrhoids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prolapsed internal hemorrhoids</div><div class=\"cntnt\"><img style=\"width:280px; height:280px;\" src=\"images/GAST/75759_Prolapsed_internal_hemorrho.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Internal hemorrhoids that have prolapsed outside of the anal canal and are visibly bleeding.</div><div class=\"graphic_reference\">Reproduced with permission from the American Society of Colon and Rectal Surgeons.</div><div id=\"graphicVersion\">Graphic 75759 Version 2.0</div></div></div>"},"75761":{"type":"graphic_table","displayName":"Antimalarial ppx adults","title":"Drug regimens for prophylaxis against malaria in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug regimens for prophylaxis against malaria in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug </td> <td class=\"subtitle1\">Tablet size </td> <td class=\"subtitle1\">Dose </td> <td class=\"subtitle1\">Frequency* </td> <td class=\"subtitle1\"> <p>Initiation</p> <p>(time before first exposure to malaria)</p> </td> <td class=\"subtitle1\"> <p>Discontinuation</p> <p>(time after last exposure)</p> </td> <td class=\"subtitle1\">Use in pregnancy </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Areas with chloroquine-resistant <em>Plasmodium falciparum </em></td> </tr> <tr> <td class=\"indent1\">Atovaquone-proguanil (Malarone) </td> <td>250 mg atovaquone and 100 mg proguanil</td> <td>One tablet orally</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Seven&nbsp;days</td> <td>No; insufficient data on use in pregnancy</td> </tr> <tr> <td class=\"indent1\">Mefloquine hydrochloride (Lariam and generic agents) </td> <td>250 mg salt (228 mg base)</td> <td>One tablet orally</td> <td>Once weekly</td> <td>Three&nbsp;weeks preferable;&nbsp;two weeks acceptable</td> <td>Four&nbsp;weeks</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents) </td> <td>100 mg</td> <td>One tablet orally</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Four&nbsp;weeks</td> <td>No; teratogenic</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Areas with chloroquine-sensitive <em>P. falciparum </em></td> </tr> <tr> <td class=\"indent1\">Chloroquine phosphate (Aralen and generic agents) </td> <td>500 mg salt (300 mg base)</td> <td>One tablet orally</td> <td>Once weekly</td> <td>One to two&nbsp;weeks</td> <td>Four&nbsp;weeks</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Hydroxychloroquine sulfate (Plaquenil) </td> <td>400 mg salt (310 mg base)</td> <td>One table orally</td> <td>Once weekly</td> <td>One to two&nbsp;weeks</td> <td>Four&nbsp;weeks</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Atovaquone-proguanil (Malarone) </td> <td>250 mg atovaquone and 100 mg proguanil</td> <td>One tablet orally</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Seven&nbsp;days</td> <td>No; insufficient data on use in pregnancy</td> </tr> <tr> <td class=\"indent1\">Mefloquine hydrochloride (Lariam and generic agents) </td> <td>250 mg salt (228 mg base)</td> <td>One tablet orally</td> <td>Once weekly</td> <td>Three&nbsp;weeks preferable;&nbsp;two weeks acceptable</td> <td>Four&nbsp;weeks</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents) </td> <td>100 mg</td> <td>One tablet orally</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Four&nbsp;weeks</td> <td>No; teratogenic</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Areas with <em>Plasmodium vivax </em></td> </tr> <tr> <td class=\"indent1\">Primaquine phosphate (appropriate prophylaxis for short duration travel to areas with principally <em>P. vivax</em>) </td> <td>26.3 mg salt (15 mg base)</td> <td>Two tablets orally</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Seven&nbsp;days</td> <td>No; contraindicated because of potential toxicity for fetal erythrocytes</td> </tr> <tr> <td class=\"indent1\">Chloroquine phosphate (Aralen and generic agents) </td> <td>500 mg salt (300 mg base)</td> <td>One tablet orally</td> <td>Once weekly</td> <td>One to two&nbsp;weeks</td> <td>Four&nbsp;weeks</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Hydroxychloroquine sulfate (Plaquenil) </td> <td>400 mg salt (310 mg base)</td> <td>One tablet orally</td> <td>Once weekly</td> <td>One to two&nbsp;weeks</td> <td>Four&nbsp;weeks</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Atovaquone-proguanil (Malarone) </td> <td>250 mg atovaquone and 100 mg proguanil</td> <td>One tablet orally</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Seven&nbsp;days</td> <td>No; insufficient data on use in pregnancy</td> </tr> <tr> <td class=\"indent1\">Mefloquine hydrochloride (Lariam and generic agents) </td> <td>250 mg salt (228 mg base)</td> <td>One tablet orally</td> <td>Once weekly</td> <td>Three&nbsp;weeks preferable;&nbsp;two weeks acceptable</td> <td>Four&nbsp;weeks</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Doxycycline hyclate (Vibramycin, Vibra-Tabs, other brands, and generic agents); doxycycline monohydrate (Monodox, Adoxa, and generic agents) </td> <td>100 mg</td> <td>One tablet orally</td> <td>Once daily</td> <td>One to two&nbsp;days</td> <td>Four&nbsp;weeks</td> <td>No; teratogenic</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Presumptive antirelapse therapy (to prevent relapse due to <em>P. vivax </em>or <em>P. ovale</em>) </td> </tr> <tr> <td class=\"indent1\">Primaquine phosphate </td> <td>26.3 mg salt (15 mg base)</td> <td>Two tablets orally</td> <td>Once daily</td> <td>As soon as possible following exposure for which another prophylactic drug taken</td> <td>14 days</td> <td>No; contraindicated because of potential toxicity for fetal erythrocytes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Drugs administered once daily should be taken at the same time each day; drugs administered once weekly should be taken on the same day each week.<br></div><div class=\"graphic_reference\">1. Hill DR, Ericsson CD, Pearson RD, et al. The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.<br />2. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008; 359:603.</div><div id=\"graphicVersion\">Graphic 75761 Version 3.0</div></div></div>"},"75762":{"type":"graphic_algorithm","displayName":"Rx NB testicular torsion","title":"Yale University School of Medicine's recommended algorithm for management of neonatal testicular torsion","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Yale University School of Medicine's recommended algorithm for management of neonatal testicular torsion</div><div class=\"cntnt\"><img style=\"width:604px; height:306px;\" src=\"images/PEDS/75762_Rx_NB_testicular_torsion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The recommendations are based upon the availability of a team that includes a pediatric urologist/surgeon and pediatric anesthesiologist. If pediatric specialists are unavailable, surgical intervention is delayed until tertiary care access is available. Birth examination occurs either at delivery or the initial newborn examination within 24 hours of delivery.</div><div class=\"graphic_footnotes\">US: ultrasound.</div><div class=\"graphic_reference\">Courtesy of Adam Hittelman, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75762 Version 3.0</div></div></div>"},"75763":{"type":"graphic_table","displayName":"Drug causes of AUR","title":"Pharmacologic agents associated with urinary retention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic agents associated with urinary retention</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Sympathomimetics (alpha-adrenergic agents)</strong></td> <td>Ephedrine sulfate (Marax, Tedral)</td> </tr> <tr> <td>Phenylephrine HCl (Neo-Synephrine)</td> </tr> <tr> <td>Phenylpropanolamine HCL (Conlac)</td> </tr> <tr class=\"divider_bottom\"> <td>Pseudoephedrine HCl (Sudafed, Actifed)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Sympathomimetics (beta-adrenergic agents)</strong></td> <td>Isoproterenol</td> </tr> <tr> <td>Metaproterenol</td> </tr> <tr class=\"divider_bottom\"> <td>Terbutaline</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Antidepressants</strong></td> <td>Imipramine (Tofranil)</td> </tr> <tr> <td>Nortriptyline (Aventyl)</td> </tr> <tr> <td>Amitriptyline (Elavil)</td> </tr> <tr> <td>Doxepin (Adapin)</td> </tr> <tr> <td>Amoxepine (Asendin)</td> </tr> <tr class=\"divider_bottom\"> <td>Maprotiline (Ludiomil)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Antiarrhythmics</strong></td> <td>Quinidine</td> </tr> <tr> <td>Procainamide</td> </tr> <tr class=\"divider_bottom\"> <td>Disopyramide</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"12\"><strong>Anticholinergics (selected)</strong></td> <td>Atropine</td> </tr> <tr> <td>Scopolamine hydrobromide</td> </tr> <tr> <td>Clidinium bromide (Quarzan)</td> </tr> <tr> <td>Glycopyrrolate (Robinul)</td> </tr> <tr> <td>Mepenzolate bromide (Cantil)</td> </tr> <tr> <td>Oxybutynin (Ditropan)</td> </tr> <tr> <td>Flavoxate HCl (Urispas)</td> </tr> <tr> <td>Hyoscyamine sulfate (Anaspaz)</td> </tr> <tr> <td>Belladonna</td> </tr> <tr> <td>Homatropine methylbromide</td> </tr> <tr> <td>Propantheline bromide (Probanthine)</td> </tr> <tr class=\"divider_bottom\"> <td>Dicyclomine HCl (Bentyl)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Antiparkinsonian agents</strong></td> <td>Trihexyphenidyl HCl (Arlane)</td> </tr> <tr> <td>Benztropine Mesylate (Cogentin)</td> </tr> <tr> <td>Amantadine HCl (Symmetrel)</td> </tr> <tr> <td>Levodopa (Sinemet)</td> </tr> <tr class=\"divider_bottom\"> <td>Bromocriptine Mesylate (Parlodel)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Hormonal agents</strong></td> <td>Progesterone</td> </tr> <tr> <td>Estrogen</td> </tr> <tr class=\"divider_bottom\"> <td>Testosterone</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Antipsychotics</strong></td> <td>Haloperidol (Haldol)</td> </tr> <tr> <td>Thiothixene (Navane)</td> </tr> <tr> <td>Thioridizine (Mellaril)</td> </tr> <tr> <td>Chlorpromazine (Thorazine)</td> </tr> <tr> <td>Fluphenazine (Prolixin)</td> </tr> <tr class=\"divider_bottom\"> <td>Prochlorperazine (Compazine)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Antihistamines (selected)</strong></td> <td>Diphenhydramine HCl (Benadryl)</td> </tr> <tr> <td>Chlorpheniramine (Chlor-Trimeton)</td> </tr> <tr> <td>Brompheniramine (Dimetane)</td> </tr> <tr> <td>Cyproheptadine (Periactin)</td> </tr> <tr class=\"divider_bottom\"> <td>Hydroxyzine (Atarax, Vistaril)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Antihypertensives</strong></td> <td>Hydralazine (Apresoline)</td> </tr> <tr class=\"divider_bottom\"> <td>Nifedipine (Procardia)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Muscle relaxants</strong></td> <td>Diazepam (Valium)</td> </tr> <tr> <td>Baclofen (Lioresal)</td> </tr> <tr class=\"divider_bottom\"> <td>Cyclobenzaprine (Flexeril)</td> </tr> <tr> <td rowspan=\"7\"><strong>Miscellaneous</strong></td> <td>Indomethacin (Indocin)</td> </tr> <tr> <td>Carbamazepine (Tegretol)</td> </tr> <tr> <td>Amphetamines</td> </tr> <tr> <td>Dopamine</td> </tr> <tr> <td>Vincristine</td> </tr> <tr> <td>Morphine sulfate and other opioids</td> </tr> <tr> <td>Anesthetic agents</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Curtis LA, Dolan TS, Cespedes RD. Acute urinary retention and urinary incontinence. Emergency Medicine Clinics of North America 2001; 19:591. Copyright &copy; 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 75763 Version 2.0</div></div></div>"},"75764":{"type":"graphic_picture","displayName":"Moisture chambers","title":"Moisture chamber","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Moisture chamber</div><div class=\"cntnt\"><img style=\"width:432px; height:304px;\" src=\"images/PC/75764_Moisture_chambers.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75764 Version 1.0</div></div></div>"},"75765":{"type":"graphic_figure","displayName":"Pressure points hemorrhage","title":"Major pressure points","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Major pressure points</div><div class=\"cntnt\"><img style=\"width:541px; height:685px;\" src=\"images/EM/75765_Pressure_points_hemorrhage.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75765 Version 2.0</div></div></div>"},"75766":{"type":"graphic_diagnosticimage","displayName":"MRI of pheochromocytoma","title":"MRI of pheochromocytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of pheochromocytoma</div><div class=\"cntnt\"><img style=\"width:281px; height:364px;\" src=\"images/ENDO/75766_Pheochromocytoma_increase.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI of the abdomen shows a 4.5 cm right adrenal pheochromocytoma (arrows).<br />Upper panel: T1-weighted image.<br />Lower panel: T2-weighted image shows increased signal intensity typical of a pheochromocytoma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of William F Young, Jr, MD.</div><div id=\"graphicVersion\">Graphic 75766 Version 4.0</div></div></div>"},"75768":{"type":"graphic_table","displayName":"Mycosis fungoides TNMB classification","title":"Mycosis Fungoides Cooperative Group TNMB classification of cutaneous T cell lymphoma (CTCL)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mycosis Fungoides Cooperative Group TNMB classification of cutaneous T cell lymphoma (CTCL)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Skin (T)</td> </tr> <tr> <td>T<sub>1</sub></td> <td>Limited patches*, papules, and/or plaques<sup>&#182;</sup> covering &#60;10 percent of the skin surface; may further stratify into T<sub>1a</sub> (patch only) versus T<sub>1b</sub> (plaque &#177; patch)</td> </tr> <tr> <td>T<sub>2</sub></td> <td>Patches, papules, or plaques covering &#8805;10 percent of the skin surface; may further stratify into T<sub>2a</sub> (patch only) versus T<sub>2b</sub> (plaque &#177; patch)</td> </tr> <tr> <td>T<sub>3</sub></td> <td>One or more tumors<sup>&#916;</sup> (&#8805;1 cm diameter)</td> </tr> <tr> <td>T<sub>4</sub></td> <td>Confluence of erythema covering &#8805;80 percent body surface area</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Node (N)</td> </tr> <tr> <td>N<sub>0</sub></td> <td>No clinically abnormal lymph nodes<sup>&#9674;</sup>; biopsy not required</td> </tr> <tr> <td class=\"sublist1_start\">N<sub>1</sub></td> <td class=\"sublist_other_start\">Clinically abnormal lymph nodes; histopathology Dutch grade 1 or NCI LN0-2</td> </tr> <tr> <td class=\"sublist1\">N<sub>1a</sub></td> <td class=\"sublist_other\">Clone negative<sup>&#167;</sup></td> </tr> <tr> <td class=\"sublist1\">N<sub>1b</sub></td> <td class=\"sublist_other\">Clone positive<sup>&#167;</sup></td> </tr> <tr> <td class=\"sublist1_start\">N<sub>2</sub></td> <td class=\"sublist_other_start\">Clinically abnormal lymph nodes; histopathology Dutch grade 2 or NCI LN3</td> </tr> <tr> <td class=\"sublist1\">N<sub>2a</sub></td> <td class=\"sublist_other\">Clone negative<sup>&#167;</sup></td> </tr> <tr> <td class=\"sublist1\">N<sub>2b</sub></td> <td class=\"sublist_other\">Clone positive<sup>&#167;</sup></td> </tr> <tr> <td>N<sub>3</sub></td> <td>Clinically abnormal lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative</td> </tr> <tr> <td>N<sub>X</sub></td> <td>Clinically abnormal lymph nodes; no histologic confirmation</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Visceral (M)</td> </tr> <tr> <td>M<sub>0</sub></td> <td>No visceral organ involvement</td> </tr> <tr> <td>M<sub>1</sub></td> <td>Visceral involvement (must have pathology confirmation<sup>&#165;</sup> and organ involved should be specified)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Blood (B)</td> </tr> <tr> <td class=\"sublist1_start\">B<sub>0</sub></td> <td class=\"sublist_other_start\">No significant blood involvement: &#8804;5 percent of S&#233;zary cells. For clinical trials, B<sub>0</sub> may also be defined as &#60;250/microL S&#233;zary cells; CD4+CD26- or CD4+CD7- cells or CD4+CD26- and CD4+CD7- cells &#60;15 percent by flow cytometry.</td> </tr> <tr> <td class=\"sublist1\">B<sub>0a</sub></td> <td class=\"sublist_other\">Clone negative</td> </tr> <tr> <td class=\"sublist1\">B<sub>0b</sub></td> <td class=\"sublist_other\">Clone positive</td> </tr> <tr> <td class=\"sublist1_start\">B<sub>1</sub></td> <td class=\"sublist_other_start\">Low blood tumor burden: Does not meet the criteria of B<sub>0</sub> or&nbsp;B<sub>2</sub></td> </tr> <tr> <td class=\"sublist1\">B<sub>1a</sub></td> <td class=\"sublist_other\">Clone negative</td> </tr> <tr> <td class=\"sublist1\">B<sub>1b</sub></td> <td class=\"sublist_other\">Clone positive</td> </tr> <tr> <td>B<sub>2</sub></td> <td>High blood tumor burden: Positive clone<sup>&#135; </sup>plus one of the following: &#8805;1000/microL&nbsp;S&#233;zary cells; CD4/CD8 &#8805;10; CD4+CD7- cells &#8805;40 percent; or CD4+CD26- cells &#8805;30 percent. For clinical trials, B<sub>2</sub> may also be defined as &#62;1000/microL CD4+CD26- or CD4+CD7- cells.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For skin, patch indicates any size lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted.<br />Â¶&nbsp;For skin, plaque indicates any size skin lesion that is elevated or indurated. Presence or absence of scale, crusting, and/or poikiloderma should be noted. Histologic features such as folliculotropism or large-cell transformation (&gt;25 percent large cells), CD30+ or CD30-, and clinical features such as ulceration are important to document.<br />Î For skin, tumor indicates at least one 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also note if histologic evidence of large-cell transformation has occurred. Phenotyping for CD30 is encouraged.<br /><FONT class=lozenge>â</FONT> For node, abnormal lymph node(s) indicates any lymph node that on physical examination is firm, irregular, clustered, fixed, or 1.5 cm or larger in diameter or on imaging is &gt;1.5 cm in the long axis or &gt;1 cm in the short axis. Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal. <br />Â§ A T cell clone is defined by&nbsp;polymerase chain reaction or Southern blot analysis of the T cell receptor gene.<br />Â¥ For viscera, spleen and liver may be diagnosed by imaging criteria alone.<br />â¡ The clone in the blood should match that of the skin. The relevance of an isolated clone in the blood or a clone in the blood that does not match the clone in the skin remains to be determined.</div><div class=\"graphic_reference\">This research was originally published in Blood. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713. Copyright Â© the American Society of Hematology.<BR>Additional data from:&nbsp;Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and SÃ©zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29:2598.</div><div id=\"graphicVersion\">Graphic 75768 Version 5.0</div></div></div>"},"75770":{"type":"graphic_figure","displayName":"Eye muscles","title":"Extraocular muscles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extraocular muscles</div><div class=\"cntnt\"><img style=\"width:434px; height:421px;\" src=\"images/NEURO/75770_Eye_muscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each eye has six extraocular muscles, which are yoked in pairs.</div><div class=\"graphic_reference\">Reproduced with permission from: Lavin, PJM. Eye movement disorders and diplopia. In: Neurology in Clinical Practice: Principles of Diagnosis and Management, 2nd ed, Bradley, WG (Ed), Butterworth-Heinemann, Boston 1996. p. 185. Copyright &#169; 1996 Elsevier.</div><div id=\"graphicVersion\">Graphic 75770 Version 1.0</div></div></div>"},"75771":{"type":"graphic_diagnosticimage","displayName":"Collateral circulation SVC syndrome","title":"Collateral circulation from superior vena cava syndrome falsely suggests a liver \"hot spot\".","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Collateral circulation from superior vena cava syndrome falsely suggests a liver \"hot spot\".</div><div class=\"cntnt\"><img style=\"width:370px; height:556px;\" src=\"images/ONC/75771_Collateral_circ_liver_perfu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced axial CT image shows a dilated internal mammary (IM) vein (arrow) connecting to the portal and hepatic venous circulation to eventually drain into the inferior vena cava (IVC). This process appears to form an enhancing liver \"hot spot\" that is actually draining venous blood from the obstructed SVC. Note also the dilated azygos and hemiazygos veins (arrowheads) that connect to the ascending lumbar veins and IVC.<br />(B): Axial image at the level of the liver shows segmental enhancement of parts of the right and left lobes due to collateral flow from the IM vein.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75771 Version 6.0</div></div></div>"},"75773":{"type":"graphic_table","displayName":"Nonbacterial causes of infectious arthritis in children","title":"Nonbacterial causes of infectious arthritis/arthralgia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonbacterial causes of infectious arthritis/arthralgia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Viruses</strong></td> <td class=\"sublist_other_start\">Viral arthritis usually involves multiple small joints</td> </tr> <tr> <td class=\"sublist1\">Varicella zoster virus (VZV)</td> <td class=\"sublist_other\">VZV may cause primary arthritis within several days of the onset of rash; monoarticular knee involvement is most common; varicella also may cause secondary bacterial arthritis by providing a portal of entry for Staphylococci or Streptococci</td> </tr> <tr> <td class=\"sublist1\">Hepatitis B virus (HBV)</td> <td class=\"sublist_other\">10 to 25 percent of patients with HBV develop arthritis, usually during the prodromal stage; joints of hands and knees most often affected; may be associated with urticarial and maculopapular eruption</td> </tr> <tr> <td class=\"sublist1\">Hepatitis C virus (HCV)</td> <td class=\"sublist_other\">2 to 20 percent of patients with HCV develop arthritis (evanescent or oligoarthritis)</td> </tr> <tr> <td class=\"sublist1\">Parvovirus</td> <td class=\"sublist_other\">Arthralgia or arthritis may accompany or follow the skin eruption; the knee is most commonly affected joint</td> </tr> <tr> <td class=\"sublist1\">Rubella</td> <td class=\"sublist_other\">Joint symptoms develop within one week before or after the rash</td> </tr> <tr> <td class=\"sublist1\">Rubella vaccine virus</td> <td class=\"sublist_other\">Joint symptoms develop approximately two weeks after vaccination</td> </tr> <tr> <td class=\"sublist1\">Mumps virus</td> <td class=\"sublist_other\">Joint symptoms usually develop after the onset of parotitis&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Chikungunya&nbsp;virus</td> <td class=\"sublist_other\">Transmitted by mosquitos; may produce severe or prolonged arthralgia</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Fungi</strong></td> </tr> <tr> <td class=\"sublist1\"><em>Candida</em></td> <td class=\"sublist_other\">May occur in neonates or immunocompromised children</td> </tr> <tr> <td class=\"sublist1\"><em>Histoplasma</em></td> <td class=\"sublist_other\">Endemic to the eastern and central United States and Canada; exposure to bird droppings, bat guano</td> </tr> <tr> <td class=\"sublist1\"><em>Coccidioides</em></td> <td class=\"sublist_other\">Endemic to the southwestern United States, northern Mexico, parts of Central and South America</td> </tr> <tr> <td class=\"sublist1\"><em>Sporothrix schenckii</em></td> <td class=\"sublist_other\">Present in soil, moss, and other organic material; may be inoculated into the skin or inhaled</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\"><em>Blastomyces dermatitidis</em></td> <td class=\"sublist_other\">Endemic in the southeastern and central states and Midwestern states bordering the Great Lakes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Post-infectious arthritis or reactive arthritis</strong></td> <td>Preceding episode of respiratory (group A streptococcus, <em>Neisseria meningitidis</em>), gastrointestinal (eg, <em>Shigella</em>, <em>Salmonella</em>, <em>Campylobacter</em>), or genitourinary infection (<em>Chlamydia trachomatis</em>); may be associated conjunctivitis, uveitis, or rash; onset of joint inflammation &#8805;7 days after acute infection; resolves without sequelae in 97 to 99 percent of cases; if obtained, synovial fluid WBC count usually is &#60;50,000 cells/microL</td> </tr> <tr> <td><strong>Rheumatic fever</strong></td> <td>Evanescent and migratory arthritis; extreme pain and limited range of motion, but minimal effusion or swelling</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WBC: white blood cell.</div><div id=\"graphicVersion\">Graphic 75773 Version 7.0</div></div></div>"},"75774":{"type":"graphic_diagnosticimage","displayName":"RUL SPN PA","title":"Malignant solitary pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant solitary pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:335px; height:268px;\" src=\"images/PULM/75774_RUL_SPN_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with right upper lobe solitary pulmonary nodule proven to be a lung cancer. Chest radiograph shows a faint opacity partially hidden by the head of the right clavicle.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75774 Version 3.0</div></div></div>"},"75776":{"type":"graphic_diagnosticimage","displayName":"Ovarian cancer color Doppler","title":"Ovarian cancer color Doppler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ovarian cancer color Doppler</div><div class=\"cntnt\"><img style=\"width:432px; height:287px;\" src=\"images/OBGYN/75776_Ovarian_cancer_color_dopple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image of an ovarian cancer of the left ovary. The ovarian mass is 4.7 cm and primarily solid, as indicated by the long arrow. Color Doppler imaging demonstrates blood flow within the solid portion of the ovarian mass (short arrow). Almost no normal ovary is visible in the image.</div><div class=\"graphic_reference\">Reproduced with permission from: Thomas D Shipp, MD. Copyright Â© Thomas D Shipp, MD.</div><div id=\"graphicVersion\">Graphic 75776 Version 4.0</div></div></div>"},"75778":{"type":"graphic_table","displayName":"Genetic mimics of vascular or prenatal insults","title":"Genetic conditions associated with microcephaly and neuroradiologic abnormalities mimicking vascular damage or prenatal infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic conditions associated with microcephaly and neuroradiologic abnormalities mimicking vascular damage or prenatal infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Genetic condition</td> <td class=\"subtitle1\">Phenocopy*</td> </tr> <tr> <td>Aicardi-Goutier&#232;s syndrome (also known as pseudo-TORCH and allelic with Cree encephalitis [at least 5 genes, common])</td> <td>Congenital infection with thrombocytopenia, increased production of alpha-interferon, ulcerative skin lesions</td> </tr> <tr> <td>Pseudo-TORCH syndrome type b</td> <td>Distinct pattern of band-like intracranial calcification, simplified gyration and polymicrogyria; severe postnatal microcephaly, seizures, developmental arrest</td> </tr> <tr> <td>Sulfite oxidase deficiency</td> <td>Neonatal encephalopathy; neuroradiology and pathology can mimic perinatal asphyxia</td> </tr> <tr> <td>Mitochondrial/respiratory chain abnormality</td> <td>Disrupted brain development with congenital infection-like calcifications, and a complex neuronal migration disorder</td> </tr> <tr> <td>PEHO-like syndrome</td> <td>Encephalopathy with hypoxic ischemic changes on MRI</td> </tr> <tr> <td>Fetal brain disruption sequence</td> <td>Traumatic brain destruction</td> </tr> <tr> <td>Cystic leukoencephalopathy</td> <td>Congenital CMV clinically and neuroradiologically</td> </tr> <tr> <td>Bilateral porencephaly; cerebellar or vermis hypoplasia or aplasia; congenital heart defect</td> <td>Bilateral porencephaly (\"basket brain\") may resemble middle cerebral artery infarct</td> </tr> <tr> <td>16p13.11 unmasking NDE1 recessive mutation</td> <td>Fetal brain disruption - severe microcephaly, callosal agenesis, cortical dysplasia, cysts</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TORCH: toxoplasmosis, other (syphilis, varicella, etc), rubella, cytomegalovirus, herpes simplex virus; PEHO: progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy; MRI: magnetic resonance imaging; CMV: cytomegalovirus.<br />* Phenocopy: a nongenetic condition with an appearance that is similar to that caused by a specific genotype.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Stephenson JB. Aicardi-Goutier&egrave;s syndrome (AGS). Eur J Paediatr Neurol 2008; 12:355. </li>&#xD;&#xA;    <li>Briggs TA, Wolf NI, D'Arrigo S, et al. Band-like intracranial calcification with simplified gyration and polymicrogyria: a distinct \"pseudo-TORCH\" phenotype. Am J Med Genet A 2008; 146A:3173. </li>&#xD;&#xA;    <li>Hobson EE, Thomas S, Crofton PM, et al. Isolated sulphite oxidase deficiency mimics the features of hypoxic ischaemic encephalopathy. Eur J Pediatr 2005; 164:655. </li>&#xD;&#xA;    <li>Hoffmann C, Ben-Zeev B, Anikster Y, et al. Magnetic resonance imaging and magnetic resonance spectroscopy in isolated sulfite oxidase deficiency. J Child Neurol 2007; 22:1214. </li>&#xD;&#xA;    <li>van Straaten HL, van Tintelen JP, Trijbels JM, et al. Neonatal lactic acidosis, complex I/IV deficiency, and fetal cerebral disruption. Neuropediatrics 2005; 36:193. </li>&#xD;&#xA;    <li>Samson JF, Barth PG, de Vries JI, et al. Familial mitochondrial encephalopathy with fetal ultrasonographic ventriculomegaly and intracerebral calcifications. Eur J Pediatr 1994; 153:510. </li>&#xD;&#xA;    <li>Longman C, Tolmie J, McWilliam R, MacLennan A. Cranial magnetic resonance imaging mistakenly suggests prenatal ischaemia in PEHO-like syndrome. Clin Dysmorphol 2003; 12:133. </li>&#xD;&#xA;    <li>Schram A, Kroes HY, Sollie K, et al. Hereditary fetal brain degeneration resembling fetal brain disruption sequence in two sibships. Am J Med Genet A 2004; 127A:172. </li>&#xD;&#xA;    <li>Behunova J, Zavadilikova E, Bozoglu TM, et al. Familial microhydranencephaly, a family that does not map to 16p13.13-p12.2:: relationship with hereditary fetal brain degeneration and fetal brain disruption sequence. Clin Dysmorphol 2010; 19:107. </li>&#xD;&#xA;    <li>Henneke M, Diekmann S, Ohlenbusch A, et al. RNASET2-deficient cystic leukoencephalopathy resembles congenital cytomegalovirus brain infection. Nat Genet 2009; 41:773. </li>&#xD;&#xA;    <li>Bonnemann CG, Meinecke P. Bilateral porencephaly, cerebellar hypoplasia, and internal malformations: two siblings representing a probably new autosomal recessive entity. Am J Med Genet 1996; 63:428. </li>&#xD;&#xA;    <li>Paciorkowksi AR, Keppler-Noreuil K, Robinson L, et al. Deletion 16p13.11 uncovers NDE1 mutations on the non-deleted homolog and extends the spectrum of severe microcephaly to include fetal brain disruption. Am J Med Genet A 2013; 161A:1523.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75778 Version 5.0</div></div></div>"},"75779":{"type":"graphic_figure","displayName":"Atriotomy scars","title":"Atriotomy scars","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Atriotomy scars</div><div class=\"cntnt\"><img style=\"width:451px; height:570px;\" src=\"images/CARD/75779_Atriotomy_scars_labels.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SVC: superior vena cava; CS: coronary sinus; IVC: inferior vena cava; TV: tricuspid valve.</div><div class=\"graphic_reference\">By permission of the Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 75779 Version 9.0</div></div></div>"},"75781":{"type":"graphic_picture","displayName":"Acute cutaneous lupus erythematosus - malar","title":"Acute cutaneous lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acute cutaneous lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/75781_ACLE_malar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Malar erythema and subtle edema are present in this patient with systemic lupus erythematosus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75781 Version 4.0</div></div></div>"},"75784":{"type":"graphic_table","displayName":"Components of a first trimester ultrasound examination","title":"Components of a first trimester ultrasound examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of a first trimester ultrasound examination</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Gestational sac location and diameter (if no embryo identified)</td> </tr> <tr> <td>Presence or absence of a yolk sac (diameter)</td> </tr> <tr> <td>Presence or absence of an embryo</td> </tr> <tr> <td>Presence or absence of cardiac activity</td> </tr> <tr> <td>Crown rump length</td> </tr> <tr> <td>Number of embryos</td> </tr> <tr> <td>Amnionicity and chorionicity of multiple gestations</td> </tr> <tr> <td>Anatomic survey, as appropriate for gestational age*</td> </tr> <tr> <td>Evaluation of the uterus, adnexa, and cul-de-sac</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">An embryo is usually visible when the gestational sac diameter is &ge;20 mm, cardiac motion may be detected when then embryo is &ge;2 mm and is usually detected when the embryo is &ge;5 mm (transvaginal examination).</div><div class=\"graphic_footnotes\">* At 11 to 14 weeks of gestation, anatomical assessment can include: head (cranial bones, midline falx, choroid plexus); neck (nuchal translucency thickness); face (eyes, nasal bone, mandible, lips); spine (vertebrae and overlying skin); chest (lung fields, effusions, masses); heart (regular activity, four symmetrical chambers); abdomen (stomach in left upper quadrant ); bladder; kidneys; abdominal wall; cord (insertion site, number of vessels); extremities (number, hand/foot position).</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>ACOG Practice Bulletin No. 98. Ultrasonography in pregnancy. Obstet Gynecol 2008; 112:951.</li>&#xD;&#xA;    <li>ISUOG practice guidelines: performance of first trimester fetal ultrasound scan. Ultrasound Obstet Gynecol 2013; 41:102.</li>&#xD;&#xA;    <li>Reddy UM, Abuhamad AZ, Levine D, et al. Fetal Imaging. Executive Summary of a Joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop. Obstet Gynecol 2014; 123:1070.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75784 Version 5.0</div></div></div>"},"75786":{"type":"graphic_table","displayName":"Pharmacologic approaches to manage opioid side effects","title":"Commonly used pharmacologic approaches in the management of opioid side effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used pharmacologic approaches in the management of opioid side effects</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Side effect </td> <td class=\"subtitle1\">Treatment </td> </tr> <tr> <td rowspan=\"11\">Constipation </td> <td class=\"sublist1_start\">General approach </td> </tr> <tr> <td class=\"sublist1\">&#8226; Ensure comfort and convenience for defecation </td> </tr> <tr> <td class=\"sublist1\">&#8226; Rule out impaction </td> </tr> <tr> <td class=\"sublist1\">&#8226; Improve hydration </td> </tr> <tr> <td class=\"sublist1\">&#8226; Avoid adding fiber if the patient is debilitated or nutrition or hydration is poor </td> </tr> <tr> <td class=\"sublist1_start\">Pharmacologic approaches </td> </tr> <tr> <td class=\"sublist1\">&#8226; Periodic enemas </td> </tr> <tr> <td class=\"sublist1\">&#8226; Oral therapy usually starts with stimulant laxative (eg, senna), stool softener (docusate), and/or an osmotic laxative (eg, lactulose or polyethylene glycol) </td> </tr> <tr> <td class=\"sublist1\">&#8226; For refractory cases, the initial step is to adjust the doses or change the combination of the usual starting regimen, or add more rapid acting osmotic drug (eg, magnesium citrate) </td> </tr> <tr> <td class=\"sublist1\">&#8226; For refractory cases, consider second-line approaches (eg, metoclopramide, lubiprostone, colchicine, oral naloxone) </td> </tr> <tr> <td class=\"sublist1\">&#8226; Peripherally-acting opioid antagonist drugs (eg, methylnaltrexone, naloxegol) an option for refractory cases </td> </tr> <tr> <td rowspan=\"6\">Somnolence or cognitive impairment </td> <td class=\"sublist1_start\">General approach </td> </tr> <tr> <td class=\"sublist1\">&#8226; Treatment of potential etiologies </td> </tr> <tr> <td class=\"sublist1\">&#8226; Reduce opioid dose by 25 to 50 percent </td> </tr> <tr> <td class=\"sublist1_start\">Pharmacologic approaches </td> </tr> <tr> <td class=\"sublist1\">&#8226; Add psychostimulant (eg, methylphenidate, modafinil) </td> </tr> <tr> <td class=\"sublist1\">&#8226; Consider cholinesterase inhibitor (eg, donepezil) </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75786 Version 4.0</div></div></div>"},"75787":{"type":"graphic_diagnosticimage","displayName":"Large pneumomediastinum","title":"Pneumomediastinum on plain radiograph of the chest","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Pneumomediastinum on plain radiograph of the chest</div><div class=\"cntnt\"><img style=\"width:550px; height:297px;\" src=\"images/PEDS/75787_Large_pneumomediastinum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The films demonstrate a large pneumomediastinum.<br />(A) Posterior-anterior (PA) view; bilateral subcutaneous emphysema in the upper thorax and neck, marked by arrows.<br />(B) Lateral view; pneumomediastinum, marked by arrows.</div><div id=\"graphicVersion\">Graphic 75787 Version 6.0</div></div></div>"},"75788":{"type":"graphic_picture","displayName":"Persist fetal vasculature","title":"Persistent fetal vasculature","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Persistent fetal vasculature</div><div class=\"cntnt\"><img style=\"width:432px; height:296px;\" src=\"images/PEDS/75788_Persist_fetal_vasculature.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Persistent fetal vasculature (right eye). A typical presentation of esotropia, leukocoria, and microphthalmia.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75788 Version 3.0</div></div></div>"},"75789":{"type":"graphic_diagnosticimage","displayName":"Presyrinx","title":"Four-year-old girl with Chiari I malformation and previous incomplete decompressive surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Four-year-old girl with Chiari I malformation and previous incomplete decompressive surgery</div><div class=\"cntnt\"><img style=\"width:419px; height:586px;\" src=\"images/NEURO/75789_Presyrinx_final.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) T1-weighted sagittal MRI of the cervical and thoracic spine before repeat surgery shows herniation of the cerebellar tonsils to C2-3, hypointensity and frank cavitation from C6-T1 (syrinx), and indistinct parenchymal hypointensity from C2-5 and T2-3 (presyrinx).<br />(B) T2-weighted sagittal MRI of the cervical and thoracic spine before repeat surgery shows T2 prolongation in the areas of the syrinx and presyrinx.<br />(C) T2-weighted sagittal MRI of the cervical and thoracic spine after decompression shows decreased size of the large cervical cord syrinx (C6-7) and complete resolution of the presyrinx.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Goh S, Bottrell CL, Aiken AH, et al. Presyrinx in children with Chiari malformations. Neurology 2008; 71:351. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 75789 Version 12.0</div></div></div>"},"75790":{"type":"graphic_figure","displayName":"Cannulation following precut","title":"Sphinterome insertion with guidewire assistance to complete precut sphincterotomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sphinterome insertion with guidewire assistance to complete precut sphincterotomy</div><div class=\"cntnt\"><img style=\"width:377px; height:252px;\" src=\"images/GAST/75790_Cannulation_following_precu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once access has been gained, a standard guidewire and papilltome can be used to complete the sphincterotomy.</div><div class=\"graphic_reference\">Courtesy of Douglas A Howell, MD and David J Desilets, MD.</div><div id=\"graphicVersion\">Graphic 75790 Version 2.0</div></div></div>"},"75793":{"type":"graphic_picture","displayName":"Sezary cells mycosis fungoides","title":"Sezary cells in mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sezary cells in mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:438px; height:178px;\" src=\"images/HEME/75793_Sezary_cells_mycosis_fungoi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Peripheral blood smear from a 58-year-old woman with a two-year history of generalized erythroderma, illustrating the &quot;cerebriform&quot; shape of the nucleus of this circulating Sezary cell. Right panel: Electron micrograph showing the markedly irregular nucleus with a single prominent nucleolus.</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 75793 Version 1.0</div></div></div>"},"75794":{"type":"graphic_diagnosticimage","displayName":"Parasternal long axis view of VSD","title":"Parasternal long axis view of membranous ventricular septal defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis view of membranous ventricular septal defect</div><div class=\"cntnt\"><img style=\"width:442px; height:298px;\" src=\"images/CARD/75794_Paraster_long_axis_view_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis view with Color Flow Doppler demonstrating membranous VSD (arrow) underneath the aortic valve with Color Flow Doppler demonstrating a left-to-right shunt from the left ventricular outflow tract into the right ventricle (double arrow).</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle; RV: right ventricle; Ao: aorta.</div><div class=\"graphic_reference\">Courtesy of Dr. Naser Ammash.</div><div id=\"graphicVersion\">Graphic 75794 Version 4.0</div></div></div>"},"75796":{"type":"graphic_figure","displayName":"In-toeing and out-toeing","title":"In-toeing and out-toeing","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">In-toeing and out-toeing</div><div class=\"cntnt\"><img style=\"width:522px; height:491px;\" src=\"images/PEDS/75796_In-toeing-and-out-toeing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In-toeing (upper panel) is a rotational variation in which the feet or toes point toward the midline during gait. Out-toeing (lower panel) is a rotational variation in which the feet or toes point away from the midline during gait.</div><div id=\"graphicVersion\">Graphic 75796 Version 1.0</div></div></div>"},"75797":{"type":"graphic_figure","displayName":"Creation of a cervical esophagostomy","title":"Creation of a cervical esophagostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Creation of a cervical esophagostomy</div><div class=\"cntnt\"><img style=\"width:434px; height:316px;\" src=\"images/SURG/75797_Creation-cerv-esogast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the portion of the cervical esophagus proximal to the perforation which was dissected for creation of a cervical esophagostomy. The esophagostomy site is located on the anterior chest wall, below the clavicle. A subcutaneous tunnel is made to pass the proximal end of the esophagus to the outside of the chest wall.</div><div id=\"graphicVersion\">Graphic 75797 Version 2.0</div></div></div>"},"75798":{"type":"graphic_picture","displayName":"Nondisplaced femoral neck fracture","title":"Nondisplaced femoral neck fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced femoral neck fracture</div><div class=\"cntnt\"><img style=\"width:296px; height:500px;\" src=\"images/EM/75798_Femoral_neck_fx_pict.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracapsular, or femoral neck, fractures have higher rates of nonunion and malunion, and are more likely to lead to avascular necrosis of the femoral head.</div><div class=\"graphic_reference\">Reproduced with permission from: Lippincott Williams &amp; Wilkins. Copyright Â© 2008.</div><div id=\"graphicVersion\">Graphic 75798 Version 2.0</div></div></div>"},"75801":{"type":"graphic_table","displayName":"Risk factors for abruption","title":"Major risk factors for placental abruption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major risk factors for placental abruption</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk factor </td> <td class=\"subtitle1\" colspan=\"2\">Singleton gestations </td> <td class=\"subtitle1\" colspan=\"2\">Twin gestations </td> </tr> <tr> <td class=\"subtitle2\">Strength </td> <td class=\"subtitle2\">RR/OR </td> <td class=\"subtitle2\">Strength </td> <td class=\"subtitle2\">RR/OR </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Acute etiology </td> </tr> <tr> <td class=\"indent1\">Abdominal trauma/accidents </td> <td>+++</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cocaine or other drug abuse </td> <td>+++</td> <td>5.0-10.0</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Polyhydramnios </td> <td>++</td> <td>2.0-3.0</td> <td>++</td> <td>1.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Obstetrical/medical risk factors </td> </tr> <tr> <td class=\"indent1\">Chronic hypertension </td> <td>++</td> <td>1.8-5.1</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Preeclampsia/Pregnancy induced hypertension </td> <td>++</td> <td>0.4-4.5</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Eclampsia </td> <td>+++</td> <td>3.0-5.5</td> <td>++</td> <td>1.6-2.0</td> </tr> <tr> <td class=\"indent1\">Premature rupture of membranes </td> <td>++</td> <td>1.8-5.1</td> <td>++</td> <td>1.5-2.5</td> </tr> <tr> <td class=\"indent1\">Chorioamnionitis </td> <td>++</td> <td>2.0-2.5</td> <td>++</td> <td>1.7</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">Previous ischemic placental disease </td> </tr> <tr> <td class=\"sublist2\">Preeclampsia </td> <td>++</td> <td>1.5</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Fetal growth restriction/Small for gestation age infant </td> <td>++</td> <td>1.4</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">&nbsp;&nbsp;&nbsp;&nbsp; Previous abruption </td> <td>++++</td> <td>8.0-12.0</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Sociodemographic/behavioral </td> </tr> <tr> <td class=\"indent1\">Maternal age </td> <td>+</td> <td>1.1-1.3</td> <td>+</td> <td>1.1-1.4</td> </tr> <tr> <td class=\"indent1\">Parity </td> <td>+</td> <td>1.1-1.6</td> <td>+</td> <td>1.1-1.7</td> </tr> <tr> <td class=\"indent1\">Smoking during pregnancy </td> <td>++</td> <td>1.4-2.5</td> <td>++</td> <td>1.7</td> </tr> <tr> <td class=\"indent1\">Male infant sex </td> <td>+/-</td> <td>0.9-1.3</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OR: odds ratio; RR: relative risk.</div><div id=\"graphicVersion\">Graphic 75801 Version 3.0</div></div></div>"},"75802":{"type":"graphic_table","displayName":"Modified FOLFOX7 plus bevacizumab chemotherapy","title":"Modified FOLFOX7 plus bevacizumab chemotherapy for advanced colorectal cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified FOLFOX7 plus bevacizumab chemotherapy for advanced colorectal cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Bevacizumab</td> <td>5 mg/kg IV</td> <td>Dilute into a total volume of 100 mL normal saline (NS).* The first dose should be administered over 90 minutes following chemotherapy. If well tolerated, the second infusion may be administered over 60 minutes after oxaliplatin and leucovorin. If well tolerated, all subsequent doses may be administered over 10 to 30 minutes before chemotherapy.<sup>&#182;</sup><sup>[2,3]</sup></td> <td>Day 1</td> </tr> <tr> <td>Oxaliplatin</td> <td>85 mg/m<sup>2</sup> IV<sup>&#916;</sup></td> <td>Dilute with 500 mL 5% dextrose in water (D5W)* and administer over two hours (on days 1 and 15, oxaliplatin and leucovorin can be administered concurrently in separate bags using a Y-connector).</td> <td>Day 1</td> </tr> <tr> <td>Leucovorin<sup>&#9674;</sup></td> <td>200 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL D5W* and administer over two hours, concurrent with oxaliplatin.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil (FU)</td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 to 1000 mL D5W and administer over 46 hours. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin and FU are classified as irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia &#60;5%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of oxaliplatin may be needed for severe renal impairment.<sup>[4]</sup> A lower starting dose of FU may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in blood pressure, urine protein concentration, neurologic function, and risk for bleeding prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment cycle one week for absolute neutrophil count &#60;1200/microL, or platelets &#60;75,000/microL on the day of treatment. If treatment is delayed for two weeks or delayed for one week on two separate occasions, reduce infusional FU by 20% and reduce oxaliplatin dose from 85 to 65 mg/m<sup>2</sup>. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 paresthesias/dysesthesias lasting longer than seven days, decrease oxaliplatin dose by 25%. Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia.<sup>[1]</sup> The United States Prescribing Information recommends a dose reduction in oxaliplatin to 65 mg/m<sup>2</sup> for persistent grade 2 neurosensory events that do not resolve, and discontinuation for persistent grade 3 neurosensory events.<sup>[4]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Delay next treatment by one week for any diarrhea above baseline.<sup>[1]</sup> Delay by an additional week if diarrhea not resolved to &#8804;grade 1. For grade 3 or 4 diarrhea, restart at a lower dose after complete resolution.<sup>[1]</sup> The United States Prescribing Information recommends dose reduction of oxaliplatin to 65 mg/m<sup>2</sup> as well as a reduction of infusional FU after recovery from grade 3 or 4 diarrhea during the prior cycle.<sup>[4]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicities</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment cycle by one week for any other toxicity &#62;grade 1 (except alopecia, hypertension, and asthenia). Delay an additional week if the toxicity has not resolved to &#8804;grade 1. Reduce FU and oxaliplatin doses for grade 3 or 4 mucositis, vomiting, and grade 3 other non-hematologic toxicities. Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS).<sup>[2]</sup> Do not administer bevacizumab within 28 days of surgery; suspend prior to elective surgery. </li> <li>Refer to UpToDate topics on \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\" and \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ECG: electrocardiogram; CBC: complete blood count.<br />&#x9;&#x9;&#x9;&#x9;&#x9;* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />&#x9;&#x9;&#x9;&#x9;&#x9;&para; For the 5 mg/kg dose, many clinicians administer the first dose over 60 minutes and if well tolerated, subsequent doses are administered over 10 minutes.<sup>[3]</sup><br />&#x9;&#x9;&#x9;&#x9;&#x9;&Delta; Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.<br />&#x9;&#x9;&#x9;&#x9;&#x9;<span class=\"lozenge\">&loz;</span> Leucovorin dose is given for d,l-racemic mixture.<sup>[6]</sup> Use half the dose for LEVOleucovorin (l-leucovorin).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hochster HS, et al. Ann Oncol 2014; 25:1172.</LI>&#xD;&#xA;<LI>Bevacizumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Reidy DL, et al. J Clin Oncol 2007; 25:2691.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 75802 Version 28.0</div></div></div>"},"75805":{"type":"graphic_figure","displayName":"Thermophilic actinomycetes HP","title":"Hypersensitivity to thermophilic actinomycetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypersensitivity to thermophilic actinomycetes</div><div class=\"cntnt\"><img style=\"width:410px; height:300px;\" src=\"images/PULM/75805_Thermophilic_actinomycetes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical clinical and two stage physiologic response to inhalation challenge with an extract of thermophilic actinomycetes.</div><div class=\"graphic_footnotes\">FVC: forced vital capacity; FEV<SUB>1</SUB>: forced expiratory volume in one second; D<SUB>L</SUB>CO: diffusing capacity, mL/min/mmHg.</div><div class=\"graphic_reference\">Redrawn from: Schlueter DP, Am J Med 1974; 57:476.</div><div id=\"graphicVersion\">Graphic 75805 Version 2.0</div></div></div>"},"75806":{"type":"graphic_figure","displayName":"BMT v immunosuppression in AA","title":"Survival after bone marrow transplantation or immunosuppressive therapy in aplastic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival after bone marrow transplantation or immunosuppressive therapy in aplastic anemia</div><div class=\"cntnt\"><img style=\"width:428px; height:294px;\" src=\"images/HEME/75806_BMT_v_immunosuppression_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actuarial survival after therapy for acquired aplastic anemia comparing 168 patients who underwent bone marrow transplantation (BMT) to 227 patients who received immunosuppressive therapy. Survival was significantly improved in the patients receiving a transplant (p&lt;0.001; log-rank test).</div><div class=\"graphic_reference\">Data from Doney K, Leisenring W, Storb R, et al. Ann Intern Med 1997; 126:107.</div><div id=\"graphicVersion\">Graphic 75806 Version 3.0</div></div></div>"},"75807":{"type":"graphic_table","displayName":"Classification of secondary esophageal motility abnormalities","title":"Classification of secondary esophageal motility abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of secondary esophageal motility abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Conventional manometry</td> </tr> <tr> <td rowspan=\"3\">Systemic sclerosis</td> <td>Loss of distal (smooth muscle) peristalsis</td> </tr> <tr> <td>Weak lower esophageal sphincter pressure (&#60;10 mmHg)</td> </tr> <tr> <td>Normal proximal esophagus and UES (striated muscle)</td> </tr> <tr class=\"divider_top\"> <td>Chagas' disease</td> <td>Identical to idiopathic achalasia</td> </tr> <tr class=\"divider_top\"> <td>Diabetes mellitus</td> <td>A variety of motility abnormalities of the esophageal body</td> </tr> <tr class=\"divider_top\"> <td>Chronic idiopathic intestinal pseudo-obstruction</td> <td>Loss of distal esophageal motility</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Chronic gastroesophageal reflux disease</td> <td>Ineffective esophageal motility (IEM)</td> </tr> <tr> <td>Hypotensive lower esophageal sphincter</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UES: upper esophageal sphincter.</div><div id=\"graphicVersion\">Graphic 75807 Version 4.0</div></div></div>"},"75809":{"type":"graphic_figure","displayName":"Manometry in achalasia","title":"Manometric features of achalasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manometric features of achalasia</div><div class=\"cntnt\"><img style=\"width:405px; height:273px;\" src=\"images/GAST/75809_Manometry_achalasia_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are three characteristic manometric features of achalasia: elevated resting lower esophageal sphincter (LES) pressure (above 45 mmHg); incomplete LES relaxation after a swallow (S); aperistalsis in the smooth muscle portion of the body of the esophagus. Swallows may elicit no esophageal contraction or may be followed by simultaneous contractions. The esophagus may also contract spontaneously in a simultaneous fashion. In some cases, the simultaneous esophageal contractions have amplitudes &gt;60 mmHg, a condition known as &quot;vigorous&quot; achalasia.</div><div class=\"graphic_reference\">Reprinted, courtesy of the Clinical Teaching Project of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 75809 Version 3.0</div></div></div>"},"75810":{"type":"graphic_diagnosticimage","displayName":"T4b esophageal cancer EUS","title":"T4b esophageal cancer by endoscopic ultrasound (EUS)","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">T4b esophageal cancer by endoscopic ultrasound (EUS)</div><div class=\"cntnt\"><img style=\"width:468px; height:353px;\" src=\"images/GAST/75810_T4_esophageal_cancer_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image showing stage T4b esophageal cancer invading the wall of the aorta.</div><div class=\"graphic_reference\">Courtesy of John R Saltzman, MD.</div><div id=\"graphicVersion\">Graphic 75810 Version 3.0</div></div></div>"},"75814":{"type":"graphic_figure","displayName":"XDR TB countries 2013","title":"Countries that reported at least one case of extensively drug resistant tuberculosis (XDR-TB)Â by the end of 2013","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Countries that reported at least one case of extensively drug resistant tuberculosis (XDR-TB)&nbsp;by the end of 2013</div><div class=\"cntnt\"><img style=\"width:586px; height:304px;\" src=\"images/ID/75814_XDR_TB_countries_2013.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shaded countries had notified at least one case of XDR-TB by the end of 2013.</div><div class=\"graphic_reference\">Reproduced with permission from: World Health Organization. Drug-Resistant TB Surveillance and Response. Supplement: Global Tuberculosis Report 2014. WHO, Geneva 2014. Copyright &copy; 2014 World Health Organization.</div><div id=\"graphicVersion\">Graphic 75814 Version 4.0</div></div></div>"},"75815":{"type":"graphic_figure","displayName":"Summary of public health actions based on blood lead levels","title":"Summary of public health actions based on maternal and infant blood lead levels","html":"<div class=\"graphic\"><div style=\"width: 934px\" class=\"figure\"><div class=\"ttl\">Summary of public health actions based on maternal and infant blood lead levels</div><div class=\"cntnt\"><img style=\"width:914px; height:822px;\" src=\"images/PC/75815_Pub_health_blood_lead_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BLL: blood lead level.</div><div class=\"graphic_reference\">Reproduced from: Ettinger AS, Gurthrie Wengrovitz A, (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010. Available at <a href=\"http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\" target=\"_blank\">http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf</a>.</div><div id=\"graphicVersion\">Graphic 75815 Version 4.0</div></div></div>"},"75816":{"type":"graphic_picture","displayName":"Cutaneous squamous cell carcinoma - poorly differentiated","title":"Poorly differentiated cutaneous squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Poorly differentiated cutaneous squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/75816_Cutan_squamous_poorly_diff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A soft, fleshy, granulomatous tumor is present on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75816 Version 3.0</div></div></div>"},"75818":{"type":"graphic_diagnosticimage","displayName":"Annular CA descend colon BE","title":"Cancer of the colon as seen on barium enema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cancer of the colon as seen on barium enema</div><div class=\"cntnt\"><img style=\"width:245px; height:288px;\" src=\"images/GAST/75818_Annular_CA_descend_colon_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast barium enema shows an apple-core lesion surrounding the lumen of the descending colon.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 75818 Version 3.0</div></div></div>"},"75820":{"type":"graphic_table","displayName":"IOM weight gain recommendations for pregnant women","title":"Recommendations for total and rate of weight gain during pregnancy by prepregnancy BMI","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for total and rate of weight gain during pregnancy by prepregnancy BMI</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Total weight gain</td> <td class=\"subtitle1\" colspan=\"2\">Rates of weight gain*<br /> second and third trimester</td> </tr> <tr> <td class=\"subtitle2\">Prepregnancy BMI</td> <td class=\"subtitle2\">Range in kg</td> <td class=\"subtitle2\">Range in lb</td> <td class=\"subtitle2\">Mean (range) in kg/week</td> <td class=\"subtitle2\">Mean (range) in lb/week</td> </tr> <tr> <td>Underweight (&#60;18.5 kg/m<sup>2</sup>)</td> <td>12.5 to 18</td> <td>28 to 40</td> <td>0.51 (0.44 to 0.58)</td> <td>1 (1 to 1.3)</td> </tr> <tr> <td>Normal weight (18.5 to 24.9 kg/m<sup>2</sup>)</td> <td>11.5 to 16</td> <td>25 to 35</td> <td>0.42 (0.35 to 0.50)</td> <td>1 (0.8 to 1)</td> </tr> <tr> <td>Overweight (25.0 to 29.9 kg/m<sup>2</sup>)</td> <td>7 to 11.5</td> <td>15 to 25</td> <td>0.28 (0.23 to 0.33)</td> <td>0.6 (0.5 to 0.7)</td> </tr> <tr> <td>Obese (&#8805;30.0 kg/m<sup>2</sup>)</td> <td>5 to 9</td> <td>11 to 20</td> <td>0.22 (0.17 to 0.27)</td> <td>0.5 (0.4 to 0.6)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index.<br />* Calculations assume a 0.5 to 2 kg (1.1 to 4.4 lb) weight gain in the first trimester.</div><div class=\"graphic_reference\">Weight Gain During Pregnancy: Reexamining the Guidelines. Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines, Rasmussen KM, Yaktine AL (Eds), National Academies Press (US), The National Academies Collection: Reports funded by National Institutes of Health, Washington (DC) 2009. Reprinted with permission from the National Academies Press, Copyright Â© 2009 National Academy of Sciences.</div><div id=\"graphicVersion\">Graphic 75820 Version 17.0</div></div></div>"},"75822":{"type":"graphic_picture","displayName":"Bilateral TRAM reconstruction","title":"Bilateral transverse rectus abdominis muscle (TRAM) flap reconstruction","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Bilateral transverse rectus abdominis muscle (TRAM) flap reconstruction</div><div class=\"cntnt\"><img style=\"width:551px; height:268px;\" src=\"images/ONC/75822_Bilateral_TRAM_reconstructi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immediate TRAM reconstruction following bilateral mastectomy. Left panel: preoperative appearance. Right panel: postoperative appearance.</div><div class=\"graphic_reference\">Courtesy of Jorge de la Pedraja, MD.</div><div id=\"graphicVersion\">Graphic 75822 Version 2.0</div></div></div>"},"75824":{"type":"graphic_diagnosticimage","displayName":"IVP distal ureteral tumor","title":"IVP findings with ureteral tumor","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">IVP findings with ureteral tumor</div><div class=\"cntnt\"><img style=\"width:504px; height:277px;\" src=\"images/ONC/75824_IVP_distal_ureteral_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intravenous pyelogram (IVP) demonstrating a distal left ureteral tumor, causing stenosis (arrows) and mild ureteral obstruction.</div><div class=\"graphic_reference\">Courtesy of Machele Donat, MD.</div><div id=\"graphicVersion\">Graphic 75824 Version 2.0</div></div></div>"},"75825":{"type":"graphic_diagnosticimage","displayName":"Intussusception lymphoma CT","title":"Intussusception of small bowel lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intussusception of small bowel lymphoma</div><div class=\"cntnt\"><img style=\"width:336px; height:288px;\" src=\"images/GAST/75825_Intussusception_lymphoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographyÂ scan of the abdomen demonstrates a large mass in the lumen of a distended loop of small bowel. Note mesenteric fat in the center of this intraluminal mass (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75825 Version 3.0</div></div></div>"},"75827":{"type":"graphic_picture","displayName":"Hydatid membranes","title":"Hydatid membranes","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Hydatid membranes</div><div class=\"cntnt\"><img style=\"width:468px; height:436px;\" src=\"images/GAST/75827_Hydatid_membranes_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography showing hydatid membranes that have been extracted from the common bile duct.</div><div id=\"graphicVersion\">Graphic 75827 Version 2.0</div></div></div>"},"75828":{"type":"graphic_picture","displayName":"Polyarteritis nodosa","title":"Polyarteritis nodosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polyarteritis nodosa</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75828_Polyarteritis_nodosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous nodules are present on the extremity in this patient with polyarteritis nodosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75828 Version 3.0</div></div></div>"},"75830":{"type":"graphic_table","displayName":"Iodine-containing foods","title":"Foods to avoid for two weeks before 131-I scanning and treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods to avoid for two weeks before 131-I scanning and treatment</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Iodized salt or sea salt, including salty snacks</td>\n\n    </tr>\n\n    <tr>\n      <td>Milk or other dairy products (small amounts in prepared foods are allowed)</td>\n    </tr>\n    <tr>\n      <td>Eggs (small amounts in prepared foods are allowed)</td>\n    </tr>\n    <tr>\n      <td>Seafood, especially shellfish, kelp, or seaweed </td>\n    </tr>\n    <tr>\n      <td>Any item with added carrageen, agar-agar, algin, or alginates</td>\n    </tr>\n    <tr>\n      <td>Cured foods, such as ham, corned beef, and sauerkraut</td>\n    </tr>\n    <tr>\n      <td>Breads (usually white breads) made from iodate dough conditioners</td>\n    </tr>\n    <tr>\n      <td>Foods and medicine (eg, vitamin-mineral tablets) containing red food dyes</td>\n    </tr>\n    <tr>\n      <td>Chocolate</td>\n    </tr>\n    <tr>\n      <td>Molasses</td>\n    </tr>\n    <tr>\n      <td>Soy products</td>\n    </tr>\n    <tr>\n      <td>Restaurant foods and Asian food </td>\n    </tr>\n    <tr>\n      <td>Pizza</td>\n    </tr>\n    <tr>\n      <td>Chili</td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_single\">Foods allowed</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fresh meat</td>\n\n    </tr>\n    <tr>\n      <td>Poultry</td>\n    </tr>\n    <tr>\n      <td>Potatoes or rice</td>\n    </tr>\n    <tr>\n      <td>Wheat or rye bread </td>\n    </tr>\n    <tr>\n      <td>Fresh or frozen vegetables</td>\n    </tr>\n    <tr>\n      <td>Fresh or frozen fruit</td>\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15170&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Iodine_containing_foods.htm</title></head></div><div class=\"graphic_footnotes\">131-I: radioiodine.</div><div class=\"graphic_reference\">Adapted from: Cavalieri RR. Nuclear imaging in the management of thyroid carcinoma. Thyroid 1996; 6:485.</div><div id=\"graphicVersion\">Graphic 75830 Version 3.0</div></div></div>"},"75831":{"type":"graphic_table","displayName":"Accuracy IDUS cytology biopsy","title":"Diagnostic accuracy for intraductal ultrasound (IDUS), bile cytology, and percutaneous transhepatic cholangioscopy (PTCS)-guided biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic accuracy for intraductal ultrasound (IDUS), bile cytology, and percutaneous transhepatic cholangioscopy (PTCS)-guided biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">IDUS (percent)</td> <td class=\"subtitle1\">Cytology (percent)</td> <td class=\"subtitle1\">PTCS (percent)</td> </tr> <tr> <td><strong>Sensitivity</strong></td> <td class=\"centered\">89*</td> <td class=\"centered\">64</td> <td class=\"centered\">93*</td> </tr> <tr> <td><strong>Specificity</strong></td> <td class=\"centered\">50</td> <td class=\"centered\">93<sup>&#182;</sup></td> <td class=\"centered\">100<sup>&#182;</sup></td> </tr> <tr> <td><strong>Positive predictive value</strong></td> <td class=\"centered\">96</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> </tr> <tr> <td><strong>Negative predictive value</strong></td> <td class=\"centered\">100<sup>&#916;</sup></td> <td class=\"centered\">63</td> <td class=\"centered\">87</td> </tr> <tr> <td><strong>Accuracy</strong></td> <td class=\"centered\">76</td> <td class=\"centered\">74</td> <td class=\"centered\">95<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IDUS: intraductal ultrasound; PTCS: percutaneous transhepatic cholangioscopy.<br />* p&lt;0.05 versus cytology.<br />&para; p&lt;0.05 versus IDUS.<br />&Delta; p&lt;0.05 versus cytology.<br /><span class=\"lozenge\">&loz;</span> p&lt;0.05 versus IDUS and cytology.</div><div class=\"graphic_reference\">Data from: Tamada K, Ueno N, Tomiyama T, et al. Gastrointest Endosc 1998; 47:341.</div><div id=\"graphicVersion\">Graphic 75831 Version 5.0</div></div></div>"},"75832":{"type":"graphic_algorithm","displayName":"Dx chronic diarrhea I","title":"Diagnostic approach to chronic diarrhea - part I","html":"<div class=\"graphic\"><div style=\"width: 821px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to chronic diarrhea - part I</div><div class=\"cntnt\"><img style=\"width:801px; height:792px;\" src=\"images/GAST/75832_DxchronicdiarrheaIedt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission from: Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.</div><div id=\"graphicVersion\">Graphic 75832 Version 4.0</div></div></div>"},"75833":{"type":"graphic_picture","displayName":"Discoid lupus - left ear","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/75833_Discoidlupusleftear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well-defined, erythematous plaque with scale, pigmentary alteration, and scarring is present on this patient with discoid lupus erythematosus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75833 Version 4.0</div></div></div>"},"75835":{"type":"graphic_diagnosticimage","displayName":"Atherosclerotic plaque on CT","title":"Atherosclerotic plaque on CT","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Atherosclerotic plaque on CT</div><div class=\"cntnt\"><img style=\"width:584px; height:303px;\" src=\"images/SURG/75835_Atherosclerotic_plaque_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atherosclerotic plaque of the descending thoracic and abdominal aorta on CT. Severe atherosclerotic plaque (arrows) visualized by CT in axial (panel A) and sagittal (panel B) projections.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Pierre Maldjian.</div><div id=\"graphicVersion\">Graphic 75835 Version 2.0</div></div></div>"},"75836":{"type":"graphic_diagnosticimage","displayName":"Progression of acromioclavicular arthritis on MRI","title":"Progression of acromioclavicular arthritis on MRI","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Progression of acromioclavicular arthritis on MRI</div><div class=\"cntnt\"><img style=\"width:514px; height:515px;\" src=\"images/EM/75836_AC_arthritis_progr_MRI_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of four MRI images depicts the changes seen with osteoarthritis of the acromioclavicular joint. Note the progression of joint space narrowing, subchondral cyst formation (thin arrow), and joint irregularity. The joint space in image A is indicated by the thick arrow.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 75836 Version 6.0</div></div></div>"},"75837":{"type":"graphic_figure","displayName":"Beta globin gene sequencing","title":"Beta globin gene sequencing: Family study","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Beta globin gene sequencing: Family study</div><div class=\"cntnt\"><img style=\"width:547px; height:505px;\" src=\"images/HEME/75837_Beta_globin_gene_sequencing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequencing of the beta-globin gene from: (A) Father with beta thalassemia trait due to the insertion of a G between codons 8 and 9 resulting in a frameshift and premature termination; (B) Mother with heterozygous Hb D Iran (beta22 GluâGln), resulting from a GAAâCAA mutation in codon 22. This couple had a child with Hb D-Iran-beta0 thalassemia who presented with moderate hypochromic microcytic anemia and hence was referred for consultation.<br> The downward arrows indicate the first nucleotide after the insertion of a &quot;G&quot;. This disrupts the reading frame of the rest of the beta globin gene as can be seen in the garbled sequence (peaks of various colors on top of each other), which results from the frameshift on the mutated allele and the continued normal sequence on the other allele. The bracket underneath shows the start of the frameshift. &quot;N&quot; indicates any nucleotide that the system is unable to clearly identify and read as a &quot;C&quot; (blue), &quot;T&quot; (red), &quot;G&quot; (black), and &quot;A&quot; (green). Since the sequence to the right of the arrow (insertion of &quot;G&quot;) is frameshifted and difficult to read, there are a lot of &quot;N&quot;s. The normal pattern should be like Part B of the graph where the sequence can be read clearly and nucleotides clearly identified except for where pointed by the arrow, which denotes the mutation. Instead of a normal &quot;G&quot; that should be in this position, there is a &quot;C&quot; in the mutated allele, and therefore, underneath the arrow, in addition to a &quot;G&quot; peak (black), you can also see a &quot;C&quot; (blue). This is the mutation that leads to Hb D-Iran as indicated above.</div><div id=\"graphicVersion\">Graphic 75837 Version 3.0</div></div></div>"},"75838":{"type":"graphic_table","displayName":"Physical activity assessment in children","title":"Assessment of physical activity in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of physical activity in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Sedentary behaviors</td> </tr> <tr> <td>Hours spent watching television, including videos or movies</td> </tr> <tr> <td>Hours spent playing video games (hand-held, internet or on-line, or television/video-based)</td> </tr> <tr> <td>Hours spent on computer or in internet-based activities, aside from school work</td> </tr> <tr> <td>Hours spent talking on telephone or texting</td> </tr> <tr> <td>Hours spent doing productive sedentary behaviors, such as homework, reading, and computer-based learning</td> </tr> <tr> <td class=\"subtitle1_single\">Physical activity behaviors</td> </tr> <tr> <td>Type, frequency, duration, and intensity of structured physical activity (organized physical activity, such as sports)</td> </tr> <tr> <td>Time spent in unstructured play (eg, outside play, and routine activity such as walking to school)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Example of questions to ask for a brief semi-quantitative assessment of physical activity in children. Evaluating activity in each of these areas provides an estimate of the child's overall activity level, and helps identify areas for potential improvement.</div><div class=\"graphic_reference\">Based on recommendations in: Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D. Assessment of child and adolescent overweight and obesity. Pediatrics 2007; 120 Suppl 4:S193-228.</div><div id=\"graphicVersion\">Graphic 75838 Version 7.0</div></div></div>"},"75839":{"type":"graphic_table","displayName":"Paraneo pain synds","title":"Pain from paraneoplastic syndromes in cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pain from paraneoplastic syndromes in cancer patients</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1\">\n   Syndrome\n   </td>\n   <td   class=\"subtitle1\">\n   Characteristics\n   </td>\n   </tr>\n   <tr>\n   <td>Chronic sensorimotor neuropathy</td>\n   <td>Mild to moderate distal symmetric sensorimotor defects with symmetric pain that begins in the feet and gradually ascends</td>\n   </tr>\n   <tr>\n   <td   rowspan=\"2\">\n   Hypertrophic osteoarthropathy\n   </td>\n   <td>Clubbing of fingers, periostitis of long bones, and occasionally a rheumatoid-like polyarthritis</td>\n   </tr>\n   <tr>\n   <td>Pain, tenderness, and swelling in the knees, wrists, and ankles</td>\n   </tr>\n   <tr>\n   <td>Paraneoplastic gynecomastia</td>\n   <td>Breast enlargement, usually presenting with pain</td>\n   </tr>\n   <tr>\n   <td   rowspan=\"2\">\n   Paraneoplastic pemphigus\n   </td>\n   <td>Widespread mucocutaneous lesions involving the lips, conjunctiva, and genitalia</td>\n   </tr>\n   <tr>\n   <td>When severe, desquamation can occur and death may occur from fluid loss, infection, or an associated bronchiolitis obliterans</td>\n   </tr>\n   <tr>\n   <td>Paraneoplastic Raynaud's phenomenon</td>\n   <td>Intense vasospasm of digital arterioles leading to pallor, followed by cyanosis and subsequent hyperemia of the fingertips</td>\n   </tr>\n   <tr>\n   <td>Subacute sensory neuronopathy</td>\n   <td>\"Pins and needles\" or electric-shock sensations initially affecting an extremity and progresses to involve other extremities, the face, abdomen, and trunk</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 75839 Version 1.0</div></div></div>"},"75840":{"type":"graphic_figure","displayName":"SERM signal transduction","title":"Complexity of SERM signal transduction","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Complexity of SERM signal transduction</div><div class=\"cntnt\"><img style=\"width:550px; height:370px;\" src=\"images/ONC/75840_SERM_signal_transduction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The decision network for estrogen or SERM action binding to nuclear estrogen receptor (ER) a or b receptor or membrane ER (decision 1). Receptor-specific or mixed specificity ligands bind to the ligand binding domain (E region) of the ERs to cause a ligand-specific perturbation in the receptor complex that creates opportunities for the complex to bind either coactivators or corepressors on the external surface (decision 2). The interactive proteins shunt the ER complex into transcriptionally active or inactive states. Although the expanding family of coregulators are being defined, this does not exclude the possibility that other interactive proteins could alter gene transcription through phosphorylation activation. This could be initiated rapidly either by membrane ER or constitutively through cell surface growth factor receptors. The next decision point (3) is where the complex or coregulators are ubiquitinated and destroyed by the proteasome or accumulate to become promiscuous estrogen-like complexes. Again, phosphorylation may play an important role in the activity of the ER complex. The decision (4) to interact with the machinery involved with gene transcription can shunt the signaling pathway from positive or negative regulation based upon the ER concerned, the ligand, or whether there is a direct interaction with an estrogen response element (ERE) or a tethered interaction to proteins at AP-1 or SP-1 sites. Overall, the decision network creates a complex regulatory system at target tissues or in cancer where a growth advantage can be exploited in response to antiestrogen therapies.</div><div class=\"graphic_reference\">Reproduced with permission from: Jordan VC. Selective estrogen receptor modulation: Concept and consequences in cancer. Cancer Cell 2004; 5:208. Copyright &#169;2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 75840 Version 2.0</div></div></div>"},"75841":{"type":"graphic_picture","displayName":"Periungual erythema PI","title":"Periungual erythema in a patient with dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Periungual erythema in a patient with dermatomyositis</div><div class=\"cntnt\"><img style=\"width:397px; height:243px;\" src=\"images/PI/75841_Periungual_erythema_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 75841 Version 2.0</div></div></div>"},"75842":{"type":"graphic_diagnosticimage","displayName":"Chest XRay bronchogenic cyst","title":"Bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:515px; height:275px;\" src=\"images/PEDS/75842_Chest_XRay_bronchogenic_cys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior-posterior and lateral views demonstrate a cystic lesion in the left upper lobe. There is an air-fluid level present, suggesting prior or current infection.</div><div class=\"graphic_reference\">Courtesy of Christopher M Oermann, MD.</div><div id=\"graphicVersion\">Graphic 75842 Version 2.0</div></div></div>"},"75843":{"type":"graphic_table","displayName":"History and prognosis of RA","title":"Natural history and prognosis of rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Natural history and prognosis of rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>70% of joint erosions detectable by&nbsp;radiograph of hands and feet occur in the first two years of disease</td> </tr> <tr> <td class=\"sublist1_start\">Increased evidence of:</td> </tr> <tr> <td class=\"sublist1\">Infections</td> </tr> <tr> <td class=\"sublist1\">Cardiovascular disease</td> </tr> <tr> <td class=\"sublist1\">Lymphomas</td> </tr> <tr> <td class=\"sublist1_start\">Life expectancy of RA less than age- and sex-matched control populations, especially in patients with:</td> </tr> <tr> <td class=\"sublist1\">Polyarticular disease</td> </tr> <tr> <td class=\"sublist1\">Systemic extraarticular disease</td> </tr> <tr> <td class=\"sublist1\">Persistent disease activity (high ESR, CRP)</td> </tr> <tr> <td class=\"sublist1\">Rheumatoid factor and circulatory immune complex positivity</td> </tr> <tr> <td class=\"sublist1\">HLA-DR &#38; chain \"shared epitope\" (especially bialleic)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">RA: rheumatoid arthritis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HLA: human leukocyte antigen.</div><div id=\"graphicVersion\">Graphic 75843 Version 4.0</div></div></div>"},"75844":{"type":"graphic_table","displayName":"Uveitis with eye disease alone","title":"Uveitis syndromes confined primarily to the eye","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Uveitis syndromes confined primarily to the eye</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acute multifocal placoid pigmentary epitheliopathy</td> </tr> <tr> <td>Acute retinal necrosis</td> </tr> <tr> <td>Autosomal dominant neovascular inflammatory vitreoretinopathy</td> </tr> <tr> <td>Birdshot choroidopathy</td> </tr> <tr> <td>Fuchs' heterochromic cyclitis (post rubella)</td> </tr> <tr> <td>Glaucomatocyclitic crisis</td> </tr> <tr> <td>Immune recovery (reconstitution) uveitis</td> </tr> <tr> <td>Iridocorneal endothelial syndrome</td> </tr> <tr> <td>Leber's neuroretinitis</td> </tr> <tr> <td>Multifocal evanescent white dot syndrome</td> </tr> <tr> <td>Pars planitis</td> </tr> <tr> <td>Punctate inner choroidopathy</td> </tr> <tr> <td>Serpiginous choroidopathy</td> </tr> <tr> <td>Subretinal fibrosis</td> </tr> <tr> <td>Sympathetic ophthalmia</td> </tr> <tr> <td>Trauma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75844 Version 3.0</div></div></div>"},"75847":{"type":"graphic_table","displayName":"Performance of Down syndrome screening tests by maternal age","title":"Performance of three different screening tests in the FASTER trial in women under 35 and in women 35 and older","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Performance of three different screening tests in the FASTER trial in women under 35 and in women 35 and older</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Screening test</td>\n<td colspan=\"2\" class=\"subtitle1\">&#60;35 years old</td>\n<td colspan=\"2\" class=\"subtitle1\">&#8805;35 years old</td>\n<td colspan=\"2\" class=\"subtitle1\">Overall</td>\n</tr>\n<tr>\n\n<td class=\"subtitle2\">DR, percent</td>\n<td class=\"subtitle2\">FPR, percent</td>\n<td class=\"subtitle2\">DR, percent</td>\n<td class=\"subtitle2\">FPR, percent</td>\n<td class=\"subtitle2\">DR, percent</td>\n<td class=\"subtitle2\">FPR, percent</td>\n</tr>\n<tr>\n<td>1st trimester combined</td>\n<td>75</td>\n<td>5.0</td>\n<td>95</td>\n<td>22</td>\n<td>86</td>\n<td>5.6</td>\n</tr>\n<tr>\n<td>2nd trimester quadruple test</td>\n<td>77</td>\n<td>2.3</td>\n<td>92</td>\n<td>13</td>\n<td>85</td>\n<td>8.5</td>\n</tr>\n<tr>\n<td>1st and 2nd trimester full integrated test</td>\n<td>77</td>\n<td>0.4</td>\n<td>91</td>\n<td>2</td>\n<td>85</td>\n<td>about 1</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Malone, FD, Canick, JA, Ball, RH, et al. N Engl J Med 2005; 353:2001.</div><div id=\"graphicVersion\">Graphic 75847 Version 2.0</div></div></div>"},"75848":{"type":"graphic_picture","displayName":"Diabetic foot ulcer 3 PI","title":"Deep diabetic foot ulcer involving bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep diabetic foot ulcer involving bone</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/PI/75848_Diab_foot_ulcer_3_new_PI_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has an ulcer on the bottom of the foot that extends through several layers of skin and muscle. After the wound was cleaned and drained, exposed bone was visible.</div><div class=\"graphic_reference\">Courtesy of Paul Thottingal, MD.</div><div id=\"graphicVersion\">Graphic 75848 Version 4.0</div></div></div>"},"75849":{"type":"graphic_diagnosticimage","displayName":"Hurler brain MRI","title":"Brain MRI in a patient with mucopolysaccharidosis type I (MPS I, Hurler syndrome) ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI in a patient with mucopolysaccharidosis type I (MPS I, Hurler syndrome) </div><div class=\"cntnt\"><img style=\"width:277px; height:370px;\" src=\"images/PEDS/75849_Hurler_brain_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Horizontal T2-weighted&nbsp;magnetic resonance&nbsp;cranial image in a five year old with Hurler syndrome. The large lateral ventricles are due to severe communicating hydrocephalus with possible atrophy.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Emil Kakkis, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75849 Version 5.0</div></div></div>"},"75851":{"type":"graphic_picture","displayName":"HSV keratitis as seen with slit lamp","title":"HSV keratitis as seen with slit lamp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HSV keratitis as seen with slit lamp</div><div class=\"cntnt\"><img style=\"width:432px; height:275px;\" src=\"images/EM/75851_Slit_lamp_keratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows the characteristic dendritic appearance of corneal lesions caused by a herpes simplex virus (HSV) infection. Note how little fluorescein is needed to highlight the lesion; scant fluorescein is visible on the remainder of the cornea.</div><div class=\"graphic_reference\">Courtesy of Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 75851 Version 3.0</div></div></div>"},"75853":{"type":"graphic_picture","displayName":"Endoscopy showing Schatzki ring dilation ","title":"Schatzki ring dilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schatzki ring dilation</div><div class=\"cntnt\"><img style=\"width:252px; height:257px;\" src=\"images/GAST/75853_Schatzki_ring_dilation_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic imaging showing balloon dilation of the distal esophageal ring.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Douglas A. Horst, MD.</div><div id=\"graphicVersion\">Graphic 75853 Version 2.0</div></div></div>"},"75855":{"type":"graphic_figure","displayName":"PMN development and kinetics","title":"Neutrophil development and kinetics","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">Neutrophil development and kinetics</div><div class=\"cntnt\"><img style=\"width:690px; height:498px;\" src=\"images/HEME/75855_PMN_development_and_kinetic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of PMN development and kinetics expressed as the flux time myeloid precursors spend at each stage of maturation in the bone marrow. Note the larger pool size and longer period PMNs spend in the marrow compared with the smaller pool size (in red) and shorter period PMNs spend in the blood before entering the tissue pool (in blue) where they undergo apoptosis.</div><div class=\"graphic_footnotes\">PMN: polymorphonuclear neutrophil.</div><div class=\"graphic_reference\">Adapted from: Bainton DF. Developmental biology of neutrophils and esinophils. In: Inflammation Basic Principles and Clinical Correlates, 2d ed, Raven Press, New York, 1992.</div><div id=\"graphicVersion\">Graphic 75855 Version 4.0</div></div></div>"},"75856":{"type":"graphic_table","displayName":"Characteristics of theophylline","title":"Absorption characteristics of selected slow-release formulations of theophylline marketed in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Absorption characteristics of selected slow-release formulations of theophylline marketed in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Formulation</td>\n\n      <td class=\"subtitle1\">Time to peak serum\nconcentration</td>\n\n      <td class=\"subtitle1\">Comments</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Theo-24</td>\n\n      <td>Variable depending on whether taken in the morning\nafter an overnight fast, after breakfast, or in the evening.</td>\n\n      <td>Incomplete absorption occurs when taken after an\novernight fast; pH-dependent dissolution causes much more rapid (ie,\ndose-dumping) and complete absorption when taken after food or in the\nevening.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Generic SR tablets</td>\n\n      <td>3 to 7 hours after morning dose when given every 12\nhours.</td>\n\n      <td>Scored tablets can be split without affecting\nabsorption characteristics; complete absorption occurs in the presence\nor absence of food.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Generic SR capsules</td>\n\n      <td>3 to 7 hours after morning dose when given every 12\nhours.</td>\n\n      <td>Can be opened and sprinkled on a spoonful of soft food\nfor children who cannot swallow the capsule; contents must be swallowed\nwithout chewing; complete absorption occurs in the presence or absence\nof food.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Uniphyl</td>\n\n      <td>8 to 12 hours after once-daily evening dose.</td>\n\n      <td>Incomplete absorption occurs when taken after overnight\nfast; more complete absorption occurs when taken after food or in the\nevening.</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">The times selected for this table represent the times for a reasonable approximation of the peak serum concentration at the dosing interval most commonly used for the product.</div><div class=\"graphic_reference\">Adapted from Weinberger, M, Hendeles, L, N Engl J Med 1996; 334:1380.</div><div id=\"graphicVersion\">Graphic 75856 Version 1.0</div></div></div>"},"75858":{"type":"graphic_picture","displayName":"Prone knee-chest position","title":"Three-year-old girl in the prone knee-chest position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three-year-old girl in the prone knee-chest position</div><div class=\"cntnt\"><img style=\"width:432px; height:306px;\" src=\"images/EM/75858_Prone_knee_chest_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To allow visualization of the vaginal vault, the child should separate her knees and relax her abdominal muscles, and an assistant should retract the child's buttocks and labia majora. An otoscope head is a simple means of magnification and illumination.</div><div class=\"graphic_reference\">Courtesy of Jan E Paradise, MD.</div><div id=\"graphicVersion\">Graphic 75858 Version 1.0</div></div></div>"},"75859":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph - tropical pulmonary eosinophilia","title":"Chest radiograph - Tropical pulmonary eosinophilia","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Chest radiograph - Tropical pulmonary eosinophilia</div><div class=\"cntnt\"><img style=\"width:514px; height:375px;\" src=\"images/ID/75859_Chest_x_trop_pulm_esinoph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph of young Indian male presenting with symptoms suggestive of asthma. <br />(B) Follow-up chest radiograph two weeks after diethylcarbazine therapy for suspected tropical pulmonary eosinophilia demonstrates improvement in subtle chest radiograph findings.</div><div class=\"graphic_reference\">Courtesy of Peter Weller, MD.</div><div id=\"graphicVersion\">Graphic 75859 Version 2.0</div></div></div>"},"75861":{"type":"graphic_picture","displayName":"Polymorphic eruption of pregnancy abdomen","title":"Polymorphic eruption of pregnancy (pruritic papules and plaques of pregnancy)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphic eruption of pregnancy (pruritic papules and plaques of pregnancy)</div><div class=\"cntnt\"><img style=\"width:432px; height:344px;\" src=\"images/DERM/75861_PUPPP_abdomen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and plaques with accentuation in abdominal striae and relative sparing of the umbilicus are present on this patient with polymorphic eruption of pregnancy (PEP), also called pruritic papules and plaques of pregnancy (PUPPP). Erythematous papules are also visible on the hands.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75861 Version 5.0</div></div></div>"},"75862":{"type":"graphic_table","displayName":"Major causes of rhinitis","title":"Major causes of rhinitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of rhinitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\"><strong>Allergic rhinitis</strong></td> </tr> <tr> <td class=\"sublist1\">Seasonal</td> </tr> <tr> <td class=\"sublist1\">Perennial</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Nonallergic rhinitis</strong></td> </tr> <tr> <td class=\"sublist1\">Vasomotor</td> </tr> <tr> <td class=\"sublist1\">Gustatory</td> </tr> <tr> <td class=\"sublist1\">Nonallergic rhinitis with eosinophilia syndrome</td> </tr> <tr> <td><strong>Mixed rhinitis</strong></td> </tr> <tr> <td><strong>CPAP-associated rhinitis</strong></td> </tr> <tr> <td><strong>Occupational rhinitis</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>Rhinitis medicamentosa</strong></td> </tr> <tr> <td class=\"sublist1\">Nasal decongestant sprays</td> </tr> <tr> <td class=\"sublist1\">Intranasal cocaine</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Systemic medication-induced rhinitis</strong></td> </tr> <tr> <td class=\"sublist1\">Oral contraceptives</td> </tr> <tr> <td class=\"sublist1\">Erectile dysfunction drugs</td> </tr> <tr> <td class=\"sublist1\">Some antihypertensives</td> </tr> <tr> <td class=\"sublist1\">Aspirin and other NSAIDs (more prevalent among patients with asthma and/or chronic rhinosinusitis with nasal polyposis)</td> </tr> <tr> <td class=\"sublist1\">Some antidepressants</td> </tr> <tr> <td class=\"sublist1\">Some benzodiazepines</td> </tr> <tr> <td><strong>Pregnancy</strong></td> </tr> <tr> <td><strong>Atrophic rhinitis</strong></td> </tr> <tr> <td class=\"sublist1_start\"><strong>Systemic diseases</strong></td> </tr> <tr> <td class=\"sublist1\">Hypothyroidism</td> </tr> <tr> <td class=\"sublist1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"sublist1\">Midline granuloma</td> </tr> <tr> <td class=\"sublist1\">Sarcoidosis</td> </tr> <tr> <td class=\"sublist1\">Cystic fibrosis</td> </tr> <tr> <td class=\"sublist1\">Immotile cilia syndromes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPAP: continuous positive airway pressure; NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div id=\"graphicVersion\">Graphic 75862 Version 7.0</div></div></div>"},"75863":{"type":"graphic_table","displayName":"Echinococcus species","title":"<EM>Echinococcus </EM>species, strains and genotypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\"><EM>Echinococcus </EM>species, strains and genotypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Species</td> <td class=\"subtitle1\">Strain/genotype</td> <td class=\"subtitle1\">Known intermediate hosts</td> <td class=\"subtitle1\">Infective to humans</td> <td class=\"subtitle1\">Disease in humans</td> <td class=\"subtitle1\">Known definitive hosts</td> </tr> <tr> <td><em>Echinococcus granulosus</em></td> <td>Sheep/G1</td> <td>Sheep (cattle, pigs, camels, goats, macropods)</td> <td>Yes</td> <td>Cystic (Unilocular)</td> <td>Dog, fox, dingo, jackal and hyena</td> </tr> <tr> <td>&nbsp;</td> <td>Tasmanian sheep/G2</td> <td>Sheep (cattle?)</td> <td>Yes</td> <td>Cystic (Unilocular)</td> <td>Dog, fox</td> </tr> <tr> <td>&nbsp;</td> <td>Buffalo/G3</td> <td>Buffalo (cattle?)</td> <td>?</td> <td>?</td> <td>Dog, fox?</td> </tr> <tr> <td>&nbsp;</td> <td>Camel/G6</td> <td>Camels (sheep)</td> <td>Yes</td> <td>Cystic (Unilocular)</td> <td>Dog</td> </tr> <tr> <td>&nbsp;</td> <td>Pig/G7</td> <td>Pigs</td> <td>Yes</td> <td>Cystic (Unilocular)</td> <td>Dog</td> </tr> <tr> <td>&nbsp;</td> <td>Cervid/G8 and G10</td> <td>Cervids</td> <td>Yes</td> <td>Cystic (Unilocular)</td> <td>Wolf, dog</td> </tr> <tr> <td>&nbsp;</td> <td>?/G9</td> <td>&nbsp;</td> <td>Yes</td> <td>Cystic (Unilocular)</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>Lion/?</td> <td>Zebra, wildebeest, warthog, bushpig, buffalo, various Antelope, giraffe? Hippopotamus?</td> <td>?</td> <td>?</td> <td>Lion</td> </tr> <tr> <td><em>Echinococcus equines</em></td> <td>Horse/G4</td> <td>Horses and other equines</td> <td>No</td> <td>-</td> <td>Dog</td> </tr> <tr> <td><em>Echinococcus ortleppi</em></td> <td>Cattle/G5</td> <td>Cattle</td> <td>Yes</td> <td>Cystic (Unilocular)</td> <td>Dog</td> </tr> <tr> <td><em>Echinococcus multilocularis</em></td> <td>Some isolate variation (see text)</td> <td>Rodents, domestic and wild pig, dog, monkey, (hors?)</td> <td>Yes</td> <td>Alveolar (multivesicular)</td> <td>Fox, dog, cat, wolf, racoon-dog, coyote</td> </tr> <tr> <td><em>Echinococcus shiquicus</em></td> <td>?</td> <td>Lagomorphs (pika)</td> <td>?</td> <td>?</td> <td>Tibetan fox</td> </tr> <tr> <td><em>Echinococcus vogeli</em></td> <td>None reported</td> <td>Rodents</td> <td>Yes</td> <td>Polycystic</td> <td>Bush dog</td> </tr> <tr> <td><em>Echinococcus oligarthrus</em></td> <td>None reported</td> <td>Rodents</td> <td>Yes</td> <td>Polycystic</td> <td>Wild felids</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Jenkins DJ, Romig T, Thompson RC. Emergence/re-emergence of Echinococcus spp.--a global update. Int J Parasitol 2005; 35:1205. Copyright Â©2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 75863 Version 3.0</div></div></div>"},"75866":{"type":"graphic_figure","displayName":"Fibroid embolization 1 PI","title":"Fibroid embolization 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibroid embolization 1</div><div class=\"cntnt\"><img style=\"width:361px; height:308px;\" src=\"images/PI/75866_Fibroid_embolization_1_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing superselective catheter position in the right uterine artery via left femoral arterial approach.</div><div id=\"graphicVersion\">Graphic 75866 Version 1.0</div></div></div>"},"75867":{"type":"graphic_figure","displayName":"Horseshoe kidney","title":"Horseshoe kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Horseshoe kidney</div><div class=\"cntnt\"><img style=\"width:411px; height:396px;\" src=\"images/PEDS/75867_Horseshoe_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic horseshoe kidney with fusion of the lower poles forming a parenchymal isthmus and shifting the axis of the kidney so that the renal pelvis lies anteriorly and the ureters traverse the anterior surface and the isthmus of the horseshoe kidney.</div><div id=\"graphicVersion\">Graphic 75867 Version 2.0</div></div></div>"},"75869":{"type":"graphic_picture","displayName":"External rotation for shoulder reduction","title":"External rotation technique for reduction of anterior shoulder dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External rotation technique for reduction of anterior shoulder dislocation</div><div class=\"cntnt\"><img style=\"width:432px; height:328px;\" src=\"images/EM/75869_Shoulder_reduct_ext_rot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the patient's arm adducted and the elbow flexed, the forearm is slowly and gently externally rotated. If pain or spasm is felt, the physician stops and allows the patient to relax. No longitudinal traction is necessary. In most cases, by the time the shoulder is fully externally rotated, the shoulder will have been reduced.</div><div class=\"graphic_reference\">Courtesy of Scott C Sherman, MD.</div><div id=\"graphicVersion\">Graphic 75869 Version 5.0</div></div></div>"},"75871":{"type":"graphic_table","displayName":"Pretest probability of DVT","title":"Pretest probability of deep vein thrombosis (Wells score)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pretest probability of deep vein thrombosis (Wells score)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td>Active cancer (treatment ongoing or within the previous&nbsp;six months or palliative)</td> <td>1</td> </tr> <tr> <td>Paralysis, paresis, or recent plaster immobilization of the lower extremities </td> <td>1</td> </tr> <tr> <td>Recently bedridden for more than&nbsp;three days or major surgery, within&nbsp;four weeks</td> <td>1</td> </tr> <tr> <td>Localized tenderness along the distribution of the deep venous system</td> <td>1</td> </tr> <tr> <td>Entire leg swollen</td> <td>1</td> </tr> <tr> <td>Calf swelling by more than 3 cm when compared to the asymptomatic leg (measured below tibial tuberosity)</td> <td>1</td> </tr> <tr> <td>Pitting edema (greater in the symptomatic leg)</td> <td>1</td> </tr> <tr> <td>Collateral superficial veins (nonvaricose)</td> <td>1</td> </tr> <tr> <td>Alternative diagnosis as likely or more likely than that of deep venous thrombosis</td> <td>-2</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Score</td> </tr> <tr> <td>High probability</td> <td>&nbsp;3 or greater</td> </tr> <tr> <td>Moderate probability </td> <td>1 or 2</td> </tr> <tr> <td>Low probability</td> <td>0 or less</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Modification:</td> </tr> <tr> <td colspan=\"2\">This clinical model has been modified to take one other clinical feature into account: a previously documented deep vein thrombosis (DVT) is given the score of 1. Using this modified scoring system, DVT is either likely or unlikely, as follows:</td> </tr> <tr> <td class=\"indent1\">DVT likely</td> <td>2 or greater&nbsp;</td> </tr> <tr> <td class=\"indent1\">DVT unlikely</td> <td>1 or less</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350:1795</LI>&#xD;&#xA;<LI>Wells PS, Anderson,DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349:1227.</LI></OL></div><div id=\"graphicVersion\">Graphic 75871 Version 2.0</div></div></div>"},"75872":{"type":"graphic_waveform","displayName":"Intermediate case 3","title":"Intermediate case 3","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intermediate case 3</div><div class=\"cntnt\"><img style=\"width:421px; height:99px;\" src=\"images/CARD/75872_Intermediate_case_3.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75872 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"75873":{"type":"graphic_table","displayName":"Specific cough child","title":"Approach to a child with chronic specific cough*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to a child with chronic specific cough*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition </td> <td class=\"subtitle1\">Underlying causes </td> <td class=\"subtitle1\">Evaluation </td> </tr> <tr> <td>Asthma</td> <td> <p>Bronchospasm</p> <p>Environmental triggers</p> </td> <td> <p>Spirometry</p> <p>Chest radiography</p> <p>Allergy testing</p> <p>Trial of antiasthma medications</p> </td> </tr> <tr> <td>Protracted bacterial bronchitis</td> <td> <p><em>Haemophilus influenzae</em></p> <p><em>Streptococcus pneumoniae</em></p> <p><em>Moraxella catarrhalis</em></p> </td> <td> <p>Empiric treatment with antibiotics (two-week course or more)</p> <p>Bronchoscopy with cultures</p> </td> </tr> <tr> <td>Chronic suppurative lung disease/bronchiectasis, or recurrent pneumonia</td> <td> <p>Cystic fibrosis</p> <p>Ciliary dyskinesia</p> <p>Previous severe pneumonia</p> <p>Immunodeficiency</p> <p>Structural airway lesions</p> <p>Congenital lung lesions</p> <p>Missed foreign body</p> <p>TEF/H-fistula</p> </td> <td> <p>Sweat test</p> <p>Bronchoscopy</p> <p>Cilia biopsy</p> <p>Immune workup</p> <p>HRCT chest</p> <p>Barium swallow</p> <p>Sputum cultures</p> </td> </tr> <tr> <td>Airway abnormality&nbsp;</td> <td> <p>Foreign body</p> <p>Tracheo-bronchomalacia</p> <p>Other intraluminal lesions (eg, tumors)</p> <p>Extrinsic compressive lesions&nbsp;</p> </td> <td> <p>Chest radiography</p> <p>Bronchoscopy and lavage</p> <p>CT chest</p> <p>MRI chest</p> &nbsp;</td> </tr> <tr> <td>Aspiration</td> <td> <p>Neurologic abnormalities</p> <p>Weak cough reflex</p> <p>Neuromuscular disease</p> <p>Laryngeal abnormalities</p> <p>Adenotonsillar hypertrophy</p> <p>TEF/H-fistula</p> <p>Severe GERD</p> </td> <td> <p>Barium swallow</p> <p>Bronchoscopy and lavage</p> <p>Video fluoroscopy</p> <p>pH monitor</p> <p>Lung milk scan/salivagram</p> </td> </tr> <tr> <td>Chronic or less common infections</td> <td> <p>Tuberculosis</p> <p>Nontuberculous mycobacteria</p> <p>Mycoses</p> <p>Parasites</p> </td> <td> <p>Mantoux test</p> <p>Bronchoscopy and lavage</p> <p>HRCT chest</p> <p>Sputum cultures</p> </td> </tr> <tr> <td>Interstitial lung disease</td> <td> <p>Rheumatic diseases</p> <p>Cytotoxic drugs</p> <p>Drugs</p> <p>External beam radiation</p> </td> <td> <p>Autoimmune markers</p> <p>HRCT chest</p> <p>Lung biopsy</p> </td> </tr> <tr> <td>Cardiac</td> <td> <p>Pulmonary hypertension</p> <p>Cardiac edema</p> </td> <td> <p>Pediatric cardiology consultation</p> <p>Echocardiogram</p> <p>Cardiac catheterization</p> </td> </tr> <tr> <td>Other</td> <td> <p>Upper airway cough syndrome</p> <p>Post-pertussis cough</p> <p>&nbsp;</p> </td> <td> <p>Evaluate for sinusitis and chronic rhinitis&nbsp;</p> <p>PCR, culture and serology for <em>Bordetella pertussis</em></p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TEF: tracheoesophageal fistula; HRCT: high-resolution chest computerized tomography; GERD: gastroesophageal reflux disease; CT: computerized tomography; MRI: magnetic resonance imaging; PCR: polymerase chain reaction.<br />* \"Specific cough\" refers to a cough that is caused by an underlying abnormality or disease.</div><div class=\"graphic_reference\">Adapted from guidelines in: Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest 2006; 129(1) Supplement: 260S-283S.</div><div id=\"graphicVersion\">Graphic 75873 Version 6.0</div></div></div>"},"75874":{"type":"graphic_diagnosticimage","displayName":"Intraluminal lesion CT","title":"Computed tomographic scans with intraluminal tracheal lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomographic scans with intraluminal tracheal lesions</div><div class=\"cntnt\"><img style=\"width:397px; height:510px;\" src=\"images/PULM/75874_Intraluminal_lesion_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper panel shows an incidental finding of a mucus plug (arrow) in the trachea. In contrast, the lower panel demonstrates a mucosal tracheal metastasis (arrowhead) from adenocarcinoma of the lung in a patient status post right upper lobe lobectomy.</div><div id=\"graphicVersion\">Graphic 75874 Version 3.0</div></div></div>"},"75875":{"type":"graphic_table","displayName":"Patient education - Sleep disorders and driving","title":"Patient education: Sleep disorders and automobile driving","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient education: Sleep disorders and automobile driving</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>You have been diagnosed with sleep apnea or another sleep disorder which may adversely affect your driving. People with sleep apnea or other sleep disorders may have a threefold increased rate of automobile crashes or other accidents. These accidents may cause serious injury or death to yourself or others.</td> </tr> <tr> <td>If you have had an automobile crash or frequent near-crashes due to sleepiness or inattention, you should stop driving and operating dangerous machinery until your sleep disorder has been treated and you no longer become sleepy or inattentive while driving. It is your responsibility not to drive if you are sleepy or inattentive while driving.</td> </tr> <tr> <td>Until your treatment has begun, have your spouse or friends drive for you. If you drive against medical advice, plan ahead so that you avoid driving at times of day when you are most likely to be sleepy, such as mid-afternoon, late at night, or after a poor night's sleep. If you have further concerns about your driving, talk to your doctor.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75875 Version 3.0</div></div></div>"},"75876":{"type":"graphic_diagnosticimage","displayName":"Cholangiogram of hepaticojejunostomy","title":"Cholangiogram of hepaticojejunostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholangiogram of hepaticojejunostomy</div><div class=\"cntnt\"><img style=\"width:352px; height:432px;\" src=\"images/SURG/75876_Imaging_hepaticojejunostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cholangiogram demonstrates bilateral hepaticojejunostomy anastomoses. There is opacification across the anastomoses and no evidence of leak.</div><div id=\"graphicVersion\">Graphic 75876 Version 3.0</div></div></div>"},"75877":{"type":"graphic_figure","displayName":"QT dispersion patient groups","title":"Mean QT dispersion in various patient groups","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Mean QT dispersion in various patient groups</div><div class=\"cntnt\"><img style=\"width:543px; height:292px;\" src=\"images/CARD/75877_QT_dispersion_patient_group.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A summary of many studies shows that the mean QT dispersion is very variable within each patient group and there is much overlap in values between groups.</div><div class=\"graphic_footnotes\">MI: myocardial infarction; LVH: left ventricular hypertrophy; HF: heart failure; DCM: dilated cardiomyopathy; HCM: hypertrophic cardiomyopathy; AMI: acute myocardial infarction; LQTS: long QT syndrome.</div><div id=\"graphicVersion\">Graphic 75877 Version 1.0</div></div></div>"},"75878":{"type":"graphic_table","displayName":"Maintenance tocolysis trials","title":"Maintenance tocolysis compared to placebo","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maintenance tocolysis compared to placebo</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"26%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"26%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Treatments</td> <td class=\"subtitle1\">Sample size</td> <td class=\"subtitle1\">Primary endpoint</td> <td class=\"subtitle1\">Conclusion</td> </tr> <tr> <td>Creasy</td> <td>Ritodrine versus placebo</td> <td>55</td> <td>Time to recurrent PTL</td> <td>Ritodrine significantly delayed time to recurrence and number of recurrences</td> </tr> <tr> <td>Brown</td> <td>Terbutaline versus placebo</td> <td>46</td> <td>Days to delivery</td> <td>Terbutaline significantly prolonged pregnancy</td> </tr> <tr> <td>Holleboom</td> <td>Ritodrine versus placebo</td> <td>95</td> <td>Recurrent PTL during oral treatment (7 d)</td> <td>Ritodrine significantly reduced recurrences</td> </tr> <tr> <td>Lewis</td> <td>Terbutaline versus placebo</td> <td>200</td> <td>Prolongation of pregnancy &#62;7 d</td> <td>Terbutaline significantly prolonged pregnancy in women recruited &#60;32 weeks; otherwise, no benefit</td> </tr> <tr> <td>Valenzuela</td> <td>Atosiban versus placebo</td> <td>512</td> <td>Time to recurrent PTL</td> <td>Atosiban significantly delayed time to recurrent labor</td> </tr> <tr> <td>Carr</td> <td>Nifedipine versus no nifedipine</td> <td>74</td> <td>Days until delivery</td> <td>No benefit with nifedipine</td> </tr> <tr> <td>Parilla</td> <td>Terbutaline versus placebo</td> <td>55</td> <td>Days until delivery</td> <td>No benefit of terbutaline either in prolongation or number of recurrences</td> </tr> <tr> <td>Rust</td> <td>Magnesium chloride versus terbutaline vs placebo</td> <td>205</td> <td>Days until delivery</td> <td>No benefit with either magnesium or terbutaline in pregnancy prolongation</td> </tr> <tr> <td>Guinn</td> <td>Terbutaline pump versus placebo</td> <td>52</td> <td>Days until delivery</td> <td>No benefit with terbutaline in prolongation</td> </tr> <tr> <td rowspan=\"2\">How</td> <td rowspan=\"2\">Terbutaline versus no terbutaline</td> <td rowspan=\"2\">184</td> <td>Re-admissions</td> <td rowspan=\"2\">No benefit with terbutaline in re-admissions or pregnancy prolongation</td> </tr> <tr> <td>Days until delivery</td> </tr> <tr> <td>Lyell</td> <td>Nifedipine versus placebo</td> <td>71</td> <td>Achievement of 37 weeks of gestation</td> <td>No benefit with nifedipine</td> </tr> <tr> <td>Sayin</td> <td>Nifedipine versus placebo</td> <td>73</td> <td>Days until delivery</td> <td>Nifedipine group has significantly longer days until delivery and greater gestational age at delivery</td> </tr> <tr> <td>Roos</td> <td>Nifedipine versus placebo</td> <td>406</td> <td>Adverse perinatal outcome</td> <td>No benefit with nifedipine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">vs: versus; PTL: preterm labor; d: days.</div><div id=\"graphicVersion\">Graphic 75878 Version 4.0</div></div></div>"},"75880":{"type":"graphic_table","displayName":"Indications for NMB","title":"Indications for the use of neuromuscular blocking agents in the ICU","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for the use of neuromuscular blocking agents in the ICU</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">To facilitate mechanical ventilation in patients with severe hypoxemia (increase chest wall compliance, prevent poorly coordinated respiratory movements, reduce peak airway pressures, and facilitate permissive hypercapnia)</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Shivering due to therapeutic hypothermia following cardiac arrest</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Emergent intubation</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">To facilitate treatment of medical conditions associated with increased muscle activity, including tetanus, neuroleptic malignant syndrome, or status asthmaticus</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">To facilitate short procedures under general anesthesia (endotracheal intubation, bronchoscopy, gastrointestinal endoscopy, specialized radiologic procedures)</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">To prevent unwanted motor movement such as respiratory distress, and coughing on tracheal suction in patients with increased intracranial pressure or massive hemoptysis</span></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These indications are predicted on conventional strategies of sedation and analgesia that have failed.</div><div id=\"graphicVersion\">Graphic 75880 Version 3.0</div></div></div>"},"75881":{"type":"graphic_picture","displayName":"Subungual melanoma - advanced","title":"Subungual acral lentiginous melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subungual acral lentiginous melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/75881_Sub_melanoma_advanced.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Destruction of the nail bed by the tumor is present in this patient with subungual melanoma involving the toe. Note the presence of pigment involving the periungual skin (Hutchinson's sign).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75881 Version 3.0</div></div></div>"},"75883":{"type":"graphic_picture","displayName":"Lichen sclerosis with ecchymosis","title":"Lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:256px; height:395px;\" src=\"images/OBGYN/75883_Lichen_sclerosus_ecchymosi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Areas of ecchymosis from minor trauma.</div><div class=\"graphic_reference\">Reproduced with permission from Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright Â© 1999 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 75883 Version 4.0</div></div></div>"},"75884":{"type":"graphic_picture","displayName":"Melasma forehead","title":"Melasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melasma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75884_Melasma_forehead_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mottled hyperpigmented patches are present on the forehead.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75884 Version 5.0</div></div></div>"},"75886":{"type":"graphic_figure","displayName":"Bismuth-Corlette classification of biliary tumors","title":"Bismuth-Corlette classification of biliary tract cancers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bismuth-Corlette classification of biliary tract cancers</div><div class=\"cntnt\"><img style=\"width:445px; height:638px;\" src=\"images/GAST/75886_Bismuth-classification-new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Bismuth-Corlette classification of biliary tract.&#160;White areas represent tumor and green areas normal bile duct.</div><div class=\"graphic_reference\">Modified&#160;from de Groen PC, Gores GJ, LaRusso NF, et al. N Engl J Med 1999; 341:1368.</div><div id=\"graphicVersion\">Graphic 75886 Version 5.0</div></div></div>"},"75887":{"type":"graphic_picture","displayName":"Oropharyngeal candidiasis","title":"Oropharyngeal candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oropharyngeal candidiasis</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ID/75887_Oropharyngeal_candidiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The buccal mucosa is involved here in the pseudomembranous form of oropharyngeal candidiasis.</div><div class=\"graphic_reference\">Courtesy of Carol A Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 75887 Version 2.0</div></div></div>"},"75892":{"type":"graphic_figure","displayName":"Complete fracture reduction B","title":"Complete fracture reduction: Realignment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete fracture reduction: Realignment</div><div class=\"cntnt\"><img style=\"width:418px; height:454px;\" src=\"images/EM/75892_CompletefxreductionB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels A and B) Once length has been reestablished, the distal fragment is flexed into the correct position. Alignment is checked by determining the position of the fragments with the thumb and forefingers of each hand.</div><div class=\"graphic_reference\">Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 75892 Version 13.0</div></div></div>"},"75893":{"type":"graphic_diagnosticimage","displayName":"MRI of oral appliance induced changes","title":"MRI of oral appliance induced changes","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">MRI of oral appliance induced changes</div><div class=\"cntnt\"><img style=\"width:504px; height:530px;\" src=\"images/PULM/75893_Oral_appl_induced_changes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial magnetic resonance imaging (MRI) images of the upper airway at velopharyngeal (VP) and oropharyngeal (OP) levels, showing the effect of mandibular advancement splint (MAS) in a complete responder to treatment. Note the increase in lateral airway dimensions at both velopharyngeal and oropharyngeal levels.</div><div id=\"graphicVersion\">Graphic 75893 Version 5.0</div></div></div>"},"75894":{"type":"graphic_figure","displayName":"Estimated global mortality rates from developing countries","title":"Estimated global mortality rates from fire-related burn injuries in 2010: Developing countries ","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Estimated global mortality rates from fire-related burn injuries in 2010: Developing countries </div><div class=\"cntnt\"><img style=\"width:572px; height:386px;\" src=\"images/SURG/75894_Burns_epi_mort_devel_count.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Graph based on data from the Global Burden of Disease 2010 study. Institute for Health Metrics and Evaluation (IHME). GBD Compare. Seattle, WA: IHME, University of Washington, 2012. Available at: <A href=\"http://viz.healthmetricsandevaluation.org/gbd-compare/\" target=_blank>http://viz.healthmetricsandevaluation.org/gbd-compare/</A> (Accessed on July 1, 2013). Copyright Â© 2012. Reprinted with permission.</div><div id=\"graphicVersion\">Graphic 75894 Version 4.0</div></div></div>"},"75895":{"type":"graphic_picture","displayName":"Juvenile xanthogranuloma periocular","title":"Juvenile xanthogranuloma ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile xanthogranuloma </div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/75895_Juvenile_xanth_ocular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple periocular lesions in a young child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75895 Version 4.0</div></div></div>"},"75897":{"type":"graphic_figure","displayName":"Gastrocolic ligament and the lesser sac","title":"Gastrocolic ligament and the lesser sac","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Gastrocolic ligament and the lesser sac</div><div class=\"cntnt\"><img style=\"width:481px; height:427px;\" src=\"images/SURG/75897_Gastrocolic-ligament.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75897 Version 1.0</div></div></div>"},"75898":{"type":"graphic_waveform","displayName":"Ventriculophasic block tutorial","title":"Ventriculophasic sinus arrhythmia","html":"<div class=\"graphic normal\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Ventriculophasic sinus arrhythmia</div><div class=\"cntnt\"><img style=\"width:453px; height:101px;\" src=\"images/CARD/75898_Ventriculophasic_block_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ventriculophasic sinus arrhythmia is characterized by episodic or permanent failure of conduction throught the atrioventricular (AV) node. In contrast to the typical second or third degree AV block, the PP intervals are not constant; the two P waves surrounding a QRS complex have a shortened interval or occur at a faster rate when compared to two P waves that occur sequentially without an intervening QRS complex.</div><div id=\"graphicVersion\">Graphic 75898 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"75900":{"type":"graphic_diagnosticimage","displayName":"U-S choriocarcinoma","title":"Ultrasound choriocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ultrasound choriocarcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:407px;\" src=\"images/OBGYN/75900_U-S_choriocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Choriocarcinoma: Patient with stage 3 choriocarcinoma after term pregnancy. The endometrial cavity is filled with a hyperechoic mass measuring 3.0 x 2.9 x 2.8 cm.</div><div class=\"graphic_reference\">Courtesy of Department of Radiology, Santa Clara Valley Medical Center.</div><div id=\"graphicVersion\">Graphic 75900 Version 3.0</div></div></div>"},"75902":{"type":"graphic_picture","displayName":"Swollen gingival tissues","title":"Gingivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingivitis</div><div class=\"cntnt\"><img style=\"width:432px; height:305px;\" src=\"images/PC/75902_Swollen_gingival_tissues.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red and swollen gingival tissues which bleed easily upon flossing and brushing.</div><div id=\"graphicVersion\">Graphic 75902 Version 1.0</div></div></div>"},"75905":{"type":"graphic_picture","displayName":"Melioidosis osteomyelitis","title":"Melioidosis osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melioidosis osteomyelitis</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/ID/75905_Melioidosis_osteomyelitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic draining leg ulcer with underlying osteomyelitis due to melioidosis.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 75905 Version 2.0</div></div></div>"},"75907":{"type":"graphic_table","displayName":"Inflammatory markers in CKD","title":"Inflammatory markers that have been studied in CKD patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inflammatory markers that have been studied in CKD patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category </td> <td class=\"subtitle1\">Marker (and commonly used abbreviation) </td> <td class=\"subtitle1\">Evidence for outcome predictability in CKD* </td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Short pentraxins </td> <td>C-reactive protein (CRP)</td> <td>++++</td> </tr> <tr> <td>Serum amyloid P (SAP)</td> <td>++</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Long pentraxins </td> <td>Pentraxin-3 (PTX3)</td> <td>++</td> </tr> <tr> <td>Neuronal pentraxins</td> <td>?</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"7\">Pro-inflammatory cytokines </td> <td>Interleukin-6 (IL-6)</td> <td>++++</td> </tr> <tr> <td>Interleukin-1 beta (IL-1-beta)</td> <td>+</td> </tr> <tr> <td>Tumor necrosis factor alpha (TNF-alpha)</td> <td>+/-</td> </tr> <tr> <td>Interleukin-8 (IL-8)</td> <td>+</td> </tr> <tr> <td>Interleukin-18 (IL-18)</td> <td>?</td> </tr> <tr> <td>Interleukin-12 (IL-12)</td> <td>?</td> </tr> <tr> <td>Interferon gamma (IFN-gamma)</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">Anti-inflammatory cytokines </td> <td>Interleukin-10 (IL-10)</td> <td>?</td> </tr> <tr> <td>IL-1 receptor antagonist (IL-1ra)</td> <td>+</td> </tr> <tr> <td>Interleukin-4 (IL-4)</td> <td>?</td> </tr> <tr> <td>Transforming growth factor beta (TGF-beta)</td> <td>?</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"5\">Adipokines and related compounds </td> <td>Adiponectin</td> <td>++</td> </tr> <tr> <td>Visfatin</td> <td>+</td> </tr> <tr> <td>Resistin</td> <td>+</td> </tr> <tr> <td>Leptin</td> <td>+</td> </tr> <tr> <td>CD163</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"3\">Adhesion molecules and endothelial markers </td> <td>Intercellular adhesion molecule-1 (ICAM-1)</td> <td>++</td> </tr> <tr> <td>Vascular cell adhesion molecule-1 (VCAM-1)</td> <td>++</td> </tr> <tr> <td>E-selectin</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"5\">Coagulation markers </td> <td>Fibrinogen</td> <td>+</td> </tr> <tr> <td>Tissue plasminogen activator (t-PA)</td> <td>+</td> </tr> <tr> <td>Plasminogen activator inhibitor-1 [PAI-1])</td> <td>+</td> </tr> <tr> <td>von Willebrand factor (vWF) &#38; factor VII</td> <td>?</td> </tr> <tr> <td>Fibrin D-dimer</td> <td>?</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">Inflammatory molecules with negative acute phase reaction </td> <td>Albumin (negative)</td> <td>++++</td> </tr> <tr> <td>Transferrin or TIBC</td> <td>++</td> </tr> <tr> <td>Iron</td> <td>++</td> </tr> <tr> <td>Fetuin</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Inflammatory lipoproteins </td> <td>HDL inflammatory index (HII)</td> <td>++</td> </tr> <tr> <td>Oxidized LDL (oxLDL)</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Inflammatory enzymes </td> <td>Myeloperoxidase (MPO)</td> <td>+</td> </tr> <tr> <td>Matrix metalloproteinase (MMP-9)</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Pro-inflammatory transcription factors </td> <td>Activator protein-1 (AP-1)</td> <td>+</td> </tr> <tr> <td>Nuclear factor-kappa B (NF-&#954;B)</td> <td>+</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"7\">Other inflammatory markers </td> <td>Serum ferritin</td> <td>+++</td> </tr> <tr> <td>Serum amyloid A (SAA)</td> <td>+</td> </tr> <tr> <td>Neopterin (monocyte/macrophage activator)</td> <td>+</td> </tr> <tr> <td>Platelet count</td> <td>+++</td> </tr> <tr> <td>WBC count</td> <td>++</td> </tr> <tr> <td>Neutrophil count</td> <td>+</td> </tr> <tr> <td>Erythrocyte sedimentation rate (ESR)</td> <td>+</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; WBC: white blood cell.<br />* Evidence for CKD outcome predictability pertains to CKD progression or patient survival.</div><div class=\"graphic_reference\">Reproduced with permission from: Kalantar-Zadeh K. Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2007; 2:872. Copyright Â©2007 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 75907 Version 2.0</div></div></div>"},"75910":{"type":"graphic_figure","displayName":"Dobutamine echo mortality-II","title":"Dobutamine echocardiography predicts cardiac mortality","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Dobutamine echocardiography predicts cardiac mortality</div><div class=\"cntnt\"><img style=\"width:477px; height:437px;\" src=\"images/CARD/75910_Dobutamine_echo_mortality1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 3156 patients, those with an abnormal dobutamine echocardiogram (ischemic, scar, or mixed) have a higher cardiac mortality compared to those with a normal echocardiogram. The highest mortality is in those with both scar and ischemia (mixed). Kaplan-Meier survival curves for the prediction of cardiac mortality based on results of dobutamine echocardiography.</div><div class=\"graphic_reference\">Data from Marwick, TH, Case, C, Sawada, S, J Am Coll Cardiol 2001; 37:754.</div><div id=\"graphicVersion\">Graphic 75910 Version 1.0</div></div></div>"},"75912":{"type":"graphic_figure","displayName":"Nexplanon","title":"Nexplanon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nexplanon</div><div class=\"cntnt\"><img style=\"width:378px; height:238px;\" src=\"images/OBGYN/75912_Nexplanon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Applicator design elements:<br /><ul>&#xD;&#xA;    <li>Cap-blocking mechanism with cap/lever</li>&#xD;&#xA;    <li>Implant retained in needle before insertion</li>&#xD;&#xA;    <li>Single-handed movement with slider</li>&#xD;&#xA;    <li>Self-explaining actions</li>&#xD;&#xA;    <li>Needle partly visible</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Reproduced with permission of MSD Oss B.V., a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, New Jersey, USA. All rights reserved. NEXPLANON is a registered trademark of MSD Oss B.V. All requests to reproduce this copyrighted material should be directed to MSD Oss B.V.</div><div id=\"graphicVersion\">Graphic 75912 Version 3.0</div></div></div>"},"75913":{"type":"graphic_figure","displayName":"Wall thickness sudden death HCM","title":"Left ventricular wall thickness predicts sudden death in HCM","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular wall thickness predicts sudden death in HCM</div><div class=\"cntnt\"><img style=\"width:429px; height:300px;\" src=\"images/CARD/75913_Wall_thickness_sudden_death.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 480 patients with an HCM, the incidence of sudden death during a 6.5 year follow-up was directly related to maximal wall thickness. The incidence of sudden death almost doubled for each 5 mm increase in wall thickness.</div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy.</div><div class=\"graphic_reference\">Data from Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular&nbsp;hypertrophy and risk of&nbsp;sudden death in hypertrophic cardiomyopathy.&nbsp;N Engl J Med 2000; 342:1778.</div><div id=\"graphicVersion\">Graphic 75913 Version 3.0</div></div></div>"},"75914":{"type":"graphic_table","displayName":"Drugs cause hyperprolactinemia","title":"Medications that cause hyperprolactinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that cause hyperprolactinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication class</td> <td class=\"subtitle1\">Frequency of prolactin elevation*</td> <td class=\"subtitle1\">Mechanism</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antipsychotics, first generation</td> </tr> <tr> <td class=\"indent1\">Chlorpromazine</td> <td>Moderate</td> <td rowspan=\"8\">Dopamine D<sub>2</sub> receptor blockade within hypothalamic tuberoinfundibular system.</td> </tr> <tr> <td class=\"indent1\">Fluphenazine</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Haloperidol</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Loxapine</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Perphenazine</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Pimozide</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Thiothixene</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Trifluoperazine</td> <td>Moderate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antipsychotics, second generation</td> </tr> <tr> <td class=\"indent1\">Aripiprazole</td> <td>None or low</td> <td rowspan=\"10\">Dopamine D<sub>2</sub> receptor blockade.</td> </tr> <tr> <td class=\"indent1\">Asenapine</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Clozapine</td> <td>None or low</td> </tr> <tr> <td class=\"indent1\">Iloperidone</td> <td>None or low</td> </tr> <tr> <td class=\"indent1\">Lurasidone</td> <td>None or low</td> </tr> <tr> <td class=\"indent1\">Olanzapine</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Paliperidone</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Quetiapine</td> <td>None or low</td> </tr> <tr> <td class=\"indent1\">Risperidone</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Ziprasidone</td> <td>Low</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antidepressants, cyclic</td> </tr> <tr> <td class=\"indent1\">Amitriptyline</td> <td>Low</td> <td rowspan=\"4\">Not well understood. Possibly by GABA stimulation and indirect modulation of prolactin release by serotonin.</td> </tr> <tr> <td class=\"indent1\">Desipramine</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Clomipramine</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Nortriptyline</td> <td>None</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antidepressants, SSRI</td> </tr> <tr> <td class=\"indent1\">Citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline</td> <td>None or low (rare reports)</td> <td>Same as for cyclic antidepressants.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antidepressants, other</td> </tr> <tr> <td class=\"indent1\">Bupropion, venlafaxine, mirtazapine, nefazodone, trazodone</td> <td>None</td> <td>Not applicable.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antiemetic and gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Metoclopramide</td> <td>High</td> <td rowspan=\"3\">Dopamine D<sub>2</sub> receptor blockade.</td> </tr> <tr> <td class=\"indent1\">Domperidone (not available in United States)</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Prochlorperazine</td> <td>Low</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antihypertensives</td> </tr> <tr> <td class=\"indent1\">Verapamil</td> <td>Low</td> <td>Not well understood. Specific to verapamil. May involve calcium influx inhibition within tuberoinfundibular dopaminergic neurons.</td> </tr> <tr> <td class=\"indent1\">Methyldopa</td> <td>Moderate</td> <td>Decreased conversion of L-dopa to dopamine; suppression of dopamine synthesis.</td> </tr> <tr> <td class=\"indent1\">Most other antihypertensives (including other calcium channel blockers)</td> <td>None</td> <td>Not applicable.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Opioid analgesics</td> </tr> <tr> <td class=\"indent1\">Methadone, morphine, others</td> <td>Transient increase for several hours following dose</td> <td>Potentially an indirect effect of mu opiate receptor activation.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Medication induced hyperprolactinemia can cause decreased libido and erectile dysfunction in men and galactorrhea and amenorrhea in women.</div><div class=\"graphic_footnotes\">GABA: gamma-aminobutyric acid; SSRI: selective serotonin reuptake inhibitor.<br />* Frequency of increase to abnormal prolactin levels with chronic use: high: &gt;50 percent; moderate: 25 to 50 percent; low: &lt;25 percent; none or low: case reports. Effect may be dose-dependent.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Molitch ME. Drugs and prolactin. Pituitary 2008; 11:209.</li>&#xD;&#xA;    <li>Molitch ME. Medication induced hyperprolactinemia. Mayo Clin Proc 2005; 80:1050.</li>&#xD;&#xA;    <li>Coker F, Taylor D. Antidepressant induced hyperprolactinemia. CNS Drugs 2010; 24:563.</li>&#xD;&#xA;    <li>Drugs for psychiatric disorders. Treat Guidel Med Lett 2013; 11:53.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 75914 Version 11.0</div></div></div>"},"75915":{"type":"graphic_figure","displayName":"Bladder neck exposed","title":"Bladder neck exposed during radical vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bladder neck exposed during radical vulvectomy</div><div class=\"cntnt\"><img style=\"width:395px; height:333px;\" src=\"images/OBGYN/75915_Bladder_neck_exposed.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75915 Version 2.0</div></div></div>"},"75916":{"type":"graphic_figure","displayName":"Normal flow volume curve","title":"Normal flow-volume curve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal flow-volume curve</div><div class=\"cntnt\"><img style=\"width:420px; height:340px;\" src=\"images/PEDS/75916_Normal_flow_volume_curve.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal expiratory portion of the flow-volume curve is characterized by a rapid rise to the peak flow, followed by a nearly linear fall in flow as the patient exhales toward residual volume.</div><div id=\"graphicVersion\">Graphic 75916 Version 2.0</div></div></div>"},"75919":{"type":"graphic_diagnosticimage","displayName":"Sunrise xray of patella","title":"Bilateral sunrise views of the patellofemoral joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral sunrise views of the patellofemoral joint</div><div class=\"cntnt\"><img style=\"width:364px; height:280px;\" src=\"images/PC/75919_Sunrise_xray_of_patella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral sunrise x-rays of the patellofemoral joint are obtained to confirm subluxation, early cartilagenous injury, or patellofemoral arthritis. The position of the patella should be centered in the femoral groove. The thicknesses of the medial and lateral cartilage should be equal. With advancing wear and tear, the lateral cartilage thins, the subchondral bone thickens, and, in rare cases, osteochondritis dessicans occurs.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 75919 Version 2.0</div></div></div>"},"75922":{"type":"graphic_table","displayName":"Abx for meningitis based on Gram stain","title":"Recommendations for antimicrobial therapy of bacterial meningitis in adults with presumptive pathogen identification by positive Gram stain*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for antimicrobial therapy of bacterial meningitis in adults with presumptive pathogen identification by positive Gram stain*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Microorganism</td> <td class=\"subtitle1\">Recommended therapy</td> <td class=\"subtitle1\">Alternative therapies</td> </tr> <tr> <td><em>Streptococcus pneumoniae</em></td> <td>Vancomycin plus a third-generation cephalosporin<sup>&#182;</sup><sup>&#916;</sup></td> <td>Fluoroquinolone<sup>&#9674;</sup></td> </tr> <tr> <td><em>Neisseria meningitidis</em></td> <td>Third-generation cephalosporin<sup>&#182;</sup></td> <td>Chloramphenicol, fluoroquinolone, aztreonam</td> </tr> <tr> <td><em>Listeria monocytogenes</em></td> <td>Ampicillin<sup>&#167;</sup> or penicillin G<sup>&#167;</sup></td> <td>Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td><em>Haemophilus influenzae</em></td> <td>Third-generation cephalosporin<sup>&#182;</sup></td> <td>Chloramphenicol, cefepime, meropenem, fluoroquinolone</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For recommended dosages,&nbsp;refer to the UpToDate table on recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis.<br />Â¶ Ceftriaxone or cefotaxime.<br />Î Some experts would add rifampin if dexamethasone is also given.<br /><FONT class=lozenge>â</FONT> Moxifloxacin is recommended given its excellent cerebrospinal fluid penetration and in vitro activity against <EM>Streptococcus pneumoniae</EM>, although there are no clinical data available. If used, many authorities would combine moxifloxacin with vancomycin or a third-generation cephalosporin (cefotaxime or ceftriaxone).<br />Â§ Addition of an aminoglycoside should be considered.</div><div class=\"graphic_reference\">Modified with permission from: Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 75922 Version 6.0</div></div></div>"},"75924":{"type":"graphic_picture","displayName":"Pneumococcus in sputum","title":"Sputum from a patient with pneumococcal pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sputum from a patient with pneumococcal pneumonia</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/ID/75924_Pneumococcus_in_sputum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of sputum (x1000) shows abundant inflammatory cells and gram-positive diplococci; <EM>Streptococcus pneumoniae</EM> was identified from this specimen by culture and by the optochin disk test.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 75924 Version 5.0</div></div></div>"},"75926":{"type":"graphic_table","displayName":"Etiology of upper extremity ischemia","title":"Etiology of upper extremity ischemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of upper extremity ischemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Large artery disease</td> </tr> <tr> <td>Atherosclerosis</td> </tr> <tr> <td>Arterial injury</td> </tr> <tr> <td>Arterial dissection</td> </tr> <tr> <td>Thrombosed aneurysm</td> </tr> <tr> <td>Atheroembolism</td> </tr> <tr> <td>Thromboembolism</td> </tr> <tr> <td>Arterial fibrodysplasia</td> </tr> <tr> <td>Arterial tumor</td> </tr> <tr> <td class=\"sublist1_start\">Arteritis</td> </tr> <tr> <td class=\"sublist1\">Giant cell arteritis*</td> </tr> <tr> <td class=\"sublist1\">Takayasu's arteritis</td> </tr> <tr> <td class=\"sublist1_start\">Repetitive injury</td> </tr> <tr> <td class=\"sublist1\">Thoracic outlet syndrome (subclavian artery, often with cervical rib)</td> </tr> <tr> <td class=\"sublist1\">Crutch injury (axillary artery)</td> </tr> <tr> <td class=\"subtitle1_single\">Small artery disease</td> </tr> <tr> <td class=\"sublist1_start\">Vasculitis</td> </tr> <tr> <td class=\"sublist1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"sublist1\">Systemic lupus erythematosis</td> </tr> <tr> <td class=\"sublist1\">Scleroderma</td> </tr> <tr> <td class=\"sublist1\">Sj&#246;gren's syndrome</td> </tr> <tr> <td class=\"sublist1\">Mixed connective tissue disease</td> </tr> <tr> <td class=\"sublist1_start\">Repetitive injury</td> </tr> <tr> <td class=\"sublist1\">Vibratory tool arterial injury</td> </tr> <tr> <td class=\"sublist1\">Hypothenar hammer syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Drug-related</td> </tr> <tr> <td class=\"sublist1\">Vasopressors</td> </tr> <tr> <td class=\"sublist1\">Ergot toxicity</td> </tr> <tr> <td class=\"sublist1_start\">Vasospasm</td> </tr> <tr> <td class=\"sublist1\">Raynaud's syndrome</td> </tr> <tr> <td class=\"sublist1\">Buerger's disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* An important cause of upper extremity arterial obstruction (as distinct from Takayasu's), especially in middle-aged women.</div><div id=\"graphicVersion\">Graphic 75926 Version 2.0</div></div></div>"},"75927":{"type":"graphic_table","displayName":"Hypertens CKD T162","title":"90th percentile of blood pressure in girls 2 to 17 years of age according to height percentile","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">90th percentile of blood pressure in girls 2 to 17 years of age according to height percentile</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Age</td>\n\n\t\t\t\t<td colspan=\"5\" rowspan=\"1\" class=\"subtitle1\">90th percent systolic BP for height percentile of:</td>\n\n\t\t\t\t<td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">90th percent diastolic BP for height percentile of:</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle2\">5th</td>\n\n\t\t\t\t<td class=\"subtitle2\">25th</td>\n\n\t\t\t\t<td class=\"subtitle2\">50th</td>\n\n\t\t\t\t<td class=\"subtitle2\">75th</td>\n\n\t\t\t\t<td class=\"subtitle2\">95th</td>\n\n\t\t\t\t<td class=\"subtitle2\">5th</td>\n\n\t\t\t\t<td class=\"subtitle2\">25th</td>\n\n\t\t\t\t<td class=\"subtitle2\">50th</td>\n\n\t\t\t\t<td class=\"subtitle2\">75th</td>\n\n\t\t\t\t<td class=\"subtitle2\">95th</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>2</td>\n\n\t\t\t\t<td>99</td>\n\n\t\t\t\t<td>100</td>\n\n\t\t\t\t<td>102</td>\n\n\t\t\t\t<td>103</td>\n\n\t\t\t\t<td>104</td>\n\n\t\t\t\t<td>57</td>\n\n\t\t\t\t<td>58</td>\n\n\t\t\t\t<td>58</td>\n\n\t\t\t\t<td>59</td>\n\n\t\t\t\t<td>60</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>4</td>\n\n\t\t\t\t<td>101</td>\n\n\t\t\t\t<td>103</td>\n\n\t\t\t\t<td>104</td>\n\n\t\t\t\t<td>106</td>\n\n\t\t\t\t<td>107</td>\n\n\t\t\t\t<td>63</td>\n\n\t\t\t\t<td>64</td>\n\n\t\t\t\t<td>65</td>\n\n\t\t\t\t<td>65</td>\n\n\t\t\t\t<td>66</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>6</td>\n\n\t\t\t\t<td>104</td>\n\n\t\t\t\t<td>106</td>\n\n\t\t\t\t<td>107</td>\n\n\t\t\t\t<td>109</td>\n\n\t\t\t\t<td>110</td>\n\n\t\t\t\t<td>67</td>\n\n\t\t\t\t<td>68</td>\n\n\t\t\t\t<td>69</td>\n\n\t\t\t\t<td>69</td>\n\n\t\t\t\t<td>70</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>8</td>\n\n\t\t\t\t<td>108</td>\n\n\t\t\t\t<td>110</td>\n\n\t\t\t\t<td>111</td>\n\n\t\t\t\t<td>112</td>\n\n\t\t\t\t<td>113</td>\n\n\t\t\t\t<td>70</td>\n\n\t\t\t\t<td>71</td>\n\n\t\t\t\t<td>71</td>\n\n\t\t\t\t<td>72</td>\n\n\t\t\t\t<td>73</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>10</td>\n\n\t\t\t\t<td>112</td>\n\n\t\t\t\t<td>114</td>\n\n\t\t\t\t<td>115</td>\n\n\t\t\t\t<td>116</td>\n\n\t\t\t\t<td>117</td>\n\n\t\t\t\t<td>73</td>\n\n\t\t\t\t<td>73</td>\n\n\t\t\t\t<td>74</td>\n\n\t\t\t\t<td>75</td>\n\n\t\t\t\t<td>76</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>12</td>\n\n\t\t\t\t<td>116</td>\n\n\t\t\t\t<td>118</td>\n\n\t\t\t\t<td>119</td>\n\n\t\t\t\t<td>120</td>\n\n\t\t\t\t<td>121</td>\n\n\t\t\t\t<td>75</td>\n\n\t\t\t\t<td>76</td>\n\n\t\t\t\t<td>76</td>\n\n\t\t\t\t<td>77</td>\n\n\t\t\t\t<td>78</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>14</td>\n\n\t\t\t\t<td>119</td>\n\n\t\t\t\t<td>121</td>\n\n\t\t\t\t<td>122</td>\n\n\t\t\t\t<td>124</td>\n\n\t\t\t\t<td>125</td>\n\n\t\t\t\t<td>77</td>\n\n\t\t\t\t<td>78</td>\n\n\t\t\t\t<td>79</td>\n\n\t\t\t\t<td>79</td>\n\n\t\t\t\t<td>80</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>16</td>\n\n\t\t\t\t<td>122</td>\n\n\t\t\t\t<td>123</td>\n\n\t\t\t\t<td>125</td>\n\n\t\t\t\t<td>126</td>\n\n\t\t\t\t<td>127</td>\n\n\t\t\t\t<td>79</td>\n\n\t\t\t\t<td>79</td>\n\n\t\t\t\t<td>80</td>\n\n\t\t\t\t<td>81</td>\n\n\t\t\t\t<td>82</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>17</td>\n\n\t\t\t\t<td>122</td>\n\n\t\t\t\t<td>124</td>\n\n\t\t\t\t<td>125</td>\n\n\t\t\t\t<td>126</td>\n\n\t\t\t\t<td>128</td>\n\n\t\t\t\t<td>79</td>\n\n\t\t\t\t<td>79</td>\n\n\t\t\t\t<td>80</td>\n\n\t\t\t\t<td>81</td>\n\n\t\t\t\t<td>82</td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=37191&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Hypertens_CKD_T162.htm</title></head></div><div id=\"graphicVersion\">Graphic 75927 Version 1.0</div></div></div>"},"75928":{"type":"graphic_picture","displayName":"Tinea corporis on trunk","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/75928_Tinea_corporis_trunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An inflammatory, annular plaque with peripheral scale is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75928 Version 3.0</div></div></div>"},"75929":{"type":"graphic_picture","displayName":"Dissecting cellulitis of the scalp","title":"Dissecting cellulitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dissecting cellulitis of the scalp</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/75929_Dissecting_cellulitis_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluctuant nodules and areas of scarring alopecia on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 75929 Version 4.0</div></div></div>"},"75931":{"type":"graphic_waveform","displayName":"12 lead ECG atrial flutter","title":"12 lead ECG of atrial flutter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">12 lead ECG of atrial flutter</div><div class=\"cntnt\"><img style=\"width:504px; height:243px;\" src=\"images/CARD/75931_12_lead_ECG_atrial_flutter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12 lead electrocardiogram (ECG) of atrial flutter shows a regular rhythm with a narrow QRS complex. Flutter waves are present, best seen in leads II, III, and aVF (*). In this ECG, the flutter waves are negative in leads II, III, and aVF, and positive in lead V1. One flutter wave is obvious between the QRS complexes, while the second one is superimposed on the terminal portion of the QRS complex; hence there is 2:1 atrioventricular nodal block, which is the most common presentation for atrial flutter.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 75931 Version 3.0</div></div></div>"},"75935":{"type":"graphic_diagnosticimage","displayName":"Bamboo spine in AS","title":"Bamboo spine in AS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bamboo spine in AS</div><div class=\"cntnt\"><img style=\"width:230px; height:329px;\" src=\"images/RHEUM/75935_Bamboo_spine_in_AS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of the lumbar sacral spine in a patient with advanced ankylosing spondylitis showing a &quot;bamboo spine&quot; with vertebral fusion (arrows).</div><div class=\"graphic_reference\">Courtesy of Craig W Wiesenhutter, MD.</div><div id=\"graphicVersion\">Graphic 75935 Version 2.0</div></div></div>"},"75936":{"type":"graphic_diagnosticimage","displayName":"Pulmonary edema II PA","title":"Acute left ventricular failure","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute left ventricular failure</div><div class=\"cntnt\"><img style=\"width:363px; height:302px;\" src=\"images/CARD/75936_Pulmonary_edema_II_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain frontal radiograph of the chest of a 30-year-old male demonstrates bilateral perihilar alveolar edema, giving a typical butterfly appearance, with bilateral interstitial edema and pulmonary venous redistribution to the upper lobes. The acute nature of this condition is manifest by the absence of pleural effusions or an enlarged cardiac silhouette.</div><div class=\"graphic_reference\">Photo courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 75936 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"75937":{"type":"graphic_diagnosticimage","displayName":"Normal postoperative esophagram after gastric banding","title":"Normal postoperative esophagram after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal postoperative esophagram after gastric banding</div><div class=\"cntnt\"><img style=\"width:293px; height:444px;\" src=\"images/SURG/75937_Normal_postop_esophagr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow pointing to the band and its axis, approximately 2 to 8 o'clock.</div><div id=\"graphicVersion\">Graphic 75937 Version 4.0</div></div></div>"},"75939":{"type":"graphic_table","displayName":"Likelihood ratios preop tests","title":"Value of preoperative tests in influencing preoperative management and predicting postoperative complications in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Value of preoperative tests in influencing preoperative management and predicting postoperative complications in adults</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Test\n   </td>\n   <td  class=\"subtitle1\">\n   Incidence of abnormalities that influence management, percent\n   </td>\n   <td  class=\"subtitle1\">\n   Positive likelihood ratio of postoperative complication, LR+\n   </td>\n   <td  class=\"subtitle1\">\n   Negative likelihood ratio of postoperative complication, LR-\n   </td>\n   </tr>\n   <tr>\n   <td>Hemoglobin</td>\n   <td>0.1</td>\n   <td>3.3</td>\n   <td>0.90</td>\n   </tr>\n   <tr>\n   <td>White blood cell count</td>\n   <td>0.0</td>\n   <td>0.0</td>\n   <td>1.00</td>\n   </tr>\n   <tr>\n   <td>Platelet count</td>\n   <td>0.0</td>\n   <td>0.0</td>\n   <td>1.00</td>\n   </tr>\n   <tr>\n   <td>Prothrombin time (PT)</td>\n   <td>0.0</td>\n   <td>0.0</td>\n   <td>1.01</td>\n   </tr>\n   <tr>\n   <td>Partial thromboplastin time (PTT)</td>\n   <td>0.1</td>\n   <td>1.7</td>\n   <td>0.86</td>\n   </tr>\n   <tr>\n   <td>Electrolytes</td>\n   <td>1.8</td>\n   <td>4.3*</td>\n   <td>0.80</td>\n   </tr>\n   <tr>\n   <td>Renal function</td>\n   <td>2.6</td>\n   <td>3.3</td>\n   <td>0.81</td>\n   </tr>\n   <tr>\n   <td>Glucose</td>\n   <td>0.5</td>\n   <td>1.6</td>\n   <td>0.85</td>\n   </tr>\n   <tr>\n   <td>Liver function tests</td>\n   <td>0.1</td>\n   <td>NA**</td>\n   <td>NA**</td>\n   </tr>\n   <tr>\n   <td>Urinalysis</td>\n   <td>1.4</td>\n   <td>1.7</td>\n   <td>0.97</td>\n   </tr>\n   <tr>\n   <td>Electrocardiogram</td>\n   <td>2.6</td>\n   <td>1.6</td>\n   <td>0.96</td>\n   </tr>\n   <tr>\n   <td>Chest radiograph</td>\n   <td>3.0</td>\n   <td>2.5</td>\n   <td>0.72</td>\n   </tr>\n </table></div><div class=\"graphic_lgnd\">*Although the LR+ value is higher for electrolytes than for other preoperative tests, most of these patients could have been selectively identified as candidates for testing based on clinical criteria. The authors therefore do not recommend routine measurement of preoperative electrolytes.<br> **NA = Not available; no studies have reported the incidence of adverse events in a cohort of healthy patients with normal or abnormal liver function tests.</div><div class=\"graphic_reference\">Reproduced with permission from Smetana, GW, Macpherson, DS. The case against routine preoperative laboratory testing. Med Clin North Am 2003; 87:7. Copyright &#169; 2003 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 75939 Version 2.0</div></div></div>"},"75940":{"type":"graphic_diagnosticimage","displayName":"Normal MLO view","title":"Normal MLO (mediolateral oblique) view of both breasts","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Normal MLO (mediolateral oblique) view of both breasts</div><div class=\"cntnt\"><img style=\"width:504px; height:433px;\" src=\"images/PC/75940_Normal_MLO_view_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">By convention, the mammograms of both breasts are viewed as mirror images. The pectoralis muscle is seen at least till the level of the nipple. The top portion of the image represents the upper half of the breast and the bottom portion of the image represents the lower half of the breast.</div><div id=\"graphicVersion\">Graphic 75940 Version 4.0</div></div></div>"},"75945":{"type":"graphic_table","displayName":"Causes of optic neuropathy","title":"Causes of optic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of optic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ischemic optic neuropathy</td> </tr> <tr> <td class=\"indent1\">Arteritic ischemic optic neuropathy</td> </tr> <tr> <td class=\"indent1\">Nonarteritic ischemic optic neuropathy</td> </tr> <tr> <td class=\"subtitle1_single\">Optic neuritis</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"indent1\">Neuroretinitis: viruses, toxoplasmosis, bartonella, others</td> </tr> <tr> <td class=\"indent1\">Meningitis (any cause)</td> </tr> <tr> <td class=\"indent1\">Syphilis, Lyme disease</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Parainfectious</td> </tr> <tr> <td class=\"indent1\">Systemic autoimmune disease: systemic lupus erythematosus, Sjogren's syndrome, others</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic</td> </tr> <tr> <td class=\"indent1\">Leber's hereditary optic neuropathy</td> </tr> <tr> <td class=\"indent1\">Kjer type autosomal dominant optic atrophy</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplasms (compressive, infiltrative)</td> </tr> <tr> <td class=\"indent1\">Optic glioma</td> </tr> <tr> <td class=\"indent1\">Meningioma</td> </tr> <tr> <td class=\"indent1\">Metastasis</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Compression</td> </tr> <tr> <td class=\"indent1\">Abscess</td> </tr> <tr> <td class=\"indent1\">Carotid-ophthalmic artery aneurysm</td> </tr> <tr> <td class=\"indent1\">Thyroid ophthalmopathy</td> </tr> <tr> <td class=\"indent1\">Orbital pseudotumor</td> </tr> <tr> <td class=\"indent1\">Pseudotumor cerebri</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic/metabolic</td> </tr> <tr> <td class=\"indent1\">Drugs</td> </tr> <tr> <td class=\"indent1\">Toxins</td> </tr> <tr> <td class=\"indent1\">Nutritional deficiency (vitamin B1, B12, folate)</td> </tr> <tr> <td class=\"indent1\">Tobacco-Alcohol amblyopia</td> </tr> <tr> <td class=\"indent1\">Radiation</td> </tr> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75945 Version 3.0</div></div></div>"},"75946":{"type":"graphic_table","displayName":"Disorders impaired language","title":"Conditions associated with language impairment in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with language impairment in children and adolescents</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Intellectual disability (mental retardation)</td>\n   </tr>\n   <tr>\n   <td>Learning disabilities</td>\n   </tr>\n   <tr>\n   <td>Attention deficit hyperactivity disorder</td>\n   </tr>\n   <tr>\n   <td>Autism/pervasive developmental disorder</td>\n   </tr>\n   <tr>\n   <td>Traumatic brain injury</td>\n   </tr>\n   <tr>\n   <td>Hearing loss</td>\n   </tr>\n   <tr>\n   <td>Neglect/abuse</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 75946 Version 2.0</div></div></div>"},"75948":{"type":"graphic_figure","displayName":"DiGeorge embryology","title":"DiGeorge embryology","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">DiGeorge embryology</div><div class=\"cntnt\"><img style=\"width:598px; height:546px;\" src=\"images/ALLRG/75948_DiGeorge_embryology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Migration of neural crest cells during embryonic development and contribution to structures affected in DiGeorge syndrome with or without chromosome 22q11.2 deletion patients. The migration pathway of neural crest cells (orange) from the hindbrain to the brachial arch/pharyngeal pouch system and cardiac outflow tract is indicated by the arrows. Examples of affected malformations associated with perturbations in this developmental sequence are denoted.</div><div class=\"graphic_footnotes\">AAA: aortic arch arteries; IAA: interrupted aortic arch; PDA: persistent ductus arteriosus.</div><div class=\"graphic_reference\">Reproduced with permission from: Emanuel BS, et al. The genetic basis of conotruncal heart defects: The chromosome 22q11.2 deletion. In: Heart Development, Rosenthal N, Harvey R (Eds), Academic Press, 1998. Copyright &copy; 1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 75948 Version 3.0</div></div></div>"},"75949":{"type":"graphic_table","displayName":"Nicotine replacement therapy relevant to adolescents","title":"Nicotine replacement therapy relevant to adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nicotine replacement therapy relevant to adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n  <td class=\"subtitle1_single\">Transdermal patches</td>\n </tr>\n <tr>\n  <td>Patches are available without prescription for adults; a prescription is required in the United States for individuals under 18 years.</td>\n </tr>\n <tr>\n  <td>The advantages of patches are that they are very simple to use and provide steady action over the course of the day. However, patients may need an additional short-acting agent (gum, spray, or lozenge) to respond to acute nicotine craving.</td>\n </tr>\n <tr>\n  <td>Several strengths are available; the patient should follow the package directions to choose the appropriate strength based on their history of tobacco use. Most heavy smokers begin with a high-strength patch (eg, 21 mg/patch), and gradually decrease the strength over 6 to 8 weeks. Patients who are light smokers or who weigh less than 100 lbs (45 kg) should start with a lower strength patch.</td>\n </tr>\n <tr>\n  <td>Each patch can be used for 24 hours. If patients have problems sleeping, they may prefer to remove the patch at bedtime (16 hour patch).</td>\n </tr>\n <tr>\n  <td>Patches are applied to a clean, dry, hairless area of skin (usually trunk or neck) and removed at the end of the day (16 hours) or the next day (24 hours).</td>\n </tr>\n <tr>\n  <td>Skin irritation is the most common side effect; to minimize this problem rotate the patch to different sites each day.</td>\n </tr>\n <tr>\n  <td class=\"subtitle1_single\">Gum*</td>\n </tr>\n <tr>\n  <td>Nicotine replacement therapy gum is available in 2 mg and 4 mg strengths without prescription for adults; a prescription is required in the United States for individuals under 18 years.</td>\n </tr>\n <tr>\n  <td>The advantage of nicotine gum is that it increases nicotine levels quickly, so it can be used to respond to an acute craving. For some patients gum is not effective because they do not use it often enough or chew long enough.</td>\n </tr>\n <tr>\n  <td>The nicotine from the gum is absorbed through the oral mucosa, and is optimized by a sequence of chewing and \"parking\" the gum between the cheek and gums. Chewing gum too vigorously usually results in more nicotine being swallowed. This is not dangerous but reduces nicotine absorption and may also cause local irritation and hiccups.</td>\n </tr>\n <tr>\n  <td>Most heavy smokers use the 4 mg strength gum. Patients who are light smokers or who weigh less than 100 lbs (45 kg) should start with the 2 mg strength.</td>\n </tr>\n <tr>\n  <td>Patients with significant symptoms of nicotine dependence typically start with chewing a piece of gum every one to two hours, and use 10 to 24 pieces a day.</td>\n </tr>\n <tr>\n  <td>Each piece of gum should be chewed slowly to release the nicotine. After a few minutes of chewing, the nicotine will be released, indicated by a hot peppery taste. The gum should then be \"parked\" between the cheek and gums so that the nicotine can be absorbed. The process of slowly chewing then \"parking\" the gum should be repeated every few minutes for 20 - 30 minutes.</td>\n </tr>\n <tr>\n  <td class=\"subtitle1_single\">Lozenge*</td>\n </tr>\n <tr>\n  <td>Oral lozenges are available without prescription for adults; a prescription is required in the United States for individuals under 18 years.</td>\n </tr>\n <tr>\n  <td>Like nicotine gum, lozenges increase nicotine levels rapidly (peak levels at 20-30 minutes) and may be helpful for acute nicotine craving.</td>\n </tr>\n <tr>\n  <td>Patients should suck the lozenge until it dissolves; lozenges should not be chewed or swallowed.</td>\n </tr>\n <tr>\n  <td>Most smokers should use the 2 mg dose lozenge. Patients with significant symptoms of nicotine dependence (eg, those who smoke within 30 minutes of awakening) may require the 4 mg lozenge.</td>\n </tr>\n <tr>\n  <td>Patients should start by taking one lozenge every 1 to 2 hours during the first few weeks of smoking cessation, then gradually decrease the frequency over the next two months.</td>\n </tr>\n <tr>\n  <td class=\"subtitle1_single\">Inhalers*</td>\n </tr>\n <tr>\n  <td>Nicotine inhalers are available by prescription.</td>\n </tr>\n <tr>\n  <td>The inhaler consists of a mouthpiece and a replaceable nicotine cartridge. When the smoker inhales through the cartridge, nicotine vapor is deposited in the mouth and throat and absorbed through the mucosa.</td>\n </tr>\n <tr>\n  <td>The pharmacokinetics of nicotine delivery are similar to gum, but some patients prefer the inhaler because its use mimics the action of smoking and provides some behavioral replacement.</td>\n </tr>\n <tr>\n  <td>Smokers should use the inhaler for a 20-minute puffing session about once an hour. Each cartridge can be used for four 20-minute puffing sessions.</td>\n </tr>\n <tr>\n  <td>Patients with significant symptoms of nicotine dependence should start with between 6 and 16 cartridges per day, and gradually decrease over up to 12 weeks.</td>\n </tr>\n <tr>\n  <td class=\"subtitle1_single\">Nasal spray</td>\n </tr>\n <tr>\n  <td>Nicotine nasal spray is available by prescription.</td>\n </tr>\n <tr>\n  <td>Nasal spray produces a more rapid rise in nicotine level than orally-absorbed products (gum, lozenge, and inhaler), so it may provide the most rapid relief of nicotine craving symptoms.</td>\n </tr>\n <tr>\n  <td>Studies of nasal spray in adolescents had a high drop-out rate due to irritant side effects.</td>\n </tr>\n <tr>\n  <td>The main side effects are nasal irritation and burning, as well as unpleasant taste and smell; all of these tend to improve after a few days of use but may not resolve completely.</td>\n </tr>\n <tr>\n  <td>Patients should use one spray in each nostril, without sniffing or inhaling, and should not blow their nose for 2 to 3 minutes after spraying.</td>\n </tr>\n <tr>\n  <td>The spray is used at least 8 times per day, with a maximum of 5 doses per hour or 40 doses per day. The frequency of use is gradually decreased over 2 to 3 months.</td>\n </tr>\n <tr>\n  <td class=\"subtitle1_single\">Combination therapy</td>\n </tr>\n <tr>\n  <td>Combining nicotine replacement products increases abstinence rates.</td>\n </tr>\n <tr>\n  <td>The nicotine patch is usually combined with one of the oral products (gum, lozenge or nasal spray). The patch provides a steady level of nicotine to prevent withdrawal symptoms, and the oral product can provide a more rapid surge of nicotine to respond to an acute craving to smoke.</td>\n </tr>\n <tr>\n  <td>If products are combined, the optimal dose may be less than those outlined above. For example, if a patch effectively reduces nicotine craving, a patient may choose to use nicotine gum or lozenge only a few times a day, when they have an acute urge to smoke.</td>\n </tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">All forms of nicotine replacement therapy (NRT) are not recommended for nonsmokers. NRT is safer and less addictive than cigarettes and does not create a new addiction. The safety and effectiveness of nicotine replacement products in patients below the age of 18 years have not been established. However, no specific medical risk is known or expected in nicotine dependent adolescents. For any product one must decide whether the potential benefits justify the potential risk. Because some nicotine replacement products are available over the counter and may be accessible to teens, adolescents who indicate that they plan to use them should be counseled regarding proper use.</div><div class=\"graphic_footnotes\">* Oral products can be used on a regular schedule to avoid nicotine withdrawal symptoms, and can also be used to relieve acute urges to smoke. Each of these may have an initial unpleasant taste, which can be a barrier to correct use; most users become tolerant to the taste within a few days. Patients should not eat or drink acidic beverages (coffee, juice, or soda) for 15 minutes before or during use of these oral products.</div><div class=\"graphic_reference\">Courtesy of Drs. Joseph Rosen and Marianna Sockrider, and from Kozlowski et al. Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking. Addict Behav. 2007; 32:2140.</div><div id=\"graphicVersion\">Graphic 75949 Version 2.0</div></div></div>"},"75950":{"type":"graphic_diagnosticimage","displayName":"Cholangiocarcinoma ERCP","title":"Cholangiocarcinoma of the common bile duct, as seen during an ERCP procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholangiocarcinoma of the common bile duct, as seen during an ERCP procedure</div><div class=\"cntnt\"><img style=\"width:258px; height:284px;\" src=\"images/GAST/75950_Cholangiocarcinoma_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following administration of contrast material into the biliary system and duodenum during an endoscopic retrograde cholangiopancreatography (ERCP) examination (black), circumferential narrowing of the distal common bile duct is produced by a cholangiocarcinoma (arrow). The tumor is causing proximal bile duct dilatation and is also extending into the adjacent duodenum (arrowhead), producing a C-shaped eccentric impression.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 75950 Version 4.0</div></div></div>"},"75951":{"type":"graphic_table","displayName":"Adenoviral syndromes","title":"Adenoviral diseases according to patient population","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adenoviral diseases according to patient population</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Patient population</td>\n\n      <td class=\"subtitle1\">Clinical syndromes</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">Infants</td>\n\n      <td>Pharyngitis, coryza, otitis media</td>\n\n    </tr>\n\n    <tr>\n      <td>Pneumonia</td>\n    </tr>\n    <tr>\n      <td>Diarrhea</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\">Children</td>\n\n      <td>Upper respiratory disease, pneumonia</td>\n\n    </tr>\n\n    <tr>\n      <td>Pharyngoconjunctival fever</td>\n    </tr>\n    <tr>\n      <td>Diarrhea, mesenteric adenitis</td>\n    </tr>\n    <tr>\n      <td>Hemorrhagic cystitis</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Adults</td>\n\n      <td>Acute respiratory disease</td>\n\n    </tr>\n\n    <tr>\n      <td>Epidemic keratoconjunctivitis</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\">Immunocompromised</td>\n\n      <td>Pneumonia</td>\n\n    </tr>\n    <tr>\n      <td>Gastroenteritis, hepatitis </td>\n    </tr>\n    <tr>\n      <td>Hemorrhagic cystitis, interstitial nephritis</td>\n    </tr>\n    <tr>\n      <td>Meningoencephalitis</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 75951 Version 1.0</div></div></div>"},"75954":{"type":"graphic_picture","displayName":"Ulceroglandular tularemia","title":"Ulceroglandular tularemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulceroglandular tularemia</div><div class=\"cntnt\"><img style=\"width:395px; height:252px;\" src=\"images/ID/75954_Ulceroglandular_tularemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The primary inoculation site in this patient with ulceroglandular tularemia is an ulcerated nodule that is accompanied by lymphadenopathy.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders. (The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 75954 Version 3.0</div></div></div>"},"75955":{"type":"graphic_movie","displayName":"Echo 4-chamber view MR","title":"Echocardiography apical four chamber view of mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiography apical four chamber view of mitral regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/75955_4chcodmrconv.mp4\" style=\"width:360px;height:272px\"></div><img style=\"width:324px; height:462px;\" src=\"images/CARD/75955_4chcodmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four chamber view with color flow Doppler shows severe mitral regurgitation during systole associated with marked enlargement of the left ventricle and left atrium.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 75955 Version 3.0</div></div></div>"},"75956":{"type":"graphic_table","displayName":"Treatment of VWD","title":"Treatment of von Willebrand disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of von Willebrand disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Desmopressin (DDAVP)</td> <td> <p>IV: 0.3 mcg/kg in 50 mL saline over 20 minutes</p> Nasal spray: weight &#62;50 kg: 300 mcg (1 spray in each nostril); &#60;50 kg: 150 mcg (1 spray in one nostril)</td> <td> <p>DDAVP should not be used together with antifibrinolytic agents such as tranexamic acid or aminocaproic acid.</p> <p>Useful in most patients with type 1; variable in type 2*; not useful in type 3.</p> <p>Patient should have therapeutic trial to measure response before use.</p> May repeat dose after 12 hours and 24 hours. Tachyphylaxis and hyponatremia may occur; need to monitor patient.</td> </tr> <tr> <td>VWF concentrates containing all VWF multimers</td> <td><strong>Major bleeding or surgery:</strong> Initial dose 40 to 60 ristocetin cofactor units per kg followed by 20 to 40 ristocetin cofactor units per kg every 12 to 24 hours to keep VWF level 50 to 100 international units/dL for 7 to 14 days, or as indicated clinically.<br /> <strong>Minor bleeding or surgery:</strong> Initial dose 30 to 60 ristocetin cofactor units per kg followed by 20 to 40 ristocetin cofactor units per kg&nbsp;every 12 to 48 hours to keep VWF level &#62;30 international units/dL for 3 to 5 days, or less as indicated clinically.</td> <td>Dose and duration based on clinical experience. Case reports have described the use of continuous infusion (2 to 15 IU of VWF per kg per hour) in cases of serious bleeding that does not respond to intermittent dosing. </td> </tr> <tr> <td>Recombinant VWF&nbsp;</td> <td> <p><strong>Major bleeding or surgery: </strong>Initial dose 50 to 80 international units/kg followed by 40 to 60 international units/kg every 8 to 24 hours to keep the VWF level 50 to 100 international units/kg for 2 to 3 days or longer, as needed clinically. </p> <p><strong>Minor bleeding or surgery:</strong> Initial dose 40 to 50 international units/kg followed by 40 to 50 international units/kg every 8 to 24 hours as needed clinically. </p> </td> <td> <p>In patients with less than 40 international units/dL of factor VIII, one dose of recombinant factor VIII is given (dose ratio of 1.0 to 1.3 for rFVIII to rVWF) within 10 minutes of the first dose of rVWF.</p> <p>Experience with rVWF is limited, and more clinical studies are needed to assess responses in patients with differing age, severity of VWD, and in specific clinical settings.</p> </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Antifibrinolytic agents:</td> </tr> <tr> <td class=\"sublist1\">Aminocaproic acid</td> <td class=\"sublist_other\">25 to 50 mg/kg orally (maximum 5 g dose)&nbsp;four times&nbsp;per day</td> <td class=\"sublist_other\" rowspan=\"2\">Use alone or in conjunction with other therapy except DDAVP. Especially useful for mucosal bleeding (often for dental procedures).</td> </tr> <tr> <td class=\"sublist1\">Tranexamic acid</td> <td class=\"sublist_other\">10 mg/kg intravenously three times per day</td> </tr> <tr> <td>IVIG (immune acquired inhibitors of VWF)</td> <td>1 g/kg intravenously one time per day for two days**</td> <td>Use after trial of DDAVP or other measures in patients with acquired von Willebrand syndrome (aVWS), particularly when associated with autoimmune diseases. May be used in conjunction with VWF concentrates to increase the half-life of VWF.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for additional information on the management of VWD.</div><div class=\"graphic_footnotes\">DDVAP: desmopressin; VWF: von Willebrand factor; IVIG: intravenous immune globulin; VWD: von Willebrand disease.<br />* Thrombocytopenia may worsen in some type 2B patients.<br />** Divided doses may be required; refer to UpToDate on the use of IVIG for details.</div><div class=\"graphic_reference\">Adapted from: Rick ME. Diagnosis and management of von Willebrand's syndrome. Med Clin North Am 1994; 78:609. Copyright 1994 WB Saunders.</div><div id=\"graphicVersion\">Graphic 75956 Version 9.0</div></div></div>"},"75957":{"type":"graphic_picture","displayName":"Shoulder stretch","title":"Flexibility exercise: Shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexibility exercise: Shoulder</div><div class=\"cntnt\"><img style=\"width:378px; height:302px;\" src=\"images/PC/75957_Shoulder_stretch_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise to stretch your shoulder muscles will help improve your posture. <ol> <li>Stand back against a wall, feet shoulder-width apart and arms at shoulder height. </li> <li>Bend your elbows so your fingertips point toward the ceiling and touch the wall behind you. Stop when you feel a stretch or slight discomfort, and stop immediately if you feel sharp pain. </li> <li>Hold position for 10 to 30 seconds. </li> <li>Let your arms slowly roll forward, remaining bent at the elbows, to point toward the floor and touch the wall again, if possible. Stop when you feel a stretch or slight discomfort. </li> <li>Hold position for 10 to 30 seconds. </li> <li>Alternate pointing above head, then toward hips. </li> <li>Repeat at least three to five times. </li> </ol></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 75957 Version 2.0</div></div></div>"},"75958":{"type":"graphic_table","displayName":"Chemical peels","title":"Types of chemical peels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of chemical peels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Depth</td> <td class=\"subtitle1\">Agents</td> </tr> <tr> <td rowspan=\"4\">Very superficial</td> <td>Glycolic acid, 30 to 50% applied for&nbsp;one to two&nbsp;minutes</td> </tr> <tr> <td>Jessner (resorcinol, salicylic acid, lactic acid, ethanol) solution applied in&nbsp;one to three&nbsp;coats</td> </tr> <tr> <td>Low concentration resorcinol, 20 to 30% applied for 5 to 10 minutes</td> </tr> <tr> <td>TCA 10% applied in&nbsp;one coat</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Superficial</td> <td>Glycolic acid, 50 to 70%, applied for&nbsp;two to five&nbsp;minutes</td> </tr> <tr> <td>Pyruvic acid, 40 to 50% applied for&nbsp;three to five&nbsp;minutes</td> </tr> <tr> <td>Jessner solution applied in 4 to 10 coats</td> </tr> <tr> <td>Resorcinol, 40 to 50% applied for 30 to 60 minutes</td> </tr> <tr> <td>TCA, 10 to 30%</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Medium</td> <td>Glycolic acid 70% applied for 3 to 15 minutes</td> </tr> <tr> <td>Pyruvic acid 60% applied for&nbsp;three to five&nbsp;minutes</td> </tr> <tr> <td>TCA, 35 to 50%</td> </tr> <tr> <td>Augmented TCA (carbon dioxide and TCA 35%; Jessner solution and TCA 35%; glycolic acid 70% and TCA 35%)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Deep</td> <td>Phenol 88%</td> </tr> <tr> <td>Baker-Gordon phenol formula (88% phenol, distilled water, Septisol, croton oil)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TCA: trichloroacetic acid.</div><div class=\"graphic_reference\">Source: Fabbrocini G, De Padova MP, Tosti A. Chemical peels: what's new and what isn't new but still works well. Facial Plast Surg 2009; 25:329.</div><div id=\"graphicVersion\">Graphic 75958 Version 2.0</div></div></div>"},"75960":{"type":"graphic_table","displayName":"Clinical features of clonidine poisoning in children","title":"Clinical features of clonidine poisoning in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of clonidine poisoning in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finding </td> <td class=\"subtitle1\">Children, hospital based*<br /> (&#60;10 years of age, percent [N=180])</td> <td class=\"subtitle1\">Children, Poison Control Center <br /> (&#60;19 years of age, percent [N=33,867<sup>&#182;</sup>])</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Central nervous system</td> </tr> <tr> <td class=\"indent1\">Lethargy/coma</td> <td>87</td> <td>82 to 90</td> </tr> <tr> <td class=\"indent1\">Miosis</td> <td>16</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Hypotonia</td> <td>12</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Irritiability</td> <td>11</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Hyporeflexia</td> <td>10</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Unreactive pupils</td> <td>60</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Babinski's sign present</td> <td>40</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Mydriasis</td> <td>4% (2/47)</td> <td>-</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ataxia/dizziness</td> <td>-</td> <td>4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cardiovascular system</td> </tr> <tr> <td class=\"indent1\">Bradycardia</td> <td>32</td> <td>10 to 17</td> </tr> <tr> <td class=\"indent1\">Hypotension</td> <td>25</td> <td>9 to 15</td> </tr> <tr> <td class=\"indent1\">Arrhythmia</td> <td>11</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td>7</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cardiac arrest</td> <td>0</td> <td>&#60;0.01</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Respiratory system</td> </tr> <tr> <td class=\"indent1\">Respiratory depression</td> <td>16</td> <td>3 to 5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Apnea</td> <td>7</td> <td>0.2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Other findings</td> </tr> <tr> <td class=\"indent1\">Pallor</td> <td>22</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> <td>17 (8/47)</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Dry mouth</td> <td>2</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Age-specific definitions of bradycardia, hypotension, and hypertension were used for pediatric findings in the hospital-based pediatric reports.<br />Â¶ Data compiled from different poison control center reports with upper age range varying from 12 to 19 years of age.</div><div class=\"graphic_reference\">Adapted from: Wang GS, Le Lait MC, Heard K. Unintentional pediatric exposures to central alpha-2 agonits reported to the national poison data system. J Pediatr 2014; 164:149.<br />Klein-Schwartz, W: Trends and toxic effects from pediatric clonidine exposures. Arch Pediatr Adolesc 2002; 156:392-396.<br />Stein, B, Volans, GN: Dixarit overdose: the problem of attractive tablets. BMJ 1978; 2:667-668.<br />Wiley, JF II, Wiley, CC, Torrey, SB, Henretig, FM: Clonidine poisoning in young children. J Pediatr 1980; 116:654-658.</div><div id=\"graphicVersion\">Graphic 75960 Version 5.0</div></div></div>"},"75962":{"type":"graphic_figure","displayName":"Graft versus leukemia in CML","title":"Kinetics of the graft-versus-leukemia effect in chronic myeloid leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kinetics of the graft-versus-leukemia effect in chronic myeloid leukemia</div><div class=\"cntnt\"><img style=\"width:448px; height:298px;\" src=\"images/HEME/75962_Graft_versus_leukemia_in_CM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These graphs show the kinetics of attainment of molecular complete remission (CR) in chronic myelogenous leukemia following allogeneic non-myeloablative hematopoietic cell transplantation (HCT). Residual malignant disease was tracked via reverse transcriptase polymerase chain reaction, using the ratio of BCR-ABL to ABL (graph on left). The time course for attainment of donor T-cell chimerism (percent T-cells of donor origin) is shown on the right. One to three months post-HCT, no patient achieved molecular CR (ie, minimal residual disease [MRD] negative status), a time when only two (1 month) or eight (3 months) of 15 patients had achieved full donor T-cell chimerism (ie, 100 percent donor T-cells). At six months, 12 of the 14 tested patients had achieved full donor chimerism, by which time most (8 of the 10 tested) had also achieved molecular CR. These graphs show that attainment of molecular CR following non-myeloablative HCT requires the presence of a graft-versus-leukemia effect, which is not maximally effective until virtually all of the patient's T-cells are of donor origin. This is in contrast to conventional (myeloablative) HCT, following which most patients have 100 percent donor T-cell chimerism and are MRD negative within one to three months of transplantation.</div><div class=\"graphic_reference\">Data from Uzunel, M, et al. Blood 2003; 101:469.</div><div id=\"graphicVersion\">Graphic 75962 Version 2.0</div></div></div>"},"75963":{"type":"graphic_diagnosticimage","displayName":"48h postpneumonectomy PA","title":"Expected chest radiographic changes in the early postpneumonectomy period","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Expected chest radiographic changes in the early postpneumonectomy period</div><div class=\"cntnt\"><img style=\"width:316px; height:324px;\" src=\"images/PULM/75963_48h_postpneumonectomy_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forty-eight hours after surgery, fluid has quickly accumulated in the postpneumonectomy space after removal of the chest tube. Note the shift in the trachea towards the operative side (arrow).</div><div class=\"graphic_reference\">Courtesy of Richard Irwin, MD.</div><div id=\"graphicVersion\">Graphic 75963 Version 2.0</div></div></div>"},"75964":{"type":"graphic_diagnosticimage","displayName":"Central calcification on CT","title":"Pulmonary nodule with central calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary nodule with central calcification</div><div class=\"cntnt\"><img style=\"width:310px; height:238px;\" src=\"images/PULM/75964_Central_calcification_on_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharply defined solitary pulmonary nodule with smooth border and target-like central calcification.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 75964 Version 2.0</div></div></div>"},"75966":{"type":"graphic_table","displayName":"Risk factors for bleomycin toxicity","title":"Risk factors for bleomycin pulmonary toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for bleomycin pulmonary toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Probable risk factors </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Total cumulative dose &#8805;400 units</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Renal insufficiency</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Exposure to high partial pressure of oxygen</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Radiation therapy</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Age over 40</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cigarette smoking</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Possible risk factors </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Concurrent use of cisplatin</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Concurrent use of granulocyte colony stimulating factor</td>\r\n        </tr>\r\n    </tbody>\r\n</table>\r\n<!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=64943&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div id=\"graphicVersion\">Graphic 75966 Version 2.0</div></div></div>"},"75967":{"type":"graphic_picture","displayName":"Granulation tissue nr stent","title":"Granulation tissue near stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granulation tissue near stent</div><div class=\"cntnt\"><img style=\"width:288px; height:311px;\" src=\"images/PULM/75967_Granulation_tissue_nr_stent.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75967 Version 2.0</div></div></div>"},"75969":{"type":"graphic_table","displayName":"Predictive value TM exam","title":"Predictive value of combinations of otoscopic findings in children with acute ear symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictive value of combinations of otoscopic findings in children with acute ear symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"subtitle1\">Position of TM</td>\r\n\t\t\t\t\t\t\t\t<td class=\"subtitle1\">Mobility of TM</td>\r\n\t\t\t\t\t\t\t\t<td class=\"subtitle1\">Color of TM</td>\r\n\t\t\t\t\t\t\t\t<td class=\"subtitle1\">Predictive value, percent</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"4\"rowspan=\"1\">Combinations with &#62;80 percent predictive value of AOM compared with myringotomy</td>\r\n\r\n\t\t\t\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Bulging</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Cloudy</td>\r\n\t\t\t\t\t\t\t\t<td>99</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Bulging</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Cloudy</td>\r\n\t\t\t\t\t\t\t\t<td>99</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Bulging</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly red</td>\r\n\t\t\t\t\t\t\t\t<td>94</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Bulging</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly red</td>\r\n\t\t\t\t\t\t\t\t<td>93</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Bulging</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly red</td>\r\n\t\t\t\t\t\t\t\t<td>85</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Bulging</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly red</td>\r\n\t\t\t\t\t\t\t\t<td>83</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Cloudy</td>\r\n\t\t\t\t\t\t\t\t<td>97</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly red</td>\r\n\t\t\t\t\t\t\t\t<td>89</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"4\"rowspan=\"1\">Combinations with &#60;50 percent predictive value of AOM compared with myringotomy</td>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly red</td>\r\n\t\t\t\t\t\t\t\t<td>47</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly red</td>\r\n\t\t\t\t\t\t\t\t<td>41</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Cloudy</td>\r\n\t\t\t\t\t\t\t\t<td>37</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly red</td>\r\n\t\t\t\t\t\t\t\t<td>15</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly red</td>\r\n\t\t\t\t\t\t\t\t<td>7</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Normal</td>\r\n\t\t\t\t\t\t\t\t<td>Normal</td>\r\n\t\t\t\t\t\t\t\t<td>0.1</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Retracted </td>\r\n\t\t\t\t\t\t\t\t<td>Distinctly impaired </td>\r\n\t\t\t\t\t\t\t\t<td>Normal</td>\r\n\t\t\t\t\t\t\t\t<td>29</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t\t<td class=\"indent1\">Retracted</td>\r\n\t\t\t\t\t\t\t\t<td>Slightly impaired</td>\r\n\t\t\t\t\t\t\t\t<td>Normal</td>\r\n\t\t\t\t\t\t\t\t<td>3</td>\r\n\t\t\t\t\t\t\t</tr>\r\n\t\t\t</table></div><div class=\"graphic_footnotes\">TM: tympanic membrane.</div><div class=\"graphic_reference\">Data from:<br>Pelton, SI. Otoscopy for the diagnosis of otitis media. Pediatr Infect Dis J 1998; 17:540.<br>Karma, PH, Sipila, MM, Kayaja, MJ, Penttila, MA. Pneumatic otoscopy and otitis media: The value of different tympanic membrane findings and their combinations. In: Recent advances in otitis media: proceedings of the Fifth International Symposium, Lim, DJ, Bluestone, CD, Klein, JO, et al (Eds), Decker, Burlington, Ontario, Canada, 1993. p. 41.</div><div id=\"graphicVersion\">Graphic 75969 Version 1.0</div></div></div>"},"75970":{"type":"graphic_table","displayName":"Toxic ingredients inhalants","title":"Toxic ingredients in abused inhalants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxic ingredients in abused inhalants</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Abused inhalant</td>\n<td class=\"subtitle1\">Toxic ingredients</td>\n</tr>\n<tr>\n<td>Aerosol propellants</td>\n<td>Halogenated hydrocarbons, propane, isobutane</td>\n</tr>\n<tr>\n<td>Dry-cleaning fluids, spot removers, furniture polish</td>\n<td>Chlorinated hydrocarbons, aliphatic (gasoline) hydrocarbons</td>\n</tr>\n<tr>\n<td>Glues, cements, rubber patching</td>\n<td>Toluene, acetone, benzene, aliphatic acetates, n-hexane, cyclohexane, halocarbons, xylene, butyl alcohol, methylethylketone, methylethylisobutylketone, chloroform, ethanol, triorthocresyl phosphate, naphtha, isopropanol, glycol</td>\n</tr>\n<tr>\n<td>Lighter fluid</td>\n<td>Aliphatic and aromatic hydrocarbons</td>\n</tr>\n<tr>\n<td>Fire-extinguishing agents</td>\n<td>Fluorocarbons</td>\n</tr>\n<tr>\n<td>Fingernail polish remover</td>\n<td>Acetone, aliphatic acetates, benzene, alcohol</td>\n</tr>\n<tr>\n<td>Bottle fuel gas</td>\n<td>Butane, propane</td>\n</tr>\n<tr>\n<td>Typewriter correction fluid</td>\n<td>Trichloroethane, trichloroethylene</td>\n</tr>\n<tr>\n<td>Natural gas</td>\n<td>Methane, ethane, propane, butane</td>\n</tr>\n<tr>\n<td>Marker pens</td>\n<td>Toluene, xylene</td>\n</tr>\n<tr>\n<td>Paints, enamels, lacquers, lacquer and paint thinners</td>\n<td>Toluene, methylene chloride, aliphatic acetates, benzene, ethanol</td>\n</tr>\n<tr>\n<td>Paint strippers</td>\n<td>Dichloromethane</td>\n</tr>\n<tr>\n<td>Petroleum (gasoline, naphtha, benzene)</td>\n<td>Aliphatic and aromatic hydrocarbons, butane, hexane, pentane, benzene, toluene, xylene; tetraethyl lead</td>\n</tr>\n<tr>\n<td>Whipped cream dispensers</td>\n<td>Nitrous oxide</td>\n</tr>\n<tr>\n<td>Anesthetics</td>\n<td>Nitrous oxide, diethyl ether, halothane, chloroform, enflurane, isoflurane, trichloroethylene</td>\n</tr>\n<tr>\n<td>Room odorizers</td>\n<td>Amyl, butyl, isobutyl nitrite</td>\n</tr>\n<tr>\n<td>Solvents</td>\n<td>Methylethylketone, carbon tetrachloride, chloroform, diethyl ether, n-hexane, methylisobutylketone</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Dinwiddle, SH. Addiction 1994; 89:925; Brust, JC. Neurol Clin North Am 1998; 16:503; Caputo, RA. Int J Addict 1993; 28:1015.</div><div id=\"graphicVersion\">Graphic 75970 Version 1.0</div></div></div>"},"75971":{"type":"graphic_algorithm","displayName":"Verbal children UTI","title":"Diagnostic algorithm for verbal children older than 24 months with urinary or abdominal symptoms","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for verbal children older than 24 months with urinary or abdominal symptoms</div><div class=\"cntnt\"><img style=\"width:489px; height:564px;\" src=\"images/PEDS/75971_Verbal_children_UTI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">UTI: urinary tract infection; LR: likelihood ratio.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaikh N, Morone NE, Lopez L, et al. Does this child have a urinary tract infection? JAMA 2007; 298:2895. Copyright Â© 2008 American Medical Association.</div><div id=\"graphicVersion\">Graphic 75971 Version 6.0</div></div></div>"},"75972":{"type":"graphic_figure","displayName":"Classification of rhinosinusitis by duration of disease","title":"Classification of rhinosinusitis by duration of disease","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Classification of rhinosinusitis by duration of disease</div><div class=\"cntnt\"><img style=\"width:522px; height:220px;\" src=\"images/PC/75972_Classify_rhinosinusitis.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75972 Version 2.0</div></div></div>"},"75974":{"type":"graphic_table","displayName":"Symptoms and signs of lumbosacral radiculopathies","title":"Symptoms and signs of lumbosacral radiculopathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms and signs of lumbosacral radiculopathies</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Nerve</td>\n<td class=\"subtitle1\">Symptoms</td>\n<td class=\"subtitle1\">Signs</td>\n</tr>\n<tr>\n<td>L5</td>\n<td>Back pain radiating down the lateral leg to foot</td>\n<td>Decreased foot dorsiflexion, toe extension, foot inversion and eversion; mild weakness of leg abduction in severe cases</td>\n</tr>\n<tr>\n<td>S1</td>\n<td>Pain radiating down the posterior leg to foot; leg pain greater than back pain</td>\n<td>Decreased leg extension, foot inversion, plantar flexion, and toe flexion; decreased sensation in the posterior leg and lateral foot; loss of ankle jerk</td>\n</tr>\n<tr>\n<td>L2-4</td>\n<td>Acute back pain radiating around the anterior leg into the knee and possibly foot</td>\n<td>Decreased hip flexion, knee extension, leg abduction; decreased sensation in the anterior thigh down the medial aspect of the shin; diminished knee jerk in severe cases</td>\n</tr>\n<tr>\n<td>S2-4</td>\n<td>Sacral or buttock pain radiating down the posterior leg or into the perineum</td>\n<td>Minimal weakness; bowel and bladder dysfunction</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=59675&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Lumbosacral_radiculopathies.htm</title></head></div><div id=\"graphicVersion\">Graphic 75974 Version 3.0</div></div></div>"},"75979":{"type":"graphic_table","displayName":"Example of 12-step desensitization protocol for IV infliximab","title":"Example of 12-step desensitization protocol for intravenous infliximab (600 mg dose, 250 mL per solution)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of 12-step desensitization protocol for intravenous infliximab (600 mg dose, 250 mL per solution)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle2\">Solution</td> <td class=\"subtitle2\" colspan=\"2\">Total volume</td> <td class=\"subtitle2\" colspan=\"2\">Concentration</td> <td class=\"subtitle2\" colspan=\"2\">Dose</td> </tr> <tr> <td>Solution 1</td> <td colspan=\"2\">250 mL</td> <td colspan=\"2\">0.024 mg/mL</td> <td colspan=\"2\">6 mg</td> </tr> <tr> <td>Solution 2</td> <td colspan=\"2\">250 mL</td> <td colspan=\"2\">0.24 mg/mL</td> <td colspan=\"2\">60 mg</td> </tr> <tr> <td>Solution 3</td> <td colspan=\"2\">250 mL</td> <td colspan=\"2\">2.38 mg/mL</td> <td colspan=\"2\">600 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\">Step</td> <td class=\"subtitle1\">Solution</td> <td class=\"subtitle1\">Rate (mL/hour)</td> <td class=\"subtitle1\">Time (minutes)</td> <td class=\"subtitle1\">Volume infused per step (mL)</td> <td class=\"subtitle1\">Dose administered with this step (mg)</td> <td class=\"subtitle1\">Cumulative dose (mg)</td> </tr> <tr> <td>1</td> <td>1</td> <td>2.0</td> <td>15</td> <td>0.50</td> <td>0.012</td> <td>0.012</td> </tr> <tr> <td>2</td> <td>1</td> <td>5.0</td> <td>15</td> <td>1.25</td> <td>0.030</td> <td>0.042</td> </tr> <tr> <td>3</td> <td>1</td> <td>10.0</td> <td>15</td> <td>2.50</td> <td>0.060</td> <td>0.102</td> </tr> <tr> <td>4</td> <td>1</td> <td>20.0</td> <td>15</td> <td>5.00</td> <td>0.120</td> <td>0.222</td> </tr> <tr> <td>5</td> <td>2</td> <td>5.0</td> <td>15</td> <td>1.25</td> <td>0.300</td> <td>0.522</td> </tr> <tr> <td>6</td> <td>2</td> <td>10.0</td> <td>15</td> <td>2.50</td> <td>0.600</td> <td>1.122</td> </tr> <tr> <td>7</td> <td>2</td> <td>20.0</td> <td>15</td> <td>5.00</td> <td>1.200</td> <td>2.322</td> </tr> <tr> <td>8</td> <td>2</td> <td>40.0</td> <td>15</td> <td>10.00</td> <td>2.400</td> <td>4.722</td> </tr> <tr> <td>9</td> <td>3</td> <td>10.0</td> <td>15</td> <td>2.50</td> <td>5.953</td> <td>10.675</td> </tr> <tr> <td>10</td> <td>3</td> <td>20.0</td> <td>15</td> <td>5.00</td> <td>11.906</td> <td>22.580</td> </tr> <tr> <td>11</td> <td>3</td> <td>40.0</td> <td>15</td> <td>10.00</td> <td>23.811</td> <td>46.392</td> </tr> <tr> <td>12</td> <td>3</td> <td>80.0</td> <td>174.38</td> <td>232.50</td> <td>553.609</td> <td>600.000</td> </tr> <tr> <td colspan=\"7\"><strong>NOTE:</strong> Each step is administered over 15 minutes. At conclusion of protocol, observe patient for 30 minutes, and then give full therapeutic dose by the desired route.</td> </tr> <tr> <td colspan=\"7\">Total time = 339 minutes (5.7 hours).</td> </tr> <tr> <td colspan=\"7\">Standard premedications included diphenhydramine, 25 mg administered intravenously and famotidine, 20 mg administered intravenously, 20 minutes before desensitization. Medications at the bedside included intramuscular epinephrine (1:1000, 0.3 mg); diphenhydramine, 25 to 50 mg administered intravenously; famotidine, 20 mg administered intravenously; methylprednisolone, 50 mg administered intravenously; aspirin, 325 mg administered orally; montelukast, 10 mg administered orally; albuterol, two puffs; and lorazepam, 0.5 mg administered intravenously.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Desensitization protocol instructions:</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">1. Confirm written consent is in medical record.</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">2. Ensure preceding dose of beta-blockers was held, unless otherwise advised by supervising clinician.</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">3. Obtain IV access and vital signs (temperature, HR, BP, RR, oxygen saturation, peak flow).</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">4. Have at bedside: Epinephrine 0.3 mg (for adults) for IM injection, oxygen, normal saline, peak flow meter, and BP cuff, albulterol, injectable preparation of diphenhydramine, and methylprednisolone.</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">5. A nurse must closely observe the patient throughout the protocol (one-to-one).</td> </tr> <tr> <td colspan=\"7\"><strong>Administration:</strong> Hang each solution successively. Each step is administered over 15 minutes per protocol. There is no reason to wait between bags. Vital signs should be taken and recorded every 15 minutes and every 30 minutes during the last step.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Monitoring and charting during desensitization:</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"7\">Clearly document any reaction, including:</td> </tr> <tr> <td class=\"sublist2\" colspan=\"7\">a. Patient's symptoms, vital signs, and physical findings.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"7\">b. Exactly when the reaction occurred (ie, what step, how many minutes into that step).</td> </tr> <tr> <td class=\"sublist2\" colspan=\"7\">c. Treatment administered, how and when the reaction resolved, and when the protocol was restarted.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Treatment of allergic reactions:</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\"><strong>For mild reactions:</strong> In case of isolated itching, flushing, hives, mild chest tightness, nausea, abdominal pain, or back pain with normal vital signs, stop the infusion and treat with IV diphenhydramine. Observe patient until the reaction subsides, and then resume the protocol by repeating the step at which the reaction occurred.</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\"><strong>For severe reactions:</strong> In case of hypotension, throat swelling, wheezing/respiratory distress, or decreased oxygen saturation, stop the infusion and treat with epinephrine 0.3 mg IM x 1, diphenhydramine and methylprednisolone IV, oxygen, inhaled albuterol for bronchospasm, and IV fluids (normal saline). Place patient in a recumbent position if hypotensive. Consider glucagon 1 to 2 mg IV bolus if patient has taken beta-blockers, followed by infusion at 1 to 5 mg/hour. <strong>Immediately alert the housestaff and supervising clinician.</strong> When the patient is stable, the protocol will be resumed as instructed by the supervising clinician.</td> </tr> <tr> <td colspan=\"7\"><strong>Contact the supervising clinician for ANY severe or prolonged reaction or any questions regarding the protocol, reactions, and appropriate management.</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; HR: heart rate; BP: blood pressure; RR: respiratory rate; IM: intramuscular.</div><div class=\"graphic_reference\">Reproduced with permission from: Brennan PJ, Bouza TR, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allerg Clin Immunol 2009; 124:1259. Illustration used with the permission of Elsevier Inc. All rights reserved.<br />Instructions courtesy of Mariana Castells, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75979 Version 5.0</div></div></div>"},"75980":{"type":"graphic_figure","displayName":"Hemodynamics tamponade","title":"Hemodynamics in cardiac tamponade","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemodynamics in cardiac tamponade</div><div class=\"cntnt\"><img style=\"width:387px; height:432px;\" src=\"images/CARD/75980_Hemodynamics_tamponade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode through the minor axis in a patient with an anterior and posterior pericardial effusion and tamponade is seen in panel A; during inspiration, the right ventricle (RV) fills and the left ventricle (LV) becomes smaller; during expiration, the opposite occurs. In the graph in panel B, RV (RVEDd) and LV end diastolic diameters (LVEDd) are plotted against one another and demonstrate a negative correlation, a result of reciprocation of the chambers within the pericardium. Since the pericardium is a rigid box, as respiration brings more blood into the RV, there is less room in the LV; blood pools in the inflating lungs during inspiration. This blood plus the increased stroke volume sent to the lungs during RV inspiratory expansion reaches the lLV during expiration. As the LV expands, the RV is compressed. During RV expansion underfilling of the LV results in a drop in pulse pressure perceived as the paradoxical pulse.</div><div id=\"graphicVersion\">Graphic 75980 Version 1.0</div></div></div>"},"75983":{"type":"graphic_figure","displayName":"Lumbosacral plexus","title":"Anatomy of the lumbosacral plexus","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Anatomy of the lumbosacral plexus</div><div class=\"cntnt\"><img style=\"width:492px; height:616px;\" src=\"images/NEURO/75983_Lumbosacral_plexus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75983 Version 1.0</div></div></div>"},"75985":{"type":"graphic_figure","displayName":"Infant asymmetric tonic neck reflex","title":"Infant asymmetrical tonic neck reflex","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Infant asymmetrical tonic neck reflex</div><div class=\"cntnt\"><img style=\"width:517px; height:423px;\" src=\"images/PEDS/75985_Asym_tonic_neck_reflex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetrical tonic neck reflex is characterized by extension of the upper and lower extremities on the side to which the head and neck is turned with flexion of the contralateral upper extremity (fencing posture). It appears beginning at 35 weeks gestation, is well established by one month of age, and disappears by three to&nbsp;four months of age in a term infant.</div><div id=\"graphicVersion\">Graphic 75985 Version 4.0</div></div></div>"},"75986":{"type":"graphic_table","displayName":"Efficacy antifungal agents","title":"Effectiveness of antifungal agents against common yeast, fungi, and bacteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effectiveness of antifungal agents against common yeast, fungi, and bacteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Agent</td> <td class=\"subtitle1\" colspan=\"4\">Common yeast and fungi</td> <td class=\"subtitle1\" colspan=\"5\">Common bacteria</td> </tr> <tr> <td class=\"subtitle2\"><em>Aspergillus niger</em></td> <td class=\"subtitle2\"><em>Candida albicans</em></td> <td class=\"subtitle2\"><em>C. parapsilosis</em></td> <td class=\"subtitle2\"><em>Penicillium</em></td> <td class=\"subtitle2\"><em>Staphylococcus aureus</em></td> <td class=\"subtitle2\"><em>Pseudomonas</em></td> <td class=\"subtitle2\"><em>S. epidermidis</em></td> <td class=\"subtitle2\"><em>Proteus mirabilis</em></td> <td class=\"subtitle2\">Enterococci</td> </tr> <tr> <td>Amphotericin B</td> <td>+</td> <td>++</td> <td>++</td> <td>+</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Clotrimazole</td> <td>++</td> <td>++</td> <td>++</td> <td>++</td> <td>+</td> <td>0</td> <td>+</td> <td>0</td> <td>0</td> </tr> <tr> <td>Flucytosine</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>NT</td> <td>NT</td> <td>NT</td> <td>NT</td> <td>NT</td> </tr> <tr> <td>Miconazole</td> <td>+</td> <td>++</td> <td>++</td> <td>++</td> <td>+</td> <td>0</td> <td>+</td> <td>0</td> <td>0</td> </tr> <tr> <td>Natamycin</td> <td>++</td> <td>+</td> <td>+</td> <td>++</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Nystatin</td> <td>+</td> <td>++</td> <td>++</td> <td>+</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>Tolnaftate</td> <td>0</td> <td>0</td> <td>0</td> <td>+</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">++: Very effective (&gt;25 mm); +: Effective (15-25 mm); 0: Ineffective (&lt;15 mm); NT: not tested.</div><div class=\"graphic_reference\">Adapted with data from Stern, JC, Shah, MK, Lucente, FE, Laryngoscope 1988; 98:1173.</div><div id=\"graphicVersion\">Graphic 75986 Version 2.0</div></div></div>"},"75987":{"type":"graphic_figure","displayName":"LH pulses and sleep","title":"Episodic LH secretion during the follicular phase","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Episodic LH secretion during the follicular phase</div><div class=\"cntnt\"><img style=\"width:386px; height:310px;\" src=\"images/ENDO/75987_LH_pulses_and_sleep.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patterns of episodic LH secretion during the EFP, MFP, and LFP of the menstrual cycle. Day 0 is the day of the midcycle LH surge. There is a unique suppression of LH secretion during sleep in the EFP.</div><div class=\"graphic_footnotes\">EFP: early follicular phase; LFP: late follicular phase; LH: luteinizing hormone; MFP: middle follicular phase.</div><div class=\"graphic_reference\">Data from: Filicori M, Santoro N, Merriam GR, Crowley WF Jr. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab 1986; 62:1136.</div><div id=\"graphicVersion\">Graphic 75987 Version 3.0</div></div></div>"},"75988":{"type":"graphic_picture","displayName":"Retinal blot hemorrhages","title":"Retinal blot hemorrhages: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal blot hemorrhages: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:295px; height:288px;\" src=\"images/ENDO/75988_Retinal_blot_hemorrhages.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diabetic retinopathy, showing several blot hemorrhages (arrows). These lesions are due to vascular occlusion and rupture.</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 75988 Version 3.0</div></div></div>"},"75990":{"type":"graphic_figure","displayName":"Long QT genotype outcome","title":"Outcome in long QT syndrome is related to genotype","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Outcome in long QT syndrome is related to genotype</div><div class=\"cntnt\"><img style=\"width:427px; height:498px;\" src=\"images/CARD/75990_Long_QT_genotype_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panel: Kaplan-Meier estimate shows that patients with LQT1 or LQT 2 have a significantly higher probability of a cardiac event compared to those with LQT3 (63 and 46 percent versus 18 percent, p&lt;0.001). Bottom panel: Although patients with LQT1 have a higher mortality by age 15 (2.9 versus 0.4 and 1.5 percent for LQT2 and LQT3, (p = 0.006), there is no difference in mortality at the age of 40.</div><div class=\"graphic_reference\">Data from: Zareba W, Moss AJ, Schwartz PJ, et al. for the International Long-QT Syndrome Registry Research Group, N Engl J Med 1998; 339:960.</div><div id=\"graphicVersion\">Graphic 75990 Version 2.0</div></div></div>"},"75991":{"type":"graphic_table","displayName":"Bleomycin pneumonitis appearance","title":"Radiographic manifestations of bleomycin-induced pneumonitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiographic manifestations of bleomycin-induced pneumonitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Bilateral reticular or fine nodular&nbsp;opacities (50 percent)</td> </tr> <tr> <td>Consolidative opacities&nbsp;(10 percent)</td> </tr> <tr> <td>Normal (10 percent)</td> </tr> <tr> <td>Nodular lesions with smooth or irregular borders which may cavitate (rare)</td> </tr> <tr> <td>No pleural effusions or adenopathy</td> </tr> <tr> <td>Rare pneumothorax when honeycomb lung is present</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 75991 Version 3.0</div></div></div>"},"75992":{"type":"graphic_diagnosticimage","displayName":"Posterior tibial tendonitis","title":"Transverse sonogram of posterior tibial tenosynovitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transverse sonogram of posterior tibial tenosynovitis</div><div class=\"cntnt\"><img style=\"width:504px; height:270px;\" src=\"images/RHEUM/75992_Posterior_tibial_tendonitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse sonogram of the posterior tibial tendon as it passes near the medial maleolus of a patient with rheumatoid arthritis shows an irregularly echoing widening due to proliferative synovitis.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 75992 Version 2.0</div></div></div>"},"75994":{"type":"graphic_figure","displayName":"Technique of transmetatarsal amputation","title":"Technique of transmetatarsal amputation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Technique of transmetatarsal amputation</div><div class=\"cntnt\"><img style=\"width:438px; height:696px;\" src=\"images/SURG/75994_Transmetatarsal-amputation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 75994 Version 3.0</div></div></div>"},"75995":{"type":"graphic_figure","displayName":"Criteria for melanocytic lesions","title":"Dermoscopic criteria for melanocytic lesions: Structures and histopathologic correlation<sup>[1-6]</sup>","html":"<div class=\"graphic\"><div style=\"width: 641px\" class=\"figure\"><div class=\"ttl\">Dermoscopic criteria for melanocytic lesions: Structures and histopathologic correlation<sup>[1-6]</sup></div><div class=\"cntnt\"><img style=\"width:621px; height:1175px;\" src=\"images/DERM/75995_Crit_melanocyt_lesions_PR2.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DEJ: dermoepidermal junction.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Argenziano G, Soyer HP, Talamini R, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.</li>&#xD;&#xA;    <li>Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol 1987; 17:571.</li>&#xD;&#xA;    <li>Jaimes N, Marghoob AA, Rabinovitz H, et al. Clinical and dermoscopic characteristics of melanomas on nonfacial chronically sun-damaged skin. J Am Acad Dermatol 2015; 72:1027.</li>&#xD;&#xA;    <li>Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.</li>&#xD;&#xA;    <li>Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol 1987; 17:571.</li>&#xD;&#xA;    <li>Jaimes N, Marghoob AA, Rabinovitz H, et al. Clinical and dermoscopic characteristics of melanomas on nonfacial chronically sun-damaged skin. J Am Acad Dermatol 2015; 72:1027.</li>&#xD;&#xA;    <li>Marghoob AA, Braun R. Proposal for a revised 2-step algorithm for the classification of lesions of the skin using dermoscopy. Arch Dermatol 2010; 146:426.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Ashfaq Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 75995 Version 5.0</div></div></div>"},"75996":{"type":"graphic_table","displayName":"Indications for TIPS","title":"Indications for placement of transjugular intrahepatic portosystemic shunts*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for placement of transjugular intrahepatic portosystemic shunts*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\" class=\"subtitle1_single\">Accepted indications</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Active hemorrhage despite emergent endoscopic treatment</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Recurrent variceal hemorrhage despite adequate endoscopic treatment</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Other potential indications- efficacy proven but not adequately compared to existing modalities</td>\n\n      \n\n    </tr>\n\n\n    <tr>\n      <td>Bleeding isolated varices in gastric fundus</td>\n      \n    </tr>\n    <tr>\n      <td>Refractory ascites</td>\n      \n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_single\">Experimental indications- efficacy not well established by large-scale published trials</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Bleeding portal hypertensive gastropathy</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Budd-Chiari syndrome</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Hepatic veno-occlusive disease</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Hepatorenal syndrome</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Hepatic hydrothorax</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Bleeding ectopic varices</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Protein-losing enteropathy due to portal hypertension</td>\n\n      \n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Only accepted indications should be used for routine clinical practice.</div><div id=\"graphicVersion\">Graphic 75996 Version 1.0</div></div></div>"},"75997":{"type":"graphic_movie","displayName":"Mitral valvuloplasty using the Inoue balloon catheter","title":"Mitral valvuloplasty using the Inoue balloon catheter","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valvuloplasty using the Inoue balloon catheter</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/75997_mitrvlvpconv.mp4\" style=\"width:224px;height:272px\"></div><img style=\"width:605px; height:230px;\" src=\"images/CARD/75997_mitrvlvp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a balloon inflation-deflation sequence during a percutanous mitral commissurotomy using the Inoue balloon. The balloon catheter has been introduced from the right femoral vein, crosses the interatrial septum after a transseptal catheterization, and has been manipulated across the mitral valve into the left ventricle with the balloon deflated. During inflation, the distal portion of the balloon expands first and the catheter is pulled back slightly with resistance being felt from the stenotic valve. Additional inflation then expands the rear or proximal portion of the balloon, thus locking the balloon within the stenotic valve. The final inflation expands the mid-portion resulting in a controlled transmission of force resulting in a splitting of the fused commissures. The rapid inflation-deflation sequence shown here results in no important period of hypotension; most patients have little awareness of the inflation. The other catheters seen in the image are a pigtail catheter in the left ventricle and a pulmonary artery thermodilution cardiac output catheter.</div><div class=\"graphic_reference\">Courtesy of John D Carroll, MD. This type of movie will be part of The Multimedia Textbook of Coronary Arteriography and Interventions, Williams &amp; Wilkins, Baltimore, Fall, 1996.</div><div id=\"graphicVersion\">Graphic 75997 Version 3.0</div></div></div>"},"75999":{"type":"graphic_picture","displayName":"Ossicle histology","title":"Otic embryology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Otic embryology</div><div class=\"cntnt\"><img style=\"width:368px; height:279px;\" src=\"images/PEDS/75999_Ossicle_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial histolologic section of the temporal bone at 12 weeks' gestation. Note the developing incus (i), malleus (m), stapes (s), facial nerve (7), external auditory canal (eac), and mesenchyme in the middle ear space (mes).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 75999 Version 1.0</div></div></div>"}};